PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	KATT, JA				KATT, JA			CORE CURRICULUM	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIAN-PATIENT RELATIONS		A physician recounts his first experience with the death of a patient with whom he was emotionally involved and discusses the important effect of the experience on future patient interactions.			KATT, JA (corresponding author), MILWAUKEE MED CLIN, MILWAUKEE, WI 53217 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					607	607		10.7326/0003-4819-117-7-607	http://dx.doi.org/10.7326/0003-4819-117-7-607			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524335				2022-12-28	WOS:A1992JQ22600011
J	LIEBER, MR				LIEBER, MR			THE MECHANISM OF V(D)J RECOMBINATION - A BALANCE OF DIVERSITY, SPECIFICITY, AND STABILITY	CELL			English	Review							SCID MUTATION; GENE REARRANGEMENT; CODING SEGMENTS; REPAIR; MICE; CELL; DEFICIENCY; INSERTION; SEQUENCES; DEFECT				LIEBER, MR (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL PHARMACOL LAB,STANFORD,CA 94305, USA.			Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, ANNU REV GENET, V23, P605, DOI 10.1146/annurev.ge.23.120189.003133; COEN ES, 1989, MOBILE DNA, P413; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GAUSS GH, 1992, GENE DEV, V6, P1553, DOI 10.1101/gad.6.8.1553; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HARRINGTON J, 1992, IN PRESS MOL CELL BI, V12; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; KLINMAN NR, 1990, IMMUNOL REV, V115, P211, DOI 10.1111/j.1600-065X.1990.tb00792.x; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIMPENS J, 1991, ONCOGENE, V6, P2271; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309	26	86	87	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					873	876		10.1016/0092-8674(92)90237-7	http://dx.doi.org/10.1016/0092-8674(92)90237-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525825				2022-12-28	WOS:A1992JN78100002
J	LUDERUS, MEE; DEGRAAF, A; MATTIA, E; DENBLAAUWEN, JL; GRANDE, MA; DEJONG, L; VANDRIEL, R				LUDERUS, MEE; DEGRAAF, A; MATTIA, E; DENBLAAUWEN, JL; GRANDE, MA; DEJONG, L; VANDRIEL, R			BINDING OF MATRIX ATTACHMENT REGIONS TO LAMIN-B1	CELL			English	Article							KAPPA-GENE EXPRESSION; DNA TOPOISOMERASE-II; NUCLEAR MATRIX; DROSOPHILA-MELANOGASTER; STABLE INTEGRATION; CHROMATIN DOMAIN; CHICKEN LYSOZYME; TRANSGENIC MICE; CROSS-LINKING; INTRONIC MAR	Eukaryotic chromatin is organized into topologically constrained loops that are attached to the nuclear matrix. The regions of DNA that interact with the matrix are called matrix attachment regions (MARs). We studied the spatial distribution of MAR-binding sites in the nuclear matrix from rat liver cells, following a combined biochemical and ultrastructural approach. We found that MAR-binding sites are distributed equally over the internal fibrogranular network and the peripheral nuclear lamina. Internal and peripheral binding sites have similar binding characteristics: both sets of binding sites show specific and saturable binding of MARs from different organisms. By means of a DNA-binding protein blot assay and in vitro binding studies, we identified lamin B1 as a MAR-binding protein, which provides evidence for a specific interaction of DNA with the nuclear lamina.	UNIV UTRECHT, DEPT MOLEC CELL BIOL, 3584 CH UTRECHT, NETHERLANDS	Utrecht University	LUDERUS, MEE (corresponding author), UNIV AMSTERDAM, EC SLATER INST BIOCHEM RES, 1018 TV AMSTERDAM, NETHERLANDS.		de Jong, Luitzen/E-7882-2011					ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BELGRADER P, 1991, J CELL SCI, V98, P281; BENAVENTE R, 1986, J CELL BIOL, V103, P1847, DOI 10.1083/jcb.103.5.1847; BENYAJATI C, 1976, CELL, V9, P393, DOI 10.1016/0092-8674(76)90084-2; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; BONIFER C, 1991, J CELL BIOCHEM, V47, P99, DOI 10.1002/jcb.240470203; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; BOULIKAS T, 1986, BIOCHEM CELL BIOL, V64, P474, DOI 10.1139/o86-066; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; BURKE B, 1990, EXP CELL RES, V186, P169, DOI 10.1016/0014-4827(90)90223-W; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COCKERILL PN, 1986, FEBS LETT, V204, P5, DOI 10.1016/0014-5793(86)81377-1; COMINGS DE, 1980, HUM GENET, V53, P131, DOI 10.1007/BF00273484; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572; DEGRAAF A, 1991, J HISTOCHEM CYTOCHEM, V39, P1035, DOI 10.1177/39.8.1856453; DEJONG L, 1990, CELL BIOL INT REP, V14, P1051, DOI 10.1016/0309-1651(90)90014-P; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; FARACHE G, 1990, MOL CELL BIOL, V10, P5349, DOI 10.1128/MCB.10.10.5349; GASSER SM, 1989, INT REV CYTOL, V119, P57; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GERACE L, 1978, J CELL BIOL, V79, P546, DOI 10.1083/jcb.79.2.546; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; HALL G, 1991, P NATL ACAD SCI USA, V88, P9320, DOI 10.1073/pnas.88.20.9320; HANCOCK R, 1982, BIOL CELL, V44, P201; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HOGER TH, 1990, CHROMOSOMA, V99, P379, DOI 10.1007/BF01726689; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; JACKSON DA, 1988, J CELL SCI, V90, P365; JACKSON DA, 1990, NUCLEIC ACIDS RES, V12, P1863; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KAUFMANN SH, 1984, EXP CELL RES, V155, P477, DOI 10.1016/0014-4827(84)90208-8; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LAWRENCE JB, 1988, CELL, V52, P51; LEBKOWSKI JS, 1982, J MOL BIOL, V156, P309, DOI 10.1016/0022-2836(82)90331-X; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LIN L, 1990, J BIOL CHEM, V265, P12596; Maniatis T., 1982, MOL CLONING; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; ROBER RA, 1990, J CELL SCI, V95, P587; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SMITH HC, 1987, MOL CELL BIOCHEM, V77, P49; STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9; STICK R, 1980, CHROMOSOMA, V80, P219, DOI 10.1007/BF00286301; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STUURMAN N, 1989, EXP CELL RES, V180, P460, DOI 10.1016/0014-4827(89)90072-4; VANDRIEL R, 1991, J CELL BIOCHEM, V47, P311, DOI 10.1002/jcb.240470405; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WEBER K, 1990, FEBS LETT, V261, P361, DOI 10.1016/0014-5793(90)80592-7; XU M, 1989, J BIOL CHEM, V264, P21190; YUAN J, 1991, J BIOL CHEM, V266, P9211; ZINI N, 1989, HISTOCHEMISTRY, V91, P199, DOI 10.1007/BF00490133	64	313	321	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					949	959		10.1016/0092-8674(92)90245-8	http://dx.doi.org/10.1016/0092-8674(92)90245-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525831				2022-12-28	WOS:A1992JN78100010
J	AMIGORENA, S; BONNEROT, C; DRAKE, JR; CHOQUET, D; HUNZIKER, W; GUILLET, JG; WEBSTER, P; SAUTES, C; MELLMAN, I; FRIDMAN, WH				AMIGORENA, S; BONNEROT, C; DRAKE, JR; CHOQUET, D; HUNZIKER, W; GUILLET, JG; WEBSTER, P; SAUTES, C; MELLMAN, I; FRIDMAN, WH			CYTOPLASMIC DOMAIN HETEROGENEITY AND FUNCTIONS OF IGG FC-RECEPTORS IN LYMPHOCYTES-B	SCIENCE			English	Article							REPRESSOR CI PROTEIN; N-TERMINAL DOMAIN; LAMBDA-REPRESSOR; MONOCLONAL-ANTIBODIES; DIFFERENT HAPLOTYPES; IA MOLECULES; T RESPONSE; ANTIGEN; IMMUNOGLOBULIN; CELLS	B lymphocytes and macrophages express closely related immunoglobulin G (IgG) Fc receptors (Fc-gamma-RII) that differ only in the structures of their cytoplasmic domains. Because of cell type-specific alternative messenger RNA splicing, B-cell Fc-gamma-RII contains an insertion of 47 amino acids that participates in determining receptor function in these cells. Transfection of an Fc-gamma-RII-negative B-cell line with complementary DNA's encoding the two splice products and various receptor mutants indicated that the insertion was responsible for preventing both Fc-gamma-RII-mediated endocytosis and Fc-gamma-RII-mediated antigen presentation. The insertion was not required for Fc-gamma-RII to modulate surface immunoglobulin-triggered B-cell activation. Instead, regulation of activation involved a region of the cytoplasmic domain common to both the lymphocyte and macrophage receptor isoforms. In contrast, the insertion did contribute to the formation of caps in response to receptor cross-linking, consistent with suggestions that the lymphocyte but not macrophage form of the receptor can associate with the detergent-insoluble cytoskeleton.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; INST CURIE,INSERM,U255,IMMUNOL CELLULAIRE & CLIN LAB,F-75005 PARIS,FRANCE; INST PASTEUR,INSERM,NEUROBIOL CELLULAIRE LAB,U261,F-75724 PARIS 15,FRANCE; INST COCHIN GENET MOLEC,INTERACT PROT LAB,URA 228,F-75014 PARIS,FRANCE	Yale University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Choquet, Daniel/E-4203-2013; Choquet, Daniel/GOJ-8825-2022; Mellman, Ira/ABG-5896-2020; Hunziker, Walter/B-3140-2010; Hunziker, Walter/GSM-8190-2022; Choquet, Daniel/K-7893-2018	Choquet, Daniel/0000-0003-4726-9763; Hunziker, Walter/0000-0002-5265-4933; Choquet, Daniel/0000-0003-4726-9763; sautes-fridman, catherine/0000-0003-1735-8722; fridman, wolf herman/0000-0002-1332-0973; Webster, Paul/0000-0002-1980-6931; Amigorena, Sebastian/0000-0001-8583-8416				AMIGORENA S, 1989, EUR J IMMUNOL, V19, P1379, DOI 10.1002/eji.1830190805; BREYER RM, 1989, J BIOL CHEM, V264, P13348; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; DICKLER HB, 1981, J EXP MED, V153, P1329, DOI 10.1084/jem.153.5.1329; DRAKE JR, 1989, J IMMUNOL, V143, P1768; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIBBS ML, 1986, P NATL ACAD SCI USA, V83, P6980, DOI 10.1073/pnas.83.18.6980; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; JONES B, 1986, J IMMUNOL, V136, P348; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; KLAUS GGB, 1987, IMMUNOL REV, V99, P19, DOI 10.1111/j.1600-065X.1987.tb01170.x; LAI MZ, 1987, J IMMUNOL, V139, P3973; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LEWIS VA, 1986, NATURE, V324, P372, DOI 10.1038/324372a0; MANCA F, 1991, J EXP MED, V173, P37, DOI 10.1084/jem.173.1.37; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; Mellman I, 1990, Semin Immunol, V2, P229; MELLMAN I, 1988, CURR OPIN IMMUNOL, V1, P16, DOI 10.1016/0952-7915(88)90046-5; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; ROOSNEK E, 1991, J EXP MED, V173, P487, DOI 10.1084/jem.173.2.487; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; WILSON HA, 1989, J IMMUNOL, V138, P1712	33	413	438	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1808	1812		10.1126/science.1535455	http://dx.doi.org/10.1126/science.1535455			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1535455				2022-12-28	WOS:A1992JA43400033
J	POLLENZ, RS; CHEN, TLL; TRIVINOSLAGOS, L; CHISHOLM, RL				POLLENZ, RS; CHEN, TLL; TRIVINOSLAGOS, L; CHISHOLM, RL			THE DICTYOSTELIUM ESSENTIAL LIGHT CHAIN IS REQUIRED FOR MYOSIN FUNCTION	CELL			English	Article							SMOOTH-MUSCLE MYOSIN; HEAVY-CHAIN; SCALLOP MYOSIN; HOMOLOGOUS RECOMBINATION; ACANTHAMOEBA MYOSIN; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; THICK FILAMENTS; ANTISENSE RNA; BINDING-SITES	A Dictyostelium mutant (7-11) that expresses less than 0.5% of wild-type levels of the myosin essential light chain (EMLC) has been created by overexpression of antisense RNA. Cells from 7-11 contain wild-type levels of the myosin heavy chain (MHC) and regulatory light chain (RMLC). Myosin isolated from 7-11 cells consists of the MHC with the RMLC associated in reduced stoichiometry, and binds to purified actin in an ATP-sensitive fashion. Purified 7-11 myosin displays calcium-activated ATPase activity with a V(max) about 15%-25% of that of wild type, and a K(m) for ATP of 27 +/- 5-mu-M versus 83 +/- 30-mu-M for wild type. At actin concentrations as high as 17-mu-M, 7-11 myosin displays greatly reduced actin-activated ATPase activity. Phenotypically, 7-11 cells resemble MHC mutants, growing poorly in suspension and becoming large and multinucleate. When starved for multicellular development, 7-11 cells take several hours longer than wild-type cells to aggregate. Although multicellular aggregates eventually form, they fail to develop further. The cells are also unable to cap receptors in response to Con A treatment. Since cells expressing the EMLC are phenotypically similar to MHC null mutants, the EMLC appears necessary for myosin function, at least in part because it is required for normal actin-activated ATPase activity.			POLLENZ, RS (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,CHICAGO,IL 60611, USA.		Chisholm, Rex L/B-3418-2009	Chisholm, Rex L/0000-0002-5638-3990	NIGMS NIH HHS [GM39264] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039264] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BEALL CJ, 1989, GENE DEV, V3, P131, DOI 10.1101/gad.3.2.131; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; CHISHOLM RL, 1988, MOL CELL BIOL, V8, P794, DOI 10.1128/MCB.8.2.794; CLARKE M, 1974, J MOL BIOL, V86, P209, DOI 10.1016/0022-2836(74)90013-8; COLLINS JH, 1980, J BIOL CHEM, V255, P8011; CROWLEY TE, 1985, CELL, V43, P633, DOI 10.1016/0092-8674(85)90235-1; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DELOZANNE A, 1987, J CELL BIOL, V105, P2999, DOI 10.1083/jcb.105.6.2999; DREIZEN P, 1970, BIOCHEMISTRY-US, V9, P1688, DOI 10.1021/bi00810a006; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; FREDERIKSEN DW, 1968, BIOCHEMISTRY-US, V7, P3935, DOI 10.1021/bi00851a022; FUJIWARA K, 1976, J CELL BIOL, V71, P848, DOI 10.1083/jcb.71.3.848; FUKUI Y, 1991, CELL MOTIL CYTOSKEL, V18, P41, DOI 10.1002/cm.970180105; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; FUKUI Y, 1987, METHOD CELL BIOL, P347; GERSHMAN LC, 1970, BIOCHEMISTRY-US, V9, P1677, DOI 10.1021/bi00810a005; GERSHMAN LC, 1969, J MOL BIOL, V44, P2726; GOODWIN EB, 1990, J MOL BIOL, V216, P85, DOI 10.1016/S0022-2836(05)80062-2; GRIFFITH LM, 1987, J CELL BIOL, V104, P1309, DOI 10.1083/jcb.104.5.1309; HARDWICKE PMD, 1983, NATURE, V301, P478, DOI 10.1038/301478a0; HARDWICKE PMD, 1982, J MOL BIOL, V156, P141, DOI 10.1016/0022-2836(82)90463-6; HASEGAWA Y, 1990, J BIOCHEM-TOKYO, V108, P909, DOI 10.1093/oxfordjournals.jbchem.a123313; HOPKINSON SB, 1989, MOL CELL BIOL, V9, P4170, DOI 10.1128/MCB.9.10.4170; HUXLEY HE, 1963, J MOL BIOL, V7, P281, DOI 10.1016/S0022-2836(63)80008-X; IZANT JG, 1989, CELL MOTIL CYTOSKEL, V14, P81, DOI 10.1002/cm.970140117; JACKSON AP, 1986, FEBS LETT, V197, P154, DOI 10.1016/0014-5793(86)80317-9; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; KIEHART DP, 1984, J CELL BIOL, V99, P1024, DOI 10.1083/jcb.99.3.1024; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; KULESH DA, 1989, MOL CELL BIOL, V9, P1553, DOI 10.1128/MCB.9.4.1553; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MCNALLY EM, 1991, J CELL BIOL, V113, P585, DOI 10.1083/jcb.113.3.585; MITCHELL EJ, 1989, J MOL BIOL, V208, P199, DOI 10.1016/0022-2836(89)90096-X; MITCHELL EJ, 1986, EUR J BIOCHEM, V161, P25, DOI 10.1111/j.1432-1033.1986.tb10120.x; NACHMIAS VT, 1989, CELL MOTIL CYTOSKEL, V13, P158, DOI 10.1002/cm.970130304; OHALLORAN TJ, 1990, J CELL BIOL, V110, P63, DOI 10.1083/jcb.110.1.63; OKAMOTO Y, 1980, J BIOCHEM-TOKYO, V87, P167, DOI 10.1093/oxfordjournals.jbchem.a132722; OKAMOTO Y, 1986, NATURE, V324, P78, DOI 10.1038/324078a0; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLENZ RS, 1991, CELL MOTIL CYTOSKEL, V20, P83, DOI 10.1002/cm.970200202; REES DD, 1981, J BIOL CHEM, V256, P357; REINES D, 1985, J BIOL CHEM, V260, P4248; SELLERS JR, 1984, J BIOL CHEM, V259, P4203; SELLERS JR, 1980, J MOL BIOL, V144, P223, DOI 10.1016/0022-2836(80)90088-1; SIVARAMAKRISHNAN M, 1982, J BIOL CHEM, V257, P1102; SPUDICH JA, 1989, CELL REGUL, V1, P1; STAFFORD WF, 1979, BIOCHEMISTRY-US, V18, P5273, DOI 10.1021/bi00591a002; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SZENTKIRALYI EM, 1984, J MUSCLE RES CELL M, V5, P147, DOI 10.1007/BF00712153; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; Taylor D L, 1979, Int Rev Cytol, V56, P57, DOI 10.1016/S0074-7696(08)61821-5; TOKUNAGA M, 1987, J MOL BIOL, V194, P245, DOI 10.1016/0022-2836(87)90372-X; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; VARNUM B, 1984, J CELL BIOL, V99, P1151, DOI 10.1083/jcb.99.3.1151; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WAGNER PD, 1981, NATURE, V292, P560, DOI 10.1038/292560a0; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WEEDS AG, 1971, J MOL BIOL, V61, P701, DOI 10.1016/0022-2836(71)90074-X; WEEDS AG, 1967, BIOCHEM J, V105, pC25, DOI 10.1042/bj1050025C; WEEDS AG, 1969, NATURE, V322, P1362; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WITKE W, 1987, EMBO J, V6, P4143, DOI 10.1002/j.1460-2075.1987.tb02760.x; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0; YUMURA S, 1984, J CELL BIOL, V99, P894, DOI 10.1083/jcb.99.3.894	80	68	68	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					951	962		10.1016/0092-8674(92)90614-I	http://dx.doi.org/10.1016/0092-8674(92)90614-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1535025				2022-12-28	WOS:A1992HY79200007
J	FLYNN, JT; BANCALARI, E; SNYDER, ES; GOLDBERG, RN; FEUER, W; CASSADY, J; SCHIFFMAN, J; FELDMAN, HI; BACHYNSKI, B; BUCKLEY, E; ROBERTS, J; GILLINGS, D				FLYNN, JT; BANCALARI, E; SNYDER, ES; GOLDBERG, RN; FEUER, W; CASSADY, J; SCHIFFMAN, J; FELDMAN, HI; BACHYNSKI, B; BUCKLEY, E; ROBERTS, J; GILLINGS, D			A COHORT STUDY OF TRANSCUTANEOUS OXYGEN-TENSION AND THE INCIDENCE AND SEVERITY OF RETINOPATHY OF PREMATURITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RETROLENTAL-FIBROPLASIA	Background. Retinopathy of prematurity is a disease affecting the blood vessels of the retina in premature infants that may result in scarring, retinal detachment, and loss of vision. An association between this condition and the exposure of premature infants to supplemental oxygen has been postulated, but the relation between retinopathy of prematurity and blood oxygen levels has not been defined. The purpose of this study of a cohort of preterm infants was to correlate the incidence and severity of retinopathy of prematurity with the duration of exposure to different ranges of oxygen tension as measured by transcutaneous monitoring (tcPO2). Methods. One hundred one premature infants (birth weight, 500 to 1300 g) requiring supplemental oxygen had continuous monitoring of tcPO2. The number of hours during which the tCPO2 was 80 mm Hg or higher was tabulated for each infant during the first four weeks of life. Results. There was a significant association between the amount of time that the tCPO2 was greater-than-or-equal-to 80 mm Hg and the incidence and severity of retinopathy of prematurity. The odds ratio for each 12-hour period in which the tcPO2 was greater-than-or-equal-to 80 mm Hg was 1.9 (95 percent confidence interval, 1.2 to 3.0) after adjustment for the following factors: birth weight less-than-or-equal-to 1300 g (odds ratio, 2.3 [95 percent confidence interval, 1.6 to 3.4]), five-minute Apgar score of 7 or less (odds ratio, 7.2 [95 percent confidence interval, 2.5 to 21]), and exposure to inspired oxygen at a fractional concentration greater-than-or-equal-to 0.4 (odds ratio, 1.0 [95 percent confidence interval, 0.97 to 1.05]). The association was stronger for tcPO2 values of greater-than-or-equal-to 80 mm Hg occurring from the second through the fourth week of life; during this period, the adjusted odds ratio for a 12-hour period of such exposure was 3.1 (95 percent confidence interval, 1.6 to 6.1). Conclusions. This study supports an association between the incidence and severity of retinopathy of prematurity and the duration of exposure to arterial oxygen levels of 80 mm Hg or higher, measured transcutaneously.	UNIV MIAMI,SCH MED,DEPT PEDIAT,DIV NEONATOL,MIAMI,FL 33152; UNIV PENN,SCH MED,CLIN EPIDEMIOL UNIT,PHILADELPHIA,PA 19104; UNIV N CAROLINA,SCH MED,SCH PUBL HLTH,DEPT BIOSTAT,CHAPEL HILL,NC 27514	University of Miami; University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	FLYNN, JT (corresponding author), BASCOM PALMER EYE INST,DEPT OPHTHALMOL,POB 016880,MIAMI,FL 33101, USA.				NATIONAL EYE INSTITUTE [P30EY002180, R01EY003513] Funding Source: NIH RePORTER; NEI NIH HHS [R01-EY03513, 3P0 EY 02180] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGRESTI A, 1984, ANAL ORDINAL CATEGOR, P104; BANCALARI E, 1987, PEDIATRICS, V79, P663; Flynn J T, 1983, Trans Am Ophthalmol Soc, V81, P549; FLYNN JT, 1987, OPHTHALMOLOGY, V94, P620; FLYNN JT, 1987, OPHTHALMOLOGY, V94, P630; FLYNN JT, 1977, ARCH OPHTHALMOL-CHIC, V95, P217, DOI 10.1001/archopht.1977.04450020019002; FLYNN JT, 1975, A GRAEF ARCH KLIN EX, V195, P101, DOI 10.1007/BF00417113; FLYNN JT, 1981, RETINOPATHY PREMATUR, P247; GIBSON DL, 1990, PEDIATRICS, V86, P405; KINSEY VE, 1977, PEDIATRICS, V60, P655; KINSEY VE, 1956, ARCH OPHTHALMOL-CHIC, V56, P481, DOI 10.1001/archopht.1956.00930040489001; KUSHNER BJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P29, DOI 10.1001/archopht.1977.04450010031002; LANMAN JT, 1954, JAMA-J AM MED ASSOC, V155, P223, DOI 10.1001/jama.1954.03690210001001; LUCEY JF, 1984, PEDIATRICS, V73, P82; McCullagh P, 1989, GEN LINEAR MODELS, P151; PATZ A, 1952, AM J OPHTHALMOL, V35, P1248, DOI 10.1016/0002-9394(52)91140-9; QUINN GE, 1982, AM J OPHTHALMOL, V94, P744, DOI 10.1016/0002-9394(82)90298-7; REESE AB, 1953, AM J OPHTHALMOL, V36, P1333; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P227; Tanabe Y, 1972, Nippon Ganka Gakkai Zasshi, V76, P260; UEMURA Y, 1977, JPN J OPHTHALMOL, V21, P366; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; YU VYH, 1982, ARCH DIS CHILD, V57, P247, DOI 10.1136/adc.57.4.247; 1987, ARCH OPHTHALMOL-CHIC, V105, P1498; 1988, GUIDELINES PERINATAL, P246; 1984, ARCH OPHTHALMOL-CHIC, V102, P1130	26	198	210	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1992	326	16					1050	1054		10.1056/NEJM199204163261603	http://dx.doi.org/10.1056/NEJM199204163261603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN738	1549150				2022-12-28	WOS:A1992HN73800003
J	EDDY, DM				EDDY, DM			COST-EFFECTIVENESS ANALYSIS - A CONVERSATION WITH MY FATHER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									DUKE UNIV,DURHAM,NC 27706	Duke University								EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2135, DOI 10.1001/jama.266.15.2135; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1161, DOI 10.1001/jama.264.9.1161; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P417, DOI 10.1001/jama.266.3.417; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2439, DOI 10.1001/jama.266.17.2439; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218	5	75	75	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1669	&		10.1001/jama.267.12.1669	http://dx.doi.org/10.1001/jama.267.12.1669			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1542179				2022-12-28	WOS:A1992HJ59700038
J	KAN, YW				KAN, YW			DEVELOPMENT OF DNA ANALYSIS FOR HUMAN-DISEASES - SICKLE-CELL-ANEMIA AND THALASSEMIA AS A PARADIGM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BETA-GLOBIN GENE; PRENATAL-DIAGNOSIS; ALPHA-THALASSEMIA; VARIANT GENE; SEVERE FORM; EVOLUTION; MUTATIONS; HYBRIDIZATION; POLYMORPHISMS; AMPLIFICATION		UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	KAN, YW (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT LAB MED, HOWARD HUGHES MED INST LAB, SAN FRANCISCO, CA 94143 USA.				NIDDK NIH HHS [DK16666] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016666, R37DK016666] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER BP, 1976, NEW ENGL J MED, V294, P1040, DOI 10.1056/NEJM197605062941906; ANTONARAKIS SE, 1982, P NATL ACAD SCI-BIOL, V79, P137, DOI 10.1073/pnas.79.1.137; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BEAUDRY MA, 1986, J PEDIATR-US, V108, P713, DOI 10.1016/S0022-3476(86)81048-4; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CAI SP, 1989, BLOOD, V73, P372; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CAO A, 1990, ANN NY ACAD SCI, V612, P215; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Chang J C, 1982, Trans Assoc Am Physicians, V95, P71; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; CULVER KW, 1991, HUM GENE THER, V2, P107, DOI 10.1089/hum.1991.2.2-107; DOZY AM, 1979, NATURE, V280, P605, DOI 10.1038/280605a0; ENG LIL, 1960, BRIT MED J, V2, P1649, DOI 10.1136/bmj.2.5213.1649; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HILL AVS, 1985, AM J HUM GENET, V37, P571; KAN YW, 1978, LANCET, V2, P910; KAN YW, 1976, NEW ENGL J MED, V295, P1165, DOI 10.1056/NEJM197611182952104; KAN YW, 1980, SCIENCE, V209, P388, DOI 10.1126/science.7384810; KAN YW, 1976, NEW ENGL J MED, V294, P1039, DOI 10.1056/NEJM197605062941905; KAN YW, 1981, HARVEY LECT, V76, P75; KAN YW, 1975, NEW ENGL J MED, V292, P1096, DOI 10.1056/NEJM197505222922104; KAZAZIAN HH, 1990, SEMIN HEMATOL, V27, P209; KURNIT DM, 1979, LANCET, V1, P104; LEVIN RM, 1980, CELL, V21, P647; LOUKOPOULOS D, 1990, ANN NY ACAD SCI, V612, P226; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NAGEL RL, 1990, SEMIN HEMATOL, V27, P342; OKANO Y, 1991, NEW ENGL J MED, V324, P1232, DOI 10.1056/NEJM199105023241802; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; OTTOLENGHI S, 1974, NATURE, V251, P389, DOI 10.1038/251389a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; RUBIN EM, 1991, J CLIN INVEST, V87, P639, DOI 10.1172/JCI115041; RYAN TM, 1991, SCIENCE, V88, P4294; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SOLOMON E, 1979, LANCET, V1, P923; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAYLOR JM, 1974, NATURE, V251, P392, DOI 10.1038/251392a0; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; WAIKAN Y, 1978, P NATL ACAD SCI USA, V75, P5631, DOI 10.1073/pnas.75.11.5631; WASI P, 1970, Journal of the Medical Association of Thailand, V53, P677	43	11	12	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1532	1536		10.1001/jama.267.11.1532	http://dx.doi.org/10.1001/jama.267.11.1532			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1538544				2022-12-28	WOS:A1992HH48800037
J	OBRIEN, T; KELLY, M; SAUNDERS, C				OBRIEN, T; KELLY, M; SAUNDERS, C			MOTOR-NEURON DISEASE - A HOSPICE PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article								Objective - To describe and evaluate the management of patients with motor neurone disease from the perspective of a hospice. Design - Retrospective analysis of hospice medical and nursing notes. Setting - Established 62 bed teaching and research hospice. Subjects - 124 patients with motor neurone disease cared for by the hospice between january 1980 and November 1990. Main outcome measures - Patient profile; functional status; symptom control and use of opioids; insight; mode and management of death. Results - 124 patients (67 women, 57 men) had a mean age 63.9 years. The median length of admission was 61.5 days (range 1 to 2147). 84 patients (68%) were aware of their diagnosis and its implications when first seen by a hospice doctor. Functionally, the patients were very dependent. Symptoms such as pain, dyspnoea, and insomnia were major problems that responded well to opioids. Many patients were noted to deteriorate "suddenly," and in 58% of cases death occurred within 24 hours of this deterioration. When dying, 106 patients (94%) were peaceful and settled. 101 patients (89%) received opioids during this dying period. No patient choked to death. Conclusions - Although motor neurone disease is an uncommon disorder, many of its symptoms occur commonly in medical practice and must be actively treated. Opioids are both safe and effective for such treatment. The term choking is both inaccurate and inappropriate in describing the cause of death in motor neurone disease and its use should be abandoned.	ST CHRISTOPHERS HOSPICE,LONDON SE26 6DZ,ENGLAND									COCHRANE GM, 1987, MANAGEMENT MOTOR NEU; GAWEL MJ, 1989, CLIN REHABILITATION, V3, P309; Hillel A D, 1987, Adv Exp Med Biol, V209, P201; HOWARD RS, 1989, BRAIN, V112, P1155, DOI 10.1093/brain/112.5.1155; KONDO K, 1984, RES PROGR MOTOR NEUR, P20; Mulder D W, 1987, Adv Exp Med Biol, V209, P325; MULDER DW, 1976, MAYO CLIN PROC, V51, P537; NEWRICK PG, 1984, BRIT MED J, V289, P539, DOI 10.1136/bmj.289.6444.539; NEWRICK PG, 1985, J NEUROL NEUROSUR PS, V48, P838, DOI 10.1136/jnnp.48.8.838; Norris F H, 1989, Rinsho Shinkeigaku, V29, P1485; NORRIS FH, 1985, BRIT MED J, V291, P259, DOI 10.1136/bmj.291.6490.259; OLIVER D, 1989, MOTOR NEURONE DISEAS; Rose F C, 1987, Adv Exp Med Biol, V209, P167; ROSIN A J, 1976, Age and Ageing, V5, P37, DOI 10.1093/ageing/5.1.37; ROWLAND LP, 1980, DIAGNOSIS TREATMENT, P7; Saunders C., 1981, HOSPICE LIVING IDEA, P126; Schiffer D, 1987, Adv Exp Med Biol, V209, P255; SMITH RA, 1980, DIAGNOSIS TREATMENT, P241; 1989, CHURCHILLS MED DICT; 1986, CANCER PAIN RELIEF	20	101	102	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					471	473		10.1136/bmj.304.6825.471	http://dx.doi.org/10.1136/bmj.304.6825.471			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547416	Green Published, Bronze			2022-12-28	WOS:A1992HF55500019
J	HUNTER, DJ				HUNTER, DJ			LEADING FOR HEALTH - RESPONSES .3. ACCOUNTABILITY AND THE NHS	BRITISH MEDICAL JOURNAL			English	Article											HUNTER, DJ (corresponding author), UNIV LEEDS,NUFFIELD INST HLTH SERV STUDIES,LEEDS LS2 9PL,ENGLAND.							[Anonymous], 1979, CMND7615; [Anonymous], 1972, MANAGEMENT ARRANGEME; [Anonymous], 1988, IMPROVING MANAGEMENT; [Anonymous], 1989, CM555; HARRISON S, 1991, HLTH HLTH CARE; HUNTER DJ, 1984, SOC POLICY ADMIN, V18, P41, DOI 10.1111/j.1467-9515.1984.tb00196.x; NAIRNE P, 1985, BRIT MED J, V291, P121, DOI 10.1136/bmj.291.6488.121; Nairne P, 1983, POLITICAL Q, V54, P243; OWEN D, 1979, REFLECTIONS ROYAL CO; REGAN DE, 1982, SOC POLICY ADMIN, V16, P19, DOI 10.1111/j.1467-9515.1982.tb00158.x; Stowe Kenneth, 1989, CARING NATL HLTH, P44; 1983, NHS MANAGEMENT INQUI; 1979, PATIENTS 1ST; 1991, LEADING HLTH BMA AGE; 1991, ORG MANAGEMENT DEP H; 1991, LOCAL GOVT NHS TIME; 1991, 32ND COMM PUBL REP; 1987, ACCOUNTABILITIES	18	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1992	304	6824					436	438		10.1136/bmj.304.6824.436	http://dx.doi.org/10.1136/bmj.304.6824.436			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HE389	1547395	Bronze, Green Published			2022-12-28	WOS:A1992HE38900027
J	ARMSTRONG, AM; MOLYNEUX, E				ARMSTRONG, AM; MOLYNEUX, E			GLASS INJURIES TO CHILDREN	BRITISH MEDICAL JOURNAL			English	Article									ROYAL LIVERPOOL CHILDRENS HOSP,DEPT ACCIDENT & EMERGENCY,LIVERPOOL L12 2AP,ENGLAND	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital								BAKER MD, 1990, AM J DIS CHILD, V144, P87, DOI 10.1001/archpedi.1990.02150250097042; BELL D, 1984, ARCH DIS CHILD, V59, P672, DOI 10.1136/adc.59.7.672; HAYES M, 1991, CHILD SAFETY REV, P4	3	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					360	360		10.1136/bmj.304.6823.360	http://dx.doi.org/10.1136/bmj.304.6823.360			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540735	Bronze, Green Published			2022-12-28	WOS:A1992HD38700026
J	LAUER, MS; LEVY, D; ANDERSON, KM; PLEHN, JF				LAUER, MS; LEVY, D; ANDERSON, KM; PLEHN, JF			IS THERE A RELATIONSHIP BETWEEN EXERCISE SYSTOLIC BLOOD-PRESSURE RESPONSE AND LEFT-VENTRICULAR MASS - THE FRAMINGHAM HEART-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						BLOOD PRESSURE; EXERCISE TEST; ECHOCARDIOGRAPHY; HEART ENLARGEMENT; VENTRICULAR FUNCTION, LEFT	RISK-FACTORS; HYPERTROPHY; DISEASE; ECHOCARDIOGRAPHY; HYPERTENSION; SIZE; AGE; MEN	Objective: To assess the association between an exaggerated exercise systolic blood pressure response and the occurrence of left ventricular hypertrophy in healthy, normotensive individuals. Design: Cross-sectional survey using M-mode echocardiography to measure left ventricular mass and to detect left ventricular hypertrophy. Setting: The Framingham Heart Study. Subjects: Eight-hundred sixty men and 1118 women were studied who were free of cardiovascular or pulmonary disease, who were not taking any antihypertensive or cardiovascular medications, and who successfully achieved at least 90% of their age-predicted maximum heart rate during a monitored exercise treadmill test. All subjects had normal baseline and exercise electrocardiograms. Measurements and Main Results: Men with a peak exercise systolic blood pressure of 210 or more and women with a peak exercise systolic blood pressure of 190 or more were considered to have an "exaggerated" blood pressure response; 122 men and 67 women met these criteria. Subjects with an exaggerated exercise systolic blood pressure response had 10% higher left ventricular mass than those with a normal exercise systolic blood pressure response (in men: 115 +/- 25 compared with 105 +/- 24 g/m, P < 0.001; in women: 86 +/- 22 compared with 73 +/- 16 g/m, P < 0.001); they also had a higher prevalence of left ventricular hypertrophy (in men: odds ratio, 1.34, 95% Cl, 1.00 to 1.80; in women: odds ratio, 2.12, Cl, 1.48 to 3.03). After adjusting for age, resting systolic blood pressure, and body mass index, however, subjects with an exaggerated exercise systolic blood pressure response had only 5% higher left ventricular mass (in men: 111 +/- 2.1 compared with 106 +/- 0.8 g/m, P = 0.02; in women: 80 +/- 1.8 compared with 74 +/- 0.4 g/m, P = 0.002), and they no longer had a statistically increased prevalence of left ventricular hypertrophy (in men: odds ratio, 1.21, Cl, 0.87 to 1.67; in women: odds ratio, 1.30, Cl, 0.84 to 2.01). Conclusions: The apparent relation between exercise systolic blood pressure response and left ventricular mass is confounded by age, resting systolic blood pressure, and body mass; the degree of confounding is such that the biologic significance of this relationship should be questioned.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Framingham Heart Study; Harvard University; Beth Israel Deaconess Medical Center			Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021; Lauer, Michael S/L-9656-2013	Levy, Daniel/0000-0003-1843-8724; Lauer, Michael S/0000-0002-9217-8177	NHLBI NIH HHS [HL07374, N01-HC-38038] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRUCE RA, 1973, AM HEART J, V85, P546, DOI 10.1016/0002-8703(73)90502-4; DANNENBERG AL, 1989, AM J CARDIOL, V64, P1066, DOI 10.1016/0002-9149(89)90816-3; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1990, ANN INTERN MED, V112, P157, DOI 10.7326/0003-4819-112-3-157; DLIN RA, 1983, AM HEART J, V106, P316, DOI 10.1016/0002-8703(83)90198-9; DOUGLAS PS, 1986, AM J CARDIOL, V58, P805, DOI 10.1016/0002-9149(86)90358-9; ELLESTAD MH, 1986, STRESS TESTING PRINC, P472; FAGARD R, 1991, HYPERTENSION, V17, P574, DOI 10.1161/01.HYP.17.4.574; FEIGENBAUM H, 1981, ECHOCARDIOGR-J CARD, P51; GARDIN JM, 1987, HYPERTENSION, V9, P36; GOTTDIENER JS, 1990, ANN INTERN MED, V112, P161, DOI 10.7326/0003-4819-112-3-161; HAMMOND IW, 1986, J AM COLL CARDIOL, V7, P639, DOI 10.1016/S0735-1097(86)80476-4; Kannel W B, 1978, Ann N Y Acad Sci, V304, P128, DOI 10.1111/j.1749-6632.1978.tb25585.x; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; REN JF, 1985, J AM COLL CARDIOL, V5, P1224, DOI 10.1016/S0735-1097(85)80029-2; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SAVAGE DD, 1990, AM J CARDIOL, V65, P371, DOI 10.1016/0002-9149(90)90304-J; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SAVAGE DD, 1987, HYPERTENSION, V9, P40; SHEFFIELD LT, 1988, HEART DISEASE TXB CA, P237; SHEFFIELD LT, 1988, HEART DISEASE TXB CA, P227; VANDENBOSSCHE JL, 1984, J AM COLL CARDIOL, V4, P1195, DOI 10.1016/S0735-1097(84)80138-2; WILSON NV, 1981, PREV MED, V10, P62, DOI 10.1016/0091-7435(81)90006-2	31	145	154	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					203	210		10.7326/0003-4819-116-3-203	http://dx.doi.org/10.7326/0003-4819-116-3-203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1530806				2022-12-28	WOS:A1992HB35600005
J	SHAH, P; DHURJON, L; METCALFE, T; GIBSON, JM				SHAH, P; DHURJON, L; METCALFE, T; GIBSON, JM			LESSON OF THE WEEK - ACUTE ANGLE CLOSURE GLAUCOMA ASSOCIATED WITH NEBULIZED IPRATROPIUM BROMIDE AND SALBUTAMOL	BRITISH MEDICAL JOURNAL			English	Article									E BIRMINGHAM DIST GEN HOSP,DEPT OPHTHALMOL,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND; GEN INFIRM,DEPT OPHTHALMOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary				Gibson, Jonathan M/0000-0002-9281-5244				GRAY RH, 1990, HOSPITAL UPDATE, V16, P446; KALRA L, 1988, CHEST, V93, P739, DOI 10.1378/chest.93.4.739; MALANI JT, 1982, NEW ZEAL MED J, V95, P749; PACKE GE, 1984, LANCET, V2, P691	4	35	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					40	41		10.1136/bmj.304.6818.40	http://dx.doi.org/10.1136/bmj.304.6818.40			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1531182	Bronze, Green Published			2022-12-28	WOS:A1992GY90900035
J	BERO, LA; GALBRAITH, A; RENNIE, D				BERO, LA; GALBRAITH, A; RENNIE, D			THE PUBLICATION OF SPONSORED SYMPOSIUMS IN MEDICAL JOURNALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROMOTION	Background. An increasing proportion of spending by the pharmaceutical industry has gone to funding symposiums that are published by peer-reviewed medical journals. This study tests the hypothesis that such sponsorship, particularly by a single pharmaceutical company, is associated with a promotional orientation of the symposium and a distortion of the peer-review process. Methods. We counted the symposiums published in 58 journals of clinical medicine and surveyed the journal editors regarding their policies for symposium issues. We analyzed the symposium issues that appeared in the 11 journals that published the most symposiums in order to determine the sponsor or sponsors, the topics, whether the titles were misleading, whether brand names were used, and whether the featured drugs were classified by the Food and Drug Administration as innovative or approved. Results. The number of symposiums published per year increased steadily from 1966 through 1989. Forty-two percent of those analyzed (262 of 625) had a single pharmaceutical company as the sponsor. These symposiums were more likely than those with other sponsors to have misleading titles (P<0.001) and to.use brand names (P<0.001), and less likely to be peer-reviewed in the same manner as other articles in the parent journal (P<0.001). Of the 161 symposiums that focused on a single drug, 51 percent concerned unapproved therapies; 14 percent concerned drugs classified as bringing important therapeutic gains. Conclusions. Symposiums sponsored by drug companies often have promotional attributes and are not peer-reviewed. Financial relations among symposium participants, sponsors, and journals should be completely disclosed, symposiums should be clearly identified, and journal editors should maintain editorial control over contributions from symposiums.	JOURNAL AMER MED ASSOC,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,SCH PHARM,DIV CLIN PHARM,SAN FRANCISCO,CA 94143	American Medical Association; University of California System; University of California San Francisco	BERO, LA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,1388 SUTTER ST,11TH FL,SAN FRANCISCO,CA 94109, USA.							AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; BENNETT JC, 1989, AM J MED, V86, P1; BENNETT JC, 1987, AM J MED, V83, P812, DOI 10.1016/0002-9343(87)90933-8; BILLUPS NF, 1987, AM DRUG INDEX 1987; BOWMAN MA, 1986, MOBIUS, V6, P66; COHN JN, 1982, CIRCULATION, V65, P839, DOI 10.1161/01.CIR.65.5.839; DYER C, 1987, BRIT MED J, V294, P426, DOI 10.1136/bmj.294.6569.426; FINCH KT, 1989, AM J MED, V86, pA25; FINUCANE T, 1987, AM J MED, V83, P811, DOI 10.1016/0002-9343(87)90932-6; FREEMAN HL, 1989, BR J PSYCHIATRY S6, V155, P6; HEMMINKI E, 1975, SOC SCI MED, V9, P111, DOI 10.1016/0037-7856(75)90103-1; KESSLER DA, 1991, NEW ENGL J MED, V325, P201, DOI 10.1056/NEJM199107183250310; KESSLER DA, 1990, JAMA-J AM MED ASSOC, V264, P2409, DOI 10.1001/jama.264.18.2409; LEXCHIN J, 1987, INT J HEALTH SERV, V17, P77, DOI 10.2190/4W1H-E70T-TL9X-VGGC; MACKOWIAK JI, 1985, SOC SCI MED, V20, P1191, DOI 10.1016/0277-9536(85)90197-2; MOULDS RFW, 1987, MED J AUSTRALIA, V146, P660, DOI 10.5694/j.1326-5377.1987.tb120460.x; MUSHER DM, 1988, AM J MED, V85, P596; PHILLIPS I, 1983, J ANTIMICROB CHEMOTH, V12, P199, DOI 10.1093/jac/12.3.199; RENNIE D, 1990, CBE VIEWS, V13, P31; ROBERTS WC, 1987, CARDIOLOGY, V74, P254, DOI 10.1159/000174210; SPELLER DCE, 1987, J ANTIMICROB CHEMOTH, V19, P711, DOI 10.1093/jac/19.6.711; WADE VA, 1989, LANCET, V2, P1261; WICKHAM W, 1987, MED J AUSTRALIA, V147, P160; 1987, AM J MED S5A, V82, P1; 1991, DRUG CO SUPPORTED AC; 1990, OFFICES DRUG EVALUAT; 1990, ULRICHS INT PERIODIC, V1; 1991, APPROVED DRUG PRODUC; 1991, ADVERTISING MARKETIN; 1990, JAMA-J AM MED ASSOC, V263, P1311; 1991, PHYSICIANS DESK REFE; 1991, AMA SCI J CHICA 1015, P1; 1989, BUSINESS PUBLICATI 1, V71; 1990, FDC REP, V52	34	128	129	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1992	327	16					1135	1140		10.1056/NEJM199210153271606	http://dx.doi.org/10.1056/NEJM199210153271606			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JT153	1528209	Bronze			2022-12-28	WOS:A1992JT15300006
J	SEABRA, MC; BROWN, MS; SLAUGHTER, CA; SUDHOF, TC; GOLDSTEIN, JL				SEABRA, MC; BROWN, MS; SLAUGHTER, CA; SUDHOF, TC; GOLDSTEIN, JL			PURIFICATION OF COMPONENT-A OF RAB GERANYLGERANYL TRANSFERASE - POSSIBLE IDENTITY WITH THE CHOROIDEREMIA GENE-PRODUCT	CELL			English	Article							GTP-BINDING PROTEIN; SMG P25A; REGULATORY PROTEIN; SYNAPTIC VESICLES; PEPTIDE-BINDING; ALPHA-SUBUNIT; FARNESYLTRANSFERASE; CLONING; EXPRESSION; DEPENDENCE	Rab geranylgeranyl transferase (GG transferase) from rat brain contains two components, A and B. Component B comprises polypeptides of 60 and 38 kd. Here we report the purification of component A, a single 95 kd polypeptide. The holoenzyme attaches H-3-geranyl-geranyl to cysteines in two GTP-binding proteins, Rab3A and Rab1A. The reaction is abolished when both cysteines in the COOH-terminal CysCys sequence of Rab1A are mutated to serines. The mutant protein inhibits transfer of H-3-geranylgeranyl to wild-type Rab1A and Rab3A, suggesting that the enzyme recognizes conserved sequences distinct from the COOH-terminus. Six peptides from rat component A show striking similarity to the product of the defective gene in choroideremia, an X-linked retinal degeneration disease. The choroideremia protein resembles Rab3A GDI, which binds Rab3A. We hypothesize that component A binds conserved sequences in Rab and that component B transfers geranylgeranyl. A defect in this reaction may cause choroideremia.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	SEABRA, MC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Seabra, Miguel/AAC-3099-2019; Seabra, Miguel C/M-3280-2013	Seabra, Miguel C/0000-0002-6404-4892	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FODOR E, 1991, NATURE, V351, P614, DOI 10.1038/351614b0; Heckenlively J. R., 1988, RETINITIS PIGMENTOSA; HECKENLIVELY JR, 1988, CHOROIDEREMIA RETINI, P176; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MERRY DE, 1992, P NATL ACAD SCI USA, V89, P2135, DOI 10.1073/pnas.89.6.2135; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	34	258	261	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					1049	1057		10.1016/0092-8674(92)90253-9	http://dx.doi.org/10.1016/0092-8674(92)90253-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525821				2022-12-28	WOS:A1992JN78100018
J	SALZMAN, EW				SALZMAN, EW			LOW-MOLECULAR-WEIGHT HEPARIN AND OTHER NEW ANTITHROMBOTIC DRUGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							THROMBUS FORMATION; PLATELET; INHIBITION; RECEPTOR; MODEL											BOURDON P, 1991, FEBS LETT, V294, P163, DOI 10.1016/0014-5793(91)80659-Q; CARTER CJ, 1982, BLOOD, V59, P1239; CHONG BH, 1989, BLOOD, V73, P1592; COLLER BS, 1989, CIRCULATION, V80, P1766, DOI 10.1161/01.CIR.80.6.1766; DAURES JP, 1989, REV EPIDEMIOL SANTE, V37, P363; GOLD HK, 1990, J CLIN INVEST, V86, P651, DOI 10.1172/JCI114757; GRUBER A, 1990, CIRCULATION, V82, P578, DOI 10.1161/01.CIR.82.2.578; HANSON SR, 1988, P NATL ACAD SCI USA, V85, P3184, DOI 10.1073/pnas.85.9.3184; HIRSH J, 1992, BLOOD, V79, P1; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; JANG IK, 1990, CIRC RES, V67, P1552, DOI 10.1161/01.RES.67.6.1552; KRUPINSKI K, 1989, HAEMOSTASIS, V19, P74; LASSEN MR, 1991, SEMIN THROMB HEMOST, V17, P284; MARKWARDT F, 1991, THROMB HAEMOSTASIS, V66, P141; ROSENDAAL FR, 1991, THROMB HAEMOSTASIS, V65, P927; SALZMAN EW, 1991, J VASC SURG, V13, P761, DOI 10.1016/0741-5214(91)90381-4; SAVAGE B, 1990, J BIOL CHEM, V265, P11766; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; VLASUK GP, 1991, THROMB HAEMOSTASIS, V65, P257; YASUDA T, 1990, J AM COLL CARDIOL, V16, P1728, DOI 10.1016/0735-1097(90)90327-L; ZACHARSKI LR, 1991, THROMB HAEMOSTASIS, V65, P545	21	24	24	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1992	326	15					1017	1019		10.1056/NEJM199204093261510	http://dx.doi.org/10.1056/NEJM199204093261510			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM285	1545838				2022-12-28	WOS:A1992HM28500010
J	BARZILAY, J; WARRAM, JH; RAND, LI; PFEIFER, MA; KROLEWSKI, AS				BARZILAY, J; WARRAM, JH; RAND, LI; PFEIFER, MA; KROLEWSKI, AS			RISK FOR CARDIOVASCULAR AUTONOMIC NEUROPATHY IS ASSOCIATED WITH THE HLA-DR3/4 PHENOTYPE IN TYPE-I DIABETES-MELLITUS	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES-MELLITUS, INSULIN-DEPENDENT; DIABETIC NEUROPATHIES; CARDIOVASCULAR DISEASES; HLA-DR ANTIGENS	SUBCUTANEOUS INSULIN INFUSION; HEART-RATE-VARIABILITY; METABOLIC CONTROL; NERVE FUNCTION; TRANSPLANTATION; RETINOPATHY; NEPHROPATHY; PREVALENCE; EXPERIENCE; TESTS	Objective: To identify risk factors for the development of cardiovascular autonomic neuropathy in patients with juvenile-onset type I diabetes mellitus. Design: Cross-sectional examination of an inception cohort 15 to 21 years after the onset of diabetes. Setting: Outpatient diabetes clinic. Patients: Seventy-nine patients with type I diabetes who experienced onset of disease before 21 years of age and who were followed for 15 to 21 years. Measurements: Autonomic nerve function was evaluated in all patients using deep breathing and tilt tests. On the basis of these tests, an index of cardiovascular autonomic neuropathy was derived and patients were classified as having intact, mildly impaired, or significantly impaired autonomic function. Results: The group with significantly impaired function had a higher mean hemoglobin A1 at the time of examination than the group without impairment, yet the groups did not differ regarding glycemic control during the first decade of diabetes. The HLA-DR3/4 phenotype was present in more than 50% of the patients with significant autonomic dysfunction and conferred relative odds of 6.2 (95% CI, 1.7 to 23.3) for the development of autonomic neuropathy when compared with other HLA-DR phenotypes. Sex, percent ideal body weight, and smoking did not have a statistically significant effect on the development of autonomic neuropathy. Conclusions: The development of cardiovascular autonomic neuropathy in type I diabetes mellitus is strongly associated with the HLA-DR3/4 phenotype. Thus, genetic predisposition may play an important role in the development of this complication.	JOSLIN DIABET CTR, DIV RES, EPIDEMIOL & GENET SECT, 1 JOSLIN PL, BOSTON, MA 02215 USA; HUMANA HOSP, LEXINGTON, KY USA	Harvard University; Joslin Diabetes Center, Inc.					NATIONAL EYE INSTITUTE [R01EY002636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041526] Funding Source: NIH RePORTER; NEI NIH HHS [EY-02636] Funding Source: Medline; NIDDK NIH HHS [DK-41526] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPENZELLER O, 1965, J NEUROL NEUROSUR PS, V28, P510, DOI 10.1136/jnnp.28.6.510; BECKER W, 1979, J AUTONOM NERV SYST, V1, P53, DOI 10.1016/0165-1838(79)90005-5; BERGSTROM B, 1987, ACTA MED SCAND, V222, P147; BODANSKY HJ, 1982, DIABETES, V31, P70, DOI 10.2337/diabetes.31.1.70; BOULTON AJM, 1984, DIABETOLOGIA, V26, P15; BRODOWS RG, 1986, DIABETES CARE, V9, P189, DOI 10.2337/diacare.9.2.189; BROWN FM, 1989, DIABETES, V38, P938, DOI 10.2337/diabetes.38.7.938; CICMIR I, 1983, DIABETOLOGIA, V25, P147; DORNAN TL, 1982, DIABETES, V31, P226, DOI 10.2337/diabetes.31.3.226; DUCHEN LW, 1980, ANN INTERN MED, V92, P301, DOI 10.7326/0003-4819-92-2-301; DUNN PJ, 1979, METABOLISM, V28, P777, DOI 10.1016/0026-0495(79)90185-9; DYRBERG T, 1981, DIABETOLOGIA, V20, P190; EWING DJ, 1986, DIABETES CARE, V9, P648, DOI 10.2337/diacare.9.6.648; EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491; FEDELE D, 1985, HORM METAB RES, V17, P410, DOI 10.1055/s-2007-1013560; GAMBARDELLA S, 1983, J ENDOCRINOL INVEST, V6, P363, DOI 10.1007/BF03347617; GILBEY SG, 1988, DIABETIC MED, V5, P845, DOI 10.1111/j.1464-5491.1988.tb01122.x; GILBEY SG, 1986, DIABETIC MED, V3, P241, DOI 10.1111/j.1464-5491.1986.tb00753.x; GUY RJC, 1984, BRIT MED J, V289, P343, DOI 10.1136/bmj.289.6441.343; HILSTED J, 1979, ACTA MED SCAND, V205, P385; HILSTED J, 1982, DIABETES, V31, P730, DOI 10.2337/diab.31.8.730; JAKOBSEN J, 1988, DIABETES, V37, P452, DOI 10.2337/diabetes.37.4.452; KENNEDY WR, 1990, NEW ENGL J MED, V322, P1031, DOI 10.1056/NEJM199004123221503; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; KROLEWSKI AS, 1992, IN PRESS DIABETES, V41; LAURITZEN T, 1985, DIABETES, V34, P74, DOI 10.2337/diab.34.3.S74; MCCLUSKEY J, 1983, DIABETOLOGIA, V24, P162; OBRIEN IAD, 1986, Q J MED, V61, P957; PFEIFER MA, 1984, DIABETES CARE, V7, P447, DOI 10.2337/diacare.7.5.447; PFEIFER MA, 1982, DIABETES, V31, P339, DOI 10.2337/diabetes.31.4.339; RAND LI, 1985, NEW ENGL J MED, V313, P1433, DOI 10.1056/NEJM198512053132302; ROY TM, 1989, AM J MED, V87, P382; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SCHMIDT RE, 1983, DIABETES, V32, P532, DOI 10.2337/diabetes.32.6.532; SMITH SA, 1986, DIABETIC MED, V3, P330; SOLDERS G, 1987, LANCET, V2, P1232; SUNDKVIST G, 1981, DIABETES CARE, V4, P529, DOI 10.2337/diacare.4.5.529; VIBERTI GC, 1982, LANCET, V1, P1430; WIELING W, 1983, DIABETOLOGIA, V24, P422, DOI 10.1007/BF00257340; YOUNG RJ, 1983, DIABETES, V32, P142, DOI 10.2337/diabetes.32.2.142; ZACHARY A, 1981, AACHT LABORATORY MAN; ZHANG WX, 1990, DIABETES, V39, P613, DOI 10.2337/diabetes.39.5.613	42	18	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					544	549		10.7326/0003-4819-116-7-544	http://dx.doi.org/10.7326/0003-4819-116-7-544			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543308				2022-12-28	WOS:A1992HL25800004
J	TARLETON, RL; KOLLER, BH; LATOUR, A; POSTAN, M				TARLETON, RL; KOLLER, BH; LATOUR, A; POSTAN, M			SUSCEPTIBILITY OF BETA-2-MICROGLOBULIN-DEFICIENT MICE TO TRYPANOSOMA-CRUZI INFECTION	NATURE			English	Article							CD8+ T-CELLS; SUPPRESSOR CELLS; RESISTANCE; DEFICIENT; INCREASES	THE beta-2-microglobulin (beta-2m) protein associates with the products of the class I major histocompatibility (MHC) loci; this combination functions in the thymic development of and antigen presentation to CD8+ T cells. Mice in which the beta-2m gene has been disrupted by homologous recombination fail to express class I MHC gene products, and therefore lack CD8+ T cells and measurable cytotoxic T-cell responses 1,2. However, beta-2m- mice appear to have normal development of both CD4+ alpha/beta-T-cell receptor (TCR+) and gamma/delta-TCR+ T cells and are not overtly more susceptible than beta-2-m+ mice to potential environmental agents of infection 1,2 or to experimental viral infection 3. Here we show that beta-2m- mice suffer high parasitaemias and early death when infected with the obligate cytoplasmic protozoan parasite Trypanosoma cruzi. Despite this increased susceptibility, the beta-2m- mice are more responsive than their beta-2m+ littermates in terms of lymphokine production, making higher levels of both interleukin-2 and interferon-gamma in response to mitogen stimulation. In addition, the beta-2m- mice show essentially no inflammatory response in parasite-infected tissues. These results confirm previous experiments on mice depleted of CD8+ cells using antibody treatment 4 in demonstrating the importance of CD8+ T cells in immune protection in T. cruzi infection. They also implicate CD8+ T cells and/or class I MHC molecules in regulation of lymphokine production and recruitment of inflammatory cells.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	TARLETON, RL (corresponding author), UNIV GEORGIA,DEPT ZOOL,ATHENS,GA 30602, USA.		Tarleton, Rick/AES-8572-2022	Tarleton, Rick/0000-0002-9589-5243				ANDRADE ZA, 1983, CIBA F SYMP, V99, P214; ARAUJO FG, 1989, INFECT IMMUN, V57, P2246, DOI 10.1128/IAI.57.7.2246-2248.1989; BELTZ LA, 1989, INT J PARASITOL, V19, P555, DOI 10.1016/0020-7519(89)90086-6; CUNNINGHAM DS, 1978, INFECT IMMUN, V22, P155, DOI 10.1128/IAI.22.1.155-160.1978; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Krettli A. U., 1984, Memorias do Instituto Oswaldo Cruz, V79, P59, DOI 10.1590/S0074-02761984000500013; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; MINOPRIO P, 1991, RES IMMUNOL, V142, P137, DOI 10.1016/0923-2494(91)90024-D; NABORS GS, 1991, J IMMUNOL, V146, P3591; POSTAN M, 1986, T ROY SOC TROP MED H, V80, P50, DOI 10.1016/0035-9203(86)90193-8; RAMOS C, 1979, J IMMUNOL, V122, P1243; RIBEIRODOSSANTOS R, 1991, RES IMMUNOL, V142, P134, DOI 10.1016/0923-2494(91)90023-C; ROTTENBERG M, 1988, SCAND J IMMUNOL, V28, P573, DOI 10.1111/j.1365-3083.1988.tb01489.x; RUSSO M, 1988, ANN INST PASTEUR IMM, V139, P225, DOI 10.1016/0769-2625(88)90136-5; Santos-Buch C. A., 1985, Immunology and pathogenesis of trypanosomiasis, P145; SCOTT MT, 1981, IMMUNOLOGY, V44, P409; TARLETON RL, 1988, J IMMUNOL, V140, P2769; TARLETON RL, 1990, J IMMUNOL, V144, P717; TRISCHMANN TM, 1983, J IMMUNOL, V130, P1953; YOUNESCHENNOUFI AB, 1988, T ROY SOC TROP MED H, V82, P84, DOI 10.1016/0035-9203(88)90271-4; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	23	328	332	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					338	340		10.1038/356338a0	http://dx.doi.org/10.1038/356338a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549177				2022-12-28	WOS:A1992HK79400064
J	OTTE, AP; MOON, RT				OTTE, AP; MOON, RT			PROTEIN-KINASE-C ISOZYMES HAVE DISTINCT ROLES IN NEURAL INDUCTION AND COMPETENCE IN XENOPUS	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; EMBRYOS; EXPRESSION; LAEVIS; GENES; RNA; DIFFERENTIATION; ACTIVATION; ECTODERM; ANTERIOR	The restricted ability of embryonic tissue to respond to inductive signals is controlled by a poorly understood phenomenon, termed competence. In Xenopus, dorsal ectoderm is more competent than ventral ectoderm to become induced to neural tissue. We tested whether the Xenopus protein kinase C (PKC) isozymes-alpha and beta have a role in neural induction and competence. We found that PKC-alpha is predominantly localized in dorsal ectoderm, whereas PKC-beta is uniformly distributed. Overexpression of PKC-beta conveys a higher propensity for neural differentiation to both dorsal and ventral ectoderm, but their difference in competence remains. However, ectopic expression of PKC-alpha elevates the level of neural competence of ventral ectoderm to that of dorsal ectoderm. These data indicate that different PKC isozymes have distinct roles in mediating both neural induction and competence.			OTTE, AP (corresponding author), UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195, USA.		Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001837] Funding Source: NIH RePORTER; NIAMS NIH HHS [K04 AR 1837] Funding Source: Medline; NICHD NIH HHS [R01 HD 2 7525] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Chen K H, 1988, Second Messengers Phosphoproteins, V12, P251; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DAVIDS M, 1988, ROUX ARCH DEV BIOL, V197, P339, DOI 10.1007/BF00375953; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GURDON JB, 1989, DEVELOPMENT, V105, P27; GURDON JB, 1987, DEVELOPMENT, V99, P285; HARVEY RP, 1988, CELL, V53, P687, DOI 10.1016/0092-8674(88)90087-6; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HUANG FL, 1987, J BIOL CHEM, V262, P15714; JONES EA, 1989, DEVELOPMENT, V107, P785; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KINTNER CR, 1987, DEVELOPMENT, V99, P311; LAFLAMME SE, 1988, GENE DEV, V2, P853, DOI 10.1101/gad.2.7.853; LONDON C, 1988, DEV BIOL, V129, P380, DOI 10.1016/0012-1606(88)90385-5; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Moon R. T., 1989, TECHNIQUE, V1, P76; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1985, J EMBRYOL EXP MORPH, V89, P333; NIEUWKOOP PD, 1985, EPIGENETIC NATURE EA; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; OTTE AP, 1990, DEVELOPMENT, V110, P461; OTTE AP, 1989, CELL, V58, P641, DOI 10.1016/0092-8674(89)90099-8; OTTE AP, 1988, NATURE, V334, P618, DOI 10.1038/334618a0; OTTE AP, 1991, SCIENCE, V251, P570, DOI 10.1126/science.1990433; SHARPE CR, 1991, NEURON, V7, P239, DOI 10.1016/0896-6273(91)90262-X; SHARPE CR, 1988, DEVELOPMENT, V103, P269; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SHARPE CR, 1989, DEVELOPMENT, V107, P710; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Smith JC, 1989, CURR OPIN CELL BIOL, V1, P1061, DOI 10.1016/S0955-0674(89)80051-1; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; USUDA N, 1991, J CELL BIOL, V112, P1241, DOI 10.1083/jcb.112.6.1241; WALKER JM, 1990, J BIOL CHEM, V265, P8016	45	106	107	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1021	1029		10.1016/0092-8674(92)90074-M	http://dx.doi.org/10.1016/0092-8674(92)90074-M			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547501				2022-12-28	WOS:A1992HK67400006
J	FARRELL, M; STRANG, J				FARRELL, M; STRANG, J			MEDICINE IN EUROPE .11. ALCOHOL AND DRUGS	BRITISH MEDICAL JOURNAL			English	Article									BETHLEM ROYAL & MAUDSLEY HOSP,DRUG DEPENDENCE CLIN RES & TREATMENT UNIT,BECKENHAM BR3 3BX,ENGLAND	South London & Maudsley NHS Trust	FARRELL, M (corresponding author), INST PSYCHIAT,NATL ADDICT CTR,LONDON SE5 8AF,ENGLAND.		Farrell, Michael P/A-4769-2012; Strang, John/H-5460-2011	Farrell, Michael P/0000-0001-7008-8130; Strang, John/0000-0002-5413-2725				Bruun K., 1975, ALCOHOL CONTROL POLI; FARRELL M, 1991, BRIT MED J, V302, P1477, DOI 10.1136/bmj.302.6791.1477; HARDING T, 1990, HIV AIDS EUROPEAN PR; LEROY B, 1991, COMMUNITY 12 DRUG DE; MCGUINESS AJ, 1991, ALCOHOL TAXATION EUR; NADELMANN EA, 1989, SCIENCE, V245, P939, DOI 10.1126/science.2772647; Stimson G., 1987, LAND FIT HEROIN; WALDEGRAVE W, 1992, BRIT MED J, V304, P56, DOI 10.1136/bmj.304.6818.56-c; WALSH D, 1982, WHO17 PUBL HLTH EUR; 1987, MULTICITY STUDY DRUG; 1986, ALCOHOL OUR FAVOURIT; 1990, STATISTICAL HDB; 1990, OFFICIAL J EUROPEAN, V33, P12; 1991, 30 EUR CTR EP MON AI; 1981, ALCOHOL REDUCING HAR	15	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					489	491		10.1136/bmj.304.6825.489	http://dx.doi.org/10.1136/bmj.304.6825.489			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547425	Green Published, Bronze			2022-12-28	WOS:A1992HF55500028
J	CHADWICK, SJD; WOLFE, JHN				CHADWICK, SJD; WOLFE, JHN			ABC OF VASCULAR DISEASES - REHABILITATION OF THE AMPUTEE	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,LONDON,ENGLAND	Imperial College London	CHADWICK, SJD (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND.								0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					373	376		10.1136/bmj.304.6823.373	http://dx.doi.org/10.1136/bmj.304.6823.373			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540739	Bronze, Green Published			2022-12-28	WOS:A1992HD38700031
J	FOUQUE, D; LAVILLE, M; BOISSEL, JP; CHIFFLET, R; LABEEUW, M; ZECH, PY				FOUQUE, D; LAVILLE, M; BOISSEL, JP; CHIFFLET, R; LABEEUW, M; ZECH, PY			CONTROLLED LOW PROTEIN DIETS IN CHRONIC RENAL-INSUFFICIENCY - METAANALYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ESSENTIAL AMINO-ACIDS; LOW-NITROGEN DIET; DIABETIC NEPHROPATHY; RESTRICTED DIETS; FAILURE; PROGRESSION; DISEASE; KETOANALOGUES; QUESTIONS; ANALOGS	Objective - To determine whether low protein diets retard the development of end stage renal disease. Design - Meta-analysis of 46 trials since 1975, from which six randomised controlled trials were selected. Setting - Five trials in Europe and one in Australia between 1982 and 1991. Subjects - 890 patients with mild to severe chronic renal failure who were followed up for at least one year. 450 patients received a low protein diet and 440 a control diet. Intervention - Difference in protein intake between control and treated groups of at least 0.2 g protein/kg/day. Main outcome measure - Number of renal deaths (the necessity to start dialysis or death of patient during study). Results - 156 renal deaths were recorded, 61 in the low protein diet group and 95 in the control group, leading to an odds ratio of low protein to control of 0.54 with a 95% confidence interval of 0.37 to 0.79. Conclusions - This result, obtained on a large population of patients suffering from chronic renal insufficiency, strongly supports the effectiveness of low protein diets in delaying the onset of end stage renal disease.	LAB PHARMACOL CLIN, CLIN PHARMACOL, F-69424 Lyon, FRANCE		FOUQUE, D (corresponding author), HOP EDOUARD HERRIOT, SERV NEPHROL, F-69437 Lyon 03, FRANCE.		Fouque, Denis/C-5338-2014	Fouque, Denis/0000-0002-9707-7199				ALVESTRAND A, 1980, AM J CLIN NUTR, V33, P1654, DOI 10.1093/ajcn/33.7.1654; ALVESTRAND A, 1983, KIDNEY INT S, V16, P268; Attman P O, 1986, Contrib Nephrol, V53, P128; ATTMAN PO, 1983, CLIN NEPHROL, V19, P217; BARSOTTI G, 1988, CLIN NEPHROL, V29, P280; BARSOTTI G, 1981, NEPHRON, V27, P113, DOI 10.1159/000182036; BARSOTTI G, 1984, CLIN NEPHROL, V21, P54; BARSOTTI G, 1983, KIDNEY INT S, V16, P278; BENNETT SE, 1983, BRIT MED J, V287, P1344, DOI 10.1136/bmj.287.6402.1344-a; BOISSEL JP, 1989, CONTROL CLIN TRIALS, V10, P254, DOI 10.1016/0197-2456(89)90067-6; BURNS J, 1978, AM J CLIN NUTR, V31, P1767, DOI 10.1093/ajcn/31.10.1767; CHAUVEAU P, 1986, NEPHROLOGIE, V7, P137; CIANCIARUSO B, 1989, KIDNEY INT, V36, pS173; Di Landro D, 1986, Contrib Nephrol, V53, P137; DRUML W, 1988, BLOOD PURIFICAT, V6, P285, DOI 10.1159/000169556; ELNAHAS AM, 1986, LANCET, V1, P597; ELNAHAS AM, 1984, BRIT MED J, V289, P1337, DOI 10.1136/bmj.289.6455.1337; FROHLING PT, 1980, AM J CLIN NUTR, V33, P1667, DOI 10.1093/ajcn/33.7.1667; FROHLING PT, 1989, BLOOD PURIFICAT, V7, P28, DOI 10.1159/000169570; FROHLING PT, 1983, CLIN NEPHROL, V20, P212; Gentile M G, 1986, Contrib Nephrol, V53, P102; Gentile M G, 1988, Scand J Urol Nephrol Suppl, V108, P13; GIOVANNETTI S, 1986, LANCET, V2, P1140; GRETZ N, 1989, AM J KIDNEY DIS, V14, P178, DOI 10.1016/S0272-6386(89)80068-X; Gretz N, 1986, Contrib Nephrol, V53, P92; GRETZ N, 1987, INFUSIONSTHERAPIE, V14, P9; GRETZ N, 1989, BLOOD PURIFICAT, V7, P33, DOI 10.1159/000169571; Gretz N, 1985, Contrib Nephrol, V49, P78; GRETZ N, 1989, NUTRITIONAL TREATMEN, P211; GRETZ N, 1983, KIDNEY INT S, V16, P263; HECKING E, 1980, AM J CLIN NUTR, V33, P1678, DOI 10.1093/ajcn/33.7.1678; Hedges L, 1985, STATISTICAL METHODS; IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601; JUNGERS P, 1987, KIDNEY INT, V32, pS67; KAMPF D, 1980, AM J CLIN NUTR, V33, P1673, DOI 10.1093/ajcn/33.7.1673; KLAHR S, 1989, NEW ENGL J MED, V320, P864, DOI 10.1056/NEJM198903303201310; KOPPLE JD, 1989, KIDNEY INT, V36, pS184; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LEVINE SE, 1989, NEPHRON, V52, P55, DOI 10.1159/000185582; LOCATELLI F, 1991, LANCET, V337, P1299, DOI 10.1016/0140-6736(91)92977-A; LUBOWITZ H, 1967, J AMER MED ASSOC, V199, P252, DOI 10.1001/jama.199.4.252; LUCAS PA, 1986, KIDNEY INT, V29, P995, DOI 10.1038/ki.1986.99; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; MASCHIO G, 1982, KIDNEY INT, V22, P371, DOI 10.1038/ki.1982.184; MEISINGER E, 1987, KIDNEY INT, V32, pS170; MITCH WE, 1984, NEW ENGL J MED, V311, P623, DOI 10.1056/NEJM198409063111002; OLDRIZZI L, 1985, KIDNEY INT, V27, P553, DOI 10.1038/ki.1985.46; Rosman J B, 1986, Contrib Nephrol, V53, P109; ROSMAN JB, 1984, LANCET, V2, P1291; ROSMAN JB, 1985, 1984 P EUR DIAL TRAN, P567; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; Schmicker R, 1987, Infusionsther Klin Ernahr, V14 Suppl 5, P34; Schmicker R, 1986, Contrib Nephrol, V53, P121; WALSER M, 1990, KIDNEY INT, V37, P1195, DOI 10.1038/ki.1990.103; Walser M, 1987, Infusionsther Klin Ernahr, V14 Suppl 5, P17; Walser M, 1975, Clin Nephrol, V3, P180; WILLIAMS AJ, 1985, 1984 P EUR DIAL TRAN, P604; WILLIAMS PS, 1987, NEPHROL DIAL TRANSPL, V7, P285; ZAKAR G, 1984, 1984 P EUR DIAL TRAN, P600; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202	60	161	165	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	1992	304	6821					216	220		10.1136/bmj.304.6821.216	http://dx.doi.org/10.1136/bmj.304.6821.216			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1531426	Bronze, Green Published			2022-12-28	WOS:A1992HA98000023
J	CAO, L; FAHA, B; DEMBSKI, M; TSAI, LH; HARLOW, E; DYSON, N				CAO, L; FAHA, B; DEMBSKI, M; TSAI, LH; HARLOW, E; DYSON, N			INDEPENDENT BINDING OF THE RETINOBLASTOMA PROTEIN AND P107 TO THE TRANSCRIPTION FACTOR E2F	NATURE			English	Article							LARGE T-ANTIGEN; ADENOVIRUS E1A PROTEINS; GENE-PRODUCT; POLYACRYLAMIDE GELS; SV40; TRANSFORMATION; REGIONS; CELLS	THE cellular protein p107 and the retinoblastoma protein (pRB) have many features in common. Most strikingly, they contain homologous protein domains that mediate interaction with the oncoproteins of several small DNA tumour viruses, including adenovirus E1A and SV40 large-T antigen 1-9. In cells that do not contain these viral oncoproteins, pRB interacts with the cellular transcription factor E2F (refs 10-12) or a related protein termed DRTF1 (ref. 13). E2F associates with a form of pRB that is found primarily in G1 cells 10. It seems that the E2F-pRB complex dissociates near the G1-S boundary before the initiation of S phase, releasing free E2F and apparently, stimulating the ability of E2F to activate transcription 14. Cells that express E1A have no or little pRB-E2F complex, presumably because of the association of E1A with pRB 10,15. During S phase, E2F forms a second complex that contains cyclin A but apparently lacks pRB 1-5. Here, we report that p107 is found in the cyclin A/E2F complex and that this complex also contains p33cdk2. These observations suggest that p107 and pRB cooperate in the regulation of E2F activity, each affecting different stages of the cell cycle. Thus, by binding to pRB and p107, E1A and large-T antigen target two distinct aspects of E2F regulation.	MASSACHUSETTS GEN HOSP CANC CTR, BLDG 149, 13TH ST, BOSTON, MA 02129 USA	Harvard University; Massachusetts General Hospital			Cao, Liang/K-7806-2017	Cao, Liang/0000-0001-7293-8338				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; EWEN ME, IN PRESS SCIENCE; FAHA B, IN PRESS SCIENCE; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HIEBERT SW, IN PRESS GENES DEV; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYERSON M, IN PRESS COLD SPRING, V58; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	35	386	394	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 9	1992	355	6356					176	179		10.1038/355176a0	http://dx.doi.org/10.1038/355176a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1530885				2022-12-28	WOS:A1992GY62900063
J	FAHA, B; EWEN, ME; TSAI, LH; LIVINGSTON, DM; HARLOW, E				FAHA, B; EWEN, ME; TSAI, LH; LIVINGSTON, DM; HARLOW, E			INTERACTION BETWEEN HUMAN CYCLIN-A AND ADENOVIRUS E1A-ASSOCIATED P107 PROTEIN	SCIENCE			English	Article							LARGE T-ANTIGEN; CELL-CYCLE; RETINOBLASTOMA PROTEIN; E1A PROTEINS; BINDING; COMPLEXES; REGIONS; PRODUCT; GENE	The products of the adenovirus early region IA (EIA) gene are potent oncoproteins when tested in standard transformation and immortalization assays. Many of the changes induced by EIA may be due to its interaction with cellular proteins. Four of these cellular proteins are the retinoblastoma protein (pRB), p107, cyclin A, and p33cdk2. The pRB and p107 proteins are structurally related and have several characteristics in common, including that they both bind to the SV40 large T oncoprotein as well as to E1A. Cyclin A and p33cdk2 are thought to function in the control of the cell cycle. They bind to one another, forming a kinase that closely resembles the cell cycle-regulating complexes containing p34cdc2. Cyclin A is now shown to bind to p107 in the absence of E1A. The association of p107 with cyclin A suggests a direct link between cell cycle control and the function of p107.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	FAHA, B (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02129 USA.				NCI NIH HHS [CA 13106, CA 55339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055339, P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DYSON N, UNPUB; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, UNPUB; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HU Q, IN PRESS MOL CELL BI; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAI LH, UNPUB	30	220	223	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	1992	255	5040					87	90		10.1126/science.1532458	http://dx.doi.org/10.1126/science.1532458			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1532458				2022-12-28	WOS:A1992GX79100044
J	SILVERMAN, K; EVANS, SM; STRAIN, EC; GRIFFITHS, RR				SILVERMAN, K; EVANS, SM; STRAIN, EC; GRIFFITHS, RR			WITHDRAWAL SYNDROME AFTER THE DOUBLE-BLIND CESSATION OF CAFFEINE CONSUMPTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHYSICAL-DEPENDENCE; VERSION; HUMANS	Background. People who stop consuming caffeine may have symptoms, but the incidence and severity of caffeine withdrawal are not known. This study was performed to determine the effects in the general population of ending one's dietary intake of caffeine. Methods. We studied 62 normal adults whose intake of caffeine was low to moderate (mean amount, 235 mg - the equivalent of 2.5 cups of coffee - per day). They completed questionnaires about symptoms and tests of their mood and performance when consuming their normal diets (base-line period) and at the end of each of two two-day periods during which they consumed caffeine-free diets and under double-blind conditions received capsules containing placebo (placebo period) or caffeine (caffeine period) in amounts equal to their daily caffeine consumption. Results. More subjects had abnormally high Beck Depression inventory scores (11 percent), high scores on the trait scale of the State-Trait Anxiety Inventory (8 percent), low vigor scores (11 percent) and high fatigue scores (8 percent) on the Profile of Mood States, and moderate or severe headache (52 percent) during the placebo period than during either the base-line period (2, 0, 0, 0, and 2 percent, respectively; P<0.05) or the caffeine period (3, 2, 2, 0, and 6 percent; P<0.05). More subjects reported unauthorized use of medications during the placebo period (13 percent) than during the caffeine period (2 percent, P = 0.017). Performance of a tapping task was slower during the placebo period than during the base-line and caffeine periods (P<0.01). Conclusions. Persons who consume low or moderate amounts of caffeine may have a withdrawal syndrome after their daily consumption of caffeine ceases.	JOHNS HOPKINS UNIV,SCH MED,BEHAV BIOL RES CTR,DEPT PSYCHIAT & BEHAV SCI,5510 NATHAN SHOCK DR,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21224; NIDA,ADDICT RES CTR,LEXINGTON,KY 40583	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)			/ABG-5735-2021	Silverman, Kenneth/0000-0003-2724-1413	NIDA NIH HHS [R01 DA03890] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003890] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1971, EITS MANUAL PROFILE; [Anonymous], 1991, DICT OCCUPATIONAL TI; Barone JJ, 1984, CAFFEINE PERSPECTIVE, P59, DOI 10.1007/978-3-642-69823-1_4; Beck A.T., 1987, BECK DEPRESSION INVE; Costa P.T., 1985, NEO PERSONALITY INVE; Derogatis LR, 1983, ADM SCORING PROCEDUR; Doucette S R, 1980, US Navy Med, V71, P6; EVANS SM, 1991, NIDA RES MONOGR, V105, P446; FENNELLY M, 1991, ANESTH ANALG, V72, P449; FOREMAN N, 1989, PHARMACOL BIOCHEM BE, V32, P399, DOI 10.1016/0091-3057(89)90169-X; GALLETLY DC, 1989, LANCET, V1, P1335; GILBERT RM, 1984, METHYLXANTHINE BEVER, P185; GRAHAM DM, 1978, NUTR REV, V36, P97, DOI 10.1111/j.1753-4887.1978.tb03717.x; GRIFFITHS RR, 1990, J PHARMACOL EXP THER, V255, P1123; GRIFFITHS RR, 1988, PSYCHOPHARMACOLOGY, V94, P437, DOI 10.1007/BF00212836; GRIFFITHS RR, 1983, APPLICATION BEHAVIOR, P367; HOCHBERG Y, 1987, MULTIPLE COMP PROCED, P66; Hughes J R, 1988, J Subst Abuse, V1, P67, DOI 10.1016/S0899-3289(88)80009-9; HUGHES JR, 1992, AM J PSYCHIAT, V149, P33; Huynh H, 1976, J EDUC STATIST, V1, P69, DOI DOI 10.3102/10769986001001069; JACOB P, 1981, J CHROMATOGR, V222, P61, DOI 10.1016/S0378-4347(00)81033-6; MCLEOD DR, 1982, BEHAV RES METH INSTR, V14, P463, DOI 10.3758/BF03203313; ROACHE JD, 1987, J PHARMACOL EXP THER, V243, P978; SILVERMAN K, 1992, J EXP ANAL BEHAV, V57, P91, DOI 10.1901/jeab.1992.57-91; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; 1987, DIAGNOSTIC STATISTIC	26	278	284	0	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1992	327	16					1109	1114		10.1056/NEJM199210153271601	http://dx.doi.org/10.1056/NEJM199210153271601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT153	1528206	Bronze			2022-12-28	WOS:A1992JT15300001
J	BODOR, N; PROKAI, L; WU, WM; FARAG, H; JONALAGADDA, S; KAWAMURA, M; SIMPKINS, J				BODOR, N; PROKAI, L; WU, WM; FARAG, H; JONALAGADDA, S; KAWAMURA, M; SIMPKINS, J			A STRATEGY FOR DELIVERING PEPTIDES INTO THE CENTRAL-NERVOUS-SYSTEM BY SEQUENTIAL METABOLISM	SCIENCE			English	Article							BLOOD-BRAIN-BARRIER; RAT-BRAIN; ENKEPHALIN; AMINOPEPTIDASE	Most peptides do not enter the central nervous system because of their hydrophilic character and the presence of peptidolytic enzymes in the lipoidal blood-brain barrier. To achieve brain delivery of a peptide conjugate, an opioid peptide (enkephalin) was placed in a molecular environment that disguises its peptide nature and provides biolabile, lipophilic functions to penetrate the blood-brain barrier by passive transport. The strategy also incorporates a 1,4-dihydrotrigonellinate targetor that undergoes an enzymatically mediated oxidation to a hydrophilic, membrane-impermeable trigonellinate salt. The polar targetor-peptide conjugate that is trapped behind the lipoidal blood-brain barrier is deposited in the central nervous system. Analgesia was observed with "packaged" enkephalin but not with the unmodified peptide or lipophilic peptide precursors.			BODOR, N (corresponding author), UNIV FLORIDA,J HILLIS MILLER HLTH CTR,COLL PHARM,CTR DRUG DISCOVERY,GAINESVILLE,FL 32610, USA.			Prokai, Laszlo/0000-0002-4559-3458	NIA NIH HHS [1 PO AG10485] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG010485] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BODOR N, 1983, SCIENCE, V221, P65, DOI 10.1126/science.6857264; Bodor N., 1983, PHARMACOL THERAPEUT, V19, P337; BRIGHTMAN MW, 1977, EXP EYE RES, V25, P1, DOI 10.1016/S0014-4835(77)80008-0; GIBSON AM, 1989, NEUROPEPTIDES, V13, P259, DOI 10.1016/0143-4179(89)90079-6; GORENSTEIN C, 1980, PROC R SOC SER B-BIO, V210, P123, DOI 10.1098/rspb.1980.0123; HAMBROOK JM, 1976, NATURE, V262, P782, DOI 10.1038/262782a0; HERSH LB, 1987, PEPTIDES, V8, P523, DOI 10.1016/0196-9781(87)90019-2; HOEK JB, 1988, BIOCHEM J, V254, P1; ITO F, 1984, MOL CELL ENDOCRINOL, V36, P165, DOI 10.1016/0303-7207(84)90032-7; McKelvy J.F., 1983, P117; NEUWELT EA, 1984, FED PROC, V43, P214; OLDENDORF WH, 1971, AM J PHYSIOL, V221, P1629, DOI 10.1152/ajplegacy.1971.221.6.1629; PARDRIDGE WM, 1981, ENDOCRINOLOGY, V109, P1138, DOI 10.1210/endo-109-4-1138; PARDRIDGE WM, 1986, ENDOCR REV, V7, P314, DOI 10.1210/edrv-7-3-314; PARDRIDGE WM, 1991, PEPTIDE DRUG DELIVER, P244; POPLACK DG, 1981, NEUROBIOLOGY CEREBRO, P561; TSUZUKI N, 1991, BIOCHEM PHARMACOL, V41, pR5, DOI 10.1016/0006-2952(91)90616-D	18	128	139	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1698	1700		10.1126/science.1529356	http://dx.doi.org/10.1126/science.1529356			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529356				2022-12-28	WOS:A1992JN50100035
J	ALBERT, VA; WILLIAMS, SE; CHASE, MW				ALBERT, VA; WILLIAMS, SE; CHASE, MW			CARNIVOROUS PLANTS - PHYLOGENY AND STRUCTURAL EVOLUTION	SCIENCE			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; BROCCHINIA-REDUCTA; LARGE SUBUNIT; TREES; DNA	The carnivorous habit in flowering plants represents a grade of structural organization. Different morphological features associated with the attraction, trapping, and digestion of prey characterize a diversity of specialized forms, including the familiar pitcher and flypaper traps. Phylogenetic analysis of nucleotide sequence data from the plastid rbcL gene indicates that both carnivory and stereotyped trap forms have arisen independently in different lineages of angiosperms. Furthermore, these results demonstrate that flypaper traps share close common ancestry with all other trap forms. Recognition of these patterns of diversification may provide ideal, naturally occurring systems for studies of developmental processes underlying macromorphological evolution in angiosperms.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; LEBANON VALLEY COLL, DEPT BIOL, ANNVILLE, PA 17003 USA	University of North Carolina; University of North Carolina Chapel Hill			Albert, Victor A/A-1690-2010; Chase, Mark W/A-6642-2011					Airy Shaw H.K., 1951, KEW BULL, V6, P327; ALBERT VA, UNPUB; ALBERT VA, 1992, MOL SYSTEMATICS PLAN, P369; ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; BEEBE JD, 1980, BOT GAZ, V141, P396, DOI 10.1086/337173; BENZING DH, 1985, SYST BOT, V10, P81, DOI 10.2307/2418437; BJORKMAN O, 1973, SCI AM, V229, P80; BREMER K, 1987, Cladistics, V3, P210, DOI 10.1111/j.1096-0031.1987.tb00509.x; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; CHASE MW, UNPUB; CROIZAT L, 1960, PRINCIPIA BOTANICA, P25; Cronquist A., 1981, INTEGRATED SYSTEM CL; DANSER B. H., 1928, BULL JARD BOT BUITENZORG, V9, P249; Darwin C., 1875, INSECTIVOROUS PLANTS; DIELS L, 1906, PFLANZENREICH, V4, P1; DOEBLEY J, 1990, EVOLUTION, V44, P1097, DOI [10.2307/2409569, 10.1111/j.1558-5646.1990.tb03828.x]; DONOGHUE MJ, 1989, EVOLUTION, V43, P1137, DOI [10.2307/2409353, 10.1111/j.1558-5646.1989.tb02565.x]; DONOGHUE MJ, 1992, ANN MO BOT GARD, V79, P333, DOI 10.2307/2399772; Donoghue MJ, 1989, HIERARCHY LIFE MOL M; Donoghue MJ, 1989, EVOLUTION SYSTEMATIC, V40A, P17; Downie S, 1992, MOL SYSTEMATICS PLAN, P14, DOI DOI 10.1007/978-1-4615-3276-7_2; DOWNIE SR, 1991, EVOLUTION, V45, P1245, DOI [10.2307/2409731, 10.1111/j.1558-5646.1991.tb04390.x]; DOYLE JA, 1986, BOT REV, V52, P321, DOI 10.1007/BF02861082; FARRIS JS, 1989, CLADISTICS, V5, P417, DOI 10.1111/j.1096-0031.1989.tb00573.x; FARRIS JS, 1970, SYST ZOOL, V19, P83, DOI 10.2307/2412028; FINK WL, 1982, PALEOBIOLOGY, V8, P254, DOI 10.1017/S0094837300006977; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; GHISELIN MT, 1984, VARIOUS CONTRIVANCES, pR1; GIVNISH TJ, 1984, AM NAT, V124, P479, DOI 10.1086/284289; GOLOBOFF PA, 1991, CLADISTICS, V7, P215, DOI 10.1111/j.1096-0031.1991.tb00035.x; Gould S. J., 1977, ONTOGENY PHYLOGENY; GOULD SJ, 1979, PROC R SOC SER B-BIO, V205, P581, DOI 10.1098/rspb.1979.0086; GREEN S, 1979, BOT J LINN SOC, V78, P99, DOI 10.1111/j.1095-8339.1979.tb02188.x; GREHAN JR, 1985, SYST ZOOL, V34, P174, DOI 10.2307/2413325; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; Heslop-Harrison Y, 1975, Front Biol, V43, P525; HUDSON GS, 1990, J BIOL CHEM, V265, P808; HUFFORD L, 1992, ANN MO BOT GARD, V79, P218, DOI 10.2307/2399767; Hutchinson J., 1959, FAMILIES FLOWERING P; Juniper B.E., 1989, CARNIVOROUS PLANTS; KARIS PO, 1992, ANN MO BOT GARD, V79, P416, DOI 10.2307/2399778; KIM KJ, 1992, ANN MO BOT GARD, V79, P428, DOI 10.2307/2399779; Kluge A.G., 1988, P57; KLUGE AG, 1969, SYST ZOOL, V18, P1, DOI 10.2307/2412407; Leavitt RG, 1909, BOT GAZ, V47, P30, DOI 10.1086/329802; LLOYD FRANCIS E., 1934, CANADIAN JOUR RES, V10, P780; LOWRIE A, 1987, CARNIVOROUS PLANTS A, V1; Lowrie A., 1989, CARNIVOROUS PLANTS A, V2; Lyndon RF, 1990, PLANT DEV CELLULAR B; MACFARLANE JM, 1908, PFLANZENREICH, V4, P1; MADDISON DR, 1991, SYST ZOOL, V40, P315, DOI 10.2307/2992325; Mameli E., 1916, ATTI U PAVIA 2, V16, P137; MARBURGER JE, 1979, AM J BOT, V66, P404, DOI 10.2307/2442395; Marloth R, 1903, ANN BOT-LONDON, V17, P151, DOI 10.1093/oxfordjournals.aob.a088908; Metcalfe CR, 1951, KEW B, V6, P351; Obermeyer AA, 1970, FLORA SO AFRICA, V13, P201; OLMSTEAD RG, 1992, ANN MO BOT GARD, V79, P249, DOI 10.2307/2399768; PAGE RDM, 1989, CLADISTICS, V5, P167, DOI 10.1111/j.1096-0031.1989.tb00563.x; PAMILO P, 1988, MOL BIOL EVOL, V5, P568; RAFF RA, 1989, J EVOLUTION BIOL, V2, P409, DOI 10.1046/j.1420-9101.1989.2060409.x; ROBERTS JA, 1988, PLANT GROWTH REGULAT; RUTISHAUSER R, 1989, Botanische Jahrbuecher fuer Systematik Pflanzengeschichte und Pflanzengeographie, V111, P121; SACHS T, 1982, ACTA BIOTHEOR, V31A, P118; SACHS T, 1988, PLANT EVOLUTIONARY B; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDERSON MJ, 1991, EVOLUTION, V45, P351, DOI 10.1111/j.1558-5646.1991.tb04409.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATTLER R, 1988, AM J BOT, V75, P1606, DOI 10.2307/2444710; Schmid R., 1964, BOT JB SYST, V83, P1; SCHUH RT, 1981, SYST ZOOL, V30, P331, DOI 10.2307/2413254; Swofford D. L., 1991, PAUP PHYLOGENETIC AN; SWOFFORD DL, 1987, MATH BIOSCI, V87, P199, DOI 10.1016/0025-5564(87)90074-5; TAKHTAJAN AL, 1980, BOT REV, V46, P225, DOI 10.1007/BF02861558; THORNE R F, 1992, Aliso, V13, P365; VANI-HARDEV, 1972, Beitraege zur Biologie der Pflanzen, V48, P339; WILLIAMS SE, 1982, SCIENCE, V218, P1120, DOI 10.1126/science.218.4577.1120; WILLIAMS SE, 1976, P AM PHILOS SOC, V120, P187	77	245	334	9	313	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1992	257	5076					1491	1495		10.1126/science.1523408	http://dx.doi.org/10.1126/science.1523408			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523408				2022-12-28	WOS:A1992JM57000020
J	CUNNINGHAM, FG; LINDHEIMER, MD				CUNNINGHAM, FG; LINDHEIMER, MD			CURRENT CONCEPTS - HYPERTENSION IN PREGNANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SEVERE PRE-ECLAMPSIA; MAGNESIUM-SULFATE; CESAREAN-SECTION; CONTROLLED TRIAL; BLOOD-PRESSURE; PREECLAMPSIA; MANAGEMENT; DELIVERY; SEIZURES; FLOW		UNIV CHICAGO,PRITZKER SCH MED,DEPT OBSTET & GYNECOL,CHICAGO,IL 60637; UNIV CHICAGO,PRITZKER SCH MED,DEPT MED,CHICAGO,IL 60637	University of Chicago; University of Chicago	CUNNINGHAM, FG (corresponding author), UNIV TEXAS,SW MED CTR,DEPT OBSTET & GYNECOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							ARON DC, 1990, AM J OBSTET GYNECOL, V162, P244, DOI 10.1016/0002-9378(90)90859-6; BAKER PN, 1991, BRIT J OBSTET GYNAEC, V98, P436, DOI 10.1111/j.1471-0528.1991.tb10336.x; BARRON WM, 1991, MED DISORDERS PREGNA, P1; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; BLAKE S, 1991, BRIT J OBSTET GYNAEC, V98, P244, DOI 10.1111/j.1471-0528.1991.tb13387.x; BRIZGYS RV, 1987, ANESTHESIOLOGY, V67, P782; BROWN CEL, 1987, J REPROD MED, V32, P499; BROWN MA, 1989, CLIN SCI, V77, P599, DOI 10.1042/cs0770599; BROWN MA, 1990, J HYPERTENS, V8, P295, DOI 10.1097/00004872-199004000-00001; Chesley L, 1978, HYPERTENSIVE DISORDE; CLARK SL, 1988, AM J OBSTET GYNECOL, V158, P453, DOI 10.1016/0002-9378(88)90003-8; COCKBURN J, 1982, LANCET, V1, P647; COLLINS R, 1985, BMJ-BRIT MED J, V290, P17, DOI 10.1136/bmj.290.6461.17; COLLINS R, 1989, EFFECTIVE CARE PREGN, V1, P512; CROWTHER C, 1990, BRIT J OBSTET GYNAEC, V97, P110, DOI 10.1111/j.1471-0528.1990.tb01735.x; CUNNINGHAM FG, 1989, NEW ENGL J MED, V321, P606, DOI 10.1056/NEJM198908313210908; CUNNINGHAM FG, 1988, HDB HYPERTENSION, V10, P290; DINSDALE HB, 1988, ARCH NEUROL-CHICAGO, V45, P1360, DOI 10.1001/archneur.1988.00520360078016; DOMMISSE J, 1990, BRIT J OBSTET GYNAEC, V97, P104, DOI 10.1111/j.1471-0528.1990.tb01734.x; EASTERLING TR, 1991, OBSTET GYNECOL, V78, P921; EASTERLING TR, 1990, OBSTET GYNECOL, V76, P1061; FISHER KA, 1981, MEDICINE, V60, P267, DOI 10.1097/00005792-198107000-00002; FITZGERALD DJ, 1990, HYPERTENSION PATHOPH, V2, P1789; GANT NF, 1973, J CLIN INVEST, V52, P2682, DOI 10.1172/JCI107462; GINSBURG J, 1969, Journal of Obstetrics and Gynaecology of the British Commonwealth, V76, P705; GREENBERG M, 1985, RADIOLOGY, V161, P475; HANKINS GDV, 1984, AM J OBSTET GYNECOL, V150, P506, DOI 10.1016/S0002-9378(84)90429-0; HODGKINSON R, 1980, CAN ANAESTH SOC J, V27, P389, DOI 10.1007/BF03007461; JOUPPILA P, 1982, OBSTET GYNECOL, V59, P158; KAPLAN PW, 1988, ARCH NEUROL-CHICAGO, V45, P1361, DOI 10.1001/archneur.1988.00520360079017; KILLAM AP, 1975, AM J OBSTET GYNECOL, V123, P823, DOI 10.1016/0002-9378(75)90856-X; LINDHEIMER MD, 1985, NEW ENGL J MED, V313, P675, DOI 10.1056/NEJM198509123131107; LINDHEIMER MD, 1992, KIDNEY PHYSL PATHOPH, P3371; MANAS KJ, 1985, NEW ENGL J MED, V312, P424, DOI 10.1056/NEJM198502143120707; OIAN P, 1986, BRIT J OBSTET GYNAEC, V93, P235, DOI 10.1111/j.1471-0528.1986.tb07899.x; PRITCHARD JA, 1954, NEW ENGL J MED, V250, P89, DOI 10.1056/NEJM195401212500301; PRITCHARD JA, 1984, AM J OBSTET GYNECOL, V148, P951, DOI 10.1016/0002-9378(84)90538-6; REMUZZI G, 1909, AM J KIDNEY DIS, V18, P285; ROBERTS JM, 1991, AM J HYPERTENS, V4, P700, DOI 10.1093/ajh/4.8.700; ROBIN ED, 1987, CHEST, V92, P727, DOI 10.1378/chest.92.4.727; ROSA FW, 1989, OBSTET GYNECOL, V74, P371; RUBIN PC, 1983, LANCET, V1, P431; RUBIN PC, 1988, HDB HYPERTENSION, V10; SIBAI BM, 1990, AM J OBSTET GYNECOL, V162, P960, DOI 10.1016/0002-9378(90)91297-P; SIBAI BM, 1990, AM J OBSTET GYNECOL, V162, P311, DOI 10.1016/0002-9378(90)90376-I; Sibai BM, 1988, HDB HYPERTENSION, V10, P320; STURGISS SN, 1991, INT YB NEPHROLOGY 19, P163; TAUFIELD PA, 1987, NEW ENGL J MED, V316, P715, DOI 10.1056/NEJM198703193161204; TAYLOR RN, 1990, AM J OBSTET GYNECOL, V163, P1839, DOI 10.1016/0002-9378(90)90761-U; TAYLOR RN, 1991, AM J REPROD IMMUNOL, V25, P105, DOI 10.1111/j.1600-0897.1991.tb01075.x; VILLAR J, 1989, AM J OBSTET GYNECOL, V161, P1019, DOI 10.1016/0002-9378(89)90777-1; VISSER W, 1991, HYPERTENSION, V17, P1072, DOI 10.1161/01.HYP.17.6.1072; Wallenburg HCS., 1988, HDB HYPERTENSION, P66; WALSH SW, 1985, AM J OBSTET GYNECOL, V152, P335, DOI 10.1016/S0002-9378(85)80223-4; ZINAMAN M, 1985, LANCET, V1, P1245; 1987, WHO TECH REP SER, V758, P1; 1990, AM J OBSTET GYNECOL, V163, P1689; 1989, WILLIAMS OBSTETRICS, P653; 1988, AM COLLEGE OBSTETRIC, V128; 1988, AM COLLEGE OBSTETRIC, V112; 1984, FDA DRUG B, V14, P3	61	244	251	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					927	932						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1542342				2022-12-28	WOS:A1992HL26100005
J	SCHROEDER, SA				SCHROEDER, SA			THE TROUBLED PROFESSION - IS MEDICINES GLASS HALF FULL OR HALF EMPTY	ANNALS OF INTERNAL MEDICINE			English	Article						JOB SATISFACTION; CAREER CHOICE; SPECIALTIES, MEDICAL; KNOWLEDGE, ATTITUDES, PRACTICE	INTERNAL MEDICINE; ACADEMIC MEDICINE; RESIDENCY	Abundant evidence that medicine is in trouble includes serious career dissatisfaction among practicing and would-be physicians as well as steeply declining interest in generalist careers, especially internal medicine. Medicine is threatened by ever-rising health care expenditures and ineffectual but vexing administrative efforts to contain them. Additional problems challenge internal medicine in particular: the clinical complexity of practice, lower income potential, and incomplete clinical experiences for medical students. Yet, in the past 25 years, spectacular advances in science and technology enabled improved patient care and outcomes; more women and minorities entering the profession brought it into better demographic balance; relative physician incomes rose; and access to physician services improved with Medicare and Medicaid and the desegregation of southern hospitals. Despite an unfinished agenda, never before has medicine held so much promise for improving the health of the public. Despite various professional problems, no other career offers the unique blend of state-of-the-art science and humanism the epitomizes internal medicine-medicine's integrating specialty.			SCHROEDER, SA (corresponding author), ROBERT WOOD JOHNSON FDN, POB 2316, PRINCETON, NJ 08543 USA.							BABBOTT D, 1991, ANN INTERN MED, V114, P16, DOI 10.7326/0003-4819-114-1-16; BANTA HD, 1980, 4 OFF TECHN ASS BACK; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; COHEN AB, 1990, HEALTH AFFAIR, V9, P138, DOI 10.1377/hlthaff.9.4.138; COLQUITT WL, 1991, ACAD MED, V66, P273, DOI 10.1097/00001888-199105000-00010; Colwill J M, 1988, Fam Med, V20, P250; COX MW, 1987, ANN INTERN MED, V106, P734, DOI 10.7326/0003-4819-106-5-734; Davis K, 1978, HLTH WAR POVERTY 10; EISENBERG C, 1986, NEW ENGL J MED, V314, P1113, DOI 10.1056/NEJM198604243141710; GONZALEZ ML, 1990, PHYSICIAN MARKETPLAC, P69; HARDISON JE, 1986, NEW ENGL J MED, V314, P1713, DOI 10.1056/NEJM198606263142619; HAYWARD RA, 1991, ANN INTERN MED, V114, P23, DOI 10.7326/0003-4819-114-1-23; HUGHES RG, 1991, NEW ENGL J MED, V325, P404, DOI 10.1056/NEJM199108083250606; JOLLY P, 1991, STATISTICAL INFORMAT; JOLLY P, 1991, AAMC DATA BOOK STATI; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; LUFT SL, 1990, HOSPITAL VOLUME PHYS; MCPHEE SJ, 1987, AM J CARDIAC IMAGING, V1, P204; Owens A, 1990, Med Econ, V67, P90; OWENS A, 1990, MED ECON, V67, P108; OWENS A, 1990, MED ECON, V67, P104; OWENS A, 1966, MED ECON, V43, P78; PETERSDORF RG, 1981, NEW ENGL J MED, V304, P841, DOI 10.1056/NEJM198104023041412; REYNOLDS RA, 1984, SOCIOECONOMIC CHARAC, P110; SCHROEDER S A, 1988, Journal of General Internal Medicine, V3, pS5, DOI 10.1007/BF02600247; SCHROEDER SA, 1989, JAMA-J AM MED ASSOC, V262, P803, DOI 10.1001/jama.262.6.803; SCHROEDER SA, 1978, MED CARE, V16, P289, DOI 10.1097/00005650-197804000-00002; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P373, DOI 10.1001/jama.252.3.373; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; SCHROEDER SA, 1991, NEW ENGL J MED, V325, P1099, DOI 10.1056/NEJM199110103251510; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; SUTHERLAND JE, 1990, JAMA-J AM MED ASSOC, V264, P3178, DOI 10.1001/jama.264.24.3178; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; 1975, VITAL STATISTICS US, V2; 1991, AAMC DATA BOOK; 1990, MONTHLY VITAL STATIS, V38, P19; 1984, EXECUTIVE SUMMARY UP; 1984, NATIONAL RESIDENCY M, P21; 1949, ANN INTERN MED, V112, P641; 1990, HRSPOD906 US DEP HLT; 1991, NATIONAL RESIDENCY M, P6; 1991, MONTHLY VITAL STATIS, V39, P1; 1991, JAMA-J AM MED ASSOC, V265, P2451; [No title captured]	44	40	41	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					583	592		10.7326/0003-4819-116-7-583	http://dx.doi.org/10.7326/0003-4819-116-7-583			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543314				2022-12-28	WOS:A1992HL25800011
J	HEDSTROM, L; SZILAGYI, L; RUTTER, WJ				HEDSTROM, L; SZILAGYI, L; RUTTER, WJ			CONVERTING TRYPSIN TO CHYMOTRYPSIN - THE ROLE OF SURFACE LOOPS	SCIENCE			English	Article							HUMAN-LEUKOCYTE ELASTASE; STREPTOMYCES-GRISEUS PROTEASE-3; REFINED CRYSTAL-STRUCTURE; ALPHA-CHYMOTRYPSIN; CRYSTALLOGRAPHIC REFINEMENT; SUBSTRATE-SPECIFICITY; CATALYZED HYDROLYSIS; PARA-NITROANILIDES; BOVINE TRYPSIN; BINDING POCKET	Trypsin (Tr) and chymotrypsin (Ch) have similar tertiary structures, yet Tr cleaves peptides at arginine and lysine residues and Ch prefers large hydrophobic residues. Although replacement of the S1 binding site of Tr with the analogous residues of Ch is sufficient to transfer Ch specificity for ester hydrolysis, specificity for amide hydrolysis is not transferred. Trypsin is converted to a Ch-like protease when the binding pocket alterations are further modified by exchange of the Ch surface loops 185 through 188 and 221 through 225 for the analogous Tr loops. These loops are not structural components of either the S1 binding site or the extended substrate binding sites. This mutant enzyme is equivalent to Ch in its catalytic rate, but its substrate binding is impaired. Like Ch, this mutant utilizes extended substrate binding to accelerate catalysis, and substrate discrimination occurs during the acylation step rather than in substrate binding.	UNIV CALIF SAN FRANCISCO, HORMONE RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; EOTVOS LORAND UNIV, DEPT BIOCHEM, H-1364 BUDAPEST 5, HUNGARY	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Eotvos Lorand University					NIDDK NIH HHS [DK21344] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021344, R56DK021344, R01DK021344] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUER CA, 1978, BIOCHEMISTRY-US, V17, P375, DOI 10.1021/bi00595a028; BAUER CA, 1976, BIOCHEMISTRY-US, V15, P1291, DOI 10.1021/bi00651a019; BENDER ML, 1964, J AM CHEM SOC, V86, P3697, DOI 10.1021/ja01072a019; BLEVINS RA, 1985, J BIOL CHEM, V260, P4264; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BRADY K, 1990, BIOCHEMISTRY-US, V29, P7608, DOI 10.1021/bi00485a010; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; BROWN JR, 1966, BIOCHEM J, V101, P214, DOI 10.1042/bj1010214; CHRISTENSEN U, 1979, BIOCHIM BIOPHYS ACTA, V569, P177, DOI 10.1016/0005-2744(79)90052-4; COHEN GH, 1981, J MOL BIOL, V148, P449, DOI 10.1016/0022-2836(81)90186-8; CRAIK CS, 1984, J BIOL CHEM, V259, P4255; de Haen C, 1975, J Mol Biol, V92, P225, DOI 10.1016/0022-2836(75)90225-9; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GRAF L, 1987, BIOCHEMISTRY-US, V26, P2616, DOI 10.1021/bi00383a031; GRAF L, 1988, P NATL ACAD SCI USA, V85, P4961, DOI 10.1073/pnas.85.14.4961; GRAF L, 1990, PROTEIN STRUCTURE-FUNCTION, P49; HARPER JW, 1981, ANAL BIOCHEM, V118, P382, DOI 10.1016/0003-2697(81)90597-2; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; JONES PG, 1979, J CHEM SOC CHEM COMM, P288, DOI 10.1039/c39790000288; MOORE DE, 1975, BIOCHEMISTRY-US, V14, P2386, DOI 10.1021/bi00682a018; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; PHILLIPS MA, 1990, J BIOL CHEM, V265, P20692; PINSKY SD, 1983, P NATL ACAD SCI-BIOL, V80, P7486, DOI 10.1073/pnas.80.24.7486; Polgar L., 1989, MECHANISMS PROTEASE; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SHOTTON D M, 1970, Nature (London), V225, P811, DOI 10.1038/225811a0; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P1301, DOI 10.1021/bi00379a015; STEIN RL, 1984, J AM CHEM SOC, V106, P796, DOI 10.1021/ja00315a059; STEITZ TA, 1969, J MOL BIOL, V46, P337, DOI 10.1016/0022-2836(69)90426-4; STROUD RM, 1974, J MOL BIOL, V83, P185, DOI 10.1016/0022-2836(74)90387-8; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; THOMPSON RC, 1973, BIOCHEMISTRY-US, V12, P57, DOI 10.1021/bi00725a011; THOMPSON RC, 1970, P NATL ACAD SCI USA, V67, P1734, DOI 10.1073/pnas.67.4.1734; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; TITANI K, 1975, BIOCHEMISTRY-US, V14, P1358, DOI 10.1021/bi00678a003; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YOSHIDA N, 1980, BIOCHEMISTRY-US, V19, P5799, DOI 10.1021/bi00566a021; ZERNER B, 1964, J AM CHEM SOC, V86, P3669, DOI 10.1021/ja01072a015; ZIMMERMAN M, 1977, ANAL BIOCHEM, V78, P47, DOI 10.1016/0003-2697(77)90006-9	44	442	473	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1249	1253		10.1126/science.1546324	http://dx.doi.org/10.1126/science.1546324			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546324				2022-12-28	WOS:A1992HG67700041
J	KIM, SH				KIM, SH			BETA-RIBBON - A NEW DNA RECOGNITION MOTIF	SCIENCE			English	Editorial Material							BINDING; PROTEIN; RNA; MODEL		UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	KIM, SH (corresponding author), UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720, USA.							BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; CARTER CW, 1974, P NATL ACAD SCI USA, V71, P283, DOI 10.1073/pnas.71.2.283; CHURCH GM, 1977, P NATL ACAD SCI USA, V74, P1458, DOI 10.1073/pnas.74.4.1458; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; SOMERS W, UNPUB; SOMERS WS, 1990, THESIS U LEEDS UK; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; WARRANT RW, 1978, NATURE, V271, P130, DOI 10.1038/271130a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	12	14	14	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1217	1218		10.1126/science.1546321	http://dx.doi.org/10.1126/science.1546321			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546321				2022-12-28	WOS:A1992HG67700031
J	ALBRIGHT, TD				ALBRIGHT, TD			FORM-CUE INVARIANT MOTION PROCESSING IN PRIMATE VISUAL-CORTEX	SCIENCE			English	Article							SUPERIOR TEMPORAL SULCUS; STRIATE PROJECTION ZONE; AREA MT; TOPOGRAPHIC ORGANIZATION; FUNCTIONAL-PROPERTIES; RECEPTIVE-FIELDS; MACAQUE MONKEY; HUMAN-VISION; SIMPLE CELLS; PERCEPTION	The direction and rate at which an object moves are normally not correlated with the manifold physical cues (for example, brightness and texture) that enable it to be seen. As befits its goals, human perception of visual motion largely evades this diversity of cues for image form; direction and rate of motion are perceived (with few exceptions) in a fashion that does not depend on the physical characteristics of the object. The middle temporal visual area of the primate cerebral cortex contains many neurons that respond selectively to motion in a particular direction and is an integral part of the neural substrate for perception of motion. When stimulated with moving patterns characterized by one of three very diverse cues for form, many middle temporal neurons exhibited similar directional tuning. This lack of sensitivity for figural cue characteristics may allow the uniform perception of motion of objects having a broad spectrum of physical cues.			ALBRIGHT, TD (corresponding author), SALK INST BIOL STUDIES, LA JOLLA, CA 92186 USA.							ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; ALBRIGHT T D, 1987, Society for Neuroscience Abstracts, V13, P1626; ALBRIGHT T D, 1989, Society for Neuroscience Abstracts, V15, P323; ALBRIGHT TD, 1989, VISUAL NEUROSCI, V2, P177, DOI 10.1017/S0952523800012037; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ANDERSON CH, 1985, SPIE P INTELL ROBOTS, V579, P71; BATSCHELET E, 1965, STATISTICAL METHODS; CAVANAGH P, 1989, Spatial Vision, V4, P103, DOI 10.1163/156856889X00077; CHARLES E R, 1989, Investigative Ophthalmology and Visual Science, V30, P427; CHAUDHURI A, UNPUB; CHUBB C, 1988, J OPT SOC AM A, V5, P1986, DOI 10.1364/JOSAA.5.001986; DOBKINS KR, 1991, INVEST OPHTH VIS SCI, V32, P823; FAHLE M, 1981, PROC R SOC SER B-BIO, V213, P451, DOI 10.1098/rspb.1981.0075; GATTASS R, 1981, J NEUROPHYSIOL, V46, P621, DOI 10.1152/jn.1981.46.3.621; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; KELLY DH, 1972, VISION RES, V12, P89, DOI 10.1016/0042-6989(72)90139-3; LELKENS AMM, 1984, VISION RES, V24, P1083, DOI 10.1016/0042-6989(84)90086-5; LEVINSON E, 1975, J PHYSIOL-LONDON, V250, P347, DOI 10.1113/jphysiol.1975.sp011058; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MOVSHON J A, 1991, Society for Neuroscience Abstracts, V17, P524; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P53, DOI 10.1113/jphysiol.1978.sp012488; PANTLE A, 1974, VISION RES, V14, P1229, DOI 10.1016/0042-6989(74)90221-1; PANTLE A, 1986, Investigative Ophthalmology and Visual Science, V27, P141; PETERSIK JT, 1978, PERCEPTION, V7, P371, DOI 10.1068/p070371; POLLEN DA, 1981, SCIENCE, V212, P1409, DOI 10.1126/science.7233231; RAMACHAN.VS, 1973, VISION RES, V13, P1399, DOI 10.1016/0042-6989(73)90219-8; Reichardt W, 1961, SENS COMMUN, P303; REID RC, 1987, P NATL ACAD SCI USA, V84, P8740, DOI 10.1073/pnas.84.23.8740; SAITO H, 1989, EXP BRAIN RES, V75, P1; SCHILLER PH, 1976, J NEUROPHYSIOL, V39, P1288, DOI 10.1152/jn.1976.39.6.1288; SPERLING G, 1976, BEHAV RES METH INSTR, V8, P144, DOI 10.3758/BF03201762; STONER GR, IN PRESS VISION RES; UNGERLEIDER LG, 1979, J COMP NEUROL, V188, P347, DOI 10.1002/cne.901880302; VANESSEN DC, 1981, J COMP NEUROL, V199, P293, DOI 10.1002/cne.901990302; VANSANTEN JPH, 1984, J OPT SOC AM A, V1, P451, DOI 10.1364/JOSAA.1.000451; VICTOR JD, 1990, VISION RES, V30, P289, DOI 10.1016/0042-6989(90)90044-L; WATSON AB, 1985, J OPT SOC AM A, V2, P322, DOI 10.1364/JOSAA.2.000322; ZEKI SM, 1974, J PHYSIOL-LONDON, V236, P549, DOI 10.1113/jphysiol.1974.sp010452	38	261	263	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 28	1992	255	5048					1141	1143		10.1126/science.1546317	http://dx.doi.org/10.1126/science.1546317			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546317				2022-12-28	WOS:A1992HF63200046
J	CULLITON, JJ				CULLITON, JJ			INDIRECT COSTS ARE REAL COSTS AT MASSACHUSETTS INSTITUTE OF TECHNOLOGY	SCIENCE			English	Editorial Material											CULLITON, JJ (corresponding author), MIT,OFF FINANCIAL OPERAT,CAMBRIDGE,MA 02139, USA.								0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					778	779		10.1126/science.1535998	http://dx.doi.org/10.1126/science.1535998			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1535998				2022-12-28	WOS:A1992HD54800002
J	ATTAYA, M; JAMESON, S; MARTINEZ, CK; HERMEL, E; ALDRICH, C; FORMAN, J; LINDAHL, KF; BEVAN, MJ; MONACO, JJ				ATTAYA, M; JAMESON, S; MARTINEZ, CK; HERMEL, E; ALDRICH, C; FORMAN, J; LINDAHL, KF; BEVAN, MJ; MONACO, JJ			HAM-2 CORRECTS THE CLASS-I ANTIGEN-PROCESSING DEFECT IN RMA-S CELLS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCLONAL-ANTIBODIES; VIRAL PEPTIDES; LYMPHOCYTES-T; MHC; MOLECULES; REGION; GENE; DETERMINANT; EXPRESSION	THE murine major histocompatibility complex (MHC) contains two genes (Ham-1 and Ham-2) that encode members of a super-family of ATP-dependent transport proteins 1,2. These genes are believed to mediate the transport of peptide antigen from the cytoplasm into the lumen of the endoplasmic reticulum for binding by MHC class I molecules. Evidence for such a function has come from the rescue of class I surface expression by a cloned copy of the human homologue of Ham-1, PSF-1, in a human cell line that is defective in antigen processing 3. A mutant murine cell line, RMA-S, has an identical antigen-processing-defective phenotype 4,5. Here we show that expression of a cloned copy of the Ham-2 gene in RMA-S cells results in recovery of the ability to process and present class I-restricted antigens to cytotoxic T lymphocytes, and in partial recovery of class I surface expression. Processing defects for classical (H-2 K and D) and non-classical (Qa1 and HMT) class I molecules are corrected by Ham-2. These data indicate that both MHC-linked transporter genes are probably required for class I antigen processing, and that the functional transporter in this pathway may consist of a Ham-1/Ham-2 heterodimer.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298; UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,GRAD IMMUNOL PROGRAM,DALLAS,TX 75235	Virginia Commonwealth University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Jameson, Stephen C/D-9892-2013	Jameson, Stephen C/0000-0001-9137-1146				ALDRICH CJ, 1988, IMMUNOGENETICS, V28, P334, DOI 10.1007/BF00364232; CARBONE FR, 1988, J EXP MED, V167, P1767, DOI 10.1084/jem.167.6.1767; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; HERMEL E, 1991, INT IMMUNOL, V3, P407, DOI 10.1093/intimm/3.4.407; HOSKEN NA, 1989, J IMMUNOL, V142, P1079; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HOSKEN NA, IN PRESS J EXP MED; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LINDAHL KF, 1986, J EXP MED, V163, P334, DOI 10.1084/jem.163.2.334; LINDAHL KF, 1991, ANNU REV IMMUNOL, V9, P351, DOI 10.1146/annurev.iy.09.040191.002031; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MONACO J, IN PRESS J IMMUN RES; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NIKOLICZUGIC J, 1990, EUR J IMMUNOL, V20, P2431, DOI 10.1002/eji.1830201111; OZATO K, 1980, J IMMUNOL, V125, P2473; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P4200, DOI 10.1073/pnas.88.10.4200; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TADA N, 1980, IMMUNOGENETICS, V11, P441, DOI 10.1007/BF01567813; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0	31	296	302	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					647	649		10.1038/355647a0	http://dx.doi.org/10.1038/355647a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538753				2022-12-28	WOS:A1992HD54700059
J	ANTMAN, EM; LAU, J; KUPELNICK, B; MOSTELLER, F; CHALMERS, TC				ANTMAN, EM; LAU, J; KUPELNICK, B; MOSTELLER, F; CHALMERS, TC			A COMPARISON OF RESULTS OF METAANALYSES OF RANDOMIZED CONTROL TRIALS AND RECOMMENDATIONS OF CLINICAL EXPERTS - TREATMENTS FOR MYOCARDIAL-INFARCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SCIENTIFIC DISCIPLINE; REPLICATE VARIABILITY; THROMBOLYTIC THERAPY; MORTALITY; STREPTOKINASE; INTRACORONARY; REHABILITATION; METAANALYSIS; CHOLESTEROL	Objective.-To examine the temporal relationship between accumulating data from randomized control trials of treatments for myocardial infarction and the recommendations of clinical experts writing review articles and textbook chapters. Data Sources.-(1) MEDLINE search from 1966 to present; search terms used were myocardial infarction, clinical trials, multicenter studies, double-blind method, meta-analysis, and the text word "random:"; (2) references from pertinent articles and books; and (3) all editions of English-language general medical texts and manuals and review articles on treatment of myocardial infarction. Study Selection.-Randomized control trials of therapies for reducing the risk of total mortality in myocardial infarction (acute and secondary prevention). Review articles and textbook chapters dealing with the general clinical management of patients with myocardial infarction. Data Extraction.-Two authors read the material and recorded the results; disagreements were resolved by conference. Data Synthesis.-We used the technique of cumulative meta-analysis (performing a new meta-analysis when the results of a new clinical trial are published) and compared the results with the recommendations of the experts for various treatments for myocardial infarction. Discrepancies were detected between the meta-analytic patterns of effectiveness in the randomized trials and the recommendations of reviewers. Review articles often failed to mention important advances or exhibited delays in recommending effective preventive measures. In some cases, treatments that have no effect on mortality or are potentially harmful continued to be recommended by several clinical experts. Conclusions.-Finding and analyzing all therapeutic trials in a given field has become such a difficult and specialized task that the clinical experts called on to summarize the evidence in a timely fashion need access to better databases and new statistical techniques to assist them in this important task.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, TECHNOL ASSESSMENT GRP, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; NEW ENGLAND MED CTR HOSP, CTR CARDIOVASC HLTH SERV RES, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; DEPT VET AFFAIRS MED CTR, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Tufts Medical Center; Harvard University; Harvard Medical School					AHRQ HHS [R01 HS-05936, 1-PO1-HS-06341-02] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1980, LANCET, V1, P1172; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1988, BRIT MED J, V296, P320; BABER NS, 1983, CIRCULATION, V67, P71; BABER NS, 1982, BRIT MED J, V284, P1749, DOI 10.1136/bmj.284.6331.1749; CANNER PL, 1987, STAT MED, V6, P255, DOI 10.1002/sim.4780060310; CANNER PL, 1983, ISRAEL J MED SCI, V19, P413; CHALMERS I, 1991, BRIT MED J, P127; CHALMERS I, 1991, OXFORD DATABASE PERI; CHALMERS TC, 1987, STAT MED, V6, P733, DOI 10.1002/sim.4780060704; CHALMERS TC, 1977, NEW ENGL J MED, V297, P1091, DOI 10.1056/NEJM197711172972004; CHALMERS TC, 1982, T AM CLIN CLIMAT ASS, V94, P204; ERKELENS DW, 1990, CARDIOLOGY, V77, P33; FREIMAN JA, 1992, MED USES STATISTICS; FURBERG CD, 1983, CIRCULATION, V67, P83; FURBERG CD, 1984, AM J CARDIOL, V53, P626, DOI 10.1016/0002-9149(84)90042-0; HELD PH, 1990, CIRCULATION, V82, P1668, DOI 10.1161/01.CIR.82.5.1668; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; KAPLAN K, 1986, ARCH INTERN MED, V146, P593, DOI 10.1001/archinte.146.3.593; LAU J, IN PRESS N ENGL J ME; LEIZOROVICZ A, 1983, EUR J CLIN PHARMACOL, V24, P333, DOI 10.1007/BF00610050; LEWIS JA, 1982, BRIT J CLIN PHARMACO, V14, pS15, DOI 10.1111/j.1365-2125.1982.tb02055.x; Lewis JA., 1982, PRIM CARDIOL, V1, P31; LOELIGER EA, 1981, ACTA MED SCAND, P305; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MACMAHON S, 1987, ACUTE CORONARY CARE, P51; MARDER VJ, 1984, AM J MED, V77, P921, DOI 10.1016/0002-9343(84)90543-6; MAY GS, 1982, PROG CARDIOVASC DIS, V24, P331, DOI 10.1016/0033-0620(82)90010-X; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; NAYLOR CD, 1990, JAMA-J AM MED ASSOC, V264, P697, DOI 10.1001/jama.264.6.697; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; PATEL B, 1987, AM J CARDIOL, V59, P501, DOI 10.1016/0002-9149(87)91156-8; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; STAMPFER MJ, 1982, NEW ENGL J MED, V307, P1180, DOI 10.1056/NEJM198211043071904; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; Topol E J, 1989, Cardiol Clin, V7, P827; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1988, LANCET, V1, P1088; 1982, LANCET, V1, P1159	48	1051	1071	0	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					240	248		10.1001/jama.268.2.240	http://dx.doi.org/10.1001/jama.268.2.240			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1535110				2022-12-28	WOS:A1992JB27900032
J	BILEZIKIAN, JP				BILEZIKIAN, JP			DRUG-THERAPY - MANAGEMENT OF ACUTE HYPERCALCEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CANCER-ASSOCIATED HYPERCALCEMIA; MALIGNANCY-ASSOCIATED HYPERCALCEMIA; INTRAVENOUS DICHLOROMETHYLENE DIPHOSPHONATE; PARATHYROID-HORMONE SECRETION; ETIDRONATE DISODIUM; GALLIUM NITRATE; AMINOHYDROXYPROPYLIDENE DIPHOSPHONATE; CIRCULATING CONCENTRATIONS; HUMORAL HYPERCALCEMIA; CALCIUM REABSORPTION		COLUMBIA UNIV COLL PHYS & SURG, DEPT PHARMACOL, NEW YORK, NY 10032 USA	Columbia University	BILEZIKIAN, JP (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT MED 9-410, 630 W 168TH ST, NEW YORK, NY 10032 USA.				NIDDK NIH HHS [R01 DK032333, DK32333] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032333] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1991, J Bone Miner Res, V6 Suppl 2, pS1; ATTIE MF, 1985, J CLIN INVEST, V75, P1191, DOI 10.1172/JCI111815; ATTIE MF, 1989, ENDOCRIN METAB CLIN, V18, P807, DOI 10.1016/S0889-8529(18)30368-2; BERESFORD JN, 1986, ENDOCRINOLOGY, V119, P1776, DOI 10.1210/endo-119-4-1776; BILEZIKIAN JP, 1990, NEW ENGL J MED, V322, P1151, DOI 10.1056/NEJM199004193221610; Bilezikian JP, 1991, CURRENT THERAPY ENDO, P448; Bilezikian JP, 1992, DISORDERS BONE MINER, P493; BINSTOCK ML, 1980, ANN INTERN MED, V93, P269, DOI 10.7326/0003-4819-93-2-269; BOCKMAN RS, 1986, CALCIFIED TISSUE INT, V39, P376, DOI 10.1007/BF02555174; BONJOUR JP, 1990, CALCIFIED TISSUE INT, V46, pS20, DOI 10.1007/BF02553289; BRENNER DE, 1982, CANCER-AM CANCER SOC, V49, P556, DOI 10.1002/1097-0142(19820201)49:3<556::AID-CNCR2820490327>3.0.CO;2-Z; BRERETON HD, 1974, NEW ENGL J MED, V291, P83, DOI 10.1056/NEJM197407112910207; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BUDAYR AA, 1989, ANN INTERN MED, V111, P807, DOI 10.7326/0003-4819-111-10-807; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; CANIGGIA A, 1981, J STEROID BIOCHEM, V15, P153, DOI 10.1016/0022-4731(81)90270-3; CANTWELL BMJ, 1987, BRIT MED J, V294, P467, DOI 10.1136/bmj.294.6570.467; CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459; CARDELLA CJ, 1979, CLIN NEPHROL, V12, P285; CAREY RW, 1968, ARCH INTERN MED, V122, P150, DOI 10.1001/archinte.122.2.150; CHAPUY MC, 1980, J CLIN INVEST, V65, P1243, DOI 10.1172/JCI109780; COHEN AI, 1981, CANCER TREAT REP, V65, P651; COOMBES RC, 1976, PROSTAGLANDINS, V12, P1027, DOI 10.1016/0090-6980(76)90136-2; DELMAS PD, 1982, METAB BONE DIS RELAT, V4, P163, DOI 10.1016/0221-8747(82)90013-3; DOUGLAS DL, 1980, LANCET, V1, P1043; ELOMAA I, 1985, LANCET, V1, P1155; FALLON MD, 1984, CALCIFIED TISSUE INT, V36, P481; FAST DK, 1978, BIOCHEM J, V172, P97, DOI 10.1042/bj1720097; FATEMI S, 1992, CALCIFIED TISSUE INT, V50, P107, DOI 10.1007/BF00298784; FELIX R, 1981, CALCIFIED TISSUE INT, V33, P549, DOI 10.1007/BF02409488; FITTON A, 1991, DRUGS, V41, P289, DOI 10.2165/00003495-199141020-00009; FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262; FLEISCH H, 1987, BONE, V8, pS23; Fleisch H, 1989, Recent Results Cancer Res, V116, P1; GLOVER D, 1983, NEW ENGL J MED, V309, P1137, DOI 10.1056/NEJM198311103091901; GLOVER D, 1986, INT J RADIAT ONCOL, V12, P1509, DOI 10.1016/0360-3016(86)90205-1; GLOVER DJ, 1985, ANN INTERN MED, V103, P55, DOI 10.7326/0003-4819-103-1-55; GOODWIN JS, 1986, J CLIN INVEST, V77, P1244, DOI 10.1172/JCI112427; GREEN L, 1984, CANCER TREAT REP, V68, P1379; GUCALP R, 1992, J CLIN ONCOL, V10, P134, DOI 10.1200/JCO.1992.10.1.134; HARINCK HIJ, 1987, AM J MED, V82, P1133, DOI 10.1016/0002-9343(87)90215-4; HASLING C, 1987, AM J MED, V82, P51, DOI 10.1016/0002-9343(87)90487-6; HENDERSON JE, 1990, J BONE MINER RES, V5, P105, DOI 10.1002/jbmr.5650050203; HEYBURN PJ, 1980, BRIT MED J, V280, P525, DOI 10.1136/bmj.280.6213.525; HIRSCHELSCHOLZ S, 1985, CLIN ENDOCRINOL, V23, P313, DOI 10.1111/j.1365-2265.1985.tb00229.x; HIRSCHELSCHOLZ S, 1986, J CLIN INVEST, V78, P319, DOI 10.1172/JCI112568; HIRSCHELSCHOLZ S, 1985, J CLIN INVEST, V76, P1851, DOI 10.1172/JCI112178; HOSKING DJ, 1990, EUR J CLIN PHARMACOL, V38, P37, DOI 10.1007/BF00314800; HOSKING DJ, 1981, Q J MED, V50, P473; HOSKING DJ, 1984, Q J MED, V53, P359; JACOBS TP, 1981, ANN INTERN MED, V94, P312, DOI 10.7326/0003-4819-94-3-312; JACOBS TP, 1987, AM J MED, V82, P42, DOI 10.1016/0002-9343(87)90486-4; JUNG A, 1983, NEW ENGL J MED, V308, P1499, DOI 10.1056/NEJM198306233082503; KANIS JA, 1987, AM J MED, V82, P55, DOI 10.1016/0002-9343(87)90488-8; KAO PC, 1990, MAYO CLIN PROC, V65, P1399, DOI 10.1016/S0025-6196(12)62163-6; KIANG DT, 1979, J CLIN ENDOCR METAB, V48, P341, DOI 10.1210/jcem-48-2-341; MARTIN TJ, 1987, CLIN ENDOCRINOLOGY C, P1; MAUTALEN C, 1986, CLIN ORTHOP RELAT R, P150; MEUNIER PJ, 1987, AM J MED, V82, P71, DOI 10.1016/0002-9343(87)90489-X; MINKIN C, 1973, CALC TISS RES, V13, P249, DOI 10.1007/BF02015415; MUNDY GR, 1988, J CLIN INVEST, V82, P1, DOI 10.1172/JCI113555; MUNDY GR, 1990, INTERNAL MED, P2379; NORDIN BEC, 1976, CALCIUM PHOSPHATE MA, P186; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; PERCIVAL RC, 1984, BRIT MED J, V289, P287, DOI 10.1136/bmj.289.6440.287; Perlia C P, 1970, Cancer, V25, P389, DOI 10.1002/1097-0142(197002)25:2<389::AID-CNCR2820250217>3.0.CO;2-X; POTTS JT, 1990, J CLIN ENDOCR METAB, V70, P1489, DOI 10.1210/jcem-70-6-1489; POTTS JT, 1991, ANN INTERN MED, V114, P593, DOI 10.7326/0003-4819-114-7-593; RALSTON SH, 1986, BRIT MED J, V292, P1549, DOI 10.1136/bmj.292.6535.1549; RALSTON SH, 1988, Q J MED, V69, P825; RALSTON SH, 1990, ANN INTERN MED, V112, P499, DOI 10.7326/0003-4819-112-7-499; RALSTON SH, 1985, LANCET, V2, P907; RINGENBERG QS, 1987, CLIN THER, V9, P318; RITCH PS, 1990, SEMIN ONCOL, V17, P26; RYZEN E, 1985, ARCH INTERN MED, V145, P449, DOI 10.1001/archinte.145.3.449; SANDLER LM, 1984, Q J MED, V53, P165; SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107; SCHILLER JH, 1987, ARCH INTERN MED, V147, P963, DOI 10.1001/archinte.147.5.963; SEYBERTH HW, 1975, NEW ENGL J MED, V293, P1278, DOI 10.1056/NEJM197512182932502; SHACKNEY S, 1967, ANN INTERN MED, V66, P906, DOI 10.7326/0003-4819-66-5-906; SHANE E, 1982, AM J MED, V72, P939, DOI 10.1016/0002-9343(82)90855-5; SHANE E, 1990, ASBMR PRIMER METABOL, P107; SILVA OL, 1973, ARCH INTERN MED, V132, P337, DOI 10.1001/archinte.132.3.337; SINGER FR, 1990, SEMIN ONCOL, V17, P34; SINGER FR, 1991, ARCH INTERN MED, V151, P471, DOI 10.1001/archinte.151.3.471; SIRIS ES, 1980, NEW ENGL J MED, V302, P310, DOI 10.1056/NEJM198002073020602; Slavik M, 1975, Adv Pharmacol Chemother, V12, P1, DOI 10.1016/S1054-3589(08)60218-5; SLEEBOOM HP, 1982, CONTRIB NEPHROL, V33, P178; STEWART AF, 1983, AM J MED, V74, P475, DOI 10.1016/0002-9343(83)90985-3; SUKI WN, 1970, NEW ENGL J MED, V283, P836, DOI 10.1056/NEJM197010152831603; THIEBAUD D, 1990, J BONE MINER RES, V5, P221, DOI 10.1002/jbmr.5650050304; THIEBAUD D, 1986, BONE, V7, P247, DOI 10.1016/8756-3282(86)90203-6; THIEBAUD D, 1990, ARCH INTERN MED, V150, P2125, DOI 10.1001/archinte.150.10.2125; VANHOLTENVERZANTVOORT AT, 1987, LANCET, V2, P983; VERNAVA AM, 1987, SURGERY, V102, P941; Warrell R P Jr, 1989, Important Adv Oncol, P205; WARRELL RP, 1988, ANN INTERN MED, V108, P669, DOI 10.7326/0003-4819-108-5-669; WARRELL RP, 1984, J CLIN INVEST, V73, P1487, DOI 10.1172/JCI111353; WARRELL RP, 1987, J CLIN ONCOL, V5, P292, DOI 10.1200/JCO.1987.5.2.292; WARRELL RP, 1990, ANN INTERN MED, V113, P847, DOI 10.7326/0003-4819-113-11-847; WARRELL RP, 1991, J CLIN ONCOL, V9, P1467, DOI 10.1200/JCO.1991.9.8.1467; WISNESKI LA, 1990, CALCIFIED TISSUE INT, V46, pS26, DOI 10.1007/BF02553290	102	151	156	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 30	1992	326	18					1196	1203						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR008	1532633				2022-12-28	WOS:A1992HR00800006
J	WEISSMANN, P; CHIN, MT; MOSS, AJ				WEISSMANN, P; CHIN, MT; MOSS, AJ			CARDIAC TACHYPACING FOR SEVERE REFRACTORY IDIOPATHIC ORTHOSTATIC HYPOTENSION	ANNALS OF INTERNAL MEDICINE			English	Note						HYPOTENSION; BRADYCARDIA; CARDIAC PACING, ARTIFICIAL; PACEMAKER, ARTIFICIAL		Idiopathic orthostatic hypotension can be a disabling disorder. Conventional medical therapy has included various attempts to expand total fluid volume and to enhance arterial and venous vasoconstriction. We report five patients (one previously reported) with this disorder, all with fixed bradycardia and disabling symptoms, refractory to conventional therapy including fluorocortisone and salt loading. These patients received pacemakers in an attempt to correct their fixed bradycardia. In four cases, improved standing blood pressure was documented, and patients noted improvement in symptoms, maintained for at least 1 year. Cardiac tachypacing is useful adjunct therapy in patients with severe, refractory idiopathic orthostatic hypotension and fixed bradycardia.	UNIV ROCHESTER, MED CTR,SCH MED & DENT,225 CRITTENDEN BLVD, RM 123 HWH, ROCHESTER, NY 14642 USA	University of Rochester			Weissmann, Peter/L-1074-2019					Bradbury S, 1925, AM HEART J, V1, P73, DOI 10.1016/S0002-8703(25)90007-5; BREVETTI G, 1981, AM HEART J, V102, P938, DOI 10.1016/0002-8703(81)90049-1; GOLDBERG MR, 1980, NEW ENGL J MED, V303, P885; KRISTINSSON A, 1983, ACTA MED SCAND, V214, P79; MOSS AJ, 1980, NEW ENGL J MED, V302, P1456, DOI 10.1056/NEJM198006263022606; ONROT J, 1986, AM J MED, V80, P454, DOI 10.1016/0002-9343(86)90720-5; ROBERTSON D, 1985, MOD CONC CARDIOV DIS, V54, P7; SHY GM, 1960, ARCH NEUROL-CHICAGO, V2, P511, DOI 10.1001/archneur.1960.03840110025004; ZIEGLER MG, 1977, NEW ENGL J MED, V296, P293, DOI 10.1056/NEJM197702102960601; 1987, LANCET, V1, P19	10	15	15	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					650	651		10.7326/0003-4819-116-8-650	http://dx.doi.org/10.7326/0003-4819-116-8-650			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546865				2022-12-28	WOS:A1992HN84400007
J	ESOLEN, LM; FASANO, MB; FLYNN, J; BURTON, A; LEDERMAN, HM				ESOLEN, LM; FASANO, MB; FLYNN, J; BURTON, A; LEDERMAN, HM			PNEUMOCYSTIS-CARINII OSTEOMYELITIS IN A PATIENT WITH COMMON VARIABLE IMMUNODEFICIENCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							EXTRAPULMONARY PNEUMOCYSTOSIS; INFECTION; PNEUMONIA; HYPOGAMMAGLOBULINEMIA; RESPONSES		JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV INFECT DIS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV RHEUMATOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,EUDOWOOD DIV PEDIAT ALLERGY & IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Fasano, Mary/0000-0001-8468-1605				AWEN CF, 1971, CAN MED ASSOC J, V104, P809; COHEN OJ, 1991, ARCH INTERN MED, V151, P1205, DOI 10.1001/archinte.151.6.1205; COULMAN CU, 1987, ANN INTERN MED, V106, P396, DOI 10.7326/0003-4819-106-3-396; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; GALLANT JE, 1988, AM J MED, V84, P303, DOI 10.1016/0002-9343(88)90429-9; GHERMAN CR, 1988, AM J MED, V85, P250, DOI 10.1016/S0002-9343(88)80354-1; HAGLER DN, 1988, CLIN EXP IMMUNOL, V74, P7; HERBERMAN RB, 1986, MANUAL CLIN LABORATO, P308; HOFMANN B, 1985, J INFECT DIS, V152, P838, DOI 10.1093/infdis/152.4.838; HOFMANN B, 1988, SCAND J INFECT DIS, V20, P389, DOI 10.3109/00365548809032473; JARNUM S, 1968, ANN INTERN MED, V68, P138, DOI 10.7326/0003-4819-68-1-138; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; LEGOLVAN DP, 1973, ARCH PATHOL, V95, P344; LIVINGSTONE CS, 1964, CAN MED ASSOC J, V90, P1223; MACHER AM, 1987, NEW ENGL J MED, V316, P1092; Maluish A, 1986, MANUAL CLIN LAB IMMU, P274; PANDOLFI F, 1982, CLIN IMMUNOL IMMUNOP, V22, P323, DOI 10.1016/0090-1229(82)90049-6; RAHIMI SA, 1974, ARCH PATHOL, V97, P162; RAO CP, 1983, J PEDIATR-US, V103, P410, DOI 10.1016/S0022-3476(83)80415-6; RAVIGLIONE MC, 1988, ANN INTERN MED, V109, P253, DOI 10.7326/0003-4819-109-3-253_1; RAVIGLIONE MC, 1990, REV INFECT DIS, V12, P1127; SAULSBURY FT, 1979, J PEDIATR-US, V95, P559, DOI 10.1016/S0022-3476(79)80766-0; UNGER PD, 1988, HUM PATHOL, V19, P113, DOI 10.1016/S0046-8177(88)80327-7	23	28	28	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1992	326	15					999	1001		10.1056/NEJM199204093261506	http://dx.doi.org/10.1056/NEJM199204093261506			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM285	1545853				2022-12-28	WOS:A1992HM28500006
J	KRAVITZ, RL; GREENFIELD, S; ROGERS, W; MANNING, WG; ZUBKOFF, M; NELSON, EC; TARLOV, AR; WARE, JE				KRAVITZ, RL; GREENFIELD, S; ROGERS, W; MANNING, WG; ZUBKOFF, M; NELSON, EC; TARLOV, AR; WARE, JE			DIFFERENCES IN THE MIX OF PATIENTS AMONG MEDICAL SPECIALTIES AND SYSTEMS OF CARE - RESULTS FROM THE MEDICAL OUTCOMES STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERNISTS; MORTALITY; SEVERITY; ILLNESS	Objective. - To determine differences in the mix of patients among medical specialties and among organizational systems of care. Study Design.-Cross-sectional analysis of 20158 adults (greater-than-or-less-than 18 years of age) who visited providers' offices during 9-day screening periods in 1986. Patient and physician information was obtained by self-administered, standardized questionnaires. Setting. - Offices of 349 physicians practicing family medicine, internal medicine, endocrinology, and cardiology within health maintenance organizations, large multispecialty groups, and solo or small single-specialty group practices in three major US cities. Outcome Measures. - Demographic characteristics, prevalence of chronic disease, disease-specific severity of illness, and functional status and well-being. Results. - Among patients with selected physician-reported chronic illnesses (diabetes, hypertension, recent myocardial infarction, or congestive heart failure), increasing levels of severity were associated with decreasing levels of functional status and well-being and with increased hospitalizations, more physician visits, and higher numbers of prescription drugs. Compared with patients of general internists, patients of cardiologists were older (56 vs 47 years, P < .01), had worse functional status and well-being scores (P < .01), and carried more chronic diagnoses (mean 1.32 vs 1.02, P < .01); patients of family practitioners were younger (40 vs 47 years, P < .01) and more functional (P < .01), carried fewer chronic diagnoses (0.70 vs 1.02, P < .01), and (among diabetic patients only) had lower disease-specific severity scores (2.06 vs 2.30 on a five-point scale, P < .01). Compared with patients in health maintenance organizations, patients visiting solo practitioners under fee-for-service payment were older (50 vs 45 years, P < .01) and sicker (had worse physical functioning) and had a higher mean number of chronic diagnoses (1.10 vs 0.93, P < .01). Conclusion. - Patient mix is related to utilization and differs significantly across medical specialties and systems of care. These differences must be taken into account when interpreting variations in utilization and outcomes across specialties and systems and when considering alternative policies for payment.	RAND CORP,SANTA MONICA,CA 90406; NEW ENGLAND MED CTR HOSP,INST HLTH,BOSTON,MA 02111; TUFTS UNIV,DEPT MED,BOSTON,MA 02111; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455; HOSP CORP AMER,NASHVILLE,TN; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03756	RAND Corporation; Tufts Medical Center; Tufts University; Harvard University; Harvard T.H. Chan School of Public Health; University of Minnesota System; University of Minnesota Twin Cities; Hospital Corporation of America; Dartmouth College	KRAVITZ, RL (corresponding author), UNIV CALIF LOS ANGELES,DEPT MED,B-544,FACTOR BLDG,LOS ANGELES,CA 90024, USA.		Kravitz, Richard/AAF-7425-2021	Greenfield, Sheldon/0000-0003-4628-1998; Kravitz, Richard/0000-0001-5575-529X				BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; CHERKIN DC, 1987, MED CARE, V25, P455, DOI 10.1097/00005650-198706000-00001; CLEARY PD, 1991, JAMA-J AM MED ASSOC, V266, P73, DOI 10.1001/jama.266.1.73; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GREENFIELD S, 1990, CLIN RES, V38, P713; GREENWALD HP, 1984, MED CARE, V22, P14, DOI 10.1097/00005650-198401000-00002; HUBER PJ, 1965, 5TH P BERK S BERK, P221; Iezzoni LI, 1989, PROVIDING QUALITY CA, P70; KOOPMANS LH, 1987, INTRO CONT STATISTIC, P341; KRAVITZ RL, 1988, CLIN RES, V3, P724; LUFT HS, 1978, NEW ENGL J MED, V298, P1336, DOI 10.1056/NEJM197806152982404; LUFT HS, 1981, HLTH MAINTENANCE ORG; MYERS RH, 1986, CLASSIC MODERN REGRE, P197; NOREN J, 1980, NEW ENGL J MED, V302, P11, DOI 10.1056/NEJM198001033020103; ROGERS WH, IN PRESS MED OUTCOME; STEIN REK, 1987, LANCET, V2, P1506; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P925; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P3298, DOI 10.1001/jama.262.23.3298; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934	26	229	229	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1617	1623		10.1001/jama.267.12.1617	http://dx.doi.org/10.1001/jama.267.12.1617			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1542171				2022-12-28	WOS:A1992HJ59700028
J	FULLERTON, SH; WOODLEY, DT; SMOLLER, BR; ANHALT, GJ				FULLERTON, SH; WOODLEY, DT; SMOLLER, BR; ANHALT, GJ			PARANEOPLASTIC PEMPHIGUS WITH AUTOANTIBODY DEPOSITION IN BRONCHIAL EPITHELIUM AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							NEOPLASIA	Paraneoplastic pemphigus is a newly described syndrome in which patients have a severe mucocutaneous eruption with clinical features reminiscent of both erythema multiforme major (Stevens-Johnson syndrome) and pemphigus vulgaris, in association with non-Hodgkin's lymphomas and other malignant neoplasms. These patients have autoantibodies that bind to a characteristic set of epidermal proteins: desmoplakin I and desmoplakin II (molecular weight equals 250 kd and 210 kd, respectively), both major cytoskeletal structural proteins associated with desmosome cellular junctions within all epithelia, the bullous pemphigoid antigen, a 230 kd protein associated with hemidesmosomes, and a 190 000-d protein that has not been characterized. In this report, we describe a patient with paraneoplastic pemphigus who had (1) non-Hodgkin's lymphoma in apparent complete remission following autologous bone marrow transplantation, (2) very tense blisters reminiscent of bullous pemphigoid, (3) a unique pattern of immune deposits within the skin, and (4) IgG deposits within the epithelium of the pulmonary bronchi associated with respiratory compromise.	STANFORD UNIV,MED CTR,SCH MED,DEPT DERMATOL,ROOM 144,EDWARDS BLDG,STANFORD,CA 94305; JOHNS HOPKINS UNIV,SCH MED,DEPT DERMATOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205	Stanford University; Johns Hopkins University; Johns Hopkins University				Smoller, Bruce/0000-0002-7301-8274	NIAMS NIH HHS [K04 AR01686, R01 AR32490, R01 AR33625] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033625, R01AR032490, K04AR001686] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANHALT GJ, 1990, NEW ENGL J MED, V323, P1729, DOI 10.1056/NEJM199012203232503; OURSLER JR, 1991, CLIN RES, V39, P195; PLEWIG G, 1990, HAUTARZT, V41, P662; STANLEY JR, 1984, J CLIN INVEST, V74, P313, DOI 10.1172/JCI111426; YOUNUS J, 1990, J AM ACAD DERMATOL, V23, P498, DOI 10.1016/0190-9622(90)70249-H	5	96	102	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1500	1502						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1538540				2022-12-28	WOS:A1992HH48800031
J	KOES, BW; BOUTER, LM; VANMAMEREN, H; ESSERS, AHM; VERSTEGEN, GMJR; HOFHUIZEN, DM; HOUBEN, JP; KNIPSCHILD, PG				KOES, BW; BOUTER, LM; VANMAMEREN, H; ESSERS, AHM; VERSTEGEN, GMJR; HOFHUIZEN, DM; HOUBEN, JP; KNIPSCHILD, PG			RANDOMIZED CLINICAL-TRIAL OF MANIPULATIVE THERAPY AND PHYSIOTHERAPY FOR PERSISTENT BACK AND NECK COMPLAINTS - RESULTS OF ONE YEAR FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article							PAIN	Objective - To compare the effectiveness of manipulative therapy, physiotherapy, treatment by the general practitioner, and placebo therapy in patients with persistent non-specific back and neck complaints. Design - Randomised clinical trial. Setting - Primary health care in the Netherlands. Patients - 256 patients with non-specific back and neck complaints of at least six weeks' duration who had not received physiotherapy or manipulative therapy in the past two years. Interventions - At the discretion of the manipulative therapists, physiotherapists, and general practitioners. Physiotherapy consisted of exercises, massage, and physical therapy (heat, electrotherapy, ultrasound, shortwave diathermy). Manipulative therapy consisted of manipulation and mobilisation of the spine. Treatment by general practitioners consisted of drugs (for example, analgesics), advice about posture, home exercises, and (bed)rest. Placebo treatment consisted of detuned shortwave diathermy (10 minutes) and detuned ultrasound (10 minutes). Main outcome measures - Changes in severity of the main complaint and limitation of physical functioning measured on 10 point scales by a blinded research assistant and global perceived effect measured on a 6 point scale by the patients. Results - Many patients in the general practitioner and placebo groups received other treatment during follow up. Improvement in the main complaint was larger with manipulative therapy (4.5) than with physiotherapy (3.8) after 12 months' follow up (difference 0.9; 95% confidence interval 0.1 to 1.7). Manipulative therapy also gave larger improvements in physical functioning (difference 0.6; -0.1 to 1.3). The global perceived effect after six and 12 months' follow up was similar for both treatments. Conclusions - Manipulative therapy and physiotherapy are better than general practitioner and placebo treatment. Furthermore, manipulative therapy is slightly better than physiotherapy after 12 months.	UNIV LIMBURG,DEPT ANAT & EMBRYOL,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG HOSP,DEPT PHYSIOTHERAPY,MAASTRICHT,NETHERLANDS; INST HIGHER EDUC,DEPT PHYSIOTHERAPY,HEERLEN,NETHERLANDS; PHYSIOTHERAPY & MANUAL THERAPY PRACTICE,MAASTRICHT,NETHERLANDS	Hasselt University; Maastricht University; Maastricht University Medical Centre (MUMC)	KOES, BW (corresponding author), UNIV LIMBURG,DEPT EPIDEMIOL & BIOSTAT,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Koes, Bart w/K-4614-2016	Koes, Bart w/0000-0002-0450-9969; Bouter, Lex/0000-0002-2659-5482				BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S, V170, P11; COXHEAD CE, 1981, LANCET, V1, P1065; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; Dixon W. J., 1990, BMDP STATISTICAL SOF; DORAN DML, 1975, BRIT MED J, V2, P161, DOI 10.1136/bmj.2.5964.161; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; KOES BW, IN PRESS SPINE; KOES BW, IN PRESS J MANIPULAT; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; NACHEMSON A, 1979, SCAND J REHABIL MED, V11, P143; Siehl D, 1971, J Am Osteopath Assoc, V70, P433; SIMSWILLIAMS H, 1978, BMJ-BRIT MED J, V2, P1338, DOI 10.1136/bmj.2.6148.1338; SIMSWILLIAMS H, 1979, BMJ-BRIT MED J, V2, P1318, DOI 10.1136/bmj.2.6201.1318; SPITZER WO, 1987, SPINE S1, V1, P59; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002	17	177	179	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					601	605		10.1136/bmj.304.6827.601	http://dx.doi.org/10.1136/bmj.304.6827.601			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH733	1532760	Green Published, Bronze			2022-12-28	WOS:A1992HH73300021
J	HOLM, S				HOLM, S			MEDICINE IN EUROPE - A COMMON ETHICS FOR A COMMON-MARKET	BRITISH MEDICAL JOURNAL			English	Article									ESBJERG CENT HOSP,DEPT MED,DK-6700 ESBJERG,DENMARK		HOLM, S (corresponding author), UNIV MANCHESTER,CTR SOCIAL ETH & POLICY,MANCHESTER M13 9PL,LANCS,ENGLAND.			Holm, Soren/0000-0002-7200-5607				[Anonymous], 1980, INEQUALITIES HLTH RE; [Anonymous], 1987, INSTRUCTION RESPECT; BINAME G, 1990, INT DIG HLTH LEG, V41, P336; GLOVER J, 1989, FERTILITY FAMILY GLO; HOLM S, 1988, J MED ETHICS, V14, P77, DOI 10.1136/jme.14.2.77; ISAMBERT FA, 1989, J MED PHILOS, V14, P445, DOI 10.1093/jmp/14.4.445; KASIMBA P, 1990, EMBRYO EXPT, P227; Rix Bo Andreassen, 1991, Bioethics, V5, P250, DOI 10.1111/j.1467-8519.1991.tb00163.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WALTERS L, 1989, J MED PHILOS, V14, P363, DOI 10.1093/jmp/14.4.363; 1989, HUMAN ARTIFICIAL PRO; 1990, 1992 SOCIAL DIMENSIO; 1989, OFFICIAL J EURO 0722; 1991, B MED ETH, V69, P25; 1990, OFFICIAL J EURO 1212; 1991, 1991 EUR SCI F REP	16	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1992	304	6824					434	436		10.1136/bmj.304.6824.434	http://dx.doi.org/10.1136/bmj.304.6824.434			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HE389	1547394	Green Published, Bronze			2022-12-28	WOS:A1992HE38900026
J	VONHIPPEL, PH; YAGER, TD				VONHIPPEL, PH; YAGER, TD			THE ELONGATION-TERMINATION DECISION IN TRANSCRIPTION	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; TERNARY COMPLEXES; CHAIN ELONGATION; FACTOR-RHO; KINETICS	At any template position, the decision to extend the transcript by one residue or to release the nascent RNA represents a kinetic competition between elongation and termination pathways. This competition is discussed in terms of alternative Eyring transition state barriers; changes in termination efficiency correspond to small changes in the relative heights of these barriers. Elongation complexes are stable at nonterminator positions; a model is presented to explain the destabilization of these complexes at intrinsic termination sites. Functionally analogous effects can operate at rho-dependent terminators. Mechanisms for modulation of termination efficiency by regulatory proteins are described.	UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon	VONHIPPEL, PH (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.			von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R37GM015792, R01GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS C, 1985, J BIOL CHEM, V260, P5826; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; GILL SC, 1990, BIOPHYS CHEM, V37, P239; JIN D, IN PRESS P NATL ACAD; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MORGAN WD, 1983, J BIOL CHEM, V258, P9565; RHODES G, 1974, J BIOL CHEM, V249, P6675; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; WHELAN WL, UNPUB; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, CELLULAR MOL BIOL, P1241; YAGER TD, UNPUB; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301	15	85	85	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					809	812		10.1126/science.1536005	http://dx.doi.org/10.1126/science.1536005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1536005				2022-12-28	WOS:A1992HD54800026
J	PRANDONI, P; LENSING, AWA; BULLER, HR; COGO, A; PRINS, MH; CATTELAN, AM; CUPPINI, S; NOVENTA, F; TENCATE, JW				PRANDONI, P; LENSING, AWA; BULLER, HR; COGO, A; PRINS, MH; CATTELAN, AM; CUPPINI, S; NOVENTA, F; TENCATE, JW			DEEP-VEIN THROMBOSIS AND THE INCIDENCE OF SUBSEQUENT SYMPTOMATIC CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE PULMONARY-EMBOLISM; VENOUS THROMBOSIS; OCCULT CANCER; INITIAL TREATMENT; UNTREATED CANCER; DIAGNOSIS; HEPARIN; COMPLICATIONS; RECURRENT; SURGERY	Background. In contrast to the established relation between overt cancer and subsequent venous thromboembolism, it is unclear whether symptomatic deep-vein thrombosis is associated with a risk of subsequent overt malignant disease. Methods. Two hundred sixty consecutive patients with symptomatic, venographically proved deep-vein thrombosis were enrolled in a study, of whom 250 were followed during a two-year period. Among those assessed during follow-up, the incidence of subsequently detected cancer in the 105 patients with secondary venous thrombosis (i.e., thrombosis associated with a well-recognized risk factor other than cancer) was compared with the incidence of cancer in the 145 patients with idiopathic venous thrombosis. Results. Routine examination at the time of diagnosis of the venous thrombosis revealed cancer in 5 of the 153 enrolled patients with idiopathic venous thrombosis (3.3 percent) and in none of the 107 enrolled patients with secondary venous thrombosis. During follow-up, overt cancer developed in 2 of the 105 patients with secondary venous thrombosis (1.9 percent) and in 11 of the 145 patients with idiopathic venous thrombosis (7.6 percent; odds ratio, 2.3; 95 percent confidence interval, 1.0 to 5.2; P = 0.043). Of the 145 patients with idiopathic venous thrombosis, 35 had confirmed recurrent thromboembolism. Overt cancer subsequently developed in 6 of the 35 (17.1 percent). The incidence of cancer in the patients with recurrent idiopathic venous thrombosis was higher than that in the patients with secondary venous thrombosis (P = 0.008; odds ratio, 9.8; 95 percent confidence interval, 1.8 to 52.2) or in the patients with idiopathic venous thrombosis that did not recur (P = 0.024; odds ratio, 4.3; 95 percent confidence interval, 1.2 to 15.3). Conclusions. There is a statistically significant and clinically important association between idiopathic venous thrombosis and the subsequent development of clinically overt cancer, especially among patients in whom venous thromboembolism recurs during follow-up.	UNIV AMSTERDAM, ACAD MED CTR, CTR HAEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA, F4-237, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV HOSP PADUA, DEPT INTERNAL MED 2, PADUA, ITALY	University of Amsterdam; Academic Medical Center Amsterdam; University of Padua; Azienda Ospedaliera - Universita di Padova			Noventa, Franco/C-1202-2008	Noventa, Franco/0000-0003-4622-5523; Cattelan, Anna Maria/0000-0003-2869-2945				ACKERMAN RF, 1951, ANN INTERN MED, V34, P902, DOI 10.7326/0003-4819-34-4-902; ADERKA D, 1986, CANCER, V57, P1846, DOI 10.1002/1097-0142(19860501)57:9<1846::AID-CNCR2820570925>3.0.CO;2-3; ANLYAN WG, 1956, JAMA-J AM MED ASSOC, V161, P964, DOI 10.1001/jama.1956.62970100002009a; BIELLO DR, 1979, AM J ROENTGENOL, V133, P1033, DOI 10.2214/ajr.133.6.1033; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; DALEN JE, 1971, AM HEART J, V81, P175, DOI 10.1016/0002-8703(71)90128-1; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; GORE JM, 1982, ANN INTERN MED, V96, P556, DOI 10.7326/0003-4819-96-5-556; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HOERR SO, 1957, JAMA-J AM MED ASSOC, V164, P2033, DOI 10.1001/jama.1957.62980180001009; HUISMAN MV, 1988, ARCH INTERN MED, V148, P681, DOI 10.1001/archinte.148.3.681; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; LENSING AWA, 1990, RADIOLOGY, V177, P503, DOI 10.1148/radiology.177.2.2217792; LENSING AWA, 1992, THROMB HAEMOSTASIS, V67, P8; LENSING AWA, 1990, ANN INTERN MED, V113, P9, DOI 10.7326/0003-4819-113-1-9; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MONREAL M, 1991, CANCER, V67, P541, DOI 10.1002/1097-0142(19910115)67:2<541::AID-CNCR2820670237>3.0.CO;2-J; MONREAL M, 1988, ARCH INTERN MED, V148, P485, DOI 10.1001/archinte.148.2.485; MONREAL M, 1991, THROMB HAEMOSTASIS, V65, P1174; NAND S, 1987, J CLIN ONCOL, V5, P1998, DOI 10.1200/JCO.1987.5.12.1998; NANNINGA PB, 1990, THROMB HAEMOSTASIS, V64, P361; NASCHITZ JE, 1989, INT ANGIOL, V8, P28; OCONNOR NTJ, 1984, POSTGRAD MED J, V60, P275, DOI 10.1136/pgmj.60.702.275; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; SUELING HM, 1986, LANCET, V1, P1173; Trousseau A., 1872, LECT CLIN MED DELIVE, P281; WALSH JJ, 1974, J OBSTET GYN BR COMM, V81, P311	30	568	591	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1992	327	16					1128	1133		10.1056/NEJM199210153271604	http://dx.doi.org/10.1056/NEJM199210153271604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT153	1528208				2022-12-28	WOS:A1992JT15300004
J	COCKERILL, FR; MULLER, SR; ANHALT, JP; MARSH, HM; FARNELL, MB; MUCHA, P; GILLESPIE, DJ; ILSTRUP, DM; LARSONKELLER, JJ; THOMPSON, RL				COCKERILL, FR; MULLER, SR; ANHALT, JP; MARSH, HM; FARNELL, MB; MUCHA, P; GILLESPIE, DJ; ILSTRUP, DM; LARSONKELLER, JJ; THOMPSON, RL			PREVENTION OF INFECTION IN CRITICALLY ILL PATIENTS BY SELECTIVE DECONTAMINATION OF THE DIGESTIVE-TRACT	ANNALS OF INTERNAL MEDICINE			English	Article						INFECTION CONTROL; DIGESTIVE SYSTEM; DECONTAMINATION; INTENSIVE CARE UNITS; CEFOTAXIME	INTENSIVE-CARE UNIT; COLONIZATION; NORFLOXACIN; SEPSIS	Objective: To determine whether selective decontamination of the digestive tract using oral and nonabsorbable antimicrobial agents and parenteral cefotaxime prevents infection in critically ill patients. Design: Randomized, controlled trial without blinding. Setting: Surgical trauma and medical intensive care units in a tertiary referral hospital. Patients: One hundred fifty patients admitted to surgical trauma and medical intensive care units during a 3-year interval, whose condition suggested a prolonged stay (> 3 days). Intervention: Patients were randomly allocated to an experimental group (n = 75) that received cefotaxime, 1 g intravenously every 8 hours for the first 3 days only, and oral, nonabsorbable antibiotics (gentamicin, polymyxin, and nystatin by oral paste and oral liquid) for the entire stay in the intensive care unit. Control patients (n = 75) received usual care. Measurements: The number of infections, total hospital days, and deaths, as well as the number of days in intensive care unit, were recorded. Results: Control patients experienced more infections (36 compared with 12, P = 0.04), including bacteremias (14 compared with 4, P = 0.05) and pulmonary infections (14 compared with 4, P = 0.03). Although total hospital days, days in intensive care, and the overall death rate all were lower in the treatment group, these differences were not statistically significant. Clinically important complications of selective decontamination of the digestive tract were not encountered. Conclusions: Selective decontamination of the digestive tract decreases subsequent infection rates, especially by gram-negative bacilli, in selected patients during long-term stays in the intensive care unit.			COCKERILL, FR (corresponding author), MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA.		/AAL-3363-2020					BOW EJ, 1988, AM J MED, V84, P847, DOI 10.1016/0002-9343(88)90062-9; BRUNBUISSON C, 1989, ANN INTERN MED, V110, P873, DOI 10.7326/0003-4819-110-11-873; CHAMPION HR, 1980, CRIT CARE MED, V8, P201, DOI 10.1097/00003246-198004000-00001; FLAHERTY J, 1990, J INFECT DIS, V162, P1393, DOI 10.1093/infdis/162.6.1393; HALEY RW, 1981, AM J MED, V70, P51, DOI 10.1016/0002-9343(81)90411-3; HARTENAUER U, 1990, INFECTION, V18, pS22, DOI 10.1007/BF01644483; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; LEDINGHAM IM, 1988, LANCET, V1, P785; MCCLELLAND P, 1990, CRIT CARE MED, V18, P935, DOI 10.1097/00003246-199009000-00006; MILLER PJ, 1989, REV INFECT DIS, V11, P284; Miranda D R, 1983, Acta Anaesthesiol Belg, V34, P223; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; STOUTENBEEK CP, 1987, J ANTIMICROB CHEMOTH, V19, P513, DOI 10.1093/jac/19.4.513; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; WASHINGTON JA, 1985, LABORATORY PROCEDURE	16	86	90	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					545	553		10.7326/0003-4819-117-7-545	http://dx.doi.org/10.7326/0003-4819-117-7-545			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524328				2022-12-28	WOS:A1992JQ22600001
J	RAMIREZ, LC; ARAUZPACHECO, C; LACKNER, C; ALBRIGHT, G; ADAMS, BV; RASKIN, P				RAMIREZ, LC; ARAUZPACHECO, C; LACKNER, C; ALBRIGHT, G; ADAMS, BV; RASKIN, P			LIPOPROTEIN (A) LEVELS IN DIABETES-MELLITUS - RELATIONSHIP TO METABOLIC CONTROL	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES-MELLITUS; ATHEROSCLEROSIS; HEMOGLOBIN-A, GLYCOSYLATED; LIPOPROTEINS	LOW-DENSITY LIPOPROTEINS; CORONARY-ARTERY DISEASE; APOLIPOPROTEIN-B; HEART-DISEASE; LP(A); ATHEROSCLEROSIS; PLASMA; RISK; INFARCTION; LIPIDS	Objective: To determine the influence of diabetes control on serum lipoprotein (a) concentrations. Setting: Diabetes clinic of a large metropolitan public hospital, with primary- and secondary-care patients. Design: A cross-sectional study. Comparisons of lipoprotein (a) concentrations were made between a normal control group, a group of diabetic patients with glycated hemoglobin (HbA1c) less than 8.0%, and a group of diabetic patients with HbA1c of 8.0% or higher. Patients: Ninety-five normal controls and 93 diabetic subjects (49 with insulin-dependent diabetes mellitus and 44 with noninsulin-dependent diabetes mellitus). Results: Sixty diabetic subjects with HbA1c levels of 8.0% or higher had higher (25 mg/dL) median levels of lipoprotein (a) when compared with either 93 normal controls (8.8 mg/dL) or 33 diabetic patients with HbA1c less than 8.0% (7.5 mg/dL) (P = 0.008 and P = 0.012, respectively). A similar pattern of distribution of lipoprotein (a) levels according to degree of metabolic control was seen in patients with insulin-dependent diabetes mellitus and noninsulin-dependent diabetes mellitus. No difference in the lipoprotein (a) distribution was noted between diabetic men and women. No correlation was observed between lipoprotein (a) levels and total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels. Conclusion. Lipoprotein (a) levels are elevated in poorly controlled diabetic patients. Increased levels of lipoprotein (a) may be a contributing factor to the high risk for atherosclerosis observed in diabetic patients.	UNIV TEXAS, SW MED CTR,DEPT INTERNAL MED, 5323 HARRY HINES BLVD,G5222, DALLAS, TX 75235 USA; GENESCREEN LAB, DALLAS, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCRR NIH HHS [M01RR006331] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMER LO, 1980, ACTA ENDOCRINOL-COP, V94, P53; BEACH KW, 1980, DIABETES, V29, P882, DOI 10.2337/diabetes.29.11.882; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P162; DAHLEN G, 1975, CLIN GENET, V7, P334; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DAVIDOFF P, 1989, DIABETES S2, V38, pA70; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; Diabetes mellitus, 1985, WHO TECHNICAL REPORT, V727; DUNN FL, 1984, METABOLISM, V33, P117, DOI 10.1016/0026-0495(84)90122-7; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; FRICK MH, 1978, CHEST, V73, P62, DOI 10.1378/chest.73.1.62; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GENSINI GF, 1979, THROMB HAEMOSTASIS, V42, P983; GREENFIELD MS, 1982, ARCH INTERN MED, V142, P1498, DOI 10.1001/archinte.142.8.1498; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P265, DOI 10.1161/01.ATV.5.3.265; HAFFNER SM, 1991, DIABETES CARE, V14, P302, DOI 10.2337/diacare.14.4.302; HOWARD BV, 1987, J LIPID RES, V28, P613; KANNEL WB, 1982, DIABETES MELLITUS OB, P735; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; LEVITSKY LL, 1991, DIABETES CARE, V14, P283, DOI 10.2337/diacare.14.4.283; LORENZI M, 1984, DIABETOLOGIA, V26, P218; LUFKIN EG, 1979, METABOLISM, V28, P63, DOI 10.1016/0026-0495(79)90169-0; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MURAI A, 1986, ATHEROSCLEROSIS, V59, P199, DOI 10.1016/0021-9150(86)90048-1; NATHAN DM, 1984, CLIN CHEM, V30, P813; PYKE DA, 1979, DIABETOLOGIA, V17, P333, DOI 10.1007/BF01236266; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; ROTTER JI, 1990, DIABETES MELLITUS TH, P378; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCHONFELD G, 1974, DIABETES, V23, P827, DOI 10.2337/diab.23.10.827; STEINBRECHER UP, 1984, DIABETES, V33, P130, DOI 10.2337/diabetes.33.2.130; STOLAR MW, 1988, METABOLISM, V37, P1, DOI 10.1016/0026-0495(88)90180-1; UTERMANN G, 1989, P NATL ACAD SCI USA, V86, P4171, DOI 10.1073/pnas.86.11.4171; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; 1974, NIH DHEW753628 PUBL	38	110	110	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					42	47		10.7326/0003-4819-117-1-42	http://dx.doi.org/10.7326/0003-4819-117-1-42			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1534477				2022-12-28	WOS:A1992JA43500007
J	WALLACE, DC				WALLACE, DC			MITOCHONDRIAL GENETICS - A PARADIGM FOR AGING AND DEGENERATIVE DISEASES	SCIENCE			English	Article							KEARNS-SAYRE SYNDROME; HEREDITARY OPTIC NEUROPATHY; OXIDATIVE-PHOSPHORYLATION; PARKINSONS-DISEASE; HUNTINGTONS-DISEASE; ELECTRON-TRANSPORT; DNA MUTATIONS; COMPLEX-I; DELETIONS; SEQUENCE	Studies of diseases caused by mitochondrial DNA mutations suggest that a variety of degenerative processes may be associated with defects in oxidative phosphorylation (OXPHOS). Application of this hypothesis has provided new insights into such diverse clinical problems as ischemic heart disease, late-onset diabetes, Parkinson's disease, Alzheimer's disease, and aging.			WALLACE, DC (corresponding author), EMORY UNIV, SCH MED, DEPT GENET & MOLEC MED, ATLANTA, GA 30322 USA.				NHLBI NIH HHS [HL45572] Funding Source: Medline; NIGMS NIH HHS [GM46915] Funding Source: Medline; NINDS NIH HHS [NS21328] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T; BRENNAN WA, 1985, J NEUROCHEM, V44, P1948, DOI 10.1111/j.1471-4159.1985.tb07192.x; BROWN MD, 1992, GENETICS, V130, P163; BROWN MD, 1991, AM J HUM GENET, V49, P183; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; BU XD, 1991, P NATL ACAD SCI USA, V88, P8198, DOI 10.1073/pnas.88.18.8198; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CORMIER V, 1991, AM J HUM GENET, V48, P643; CORMIER V, 1990, J PEDIATR-US, V117, P599, DOI 10.1016/S0022-3476(05)80698-5; CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; DORNER G, 1975, ENDOKRINOLOGIE, V66, P225; DORNER G, 1987, EXP CLIN ENDOCRINOL, V89, P84; FREINKEL N, 1986, HORM METAB RES, V18, P427, DOI 10.1055/s-2007-1012338; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0; HAINES JL, 1991, AM J HUM GENET, V48, P1021; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLT IJ, 1990, AM J HUM GENET, V46, P428; HOWELL N, 1991, AM J HUM GENET, V48, P935; HOWELL N, 1991, AM J HUM GENET, V49, P939; HUOPONEN K, 1991, AM J HUM GENET, V48, P1147; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; JOHNS DR, 1991, BIOCHEM BIOPH RES CO, V174, P1324, DOI 10.1016/0006-291X(91)91567-V; JOHNSON WG, 1991, NEUROLOGY, V41, P82, DOI 10.1212/WNL.41.5_Suppl_2.82; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011; LESTIENNE P, 1988, LANCET, V1, P885; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; LOTT MT, 1990, AM J OPHTHALMOL, V109, P625, DOI 10.1016/S0002-9394(14)72429-8; MCSHANE MA, 1991, AM J HUM GENET, V48, P39; MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509; MORAES CT, 1991, AM J HUM GENET, V48, P492; MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9; MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167; MYERS RH, 1985, AM J HUM GENET, V37, P511; NEWMAN NJ, 1991, AM J OPHTHALMOL, V111, P750, DOI 10.1016/S0002-9394(14)76784-4; NEWMAN NJ, 1990, AM J OPHTHALMOL, V109, P726, DOI 10.1016/S0002-9394(14)72445-6; NOVOTNY EJ, 1986, NEUROLOGY, V36, P1053, DOI 10.1212/WNL.36.8.1053; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V170, P830, DOI 10.1016/0006-291X(90)92166-W; PARKER WD, 1990, NEUROLOGY, V40, P1231, DOI 10.1212/WNL.40.8.1231; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302; PIKO L, 1988, MECH AGEING DEV, V43, P279, DOI 10.1016/0047-6374(88)90037-1; POULTON J, 1989, LANCET, V1, P236; ROTIG A, 1988, LANCET, V2, P567; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; SHOFFNER JM, 1990, ADV HUM GENET, V19, P267; SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SHOFFNER JM, 1991, REV NEUROL-FRANCE, V147, P431; SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A; SINGER TP, 1987, J NEUROCHEM, V49, P1, DOI 10.1111/j.1471-4159.1987.tb03384.x; SINGH G, 1989, NEW ENGL J MED, V320, P1300, DOI 10.1056/NEJM198905183202002; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; Wallace D C, 1987, Birth Defects Orig Artic Ser, V23, P137; WALLACE DC, 1986, AM J HUM GENET, V38, P461; WALLACE DC, 1989, TRENDS GENET, V5, P9, DOI 10.1016/0168-9525(89)90005-X; WALLACE DC, 1986, HOSP PRACT, V21, P77; WALLACE DC, 1986, SOMAT CELL MOLEC GEN, V12, P41, DOI 10.1007/BF01560726; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; WALLACE DC, 1991, CYTOGENET CELL GENET, V58, P1103, DOI 10.1159/000133724; WALLACE DC, IN PRESS ANN NEUROL; WELSH N, 1991, DIABETOLOGIA, V34, P626, DOI 10.1007/BF00400991; YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0; YOUSUFZAI SYK, 1982, FEBS LETT, V137, P205, DOI 10.1016/0014-5793(82)80350-5; ZEVIANI M, 1988, NEUROLOGY, V38, P1339; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0	84	1126	1154	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					628	632		10.1126/science.1533953	http://dx.doi.org/10.1126/science.1533953			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1533953				2022-12-28	WOS:A1992HR18500023
J	DAVIS, TH; MORTON, CC; MILLERCASSMAN, R; BALK, SP; KADIN, ME				DAVIS, TH; MORTON, CC; MILLERCASSMAN, R; BALK, SP; KADIN, ME			HODGKINS-DISEASE, LYMPHOMATOID PAPULOSIS, AND CUTANEOUS T-CELL LYMPHOMA DERIVED FROM A COMMON T-CELL CLONE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REED-STERNBERG CELLS; IMMUNOGLOBULIN GENE REARRANGEMENTS; RECEPTOR BETA-CHAIN; MYCOSIS-FUNGOIDES; CHROMOSOME-ABNORMALITIES; IMMUNOBLASTIC LYMPHOMA; MONOCLONAL-ANTIBODIES; EXPRESSION; ANTIGENS; ORIGIN	Background. Lymphomatoid papulosis is a benign cutaneous eruption that in 10 to 20 percent of patients is associated with the development of lymphoma. The atypical cells of lymphomatoid papulosis histologically resemble the malignant cells of cutaneous T-cell lymphoma or the Reed-Sternberg cells of Hodgkin's disease. We studied a patient in whom lymphomatoid papulosis developed in 1971, Hodgkin's disease in 1975, and cutaneous T-cell lymphoma in 1985, to determine whether these diseases are clonally related. Methods. The T-cell-receptor alpha-chain gene was cloned and sequenced from a cell line derived from the advanced-stage cutaneous T-cell lymphoma, and the polymerase chain reaction was used to search for this rearrangement of the alpha-chain gene in tissues obtained earlier-that were affected by Hodgkin's disease or lymphomatoid papulosis. Results. The tumor-specific rearrangement of the alpha-chain gene was detected in the patient's earlier tissues affected by lymphomatoid papulosis and Hodgkin's disease, but not in control tissue, including uninvolved tissues from the staging laparotomy for Hodgkin's disease. Cytogenetic studies revealed a translocation, t(8;9)(p22;p24), in cutaneous T-cell lymphoma lines and in a dermatopathic lymph node removed two years before the clinical onset of the cutaneous T-cell lymphoma. Immunohistochemical findings were consistent with an activated T-cell phenotype for the atypical cells of lymphomatoid papulosis, the Reed-Sternberg cells of Hodgkin's disease, and the malignant cells of the T-cell lymphoma. Conclusions. Lymphomatoid papulosis, Hodgkin's disease, and cutaneous T-cell lymphoma can be derived from a single T-cell clone. A t(8;9) genetic translocation may be involved in the pathogenesis of lymphomatoid papulosis or its progression to malignant disease.	BETH ISRAEL HOSP,DEPT PATHOL,330 BROOKLINE AVE,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL 07516] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007516] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BRINKER MGL, 1987, BLOOD, V70, P186; CABANILLAS F, 1988, CANCER RES, V48, P5557; CASEY TT, 1989, BLOOD, V74, P2624; CASPERSSON T, 1971, HEREDITAS-GENETISK A, V67, P89; CHAN WC, 1979, CANCER, V44, P1408, DOI 10.1002/1097-0142(197910)44:4<1408::AID-CNCR2820440435>3.0.CO;2-K; CHEN KTK, 1985, AM J DERMATOPATH, V7, P555, DOI 10.1097/00000372-198512000-00010; DALLENBACH FE, 1989, LANCET, V2, P828; DREXLER HG, 1989, HEMATOL ONCOL, V7, P95, DOI 10.1002/hon.2900070202; FALINI B, 1987, HISTOPATHOLOGY, V11, P1229, DOI 10.1111/j.1365-2559.1987.tb01869.x; Fonatsch C, 1989, Recent Results Cancer Res, V117, P35; FUJITA K, 1986, INT J CANCER, V37, P517, DOI 10.1002/ijc.2910370408; GREER JP, 1991, J CLIN ONCOL, V9, P539, DOI 10.1200/JCO.1991.9.4.539; GRIESSER H, 1987, INT J CANCER, V40, P157, DOI 10.1002/ijc.2910400205; HARRINGTON DS, 1989, J AM ACAD DERMATOL, V21, P951, DOI 10.1016/S0190-9622(89)70281-4; HAWKINS KA, 1983, AM J HEMATOL, V14, P355, DOI 10.1002/ajh.2830140406; HERBST H, 1989, LEUKEMIA RES, V13, P103, DOI 10.1016/0145-2126(89)90134-3; KADIN M, 1985, AM J PATHOL, V119, P315; KADIN ME, 1988, AM J PATHOL, V130, P345; KADIN ME, 1987, AM J PATHOL, V126, P13; KADIN ME, 1986, BLOOD, V68, P1042; KADIN ME, 1985, LANCET, V2, P864; KADIN ME, 1990, CURR PROBL DERMATOL, V19, P132; KAUDEWITZ P, 1990, J AM ACAD DERMATOL, V22, P999, DOI 10.1016/0190-9622(90)70141-4; LEDERMAN JS, 1987, J AM ACAD DERMATOL, V16, P331, DOI 10.1016/S0190-9622(87)70045-0; LEVINE EG, 1985, BLOOD, V66, P1414; MACAULAY WL, 1968, ARCH DERMATOL, V97, P23, DOI 10.1001/archderm.97.1.23; MADISON JF, 1983, J AM ACAD DERMATOL, V9, P743, DOI 10.1016/S0190-9622(83)70189-1; MOORHEAD PS, 1960, EXP CELL RES, V20, P613, DOI 10.1016/0014-4827(60)90138-5; MURAMOTO LM, 1987, AM J CLIN PATHOL, V88, P589, DOI 10.1093/ajcp/88.5.589; PINKUS GS, 1988, AM J PATHOL, V133, P211; RALFKIAER E, 1985, AM J CLIN PATHOL, V84, P587, DOI 10.1093/ajcp/84.5.587; SANCHEZ NP, 1983, J AM ACAD DERMATOL, V8, P81, DOI 10.1016/S0190-9622(83)70011-3; SEABRIGH.M, 1971, LANCET, V2, P971; SEHESTED J, 1974, HUMANGENETIK, V21, P55, DOI 10.1007/BF00278565; STEIN H, 1985, BLOOD, V66, P848; STETLERSTEVENSON M, 1990, J NATL CANCER I, V82, P855, DOI 10.1093/jnci/82.10.855; TILLY H, 1991, BLOOD, V77, P1298; TOYONAGA B, 1987, ANNU REV IMMUNOL, V5, P585, DOI 10.1146/annurev.immunol.5.1.585; TOYONAGA B, 1985, P NATL ACAD SCI USA, V82, P8624, DOI 10.1073/pnas.82.24.8624; TUCKER WFG, 1984, CLIN EXP DERMATOL, V9, P190, DOI 10.1111/j.1365-2230.1984.tb00782.x; WANTZIN GL, 1985, ARCH DERMATOL, V121, P792, DOI 10.1001/archderm.121.6.792; WEINMAN VF, 1981, AM J DERMATOPATH, V3, P129, DOI 10.1097/00000372-198100320-00004; WEISS LM, 1986, NEW ENGL J MED, V315, P475, DOI 10.1056/NEJM198608213150802; WEISS LM, 1986, HUM PATHOL, V17, P1009, DOI 10.1016/S0046-8177(86)80084-3; WEISS LM, 1986, HUM PATHOL, V17, P1106; WHITTAKER S, 1991, J INVEST DERMATOL, V96, P786, DOI 10.1111/1523-1747.ep12471773; WILLEMZE R, 1982, BRIT J DERMATOL, V107, P131, DOI 10.1111/j.1365-2133.1982.tb00331.x; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153	51	252	256	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1115	1122		10.1056/NEJM199204233261704	http://dx.doi.org/10.1056/NEJM199204233261704			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1532439				2022-12-28	WOS:A1992HP80000004
J	LINGENFELSER, T; DUERK, H; STEVENS, A; GROSSMANN, T; KNORR, M; SAAL, JG				LINGENFELSER, T; DUERK, H; STEVENS, A; GROSSMANN, T; KNORR, M; SAAL, JG			GENERALIZED MYOSITIS IN BEHCET DISEASE - TREATMENT WITH CYCLOSPORINE	ANNALS OF INTERNAL MEDICINE			English	Note						BEHCET SYNDROME; MYOSITIS; CYCLOSPORINE; VASCULITIS; PREDNISOLONE	TRIAL	A young Turkish man had classic Behcet disease with oral and genital aphthous ulcerations, chorioretinitis, and pseudofolliculitis. The clinical picture was dominated by associated generalized myositis, an exceptional occurrence in the disease. All clinical features except the myositis improved when the patient was given conventional immunosuppressive therapy; however, the myositis responded to treatment with cyclosporine. This case appears to be the first in which successful treatment of generalized myositis in a patient with Behcet disease was achieved with cyclosporine.			LINGENFELSER, T (corresponding author), UNIV TUBINGEN, DEPT MED, SCHNARRENBERG, W-7400 TUBINGEN 1, GERMANY.		Knorr, Michael/Q-3109-2019					ARKIN CR, 1980, ARTHRITIS RHEUM, V23, P600, DOI 10.1002/art.1780230512; Behcet H, 1937, DERMATOL WOCHENSCHR, V105, P1152; FINUCANE P, 1985, BRIT J RHEUMATOL, V24, P372; LANG BA, 1990, ARTHRITIS RHEUM, V33, P418, DOI 10.1002/art.1780330317; MASUDA K, 1989, LANCET, V1, P1093; NUSSENBLATT RB, 1985, ARTHRITIS RHEUM, V28, P671, DOI 10.1002/art.1780280611; ODUFFY JD, 1990, NEW ENGL J MED, V322, P326, DOI 10.1056/NEJM199002013220509; SILMAN AJ, 1990, LANCET, V335, P1078; THEOHARIS G, 1988, REV RHUM, V55, P965; YAZICI H, 1990, NEW ENGL J MED, V322, P281, DOI 10.1056/NEJM199002013220501	10	30	30	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					651	653		10.7326/0003-4819-116-8-651	http://dx.doi.org/10.7326/0003-4819-116-8-651			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546866				2022-12-28	WOS:A1992HN84400008
J	SUTER, PM; SCHUTZ, Y; JEQUIER, E				SUTER, PM; SCHUTZ, Y; JEQUIER, E			THE EFFECT OF ETHANOL ON FAT STORAGE IN HEALTHY-SUBJECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MIDDLE-AGED MEN; ALCOHOL-CONSUMPTION; NUTRIENT INTAKE; ENERGY-EXPENDITURE; INDIRECT CALORIMETRY; RESPIRATION CHAMBER; UNITED-STATES; METABOLISM; OVERWEIGHT; OBESITY	Background. Ethanol can account for up to 10 percent of the energy intake of persons who consume moderate amounts of ethanol. Its effect on energy metabolism, however, is not known. Methods. We studied the effect ot ethanol on 24-hour substrate-oxidation rates in eight normal men during two 48-hour sessions in an indirect-calorimetry chamber. In each session, the first 24 hours served as the control period. On the second day of one session, an additional 25 percent of the total energy requirement was added as ethanol (mean [+/- SD], 96 +/- 4 g per day); during the other session, 25 percent of the total energy requirement was replaced by ethanol, which was isocalorically substituted for lipids and carbohydrates. Results. Both the addition of ethanol and the isocaloric substitution of ethanol for other foods reduced 24-hour lipid oxidation. The respective mean (+/- SE) decreases were 49.4 +/- 6.7 and 44.1 +/- 9.3 g per day (i.e., reductions of 36 +/- 3 percent and 31 +/- 7 percent from the oxidation rate during the control day; P < 0.001 and P < 0.0025). This effect occurred only during the daytime period (8:30 a.m. to 11:30 p.m.), when ethanol was consumed and metabolized. Neither the addition of ethanol to the diet nor the isocaloric substitution of ethanol for other foods significantly altered the oxidation of carbohydrate or protein. Both regimens including ethanol produced an increase in 24-hour energy expenditure (7 +/- 1 percent with the addition of ethanol, P < 0.001; 4 +/- 1 percent with the substitution of ethanol for other energy sources, P < 0.025). Conclusions. Ethanol, either added to the diet or substituted for other foods, increases 24-hour energy expenditure and decreases lipid oxidation. Habitual consumption of ethanol in excess of energy needs probably favors lipid storage and weight gain.			SUTER, PM (corresponding author), UNIV LAUSANNE,FAC MED,INST PHYSIOL,7 RUE BUGNON,CH-1005 LAUSANNE,SWITZERLAND.							AKANJI AO, 1990, AM J CLIN NUTR, V51, P112, DOI 10.1093/ajcn/51.1.112; BAECKE JAH, 1983, INT J OBESITY, V7, P13; BEBB HT, 1971, AM J CLIN NUTR, V24, P1042; BLOCK G, 1985, AM J EPIDEMIOL, V122, P27, DOI 10.1093/oxfordjournals.aje.a114084; BURSZTEIN S, 1989, ENERGY METABOLISM; CAMARGO CA, 1987, J AM COLL NUTR, V6, P271; CONTALDO F, 1989, METABOLISM, V38, P166, DOI 10.1016/0026-0495(89)90257-6; CROUT J. RICHARD, 1961, STANDARD METHODS CLIN CHEM, V3, P62; Denney R C, 1984, Contemp Issues Clin Biochem, V1, P51; DENNIS BH, 1985, AM J CLIN NUTR, V41, P312, DOI 10.1093/ajcn/41.5.1103; FRAYN KN, 1990, METABOLISM, V39, P958, DOI 10.1016/0026-0495(90)90308-Y; GRUCHOW HW, 1985, AM J CLIN NUTR, V42, P289, DOI 10.1093/ajcn/42.2.289; JEQUIER E, 1987, ANNU REV NUTR, V7, P187, DOI 10.1146/annurev.nu.07.070187.001155; JEQUIER E, 1983, AM J CLIN NUTR, V38, P989, DOI 10.1093/ajcn/38.6.989; JONES BR, 1982, AM J CLIN NUTR, V35, P135, DOI 10.1093/ajcn/35.1.135; KLUTHE R, 1985, ANN INTERN MED, V103, P1037, DOI 10.7326/0003-4819-103-6-1037; KROMHOUT D, 1983, AM J CLIN NUTR, V37, P295, DOI 10.1093/ajcn/37.2.295; KROMHOUT D, 1983, AM J CLIN NUTR, V37, P287, DOI 10.1093/ajcn/37.2.287; KROMHOUT D, 1990, AM J CLIN NUTR, V51, P123, DOI 10.1093/ajcn/51.1.123; LIEBER CS, 1966, J CLIN INVEST, V45, P1400, DOI 10.1172/JCI105448; LIEBER CS, 1988, NEW ENGL J MED, V319, P1639; LIEBER CS, 1982, MED DISORDERS ALCOHO; LIEBER CS, 1985, ACTA MED SCAND S, V703, P11; LIVESEY G, 1988, AM J CLIN NUTR, V47, P608, DOI 10.1093/ajcn/47.4.608; LUKASKI HC, 1987, AM J CLIN NUTR, V46, P537, DOI 10.1093/ajcn/46.4.537; MCDONALD JT, 1976, AM J CLIN NUTR, V29, P1093, DOI 10.1093/ajcn/29.10.1093; MEZEY E, 1985, FED PROC, V44, P134; MILLAR WJ, 1987, AM J PUBLIC HEALTH, V77, P38, DOI 10.2105/AJPH.77.1.38; NACE EP, 1984, ANNU REV MED, V35, P293, DOI 10.1146/annurev.me.35.020184.001453; PIROLA RC, 1972, PHARMACOLOGY, V7, P185, DOI 10.1159/000136288; PIROLA RC, 1976, AM J CLIN NUTR, V29, P90, DOI 10.1093/ajcn/29.1.90; REINUS JF, 1989, METABOLISM, V38, P125, DOI 10.1016/0026-0495(89)90251-5; SCHUTZ Y, 1982, INT J OBESITY, V6, P23; SHELMET JJ, 1988, J CLIN INVEST, V81, P1137, DOI 10.1172/JCI113428; SIMONSON DC, 1990, AM J PHYSIOL, V258, pE399, DOI 10.1152/ajpendo.1990.258.3.E399; SKUTCHES CL, 1983, KIDNEY INT, V23, P57, DOI 10.1038/ki.1983.11; SUTHERLAND WHF, 1980, AM J CLIN NUTR, V33, P2581, DOI 10.1093/ajcn/33.12.2581; THOMSON M, 1988, AM J CLIN NUTR, V47, P139, DOI 10.1093/ajcn/47.1.139; WEATHERALL R, 1988, EUR J CLIN NUTR, V42, P221; WINDHAM CT, 1983, J AM DIET ASSOC, V82, P364; YKIJARVINEN H, 1988, AM J PHYSIOL, V254, pE175, DOI 10.1152/ajpendo.1988.254.2.E175	41	165	168	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1992	326	15					983	987		10.1056/NEJM199204093261503	http://dx.doi.org/10.1056/NEJM199204093261503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM285	1545851	Green Published			2022-12-28	WOS:A1992HM28500003
J	AITKEN, ML; BURKE, W; MCDONALD, G; SHAK, S; MONTGOMERY, AB; SMITH, A				AITKEN, ML; BURKE, W; MCDONALD, G; SHAK, S; MONTGOMERY, AB; SMITH, A			RECOMBINANT HUMAN DNASE INHALATION IN NORMAL SUBJECTS AND PATIENTS WITH CYSTIC-FIBROSIS - A PHASE-1 STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPUTUM	Objective. - To evaluate the safety of recombinant human DNase (rhDNase) in normal subjects and in patients with cystic fibrosis. Design. - Nonrandomized trial in which individuals inhaled rhDNase three times a day Monday through Friday on two consecutive weeks. Setting. - The study was performed in the Clinical Research Center at the University of Washington, Seattle. Patients were recruited from the Cystic Fibrosis Center at the University of Washington. Subjects and Patients. - Twelve normal subjects and 14 patients with cystic fibrosis were studied (12 patients completed the protocol), The subjects and patients had to be aged 18 to 65 years and have a negative pregnancy test, if female. The normal subjects had to have a normal chest roentgenogram, be nonsmokers, and have normal pulmonary function testing. The patients with cystic fibrosis had to have a forced vital capacity greater than 40% predicted normal and have no recent exacerbation (within 2 weeks) of their lung infection or change in their medication. Interventions. - The study design was a repetitive dose escalation of aerosolized rhDNase. The subjects inhaled rhDNase three times a day, Monday through Friday, on 2 consecutive weeks and were rechallenged with a single dose 21 days after the last dose. Spirometry was measured before and 30 minutes after every rhDNase dose. Main Outcome Measures. - Pulmonary function testing, serum DNase concentrations, and anti-DNase antibodies. Secondary outcome measures were dyspnea score and quantitative bacterial culture. Main Results. - Inhalation of rhDNase was well tolerated by all persons. There were no serious adverse reactions, and no allergic reactions were observed, even on rechallenge. No individual developed rhDNase antibodies. Improvement in both lung function and dyspnea score was observed in the adults with cystic fibrosis. Forced vital capacity was 3.2 +/- 0.3 L (mean +/- SE) on day 1 and was 3.5 +/- 0.3 L on day 12. Forced expiratory volume in 1 second was 2.1 +/- 0.2 L (mean +/- SE) on day 1 and was 2.3 +/- 0.3 L on day 12. Conclusions. - Aerosolized rhDNase appears safe in normal subjects and in adults with cystic fibrosis and may improve lung function with short-term therapy.	GENENTECH INC,S SAN FRANCISCO,CA; UNIV WASHINGTON,DIV INTERNAL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,DIV INFECT DIS,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195	Roche Holding; Genentech; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	AITKEN, ML (corresponding author), UNIV WASHINGTON,DIV PULM & CRIT CARE,MAIL STOP RM-12,SEATTLE,WA 98195, USA.			Roman, Ashley/0000-0001-5318-6038				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BOAT TF, 1988, TXB RESPIRATORY MED, P1126; CHEN AB, 1986, J INTERFERON RES, V6, P313, DOI 10.1089/jir.1986.6.313; CHERNICK WS, 1959, PEDIATRICS, V24, P739; CRAPO RO, 1982, B EUR PHYSIOPATH RES, V18, P419; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; ELMES PC, 1953, THORAX, V8, P295, DOI 10.1136/thx.8.4.295; HUBBARD RC, 1989, J CLIN INVEST, V84, P1349, DOI 10.1172/JCI114305; JONES RS, 1960, LANCET, V1, P94; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KURNICK NB, 1950, ARCH BIOCH, V9, P41; LIEBERMAN J, 1968, J AMER MED ASSOC, V205, P312, DOI 10.1001/jama.205.5.312; LOVE JD, 1979, J BIOL CHEM, V254, P2588; MUZA SR, 1990, AM REV RESPIR DIS, V141, P909, DOI 10.1164/ajrccm/141.4_Pt_1.909; OBRIEN PC, 1988, MAYO CLIN PROC, V63, P918, DOI 10.1016/S0025-6196(12)62696-2; POTTER J, 1960, AM J DIS CHILD, V100, P493; PUCHELLE E, 1984, J LAB CLIN MED, V103, P347; RASKIN P, 1968, AM REV RESPIR DIS, V98, P597; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SALOMON A, 1954, Ann Allergy, V12, P71; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; SINICROPI D, 1991, PEDIATR PULM S, V6, pA278; SMITH AL, 1988, J PEDIATR-US, V112, P547, DOI 10.1016/S0022-3476(88)80165-3; SPIER R, 1961, JAMA-J AM MED ASSOC, V178, P878, DOI 10.1001/jama.1961.03040480008003	24	124	128	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1947	1951		10.1001/jama.267.14.1947	http://dx.doi.org/10.1001/jama.267.14.1947			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL677	1548827				2022-12-28	WOS:A1992HL67700029
J	FISHER, ES; WELCH, HG; WENNBERG, JE				FISHER, ES; WELCH, HG; WENNBERG, JE			PRIORITIZING OREGON HOSPITAL RESOURCES - AN EXAMPLE BASED ON VARIATIONS IN DISCRETIONARY MEDICAL UTILIZATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-HAVEN; BOSTON; CARE; COST	Objective. - To provide an alternative to Oregon's treatment-specific approach to rationing, we propose a prioritization based on the local hospital resources invested in discretionary medical admissions. Design. - We used 1988 Oregon hospital discharge data to determine age- and sex-adjusted per-capita rates of inpatient days for discretionary medical admissions (for high-variation medical conditions) in each of 33 hospital service areas. Potential ceiling rates were defined based on prevailing utilization rates for discretionary medical admissions in each hospital service area. Savings were calculated under the assumption that resources allocated for inpatient treatment of these conditions in areas that exceed the ceiling rates were reduced accordingly. Setting. - Nonfederal, acute-care hospitals used by Oregon residents. Study population. - Oregon residents. Main Outcome Measures. - Savings were defined in terms of patient days, hospital beds, hospital charges, and average costs. Results. - Among the 16 largest hospital service areas, patient-day rates for discretionary medical admissions ranged from 188 to 335 patient days per thousand. Potential savings from applying different ceiling rates ranged from $0.4 million to $94.7 million per year. If the rate in the state capital (Salem) were used as the ceiling (218 days per thousand), then 238 beds could be closed in 20 hospital service areas, for an estimated cost savings of $47.3 million. Conclusions. - Hospital resources invested in discretionary admissions in high-rate areas represent an important potential source of funds for reallocation to meet other defined health care needs. Setting limits based on units of health care supply (eg, beds, capital equipment, and physicians) should be considered as an option for resource reallocation within health care.	US DEPT VET AFFAIRS MED CTR,WHITE RIVER JCT,VT; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03756	Dartmouth College; Dartmouth College	FISHER, ES (corresponding author), DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,CTR EVALUAT CLIN SCI,HB 7250,HANOVER,NH 03756, USA.				AHRQ HHS [R18 HS05745] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BROWN LD, 1991, HEALTH AFFAIR, V10, P28, DOI 10.1377/hlthaff.10.2.28; CALLAHAN D, 1991, HEALTH AFFAIR, V10, P78, DOI 10.1377/hlthaff.10.2.78; DUGGAN JM, 1989, LANCET, V1, P772; ETZIONI A, 1991, HEALTH AFFAIR, V10, P88, DOI 10.1377/hlthaff.10.2.88; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FOX DM, 1991, HEALTH AFFAIR, V10, P7, DOI 10.1377/hlthaff.10.2.7; Friedman B, 1983, Health Care Financ Rev, V4, P105; GORE A, 1990, ACAD MED, V65, P634, DOI 10.1097/00001888-199010000-00007; GRIFFITH JR, 1985, HEALTH SERV RES, V20, P131; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HELMS DW, 1991, 910017 US DEP HLTH H; HOLLINGSBAUM F, 1991, BRIT MED J, V302, P288; HUGHES JS, 1991, JAMA-J AM MED ASSOC, V265, P2347, DOI 10.1001/jama.265.18.2347; PAULSHAHEEN P, 1987, J HEALTH POLIT POLIC, V12, P741, DOI 10.1215/03616878-12-4-741; RELMAN AS, 1990, NEW ENGL J MED, V323, P911, DOI 10.1056/NEJM199009273231310; ROEMER M I, 1961, Hospitals, V35, P36; Roos N P, 1988, Health Care Financ Rev, V9, P53; SANDERS D, 1989, VARIATIONS HOSPITAL; SCHWARTZ WB, 1991, NEW ENGL J MED, V324, P1037, DOI 10.1056/NEJM199104113241506; SCWARTZ W, 1990, NY TIMES        0709; WELCH HG, 1991, ANN INTERN MED, V115, P223, DOI 10.7326/0003-4819-115-3-223; WELCH HG, 1989, NEW ENGL J MED, V321, P1261, DOI 10.1056/NEJM198911023211809; WENNBERG J, 1986, NEW ENGL J MED, V314, P310, DOI 10.1056/NEJM198601303140509; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WENNBERG J, 1980, HRA8014012 US DEP HL; WENNBERG J, 1990, RES METHODOLOGY STRE, P176; Wennberg J E, 1975, J Maine Med Assoc, V66, P298; WENNBERG JE, 1984, NEW ENGL J MED, V311, P295, DOI 10.1056/NEJM198408023110505; WENNBERG JE, 1982, NEW ENGL J MED, V307, P1374, DOI 10.1056/NEJM198211253072204; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; WENNBERG JE, 1985, MED CARE, V23, P512, DOI 10.1097/00005650-198505000-00012; WENNBERG JE, 1973, SCIENCE, V183, P1102; WENNBERG JE, IN PRESS MED INNOVAT; WILSON P, 1984, HEALTH SERV RES, V19, P333; 1990, HLTH CARE FINAN REV, V11, P1; 1991, AVAILABLE RES SHOWS; 1991, FAULKNER GRAYS MED H, V45, P1	38	43	43	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1925	1931		10.1001/jama.267.14.1925	http://dx.doi.org/10.1001/jama.267.14.1925			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HL677	1548824				2022-12-28	WOS:A1992HL67700025
J	HSIAO, W; BRAUN, P; BECKER, ER; DUNN, D				HSIAO, W; BRAUN, P; BECKER, ER; DUNN, D			RBRVS - OBJECTIONS TO MALONEY .1.	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							WORK				HSIAO, W (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,PROGRAM HLTH CARE FINANCE,CAMBRIDGE,MA 02138, USA.							DUNN D, 1988, JAMA-J AM MED ASSOC, V260, P2371, DOI 10.1001/jama.260.16.2371; HSIAO WC, 1988, JAMA-J AM MED ASSOC, V260, P2361, DOI 10.1001/jama.260.16.2361; HSIAO WC, 1990, NATIONAL STUDY RESOU; MALONEY JV, 1991, JAMA-J AM MED ASSOC, V266, P3453; MENDENHALL R, 1981, MED PRACTICE US SPEC; RADECKI SE, 1992, JAMA-J AM MED ASSOC, V267, P1824, DOI 10.1001/jama.267.13.1824; 1990, PHYSICIAN MARKETPLAC	7	7	7	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1822	1823		10.1001/jama.267.13.1822	http://dx.doi.org/10.1001/jama.267.13.1822			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545468				2022-12-28	WOS:A1992HK67200035
J	WASSON, J; GAUDETTE, C; WHALEY, F; SAUVIGNE, A; BARIBEAU, P; WELCH, HG				WASSON, J; GAUDETTE, C; WHALEY, F; SAUVIGNE, A; BARIBEAU, P; WELCH, HG			TELEPHONE CARE AS A SUBSTITUTE FOR ROUTINE CLINIC FOLLOW-UP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTIVARIATE PREDICTION MODEL; RAPID ESTIMATION; CONTROLLED TRIAL; CHARGES	Design. - Randomized trial.(~)Setting. - A primary care clinic.(~)Patients. - Four hundred ninety-seven men aged 54 years or older. Objective. - We examined the hypothesis that substituting clinician-initiated telephone calls (telephone care) for some clinic visits would reduce medical care utilization without adversely affecting patient health. Intervention. - Clinicians were asked to double their recommended interval for face-to-face follow-up and schedule three intervening telephone contacts; for control patients, the follow-up interval recommended by their clinician was unchanged. Main Outcome Measures. - Use of medical services and health status. Results. - During the 2-year follow-up period, 7% of patients withdrew or became unavailable. Telephone-care patients had fewer total clinic visits, scheduled and unscheduled, than usual-care patients (19%, P < .001). In addition, telephone-care patients had less medication use (14%, P = .006), fewer admissions, and shorter stays in the hospital (28% fewer total hospital days, P = .005), and 41% fewer intensive care unit days (P = .03). Estimated total expenditures for telephone care were 28% less per patient for the 2 years ($1656, P = .004). For the subgroup of patients with fair or poor overall health at the beginning of the study (n = 180), savings were somewhat greater ($1976, P = .01). In this subgroup, improvement in physical function from baseline (P = .02) and a possible reduction in mortality (P = .06) were also observed. Conclusion. - We conclude that substituting telephone care for selected clinic visits significantly reduces utilization of medical services. For more severely ill patients, the increased contact made possible by telephone care may also improve health status and reduce mortality.	DARTMOUTH COLL, DEPT COMMUNITY & FAMILY MED, HANOVER, NH 03755 USA; DARTMOUTH COLL, DEPT MED, HANOVER, NH 03755 USA	Dartmouth College; Dartmouth College	WASSON, J (corresponding author), DARTMOUTH COLL, CTR AGING, 7265 STRASENBURGH HALL, HANOVER, NH 03755 USA.							APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1572, DOI 10.1056/NEJM199005313222205; BERTERA EM, 1981, AM J PUBLIC HEALTH, V71, P626, DOI 10.2105/AJPH.71.6.626; EGGERT GM, 1988, HLTH CARE FINANCIN S, V1988, P57; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FISCHER PM, 1979, J FAM PRACTICE, V8, P321; Greenlick M R, 1973, Med Care, V11, P121, DOI 10.1097/00005650-197303000-00004; HALLAM L, 1989, FAM PRACT, V6, P47, DOI 10.1093/fampra/6.1.47; HENDRIKSEN C, 1984, BMJ-BRIT MED J, V289, P1522, DOI 10.1136/bmj.289.6457.1522; JOHNSON BE, 1990, J GEN INTERN MED, V5, P234, DOI 10.1007/BF02600541; KUKULL WA, 1986, MED CARE, V24, P961, DOI 10.1097/00005650-198610000-00009; NELSON EC, 1990, MED CARE, V28, P1111, DOI 10.1097/00005650-199012000-00001; QUADE D, 1982, BIOMETRICS, V38, P597, DOI 10.2307/2530042; RUBENSTEIN L Z, 1991, Journal of the American Geriatrics Society, V39, p37S; SPENCER DC, 1988, J FAM PRACTICE, V27, P201; Ware J E Jr, 1983, Eval Program Plann, V6, P247, DOI 10.1016/0149-7189(83)90005-8; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WASSON JH, 1987, MED CARE, V25, P1002, DOI 10.1097/00005650-198710000-00008; WEINGARTEN MA, 1982, J ROY COLL GEN PRACT, V32, P766; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WELCH HG, 1989, MED CARE, V27, P900, DOI 10.1097/00005650-198909000-00005; 1989, RELATIVE VALUES PHYS; 1991, FED REG         1125, V56, P59501	22	303	304	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1788	1793		10.1001/jama.267.13.1788	http://dx.doi.org/10.1001/jama.267.13.1788			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545464				2022-12-28	WOS:A1992HK67200028
J	COMENZO, RL; MALACHOWSKI, ME; ROHRER, RJ; FREEMAN, RB; RABSON, A; BERKMAN, EM				COMENZO, RL; MALACHOWSKI, ME; ROHRER, RJ; FREEMAN, RB; RABSON, A; BERKMAN, EM			ANOMALOUS ABO PHENOTYPE IN A CHILD AFTER AN ABO-INCOMPATIBLE LIVER-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							VERSUS-HOST DISEASE; BLOOD-GROUP BARRIERS; HEMOLYTIC-ANEMIA; RECIPIENT; CYCLOSPORINE; ANTIGENS		NEW ENGLAND MED CTR HOSP,DEPT MED,DIV HEMATOL ONCOL,750 WASHINGTON ST,BOSTON,MA 02111; NEW ENGLAND MED CTR HOSP,DEPT PATHOL,BOSTON,MA 02111; NEW ENGLAND MED CTR HOSP,DIV TRANSPLANT SURG,BOSTON,MA 02111; NEW ENGLAND MED CTR HOSP,TRANSFUS MED SERV,BOSTON,MA 02111; TUFTS UNIV,SCH MED,BOSTON,MA 02111	Tufts Medical Center; Tufts Medical Center; Tufts Medical Center; Tufts Medical Center; Tufts University								ALBRECHTSEN D, 1988, TRANSPLANT P, V20, P959; Ashby W, 1919, J EXP MED, V29, P267, DOI 10.1084/jem.29.3.267; BARBOLLA L, 1988, BRIT J HAEMATOL, V69, P93, DOI 10.1111/j.1365-2141.1988.tb07608.x; BHADURI BR, 1990, TRANSPLANT P, V22, P2378; Billingham R E, 1966, Harvey Lect, V62, P21; BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107; Crookston M C, 1980, Prog Clin Biol Res, V43, P99; Crookston MC, 1983, BLOOD GROUP ANTIGENS, P67; DEIERHOI MH, 1986, TRANSPLANTATION, V41, P544; DEVECCHI A, 1985, ACTA HAEMATOL-BASEL, V73, P216, DOI 10.1159/000206332; DZIK WH, 1987, TRANSFUSION, V27, P384, DOI 10.1046/j.1537-2995.1987.27587320528.x; FAURE JL, 1989, TRANSPLANT P, V21, P2242; FISCHEL RJ, 1989, TRANSPLANT P, V21, P2221; Goldstein J, 1989, Transfus Med Rev, V3, P206, DOI 10.1016/S0887-7963(89)70080-8; GORDON RD, 1986, SURGERY, V100, P342; GRANT D, 1990, TRANSPLANT P, V22, P2464; GUGENHEIM J, 1990, LANCET, V336, P519, DOI 10.1016/0140-6736(90)92082-S; HAKOMORI SI, 1981, SEMIN HEMATOL, V18, P39; HOFFMAN AL, 1989, SURGERY, V106, P354; MOLLISON PL, 1987, BLOOD TRANSFUSION CL, P810; Muramatsu T, 1978, Methods Enzymol, V50, P555; ORIOL R, 1981, AM J HUM GENET, V33, P551; RAMSEY G, 1987, TRANSPLANT P, V19, P4591; RAMSEY G, 1984, NEW ENGL J MED, V311, P1167, DOI 10.1056/NEJM198411013111807; SCHENKELBRUNNER H, 1973, EUR J BIOCHEM, V34, P125, DOI 10.1111/j.1432-1033.1973.tb02738.x; SOLLINGER HW, 1985, TRANSPLANT P, V17, P141; WALKER RH, 1990, TECHNICAL MANUAL; YOSHIDA A, 1980, BLOOD, V55, P699	28	31	31	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1992	326	13					867	870		10.1056/NEJM199203263261305	http://dx.doi.org/10.1056/NEJM199203263261305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK523	1542324	Bronze			2022-12-28	WOS:A1992HK52300005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ACTION AGAINST ILLEGALLY PROMOTED, FOREIGN-MANUFACTURED, UNAPPROVED PRESCRIPTION DRUGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1442	1442						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1538524				2022-12-28	WOS:A1992HH48800003
J	GEARING, DP; COMEAU, MR; FRIEND, DJ; GIMPEL, SD; THUT, CJ; MCGOURTY, J; BRASHER, KK; KING, JA; GILLIS, S; MOSLEY, B; ZIEGLER, SF; COSMAN, D				GEARING, DP; COMEAU, MR; FRIEND, DJ; GIMPEL, SD; THUT, CJ; MCGOURTY, J; BRASHER, KK; KING, JA; GILLIS, S; MOSLEY, B; ZIEGLER, SF; COSMAN, D			THE IL-6 SIGNAL TRANSDUCER, GP130 - AN ONCOSTATIN-M RECEPTOR AND AFFINITY CONVERTER FOR THE LIF RECEPTOR	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; LEUKEMIA INHIBITORY FACTOR; EXPRESSION CLONING; MOLECULAR-CLONING; CELLS; DIFFERENTIATION; BINDING	Leukemia inhibitory factor (LIF) and interleukin-6 (IL-6) are multifunctional cytokines with many similar activities. LIF is structurally and functionally related to another cytokine, Oncostatin M (OSM), that binds to the high-affinity LIF receptor but not to the low-affinity LIF receptor. A complementary DNA was isolated that encodes the high-affinity converting subunit of the LIF receptor. The converter conferred high-affinity binding of both LIF and OSM when expressed with the low-affinity LIF receptor and is identical to the signal transducing subunit of the IL-6 receptor, gp130. The gp130 subunit alone confers low-affinity binding of OSM when expressed in COS-7 cells. This receptor system resembles the high-affinity receptors for granulocyte-macrophage colony-stimulating factor, IL-3, and IL-5, which share a common subunit.			GEARING, DP (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.							BAUMANN H, 1988, J BIOL CHEM, V263, P17390; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1991, ANN NY ACAD SCI, V628, P9, DOI 10.1111/j.1749-6632.1991.tb17218.x; GEARING DP, 1991, CELL, V66, P175; GEARING DP, UNPUB; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; Honjo T, 1991, Curr Biol, V1, P201, DOI 10.1016/0960-9822(91)90055-2; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; RODAN SB, 1990, ENDOCRINOLOGY, V127, P1602, DOI 10.1210/endo-127-4-1602; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOMIDA M, 1990, FEBS LETT, V268, P261, DOI 10.1016/0014-5793(90)81023-H; YAMAMOTOYAMAGUCHI Y, 1986, EXP CELL RES, V164, P97, DOI 10.1016/0014-4827(86)90457-X; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZIEGLER SF, 1991, NEW BIOL, V3, P1242	32	868	903	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1434	1437		10.1126/science.1542794	http://dx.doi.org/10.1126/science.1542794			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542794				2022-12-28	WOS:A1992HH74400057
J	TANG, DC; DEVIT, M; JOHNSTON, SA				TANG, DC; DEVIT, M; JOHNSTON, SA			GENETIC IMMUNIZATION IS A SIMPLE METHOD FOR ELICITING AN IMMUNE-RESPONSE	NATURE			English	Article								To produce an immune reaction against a foreign protein usually requires purification of that protein, which is then injected into an animal. The isolation of enough pure protein is time-consuming and sometimes difficult. Here we report that such a response can also be elicited by introducing the gene encoding a protein directly into the skin of mice. This is achieved using a hand-held form of the biolistic system 1-4 which can propel DNA-coated gold microprojectiles directly into cells in the living animal 3,5,6. Genetic immunization may be time- and labour-saving in producing antibodies and may offer a unique method for vaccination.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ARMALEO D, 1990, CURR GENET, V17, P97, DOI 10.1007/BF00312852; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; JOHNSTON SA, 1991, IN VITRO CELL DEV, V27, P11; LEAVITT J, 1984, MOL CELL BIOL, V4, P1961, DOI 10.1128/MCB.4.10.1961; SANFORD J C, 1991, Technique (Philadelphia), V3, P3; SANFORD JC, 1987, PARTICLE SCI TECHNOL, V5, P27, DOI DOI 10.1080/02726358708904533; SANFORD JC, IN PRESS METH ENZYM; WILLIAMS RS, 1991, P NATL ACAD SCI USA, V88, P2726, DOI 10.1073/pnas.88.7.2726	8	1235	1613	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					152	154		10.1038/356152a0	http://dx.doi.org/10.1038/356152a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545867				2022-12-28	WOS:A1992HH73100059
J	GOODRICH, J; CARPENTER, R; COEN, ES				GOODRICH, J; CARPENTER, R; COEN, ES			A COMMON GENE REGULATES PIGMENTATION PATTERN IN DIVERSE PLANT-SPECIES	CELL			English	Article							CHALCONE SYNTHASE GENE; ANTIRRHINUM-MAJUS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATORS; DROSOPHILA-MELANOGASTER; TRANSPOSABLE ELEMENTS; NUCLEOTIDE-SEQUENCE; C-MYC; MAIZE; PROTEIN	The delila (del) gene regulates the pattern of red anthocyanin pigmentation in Antirrhinum majus plants. We describe the cloning of the del locus by transposon tagging and show that it encodes a protein with extensive homology to products of the R gene family, which regulates pigmentation in maize. This shows that in spite of the many differences in morphology and coloration between maize and Antirrhinum, the control of pigmentation pattern is mediated by a common regulator. The del and R products contain a region similar to the conserved domain of the helix-loop-helix family of transcription factors. In situ hybridization and RNA analysis show that the expression of del correlates with the distribution of anthocyanins in the flowers. We discuss the implications of these findings for the evolution of regulatory networks.			GOODRICH, J (corresponding author), JOHN INNES INST,JOHN INNES CTR PLANT SCI RES,COLNEY LANE,NORWICH NR4 7UH,NORFOLK,ENGLAND.		Po, Hong/F-4126-2011					ALMEIDA J, 1989, GENE DEV, V3, P1758, DOI 10.1101/gad.3.11.1758; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BEEMAN RW, 1989, DEV BIOL, V133, P196, DOI 10.1016/0012-1606(89)90311-4; BELD M, 1989, PLANT MOL BIOL, V13, P491, DOI 10.1007/BF00027309; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRAY SJ, 1986, EMBO J, V5, P2305, DOI 10.1002/j.1460-2075.1986.tb04498.x; BRENNAN MD, 1988, P NATL ACAD SCI USA, V85, P6866, DOI 10.1073/pnas.85.18.6866; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CHANDLER VL, 1989, PLANT CELL, V1, P1175, DOI 10.1105/tpc.1.12.1175; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; COE EH, 1977, CORN CORN IMPROVEMEN, P111; COEN ES, 1986, CELL, V47, P285, DOI 10.1016/0092-8674(86)90451-4; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Dellaporta SL, 1988, CHROMOSOME STRUCTURE, P263, DOI DOI 10.1007/978-1-4613-1037-2_12; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DOONER HK, 1979, GENETICS, V91, P309; DOONER HK, 1991, ANNU REV GENET, V25, P173, DOI 10.1146/annurev.ge.25.120191.001133; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GERATS AGM, 1992, RECENT ADV PHYTOCHEM; GOFF SA, 1990, EMBO J, V9, P2517, DOI 10.1002/j.1460-2075.1990.tb07431.x; HARKER CL, 1990, PLANT CELL, V2, P185, DOI 10.1105/tpc.2.3.185; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; JACKSON D, 1991, CURR BIOL, V1, P99; Jackson DP., 1992, MOL PLANT PATHOLOGY, P163; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; KERMICLE JL, 1980, SCIENCE, V208, P1457, DOI 10.1126/science.208.4451.1457; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; LUDWIG SR, 1990, SCIENCE, V247, P449, DOI 10.1126/science.247.4941.449; LUO D, 1991, PLANT J, V1, P59, DOI 10.1111/j.1365-313X.1991.00059.x; LUTTKE HA, 1987, EMBO J, V6, P43; MARTIN C, 1991, PLANT J, V1, P37, DOI 10.1111/j.1365-313X.1991.00037.x; MARTIN C, 1987, DEV MUTANTS HIGHER P, P19; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERROT GH, 1989, NUCLEIC ACIDS RES, V17, P8003, DOI 10.1093/nar/17.19.8003; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RADICELLA JP, 1991, PLANT MOL BIOL, V17, P127, DOI 10.1007/BF00036813; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMID J, 1990, PLANT CELL, V2, P619, DOI 10.1105/tpc.2.7.619; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SOMMER H, 1986, MOL GEN GENET, V202, P429, DOI 10.1007/BF00333273; SOMMER H, 1985, MOL GEN GENET, V199, P225, DOI 10.1007/BF00330263; TONELLI C, 1991, MOL GEN GENET, V225, P401, DOI 10.1007/BF00261680; UPADHYAYA KC, 1985, MOL GEN GENET, V199, P201, DOI 10.1007/BF00330260; WALLRATH LL, 1991, P NATL ACAD SCI USA, V88, P5489, DOI 10.1073/pnas.88.13.5489; Wheldale MM, 1907, P R SOC LOND B-CONTA, V79, P288, DOI 10.1098/rspb.1907.0020; WILSON AC, 1974, P NATL ACAD SCI USA, V71, P2843, DOI 10.1073/pnas.71.7.2843; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201	58	260	303	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					955	964		10.1016/0092-8674(92)90038-E	http://dx.doi.org/10.1016/0092-8674(92)90038-E			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547495				2022-12-28	WOS:A1992HH74800014
J	RANISH, JA; LANE, WS; HAHN, S				RANISH, JA; LANE, WS; HAHN, S			ISOLATION OF 2 GENES THAT ENCODE SUBUNITS OF THE YEAST TRANSCRIPTION FACTOR-IIA	SCIENCE			English	Article							RNA POLYMERASE-II; TATA BINDING-PROTEIN; INITIATION; ACTIVATION	The yeast transcription factor IIA (TFIIA), a component of the basal transcription machinery of RNA polymerase II and implicated in vitro in regulation of basal transcription, is composed of two subunits of 32 and 13.5 kilodaltons. The genes that encode these subunits, termed TOA1 and TOA2, respectively, were cloned. Neither gene shares obvious sequence similarity with the other or with any other previously identified genes. The recombinant factor bound to a TATA binding protein-DNA complex and complemented yeast and mammalian in vitro transcription systems depleted of TFIIA. Both the TOA1 and TOA2 genes are essential for growth of yeast.	HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University	RANISH, JA (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Hahn, Steven/0000-0001-7240-2533				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURKE C, 1990, NUCLEIC ACIDS RES, V18, P3611, DOI 10.1093/nar/18.12.3611; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FEAVER WJ, 1991, J BIOL CHEM, V266, P1900; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLANAGAN PM, 1991, J BIOL CHEM, V266, P436; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; RANISH JA, 1991, J BIOL CHEM, V266, P19320; RANISH JA, UNPUB; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223	27	119	126	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1127	1129		10.1126/science.1546313	http://dx.doi.org/10.1126/science.1546313			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546313				2022-12-28	WOS:A1992HF63200041
J	ELLINGTON, AD; SZOSTAK, JW				ELLINGTON, AD; SZOSTAK, JW			SELECTION INVITRO OF SINGLE-STRANDED-DNA MOLECULES THAT FOLD INTO SPECIFIC LIGAND-BINDING STRUCTURES	NATURE			English	Article							EVOLUTION; POLYMERASE	WE have isolated a set of ligand-binding DNA sequences from a large pool of random sequence DNAs by selection and amplification in vitro, using similar methods to those described for the isolation of ligand-binding RNAs 1. The ligand-DNA interactions are both sequence- and ligand-specific, and are dependent on proper folding of the single-stranded DNA. Some ligands led to the isolation of more DNA sequences than RNA sequences, and vice versa. Analysis of individual sequences reveals that ligand binding is DNA-specific; RNAs of identical sequence could not interact with the same ligands. Ligand-binding DNAs might be more suitable than RNAs as potential pharmacological reagents 2-4 because of the greater stability of DNA. The apparent primacy of RNA in the early evolution of life 5-7 may have been due to its availability rather than to its functional superiority.			ELLINGTON, AD (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							ABELSON J, 1990, SCIENCE, V249, P488, DOI 10.1126/science.1696394; ARNOLD FH, 1986, J CHROMATOGR, V355, P1, DOI 10.1016/S0021-9673(01)97299-1; ELLINGTON A, 1987, CURRENT PROTOCOLS MO; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1991, Methods (Orlando), V2, P75, DOI 10.1016/S1046-2023(05)80127-6; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Orgel L.E., 1971, PREBIOTIC BIOCH EVOL, P89; RIORDAN ML, 1991, NATURE, V350, P442, DOI 10.1038/350442a0; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VISSER CM, 1978, J MOL EVOL, V11, P171, DOI 10.1007/BF01733892	12	619	729	16	223	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					850	852		10.1038/355850a0	http://dx.doi.org/10.1038/355850a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538766				2022-12-28	WOS:A1992HF63600064
J	SCHOUTEN, EG; DEKKER, JM; POOL, J; KOK, FJ; SIMOONS, ML				SCHOUTEN, EG; DEKKER, JM; POOL, J; KOK, FJ; SIMOONS, ML			WELL SHAPED ST SEGMENT AND RISK OF CARDIOVASCULAR MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							SUDDEN-DEATH; MEN; ELECTROCARDIOGRAM; PROGNOSIS	Objective - To investigate the prognostic value of frequently occurring slight variations in the ST segment for cardiovascular mortality in healthy subjects. Design - Follow up study of mortality in relation to variations in ST segment level in a cohort over the 28 years from 1953 to 1981. A case-cohort sampling design was applied to limit the number of electrocardiograms that had to be coded by hand. Setting - General health examination carried out in 1953 of civil servants in Amsterdam and assessment of subsequent mortality. Subjects - Apparently healthy civil servants aged 40 to 65 years: 1583 men and 1508 women. Main outcome measures - Relative risk of variations in ST segment level for mortality from all causes, cardiovascular disease, and coronary heart disease. Results - In men the multivariate relative risks of 15 year mortality from cardiovascular disease and coronary heart disease of slight ST elevation at 80 ms past the J point (compared with isoelectric ST segment) were 0.5 (95% confidence interval 0.3 to 0.9) and 0.4 (0.2 to 0.8), respectively. As expected, ST segment depression (> 0.25 mm) was associated with increased risk: 1.9 (1.1 to 3.0) and 2.2 (1.2 to 3.9), respectively. In women associations were weaker. The full 28 year period showed a similar pattern of somewhat weaker associations for men; among women, however, no predictive value was apparent. Conclusion - These results are empirical evidence for the intuitive opinion among doctors that a curved, upward sloping ST segment, resulting in slight ST elevation at 80 ms, indicates low risk compared with the isoelectric flat, stretched ST segment.	ERASMUS UNIV,CTR THORAX,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	SCHOUTEN, EG (corresponding author), AGR UNIV WAGENINGEN,DEPT EPIDEMIOL & PUBL HLTH,POB 238,6700 AE WAGENINGEN,NETHERLANDS.							[Anonymous], 1985, THEORETICAL EPIDEMIO; BLACKBURN H, 1970, Circulation Research Supplement, V41, P154; BRUCE RA, 1988, CIRCULATION, V77, P897, DOI 10.1161/01.CIR.77.4.897; BRUCE RA, 1978, HEART ARTERIES VEINS; ELLESTAD MH, 1980, STRESS TESTING PRINC, P95; FORTUIN NJ, 1979, AM J MED, V49, P459; GREENLAND S, 1986, STAT MED, V5, P579, DOI 10.1002/sim.4780050605; KAGAN A, 1989, AM J EPIDEMIOL, V130, P268, DOI 10.1093/oxfordjournals.aje.a115333; KREGER BE, 1987, AM HEART J, V113, P377, DOI 10.1016/0002-8703(87)90281-X; LIAO YL, 1988, J AM COLL CARDIOL, V12, P1494, DOI 10.1016/S0735-1097(88)80016-0; MIETTINEN OS, 1985, J CHRON DIS, V38, P543, DOI 10.1016/0021-9681(85)90039-6; MIETTINEN OS, 1982, SCAND J WORK ENV H S, V1, P7; OSTRANDER LD, 1970, AM J CARDIOL, V25, P325, DOI 10.1016/S0002-9149(70)80010-8; Prineas R., 1982, MINNESOTA CODE MANUA; QUYYUMI AA, 1983, BRIT HEART J, V50, P460; RABKIN SW, 1982, BRIT HEART J, V47, P546; Reunanen A, 1978, Adv Cardiol, V21, P310; ROSE G, 1978, BRIT HEART J, V40, P636; VANDENBROUCKE JP, 1984, AM J EPIDEMIOL, V119, P742, DOI 10.1093/oxfordjournals.aje.a113795; VANDERHEIDE RM, 1959, THESIS U AMSTERDAM; 1977, MANUAL INT STATISTIC, V1	21	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					356	359		10.1136/bmj.304.6823.356	http://dx.doi.org/10.1136/bmj.304.6823.356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540733	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992HD38700024
J	MAYEDA, A; KRAINER, AR				MAYEDA, A; KRAINER, AR			REGULATION OF ALTERNATIVE PRE-MESSENGER-RNA SPLICING BY HNRNP-A1 AND SPLICING FACTOR-SF2	CELL			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; TRANSFORMED HUMAN-CELLS; SITE SELECTION; BINDING PROTEINS; CORE PROTEINS; HELA-CELLS; PACKAGING PROTEINS; COMPLEX PROTEIN-A1; GENE-EXPRESSION; INVITRO	When messenger RNA precursors (pre-mRNAs) containing alternative 5' splice sites are spliced in vitro, the relative concentrations of the heterogeneous ribonucleoprotein (hnRNP) A1 and the essential splicing factor SF2 precisely determine which 5' splice site is selected. In general, an excess of hnRNP A1 favors distal 5' splice sites, whereas an excess of SF2 results in utilization of proximal 5' splice sites. The regulation of these antagonistic activities may play an important role in the tissue-specific and developmental control of gene expression by alternative splicing.			MAYEDA, A (corresponding author), COLD SPRING HARBOR LAB, POB 100, 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA.		Mayeda, Akila/ABC-1134-2020	Mayeda, Akila/0000-0002-9562-550X; Krainer, Adrian/0000-0001-9024-9501				ACHESON NH, 1980, DNA TUMOR VIRUSES, P125; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; AST G, 1991, EMBO J, V10, P425, DOI 10.1002/j.1460-2075.1991.tb07964.x; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BIAMONTI G, 1989, J MOL BIOL, V207, P491, DOI 10.1016/0022-2836(89)90459-2; BORSI L, 1987, J CELL BIOL, V104, P595, DOI 10.1083/jcb.104.3.595; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUVOLI M, 1990, NUCLEIC ACIDS RES, V18, P6595, DOI 10.1093/nar/18.22.6595; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CELIS JE, 1986, FEBS LETT, V194, P101, DOI 10.1016/0014-5793(86)80059-X; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; CHUNG S Y, 1986, Proteins Structure Function and Genetics, V1, P195, DOI 10.1002/prot.340010302; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; CONWAY G, 1988, MOL CELL BIOL, V8, P2884, DOI 10.1128/MCB.8.7.2884; CONWAY GC, 1989, MOL CELL BIOL, V9, P5273, DOI 10.1128/MCB.9.12.5273; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DEKOCH IG, 1981, MECHANISMS LYMPHOCYT, P222; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GATTONI R, 1991, GENE DEV, V5, P1847, DOI 10.1101/gad.5.10.1847; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GOODWIN LO, 1991, J BIOL CHEM, V266, P8408; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HARPER JE, 1991, MOL CELL BIOL, V11, P5945, DOI 10.1128/MCB.11.12.5945; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; KARN J, 1977, J BIOL CHEM, V252, P7307; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; KUMAR A, 1986, J BIOL CHEM, V261, P1266; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; KUMAR A, 1987, J BIOL CHEM, V262, P17126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LESTOURGEON WM, 1977, COLD SPRING HARB SYM, V42, P885, DOI 10.1101/SQB.1978.042.01.090; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; MANLEY JL, 1986, CANCER CELL, V4, P259; MAYEDA A, 1988, MOL CELL BIOL, V8, P4484, DOI 10.1128/MCB.8.10.4484; MAYEDA A, 1992, IN PRESS P NATL ACAD; MAYRAND SH, 1990, NUCLEIC ACIDS RES, V18, P3307, DOI 10.1093/nar/18.11.3307; MERRILL BM, 1990, EUKARYOTIC NUCLEUS M, V2, P579; MUNROE SH, 1992, IN PRESS P NATL ACAD; NADLER SG, 1991, BIOCHEMISTRY-US, V30, P2968, DOI 10.1021/bi00225a034; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PERKINS KK, 1986, P NATL ACAD SCI USA, V83, P887, DOI 10.1073/pnas.83.4.887; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PLANCK SR, 1988, NUCLEIC ACIDS RES, V16, P11663, DOI 10.1093/nar/16.24.11663; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RUBY SW, 1991, TRENDS GENET, V7, P79; SCHMITT P, 1987, CELL, V50, P31, DOI 10.1016/0092-8674(87)90659-3; SIERAKOWSKA H, 1986, NUCLEIC ACIDS RES, V14, P5241, DOI 10.1093/nar/14.13.5241; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SPECTOR DJ, 1978, J MOL BIOL, V126, P395, DOI 10.1016/0022-2836(78)90048-7; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SVENSSON C, 1983, J MOL BIOL, V165, P475, DOI 10.1016/S0022-2836(83)80214-9; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; WILK HE, 1985, EUR J BIOCHEM, V146, P71, DOI 10.1111/j.1432-1033.1985.tb08621.x; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x	84	661	664	1	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					365	375		10.1016/0092-8674(92)90477-T	http://dx.doi.org/10.1016/0092-8674(92)90477-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1531115				2022-12-28	WOS:A1992HB35300015
J	NOVELLO, AC				NOVELLO, AC			INCREASING ORGAN DONATION - A REPORT FROM THE SURGEON-GENERALS WORKSHOP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1991, TRANSPLANTATION, V51, P142	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					213	213						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1536677				2022-12-28	WOS:A1992GY04600007
J	AHISSAR, E; VAADIA, E; AHISSAR, M; BERGMAN, H; ARIELI, A; ABELES, M				AHISSAR, E; VAADIA, E; AHISSAR, M; BERGMAN, H; ARIELI, A; ABELES, M			DEPENDENCE OF CORTICAL PLASTICITY ON CORRELATED ACTIVITY OF SINGLE NEURONS AND ON BEHAVIORAL CONTEXT	SCIENCE			English	Article							LONG-TERM POTENTIATION; VISUAL-CORTEX; HEBBIAN SYNAPSES; MECHANISMS; CONNECTIVITY; HIPPOCAMPUS; DEPRESSION; POSTULATE; MEMORY; SLICES	It has not been possible to analyze the cellular mechanisms underlying learning in behaving mammals because of the difficulties in recording intracellularly from awake animals. Therefore, in the present study of neuronal plasticity in behaving monkeys, the net effect of a single neuron on another neuron (the "functional connection") was evaluated by cross-correlating the times of firing of the two neurons. When two neurons were induced to fire together within a short time window, the functional connection between them was potentiated, and when simultaneous firing was prevented, the connection was depressed. These modifications were strongly dependent on the behavioral context of the stimuli that induced them. The results indicate that changes in the temporal contingency between neurons are often necessary, but not sufficient, for cortical plasticity in the adult monkey: behavioral relevance is required.	HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT PHYSIOL, IL-91010 JERUSALEM, ISRAEL	Hebrew University of Jerusalem			Vaadia, Eilon/E-9347-2011	Ahissar, Merav/0000-0001-7694-8111				ABELES M, 1977, P IEEE, V65, P762, DOI 10.1109/PROC.1977.10559; ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; Abeles M., 1991, CORTICONICS NEURAL C, DOI DOI 10.1017/CBO9780511574566; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AHISSAR M, 1992, J NEUROPHYSIOL, V67, P203, DOI 10.1152/jn.1992.67.1.203; AOU SJ, 1992, J NEUROSCI, V12, P560; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BARANYI A, 1991, NEUROSCIENCE, V42, P321, DOI 10.1016/0306-4522(91)90378-2; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BOWER GH, 1981, THEOR LEARN, P21; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; CAREW TJ, 1984, J NEUROSCI, V4, P1217; DIPRISCO GV, 1984, PROG NEUROBIOL, V22, P89, DOI 10.1016/0301-0082(84)90021-2; Dudai Y., 1989, NEUROBIOLOGY MEMORY; FARLEY J, 1985, ANNU REV PSYCHOL, V36, P419; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; FROSTIG RD, 1983, BRAIN RES, V272, P211, DOI 10.1016/0006-8993(83)90567-X; GREUEL JM, 1988, SCIENCE, V242, P74, DOI 10.1126/science.2902687; GROSSBERG S, 1976, BIOL CYBERN, V23, P121, DOI 10.1007/BF00344744; GROSSBERG S, 1988, NEURAL NETWORKS NATU, P405; Hebb DO, 1949, ORG BEHAVIOR, P62; KANDEL ER, 1968, PHYSIOL REV, V48, P65, DOI 10.1152/physrev.1968.48.1.65; Kandel ER., 1976, CELLULAR BASIS BEHAV; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KLOPF H, 1989, NEURAL MODELS PLASTI, P104; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LEVY WB, 1983, NEUROSCIENCE, V8, P791, DOI 10.1016/0306-4522(83)90010-6; Mackintosh N. J, 1983, CONDITIONING ASS LEA; PERKEL DH, 1967, BIOPHYS J, V7, P391, DOI 10.1016/S0006-3495(67)86596-2; RAUSCHECKER JP, 1991, PHYSIOL REV, V71, P587, DOI 10.1152/physrev.1991.71.2.587; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; RESCORLA RA, 1988, ANNU REV NEUROSCI, V11, P329, DOI 10.1146/annurev.ne.11.030188.001553; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; STANTON PK, 1985, J NEUROSCI, V5, P2169; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135; THORNDIKE EL, 1965, ANIMAL INTELLIGENCE, P244; VAADIA E, 1991, NEURONAL COOPERATIVI; von der Malsburg C, 1973, Kybernetik, V14, P85; Weinberger N. M., 1990, LEARNING COMPUTATION, P91	41	273	276	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1992	257	5075					1412	1415		10.1126/science.1529342	http://dx.doi.org/10.1126/science.1529342			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529342				2022-12-28	WOS:A1992JL61200038
J	LUFKIN, EG; WAHNER, HW; OFALLON, WM; HODGSON, SF; KOTOWICZ, MA; LANE, AW; JUDD, HL; CAPLAN, RH; RIGGS, BL				LUFKIN, EG; WAHNER, HW; OFALLON, WM; HODGSON, SF; KOTOWICZ, MA; LANE, AW; JUDD, HL; CAPLAN, RH; RIGGS, BL			TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH TRANSDERMAL ESTROGEN	ANNALS OF INTERNAL MEDICINE			English	Article						OSTEOPOROSIS; ESTROGEN REPLACEMENT THERAPY; FRACTURES; ESTRADIOL; TRANSDERMAL DRUG ADMINISTRATION	BONE GLA-PROTEIN; REPLACEMENT THERAPY; POST-MENOPAUSAL; HORMONE REPLACEMENT; PROXIMAL FEMUR; FRACTURE RATE; WOMEN; ESTRADIOL; 17-BETA-ESTRADIOL; PROGESTERONE	Objective: To evaluate the tolerance and effectiveness of transdermal estrogen for women with established postmenopausal osteoporosis and vertebral fractures. Design: Double-blind, randomized, placebo-controlled clinical trial lasting 1 year. Setting: Referral-based outpatient clinic. Patients: Seventy-five postmenopausal women, 47 to 75 years of age, with one or more vertebral fractures due to osteoporosis. Interventions: Thirty-nine women received dermal patches delivering 0.1 mg of 17-beta-estradiol for days 1 to 21 and oral medroxyprogesterone acetate for days 11 to 21 of a 28-day cycle. Another 39 women received placebo. Measurements: Bone turnover assessed by biochemical markers and iliac bone histomorphometry; bone loss assessed by serial measurement of bone density; and vertebral fracture rate. Results: Compared with the placebo group, the median annual percentage change in bone mineral density in the estrogen group reflected increased or steady-state bone mineral density at the lumbar spine (5.3 compared with 0.2; P = 0.007), femoral trochanter (7.6 compared with 2.1; P = 0.03), and midradius (1.0 compared with -2.6, P < 0.001) but showed no significant difference at the femoral neck (2.6 compared with 1.4; P = 0.17). Estrogen treatment uniformly decreased bone turnover as assessed by several methods including serum osteocalcin concentration (median change, -0.35 compared with 0.02 nmol/L; P < 0.001). Histomorphometric evaluation of iliac biopsy samples confirmed the eff ect of estrogen on bone formation rate per bone volume (median change, -12.9 compared with -6.2% per year; P = 0.004). Also, 8 new fractures occurred in 7 women in the estrogen group, whereas 20 occurred in 12 women in the placebo group, yielding a lower vertebral fracture rate in the estrogen group (relative risk, 0.39; 95% Cl, 0.16 to 0.95). Conclusions: Transdermal estradiol treatment is effective in postmenopausal women with established osteoporosis.			LUFKIN, EG (corresponding author), MAYO CLIN & MAYO FDN, DIV ENDOCRINOL & METAB, 200 1ST ST SW, ROCHESTER, MN 55905 USA.		Kotowicz, Mark/AAI-4135-2021	Kotowicz, Mark/0000-0002-8094-1411				ADAMI S, 1989, BONE MINER, V7, P79, DOI 10.1016/0169-6009(89)90064-0; ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CIVITELLI R, 1988, J CLIN INVEST, V82, P1268, DOI 10.1172/JCI113725; CIVITELLI R, 1988, CALCIFIED TISSUE INT, V42, P77, DOI 10.1007/BF02556338; COCHRAN WG, 1977, SAMPLING TECHNIQUES, P153; DELMAS PD, 1983, J LAB CLIN MED, V102, P470; DEMOUSTIER BF, 1989, MATURITAS, V11, P275, DOI 10.1016/0378-5122(89)90024-8; DRAPER NR, 1981, APPL REGRESSION ANAL, P108; DUDA RJ, 1988, J CLIN ENDOCR METAB, V66, P951, DOI 10.1210/jcem-66-5-951; ERIKSEN EF, 1990, J BONE MINER RES, V5, P311, DOI 10.1002/jbmr.5650050402; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; HARDER DR, 1979, J CELL PHYSIOL, V100, P375, DOI 10.1002/jcp.1041000218; HEANEY RP, 1978, J LAB CLIN MED, V92, P964; HIRVONEN E, 1981, NEW ENGL J MED, V304, P560, DOI 10.1056/NEJM198103053041002; HODGSON SF, 1986, MAYO CLIN PROC, V61, P28, DOI 10.1016/S0025-6196(12)61395-0; JUDD HL, 1983, ANN INTERN MED, V98, P195, DOI 10.7326/0003-4819-98-2-195; JUDD HL, 1974, J CLIN ENDOCR METAB, V39, P1020, DOI 10.1210/jcem-39-6-1020; KELLER PJ, 1989, SCHWEIZ MED WSCHR, V119, P999; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LIN AL, 1986, ARTERIOSCLEROSIS, V6, P495, DOI 10.1161/01.ATV.6.5.495; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; OBRIEN PC, 1988, J AM STAT ASSOC, V83, P52, DOI 10.2307/2288918; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096; PARFITT AM, 1980, MINER ELECTROL METAB, V4, P273; POWERS MS, 1985, AM J OBSTET GYNECOL, V152, P1099, DOI 10.1016/0002-9378(85)90569-1; RIBOT C, 1990, OBSTET GYNECOL, V75, pS42; RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1990, NEW ENGL J MED, V323, P124, DOI 10.1056/NEJM199007123230209; RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462; SMITH R, 1990, BRIT MED J, V301, P452, DOI 10.1136/bmj.301.6750.452; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STANCZYK FZ, 1988, AM J OBSTET GYNECOL, V159, P1540, DOI 10.1016/0002-9378(88)90591-1; STEVENSON JC, 1990, LANCET, V336, P265, DOI 10.1016/0140-6736(90)91801-G; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680	46	659	662	0	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					1	9		10.7326/0003-4819-117-1-1	http://dx.doi.org/10.7326/0003-4819-117-1-1			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1534476				2022-12-28	WOS:A1992JA43500001
J	SPERLING, RS; STRATTON, P; OSULLIVAN, MJ; BOYER, P; WATTS, DH; LAMBERT, JS; HAMMILL, H; LIVINGSTON, EG; GLOEB, DJ; MINKOFF, H; FOX, HE				SPERLING, RS; STRATTON, P; OSULLIVAN, MJ; BOYER, P; WATTS, DH; LAMBERT, JS; HAMMILL, H; LIVINGSTON, EG; GLOEB, DJ; MINKOFF, H; FOX, HE			A SURVEY OF ZIDOVUDINE USE IN PREGNANT-WOMEN WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED TRIAL; AZT	Background and Methods. The expanding indications for zidovudine treatment make it important to elucidate the safety and toxicity of this drug for pregnant women and their fetuses. We asked pediatricians and obstetricians at the AIDS (acquired immunodeficiency syndrome) Clinical Trials Units to report information about pregnant women infected with the human immunodeficiency virus who were continuing their pregnancies and had received, or were receiving, zidovudine during gestation. Results. Reports of 43 women were received from 17 institutions. Doses of zidovudine ranged from 300 to 1200 mg per day, and 24 women took the drug for at least two trimesters. There were two reported instances of maternal toxicity (one gastrointestinal and one hematologic). No teratogenic abnormalities occurred in the 12 infants with first-trimester exposure to zidovudine. All the infants, including two sets of twins, were born alive. The 38 singleton infants born at term for whom birth weights were reported had a mean birth weight of 3287 +/- 670 g; two cases of intrauterine growth retardation were reported among the infants delivered at term. Hemoglobin values, which were available for 31 newborns, ranged from 7.0 to 12.4 mmol per liter (11.2 to 20 g per deciliter); 3 of the 7 newborns with hemoglobin values of less than 8.4 mmol per liter (13.5 g per deciliter) were born prematurely. Conclusions. Zidovudine was well tolerated by the pregnant women and was apparently not associated with malformations in the newborns, premature birth, or fetal distress. No pattern of hematologic toxicity was observed in the newborns, but the anemia and growth retardation seen in a minority of the infants could, in part, have resulted from their mothers' treatment with zidovudine.	NICHHD,PEDIAT ADOLESCENT & MATERNAL AIDS BRANCH,BETHESDA,MD 20892; UNIV MIAMI,SCH MED,DEPT OBSTET & GYNECOL,MIAMI,FL 33152; UNIV CALIF LOS ANGELES,SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90024; UNIV WASHINGTON,DEPT OBSTET & GYNECOL,SEATTLE,WA 98195; UNIV ROCHESTER,MED CTR,DEPT MED,ROCHESTER,NY 14642; BAYLOR COLL MED,DEPT OBSTET & GYNECOL,HOUSTON,TX 77030; DUKE UNIV,MED CTR,DEPT OBSTET & GYNECOL,DURHAM,NC 27710; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT OBSTET & GYNECOL,BRONX,NY 10461; SUNY HLTH SCI CTR,DEPT OBSTET & GYNECOL,BROOKLYN,NY; COLUMBIA PRESBYTERIAN MED CTR,DEPT OBSTET & GYNECOL,NEW YORK,NY 10032	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Miami; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Washington; University of Washington Seattle; University of Rochester; Baylor College of Medicine; Duke University; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Columbia University; NewYork-Presbyterian Hospital	SPERLING, RS (corresponding author), MT SINAI MED CTR,DEPT OBSTET GYNECOL & REPROD SCI,BOX 1173,1 GUSTAVE LEVY PL,NEW YORK,NY 10029, USA.		Livingston, Elizabeth/AAQ-8879-2021	Livingston, Elizabeth/0000-0003-1642-5516; lambert, john/0000-0001-5404-2415	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027667] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI-27667] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARZILAI A, 1990, PEDIATR INFECT DIS J, V9, P931, DOI 10.1097/00006454-199012000-00018; CREASY RK, 1991, NEW ENGL J MED, V325, P727, DOI 10.1056/NEJM199109053251009; DEWOLF F, 1988, LANCET, V1, P373; FERRAZIN A, 1991, 7 INT C AIDS FLOR; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GILLET JY, 1989, LANCET, V2, P269; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LOPEZANAYA A, 1991, J ACQ IMMUN DEF SYND, V4, P64; MACDONALD MG, 1991, J ACQ IMMUN DEF SYND, V4, P100; OSKI FA, 1982, HEMATOLOGIC PROBLEMS, V4, P1; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; PRITCHARD JA, 1985, WILLIAMS OBSTETRICS, P747; TOLTZIS P, 1991, J INFECT DIS, V163, P1212, DOI 10.1093/infdis/163.6.1212; VISCARELLO R R, 1991, American Journal of Obstetrics and Gynecology, V164, P248; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WATTS DH, 1991, J INFECT DIS, V163, P226, DOI 10.1093/infdis/163.2.226; 1990, AM J MED, V89, P335	18	92	92	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1992	326	13					857	861		10.1056/NEJM199203263261303	http://dx.doi.org/10.1056/NEJM199203263261303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK523	1542322				2022-12-28	WOS:A1992HK52300003
J	HEGINBOTHAM, C				HEGINBOTHAM, C			LEADING FOR HEALTH - RESPONSES .4. RATIONING	BRITISH MEDICAL JOURNAL			English	Article											HEGINBOTHAM, C (corresponding author), KINGS FUND COLL,HLTH SERV MANAGEMENT,LONDON W2 4HS,ENGLAND.							DONALDSON C, 1991, BRIT MED J, V303, P1529, DOI 10.1136/bmj.303.6816.1529; EWART I, 1991, HLTH SERVICE J  0509, P18; FOX DM, 1991, HEALTH AFFAIR, V10, P7, DOI 10.1377/hlthaff.10.2.7; HAM C, 1990, HEALTHCHECK HEALTHCA, P61; HONIGSBAUM F, 1991, WHO SHALL LIVE WHO S; HONIGSBAUM F, 1991, 1991 PRIORITIZATION, P48; LAMM RD, 1990, BRAVE NEW WORLD HEAL; PARKIN D, 1991, PROVIDING HLTH CARE; PINTO FJ, 1990, EC HLTH CARE CHALLEN, P17; ROSSER RM, 1990, MEASURING OUTCOMES M; 1990, INSIDERS GUIDE MANAG; 1991, 1991 PRIORITIZATION, P40; 1991, LEADING HLTH BMA AGE	13	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					496	499		10.1136/bmj.304.6825.496	http://dx.doi.org/10.1136/bmj.304.6825.496			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547427	Green Published, Bronze			2022-12-28	WOS:A1992HF55500031
J	GIRAUD, A				GIRAUD, A			INTERNATIONAL QUALITY ASSURANCE - MEDICAL AUDIT IN FRANCE - HISTORICAL-PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Editorial Material									ASSISTANCE PUBL HOP PARIS,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille								ARMOGATHE JF, 1989, DEV EVALUATION MED; BLUMBOISGARD C, 1988, HOPITAL PARIS, V106; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P287, DOI 10.1001/jama.263.2.287; FETTER RB, 1980, DEV TESTING EVALUATI; GIRAUD A, IN PRESS QUALITY ASS; GIRAUD A, 1991, CONSENSUS MED METHOD; JOLLY D, 1991, MONDE           0403, P18; JOLLY D, 1982, HOPITAL PARIS, V68, P102; LEGALL JR, 1990, EVALUATION REANIMATI; 1990, C CONSENSUS BASES ME	10	11	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1992	304	6824					426	428		10.1136/bmj.304.6824.426	http://dx.doi.org/10.1136/bmj.304.6824.426			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1547392	Green Published, Bronze			2022-12-28	WOS:A1992HE38900023
J	YEW, N; MELLINI, ML; VANDEWOUDE, GF				YEW, N; MELLINI, ML; VANDEWOUDE, GF			MEIOTIC INITIATION BY THE MOS PROTEIN IN XENOPUS	NATURE			English	Article							ONCOGENE PRODUCT; CELL-CYCLE; CYTOPLASMIC FACTOR; OOCYTE MATURATION; KINASE-ACTIVITY; EGGS	WHEN fully grown Xenopus oocytes are stimulated by progesterone, a period of protein synthesis is necessary for maturation 1. Synthesis of the mos proto-oncogene product, pp39mos, is necessary for the activation of M-phase promoting factor (MPF) in meiosis I (ref. 2). On the basis that mos is translated de novo on hormonal stimulation of Xenopus oocytes 3 and that injecting mos RNA into oocytes induces their maturation 3,4, we have proposed that the mos protein is a candidate initiator of oocyte maturation, needed to trigger the conversion of precursor MPF into its active form 1-3. To determine whether mos is the only protein required for initiating maturation, we have produced a soluble, active recombinant mos protein and injected it into Xenopus oocytes. We report here that in the absence of protein synthesis that mos protein efficiently induces germinal vesicle breakdown and the activation of MPF. The oocytes, however, do not proceed into meiosis II. Thus, the mos protein fulfills the requirements of an initiator protein, but the synthesis of one or more additional proteins may be necessary to complete oocyte maturation.	NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP INC,PROT ISOLAT LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	YEW, N (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP INC,ABL,BASIC RES PROGRAM,POB B,FREDERICK,MD 21702, USA.							ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MINSHULL J, 1991, J CELL BIOL, V114, P767, DOI 10.1083/jcb.114.4.767; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SMITH LD, 1989, DEVELOPMENT, V107, P685; WALLACE RA, 1978, P NATL ACAD SCI USA, V75, P5534, DOI 10.1073/pnas.75.11.5534; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WASSERMAN WJ, 1982, DEV BIOL, V89, P152, DOI 10.1016/0012-1606(82)90303-7; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604	23	223	223	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					649	652		10.1038/355649a0	http://dx.doi.org/10.1038/355649a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1531698				2022-12-28	WOS:A1992HD54700060
J	BOSANQUET, N				BOSANQUET, N			MEDICINE IN EUROPE - EUROPE AND TOBACCO	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON,ROYAL HOLLOWAY & BEDFORD NEW COLL,DEPT SOCIAL POLICY,LONDON NW8 8EG,ENGLAND	University of London; Royal Holloway University London								BOSANQUET N, 1991, RHBNC4 MAR DISC PAP; HIRSCH A, 1988, LUTTER TABAGISME; PETO R, 1988, 1985 ESTIMATES 2025; 1987, 5 YEAR ACTION PLAN S; 1981, CM1523; 1989, SMOKING WISH STOP; 1989, REDUCING HLTH CONSEQ	7	11	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					370	372		10.1136/bmj.304.6823.370	http://dx.doi.org/10.1136/bmj.304.6823.370			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540738	Bronze, Green Published			2022-12-28	WOS:A1992HD38700030
J	ALKUTOUBI, MA				ALKUTOUBI, MA			ABC OF VASCULAR DISEASES - PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY	BRITISH MEDICAL JOURNAL			English	Article											ALKUTOUBI, MA (corresponding author), ST MARYS HOSP,LONDON,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					45	47		10.1136/bmj.304.6818.45	http://dx.doi.org/10.1136/bmj.304.6818.45			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1531183	Green Published, Bronze			2022-12-28	WOS:A1992GY90900039
J	ANAND, KJS; HICKEY, PR				ANAND, KJS; HICKEY, PR			HALOTHANE MORPHINE COMPARED WITH HIGH-DOSE SUFENTANIL FOR ANESTHESIA AND POSTOPERATIVE ANALGESIA IN NEONATAL CARDIAC-SURGERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STRESS RESPONSE; CARDIOPULMONARY BYPASS; FENTANYL ANESTHESIA; SURGICAL PATIENTS; RANDOMIZED TRIAL; PRETERM BABIES; BETA-ENDORPHIN; RADIOIMMUNOASSAY; INFANTS; RECOVERY	Background. Extreme hormonal and metabolic responses to stress are associated with increased morbidity and mortality in sick adults. We hypothesized that administering deep opioid anesthesia to critically ill neonates undergoing cardiac surgery would blunt their responses to stress and might improve clinical outcomes. Methods. In a randomized trial, 30 neonates were assigned to receive deep intraoperative anesthesia with high doses of sufentanil and postoperative infusions of opiates for 24 hours; 15 neonates were assigned to receive lighter anesthesia with halothane and morphine followed postoperatively by intermittent morphine and diazepam. Hormonal and metabolic responses to surgery were evaluated by assay of arterial blood samples obtained before, during, and after the operations. Results. The neonates who received deep anesthesia (with sufentanil) had significantly reduced responses of beta-endorphin, norepinephrine, epinephrine, glucagon, aldosterone, cortisol, and other steroid hormones; their insulin responses and ratios of insulin to glucagon were greater during the operation. The neonates who received lighter anesthesia (with halothane plus morphine) had more severe hyperglycemia and lactic acidemia during surgery and higher lactate and acetoacetate concentrations postoperatively (P < 0.025). The group that received deep anesthesia had a decreased incidence of sepsis (P = 0.03), metabolic acidosis (P < 0.01), and disseminated intravascular coagulation (P = 0.03) and fewer postoperative deaths (none of 30 given sufentanil vs. 4 of 15 given halothane plus morphine, P < 0.01). Conclusions. In neonates undergoing cardiac surgery, the physiologic responses to stress are attenuated by deep anesthesia and postoperative analgesia with high doses of opioids. Deep anesthesia continued postoperatively may reduce the vulnerability of these neonates to complications and may reduce mortality.	CHILDRENS HOSP MED CTR, DEPT MED, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DEPT ANESTHESIA, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital			Hickey, Paul/GYV-3947-2022; Anand, Kanwaljeet/B-3287-2014	Anand, Kanwaljeet/0000-0001-6498-1483				ALBANO JDM, 1972, ACTA ENDOCRINOL-COP, V70, P487, DOI 10.1530/acta.0.0700487; Altman DG., 1982, STATISTICS PRACTICE, P6; ANAND KJS, 1987, LANCET, V1, P243; ANAND KJS, 1987, LANCET, V1, P62; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ANAND KJS, 1990, ANESTHESIOLOGY, V73, P661, DOI 10.1097/00000542-199010000-00012; ANAND KJS, 1986, PROG FOOD NUTR SCI, V10, P67; ANAND KJS, 1986, CURR OPIN CARDIOL, V1, P681; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, VVol. 3., P1196; BESEDOVSKY HO, 1985, J IMMUNOL, V135, pS750; BROWN MJ, 1981, CLIN SCI, V61, P591, DOI 10.1042/cs0610591; BURROWS FA, 1987, J THORAC CARDIOV SUR, V93, P253; CAHILL CA, 1983, J CLIN ENDOCR METAB, V56, P992, DOI 10.1210/jcem-56-5-992; CARR DB, 1989, ANESTH ANALG, V69, P197; Chernow B, 1989, J Neurosurg Anesthesiol, V1, P116, DOI 10.1097/00008506-198906000-00007; COLES JG, 1987, J THORAC CARDIOV SUR, V94, P526; ELLIS DJ, 1990, ANESTHESIOLOGY, V72, P812, DOI 10.1097/00000542-199005000-00007; GHATEI MA, 1983, ENDOCRINOLOGY, V112, P917, DOI 10.1210/endo-112-3-917; GREELEY WJ, 1987, ANESTH ANALG, V66, P1067; HICKEY PR, 1984, ANESTH ANALG, V63, P117; LACOUMENTA S, 1987, BRIT J ANAESTH, V59, P713, DOI 10.1093/bja/59.6.713; LANIER WL, 1987, ANESTHESIOLOGY, V66, P39, DOI 10.1097/00000542-198701000-00008; LUMPKIN MD, 1987, SCIENCE, V238, P452, DOI 10.1126/science.2821618; MILNER N, 1986, CLIN BIOMECH, V1, P29, DOI 10.1016/0268-0033(86)90034-3; MOYER E, 1981, J TRAUMA, V21, P862, DOI 10.1097/00005373-198110000-00006; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PHILBIN DM, 1978, ANESTHESIOLOGY, V49, P95, DOI 10.1097/00000542-197808000-00007; RATCLIFFE JM, 1988, THORAC CARDIOV SURG, V36, P65, DOI 10.1055/s-2007-1020047; REIER CE, 1973, ANESTH ANALG, V52, P1003; ROIZEN MF, 1987, ANESTHESIOLOGY SA1, V67; SCOTT NB, 1988, BRIT J SURG, V75, P299; SIPPELL WG, 1978, J STEROID BIOCHEM, V9, P63, DOI 10.1016/0022-4731(78)90104-8; STHAXHOLDT O, 1981, ACTA ANAESTH SCAND, V25, P434, DOI 10.1111/j.1399-6576.1981.tb01681.x; SWARTZ MN, 1991, NEW ENGL J MED, V325, P654, DOI 10.1056/NEJM199108293250910; SWEDBERG K, 1990, CIRCULATION, V82, P1730, DOI 10.1161/01.CIR.82.5.1730; TONNESEN E, 1987, ANESTHESIOLOGY, V67, P526, DOI 10.1097/00000542-198710000-00014; TUMAN KJ, 1991, ANESTH ANALG, V73, P696; VOUTILAINEN R, 1986, J CLIN ENDOCR METAB, V63, P1145, DOI 10.1210/jcem-63-5-1145; WITTNICH C, 1987, CIRCULATION, V76, P156; YEAGER MP, 1987, ANESTHESIOLOGY, V66, P729, DOI 10.1097/00000542-198706000-00004	41	489	507	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					1	9		10.1056/NEJM199201023260101	http://dx.doi.org/10.1056/NEJM199201023260101			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX315	1530752				2022-12-28	WOS:A1992GX31500001
J	OXMAN, AD; GUYATT, GH				OXMAN, AD; GUYATT, GH			A CONSUMERS GUIDE TO SUBGROUP ANALYSES	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CONGESTIVE HEART-FAILURE; CLINICAL-TRIAL OUTCOMES; MYOCARDIAL-INFARCTION; RANDOMIZED TRIALS; DIGOXIN; OVERVIEWS; THERAPY; BAYES; NEED	The extent to which a clinician should believe and act on the results of subgroup analyses of data from randomized trials or meta-analyses is controversial. Guidelines are provided in this paper for making these decisions. The strength of inference regarding a proposed difference in treatment effect among subgroups is dependent on the magnitude of the difference, the statistical significance of the difference, whether the hypothesis preceded or followed the analysis, whether the subgroup analysis was one of a small number of hypotheses tested, whether the difference was suggested by comparisons within or between studies, the consistency of the difference, and the existence of indirect evidence that supports the difference. Application of these guidelines will assist clinicians in making decisions regarding whether to base a treatment decision on overall results or on the results of a subgroup analysis.			OXMAN, AD (corresponding author), MCMASTER UNIV, HLTH SCI CTR, DEPT FAMILY MED, ROOM 2V10, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA.		Oxman, Andrew/Y-3004-2019	Oxman, Andrew/0000-0002-5608-5061				[Anonymous], 1988, LANCET, V2, P349; BAILEY KR, 1987, STAT MED, V6, P351, DOI 10.1002/sim.4780060327; BEACH ML, 1989, CONTROL CLIN TRIALS, V10, pS161; Breslow NE, 1980, STATISTICAL METHODS, V1, P122; BULPITT CJ, 1988, LANCET, V2, P31; BUYSE ME, 1989, CONTROL CLIN TRIALS, V10, pS187; BYAR DP, 1985, STAT MED, V4, P255, DOI 10.1002/sim.4780040304; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; CANNER PL, 1981, CONTROL CLIN TRIALS, V2, P231, DOI 10.1016/0197-2456(81)90013-1; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; COOK DJ, IN PRESS AM J MED; DAVIS CE, 1990, CONTROL CLIN TRIALS, V11, P37, DOI 10.1016/0197-2456(90)90030-6; DONNER A, 1982, J CHRON DIS, V35, P429, DOI 10.1016/0021-9681(82)90057-1; FEINSTEIN A, 1985, CLIN EPIDEMIOL, P306; FLETCHER RH, 1988, CLIN EPIDEMIOL, P185; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FURBERG CD, 1987, STAT MED, V6, P295, DOI 10.1002/sim.4780060316; FURBERG CD, 1983, CIRCULATION, V67, P98; GOLDMAN L, 1979, ANN INTERN MED, V90, P92, DOI 10.7326/0003-4819-90-1-92; GUYATT GH, 1988, AM J CARDIOL, V61, P371, DOI 10.1016/0002-9149(88)90947-2; HILL AB, 1971, LANCET, P312; HIROSE S, 1986, LANCET, V2, P397; Horwitz R I, 1987, Am J Med, V82, P498, DOI 10.1016/0002-9343(87)90450-5; JAESCHKE R, 1990, AM J MED, V88, P279, DOI 10.1016/0002-9343(90)90154-6; KELTON JG, 1978, BLOOD, V52, P1073; LAST JM, 1988, DICT EPIDEMIOLOGY, P41; LEE DCS, 1982, NEW ENGL J MED, V306, P699, DOI 10.1056/NEJM198203253061202; LEE TH, 1989, ANN INTERN MED, V110, P957, DOI 10.7326/0003-4819-110-12-957; LOUIS TA, 1984, J AM STAT ASSOC, V79, P393, DOI 10.2307/2288281; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P403; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; SACKETT DL, 1978, CLIN INVEST MED, V1, P37; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; SCHNEIDER B, 1989, CONTROL CLIN TRIALS, V10, pS176; SHUSTER J, 1983, CONTROL CLIN TRIALS, V4, P209, DOI 10.1016/S0197-2456(83)80026-9; STIEB DM, 1990, CAN MED ASSOC J, V142, P719; TATE DA, 1989, ANN INTERN MED, V110, P953, DOI 10.7326/0003-4819-110-12-953; YUSUF S, 1990, AM J CARDIOL, V66, P220, DOI 10.1016/0002-9149(90)90592-O; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; 1990, TREATMENT EARLY BREA, V1, P7; 1988, BR MED J CLIN RES, V296, P320	43	593	601	0	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					78	84		10.7326/0003-4819-116-1-78	http://dx.doi.org/10.7326/0003-4819-116-1-78			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1530753				2022-12-28	WOS:A1992GX15700012
J	KLATSKY, AL; ARMSTRONG, MA; FRIEDMAN, GD				KLATSKY, AL; ARMSTRONG, MA; FRIEDMAN, GD			ALCOHOL AND MORTALITY	ANNALS OF INTERNAL MEDICINE			English	Article						ALCOHOL DRINKING; SMOKING; DEATH; SEX FACTORS; CORONARY DISEASE	U-SHAPED CURVE; CARDIOVASCULAR MORTALITY; CIGARETTE-SMOKING; CORONARY-DISEASE; LIVER-DISEASE; CONSUMPTION; WOMEN; MEN; RISK; WINE	Objective: To study the relation between alcohol intake and mortality in a large ambulatory population with attention to causes of death and differences related to age, sex, race, and baseline risk. Design: Prospective cohort study. Setting: Prepaid comprehensive health care program facilities in Oakland and San Francisco, California. Participants: Adults (n = 128 934) who supplied data at health evaluations between 1978 and 1985. Measurements: Demographic data and health history were supplied using questionnaires. Death was ascertained by an automated linkage system and was individually validated. Relative risk for death at various levels of drinking was calculated by Cox proportional hazards models using lifelong nondrinkers as the reference and controlling for eight covariables. Results: Heavier drinkers were at greater risk for death from noncardiovascular causes (relative risk at greater-than-or-equal-to 6 drinks per day compared with no alcohol = 1.6, 95% Cl, 1.3 to 2.0) especially cirrhosis, unnatural death, and tobacco-related cancers. This alcohol-associated risk was higher in women (relative risk for death from all causes at greater-than-or-equal-to 6 drinks per day = 2.2; Cl, 1.4 to 3.8) and younger persons (for persons < 50 years of age, relative risk for death from all causes at greater-than-or-equal-to 6 drinks per day = 1.9; Cl, 1.3 to 2.9). Lighter drinkers were at lower risk for death from cardiovascular disease, especially coronary heart disease (relative risk at 1 to 2 drinks per day = 0.7; Cl, 0.6 to 0.9), independent of baseline risk, with the greatest reduction of risk in older persons. Lighter drinkers over 60 years of age also had a slightly lower risk for noncardiovascular death, but this finding was not independent of baseline coronary heart disease risk. Conclusions: Women and younger persons appear more susceptible to the increased mortality risk of heavy drinking. The reduced cardiovascular risk of lighter drinkers is more pronounced in older persons. Lower coronary disease prevalence may reduce the noncardiovascular mortality risk of lighter drinkers.			KLATSKY, AL (corresponding author), KAISER PERMANENTE MED CTR, DEPT MED, 280 W MACARTHUR BLVD, OAKLAND, CA 94611 USA.							ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; ANSTIE FE, 1877, USES WINES HLTH DISE, P11; ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BLACKWELDER WC, 1980, AM J MED, V68, P164, DOI 10.1016/0002-9343(80)90350-2; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CULLEN K, 1982, INT J EPIDEMIOL, V11, P67, DOI 10.1093/ije/11.1.67; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; FRIEDMAN GD, 1991, DRUG ALCOHOL DEPEN, V27, P283, DOI 10.1016/0376-8716(91)90011-M; FRIEDMAN GD, 1991, AM J EPIDEMIOL, V133, P376, DOI 10.1093/oxfordjournals.aje.a115891; FRIEDMAN GD, 1987, PRIMER EPIDEMIOLOGY, P20; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; GRANT BF, 1988, SEMIN LIVER DIS, V8, P12, DOI 10.1055/s-2008-1040525; HIATT RA, 1988, PREV MED, V17, P683, DOI 10.1016/0091-7435(88)90085-0; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; KLATSKY AL, 1990, BRIT J ADDICT, V85, P1279; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; KLATSKY AL, 1979, METABOLIC EFFECTS AL, P143; KLATSKY AL, 1990, ALCOHOL HEALTH RES W, V14, P289; KOZARAREVIC DJ, 1980, LANCET, V1, P613; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; LAPORTE RE, 1980, PREV MED, V9, P22, DOI 10.1016/0091-7435(80)90057-2; MARMOT MG, 1981, LANCET, V1, P580; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; SALONEN JT, 1987, PREV MED, V16, P647, DOI 10.1016/0091-7435(87)90048-X; SEIGNEUR M, 1990, J APPL CARDIOL, V5, P215; SHAPER AG, 1988, LANCET, V2, P1267; SHERLOCK S, 1988, WESTERN J MED, V149, P683; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; 1988, LANCET, V2, P1292; 1990, DHHS ADM901656 PUBL, P107	32	394	404	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					646	654		10.7326/0003-4819-117-8-646	http://dx.doi.org/10.7326/0003-4819-117-8-646			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530196				2022-12-28	WOS:A1992JR86100004
J	INOSHITA, T				INOSHITA, T			THE EDUCATION OF A PATHOLOGIST	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIAN-PATIENT RELATIONS; JOB SATISFACTION; PATHOLOGY; ONCOLOGY; CAREER CHOICE		A pathologist, dissatisfied with his career, decided to change fields in his mid-thirties. Despite a vigorous and often demanding internal medicine training, he enjoyed clinical medicine. In his medical oncology fellowship he enjoyed the chance to interact with and help his patients directly, especially finding the utmost joy and satisfaction in the development of closeness between a physician and his patients. This was exemplified by his interaction with one of his patients, Mrs. E. Now, as a solo oncologist in a small town, he feels blessed with his opportunity to directly contribute to the carte of his patients.			INOSHITA, T (corresponding author), PORTSMOUTH CANC CTR, 1745 27TH ST, PORTSMOUTH, OH 45662 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					608	608		10.7326/0003-4819-117-7-608	http://dx.doi.org/10.7326/0003-4819-117-7-608			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524336				2022-12-28	WOS:A1992JQ22600012
J	RAYCHAUDHURI, D; PARK, JT				RAYCHAUDHURI, D; PARK, JT			ESCHERICHIA-COLI CELL-DIVISION GENE FTSZ ENCODES A NOVEL GTP-BINDING PROTEIN	NATURE			English	Article							BUD SITE SELECTION; MOLECULAR CHARACTERIZATION; BIOCHEMICAL-PROPERTIES; YEAST; SEQUENCE; MEMBRANE; PRODUCT; SUPERFAMILY; MUTATIONS; MUTANTS	ESCHERICHIA COLI divides by forming a septum across the middle of the cell. The biochemical mechanism underlying this process is unknown. Genetic evidence suggests that of all the fts (filamentation temperature sensitive) genes1,2 involved in E. coli cell division, ftsZ plays a central role at the earliest known step of septation3-5. Here we show that FtsZ protein binds GTP in vitro using unusual sequence elements6-8. In contrast, such binding to the product of the conditional-lethal ftsZ84 allele is impaired. purified FtsZ displays a Mg2+-dependent GTPase activity which is markedly reduced in the FtsZ84 protein. FtsZ copurifies with near stoichiometric amounts of noncovalently-bound GDP, implying the presence of a GTPase cycle in vivo, similar to that known for signal-transducing GTP-binding proteins8,9. We also show that a small fraction of FtsZ exists as a distinct membrane-associated species that binds GTP. The membrane association of FtsZ and the known ability of GTPases to act as molecular switches8,9 implicate FtsZ in a GTP-activated signal transduction pathway that may regulate the start of septation in E. coli.			RAYCHAUDHURI, D (corresponding author), TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,BOSTON,MA 02111, USA.							BEALL B, 1988, J BACTERIOL, V170, P4855, DOI 10.1128/jb.170.10.4855-4864.1988; BEALL B, 1991, J BACTERIOL, V173, P5822; BEGG KJ, 1985, J BACTERIOL, V163, P615, DOI 10.1128/JB.163.2.615-622.1985; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BI E, 1990, J BACTERIOL, V172, P5602, DOI 10.1128/jb.172.10.5602-5609.1990; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CORTON JC, 1987, J BACTERIOL, V169, P1; DEBOER PAJ, 1990, ANNU REV GENET, V24, P249, DOI 10.1146/annurev.genet.24.1.249; DONACHIE WD, 1984, MICROBIAL DEV, P27; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HALL A, 1986, J BIOL CHEM, V261, P963; Hershey JW., 1987, ESCHERICHIA COLI SAL, P613; ITO K, 1977, CELL, V11, P551, DOI 10.1016/0092-8674(77)90073-3; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LUTKENHAUS J, 1990, TRENDS GENET, V6, P22, DOI 10.1016/0168-9525(90)90045-8; MARGOLIN W, 1991, J BACTERIOL, V173, P5822, DOI 10.1128/jb.173.18.5822-5830.1991; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; POE M, 1985, J BIOL CHEM, V260, P3906; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SNYDER JA, 1976, ANNU REV BIOCHEM, V45, P699, DOI 10.1146/annurev.bi.45.070176.003411; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TASCHNER PEM, 1988, J BACTERIOL, V170, P1533, DOI 10.1128/jb.170.4.1533-1540.1988; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; YI QM, 1985, GENE, V36, P241	38	355	365	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					251	254		10.1038/359251a0	http://dx.doi.org/10.1038/359251a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1528267				2022-12-28	WOS:A1992JN94400066
J	LOLAIT, SJ; OCARROLL, AM; MCBRIDE, OW; KONIG, M; MOREL, A; BROWNSTEIN, MJ				LOLAIT, SJ; OCARROLL, AM; MCBRIDE, OW; KONIG, M; MOREL, A; BROWNSTEIN, MJ			CLONING AND CHARACTERIZATION OF A VASOPRESSIN V2 RECEPTOR AND POSSIBLE LINK TO NEPHROGENIC DIABETES-INSIPIDUS	NATURE			English	Article							ARGININE-VASOPRESSIN; MESSENGER-RNAS; BINDING-SITES; LOCALIZATION; DNA; AMPLIFICATION; ANTAGONISTS; EXPRESSION; PRIMER; POTENT	THE antidiuretic effect of arginine vasopressin (AVP) is mediated by renal-type (V2) receptors linked to adenylyl cyclase 1. We report here the cloning of the rat kidney V2 AVP receptor complementary DNA that encodes a 370-amino-acid protein with a transmembrane topography characteristic of G protein-coupled receptors, and with similarity to the V1a (hepatic) AVP receptor 2 in its seven membrane-spanning domains. Expression of the cloned cDNA in mammalian cells showed specific ligand binding and activity characteristic of the native V2 AVP receptor. The receptor messenger RNA is detected only in the kidney. The human V2 receptor gene has been localized to the long arm of the X chromosome close to the locus for nephrogenic diabetes insipidus, an X-linked recessive disorder characterized by renal resistance to the antidiuretic action of AVP 3-6.	NIMH,CELL BIOL LAB,BLDG 36,ROOM 3A-17,BETHESDA,MD 20892; GRP NEUROBIOCHIM CELLULAIRE & MOLEC,F-75006 PARIS,FRANCE; NCI,CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Morel, Alain/AAU-7496-2021; Lolait, Stephen/AAG-4483-2020; Brownstein, Michael/B-8609-2009	morel, alain/0000-0003-0125-1883				ANTONI FA, 1984, NEUROPEPTIDES, V4, P413, DOI 10.1016/0143-4179(84)90116-1; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BICHET DG, 1989, KIDNEY INT, V36, P859, DOI 10.1038/ki.1989.272; BODE HH, 1969, NEW ENGL J MED, V280, P750, DOI 10.1056/NEJM196904032801404; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DORSA DM, 1983, PEPTIDES, V4, P699, DOI 10.1016/0196-9781(83)90021-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HOLMES MC, 1985, NEUROENDOCRINOLOGY, V117, P421; JANS DA, 1990, J BIOL CHEM, V265, P15379; JARD S, 1983, CURR TOP MEMBR TRANS, V18, P255; Jard S, 1987, PROG BRAIN RES <D>, V72, P173; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KIRK CJ, 1977, FEBS LETT, V83, P267, DOI 10.1016/0014-5793(77)81020-X; KNOERS N, 1988, NEPHRON, V50, P187, DOI 10.1159/000185155; KNOERS N, 1988, HUM GENET, V80, P31, DOI 10.1007/BF00451451; KONIG M, 1991, Molecular and Cellular Neuroscience, V2, P331, DOI 10.1016/1044-7431(91)90063-T; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MANNING M, 1984, J MED CHEM, V27, P423, DOI 10.1021/jm00370a002; MCBRIDE OW, 1982, NUCLEIC ACIDS RES, V10, P8155, DOI 10.1093/nar/10.24.8155; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; OLSEN AS, 1981, MOL CELL BIOL, V1, P439, DOI 10.1128/MCB.1.5.439; PHILLIPS PA, 1990, ENDOCRINOLOGY, V126, P1478, DOI 10.1210/endo-126-3-1478; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YOUNG WS, 1986, P NATL ACAD SCI USA, V83, P9827, DOI 10.1073/pnas.83.24.9827; YOUNG WS, 1987, NEUROENDOCRINOLOGY, V46, P439	28	487	493	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					336	339		10.1038/357336a0	http://dx.doi.org/10.1038/357336a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1534150				2022-12-28	WOS:A1992HW13200050
J	GREENLICK, MR				GREENLICK, MR			EDUCATING PHYSICIANS FOR POPULATION-BASED CLINICAL-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Debates about changing the current paradigm of medical education and medical practice have become fairly common in recent years. Based on my experience as a research director of a prepaid group practice program and as chair of a medical school department of public health and preventive medicine, I contend that the traditional one-to-one physician-patient role obligations should be expanded to include a set of "one-to-n" physician-population obligations. The latter include at least three components: (1) a resource allocation component, (2) a component focusing on the epidemiologic nature of clinical practice, and (3) a component focusing on members of the population who are not regularly attended to within the normal context of physician care. Discussing these in turn, I argue for a population-based clinical practice model of medical education that preserves the Hippocratic tradition while better preparing physicians for the complex practice and insurance realities of the 21st century.	OREGON HLTH SCI UNIV,DEPT PUBL HLTH & PREVENT MED,PORTLAND,OR 97201	Oregon Health & Science University	GREENLICK, MR (corresponding author), KAISER PERMANENTE CTR HLTH RES,3800 N KAISER CTR DR,PORTLAND,OR 97227, USA.							DONNELLY WJ, 1986, PERSPECT BIOL MED, V30, P81; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; FLEXNER A, 1910, CARNEGIE F ADV TEACH, V4; GREENLICK MR, 1989, HDB MED SOCIOLOGY, P381; HOWIE JGR, 1984, BRIT MED J, V289, P1770, DOI 10.1136/bmj.289.6460.1770; Nuland S. B., 1989, DOCTORS BIOGRAPHY ME; NUTTING P, 1984, COMMUNITY ORIENTED C, V1, pR6; PETERSDORF RG, 1981, RELEVANCE SOCIAL SCI; REICH JM, 1985, AM J MED, V78, P61, DOI 10.1016/0002-9343(85)90463-2; ROGERS DE, 1983, COMMUNITY ORIENTED P, P198; White K.L., 1988, TASK MED DIALOGUE WI; 1984, J MED ED 2, V59	12	101	102	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1645	1648		10.1001/jama.267.12.1645	http://dx.doi.org/10.1001/jama.267.12.1645			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1542174				2022-12-28	WOS:A1992HJ59700032
J	LECKBAND, DE; ISRAELACHVILI, JN; SCHMITT, FJ; KNOLL, W				LECKBAND, DE; ISRAELACHVILI, JN; SCHMITT, FJ; KNOLL, W			LONG-RANGE ATTRACTION AND MOLECULAR-REARRANGEMENTS IN RECEPTOR-LIGAND INTERACTIONS	SCIENCE			English	Article							STREPTAVIDIN; MONOLAYERS; SURFACES; PROTEIN	A surface force apparatus was used to measure a long-range attractive protein-ligand force at separations D < 85 angstroms. This force may effectively "steer" ligand trajectories, resulting in a greater than 27-fold enhancement of the association rate. A much stronger specific attraction is measured at contact (D < 4 angstroms). A sevenfold increase in intermembrane adhesion resulted from increased lateral mobility of the receptors and molecular rearrangements in membranes above the solid-fluid transition temperature.	MAX PLANCK INST POLYMER RES,W-6500 MAINZ,GERMANY	Max Planck Society	LECKBAND, DE (corresponding author), UNIV CALIF SANTA BARBARA,DEPT CHEM & NUCL ENGN,SANTA BARBARA,CA 93106, USA.				NIGMS NIH HHS [GM13300] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON SA, 1985, BIOPOLYMERS, V24, P1323, DOI 10.1002/bip.360240717; BAYER EA, 1990, METHOD ENZYMOL, V184, P49; BELL G, 1988, PHYSICAL BASIS CELL, pCH10; BERRY RS, 1980, PHYSICAL CHEM, P1160; BLANKENBURG R, 1989, BIOCHEMISTRY-US, V28, P8214, DOI 10.1021/bi00446a037; BONGRAND P, 1984, CELL SURFACE DYNAMIC, pCH14; CEVC G, 1984, PHOSPHOLIPID BILAYER, P242; CHRISTENSON HK, 1988, SCIENCE, V239, P390, DOI 10.1126/science.239.4838.390; CLAESSON PM, 1990, J COLLOID INTERF SCI, V136, P541, DOI 10.1016/0021-9797(90)90400-I; CREIGHTON TE, 1989, PROTEINS, P340; EVANS EA, 1985, BIOPHYS J, V48, P185, DOI 10.1016/S0006-3495(85)83771-1; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HELM CA, 1991, P NATL ACAD SCI USA, V88, P8169, DOI 10.1073/pnas.88.18.8169; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; ISRAELACHVILI J, 1982, NATURE, V300, P341, DOI 10.1038/300341a0; ISRAELACHVILI JN, 1985, INTERMOLECULAR SURFA, pCH11; LECKBAND D, UNPUB; MARGOLIASH E, 1983, TRENDS BIOCHEM SCI, V8, P316, DOI 10.1016/0968-0004(83)90100-7; MARRA J, 1985, BIOCHEMISTRY-US, V24, P4608, DOI 10.1021/bi00338a020; MARRA J, 1986, METHOD ENZYMOL, V127, P353; METZLER DE, 1977, BIOCHEMISTRY-US, P433; SLAYTON P, 1990, BIOCHEMISTRY-US, V29, P7381; WENDOLOSKI JJ, 1987, SCIENCE, V238, P794, DOI 10.1126/science.2823387; WIEGEL FW, 1984, CELL SURFACE DYNAMIC, pCH5	24	121	124	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1419	1421		10.1126/science.1542789	http://dx.doi.org/10.1126/science.1542789			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542789				2022-12-28	WOS:A1992HH74400050
J	KITAMURA, D; RAJEWSKY, K				KITAMURA, D; RAJEWSKY, K			TARGETED DISRUPTION OF MU-CHAIN MEMBRANE EXON CAUSES LOSS OF HEAVY-CHAIN ALLELIC EXCLUSION	NATURE			English	Article							PRE-B-CELLS; GENE REARRANGEMENT; IMMUNOGLOBULIN-MU; ANTIBODY; RECOMBINATION; INHIBITION; ACTIVATION; EXPRESSION; GENERATION; MATURATION	BURNET'S clonal selection theory 1 suggests that each B lymphocyte is committed to a single antibody specificity. This is achieved by a programme of somatic rearrangements of the gene segments encoding antibody variable (V) regions, in the course of B-cell development 2,3 . Evidence from immunoglobulin-transgenic mice and immunoglobulin-gene-transfected transformed pre-B cells suggests that the membrane form of the immunoglobulin heavy (H) chain of class-mu (mu-m), expressed from a rearranged H-chain (IgH) locus, may signal allelic exclusion of the homologous IgH locus in the cell 4-6 and initiation of light (L)-chain gene rearrangement in the Ig-kappa loci 6. We report here that targeted disruption of the membrane exon of the mu-chain indeed results in the loss of H-chain allelic exclusion. But, some kappa-chain gene rearrangement is still observed in the absence of mu-m expression.	UNIV COLOGNE,INST GENET,WEYERTAL 121,W-5000 COLOGNE 41,GERMANY	University of Cologne								ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BURNET FM, 1959, CLONAL SELECTION THE; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; Coffman R L, 1982, Immunol Rev, V69, P5; COHN M, 1990, IMMUNOL REV, V115, P7, DOI 10.1111/j.1600-065X.1990.tb00783.x; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GAUSE A, 1987, EUR J IMMUNOL, V17, P981, DOI 10.1002/eji.1830170714; GRUTZMANN R, 1981, THESIS U COLOGNE; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1847; JACK HM, 1989, EUR J IMMUNOL, V19, P843, DOI 10.1002/eji.1830190510; KARASUYAMA H, 1990, J EXP MED, V172, P962; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOCKS C, 1988, P NATL ACAD SCI USA, V85, P8206, DOI 10.1073/pnas.85.21.8206; KOHLER G, 1980, P NATL ACAD SCI-BIOL, V77, P2197, DOI 10.1073/pnas.77.4.2197; KUBAGAWA H, 1989, P NATL ACAD SCI USA, V86, P2356, DOI 10.1073/pnas.86.7.2356; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MCHEYZERWILLIAMS MG, 1989, J IMMUNOL METHODS, V119, P9, DOI 10.1016/0022-1759(89)90375-X; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; TONEGAWA S, 1983, NATURE, V302, P79; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; WEISS U, 1990, J EXP MED, V172, P1681, DOI 10.1084/jem.172.6.1681	34	335	352	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					154	156		10.1038/356154a0	http://dx.doi.org/10.1038/356154a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545868				2022-12-28	WOS:A1992HH73100060
J	NOVACEK, MJ				NOVACEK, MJ			MAMMALIAN PHYLOGENY - SHAKING THE TREE	NATURE			English	Review							EUTHERIAN MAMMALS; PRIMATES; CLASSIFICATION; SYSTEMATICS; SEQUENCE; EVOLUTIONARY; WHALES	Recent palaeontological discoveries and the correspondence between molecular and morphological results provide fresh insight on the deep structure of mammalian phylogeny. This new wave of research, however, has yet to resolve some important issues.			NOVACEK, MJ (corresponding author), AMER MUSEUM NAT HIST, NEW YORK, NY 10024 USA.							ADKINS RM, 1991, P NATL ACAD SCI USA, V88, P10317, DOI 10.1073/pnas.88.22.10317; ALLARD MW, 1991, NATURE, V353, P610, DOI 10.1038/353610b0; AMMERMAN L, 1990, AM ZOOL, V30, P50; Aplin K.P., 1987, pxv; ARCHER M, 1985, NATURE, V318, P363, DOI 10.1038/318363a0; ARCHER M, 1986, UNCOVERING AUSTR DRE; ARNASON U, 1974, HEREDITAS, V76, P179; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BAKER RJ, 1991, SYST ZOOL, V40, P216, DOI 10.2307/2992259; BAKER RJ, 1991, B AM MUS NAT HIST, P42; Baverstock P.R., 1987, P229; BEARD KC, 1990, NATURE, V345, P340, DOI 10.1038/345340a0; Butler P.M., 1972, P253; BUTLER P. M., 1956, PROC ZOOL SOC LONDON, V126, P453; Carroll RL, 1988, VERTEBRATE PALEONTOL; Clemens W.A., 1989, P527; COURT N, 1991, CR HEBD ACAD SCI, V3129, P559; CUCKERKANDL E, 1962, HORIZONS BIOCH, P189; Czelusniak J., 1990, Current Mammalogy, V2, P545; FAITH DP, 1991, CLADISTICS, V7, P1, DOI 10.1111/j.1096-0031.1991.tb00020.x; FARRIS JS, 1988, HENNIG 86 VERSION 1; Flower W. H, 1869, P ZOOL SOC LOND, P4, DOI DOI 10.1111/J.1469-7998.1869.TB07286.X; FLYNN JJ, 1988, PHYLOGENY CLASSIFICA, V2, P73; GAUTHIER J, 1988, CLADISTICS, V4, P105, DOI 10.1111/j.1096-0031.1988.tb00514.x; GINGERICH PD, 1990, SCIENCE, V249, P154, DOI 10.1126/science.249.4965.154; GOODMAN M, 1989, INT CONGR SER, V824, P43; GOODMAN M, 1971, SYST ZOOL, V20, P19, DOI 10.2307/2412222; Goodman M., 1982, P115; GOODMAN M, 1975, NATURE, V253, P603, DOI 10.1038/253603a0; GOODMAN M, 1985, Cladistics, V1, P171, DOI 10.1111/j.1096-0031.1985.tb00420.x; GRAUR D, 1991, NATURE, V351, P649, DOI 10.1038/351649a0; Gregory W. K., 1910, B AM MUS NAT HIST, V27, P1, DOI DOI 10.1007/S13364-013-0165-6; HENNIG W, 1999, PHYLOGENETIC SYSTEMA; HILLIS DM, 1989, INT CONGR SER, V824, P355; HOLMES EC, 1991, J MOL EVOL, V33, P209, DOI 10.1007/BF02100671; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; Janis CM., 1987, AM MUS NOVIT, V2893, P1; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIELAN-JAWOROWSKA Z, 1975, Palaeontologia Polonica, V33, P5; Kirsch J. A. W., 1977, Australian J. Zool., VNo. 52, P1; KIRSCH JAW, 1990, AUST J ZOOL, V38, P673, DOI 10.1071/ZO9900673; KRAUS F, 1991, SYST ZOOL, V40, P117, DOI 10.2307/2992252; LI WH, 1990, P NATL ACAD SCI USA, V87, P6703, DOI 10.1073/pnas.87.17.6703; Luckett W.P., 1975, PHYLOGENY PRIMATES M, P3; Luckett WP, 1985, EVOLUTIONARY RELATIO, P685; LUCKETT WP, 1985, EVOLUTIONARY RELATIO, P227; Marshall L.G., 1990, Current Mammalogy, V2, P433; MCDOWELL SAMUEL BOOKER, 1958, BULL AMER MUS NAT HIST, V115, P113; McKenna M.C., 1987, P55; McKenna M. C., 1975, PHYLOGENY PRIMATES, P21, DOI DOI 10.1007/978-1-4684-2166-8_2; MCKENNA MC, IN PRESS ACTA ZOOL F, V191; MCLAREN IA, 1960, SYST ZOOL, V9, P18, DOI 10.2307/2411537; MINDELL DP, 1991, P NATL ACAD SCI USA, V88, P10322, DOI 10.1073/pnas.88.22.10322; MIVART SG, 1885, P ZOOL SOC LOND, V1885, P484; MIYAMOTO MM, 1989, INT CONGR SER, V824, P437; MIYAMOTO MM, 1988, P NATL ACAD SCI USA, V85, P7627, DOI 10.1073/pnas.85.20.7627; Nelson G., 1981, SYSTEMATICS BIOGEORA; Novacek M.J., 1990, Current Mammalogy, V2, P507; Novacek M.J., 1982, P3; NOVACEK MJ, 1986, B AM MUS NAT HIST, V183, P1; NOVACEK MJ, 1988, PHYLOGENY CLASSIFICA, V2, P31; NOVACEK MJ, IN PRESS SYST BIOL; OWEN R, 1848, J GEOL SOC LONDON, V4, P103; PETTIGREW JD, 1986, SCIENCE, V231, P1304, DOI 10.1126/science.3945827; PETTIGREW JD, 1991, SYST ZOOL, V40, P199, DOI 10.2307/2992258; Prothero D., 1988, PHYLOGENY CLASSIFICA, P201; ROMEROHERRERA AE, 1978, PHILOS T R SOC B, V283, P61, DOI 10.1098/rstb.1978.0018; SARICH VM, 1969, SYST ZOOL, V18, P286, DOI 10.2307/2412325; SARICH VM, 1985, EVOLUTIONARY RELATIO, P423; SIMMONS EL, 1991, P NATL ACAD SCI USA, V88, P9734; Simpson G.G., 1944, TEMPO MODE EVOLUTION, DOI DOI 10.1073/pnas.1821292116; SIMPSON GG, 1945, B AM MUS NAT HIST, V85, P1; SIMPSON GG, 1978, P AM PHILOS SOC, V122, P318; SPRINGER MS, 1990, J MOL EVOL, V30, P298, DOI 10.1007/BF02100000; Swofford D.L., 1989, PAUP PHYLOGENETIC AN; SZALAY FS, 1977, MAJOR PATTERNS VERTE, P315, DOI DOI 10.1007/978-1-4684-8851-7_12; TEDFORD RH, 1976, SYST ZOOL, V25, P363, DOI 10.2307/2412511; THEWISSEN JGM, 1991, SCIENCE, V251, P934, DOI 10.1126/science.2000493; THIELE A, 1991, J COMP NEUROL, V314, P671, DOI 10.1002/cne.903140404; THOMAS RH, 1989, NATURE, V340, P465, DOI 10.1038/340465a0; WATERMAN MS, 1984, B MATH BIOL, V46, P473, DOI 10.1007/BF02459498; WESTERMAN M, 1991, AUST J ZOOL, V39, P123, DOI 10.1071/ZO9910123; WHEELER WC, 1988, MOL BIOL EVOL, V5, P90; WHITE TJ, 1989, TRENDS GENET, V5, P185, DOI 10.1016/0168-9525(89)90073-5; WOODALL PF, 1991, J SUBMICR CYTOL PATH, V23, P47; WOODBURNE MO, 1984, J PALEONTOL, V58, P913; WYSS A, 1990, NATURE, V347, P428, DOI 10.1038/347428a0; WYSS AR, 1987, MOL BIOL EVOL, V4, P99; Wyss AR, 1987, AM MUS NAT HIST NOVI, V2871, P1; [No title captured]	91	532	553	1	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1992	356	6365					121	125		10.1038/356121a0	http://dx.doi.org/10.1038/356121a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545862				2022-12-28	WOS:A1992HH73100048
J	BAILEY, IS; KARRAN, SE; TOYN, K; BROUGH, P; RANABOLDO, C; KARRAN, SJ				BAILEY, IS; KARRAN, SE; TOYN, K; BROUGH, P; RANABOLDO, C; KARRAN, SJ			COMMUNITY SURVEILLANCE OF COMPLICATIONS AFTER HERNIA SURGERY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess the effect of a programme of postoperative community surveillance on the rate of detection of wound complications after operation for inguinal hernia. Design - Prospective audit of wound complications including complications recorded in case notes and those discovered by community surveillance. Setting - Academic surgical unit of three consultant surgeons. Patients - 510 patients undergoing elective inguinal hernia repair between June 1985 and August 1989. Results - The wound infection rate recorded in the hospital notes was 3% compared with 9% when additional information was obtained from community surveillance. Wound complications were detected in 143 (28%) patients by community surveillance compared with a complication rate of 7% in the case records for the same patients. Conclusions - Wound complications are common after clean surgery in patients discharged home early. Complication rates are a reflection not only of the standards of surgical practice but also the rigour with which they are sought. Before national comparative audit data are published the method of collection must be standardised. For short stay surgery this should include meaningful community surveillance.	UNIV SOUTHAMPTON,ROYAL S HAMPSHIRE HOSP,SURG UNIT,SOUTHAMPTON SO9 4PE,ENGLAND	University of Southampton								ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; Buck N, 1987, REPORT CONFIDENTIAL; CRUSE P, 1980, CONTROVERSIES SURGIC, P327; 1989, WORKING PATIENTS; 1964, ANN SURG S, V160, P1; 1960, LANCET, V2, P659	6	146	149	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					469	471		10.1136/bmj.304.6825.469	http://dx.doi.org/10.1136/bmj.304.6825.469			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547415	Bronze, Green Published			2022-12-28	WOS:A1992HF55500018
J	MOWRY, KL; MELTON, DA				MOWRY, KL; MELTON, DA			VEGETAL MESSENGER-RNA LOCALIZATION DIRECTED BY A 340-NT RNA SEQUENCE ELEMENT IN XENOPUS OOCYTES	SCIENCE			English	Article							BICOID RNA; DROSOPHILA; VG1; LAEVIS; EGGS; IDENTIFICATION; TRANSLOCATION; TRANSCRIPTION; PROTEIN; POLE	Contained within a single cell, the fertilized egg, is information that will ultimately specify the entire organism. During early embryonic cleavages, cells acquire distinct fates and their differences in developmental potential might be explained by localization of informational molecules in the egg. The mechanisms by which Vg1 RNA, a maternal mRNA, is translocated to the vegetal pole of Xenopus oocytes may indicate how developmental signals are localized. Data presented here show that a 340-nucleotide localization signal present in the 3' untranslated region of Vg1 RNA is sufficient to direct RNA localization to the vegetal pole.			MOWRY, KL (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Mowry, Kimberly/0000-0002-4126-2889	NIGMS NIH HHS [GM 32921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; JAMRICH M, 1984, EMBO J, V3, P1939, DOI 10.1002/j.1460-2075.1984.tb02073.x; KIM J, 1991, CELL, V66, P23; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MELTON DA, 1979, CELL, V18, P1165, DOI 10.1016/0092-8674(79)90229-0; MOWRY KL, 1988, UNPUB, V7, P1749; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PONDEL MD, 1988, P NATL ACAD SCI USA, V85, P7612, DOI 10.1073/pnas.85.20.7612; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; Sambrook J, 1989, MOL CLONING LABORATO; SEEGER MA, 1990, EMBO J, V9, P2977, DOI 10.1002/j.1460-2075.1990.tb07490.x; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WEEKS DL, 1985, COLD SPRING HARB SYM, V50, P21, DOI 10.1101/SQB.1985.050.01.005; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	26	229	233	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					991	994		10.1126/science.1546297	http://dx.doi.org/10.1126/science.1546297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546297				2022-12-28	WOS:A1992HE60500043
J	HARDYTHOMPSON, C; ORRELL, MW; BERGMANN, K				HARDYTHOMPSON, C; ORRELL, MW; BERGMANN, K			EVALUATING A PSYCHOGERIATRIC DOMICILIARY VISIT SERVICE - VIEWS OF GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article								The value of the domiciliary consultation service has recently been questioned1 in view of the increasing cost from 10m pound sterling in 1983 to pound sterling 20m in 1988(23) despite a decrease in the use of the service. General practitioner fund-holding will obviously exert an influence on the future use of domiciliary visits. A recent review of general practitioners' referrals showed how little is understood about the correct level of service.4 Nevertheless, domiciliary consultations are a major component of a modern psychogeriatric service and may be preferred for new referrals. To plan or evaluate services it is vital to know the needs of general practitioners; we therefore investigated general practitioners' views and use of psychogeriatric domiciliary consultations.	MAUDSLEY HOSP & INST PSYCHIAT,DENMARK HILL,LONDON SE5 8AZ,ENGLAND; JOYCE GREEN HOSP,DARTFORD,KENT,ENGLAND	South London & Maudsley NHS Trust				Orrell, Martin/0000-0002-1169-3530				BENDALL M J, 1978, Age and Ageing, V7, P229, DOI 10.1093/ageing/7.4.229; DONALDSON LJ, 1991, BRIT MED J, V302, P449, DOI 10.1136/bmj.302.6774.449; DOWIE R, 1983, BRIT MED J, V286, P819, DOI 10.1136/bmj.286.6367.819; FORSYTHE M, 1991, BRIT MED J, V302, P426, DOI 10.1136/bmj.302.6774.426; WILKIN C, 1990, GENERAL PRACTITIONER	5	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1992	304	6824					421	422		10.1136/bmj.304.6824.421	http://dx.doi.org/10.1136/bmj.304.6824.421			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1547390	Green Published, Bronze			2022-12-28	WOS:A1992HE38900020
J	PERL, TM; HAUGEN, TH; PFALLER, MA; HOLLIS, R; LAKEMAN, AD; WHITLEY, RJ; NICHOLSON, D; HUNTER, GA; WENZEL, RP				PERL, TM; HAUGEN, TH; PFALLER, MA; HOLLIS, R; LAKEMAN, AD; WHITLEY, RJ; NICHOLSON, D; HUNTER, GA; WENZEL, RP			TRANSMISSION OF HERPES-SIMPLEX VIRUS TYPE-1 INFECTION IN AN INTENSIVE-CARE UNIT	ANNALS OF INTERNAL MEDICINE			English	Note						HERPESVIRUS-HOMINIS; HERPES SIMPLEX; GROSS INFECTION; INTENSIVE CARE UNITS; INFECTION CONTROL	DNA; ASSAY	Several cases of nosocomial transmission of Herpes simplex type 1 (HSV-1) infection occupied in a medical intensive care unit of a tertiary care center. The HSV-1 isolates from 10 exposed persons were further characterized by DNA profiles, assays for thymidine kinase, tests of susceptibility to acyclovir, and virulence studies. Intially, two nurses developed herpetic whitlow and one physician developed keratoconjunctivitis after contact with the index patient. Within 10 days, two family members, four other health care workers, and another immunocompromised patient were identified as having HSV-1 infection. The DNA profiles of four isolated strains were similar. Outbreak strains were thyumidine-kinase positive, acyclovir susceptible, and equal in virulence to control strains. Transmission of HSV-1 from a patient to medical intensive care unit staff and visitors occurred despite protocols for disease-specific isolation.	UNIV IOWA, COLL MED, IOWA CITY, IA 52242 USA; VET ADM MED CTR, IOWA CITY, IA 52240 USA; UNIV ALABAMA, BIRMINGHAM, AL 35294 USA; BURROUGHS WELLCOME CO, RES TRIANGLE PK, NC 27709 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Alabama System; University of Alabama Birmingham; Burroughs Wellcome Fund				Haugen, Thomas/0000-0003-4569-0271	PHS HHS [T32A107343] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS G, 1981, AM J EPIDEMIOL, V113, P126, DOI 10.1093/oxfordjournals.aje.a113076; BUCHMAN TG, 1978, J INFECT DIS, V138, P488, DOI 10.1093/infdis/138.4.488; HAMMER SM, 1980, J INFECT DIS, V141, P436, DOI 10.1093/infdis/141.4.436; HAMORY BH, 1975, NEW ENGL J MED, V292, P268; LAKEMAN AD, 1986, SEX TRANSM DIS, V13, P61, DOI 10.1097/00007435-198604000-00001; MARTIN JL, 1985, ANTIMICROB AGENTS CH, V28, P181, DOI 10.1128/AAC.28.2.181; MCLAREN C, 1983, ANTIVIR RES, V3, P223, DOI 10.1016/0166-3542(83)90001-3; SIBRACK CD, 1982, J INFECT DIS, V146, P673, DOI 10.1093/infdis/146.5.673; 1988, MMWR, V37, P377; 1987, MMWR S, V36, P35	10	20	20	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					584	586		10.7326/0003-4819-117-7-584	http://dx.doi.org/10.7326/0003-4819-117-7-584			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524332				2022-12-28	WOS:A1992JQ22600007
J	ORMEJOHNSON, WH				ORMEJOHNSON, WH			NITROGENASE STRUCTURE - WHERE TO NOW	SCIENCE			English	Article							IRON-MOLYBDENUM COFACTOR; AZOTOBACTER-VINELANDII; MOFE PROTEIN; CLUSTERS; METAL; SITE				ORMEJOHNSON, WH (corresponding author), MIT,DEPT CHEM,CAMBRIDGE,MA 02139, USA.							BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CHISNELL JR, 1988, J BACTERIOL, V170, P27, DOI 10.1128/jb.170.1.27-33.1988; CHRISTOU G, 1982, J AM CHEM SOC, V104, P2820, DOI 10.1021/ja00374a021; CONRADSON SD, 1987, J AM CHEM SOC, V109, P7507, DOI 10.1021/ja00258a042; COUCOUVANIS D, 1991, ACCOUNTS CHEM RES, V24, P1, DOI 10.1021/ar00001a001; DEAN DR, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P95; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GRESSHOFF PM, 1990, NITROGEN FIXATION AC; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOLM RH, 1977, IRON SULFUR PROTEINS, V3, P206; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; HUGHES DL, 1988, NITROGEN FIXATION 10, P66; Jolly W. L., 1964, INORGANIC CHEM NITRO; KAUL BB, 1990, J AM CHEM SOC, V112, P2002, DOI 10.1021/ja00161a058; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LOWE DJ, 1984, BIOCHEM J, V24, P887; LOWE DJ, 1984, BIOCHEM J, V224, P909; MAY HD, 1990, NITROGEN FIXATION AC, P162; NELSON MJ, 1983, P NATL ACAD SCI-BIOL, V80, P147, DOI 10.1073/pnas.80.1.147; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; RAWLINGS J, 1978, J BIOL CHEM, V253, P1001; SCHROCK RR, 1991, J AM CHEM SOC, V113, P725, DOI 10.1021/ja00002a079; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SURERUS KK, IN PRESS J AM CHEM S; THORNELEY RNF, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P103; TRUE AE, 1988, J AM CHEM SOC, V110, P1935, DOI 10.1021/ja00214a045; WINK DA, 1989, BIOCHEMISTRY-US, V28, P9407, DOI 10.1021/bi00450a024; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4; 1979, AMMONIA	33	70	72	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1639	1640		10.1126/science.1529351	http://dx.doi.org/10.1126/science.1529351			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529351				2022-12-28	WOS:A1992JN50100018
J	SCANU, AM				SCANU, AM			LIPOPROTEIN(A) - A GENETIC RISK FACTOR FOR PREMATURE CORONARY HEART-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LP(A) LIPOPROTEIN; FAMILIAL HYPERCHOLESTEROLEMIA; APOLIPOPROTEIN(A); ATHEROSCLEROSIS; QUANTIFICATION; SEQUENCE	Lipoprotein(a) (Lp[a]) can be defined as a lipoprotein particle having as a protein moiety apolipoprotein B-100 (the protein associated with low-density lipoprotein) disulfide-linked to apolipoprotein(a), the distinctive glycoprotein of Lp(a) that is homologous to plasminogen. Several forms of Lp(a) occur in the circulation. This polymorphism is related to the apolipoprotein(a) size heterogeneity that is controlled by the several alleles of the apolipoprotein(a) gene. High plasma levels of Lp(a) have been correlated with an increased risk for atherothrombotic cardiovascular disease by a mechanism that is as yet undefined. Pathogenicity may also derive from Lp(a) particles that have been modified by events believed to occur when Lp(a), after traversing the artery endothelium, reaches the intima. Aside from several promising leads, there are no universally accepted ways to lower high plasma Lp(a) levels. At this time, it is best to target efforts toward the modifiable risk factors by using appropriate diets and exercise programs and, whenever necessary, drug therapy.	UNIV CHICAGO,LIPOPROT STUDY UNIT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago	SCANU, AM (corresponding author), UNIV CHICAGO,DEPT MED,5841 S MARYLAND,MC5041,CHICAGO,IL 60637, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018577] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 18577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1984, BIOCHIM BIOPHYS ACTA, V795, P293, DOI 10.1016/0005-2760(84)90078-X; ARMSTRONG VW, 1989, EUR J CLIN INVEST, V19, P235, DOI 10.1111/j.1365-2362.1989.tb00223.x; AZROLAN N, 1991, J BIOL CHEM, V266, P13866; BEIL FU, 1991, ATHEROSCLEROSIS, V90, P95, DOI 10.1016/0021-9150(91)90248-2; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BORTH W, 1991, J BIOL CHEM, V266, P18149; CARLSON LA, 1989, J INTERN MED, V226, P271, DOI 10.1111/j.1365-2796.1989.tb01393.x; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DAHLEN G, 1990, LIPOPROTEIN A, V11, P151; EDELSTEIN C, 1991, ARTERIOSC THROMB, V11, pA1424; FLESS GM, 1990, J LIPID RES, V31, P909; GAVISH D, 1991, LANCET, V337, P203, DOI 10.1016/0140-6736(91)92161-T; GURAKAR A, 1985, ATHEROSCLEROSIS, V57, P293, DOI 10.1016/0021-9150(85)90041-3; HABERLAND ME, 1992, J BIOL CHEM, V267, P4143; HAFFNER SM, 1991, DIABETES CARE, V14, P302, DOI 10.2337/diacare.14.4.302; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HENRIKSSON P, 1991, ARTERIOSCLER THROMB, V11, pA1423; JENKINS AJ, 1991, DIABETES, V40, P787, DOI 10.2337/diabetes.40.6.787; JONES PH, 1991, ARTERIOSCLER THROMB, V11, pA1423; KAPELRUD H, 1991, BRIT MED J, V303, P675, DOI 10.1136/bmj.303.6804.675; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LAPLAUD PM, 1988, J LIPID RES, V29, P1157; LEVITSKY LL, 1991, DIABETES CARE, V14, P283, DOI 10.2337/diacare.14.4.283; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P672, DOI 10.1161/01.ATV.10.5.672; MAKINO K, 1991, LIPIDS, V26, P679, DOI 10.1007/BF02535613; MBEWU AD, 1990, ATHEROSCLEROSIS, V85, P1, DOI 10.1016/0021-9150(90)90177-K; MBEWU AD, 1991, ARTERIOSCLER THROMB, V11, P940, DOI 10.1161/01.ATV.11.4.940; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1990, THROMB HAEMOSTASIS, V63, P331; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; NARUSZEWICZ M, 1990, ARTERIOSCLEROSIS, V10, pA808; NIENDORF A, 1990, VIRCHOWS ARCH A, V417, P105, DOI 10.1007/BF02190527; PARRA HJ, 1987, CLIN CHEM, V33, P721; PEPIN JM, 1991, J LIPID RES, V32, P317; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; Scanu A M, 1991, Adv Intern Med, V36, P249; SCANU AM, 1990, J LAB CLIN MED, V116, P142; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1992, ARTERIOSCLER THROMB, V12, P424, DOI 10.1161/01.ATV.12.4.424; SCANU AM, 1991, TRENDS CARDIOVAS MED, V1, P294, DOI 10.1016/1050-1738(91)90046-H; SCHMIDT EB, 1991, CLIN CHIM ACTA, V198, P271, DOI 10.1016/0009-8981(91)90362-G; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; SMITH EB, 1990, ATHEROSCLEROSIS, V84, P173, DOI 10.1016/0021-9150(90)90088-Z; SORRENTINO MJ, IN PRESS AM J MED; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WALTON KW, 1974, ATHEROSCLEROSIS, V20, P323, DOI 10.1016/0021-9150(74)90016-1; WIKLUND O, 1990, LANCET, V335, P1360, DOI 10.1016/0140-6736(90)91242-3	49	181	181	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3326	3329		10.1001/jama.267.24.3326	http://dx.doi.org/10.1001/jama.267.24.3326			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1534588				2022-12-28	WOS:A1992HY94400033
J	PINNER, RW; SCHUCHAT, A; SWAMINATHAN, B; HAYES, PS; DEAVER, KA; WEAVER, RE; PLIKAYTIS, BD; REEVES, M; BROOME, CV; WENGER, JD				PINNER, RW; SCHUCHAT, A; SWAMINATHAN, B; HAYES, PS; DEAVER, KA; WEAVER, RE; PLIKAYTIS, BD; REEVES, M; BROOME, CV; WENGER, JD			ROLE OF FOODS IN SPORADIC LISTERIOSIS .2. MICROBIOLOGIC AND EPIDEMIOLOGIC INVESTIGATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTILOCUS ENZYME ELECTROPHORESIS; MONOCYTOGENES; MEDIA; MILK	Objective. - To evaluate the role of foods in sporadic listeriosis. Design. - Microbiologic survey of foods collected from refrigerators of patients with listeriosis identified through active laboratory-based surveillance. Patient and food Listeria monocytogenes isolates were subtyped to identify foods contaminated with the same strain of L monocytogenes that caused illness in the patient; samples of these foods were obtained from the retail source. Setting. - Multistate population-based study conducted between 1988 and 1990. Results. - Listeria monocytogenes grew from at least one food specimen in the refrigerators of 79 (64%) of 1 23 listeriosis patients; 11 % of more than 2000 food specimens collected in the study contained L monocytogenes. Twenty-six (33%) of 79 refrigerators with foods that grew L monocytogenes contained at least one food isolate of the same strain as that in the corresponding patient, a frequency much higher than would be expected by chance (P < .001). Multivariate analysis showed that of the food specimens that grew L monocytogenes, foods that were ready-to-eat, foods that grew L monocytogenes by a direct-plating method (a measure of the level of contamination), and foods that contained serotype 4b isolates were independently associated with an increased likelihood of containing the patient-matching strain. Conclusion. - We identified specific food and L monocytogenes isolate characteristics-ready-to-eat foods, foods containing higher concentrations of L monocytogenes, and foods containing serotype 4b-which were associated with disease-causing strains. These results can provide guidance to industry and regulatory agencies in developing strategies to prevent listeriosis.	CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,BIOSTAT & INFORMAT BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	PINNER, RW (corresponding author), CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,MENINGITIS & SPECIAL PATHOGENS BRANCH,ATLANTA,GA 30333, USA.				FDA HHS [FDA 224-88-2456] Funding Source: Medline	FDA HHS		BIBB WF, 1989, INT J FOOD MICROBIOL, V8, P233, DOI 10.1016/0168-1605(89)90018-4; BILLE J, 1990, FOODBORNE LISTERIOSI, P71; FLEMING DW, 1985, NEW ENGL J MED, V312, P404, DOI 10.1056/NEJM198502143120704; GELLIN BG, 1989, JAMA-J AM MED ASSOC, V261, P1313, DOI 10.1001/jama.261.9.1313; GILBERT R, 1990, P INT C LISTERIA FOO, P82; HAYES PS, 1991, APPL ENVIRON MICROB, V57, P2109, DOI 10.1128/AEM.57.8.2109-2113.1991; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; LOVETT J, 1987, J FOOD PROTECT, V50, P188, DOI 10.4315/0362-028X-50.3.188; MCCLAIN D, 1988, J ASSOC OFF ANA CHEM, V71, P679; MCLAUCHLIN J, 1990, PHLS MICROBIOL DIGES, V3, P54; PIFFARETTI JC, 1989, P NATL ACAD SCI USA, V86, P3818, DOI 10.1073/pnas.86.10.3818; RIEDO FX, 1990, 30TH INT C ANT AG CH, P248; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHUCHAT A, 1992, JAMA-J AM MED ASSOC, V267, P2041, DOI 10.1001/jama.267.15.2041; SCHWARTZ B, 1988, LANCET, V2, P779; Seeliger H.P.R., 1979, METHOD MICROBIOL, V13, P31, DOI [10.1016/S0580-9517(08)70372-6, DOI 10.1016/S0580-9517(08)70372-6]; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; SWAMINATHAN B, 1988, J ASSOC OFF ANA CHEM, V71, P664; VANNETTEN P, 1989, INT J FOOD MICROBIOL, V8, P299, DOI 10.1016/0168-1605(89)90001-9; WENGER JD, 1990, J FOOD PROTECT, V53, P1015, DOI 10.4315/0362-028X-53.12.1015; 1988, B WORLD HEALTH ORGAN, V66, P421	21	187	197	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2046	2050		10.1001/jama.267.15.2046	http://dx.doi.org/10.1001/jama.267.15.2046			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552640				2022-12-28	WOS:A1992HM65000029
J	SOSIN, DM; SACKS, JJ				SOSIN, DM; SACKS, JJ			MOTORCYCLE HELMET-USE LAWS AND HEAD-INJURY PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FATALITIES	Objective. - To rebut criticism of a previous study of motorcycle helmet-use laws through reanalysis with improved measures of exposure, stratification for regional differences in crash risk, and addressing of total motorcycle-related mortality and the grounds for targeting motorcyclists for helmet-use laws. Design. - Death certificate-based correlational study of motorcycle-related deaths and motorcycle helmet-use laws. Population Studied. - United States resident deaths from 1979 through 1986. Results. - Regardless of the denominator used (resident population, motorcycle registrations, or motorcycle crashes), states with full helmet-use laws had consistently lower head injury-associated death rates than states without such laws, even when stratified by region. Total motorcycle-related mortality, however, was similar between law groups. On a registration or crash basis, motorcyclists who died in crashes had a fivefold to sixfold higher risk of head injury than those who died using any other type of motor vehicle. Conclusion. - Full helmet-use laws were consistently associated with lower rates of head injury-associated death. While disagreement remains on the acceptability of the legislative approach, the scientific basis for motorcycle helmet-use laws as a head injury prevention tool appears sound.	CTR DIS CONTROL, NATL CTR ENVIRONM HLTH & INJURY CONTROL, DIV INJURY CONTROL, ATLANTA, GA 30333 USA; CTR DIS CONTROL, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ADAMS JGU, 1983, ENVIRON PLANN C, V1, P193, DOI 10.1068/c010193; BACHULIS BL, 1988, AM J SURG, V155, P708, DOI 10.1016/S0002-9610(88)80151-X; Cairns H, 1943, BMJ-BRIT MED J, V1943, P591, DOI 10.1136/bmj.1.4297.591; EVANS L, 1988, ACCIDENT ANAL PREV, V20, P447, DOI 10.1016/0001-4575(88)90043-7; HEILMAN DR, 1982, ANN EMERG MED, V11, P659, DOI 10.1016/S0196-0644(82)80258-8; HURT HH, 1981, USC TSC811 U SO CAL; KRAUS JF, 1975, AM J EPIDEMIOL, V102, P99, DOI 10.1093/oxfordjournals.aje.a112137; LUNA GK, 1981, WESTERN J MED, V135, P89; MCSWAIN NE, 1984, J TRAUMA, V24, P233, DOI 10.1097/00005373-198403000-00009; SCOTT RE, 1983, UMTRI8389 U MICH TRA; SHARP D, 1991, EASYRIDERS, V45, P34; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; WATSON GS, 1981, AM J PUBLIC HEALTH, V71, P297, DOI 10.2105/AJPH.71.3.297; 1980, MOTORCYCLE STATISTIC; DOT HS806438 US DEP; 1980, DOT HS805312 US DEP; 1985, DOT HS806867 US DEP; 1991, AM MOTORCYCLIST, V45, P34; 1988, DOT HS807296 US DEP	19	43	43	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1649	1651		10.1001/jama.267.12.1649	http://dx.doi.org/10.1001/jama.267.12.1649			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1542175				2022-12-28	WOS:A1992HJ59700033
J	HOTCHKISS, RS; KARL, IE				HOTCHKISS, RS; KARL, IE			REEVALUATION OF THE ROLE OF CELLULAR HYPOXIA AND BIOENERGETIC FAILURE IN SEPSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS SYNDROME; CRITICALLY ILL PATIENTS; FREE FATTY-ACIDS; OXYGEN DELIVERY; SEPTIC SHOCK; SKELETAL-MUSCLE; PATHO-PHYSIOLOGY; LACTIC-ACIDOSIS; ORGAN FAILURE; LACTATE PRODUCTION	Sepsis is frequently characterized by a number of metabolic abnormalities: increased plasma lactate concentration, metabolic acidosis, increased glycolysis, and an abnormal "delivery-dependent" oxygen consumption. Two hypotheses have been advanced to explain these metabolic abnormalities: (1) cellular hypoxia resulting from abnormal microcirculatory blood flow or (2) defect(s) in energy-producing metabolic pathways of cells. Results of our studies on rat muscle, liver, heart, brain, and plasma suggest that there is no evidence of bioenergetic failure in these septic tissues and that the increase in lactate production is not necessarily due to cellular hypoxia. The adequacy of cellular oxygenation and bioenergetics was verified using in vivo phosphorus 31 nuclear magnetic resonance spectroscopy, [F-18]fluoromisonidazole, and microfluorometric enzymatic techniques. Findings from these studies as well as results from several clinical investigations indicate that neither hypothesis can adequately account for the metabolic features typical of sepsis and that the pathophysiology of sepsis awaits further clarification. These studies and important clinical implications are discussed.	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV ENDOCRINOL & METAB, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	HOTCHKISS, RS (corresponding author), WASHINGTON UNIV, SCH MED, DEPT ANESTHESIOL, 660 S EUCLID AVE, BOX 8054, ST LOUIS, MO 63110 USA.							ABEL FL, 1989, AM J PHYSIOL, V257, pR1265, DOI 10.1152/ajpregu.1989.257.6.R1265; AMARAL JF, 1986, SURGERY, V100, P252; ANNAT G, 1986, AM REV RESPIR DIS, V133, P999; ARCHIE JP, 1977, ANN SURG, V186, P171, DOI 10.1097/00000658-197708000-00008; ASTIZ M, 1988, CIRC SHOCK, V26, P311; ASTIZ ME, 1988, CRIT CARE MED, V16, P655, DOI 10.1097/00003246-198807000-00001; BERGSTROM J, 1976, CRIT CARE MED, V4, P197, DOI 10.1097/00003246-197607000-00005; BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BIHARI DJ, 1988, INTENS CARE MED, V15, P2; BIHARI DJ, 1986, SEMIN LIVER DIS, V6, P119, DOI 10.1055/s-2008-1040595; BLAIR E, 1971, ARCH INTERN MED, V127, P731, DOI 10.1001/archinte.127.4.731; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; BROOKS GA, 1986, FASEB J, V45, P2924; BURNS A H, 1986, Journal of Critical Care, V1, P11, DOI 10.1016/S0883-9441(86)80112-5; Burns H J, 1982, Ciba Found Symp, V87, P293, DOI 10.1002/9780470720691.ch16; CAIN SM, 1991, CRIT CARE MED, V19, P603, DOI 10.1097/00003246-199105000-00006; CARROLL GC, 1982, AM J PHYSIOL, V243, pR131, DOI 10.1152/ajpregu.1982.243.1.R131; CERRA FB, 1987, SURGERY, V101, P1; Cohen J R, 1990, Ann Vasc Surg, V4, P276, DOI 10.1007/BF02009457; CUNNION RE, 1986, CIRCULATION, V73, P637, DOI 10.1161/01.CIR.73.4.637; DAHN MS, 1987, SURGERY, V101, P69; DANEK SJ, 1980, AM REV RESPIR DIS, V122, P387; DANTZKER D, 1989, CRIT CARE CLIN, V5, P81; DANTZKER DR, 1991, AM REV RESPIR DIS, V143, P675, DOI 10.1164/ajrccm/143.3.675; DETURCO EBR, 1988, J CLIN INVEST, V81, P700, DOI 10.1172/JCI113375; DHAINAUT JF, 1987, CIRCULATION, V75, P533, DOI 10.1161/01.CIR.75.3.533; DUFFY TE, 1972, J NEUROCHEM, V19, P959, DOI 10.1111/j.1471-4159.1972.tb01417.x; FENWICK JC, 1990, J CRIT CARE, V5, P81, DOI 10.1016/0883-9441(90)90052-B; GARBER AJ, 1976, J BIOL CHEM, V251, P836; GERTZ EW, 1981, CIRCULATION, V63, P1273, DOI 10.1161/01.CIR.63.6.1273; GIBSON GE, 1981, AM J MED, V70, P1247, DOI 10.1016/0002-9343(81)90834-2; GILBERT EM, 1986, AM REV RESPIR DIS, V134, P873, DOI 10.1164/arrd.1986.134.5.873; GUTIERREZ G, 1986, Journal of Critical Care, V1, P45, DOI 10.1016/S0883-9441(86)80116-2; GUTIERREZ G, 1988, J APPL PHYSIOL, V65, P608, DOI 10.1152/jappl.1988.65.2.608; HANNEMANN L, 1990, Critical Care Medicine, V18, pS210; HARGROVE DM, 1988, AM J PHYSIOL, V254, pE16; HOTCHKISS RS, 1990, AM J PHYSIOL, V258, pR21, DOI 10.1152/ajpregu.1990.258.1.R21; HOTCHKISS RS, 1989, AM J PHYSIOL, V257, pC1055, DOI 10.1152/ajpcell.1989.257.6.C1055; HOTCHKISS RS, 1991, AM J PHYSIOL, V260, pC50, DOI 10.1152/ajpcell.1991.260.1.C50; HOTCHKISS RS, 1991, AM J PHYSIOL, V261, pR965, DOI 10.1152/ajpregu.1991.261.4.R965; HOUTCHENS BA, 1984, CIRC SHOCK, V13, P361; JACOBS DO, 1991, SURGERY, V110, P318; JACOBS DO, 1988, ARCH SURG-CHICAGO, V123, P1425; JAHOOR F, 1989, AM J PHYSIOL, V257, pE323, DOI 10.1152/ajpendo.1989.257.3.E323; JEPSON MM, 1987, AM J PHYSIOL, V252, pE581, DOI 10.1152/ajpendo.1987.252.5.E581; KAUFMAN BS, 1984, CHEST, V85, P336, DOI 10.1378/chest.85.3.336; KREBS HA, 1975, ESSAYS MEDICAL BIOCH, V1, P81; KREISBERG RA, 1984, ANNU REV MED, V35, P181, DOI 10.1146/annurev.me.35.020184.001145; KREISBERG RA, 1972, NEW ENGL J MED, V287, P132, DOI 10.1056/NEJM197207202870307; LAUGHLIN MH, 1988, CIRC SHOCK, V25, P173; LEFEVRE G, 1988, ANN CLIN BIOCHEM, V25, P546, DOI 10.1177/000456328802500512; LIAW KY, 1980, J TRAUMA, V20, P755, DOI 10.1097/00005373-198009000-00008; MCDONOUGH KH, 1986, CIRC SHOCK, V18, P161; MELA L, 1982, PATHOPHYSIOLOGY SHOC, P90; MINK RB, 1990, CRIT CARE MED, V18, P1087, DOI 10.1097/00003246-199010000-00007; MIZOCK B, 1984, ARCH INTERN MED, V144, P579, DOI 10.1001/archinte.144.3.579; MIZOCK BA, 1987, JAMA-J AM MED ASSOC, V258, P497, DOI 10.1001/jama.1987.03400040095029; MOHSENIFAR Z, 1988, AM REV RESPIR DIS, V138, P69, DOI 10.1164/ajrccm/138.1.69; MORI E, 1987, METABOLISM, V36, P14, DOI 10.1016/0026-0495(87)90056-4; OPP MR, 1991, AM J PHYSIOL, V260, pR52, DOI 10.1152/ajpregu.1991.260.1.R52; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; PARRILLO JE, 1989, ANNU REV MED, V40, P469; PARRYBILLINGS M, 1989, INT J BIOCHEM, V21, P419, DOI 10.1016/0020-711X(89)90366-2; PRICHARD JW, 1983, P NATL ACAD SCI-BIOL, V80, P2748, DOI 10.1073/pnas.80.9.2748; RACKOW EC, 1988, JAMA-J AM MED ASSOC, V259, P1989, DOI 10.1001/jama.259.13.1989; RASEY JS, 1987, RADIAT RES, V111, P292, DOI 10.2307/3576986; SCHUMACKER PT, 1990, CLIN CHEST MED, V11, P715; SCHUMACKER PT, 1984, CHEST, V85, P453, DOI 10.1378/chest.85.4.453; SCHUMACKER PT, 1989, CRIT CARE CLIN, V5, P255; SHIBUTANI K, 1983, CRIT CARE MED, V11, P640, DOI 10.1097/00003246-198308000-00010; SHOEMAKER WC, 1988, CRIT CARE MED, V16, P1117, DOI 10.1097/00003246-198811000-00007; SHOEMAKER WC, 1987, INTENS CARE MED, V13, P230, DOI 10.1007/BF00265111; SONG SK, IN PRESS MAGN RESON; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; TANAKA J, 1982, J SURG RES, V33, P49, DOI 10.1016/0022-4804(82)90008-7; TRESADERN JC, 1988, CLIN SCI, V75, P233, DOI 10.1042/cs0750233; TRUNKEY DD, 1979, SURGERY, V85, P638; VANOSCORBY DJ, 1987, BIOCHEM PHARMACOL, V36, P3487, DOI 10.1016/0006-2952(87)90330-3; VARY TC, 1988, CIRC SHOCK, V24, P3; VARY TC, 1991, AM J PHYSIOL, V260, pE669, DOI 10.1152/ajpendo.1991.260.5.E669; VARY TC, 1986, AM J PHYSIOL, V250, pE634, DOI 10.1152/ajpendo.1986.250.6.E634; VINCENT JL, 1983, CRIT CARE MED, V11, P449, DOI 10.1097/00003246-198306000-00012; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2; WILLIAMS AJ, 1989, AM REV RESPIR DIS, V140, P1308, DOI 10.1164/ajrccm/140.5.1308; WILMORE DW, 1980, ANN SURG, V192, P491, DOI 10.1097/00000658-198010000-00008; WINDELL CC, 1990, FASEB J, V4, P1634; WOLF YG, 1987, CRIT CARE MED, V15, P198, DOI 10.1097/00003246-198703000-00003; WOLFE RR, 1991, SURGERY, V110, P54; WOODS HF, 1971, BIOCHEM J, V125, P129, DOI 10.1042/bj1250129; ZELLER WP, 1991, BIOCHEM BIOPH RES CO, V176, P535, DOI 10.1016/0006-291X(91)90958-A; ZILVA JF, 1978, ANN CLIN BIOCHEM, V15, P40, DOI 10.1177/000456327801500111	91	279	289	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1503	1510		10.1001/jama.267.11.1503	http://dx.doi.org/10.1001/jama.267.11.1503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1538541				2022-12-28	WOS:A1992HH48800032
J	PROPST, T; PROPST, A; DIETZE, O; JUDMAIER, G; BRAUNSTEINER, H; VOGEL, W				PROPST, T; PROPST, A; DIETZE, O; JUDMAIER, G; BRAUNSTEINER, H; VOGEL, W			HIGH PREVALENCE OF VIRAL-INFECTION IN ADULTS WITH HOMOZYGOUS AND HETEROZYGOUS ALPHA(1)-ANTITRYPSIN DEFICIENCY AND CHRONIC LIVER-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						ALPHA-1-ANTITRYPSIN; HEPATITIS, CHRONIC ACTIVE; LIVER CIRRHOSIS; HEPATITIS ANTIBODIES; HEPATITIS-C VIRUS	HEPATITIS-C VIRUS; ALPHA-ANTITRYPSIN DEFICIENCY; CHRONIC ACTIVE HEPATITIS; ALPHA-1-ANTITRYPSIN DEFICIENCY; MALIGNANT HEPATOMA; CYTO-TOXICITY; CIRRHOSIS; ANTIBODIES; EMPHYSEMA; PROTEIN	Objective: To determine the prevalence of chronic liver disease in adults with homozygous (Pi ZZ) and heterozygous (Pi Z) alpha1-antitrypsin deficiency and to assess the presence of other possible risk factors for the development of chronic active hepatitis and cirrhosis of the liver in these patients. Design: Cross-sectional study. Setting: A referral-based university hospital. Patients: Consecutive patients (164) with the Pi ZZ and Pi Z phenotype with and without chronic liver disease. Measurements: The presence of antibody to hepatitis C virus (anti-HCV) was determined using an assay incorporating synthetic peptide antigen from capsid protein (United Biomedical [UBI] assay) and a second-generation enzyme immunoassay (Abbott test); the presence of antibody to hepatitis B virus (anti-HBV) was determined using radioimmunoassays incorporating hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg); assays for antinuclear antibody and antimitochondrial antibody (M2 subtype) were also done, and alcohol abuse was assessed by history. Results: Among patients with cirrhosis (32%), 62% were anti-HCV positive by the Abbott test (P = 0.006), and 41% were anti-HCV positive by the UBI assay (P = 0.007). Thirty-three percent of patients with cirrhosis had hepatitis B virus (HBV) infection (P = 0.01); 41% had a history of alcoholism; and 12% had features of autoimmune liver disease. Only five patients (9%) with cirrhosis had no other risk factor for chronic liver disease. Among patients with chronic active hepatitis (7%), 80% were anti-HCV positive by the Abbott test (P = 0.002), and 75% were anti-HCV positive by the UBI assay (P < 0.001). Thirty percent of patients with chronic active hepatitis had HBV infection (P = 0.023); 18% had autoimmune hepatitis; and 8% abused alcohol. Only two patients (17%) had no additional risk factor for the development of chronic active hepatitis. Among patients with steatosis of the liver (48%), 5% were anti-HCV positive by the Abbott test, and none were anti-HCV positive by the UBI assay; 18% had serologic evidence of past HBV infection, and 28% abused alcohol. Among patients without chronic liver disease (13%), no viral infection could be found; 9% were alcoholics. Conclusions: Chronic liver disease in patients with alpha1-antitrypsin deficiency is associated with a high prevalence of viral infection; this infection, rather than alpha1-antitrypsin deficiency alone, may be the cause of the liver disease in such patients.	UNIV INNSBRUCK, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, DEPT PATHOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck; University of Innsbruck	PROPST, T (corresponding author), UNIV HOSP INNSBRUCK, DEPT INTERNAL MED, ANICHSTR 35, A-6020 INNSBRUCK, AUSTRIA.							ADES EW, 1982, SCAND J IMMUNOL, V15, P109, DOI 10.1111/j.1365-3083.1982.tb00628.x; BRANTLY M, 1988, SCIENCE, V242, P1700, DOI 10.1126/science.2904702; BREIT SN, 1985, CLIN IMMUNOL IMMUNOP, V35, P363, DOI 10.1016/0090-1229(85)90097-2; BRILLANTI S, 1989, LANCET, V2, P1390; CARLSON J, 1985, SCAND J GASTROENTERO, V20, P835, DOI 10.3109/00365528509088831; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; COX DW, 1980, HUM GENET, V53, P429, DOI 10.1007/BF00287070; CRELL RW, 1979, ESSAYS MED BIOCH, V4, P83; ERIKSSON S, 1974, ACTA MED SCAND, V195, P451; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; FATTOVICH G, 1989, LANCET, V2, P797; FISHER RL, 1976, GASTROENTEROLOGY, V71, P646; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; GELLER SA, 1990, HEPATOLOGY, V12, P40, DOI 10.1002/hep.1840120108; HODGES JR, 1981, NEW ENGL J MED, V304, P557, DOI 10.1056/NEJM198103053041001; HOSEIN B, 1991, P NATL ACAD SCI USA, V88, P3647, DOI 10.1073/pnas.88.9.3647; HUDIG D, 1981, J IMMUNOL, V126, P1569; LENZI M, 1990, LANCET, V335, P258, DOI 10.1016/0140-6736(90)90070-L; LENZI M, 1991, LANCET, V338, P277, DOI 10.1016/0140-6736(91)90418-O; MORIN T, 1975, LANCET, V1, P250; PERLMUTTER DH, 1989, AM J PHYSIOL, V257, pL147, DOI 10.1152/ajplung.1989.257.4.L147; PERLMUTTER DH, 1991, HEPATOLOGY, V13, P172, DOI 10.1002/hep.1840130125; ROGET M, 1990, HEPATOLOGY, V11, P333, DOI 10.1002/hep.1840110234; SANCHEZTAPIAS JM, 1990, ANN INTERN MED, V112, P921, DOI 10.7326/0003-4819-112-12-921; SCHROEDER WT, 1985, AM J HUM GENET, V37, P868; SHARP HL, 1971, J LAB CLIN MED, V78, P1012; SHARP HL, 1969, J LAB CLIN MED, V73, P934; SHARP HL, 1982, SEMIN LIVER DIS, V2, P314, DOI 10.1055/s-2008-1040718; SVEGER T, 1976, NEW ENGL J MED, V294, P1316, DOI 10.1056/NEJM197606102942404; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704	31	81	84	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					641	645		10.7326/0003-4819-117-8-641	http://dx.doi.org/10.7326/0003-4819-117-8-641			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530195				2022-12-28	WOS:A1992JR86100003
J	GESTELAND, RF; WEISS, RB; ATKINS, JF				GESTELAND, RF; WEISS, RB; ATKINS, JF			RECODING - REPROGRAMMED GENETIC DECODING	SCIENCE			English	Article							POLYMERASE-III HOLOENZYME; RELEASE FACTOR-II; ESCHERICHIA-COLI; READING FRAME; GAMMA-SUBUNIT; MESSENGER-RNA; SELENOCYSTEINE; CODON; PSEUDOKNOT; PEPTIDE		UNIV UTAH,ECCLES INST HUMAN GENET,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	GESTELAND, RF (corresponding author), UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112, USA.			Atkins, John/0000-0001-7933-0165				ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; HATFIELD DL, 1992, ADV VIRUS RES, V41, P193, DOI 10.1016/S0065-3527(08)60037-8; HILL KE, 1991, J BIOL CHEM, V266, P10050; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; MATSUFUJI S, UNPUB; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WEISS RB, 1990, CELL, V62, P117, DOI 10.1016/0092-8674(90)90245-A; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WEISS RB, 1988, EMBO J, V7, P1503, DOI 10.1002/j.1460-2075.1988.tb02969.x; WILLS NM, 1991, P NATL ACAD SCI USA, V88, P6991, DOI 10.1073/pnas.88.16.6991; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	20	159	162	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1640	1641		10.1126/science.1529352	http://dx.doi.org/10.1126/science.1529352			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529352				2022-12-28	WOS:A1992JN50100019
J	HOLDEN, C				HOLDEN, C			CRIME CONFERENCE - BACK TO THE DRAWING BOARD, SAYS NIH	SCIENCE			English	Editorial Material																		WALTERS R, 1992, SCIENCE, V257, P739	1	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 11	1992	257	5076					1474	1474		10.1126/science.1523404	http://dx.doi.org/10.1126/science.1523404			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523404				2022-12-28	WOS:A1992JM57000012
J	LEE, DK; MARANTZ, PR; DEVEREUX, RB; KLIGFIELD, P; ALDERMAN, MH				LEE, DK; MARANTZ, PR; DEVEREUX, RB; KLIGFIELD, P; ALDERMAN, MH			LEFT-VENTRICULAR HYPERTROPHY IN BLACK-AND-WHITE HYPERTENSIVES - STANDARD ELECTROCARDIOGRAPHIC CRITERIA OVERESTIMATE RACIAL-DIFFERENCES IN PREVALENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; ECHOCARDIOGRAPHIC DETERMINATION; CARDIAC ANATOMY; BLOOD-PRESSURE; WORK SITE; MASS; RISK; SENSITIVITY; VALIDATION; MORTALITY	Objective.-To assess racial differences in the accuracy of standard electrocardiographic (ECG) criteria in the diagnosis of left ventricular hypertrophy (LVH). Design.-The sensitivity and specificity of standard ECG criteria were compared in blacks and whites using echocardiographic LVH as the reference standard. Setting.-Eight worksite-based hypertension clinics in New York, NY. Patients.-A sample of 122 black and 148 white hypertensive patients. Results.-The prevalence of ECG-LVH was two to six times higher in blacks than in whites, depending on the criteria used (range, 6% to 24% in blacks vs 1% to 7% in whites; P=.0005 to .19 for black-white comparisons). The difference in prevalence of ECG-LVH, however, was less striking and did not attain statistical significance (26% in blacks and 20% in whites; P >.2). The sensitivity of the ECG was low (range, 3% to 17%) and did not differ significantly between the two races for any of the conventional criteria; specificity, however, was lower in blacks for all criteria (range, 73% to 94% vs 95% to 100% for whites; P=.0001 to .09). The predictive value of a positive ECG was consistently, although not significantly, lower in the black subjects. Black race was the strongest independent predictor of decreased ECG specificity in multiple logistic regression analysis that also considered age, gender, body mass index, left ventricular mass index, and smoking. Conclusions.-Commonly used ECG criteria for the detection of LVH have a poor sensitivity in both black and white hypertensives and a lower specificity in blacks than in whites; this may lead to a greater number of false-positive diagnoses in black patients, as well as to an overestimation of black-white difference in LVH prevalence.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, 1300 MORRIS PK AVE, ROOM 1301, BRONX, NY 10461 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT MED, DIV CARDIOL, NEW YORK, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Cornell University; NewYork-Presbyterian Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER; NHLBI NIH HHS [2P50 HL-18323] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALDERMAN MH, 1975, NEW ENGL J MED, V293, P65, DOI 10.1056/NEJM197507102930203; ALDERMAN MH, 1976, J OCCUP ENVIRON MED, V18, P793, DOI 10.1097/00043764-197612000-00004; BARTEL A, 1971, ARCH INTERN MED, V128, P929, DOI 10.1001/archinte.128.6.929; BEAGLEHOLE R, 1975, J CHRON DIS, V28, P549, DOI 10.1016/0021-9681(75)90061-2; BLACKBURN H, 1970, Circulation Research Supplement, V41, P154; CARR AA, 1985, HYPERTENSION, V7, P948, DOI 10.1161/01.HYP.7.6.948; CASALE PN, 1987, CIRCULATION, V75, P565, DOI 10.1161/01.CIR.75.3.565; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; COOPER R, 1984, AM HEART J, V108, P715, DOI 10.1016/0002-8703(84)90662-8; COOPER RS, 1990, AM J CARDIOL, V65, P441, DOI 10.1016/0002-9149(90)90807-D; DEVEREUX RB, 1984, J AM COLL CARDIOL, V3, P82, DOI 10.1016/S0735-1097(84)80433-7; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1983, CIRCULATION, V67, P907, DOI 10.1161/01.CIR.67.4.907; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEVEREUX RB, 1987, HYPERTENSION, V9, P69; DUNN FG, 1983, J AM COLL CARDIOL, V1, P1348, DOI 10.1016/S0735-1097(83)80150-8; Fleiss JL, 1981, STAT METHODS RATES P; Gubner R, 1943, ARCH INTERN MED, V72, P196, DOI 10.1001/archinte.1943.00210080052005; HAMMOND IW, 1986, J AM COLL CARDIOL, V7, P639, DOI 10.1016/S0735-1097(86)80476-4; HAMMOND IW, 1984, J NATL MED ASSOC, V76, P247; HOLT JH, 1978, CIRCULATION, V57, P1129, DOI 10.1161/01.CIR.57.6.1129; HYPERTENSION DETECTION FOLLOW-UP, 1977, AM J EPIDEMIOL, V106, P351; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; KRAUS JF, 1980, AM J EPIDEMIOL, V111, P407, DOI 10.1093/oxfordjournals.aje.a112915; LEE DK, 1991, AM J HYPERTENS, V4, pA19; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; MCDONOUGH JR, 1964, ANN INTERN MED, V61, P208, DOI 10.7326/0003-4819-61-2-208; MENSAH G A, 1991, Journal of the American College of Cardiology, V17, p71A; MUNROFAURE AD, 1979, BMJ-BRIT MED J, V1, P1944; MURPHY ML, 1985, AM J CARDIOL, V55, P545, DOI 10.1016/0002-9149(85)90244-9; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; OKIN PM, 1992, J ELECTROCARDIOL, V25, P111, DOI 10.1016/0022-0736(92)90115-G; Prineas R., 1982, MINNESOTA CODE MANUA; RAUTAHARJU PM, 1988, AM J CARDIOL, V62, P59, DOI 10.1016/0002-9149(88)91365-3; REICHEK N, 1981, CIRCULATION, V63, P1391, DOI 10.1161/01.CIR.63.6.1391; REICHEK N, 1982, AM HEART J, V103, P202, DOI 10.1016/0002-8703(82)90493-8; ROMAN MJ, 1987, J AM COLL CARDIOL, V9, P500, DOI 10.1016/S0735-1097(87)80041-4; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; ROMHILT DW, 1969, CIRCULATION, V40, P185, DOI 10.1161/01.CIR.40.2.185; Savage D D, 1979, J Natl Med Assoc, V71, P709; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; TYROLER HA, 1984, AM HEART J, V108, P658, DOI 10.1016/0002-8703(84)90651-3; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; WOYTHALER JN, 1983, J AM COLL CARDIOL, V2, P305, DOI 10.1016/S0735-1097(83)80167-3; 1985, HYPERTENSION, V7, P105; [No title captured]	51	103	104	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3294	3299		10.1001/jama.267.24.3294	http://dx.doi.org/10.1001/jama.267.24.3294			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1534587				2022-12-28	WOS:A1992HY94400027
J	GOODMAN, JL; WINSTON, DJ; GREENFIELD, RA; CHANDRASEKAR, PH; FOX, B; KAIZER, H; SHADDUCK, RK; SHEA, TC; STIFF, P; FRIEDMAN, DJ; POWDERLY, WG; SILBER, JL; HOROWITZ, H; LICHTIN, A; WOLFF, SN; MANGAN, KF; SILVER, SM; WEISDORF, D; HO, WG; GILBERT, G; BUELL, D				GOODMAN, JL; WINSTON, DJ; GREENFIELD, RA; CHANDRASEKAR, PH; FOX, B; KAIZER, H; SHADDUCK, RK; SHEA, TC; STIFF, P; FRIEDMAN, DJ; POWDERLY, WG; SILBER, JL; HOROWITZ, H; LICHTIN, A; WOLFF, SN; MANGAN, KF; SILVER, SM; WEISDORF, D; HO, WG; GILBERT, G; BUELL, D			A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPY; KETOCONAZOLE; RECIPIENTS; MICONAZOLE; TOXICITY	Background and Methods. Superficial and systemic fungal infections are a major problem among severely immunocompromised patients who undergo bone marrow transplantation. We performed a double-blind, randomized, multicenter trial in which patients receiving bone marrow transplants were randomly assigned to receive placebo or fluconazole (400 mg daily). Fluconazole or placebo was administered prophylactically from the start of the conditioning regimen until the neutrophil count returned to 1000 per microliter, toxicity was suspected, or a systemic fungal infection was suspected or proved. Results. By the end of the treatment period, 67.2 percent of the 177 patients assigned to placebo had a positive fungal culture of specimens from any site, as compared with 29.6 percent of the 179 patients assigned to fluconazole. Among these, superficial infections were diagnosed in 33.3 percent of the patients receiving placebo and in 8.4 percent of the patients receiving fluconazole (P < 0.001). Systemic fungal infections occurred in 28 patients who received placebo as compared with 5 who received fluconazole (15.8 percent vs. 2.8 percent, P < 0.001). Fluconazole prevented infection with all strains of candida except Candida krusei. Fluconazole was well tolerated, although patients who received it had a higher mean increase in alanine aminotransferase levels than patients who received placebo. Although there was no significant difference in overall mortality between the groups, fewer deaths were ascribed to acute systemic fungal infections in the group receiving fluconazole than in the group receiving placebo (1 of 179 vs. 10 of 177, P < 0.001). Conclusions. Prophylactic administration of fluconazole to recipients of bone marrow transplants reduces the incidence of both systemic and superficial fungal infections.	UNIV MINNESOTA HOSP & CLIN,MINNEAPOLIS,MN 55455; UNIV CALIF LOS ANGELES,MED CTR,LOS ANGELES,CA 90024; UNIV OKLAHOMA,HLTH SCI CTR HOSP,OKLAHOMA CITY,OK; WAYNE STATE UNIV,HARPER HOSP,DETROIT,MI 48202; OHIO STATE UNIV HOSP,COLUMBUS,OH 43210; RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612; UNIV PITTSBURGH,MONTEFIORE HOSP,SCH MED,PITTSBURGH,PA 15213; UNIV CALIF SAN DIEGO,MED CTR,SAN DIEGO,CA 92103; LOYOLA UNIV,FOSTER G MCGAW HOSP,MAYWOOD,IL 60153; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284; WASHINGTON UNIV,MED CTR,ST LOUIS,MO 63130; HOSP UNIV PENN,PHILADELPHIA,PA 19104; NEW YORK MED COLL,WESTCHESTER CTY MED CTR,VALHALLA,NY 10595; CLEVELAND CLIN,CLEVELAND,OH 44106; VANDERBILT UNIV,NASHVILLE,TN 37240; TEMPLE UNIV,CTR COMPREHENS CANC,PHILADELPHIA,PA 19122; UNIV MICHIGAN,MED CTR,ANN ARBOR,MI 48109; PFIZER INC,CENT RES,GROTON,CT 06340	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Wayne State University; University System of Ohio; Ohio State University; Rush University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; University of California System; University of California San Diego; Loyola University Chicago; University of Texas System; University of Texas Health San Antonio; Washington University (WUSTL); University of Pennsylvania; Pennsylvania Medicine; New York Medical College; Westchester Medical Center; Cleveland Clinic Foundation; Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Michigan System; University of Michigan; Pfizer			Stiff, Patrick/S-2676-2019	Powderly, William/0000-0001-7808-3086				BEARMAN SI, 1988, J CLIN ONCOL, V6, P1562, DOI 10.1200/JCO.1988.6.10.1562; Brammer K W, 1990, Haematol Blood Transfus, V33, P546; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; CLIFT RA, 1984, AM J MED, V77, P34; CONTI DJ, 1989, TRANSPLANTATION, V48, P692; FAINSTEIN V, 1980, ANN INTERN MED, V93, P432, DOI 10.7326/0003-4819-93-3-432; GALGIANI JN, 1987, ANTIMICROB AGENTS CH, V31, P1867, DOI 10.1128/AAC.31.12.1867; LEE ET, 1980, STATISTICAL METHODS; LEWIS JH, 1984, GASTROENTEROLOGY, V86, P503; MCILROY MA, 1991, J INFECT DIS, V163, P420, DOI 10.1093/infdis/163.2.420; MEUNIER F, 1990, REV INFECT DIS, V12, pS364; OREILLY RJ, 1983, BLOOD, V62, P941; PATTERSON TF, 1990, REV INFECT DIS, V12, pS281; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; SAAG MS, 1988, ANTIMICROB AGENTS CH, V32, P1, DOI 10.1128/AAC.32.1.1; SAMONIS G, 1990, REV INFECT DIS, V12, pS369; SHEPP DH, 1985, J INFECT DIS, V152, P1257, DOI 10.1093/infdis/152.6.1257; SUGAR AM, 1988, AM J MED, V85, P481, DOI 10.1016/S0002-9343(88)80082-2; TOLLEMAR J, 1989, BONE MARROW TRANSPL, V4, P635; VERFAILLIE C, 1991, BONE MARROW TRANSPL, V8, P177; WALSH TJ, 1990, REV INFECT DIS, V12, pS307; WINGARD JR, 1987, AM J MED, V83, P1103, DOI 10.1016/0002-9343(87)90949-1; WINGARD JR, 1982, INFECT IMMUN, V37, P833, DOI 10.1128/IAI.37.2.833-836.1982; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; 1989, AM J MED, V86, P668	25	959	979	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1992	326	13					845	851		10.1056/NEJM199203263261301	http://dx.doi.org/10.1056/NEJM199203263261301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK523	1542320				2022-12-28	WOS:A1992HK52300001
J	RICHARD, EA; LISMAN, JE				RICHARD, EA; LISMAN, JE			RHODOPSIN INACTIVATION IS A MODULATED PROCESS IN LIMULUS PHOTORECEPTORS	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; PHOSPHODIESTERASE ACTIVATION; 48-KDA PROTEIN; PHOSPHORYLATION; MEMBRANES; ARRESTIN; DROSOPHILA; LIGHT; METARHODOPSIN; HOMOLOG	MANY G-protein-coupled receptors are only transiently active because an inactivation process stops the receptor from activating G protein molecules 1-3. Although this inactivated has been investigated in vitro, the real kinetics of the process can only be obtained from intact cells. Here we describe a method for measuring the inactivation of rhodopsin in intact photoreceptors and the application of this method to the ultraviolet rhodopsin of Limulus median eye 4. The results show that the inactivation process is very rapid (< 150 ms) and occurs well before the peak of the receptor potential. We have also investigated whether the inactivation process can itself be modulated. Our results show that light-adaptation accelerates inactivation by about 10-fold, providing evidence that G-protein-mediated transduction can be modulated at this first stage.			RICHARD, EA (corresponding author), BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254, USA.							AZUMA K, 1975, BIOCHIM BIOPHYS ACTA, V393, P520, DOI 10.1016/0005-2795(75)90079-3; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; HAGINS WA, 1967, SCIENCE, V157, P813, DOI 10.1126/science.157.3790.813; HAMDORF K, 1980, NATURE, V283, P859, DOI 10.1038/283859a0; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KAHANA A, 1990, BIOL B A, V179, P230; KIRSCHFELD K, 1978, Z NATURFORSCH C, V33, P1009; KUHN H, 1974, NATURE, V250, P588, DOI 10.1038/250588a0; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LEVINE E, 1987, J GEN PHYSIOL, V90, P575, DOI 10.1085/jgp.90.4.575; LEVINE H, 1991, MECH DEVELOP, V33, P19; LIEBMAN PA, 1980, NATURE, V287, P734, DOI 10.1038/287734a0; LISMAN J, 1985, J GEN PHYSIOL, V85, P171, DOI 10.1085/jgp.85.2.171; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; NOLTE J, 1972, J GEN PHYSIOL, V59, P167, DOI 10.1085/jgp.59.2.167; PAULSEN R, 1984, J COMP PHYSIOL, V155, P39, DOI 10.1007/BF00610929; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; SIBLEY DR, 1985, J BIOL CHEM, V260, P3883; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P1205; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; TOKUNAGA F, 1975, FEBS LETT, V55, P229, DOI 10.1016/0014-5793(75)80998-7; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671	24	24	24	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					336	338		10.1038/356336a0	http://dx.doi.org/10.1038/356336a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549176				2022-12-28	WOS:A1992HK79400063
J	HARRIS, ME; HAJDUK, SL				HARRIS, ME; HAJDUK, SL			KINETOPLASTID RNA EDITING - INVITRO FORMATION OF CYTOCHROME-B GRNA-MESSENGER RNA CHIMERAS FROM SYNTHETIC SUBSTRATE RNAS	CELL			English	Article							TRYPANOSOMA-BRUCEI; SUBUNIT-III; GUIDE RNAS; MITOCHONDRIA; DNA; TRANSCRIPTS; OXIDASE; NUCLEOTIDES; INFORMATION; POLYMERASE	RNA editing in the kinetoplastid Trypanosoma brucei results in the addition and deletion of uridine residues within several mitochondrial mRNAs. The site and number of uridines added appears to be directed by small (approximately 70 nt) guide RNAs (gRNAs), which can base pair to the edited sequences. We examined reactions involving synthetic cytochrome b (CYb) gRNA and pre-edited mRNA in vitro. A major product of the in vitro reaction is a chimeric RNA molecule containing both gRNA and mRNA sequences. Formation of the CYb gRNA-mRNA chimera was specific, since such molecules did not accumulate when either the gRNA or mRNA was substituted with control RNAs. The reaction required a free 3' hydroxyl on the gRNA and was unaffected by capping of the gRNA's 5' end. Direct RNA sequencing indicated that the CYb gRNA is covalently linked via its 3' poly(U) tail to one of the editing sites on the CYb mRNA. These results suggest that the U's added during editing are donated by the poly(U) tail of a gRNA via a chimeric gRNA-mRNA intermediate.	UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	HARRIS, ME (corresponding author), UNIV ALABAMA, SCH MED, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021401, P30AI027767, R21AI021401] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21401, P30 AI27767] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x; WANG MJ, 1990, NUCLEIC ACIDS RES, V18, P6625, DOI 10.1093/nar/18.22.6625; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	24	66	66	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1091	1099		10.1016/0092-8674(92)90080-V	http://dx.doi.org/10.1016/0092-8674(92)90080-V			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547505				2022-12-28	WOS:A1992HK67400012
J	SCHLESINGER, Y; GRANOFF, DM				SCHLESINGER, Y; GRANOFF, DM			AVIDITY AND BACTERICIDAL ACTIVITY OF ANTIBODY ELICITED BY DIFFERENT HAEMOPHILUS-INFLUENZAE TYPE-B CONJUGATE VACCINES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTER-MEMBRANE-PROTEIN; HEMOPHILUS-INFLUENZAE; CAPSULAR POLYSACCHARIDE; MONOCLONAL-ANTIBODIES; FUNCTIONAL-ACTIVITY; INFANTS; AFFINITY; IMMUNIZATION; SERUM	Objective. - Antibody avidity is a measure of the functional affinity of serum antibody to bind to antigen. In this study, we compared the avidity of antibodies elicited by vaccination with three Haemophilus influenzae type b (Hib) conjugate vaccines and investigated the relationship between antibody avidity and the ability of antibody to activate complement-mediated bactericidal activity. Design. - A convenience sample of 171 postvaccination serum samples with more than 0.5-mu-g/mL of anticapsular antibody, the minimum concentration required for measurement of avidity. The serum samples were obtained from infants participating in immunogenicity trials with Hib capsular polysaccharide (PRP) conjugated to meningococcal outer membrane protein complex (PRP-OMPC) or to tetanus toxoid (PRP-T), or PRP oligomers conjugated to a nontoxic mutant diphtheria toxin, CRM197 (Oligo-CRM). Patients. - Healthy infants recruited in private practices. Primary Outcome Measures. - Avidity of vaccine-induced serum anticapsular antibody and serum bactericidal titers. Results. - In infants vaccinated at 2, 4, and 6 months of age, Oligo-CRM evoked antibody of higher avidity than PRP-OMPC (P < .001). The mean avidity of antibody elicited by PRP-T was intermediate, being lower than Oligo-CRM (P < .02) but higher than PRP-OMPC (P = .001). Also, after one dose, 18-month-old infants given Oligo-CRM had higher avidity antibodies compared with those given PRP-OMPC P < .001). Half of the infants in both age groups who were given Oligo-CRM developed antibody avidity of 2.50 nM-1 or greater, whereas more than two thirds of the infants given PRP-OMPC had avidity values of 1.25 nM-1 or less. Antibodies with avidity of 1.25 nM-1 or less were, on average, 6.6-fold less active in assays of complement-mediated bactericidal activity than antibodies with avidity of 2.50 nM-1 or greater (P < .001). Conclusions. - Oligo-CRM and PRP-T conjugate vaccines elicit higher avidity antibody than PRP-OMPC, and high-avidity antibody is more potent than low-avidity antibody in serum bactericidal assays. Consideration should be given to including measurement of antibody avidity in assessment of new vaccines since avidity may affect the ability of serum antibody to confer protection against disease.	WASHINGTON UNIV,SCH MED,MALLINCK DEPT PEDIAT,DIV INFECT DIS,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021842, R01AI017962] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 17962, AI21842] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHLSTEDT S, 1974, INT ARCH ALLER A IMM, V46, P470, DOI 10.1159/000231150; AMIR J, 1990, PEDIATR RES, V27, P358, DOI 10.1203/00006450-199004000-00008; ANDERSON P, 1987, J INFECT DIS, V156, P582, DOI 10.1093/infdis/156.4.583; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; DECKER MD, 1992, J PEDIATR-US, V120, P184, DOI 10.1016/S0022-3476(05)80424-X; EINHORN MS, 1986, LANCET, V2, P299; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; GIGLIOTTI F, 1984, J INFECT DIS, V149, P43, DOI 10.1093/infdis/149.1.43; GRANOFF DM, 1988, PEDIATR RES, V24, P180, DOI 10.1203/00006450-198808000-00008; GRANOFF DM, 1991, 31ST P INT C ANT AG; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; GRISWOLD WR, 1989, J INFECT DIS, V159, P1083, DOI 10.1093/infdis/159.6.1083; HETHERINGTON SV, 1990, J INFECT DIS, V162, P1185, DOI 10.1093/infdis/162.5.1185; HOLMES SJ, 1991, J PEDIATR-US, V118, P364, DOI 10.1016/S0022-3476(05)82148-1; HORNICK CL, 1972, IMMUNOCHEMISTRY, V9, P325, DOI 10.1016/0019-2791(72)90096-1; JOHNSON ND, 1981, NATURE, V291, P29; KAYHTY H, 1983, J INFECT DIS, V147, P1100; MADORE DV, 1990, PEDIATRICS, V85, P331; MUSHER D, 1986, J INFECT DIS, V154, P935, DOI 10.1093/infdis/154.6.935; OTTERNESS I, 1982, ANTIBODY TOOL, P97; PARKE JC, 1991, J PEDIATR-US, V118, P184, DOI 10.1016/S0022-3476(05)80480-9; PERSSON MAA, 1988, J IMMUNOL, V140, P3875; PINCUS SH, 1988, J IMMUNOL, V140, P2779; ROBBINS JB, 1973, PEDIATR RES, V7, P103, DOI 10.1203/00006450-197303000-00001; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; STEIN HE, IN PRESS J INFECT DI; WEINBERG GA, 1986, J IMMUNOL, V136, P4232	28	185	191	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1489	1494		10.1001/jama.267.11.1489	http://dx.doi.org/10.1001/jama.267.11.1489			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1538539				2022-12-28	WOS:A1992HH48800029
J	MALVIN, GM; WOOD, SC				MALVIN, GM; WOOD, SC			BEHAVIORAL HYPOTHERMIA AND SURVIVAL OF HYPOXIC PROTOZOANS PARAMECIUM-CAUDATUM	SCIENCE			English	Article								Hypoxia has been shown to elicit behavioral hypothermia in a number of different metazoan species, all with nervous systems. The protozoan, Paramecium caudatum, has no nervous system and was not expected to display behavioral hypothermia. However, this species was also found to select a lower temperature in a thermal gradient under hypoxic conditions. This response proved to be beneficial as survival of hypoxic paramecia was greatly increased at lower temperatures. This unicellular species may provide a useful model to investigate the cellular and molecular basis of adaptive thermoregulatory behavior.			MALVIN, GM (corresponding author), LOVELACE FDN MED EDUC & RES,OXYGEN TRANSPORT PROGRAM,2425 RIDGECREST SE,ALBUQUERQUE,NM 87108, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038942, R01HL040537, R01HL038942] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38942, HL-40537] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Kitching JA, 1939, BIOL BULL-US, V77, P339, DOI 10.2307/1537643; MENDELSSOHN M, 1995, PFLUGERS ARCH GES PH, V60, P1; WOOD SC, 1991, ANNU REV PHYSIOL, V53, P71, DOI 10.1146/annurev.physiol.53.1.71; WOOD SC, 1991, STRATEGIES PHYSL ADA, P295	4	53	53	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1423	1425		10.1126/science.1542790	http://dx.doi.org/10.1126/science.1542790			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542790				2022-12-28	WOS:A1992HH74400052
J	MILES, SA; MARTINEZMAZA, O; REZAI, A; MAGPANTAY, L; KISHIMOTO, T; NAKAMURA, S; RADKA, SF; LINSLEY, PS				MILES, SA; MARTINEZMAZA, O; REZAI, A; MAGPANTAY, L; KISHIMOTO, T; NAKAMURA, S; RADKA, SF; LINSLEY, PS			ONCOSTATIN-M AS A POTENT MITOGEN FOR AIDS-KAPOSIS SARCOMA DERIVED CELLS	SCIENCE			English	Article							IMMUNODEFICIENCY SYNDROME AIDS; LONG-TERM CULTURE; GROWTH-REGULATOR	Oncostatin M, a cytokine produced by activated lymphoid cells, regulates the growth and differentiation of a number of tumor and normal cells. In contrast to its effects on normal endothelia and aortic smooth muscle cell cultures, Oncostatin M was a potent mitogen for cells derived from acquired immunodeficiency syndrome-related Kaposi's sarcoma (AIDS-KS). After exposure to Oncostatin M, AIDS-KS cells assumed a spindle morphology, had an increased ability to proliferate in soft agar, and secreted increased amounts of interleukin-6. Oncostatin M RNA and immunoreactive Oncostatin M protein were found in AIDS-KS-derived cell isolates. These results suggest that Oncostatin M may play a role in the pathogenesis of AIDS-KS.	UNIV CALIF LOS ANGELES,CTR CARE,LOS ANGELES,CA 90024; HUNTINGTON MEM HOSP,INST MOLEC MED & TECHNOL,PASADENA,CA 91105; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; UNIV CALIF LOS ANGELES,SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; OSAKA UNIV,SCH MED,DEPT MED 3,OSAKA,JAPAN; UNIV SO CALIF,DEPT MED,LOS ANGELES,CA 90089	University of California System; University of California Los Angeles; University of Southern California; Huntington Memorial Hospital; Bristol-Myers Squibb; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Osaka University; University of Southern California	MILES, SA (corresponding author), UNIV CALIF LOS ANGELES,CTR AIDS,ROOM BH-412,CHS 179317,LOS ANGELES,CA 90024, USA.		Martinez-Maza, Otoniel/B-2667-2009; Kishimoto, Tadamitsu/C-8470-2009	Martinez-Maza, Otoniel/0000-0003-1364-0675; 	NATIONAL CANCER INSTITUTE [K04CA001588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027660] Funding Source: NIH RePORTER; NCI NIH HHS [CA 01588] Funding Source: Medline; NIAID NIH HHS [AI27660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMMANN AJ, 1987, J CLIN IMMUNOL, V7, P481, DOI 10.1007/BF00915059; BERMAN MA, 1987, CLIN IMMUNOL IMMUNOP, V42, P133, DOI 10.1016/0090-1229(87)90180-2; BROWN TJ, 1991, J IMMUNOL, V147, P2175; BROWN TJ, 1987, J IMMUNOL, V139, P2977; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; LAUBENSTEIN LJ, 1984, J CLIN ONCOL, V2, P1115, DOI 10.1200/JCO.1984.2.10.1115; LINSLEY PS, 1990, MOL CELL BIOL, V10, P1882, DOI 10.1128/MCB.10.5.1882; LINSLEY PS, 1989, J BIOL CHEM, V264, P4282; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; MILES SA, UNPUB; MITSUYASU RT, 1988, BLOOD REV, V2, P222, DOI 10.1016/0268-960X(88)90011-2; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; VOLBERDING P, 1989, AIDS, P345; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	18	269	281	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1432	1434		10.1126/science.1542793	http://dx.doi.org/10.1126/science.1542793			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542793				2022-12-28	WOS:A1992HH74400056
J	BERLOT, CH; BOURNE, HR				BERLOT, CH; BOURNE, HR			IDENTIFICATION OF EFFECTOR-ACTIVATING RESIDUES OF GS-ALPHA	CELL			English	Article							GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; ADENYLYL CYCLASE; PERTUSSIS TOXIN; SCANNING MUTAGENESIS; CRYSTAL-STRUCTURE; RAS; SUBUNIT; GENE; CDNA	The heterotrimeric G proteins transduce extracellular signals by interacting with specific intracellular effectors. We have used a scanning mutagenesis approach to identify amino acids of alpha(s), the alpha-subunit of G(s), that determine the specificity of its interaction with its effector, adenylyl cyclase. In a subunit chimeras, residues 236-356 of alpha(s) comprise the shortest linear stretch that is required for activation of adenylyl cyclase. Within these 121 residues, we identified four clusters of residues in which substitutions prevented effector activation. Mutations in three of these regions did not affect alpha-subunit expression or the GTP-induced conformational change. The identified alpha(s) residues in the NH2-terminal half of the 121-residue region endowed the cognate alpha(i2) segment with the ability to activate effector, while those in the COOH-terminal half did not. In a three-dimensional G-alpha model, based on the structure of p21ras the effector-activating residues of alpha(s) form a surface on the membrane-facing side of the molecule; this surface includes a region that changes conformation upon binding GTP.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	BERLOT, CH (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA.							AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; CHEE WW, 1989, J BIOL CHEM, V264, P5687; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; ITOH H, 1991, J BIOL CHEM, V266, P16226; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1987, J BIOL CHEM, V262, P14241; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MATSUOKA M, 1990, J BIOL CHEM, V265, P13215; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARIS S, 1987, J BIOL CHEM, V262, P1970; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; QUAN F, 1989, P NATL ACAD SCI USA, V86, P4321, DOI 10.1073/pnas.86.11.4321; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443	52	174	190	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					911	922		10.1016/0092-8674(92)90034-A	http://dx.doi.org/10.1016/0092-8674(92)90034-A			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547491				2022-12-28	WOS:A1992HH74800010
J	MURRAY, EA; RAUSCH, DM; LENDVAY, J; SHARER, LR; EIDEN, LE				MURRAY, EA; RAUSCH, DM; LENDVAY, J; SHARER, LR; EIDEN, LE			COGNITIVE AND MOTOR IMPAIRMENTS ASSOCIATED WITH SIV INFECTION IN RHESUS-MONKEYS	SCIENCE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS DEMENTIA COMPLEX; VIRUS-INFECTION; MEMORY	Cognitive and motor deficits are now recognized as significant clinical features of infection with the human immunodeficiency virus (HIV). Juvenile rhesus macaques infected with simian immunodeficiency virus (SIV) were found to exhibit cognitive and motor deficits characteristic of HIV infection. Impairment on a motor skill task was the most reliable indicator of infection. Various cognitive impairments were also evident. These deficits were related to SIV infection of the brain but not to inflammatory lesions at a particular locus. The results suggest that the SIV-infected rhesus macaque is a valuable model for understanding the cause of HIV-associated central nervous system dysfunction and for developing a treatment.	NIMH,CELL BIOL LAB,MOLEC & CELLULAR NEUROBIOL UNIT,BETHESDA,MD 20892; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT LAB MED & PATHOL,NEWARK,NJ 07103	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Rutgers State University New Brunswick; Rutgers State University Medical Center	MURRAY, EA (corresponding author), NIMH,NEUROPSYCHOL LAB,BLDG 9,ROOM 1E104,BETHESDA,MD 20892, USA.		Murray, Elisabeth A./X-2051-2019	Eiden, Lee/0000-0001-7524-944X; Murray, Elisabeth/0000-0003-1450-1642				ASANUMA H, 1984, J NEUROPHYSIOL, V52, P212, DOI 10.1152/jn.1984.52.2.212; BASKIN GB, 1986, J NATL CANCER I, V77, P127; DESROSIERS RC, 1987, REV INFECT DIS, V9, P438; GOETHE KE, 1989, ARCH NEUROL-CHICAGO, V46, P129, DOI 10.1001/archneur.1989.00520380029008; GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; MILLER EN, 1990, NEUROLOGY, V40, P197, DOI 10.1212/WNL.40.2.197; MISHKIN M, 1987, SCI AM, V256, P80, DOI 10.1038/scientificamerican0687-80; Mishkin M., 1984, NEUROBIOL LEARN MEM, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; OSTLE B, 1963, STAT RES, P98; PERDICES M, 1989, ANN NEUROL, V25, P460, DOI 10.1002/ana.410250507; PRICE RW, 1988, ANN NEUROL, V23, pS27, DOI 10.1002/ana.410230711; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; SHARER LR, 1988, ANN NEUROL, V23, pS108, DOI 10.1002/ana.410230727; SHARER LR, 1991, J MED PRIMATOL, V20, P211; SQUIRE LR, 1986, SCIENCE, V232, P1612, DOI 10.1126/science.3086978; TROSS S, 1988, AIDS, V2, P81, DOI 10.1097/00002030-198804000-00002; WARD JM, 1987, AM J PATHOL, V127, P199; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613; WILKIE FL, 1990, ARCH NEUROL-CHICAGO, V47, P433, DOI 10.1001/archneur.1990.00530040085022; 1984, Q J EXP PSYCHOL-B, V36, P173	21	154	156	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1246	1249		10.1126/science.1546323	http://dx.doi.org/10.1126/science.1546323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546323				2022-12-28	WOS:A1992HG67700040
J	SHARP, PA				SHARP, PA			TATA-BINDING PROTEIN IS A CLASSLESS FACTOR	CELL			English	Review							TRANSCRIPTION		MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	SHARP, PA (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.							BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; NASH HA, 1991, CELL, V67, P1037, DOI 10.1016/0092-8674(91)90280-C; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	18	202	205	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					819	821		10.1016/0092-8674(92)90023-6	http://dx.doi.org/10.1016/0092-8674(92)90023-6			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547484				2022-12-28	WOS:A1992HH74800001
J	SHINKAI, Y; RATHBUN, G; LAM, KP; OLTZ, EM; STEWART, V; MENDELSOHN, M; CHARRON, J; DATTA, M; YOUNG, F; STALL, AM; ALT, FW				SHINKAI, Y; RATHBUN, G; LAM, KP; OLTZ, EM; STEWART, V; MENDELSOHN, M; CHARRON, J; DATTA, M; YOUNG, F; STALL, AM; ALT, FW			RAG-2-DEFICIENT MICE LACK MATURE LYMPHOCYTES OWING TO INABILITY TO INITIATE V(D)J REARRANGEMENT	CELL			English	Article							PRE-B-CELLS; COMBINED IMMUNE-DEFICIENCY; REGION GENE SEGMENTS; SCID MICE; ANTIGEN RECEPTOR; VARIABLE REGION; RECOMBINATION ACTIVITY; JOINING SIGNALS; EXPRESSION; DEFECT	We have generated mice that carry a germline mutation in which a large portion of the RAG-2 coding region is deleted. Homozygous mutants are viable but fail to produce mature B or T lymphocytes. Very immature lymphoid cells were present in primary lymphoid organs of mutant animals as defined by surface marker analyses and Abelson murine leukemia virus (A-MuLV) transformation assays. However, these cells did not rearrange their immunoglobulin or T cell receptor loci. Lack of V(D)J recombination activity in mutant pre-B cell lines could be restored by introduction of a functional RAG-2 expression vector. Therefore, loss of RAG-2 function in vivo results in total inability to initiate V(D)J rearrangement, leading to a novel severe combined immune deficient (SCID) phenotype. Because the SCID phenotype was the only obvious abnormality detected in RAG-2 mutant mice, RAG-2 function and V(D)J recombinase activity, per se, are not required for development of cells other than lymphocytes.	COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University			Shinkai, Yoichi/N-3909-2014; Charron, Jean/A-9792-2013; Lam, Kong-Peng/G-5374-2012	Shinkai, Yoichi/0000-0002-6051-2484; Charron, Jean/0000-0002-5133-0056; Lam, Kong-Peng/0000-0002-1316-4333	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020047, R37AI020047] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20047] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALT F W, 1991, Current Biology, V1, P3, DOI 10.1016/0960-9822(91)90108-9; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BLACKWELL TK, 1989, J BIOL CHEM, V264, P10327; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; CARLSON LM, 1991, CELL, V64, P201, DOI 10.1016/0092-8674(91)90221-J; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; FERRIER P, 1990, J EXP MED, V171, P1909, DOI 10.1084/jem.171.6.1909; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; FULOP GM, 1988, CELL IMMUNOL, V113, P192, DOI 10.1016/0008-8749(88)90017-2; GEHA RS, 1992, IN PRESS PRIMARY IMM; HARDY RR, 1989, CURR TOP MICROBIOL, V152, P19; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENDRICKSON EA, 1990, MOL CELL BIOL, V10, P5397, DOI 10.1128/MCB.10.10.5397; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUOKA M, 1991, SCIENCE, V254, P81, DOI 10.1126/science.1925563; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARK LS, 1990, J EXP MED, V171, P1073, DOI 10.1084/jem.171.4.1073; PARKS DR, 1986, HDB EXPT IMMUNOLOGY; PETRINI JHJ, 1990, P NATL ACAD SCI USA, V87, P3450, DOI 10.1073/pnas.87.9.3450; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SCHWARTZBERG PL, 1990, P NATL ACAD SCI USA, V87, P3210, DOI 10.1073/pnas.87.8.3210; SILVERSTONE AE, 1978, DIFFERENTIATION NORM, P433; SIU G, 1984, NATURE, V311, P344, DOI 10.1038/311344a0; YANCOPOULOS GD, 1990, P NATL ACAD SCI USA, V87, P5759, DOI 10.1073/pnas.87.15.5759; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	50	2209	2300	2	73	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					855	867		10.1016/0092-8674(92)90029-C	http://dx.doi.org/10.1016/0092-8674(92)90029-C			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547487				2022-12-28	WOS:A1992HH74800005
J	SULLIVAN, SL; GOTTESMAN, ME				SULLIVAN, SL; GOTTESMAN, ME			REQUIREMENT FOR ESCHERICHIA-COLI NUSG PROTEIN IN FACTOR-DEPENDENT TRANSCRIPTION TERMINATION	CELL			English	Article							BACTERIOPHAGE-LAMBDA; ESCHERICHIA-COLI; ANTITERMINATION PROTEIN; GENE-EXPRESSION; FACTOR-RHO; SEQUENCE; OPERON; RECOGNITION; MUTATIONS	The 21 kd NusG protein is essential for E. coli viability. Cells depleted for NusG were defective for factor-dependent transcription termination. Rho-induced polarity in the gal operon and the Rho-dependent lambda-tR1 and lambda-tL1 terminators were suppressed in NusG-deficient cells. NusG depletion inactivated the phage HK022 Nun termination factor. In contrast, the factor-independent lambda-tl terminator was fully active in NusG-depleted cells and could be suppressed by phage lambda-N function.			SULLIVAN, SL (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037219] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37219] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; ADHYA S, 1968, GENETICS, V62, P231; ALIFANO P, 1991, CELL, V64, P553; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; DAS A, 1976, P NATL ACAD SCI USA, V73, P1959, DOI 10.1073/pnas.73.6.1959; DECROMBR.B, 1973, NATURE-NEW BIOL, V241, P260, DOI 10.1038/newbio241260a0; DOWNING WL, 1990, J BACTERIOL, V172, P1621, DOI 10.1128/jb.172.3.1621-1627.1990; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2, P263; GOTTESMAN ME, 1980, J MOL BIOL, V140, P57, DOI 10.1016/0022-2836(80)90356-3; HARLOW E, 1988, ANTIBODIES LABORATOR; HASHIMOTOGOTOH T, 1977, J BACTERIOL, V131, P405, DOI 10.1128/JB.131.2.405-412.1977; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LOWERYGO.C, 1974, P NATL ACAD SCI USA, V71, P2003, DOI 10.1073/pnas.71.5.2003; Maniatis T., 1982, MOL CLONING; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; Miller J.H., 1972, EXPT MOL GENETICS; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; OPPENHEIM AB, 1982, J MOL BIOL, V158, P327, DOI 10.1016/0022-2836(82)90201-7; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; REYES O, 1976, J BACTERIOL, V126, P1108, DOI 10.1128/JB.126.3.1108-1112.1976; REYNOLDS R, 1992, IN PRESS J MOL BIOL; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBLEDO R, 1991, J MOL BIOL, V220, P613, DOI 10.1016/0022-2836(91)90104-E; Silhavy T. J., 1984, EXPT GENE FUSIONS; SULLIVAN SL, 1992, IN PRESS J BACTERIOL, V174; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241	33	160	162	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					989	994		10.1016/0092-8674(92)90041-A	http://dx.doi.org/10.1016/0092-8674(92)90041-A			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547498				2022-12-28	WOS:A1992HH74800017
J	LUTHY, R; BOWIE, JU; EISENBERG, D				LUTHY, R; BOWIE, JU; EISENBERG, D			ASSESSMENT OF PROTEIN MODELS WITH 3-DIMENSIONAL PROFILES	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING; RECOGNITION; RESOLUTION; RUBISCO; DOMAINS; ENERGY; DESIGN	As methods for determining protein three-dimensional (3D) structure develop, a continuing problem is how to verify that the final protein model is correct. The revision of several protein models to correct errors 1-6 has prompted the development of new criteria for judging the validity of X-ray 7-9 and NMR 10,11 structures, as well as the formation of energetic 12-14 and empirical methods 15,16 to evaluate the correctness of protein models. The challenge is to distinguish between a mistraced or wrongly folded model, and one that is basically correct, but not adequately refined. We show that an effective test of the accuracy of a 3D protein model is a comparison of the model to its own amino-acid sequence, using a 3D profile 16, computed from the atomic coordinates of the structure 3D profiles of correct protein structures match their own sequences with high scores. In contrast, 3D profiles for protein models known to be wrong score poorly. An incorrectly modelled segment in an otherwise correct structure can be identified by examining the profile score in a moving-window scan. The accuracy of a protein model can be assessed by its 3D profile, regardless of whether the model has been derived by X-ray, NMR or computational procedures.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								BAUMANN G, 1989, PROTEIN ENG, V2, P329, DOI 10.1093/protein/2.5.329; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUNDELL TL, 1983, FED PROC, V42, P2592; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRANDEN CI, 1990, NATURE, V343, P687, DOI 10.1038/343687a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; GONZALEZ C, 1991, J MAGN RESON, V91, P659, DOI 10.1016/0022-2364(91)90397-C; GOSH D, 1982, J MOL BIOL, V158, P73; HENDLICH M, 1990, J MOL BIOL, V216, P167, DOI 10.1016/S0022-2836(05)80068-3; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KNIGHT S, 1989, SCIENCE, V244, P702, DOI 10.1126/science.244.4905.702; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; LEBIODA L, 1989, J BIOL CHEM, V264, P3685; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; NAVIA M, 1989, NATURE, V347, P615; NILGES M, 1991, J MOL BIOL, V219, P499, DOI 10.1016/0022-2836(91)90189-D; NOVOTNY J, 1988, PROTEINS, V4, P19, DOI 10.1002/prot.340040105; NOVOTNY J, 1984, J MOL BIOL, V177, P787, DOI 10.1016/0022-2836(84)90049-4; Peitsch M C, 1990, New Biol, V2, P197; RAGHUNATHAN G, 1990, PROTEINS, V8, P213, DOI 10.1002/prot.340080304; STENKAMP RE, 1978, ACTA CRYSTALLOGR B, V38, P784; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; TONG L, 1989, SCIENCE, V245, P244, DOI 10.1126/science.2665078; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	30	2467	2542	6	99	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					83	85		10.1038/356083a0	http://dx.doi.org/10.1038/356083a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538787				2022-12-28	WOS:A1992HG60200063
J	ADAMS, MD; DUBNICK, M; KERLAVAGE, AR; MORENO, R; KELLEY, JM; UTTERBACK, TR; NAGLE, JW; FIELDS, C; VENTER, JC				ADAMS, MD; DUBNICK, M; KERLAVAGE, AR; MORENO, R; KELLEY, JM; UTTERBACK, TR; NAGLE, JW; FIELDS, C; VENTER, JC			SEQUENCE IDENTIFICATION OF 2,375 HUMAN BRAIN GENES	NATURE			English	Article							CDNA CLONING; PROTEIN	WE recently described a new approach for the rapid characterization of expressed genes by partial DNA sequencing to generate 'expressed sequence tags' 1. From a set of 600 human brain complementary DNA clones, 348 were informative nuclear-encoded messenger RNAs. We have now partially sequenced 2,672 new, independent cDNA clones isolated from four human brain cDNA libraries to generate 2,375 expressed sequence tags to nuclear-encoded genes. These sequences, together with 348 brain expressed sequence tags from our previous study, comprise more than 2,500 new human genes and 870,769 base pairs of DNA sequence. These data represent an approximate doubling of the number of human genes identified by DNA sequencing and may represent as many as 5% of the genes in the human genome.	NINCDS,RECEPTOR BIOCHEM & MOLEC BIOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Kerlavage, Anthony/0000-0002-3954-9653; Fields, Chris/0000-0002-4812-0744				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARKER WC, 1991, NUCLEIC ACIDS RES, V19, P2231, DOI 10.1093/nar/19.suppl.2231; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CASERO RA, 1991, J BIOL CHEM, V266, P810; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; GALAU G, 1977, ARCH BIOCHEM BIOPHYS, V197, P584; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; KAMHOLZ J, 1986, P NATL ACAD SCI USA, V83, P4962, DOI 10.1073/pnas.83.13.4962; MCKUSICK VA, 1991, FASEB J, V5, P12, DOI 10.1096/fasebj.5.1.1991580; PAULSON KE, 1985, NATURE, V316, P3259; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; RUBENSTEIN J, NUCLEIC ACIDS RES, V18, P4833; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V	19	742	823	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					632	634		10.1038/355632a0	http://dx.doi.org/10.1038/355632a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538749				2022-12-28	WOS:A1992HD54700053
J	ORY, SJ				ORY, SJ			NEW OPTIONS FOR DIAGNOSIS AND TREATMENT OF ECTOPIC PREGNANCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUBAL PREGNANCY; METHOTREXATE INJECTION; CONSERVATIVE TREATMENT; INVITRO FERTILIZATION; NONSURGICAL TREATMENT; CLINICAL-TRIAL; MANAGEMENT; FERTILITY; ULTRASOUND; SURGERY	The incidence of ectopic pregnancy has increased 4.5-fold in the United States since 1970. Several risk factors have contributed to this rate of increase, but the primary underlying cause remains undefined. Significant advances in the diagnosis of ectopic pregnancy have occurred during this same interval as a consequence of an enhanced understanding of the natural course of the disease. Characteristic changes in human chorionic gonadotropin levels, ultrasound findings, and more frequent use of laparoscopy have contributed to earlier, more consistent diagnosis. Advances in treatment, including tubal-conserving operations, laparoscopic approaches, and medical treatment with methotrexate, have all proved to be safe and effective. The remaining principal challenge is to improve future fertility, which is often adversely affected by recurrence of an ectopic pregnancy.			ORY, SJ (corresponding author), MAYO CLIN & MAYO FDN,DEPT OBSTET & GYNECOL,REPROD ENDOCRINOL & INFERTIL SECT,ROCHESTER,MN 55905, USA.							Bello G V, 1986, Obstet Gynecol Surv, V41, P603, DOI 10.1097/00006254-198610000-00001; BROWN DL, 1991, OBSTET GYNECOL, V77, P406; CARP HJA, 1986, J REPROD MED, V31, P119; COWAN BD, 1986, OBSTET GYNECOL, V67, pS50, DOI 10.1097/00006250-198603001-00015; DERICKSTAN JSE, 1987, EUR J OBSTET GYN R B, V25, P181, DOI 10.1016/0028-2243(87)90097-9; DEVOE RW, 1948, AM J OBSTET GYNECOL, V56, P1119, DOI 10.1016/S0002-9378(48)90357-3; DIMARCHI JM, 1987, OBSTET GYNECOL, V70, P555; DIMITRY ES, 1990, FERTIL STERIL, V53, P107; EGARTER C, 1989, GEBURTSHILFE FRAUNEN, V49, P807; FEICHTINGER W, 1987, LANCET, V1, P381; FOSSUM GT, 1988, FERTIL STERIL, V49, P788; GARCIA AJ, 1987, FERTIL STERIL, V48, P395; GELDER MS, 1991, FERTIL STERIL, V55, P497; HOTZ G, 1983, J SC MED ASS, V79, P16; KADAR N, 1981, OBSTET GYNECOL, V58, P162; KADAR N, 1981, OBSTET GYNECOL, V58, P156; KENIGSBERG D, 1987, FERTIL STERIL, V47, P702; LANG P, 1989, LANCET, V2, P922; LANGER R, 1990, FERTIL STERIL, V53, P227; LEACH RE, 1989, J REPROD MED, V34, P324; LINDBLOM B, 1988, LANCET, V1, P1403; MATTHEWS CP, 1986, OBSTET GYNECOL, V68, P390, DOI 10.1097/00006250-198609000-00021; MOLLOY D, 1990, FERTIL STERIL, V53, P1068; NAGAMANI M, 1984, AM J OBSTET GYNECOL, V149, P533, DOI 10.1016/0002-9378(84)90031-0; NOVY MJ, 1983, CONTEMP OBSTET GYNEC, V21, P91; ORY SJ, 1986, AM J OBSTET GYNECOL, V154, P1299, DOI 10.1016/0002-9378(86)90716-7; PANSKY M, 1991, AM J OBSTET GYNECOL, V164, P888, DOI 10.1016/0002-9378(91)90535-Y; PANSKY M, 1989, AM J OBSTET GYNECOL, V161, P393, DOI 10.1016/0002-9378(89)90529-2; PANSKY M, 1989, LANCET, V2, P9967; PAUERSTEIN CJ, 1986, OBSTET GYNECOL, V67, P301; PITTAWAY DE, 1985, FERTIL STERIL, V43, P529; ROBERTSON DE, 1987, LANCET, V1, P974; ROSE PG, 1990, OBSTET GYNECOL, V76, P947; SAUER MV, 1987, FERTIL STERIL, V48, P752; SHEPHERD RW, 1990, OBSTET GYNECOL, V75, P417; SHERMAN D, 1982, FERTIL STERIL, V37, P497; STOVALL TG, 1991, OBSTET GYNECOL, V77, P749; STOVALL TG, 1989, FERTIL STERIL, V51, P435; STOVALL TG, 1991, OBSTET GYNECOL, V77, P754; THORBURN J, 1988, FERTIL STERIL, V49, P595; TUOMIVAARA L, 1988, FERTIL STERIL, V50, P580; VERMESH M, 1989, OBSTET GYNECOL, V73, P400; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; 1988, MMWR, V39, P9	44	48	50	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					534	537		10.1001/jama.267.4.534	http://dx.doi.org/10.1001/jama.267.4.534			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1530874				2022-12-28	WOS:A1992GZ43900030
J	COE, FL; PARKS, JH; ASPLIN, JR				COE, FL; PARKS, JH; ASPLIN, JR			MEDICAL PROGRESS - THE PATHOGENESIS AND TREATMENT OF KIDNEY-STONES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CALCIUM-OXALATE NEPHROLITHIASIS; HEREDITARY HYPOPHOSPHATEMIC RICKETS; URIC-ACID NEPHROLITHIASIS; CRYSTAL-GROWTH INHIBITORS; URINARY CITRATE EXCRETION; RENAL TUBULAR-ACIDOSIS; BONE-MINERAL CONTENT; IDIOPATHIC HYPERCALCIURIA; PRIMARY HYPEROXALURIA; VITAMIN-D				COE, FL (corresponding author), UNIV CHICAGO, PRITZKER SCH MED, NEPHROL SECT, 5841 S MARYLAND AVE, MC 5100, CHICAGO, IL 60637 USA.				NIDDK NIH HHS [DK-083349] Funding Source: Medline; PHS HHS [P01-33949] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS ND, 1979, J CLIN ENDOCR METAB, V48, P1008, DOI 10.1210/jcem-48-6-1008; AHLSTRAND C, 1984, BRIT J UROL, V56, P255, DOI 10.1111/j.1464-410X.1984.tb05383.x; ANDERSSON H, 1974, GUT, V15, P360, DOI 10.1136/gut.15.5.360; ANDRES A, 1989, KIDNEY INT, V36, P96, DOI 10.1038/ki.1989.166; [Anonymous], 1988, JAMA, V260, P977; ASPLIN J, 1991, AM J PHYSIOL, V261, pF824, DOI 10.1152/ajprenal.1991.261.5.F824; BACKMAN U, 1979, BRIT J UROL, V51, P175, DOI 10.1111/j.1464-410X.1979.tb02860.x; BACKMAN U, 1980, J UROLOGY, V123, P9, DOI 10.1016/S0022-5347(17)55749-3; BARKIN J, 1985, MINER ELECTROL METAB, V11, P19; BATAILLE P, 1991, KIDNEY INT, V39, P1193, DOI 10.1038/ki.1991.151; BENSON L, 1987, AM J MED, V82, P731, DOI 10.1016/0002-9343(87)90008-8; BIANCHI G, 1988, NEW ENGL J MED, V319, P897, DOI 10.1056/NEJM198810063191402; BLACKLOCK NJ, 1974, BRIT J UROL, V46, P385, DOI 10.1111/j.1464-410X.1974.tb10176.x; BLUTE ML, 1988, J UROLOGY, V139, P510, DOI 10.1016/S0022-5347(17)42506-7; Brand E, 1930, J BIOL CHEM, V86, P315; BRETLAND PM, 1972, ACUTE URETERIC OBSTR, P1; BROADUS AE, 1984, NEW ENGL J MED, V311, P73, DOI 10.1056/NEJM198407123110201; BROCKS P, 1981, LANCET, V2, P124, DOI 10.1016/S0140-6736(81)90302-0; BROWN AJ, 1989, J CLIN INVEST, V84, P728, DOI 10.1172/JCI114229; BROWN CM, 1992, DISORDERS BONE MINER, P613; BUCKALEW VM, 1992, DISORDERS BONE MINER, P729; BUSHINSKY DA, 1988, J CLIN INVEST, V82, P1585, DOI 10.1172/JCI113770; CARUANA RJ, 1988, MEDICINE, V67, P84, DOI 10.1097/00005792-198803000-00002; Coe F. L., 1986, KIDNEY, V3rd, P1403; COE FL, 1980, KIDNEY INT, V17, P662, DOI 10.1038/ki.1980.205; COE FL, 1977, ANN INTERN MED, V87, P404, DOI 10.7326/0003-4819-87-4-404; COE FL, 1980, MINER ELECTROL METAB, V3, P268; COE FL, 1988, KIDNEY INT, V33, P1140, DOI 10.1038/ki.1988.122; COE FL, 1975, P SOC EXP BIOL MED, V149, P926; COE FL, 1982, AM J MED, V72, P25, DOI 10.1016/0002-9343(82)90567-8; COE FL, 1979, NEW ENGL J MED, V300, P337, DOI 10.1056/NEJM197902153000703; COE FL, 1980, ANN INTERN MED, V93, P60, DOI 10.7326/0003-4819-93-1-60; COE FL, 1973, J CLIN INVEST, V52, P134, DOI 10.1172/JCI107156; COE FL, 1976, J CHRON DIS, V29, P793, DOI 10.1016/0021-9681(76)90053-9; COE FL, 1984, AM J PHYSIOL, V247, pF1, DOI 10.1152/ajprenal.1984.247.1.F1; COE FL, 1978, KIDNEY INT, V13, P418, DOI 10.1038/ki.1978.60; COE FL, 1973, LANCET, V1, P129; COE FL, 1974, NEW ENGL J MED, V291, P1344; Coe FL, 1992, DISORDERS BONE MINER, P757; COE FL, 1988, NEPHROLITHIASIS PATH, P1; CONTE A, 1989, International Urology and Nephrology, V21, P369, DOI 10.1007/BF02559631; CRYER PE, 1975, ARCH INTERN MED, V135, P1610, DOI 10.1001/archinte.135.12.1610; DABBAGH S, 1989, MINER ELECTROL METAB, V15, P221; De Simone D, 1992, DISORDERS BONE MINER, P563; DEGANELLO S, 1983, N JB MINER MH, V6, P270; DENT CE, 1964, CLIN SCI, V27, P417; DOBBINS JW, 1976, GASTROENTEROLOGY, V70, P1096; DOWLING RH, 1971, LANCET, V1, P1103; DRENICK EJ, 1978, ANN INTERN MED, V89, P594, DOI 10.7326/0003-4819-89-5-594; ELOMAA I, 1984, J UROLOGY, V132, P656, DOI 10.1016/S0022-5347(17)49809-0; EMMERSON BT, 1990, KIDNEY INT, V37, P36, DOI 10.1038/ki.1990.5; ETTINGER B, 1988, J UROLOGY, V139, P679, DOI 10.1016/S0022-5347(17)42599-7; ETTINGER B, 1976, AM J MED, V61, P200, DOI 10.1016/0002-9343(76)90170-4; ETTINGER B, 1986, NEW ENGL J MED, V315, P1386, DOI 10.1056/NEJM198611273152204; FAVUS MJ, 1992, DISORDERS BONE MINER, P57; FINLAYSON B, 1979, INVEST UROL, V17, P227; GARDIN JP, 1984, MINER ELECTROL METAB, V10, P301; GAULT MH, 1991, MEDICINE, V70, P345, DOI 10.1097/00005792-199111000-00001; GEESON MJ, 1992, DISORDERS BONE MINER, P801; GELBART DR, 1977, ARCH INTERN MED, V137, P239, DOI 10.1001/archinte.137.2.239; GRAY RW, 1977, J CLIN ENDOCR METAB, V45, P299, DOI 10.1210/jcem-45-2-299; GRIFFITH DP, 1980, CONTEMP ISS NEPHROL, V5, P231; GROVER PK, 1990, CLIN SCI, V79, P9, DOI 10.1042/cs0790009; HALABE A, 1992, DISORDERS BONE MINER, P671; HALVERSON JD, 1978, AM J MED, V64, P461, DOI 10.1016/0002-9343(78)90233-4; HAYASHI Y, 1975, METABOLISM, V24, P1273, DOI 10.1016/0026-0495(75)90065-7; HEIDRICH FE, 1991, ANN INTERN MED, V115, P1, DOI 10.7326/0003-4819-115-1-1; HERRING LC, 1962, J UROLOGY, V88, P545, DOI 10.1016/S0022-5347(17)64842-0; HESS B, 1991, AM J PHYSIOL, V260, pF569, DOI 10.1152/ajprenal.1991.260.4.F569; HOSKING DH, 1985, J LAB CLIN MED, V106, P682; HOSKING DH, 1983, J UROLOGY, V130, P1115, DOI 10.1016/S0022-5347(17)51711-5; INSOGNA KL, 1989, J UROLOGY, V141, P269, DOI 10.1016/S0022-5347(17)40737-3; ITAMI N, 1990, NEPHRON, V56, P337, DOI 10.1159/000186167; JAEGER P, 1985, AM J NEPHROL, V5, P40, DOI 10.1159/000166901; KAPLAN RA, 1977, J CLIN INVEST, V59, P756, DOI 10.1172/JCI108696; KATHPALIA SC, 1984, J CLIN INVEST, V74, P805, DOI 10.1172/JCI111496; KATZ SM, 1988, NEW ENGL J MED, V319, P263, DOI 10.1056/NEJM198808043190502; KOK DJ, 1990, KIDNEY INT, V37, P51, DOI 10.1038/ki.1990.7; KRISTENSEN C, 1987, KIDNEY INT, V32, P749, DOI 10.1038/ki.1987.270; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LADENSON J H, 1991, Journal of Bone and Mineral Research, V6, pS33; LAERUM E, 1984, ACTA MED SCAND, V215, P383; LAW WM, 1985, ANN INTERN MED, V102, P511, DOI 10.7326/0003-4819-102-4-511; LAWOYIN S, 1979, METABOLISM, V28, P1250, DOI 10.1016/0026-0495(79)90139-2; LEMANN J, 1989, KIDNEY INT, V35, P688, DOI 10.1038/ki.1989.40; LEMANN J, 1991, KIDNEY INT, V39, P973, DOI 10.1038/ki.1991.123; Lemann Jr J, 1992, DISORDERS BONE MINER, P685; LINGEMAN JE, 1989, J UROLOGY, V141, P793, DOI 10.1016/S0022-5347(17)41012-3; LINGEMAN JE, 1992, DISORDERS BONE MINER, P625; MAIERHOFER WJ, 1984, KIDNEY INT, V26, P752, DOI 10.1038/ki.1984.212; MALLETTE LE, 1987, AM J MED, V83, P1157, DOI 10.1016/0002-9343(87)90960-0; MALLUCHE HH, 1980, J CLIN ENDOCR METAB, V50, P654, DOI 10.1210/jcem-50-4-654; MARTENSSON J, 1990, KIDNEY INT, V37, P143, DOI 10.1038/ki.1990.20; MARX SJ, 1985, AM J MED, V78, P15, DOI 10.1016/0002-9343(85)90455-3; MASCHIO G, 1981, AM J MED, V71, P623, DOI 10.1016/0002-9343(81)90215-1; MEHES K, 1980, EUR J PEDIATR, V133, P239, DOI 10.1007/BF00496083; MILLMAN S, 1982, KIDNEY INT, V22, P366, DOI 10.1038/ki.1982.183; MINISOLA S, 1989, MINER ELECTROL METAB, V15, P303; NAKAGAWA Y, 1987, J CLIN INVEST, V79, P1782, DOI 10.1172/JCI113019; NAKAGAWA Y, 1985, J CLIN INVEST, V76, P1455, DOI 10.1172/JCI112124; NIKKILA M, 1989, EUR UROL, V16, P382; OTNES B, 1983, SCAND J UROL NEPHROL, P1; PACIFICI R, 1985, CALCIFIED TISSUE INT, V37, P467, DOI 10.1007/BF02557828; PAK CYC, 1979, INVEST UROL, V17, P146; PAK CYC, 1980, AM J MED, V69, P19, DOI 10.1016/0002-9343(80)90495-7; PAK CYC, 1986, ANN INTERN MED, V104, P33, DOI 10.7326/0003-4819-104-1-33; PAK CYC, 1980, MINER ELECTROL METAB, V4, P130; PAK CYC, 1985, AM J MED, V79, P284, DOI 10.1016/0002-9343(85)90305-5; PAK CYC, 1979, INVEST UROL, V17, P138; PAK CYC, 1978, AM J MED, V65, P593, DOI 10.1016/0002-9343(78)90846-X; PAK CYC, 1974, NEW ENGL J MED, V290, P175, DOI 10.1056/NEJM197401242900401; PAK CYC, 1981, AM J MED, V71, P615, DOI 10.1016/0002-9343(81)90214-X; PARKS J, 1980, ARCH INTERN MED, V140, P1479, DOI 10.1001/archinte.140.11.1479; PARKS JH, 1986, KIDNEY INT, V30, P85, DOI 10.1038/ki.1986.155; PARKS JH, 1982, NEW ENGL J MED, V306, P1088, DOI 10.1056/NEJM198205063061805; PORTALE AA, 1989, J CLIN INVEST, V83, P1494, DOI 10.1172/JCI114043; POTTS JT, 1991, ANN INTERN MED, V114, P593, DOI 10.7326/0003-4819-114-7-593; PREMINGER GM, 1988, J UROLOGY, V139, P240, DOI 10.1016/S0022-5347(17)42374-3; RIESE RJ, 1988, AM J PHYSIOL, V255, pF1025, DOI 10.1152/ajprenal.1988.255.5.F1025; RUDMAN D, 1982, J CLIN ENDOCR METAB, V55, P1052, DOI 10.1210/jcem-55-6-1052; SAKHAEE K, 1991, J CLIN ENDOCR METAB, V72, P396, DOI 10.1210/jcem-72-2-396; SCHEINMAN JI, 1991, KIDNEY INT, V40, P389, DOI 10.1038/ki.1991.224; SCHOLZ D, 1982, J UROLOGY, V128, P903, DOI 10.1016/S0022-5347(17)53269-3; SEGAL S, 1983, METABOLIC BASIS INHE, P1774; SEGURA JW, 1989, J UROLOGY, V141, P780, DOI 10.1016/S0022-5347(17)41009-3; SHEN FH, 1982, ANN INTERN MED, V96, P63, DOI 10.7326/0003-4819-96-1-63; SHEN FH, 1977, J LAB CLIN MED, V90, P955; SHIMIZU T, 1991, AM J PHYSIOL, V261, pF36, DOI 10.1152/ajprenal.1991.261.1.F36; SHIRAGA H, 1992, P NATL ACAD SCI USA, V89, P426, DOI 10.1073/pnas.89.1.426; SMITH LH, 1972, NEW ENGL J MED, V286, P1371, DOI 10.1056/NEJM197206292862601; SMITH LH, 1973, URINARY CALCULI, P188; SMITH LH, 1992, DISORDERS BONE MINER, P707; SPERLING O, 1974, ANN INTERN MED, V80, P482, DOI 10.7326/0003-4819-80-4-482; SUTHERLAND JW, 1985, MINER ELECTROL METAB, V11, P267; TIEDER M, 1987, NEW ENGL J MED, V316, P125, DOI 10.1056/NEJM198701153160302; TIEDER M, 1988, NEW ENGL J MED, V319, P845, DOI 10.1056/NEJM198809293191307; VAINDER M, 1976, JAMA-J AM MED ASSOC, V235, P1257, DOI 10.1001/jama.235.12.1257; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605; WATTS RWE, 1991, AM J MED, V90, P179; WHARTON R, 1990, CLIN NEPHROL, V34, P116; WILLIAMS JJ, 1984, NEW ENGL J MED, V311, P760, DOI 10.1056/NEJM198409203111203; WILSON DR, 1984, UROL RES, V12, P39; WORCESTER EM, 1986, J CLIN INVEST, V77, P1888, DOI 10.1172/JCI112516; WORCESTER EM, 1988, AM J PHYSIOL, V255, pF1197, DOI 10.1152/ajprenal.1988.255.6.F1197; Yanagawa N, 1992, DISORDERS BONE MINER, P3; YENDT ER, 1985, NEW ENGL J MED, V312, P953, DOI 10.1056/NEJM198504113121504; ZERWEKH JE, 1983, KIDNEY INT, V23, P838, DOI 10.1038/ki.1983.103	148	547	566	0	64	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1992	327	16					1141	1152		10.1056/NEJM199210153271607	http://dx.doi.org/10.1056/NEJM199210153271607			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT153	1528210				2022-12-28	WOS:A1992JT15300007
J	LAW, PK				LAW, PK			MYOBLAST TRANSPLANTATION	SCIENCE			English	Letter											LAW, PK (corresponding author), CELL THERAPY RES FDN,1770 MORIAH WOODS BLVD,SUITE 18,MEMPHIS,TN 38117, USA.		Pagel, Charles N/A-8890-2014	Pagel, Charles N/0000-0002-7844-2242				1992, SCIENCE, V257, P472	1	3	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1329	1329		10.1126/science.1529326	http://dx.doi.org/10.1126/science.1529326			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529326				2022-12-28	WOS:A1992JL61200002
J	YEW, PR; BERK, AJ				YEW, PR; BERK, AJ			INHIBITION OF P53 TRANSACTIVATION REQUIRED FOR TRANSFORMATION BY ADENOVIRUS EARLY 1B-PROTEIN	NATURE			English	Article							E1B-58KD TUMOR-ANTIGEN; MONOCLONAL-ANTIBODIES; CELLULAR P53; VIRAL-DNA; CELLS; PROTEIN; LOCALIZATION; ASSOCIATION; ACTIVATION; EXPRESSION	THE cellular phosphoprotein p53 inhibits progression through the mammalian cell cycle 1,2. Both p53 alleles are frequently mutated in human tumours 3,4, indicating that p53 is a tumour suppressor. Recent studies have suggested that p53 functions as a transcriptional activator 5-8, but the significance of this activity in cell-cycle control has not been established. The adenovirus 2 (Ad2) early 1B (E1B) 55K protein binds to p53 in transformed cells 9 and contributes to oncogenic transformation by Ad2 (refs 10-12). Here we report that mutants of E1B 55K and wild-type Ad12 E1B 54K proteins show a strong correlation between their ability to inhibit p53-mediated transcriptional activation and their ability to cooperate with adenovirus E1A protein in the transformation of primary cells. These results indicate that p53 probably inhibits cell cycling by functioning as a transcription factor.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	YEW, PR (corresponding author), UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024, USA.		BERK, ARNOLD/AAF-7052-2020					BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BYRD PJ, 1988, VIROLOGY, V163, P155, DOI 10.1016/0042-6822(88)90242-5; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAK I, 1986, BIOCHEM CELL BIOL, V64, P256, DOI 10.1139/o86-036; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; OROURKE RW, 1990, ONCOGENE, V5, P1829; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STILLMAN B, 1986, CANCER SURV, V5, P389; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	29	538	558	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					82	85		10.1038/357082a0	http://dx.doi.org/10.1038/357082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1533443				2022-12-28	WOS:A1992HT22900064
J	WEISS, KB; GERGEN, PJ; HODGSON, TA				WEISS, KB; GERGEN, PJ; HODGSON, TA			AN ECONOMIC-EVALUATION OF ASTHMA IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHANGING PATTERNS; CHILDHOOD ASTHMA; HOSPITALIZATION; CHILDREN; MORTALITY; COST	Background. Asthma is a common chronic illness. Recently, increases in morbidity and mortality due to this disease have been reported. We studied the distribution of health care resources used for asthma in order to lay the groundwork for further policy decisions aimed at reducing the economic burden of this disorder. Methods. Estimates of direct medical expenditures and indirect costs (in 1985 dollars) were derived from data available from the National Center for Health Statistics. These cost estimates were projected to 1990 dollars. Results. The cost of illness related to asthma in 1990 was estimated to be $6.2 billion. Inpatient hospital services represented the largest single direct medical expenditure for this chronic condition, approaching $1.6 billion. The value of reduced productivity due to loss of school days represented the largest single indirect cost, approaching $1 billion in 1990. Although asthma is often considered to be a mild chronic illness treatable with ambulatory care, we found that 43 percent of its economic impact was associated with emergency room use, hospitalization, and death. Nearly two thirds of the visits for ambulatory care were to physicians in three primary care specialties - pediatrics, family medicine or general practice, and internal medicine. Conclusions. Potential reductions in the costs related to asthma in the United States may be identified through a closer examination of the effectiveness of care associated with each category of cost. Future health policy efforts to improve the effectiveness of primary care interventions for asthma in the ambulatory setting may reduce the costs of this common illness.	GEORGE WASHINGTON UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20037; GEORGE WASHINGTON UNIV,CTR HLTH POLICY RES,WASHINGTON,DC 20052; NIAID,DIV ALLERGY IMMUNOL & TRANSPLANTAT,BETHESDA,MD 20892; CTR DIS CONTROL,NATL CTR HLTH STAT,OFF ANAL & EPIDEMIOL,HYATTSVILLE,MD	George Washington University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	WEISS, KB (corresponding author), GEORGE WASHINGTON UNIV,MED CTR,DEPT HLTH CARE SCI,RM 2B-401,2150 PENN AVE NW,WASHINGTON,DC 20037, USA.		Fahimifar, Sepideh/M-5303-2019					CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; COOPER B, 1976, EC COSTS SELECTED RE; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GONZALEZ ML, 1988, SOCIOECONOMIC CHARAC; HODGSON TA, 1982, MILBANK FUND Q, V60, P429, DOI 10.2307/3349801; HODGSON TA, 1984, 4TH P NAT C HUM VAL, P147; HUGHES DM, 1991, PEDIATRICS, V87, P54; MAX W, 1990, INQUIRY-J HEALTH CAR, V27, P332; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; Rice D P, 1985, Health Care Financ Rev, V7, P61; RICE DP, 1989, CANCER CARE AND COST, P39; Rice DP, 1989, COST INJURY US REPOR; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; VANCE VJ, 1971, ANN ALLERGY, V29, P455; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; 1983, VITAL HLTH STATIS 10, V154; 1986, VITAL HLTH STATIS 13, V96; 1988, VITAL HLTH STATIST 2, V108; 1985, VITAL HLTH STATIS 13, V91; 1991, NIH910342A NAT ASTH; 1989, PHYSICIANS DESK REFE; 1983, VITAL HLTH STATIS 13, V83; 1987, EMPLOY EARN, V34, P214; 1970, VITAL HLTH STATIST 2, V39; 1986, HOSPITAL STATISTICS; 1983, DHHS PHS832001 PUBL; 1988, DHHS PHS8811012 PUBL; 1989, DRUG TOPICS RED BOOK; 1987, VITAL HLTH STATIS 10, V166; 1987, VITAL HLTH STATIS 13, V99; 1984, VITAL HLTH STATIS 13, V84; 1988, VITAL HLTH STATIS 13, V93; 1989, EMPLOY EARN, V36, P227; 1990, HLTH CARE FINANC REV, V11, P1; 1973, VITAL HLTH STATIST 2, V54; 1980, IOM8002 I MED NAT AC; 1990, SOC SECUR B, V53, P74	41	802	811	0	57	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1992	326	13					862	866		10.1056/NEJM199203263261304	http://dx.doi.org/10.1056/NEJM199203263261304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK523	1542323				2022-12-28	WOS:A1992HK52300004
J	KORNHAUSER, JM; NELSON, DE; MAYO, KE; TAKAHASHI, JS				KORNHAUSER, JM; NELSON, DE; MAYO, KE; TAKAHASHI, JS			REGULATION OF JUN-B MESSENGER-RNA AND AP-1 ACTIVITY BY LIGHT AND A CIRCADIAN CLOCK	SCIENCE			English	Article							TRANSCRIPTION FACTOR AP-1; IMMEDIATE EARLY GENES; C-FOS; SUPRACHIASMATIC NUCLEUS; GROWTH-FACTORS; PROTEIN-SYNTHESIS; NERVOUS-SYSTEM; EXPRESSION; RHYTHMS; ONCOGENE	The suprachiasmatic nuclei (SCN) of the hypothalamus comprise the primary pacemaker responsible for generation of circadian rhythms in mammals. Light stimuli that synchronize this circadian clock induce expression of the c-fos gene in rodent SCN, which suggests a possible role for Fos in circadian entrainment. Appropriate light stimuli also induce the expression of jun-B messenger RNA in the SCN of golden hamsters but only slightly elevate c-jun messenger RNA levels. In addition, tight increases the amount of a protein complex in the SCN that binds specifically to sites on DNA known to mediate regulation by the AP-1 transcription factor. The photic regulation of both jun-B messenger RNA expression and AP-1 binding activity is dependent on circadian phase: only tight stimuli that shift behavioral rhythms induce jun-B and AP-1 expression. Thus, tight and the circadian pacemaker interact to regulate a specific set of immediate-early genes in the SCN that may participate in entrainment of the circadian clock.	NORTHWESTERN UNIV, INST NEUROSCI, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, EVANSTON, IL 60208 USA	Northwestern University; Northwestern University; Northwestern University			Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012	Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878				ABE H, 1991, NEUROSCI LETT, V127, P9, DOI 10.1016/0304-3940(91)90881-S; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CARD JP, 1984, NEUROSCIENCE, V13, P415, DOI 10.1016/0306-4522(84)90240-9; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COLWELL CS, 1990, BRAIN RES, V523, P117, DOI 10.1016/0006-8993(90)91643-U; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DUNLAP JC, 1990, TRENDS GENET, V6, P159, DOI 10.1016/0168-9525(90)90151-U; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; INOUYE ST, 1988, AM J PHYSIOL, V255, pR1055, DOI 10.1152/ajpregu.1988.255.6.R1055; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIU X, INPRESS J NEUROSCI; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; LOROS JJ, 1991, MOL CELL BIOL, V11, P558, DOI 10.1128/MCB.11.1.558; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; MOORE RY, 1973, BRAIN RES, V49, P403, DOI 10.1016/0006-8993(73)90431-9; MOORE RY, 1983, FED PROC, V42, P2783; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORSE DS, 1990, TRENDS BIOCHEM SCI, V15, P262, DOI 10.1016/0968-0004(90)90050-L; NAGY F, 1988, GENE DEV, V2, P376, DOI 10.1101/gad.2.4.376; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REA MA, 1989, BRAIN RES BULL, V23, P577, DOI 10.1016/0361-9230(89)90204-9; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; RUSAK B, 1979, PHYSIOL REV, V59, P449, DOI 10.1152/physrev.1979.59.3.449; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; TAKAHASHI JS, 1987, BRAIN RES, V405, P199, DOI 10.1016/0006-8993(87)91010-9; UHL GR, 1986, SCIENCE, V232, P390, DOI 10.1126/science.3961487; WOLLNIK F, 1989, BRAIN RES, V496, P82, DOI 10.1016/0006-8993(89)91053-6; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZWIEBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882, DOI 10.1073/pnas.88.9.3882	52	206	206	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1992	255	5051					1581	1584		10.1126/science.1549784	http://dx.doi.org/10.1126/science.1549784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1549784				2022-12-28	WOS:A1992HJ80900044
J	LEAHY, DJ; AXEL, R; HENDRICKSON, WA				LEAHY, DJ; AXEL, R; HENDRICKSON, WA			CRYSTAL-STRUCTURE OF A SOLUBLE FORM OF THE HUMAN T-CELL CORECEPTOR CD8 AT 2.6 A-RESOLUTION	CELL			English	Article							BENCE-JONES PROTEIN; SURFACE-ANTIGEN T8; CLASS-I MOLECULES; 3-DIMENSIONAL STRUCTURE; MHC CLASS; CRYSTALLOGRAPHIC REFINEMENT; 2.0-A RESOLUTION; ALPHA-3 DOMAIN; LYMPHOCYTES-T; KINASE P56LCK	A secreted fragment of the extracellular portion of human CD8-alpha has been expressed in CHO cells, and a deglycosylated and proteolyzed form of this fragment has been crystallized. We report here the crystal structure of this fragment as refined at 2.6 angstrom resolution. The structure was solved by molecular replacement using a superposition of ten variable domains from immunoglobulin light chains as the search model. Only the N-terminal 114 amino acids of CD8-alpha are visible in the electron density maps. The domain formed by these residues possesses a fold typical of immunoglobulin variable domains and associates to form F(v)-Like homodimers.	COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	LEAHY, DJ (corresponding author), COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.			Axel, Richard/0000-0002-3141-4076	PHS HHS [5-31294-3600] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BILDERBACK D, 1988, NUCL INSTRUM METH A, V266, P636, DOI 10.1016/0168-9002(88)90457-3; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLITHE DL, 1989, ENDOCRINOLOGY, V125, P2267, DOI 10.1210/endo-125-5-2267; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BRUNGER AT, 1991, J MOL BIOL, V221, P239, DOI 10.1016/0022-2836(91)90817-P; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1990, XPLOR MANUAL; CHANG CH, 1985, BIOCHEMISTRY-US, V24, P4890, DOI 10.1021/bi00339a025; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; Clare Speakman J., 1972, STRUCTURE BONDING, P141; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; FUREY W, 1983, J MOL BIOL, V167, P661, DOI 10.1016/S0022-2836(83)80104-1; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIRSZBAUM L, 1989, J IMMUNOL, V142, P3931; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MACPHERSON A, 1982, PREPARATION ANAL PRO, P94; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; PETERS D, 1981, J MOL STRUCT, V85, P107; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; RAO SN, 1980, ACTA CRYSTALLOGR A, V36, P878, DOI 10.1107/S0567739480001854; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; ROSENSTEIN Y, 1989, J EXP MED, V169, P149, DOI 10.1084/jem.169.1.149; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SANDERS SK, 1991, J EXP MED, V174, P371, DOI 10.1084/jem.174.2.371; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SAWYER L, 1982, NATURE, V295, P79, DOI 10.1038/295079a0; SCHIFFER M, 1973, BIOCHEMISTRY-US, V12, P4620, DOI 10.1021/bi00747a013; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SNOW PM, 1984, J IMMUNOL, V133, P2058; SNOW PM, 1985, J BIOL CHEM, V260, P2700; SNOW PM, 1985, EUR J IMMUNOL, V15, P529, DOI 10.1002/eji.1830150520; SUH S W, 1986, Proteins Structure Function and Genetics, V1, P74, DOI 10.1002/prot.340010112; SUKHATME VP, 1985, CELL, V40, P591, DOI 10.1016/0092-8674(85)90207-7; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TERRY LA, 1990, TISSUE ANTIGENS, V35, P82, DOI 10.1111/j.1399-0039.1990.tb01761.x; THOMAS DB, 1969, J BIOL CHEM, V244, P5943; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	74	254	265	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1145	1162		10.1016/0092-8674(92)90085-Q	http://dx.doi.org/10.1016/0092-8674(92)90085-Q			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547508				2022-12-28	WOS:A1992HK67400017
J	GUTHRIE, S; MUCHAMORE, I; KUROIWA, A; MARSHALL, H; KRUMLAUF, R; LUMSDEN, A				GUTHRIE, S; MUCHAMORE, I; KUROIWA, A; MARSHALL, H; KRUMLAUF, R; LUMSDEN, A			NEUROECTODERMAL AUTONOMY OF HOX-2.9 EXPRESSION REVEALED BY RHOMBOMERE TRANSPOSITIONS	NATURE			English	Article							CHICK HINDBRAIN; MOUSE HINDBRAIN; HOMEOTIC GENES; DROSOPHILA; SEGMENTATION; ANTERIOR; XENOPUS; ORGANIZATION; INDUCTION; PROTEIN	INVOLVEMENT of the Hox genes in regional specifications of the vertebrate body axis is suggested by sequence similarity with the homeotic selector genes of Drosophila, the conservation of a collinear relationship between genomic organization and site of expression, and mutational analysis 1-5. Subdivision of vertebrate embryo hindbrain neuroepithelium into lineage compartments 6 (rhombomeres 7,8) underlies segmental patterning of neuronal differentiation 9. The rhombomere boundaries delimit domains of expression of Hox genes 10-12, presumed to be determinants of rhombomere phenotype, suggesting that Hox genes confer positional value 13; the formation of rhombomere 4 (r4) is followed by strong expression of Hox-2.9 within its confines 14. If the Hox genes are determinants, their expression should be autonomous from the developmental stage at which regional commitment becomes fixed and irreversible. We have transplanted the future r4 region (from state-9-chick embryos) into the more anterior position of r2 and probed for Hox-2.9 transcripts. We report here that Hox-2.9 was expressed in the ectopic r4 as strongly as in the normal r4, whereas reciprocal grafts of future r2 to r4 position did not express Hox-2.9. The phenotype of ectopic rhombomeres developed according to their original position, as demonstrated by retrograde tracing of efferent cranial nerve nuclei. As early as stage-9 - (six somites), both Hox-2.9 expression and segment identity are autonomous in the chick embryo hindbrain, independent both of position in the neuroepithelium and of signals from the underlying mesoderm 15.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV ANAT & CELL BIOL,MRC,LONDON SE1 9RT,ENGLAND; NATL INST MED RES,LONDON NW7 1AA,ENGLAND; TOHOKU UNIV,DEPT CELL BIOL,SENDAI,MIYAGI 980,JAPAN	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; MRC National Institute for Medical Research; Tohoku University			Lumsden, Andrew/C-5146-2009; Guthrie, Sarah C/C-5727-2009; Krumlauf, Robb/AAH-5012-2019	Krumlauf, Robb/0000-0001-9102-7927; Kuroiwa, Atsushi/0000-0001-7710-4041; Muchamore, Ian/0000-0003-2121-1539				AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ALTABA ARI, 1990, DEVELOPMENT, V108, P595; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Graper L, 1913, ARCH MIKROSK ANAT, V83, P371; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARDING K, 1985, SCIENCE, V229, P1236, DOI 10.1126/science.3898362; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HOLTFRETER J, 1936, W ROUX ARCH ENT MECH, V134, P446; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MADEN M, 1991, DEVELOPMENT, V111, P35; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0	27	153	155	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					157	159		10.1038/356157a0	http://dx.doi.org/10.1038/356157a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545869				2022-12-28	WOS:A1992HH73100061
J	SHIMOZAWA, N; TSUKAMOTO, T; SUZUKI, Y; ORII, T; SHIRAYOSHI, Y; MORI, T; FUJIKI, Y				SHIMOZAWA, N; TSUKAMOTO, T; SUZUKI, Y; ORII, T; SHIRAYOSHI, Y; MORI, T; FUJIKI, Y			A HUMAN GENE RESPONSIBLE FOR ZELLWEGER SYNDROME THAT AFFECTS PEROXISOME ASSEMBLY	SCIENCE			English	Article							DISORDERS; COMPLEMENTATION; HETEROGENEITY; BIOGENESIS; GHOSTS; DNA	The primary defect arising from Zellweger syndrome appears to be linked to impaired assembly of peroxisomes. A human complementary DNA has been cloned that complements the disease's symptoms (including defective peroxisome assembly) in fibroblasts from a patient with Zellweger syndrome. The cause of the syndrome in this patient was a point mutation that resulted in the premature termination of peroxisome assembly factor-1. The homozygous patient apparently inherited the mutation from her parents, each of whom was heterozygous for that mutation.	GIFU UNIV,SCH MED,DEPT PEDIAT,GIFU 500,JAPAN; MEIJI INST HLTH SCI,ODAWARA,KANAGAWA 250,JAPAN	Gifu University								BOWEN P, 1964, B JOHNS HOPKINS HOSP, V114, P402; BRUL S, 1988, J CLIN INVEST, V81, P1710, DOI 10.1172/JCI113510; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P1087; ROSCHER AA, 1989, PEDIATR RES, V26, P67, DOI 10.1203/00006450-198907000-00019; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SHIMOZAWA N, UNPUB; SUZUKI Y, 1990, CELL STRUCT FUNCT, V15, P301, DOI 10.1247/csf.15.301; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; WANDERS RJA, 1988, J NEUROL SCI, V88, P1, DOI 10.1016/0022-510X(88)90203-1; WIEMER EAC, 1989, EUR J CELL BIOL, V50, P407; YAJIMA S, IN PRESS HUM GENET; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872	20	309	314	2	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1132	1134		10.1126/science.1546315	http://dx.doi.org/10.1126/science.1546315			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546315				2022-12-28	WOS:A1992HF63200043
J	DAWES, MG; GREEN, J; ASHURST, H				DAWES, MG; GREEN, J; ASHURST, H			FOR DEBATE - ROUTINE WEIGHING IN PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; MATERNAL WEIGHT; GAIN; WOMEN; TERM		NATL PERINATAL EPIDEMIOL UNIT,OXFORD,ENGLAND	University of Oxford				Dawes, Martin/0000-0003-3624-2477				ABRAMS BF, 1986, AM J OBSTET GYNECOL, V154, P503, DOI 10.1016/0002-9378(86)90591-0; ALTMAN DG, 1989, EFFECTIVE CARE PREGN, V1, P411; BILLEWICZ NZ, 1970, BR J PREV SOC MED, V24, P97; Campbell DM, 1983, NUTR PREGNANCY, P243; CEDERLOF R, 1970, ACTA PSYCHIAT SCAND, V219, P47; Chalmers I, 1989, EFFECTIVE CARE PREGN, P1465; DAWES MG, 1991, BRIT J OBSTET GYNAEC, V98, P189, DOI 10.1111/j.1471-0528.1991.tb13367.x; DAWES MG, 1991, BRIT J OBSTET GYNAEC, V98, P195, DOI 10.1111/j.1471-0528.1991.tb13368.x; GREEN J, 1989, EFFECTIVE CARE PREGN, V1, P281; GREENE GW, 1988, OBSTET GYNECOL, V71, P702; HAIEK L, 1989, J ADOLESCENT HEALTH, V10, P16, DOI 10.1016/0197-0070(89)90041-7; HERINGA M, 1988, EUR J OBSTET GYN R B, V28, P7; HYTTEN FE, 1979, J HUM NUTR, V33, P461; Hytten FE, 1980, CLIN PHYSL OBSTET, P193; LORIS P, 1985, J AM DIET ASSOC, V85, P1296; MACINTYRE S, 1983, SOCIOLOGY FOOD EATIN, P57; MOHIDE P, 1989, EFFECTIVE CARE PREGN, V1, P6; MOLLER B, 1989, BRIT J OBSTET GYNAEC, V96, P158, DOI 10.1111/j.1471-0528.1989.tb01655.x; NEWCOMBE RG, 1982, J EPIDEMIOL COMMUN H, V36, P306, DOI 10.1136/jech.36.4.306; ORR RD, 1979, J AM DIET ASSOC, V75, P126; ORSTEAD C, 1985, J AM DIET ASSOC, V85, P40; PALMER JL, 1985, J AM DIET ASSOC, V85, P946; REDMAN CWG, 1988, LANCET, V1, P809; ROOKUS MA, 1987, INT J OBESITY, V11, P609; SAMRA JS, 1988, LANCET, V2, P1420; SEIDMAN DS, 1989, OBSTET GYNECOL, V74, P240; TAFFEL SM, 1986, AM J PUBLIC HEALTH, V76, P1396, DOI 10.2105/AJPH.76.12.1396; THOMSON AM, 1957, BMJ-BRIT MED J, V1, P243, DOI 10.1136/bmj.1.5013.243; WALLENBURG HCS, 1989, EFFECTIVE CARE PREGN, V1, P382	29	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					487	489		10.1136/bmj.304.6825.487	http://dx.doi.org/10.1136/bmj.304.6825.487			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547424	Green Published, Bronze			2022-12-28	WOS:A1992HF55500027
J	STEWART, EJ; CINNAMOND, MJ; SIDDIQUI, R; NICHOLLS, DP; STANFORD, CF				STEWART, EJ; CINNAMOND, MJ; SIDDIQUI, R; NICHOLLS, DP; STANFORD, CF			EFFECT OF A HEAT AND MOISTURE RETAINING MASK ON EXERCISE INDUCED ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL VICTORIA HOSP,DEPT RESP MED,WARD 1,BELFAST BT12 6BA,NORTH IRELAND; QUEENS UNIV BELFAST,BELFAST CITY HOSP,DEPT OTOLARYNGOL,BELFAST BT9 7AB,ANTRIM,NORTH IRELAND	Belfast City Hospital; Queens University Belfast								ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; CHANYEUNG M, 1977, CHEST, V71, P320, DOI 10.1378/chest.71.3.320; CHEN WY, 1977, RESPIRATION, V34, P305, DOI 10.1159/000193842; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; 1987, J MED ENG TECHNOL, V11, P117	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					479	480		10.1136/bmj.304.6825.479	http://dx.doi.org/10.1136/bmj.304.6825.479			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547419	Bronze, Green Published			2022-12-28	WOS:A1992HF55500022
J	BJORCK, S; MULEC, H; JOHNSEN, SA; NORDEN, G; AURELL, M				BJORCK, S; MULEC, H; JOHNSEN, SA; NORDEN, G; AURELL, M			RENAL PROTECTIVE EFFECT OF ENALAPRIL IN DIABETIC NEPHROPATHY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INSULIN-DEPENDENT DIABETICS; ANTIHYPERTENSIVE TREATMENT; KIDNEY-FUNCTION; ANGIOTENSIN-II; BLOOD-PRESSURE; CAPTOPRIL; PROGRESSION; HYDROCHLOROTHIAZIDE	Objective - To determine whether inhibition of angiotensin converting enzyme can reduce the rate of decline in kidney function more than reducing blood pressure with other antihypertensive treatment. Design - Prospective, open randomised study lasting a mean of 2.2 years in patients with diabetic nephropathy. Setting - Three outpatient nephrology clinics. Patients - 40 patients with insulin dependent diabetes and diabetic nephropathy with reduced renal function. Intervention - Antihypertensive treatment with enalapril or metoprolol, usually combined with frusemide. Main outcome measure - Rate of decline in glomerular filtration rate measured as chromium-51 edetic acid clearance. Results - Glomerular filtration rate declined a mean of 2.0 (SD 3.2) ml/min/year in the group given enalapril and 5.6 (5.9) ml/min/year in the control group. The mean arterial blood pressure during the study was 102 (5) mm Hg in the patients given enalapril and 103 (5) mm Hg in the patients given metoprolol. Urinary albumin excretion during treatment with enalapril was 60% lower than during treatment with metoprolol. Conclusion - Enalapril has an antiproteinuric effect independent of the effect on systemic blood pressure. Treatment with enalapril can reduce the rate of decline in kidney function in patients with diabetic nephropathy more than equally effective antihypertensive treatment with metoprolol. This points to a specific renal protective effect of angiotensin converting enzyme inhibitors in diabetic nephropathy.	NO ALVSBORG HOSP, DEPT NEPHROL, TROLLHATTAN, SWEDEN; BORAS HOSP, DEPT NEPHROL, BORAS, SWEDEN		BJORCK, S (corresponding author), GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT NEPHROL, S-41345 GOTHENBURG, SWEDEN.							ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; BILO HJG, 1988, DIABETES RES CLIN EX, V9, P21; BJORCK S, 1986, BMJ-BRIT MED J, V293, P471, DOI 10.1136/bmj.293.6545.471; BJORCK S, 1990, BMJ-BRIT MED J, V300, P904, DOI 10.1136/bmj.300.6729.904; BJORCK S, 1983, HYPERTENSION, V5, P152; CHENG I K P, 1990, International Urology and Nephrology, V22, P295, DOI 10.1007/BF02550409; CHRISTENSEN CK, 1985, HYPERTENSION, V7, P109; CHRISTIANSEN JS, 1984, DAN MED BULL, V31, P349; GRANERUS G, 1981, SCAND J CLIN LAB INV, V41, P611, DOI 10.3109/00365518109090505; HEEG JE, 1989, KIDNEY INT, V36, P272, DOI 10.1038/ki.1989.190; HERLITZ H, 1988, INT ARCH ALLER A IMM, V85, P272, DOI 10.1159/000234517; HOMMEL E, 1986, DIABETOLOGIA, V29, P211, DOI 10.1007/BF00454877; IKEDA I, 1982, J CLIN ENDOCR METAB, V54, P423, DOI 10.1210/jcem-54-2-423; KAMPER AL, 1990, SCAND J CLIN LAB INV, V50, P611, DOI 10.3109/00365519009089178; KAPPELGAARD AM, 1976, CLIN CHIM ACTA, V67, P299; KASISKE BL, 1990, KIDNEY INT, V37, P880, DOI 10.1038/ki.1990.62; KEANE WF, 1988, AM J CLIN NUTR, V47, P157, DOI 10.1093/ajcn/47.1.157; KEANE WF, 1985, LAB INVEST, V52, P599; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MULEC H, 1990, LANCET, V335, P1537, DOI 10.1016/0140-6736(90)93090-C; NEELS HM, 1982, CLIN CHEM, V28, P1352; Norden G, 1988, J Diabet Complications, V2, P203, DOI 10.1016/S0891-6632(88)80009-6; Nyberg G, 1987, J Diabet Complications, V1, P37, DOI 10.1016/S0891-6632(87)80077-6; PARVING HH, 1989, BRIT MED J, V299, P230, DOI 10.1136/bmj.299.6693.230; PARVING HH, 1989, BMJ-BRIT MED J, V299, P533, DOI 10.1136/bmj.299.6698.533; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; PARVING HH, 1988, BRIT MED J, V297, P1086, DOI 10.1136/bmj.297.6656.1086; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; YOSHIDA Y, 1989, KIDNEY INT, V36, P626, DOI 10.1038/ki.1989.239; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202	30	434	435	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 8	1992	304	6823					339	343		10.1136/bmj.304.6823.339	http://dx.doi.org/10.1136/bmj.304.6823.339			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540729	Green Published, Bronze			2022-12-28	WOS:A1992HD38700020
J	QUINN, DA; THOMPSON, BT; TERRIN, ML; THRALL, JH; ATHANASOULIS, CA; MCKUSICK, KA; STEIN, PD; HALES, CA				QUINN, DA; THOMPSON, BT; TERRIN, ML; THRALL, JH; ATHANASOULIS, CA; MCKUSICK, KA; STEIN, PD; HALES, CA			A PROSPECTIVE INVESTIGATION OF PULMONARY-EMBOLISM IN WOMEN AND MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL-CONTRACEPTIVES; VENOUS THROMBOEMBOLISM; DISEASE; SAFETY	Objective.-The aim of this study was to compare, in women and men suspected of pulmonary embolism, the frequency, risk factor's, diagnosis, and presentation of pulmonary embolism as well as the accuracy of the ventilation/perfusion scan (V/Q scan) as a diagnostic tool. Design.-Data were collected during a prospective study (the Prospective Investigation of Pulmonary Embolism Diagnosis) to establish the accuracy of the V/Q scan compared with pulmonary angiograms. Setting.-Six tertiary medical centers in Massachusetts, Michigan, Connecticut, Pennsylvania, and North Carolina. Participants.-Patients suspected of pulmonary embolism for whom a request was made for a V/Q scan or pulmonary angiogram (496 women and 406 men). Results.-Women 50 years old and under had a decreased frequency of pulmonary embolism compared with men of that age (16% vs 32%), but there was no difference in patients over 50 years old (Breslow-Day test, P<.01). Risk factors for pulmonary embolism, the usefulness of the V/Q scan, and 1-year mortality were not different for women and men. Estrogen use in women was not associated with an increased frequency of pulmonary embolism, except in women using oral contraceptives who had undergone surgery within 3 months; four of five (80%) had emboli compared with four of 28 (14%) age-matched surgical patients not using estrogens (P<.01). Conclusion.-Women 50 years old and under (even young women using oral contraceptives) who were suspected of having pulmonary emboli and were enrolled in the Prospective investigation of Pulmonary Embolism Diagnosis study had a smaller frequency of pulmonary embolism than men of that age, The risk factors for pulmonary embolism were the same for women and men, except that women using oral contraceptives had an increased risk of pulmonary embolism following surgery. Although the V/Q scan was a useful tool in the preliminary evaluation for pulmonary embolism in these women, a pulmonary angiogram was often needed for accurate diagnosis.	MASSACHUSETTS GEN HOSP,DEPT MED,PULM CRIT CARE UNIT,BULFINCH 1,FRUIT ST,BOSTON,MA 02114; HENRY FORD HEART & VASC INST,DETROIT,MI; MASSACHUSETTS GEN HOSP,DEPT RADIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MARYLAND MED RES INST,BALTIMORE,MD	Harvard University; Massachusetts General Hospital; Henry Ford Health System; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [HR 34013, N01-HR 34008, HR 34009] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR034013, N01HR034009, N01HR034008] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNSTEIN D, 1986, AM J DIS CHILD, V140, P667, DOI 10.1001/archpedi.1986.02140210065028; BRECKENRIDGE RT, 1964, NEW ENGL J MED, V270, P298, DOI 10.1056/NEJM196402062700608; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; COON WW, 1977, ANN SURG, V186, P149, DOI 10.1097/00000658-197708000-00006; COON WW, 1973, CIRCULATION, V48, P839, DOI 10.1161/01.CIR.48.4.839; DRILL VA, 1972, J AMER MED ASSOC, V219, P583, DOI 10.1001/jama.219.5.583; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; KARWINSKI B, 1989, J CLIN PATHOL, V42, P135, DOI 10.1136/jcp.42.2.135; NIE NH, 1983, SPSSX USERS GUIDE; Palevsky H I, 1989, Cardiovasc Clin, V19, P267; RAMACHARAN S, 1980, J REPROD MED S, V25, pS345; STURTEVANT FM, 1989, INT J FERTIL, V34, P323; VESSEY MP, 1970, BMJ-BRIT MED J, V3, P123, DOI 10.1136/bmj.3.5715.123; 1991, JAMA-J AM MED ASSOC, V266, P559; 1990, JAMA-J AM MED ASSOC, V263, P2753	17	92	92	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1689	1696		10.1001/jama.268.13.1689	http://dx.doi.org/10.1001/jama.268.13.1689			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1527878				2022-12-28	WOS:A1992JQ37600030
J	THACKER, SB; ADDISS, DG; GOODMAN, RA; HOLLOWAY, BR; SPENCER, HC				THACKER, SB; ADDISS, DG; GOODMAN, RA; HOLLOWAY, BR; SPENCER, HC			INFECTIOUS-DISEASES AND INJURIES IN CHILD DAY-CARE - OPPORTUNITIES FOR HEALTHIER CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							FAMILY DAY-CARE; PRESCHOOL-CHILDREN; DIARRHEAL ILLNESS; HOME CARE; CENTERS; EPIDEMIOLOGY; TRANSMISSION; SAFETY; VIRUS; ABUSE	Objective.-To provide pertinent background information on infectious diseases and injury in child day care and outline measures to address these health care needs. Design.-We reviewed published English-language literature identified through a MEDLINE bibliographic search, major literature summaries, and bibliographies from identified articles. Setting.-Child day-care settings reviewed included family child care homes, centers, special facilities for ill children, and facilities for children with special needs. Patients or Other Participants.-Primarily children in a variety of day-care settings, often compared with children cared for at home. Main Outcomes.-The occurrence of outbreaks and illness related to infectious disease and injury. Results.-Compared with preschool-aged children reared at home, among children in day care the risk of some infectious diseases was two to four times greater, Rates of both intentional and unintentional injuries in day-care settings were somewhat lower than those for children cared for at home. Conclusions.- Because preschool-aged children spend increasing time in structured day-care settings, the risk for some infectious diseases has increased. At the same time, child day-care settings present opportunities for ensuring healthier children through enhanced development, safer environments, better nutrition, increased vaccination coverage, and health promotion.	CTR DIS CONTROL, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA; TULANE UNIV, SCH PUBL HLTH & TROP MED, NEW ORLEANS, LA 70118 USA	Centers for Disease Control & Prevention - USA; Tulane University	THACKER, SB (corresponding author), CTR DIS CONTROL, EPIDEMIOL PROGRAM OFF, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.							ADLER SP, 1989, NEW ENGL J MED, V321, P1290, DOI 10.1056/NEJM198911093211903; ALEXANDER CS, 1990, AM J EPIDEMIOL, V131, P124, DOI 10.1093/oxfordjournals.aje.a115465; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; Barber-Madden R, 1983, Child Abuse Negl, V7, P25, DOI 10.1016/0145-2134(83)90026-1; BARTLETT AV, 1985, J PEDIATR-US, V107, P495, DOI 10.1016/S0022-3476(85)80004-4; BARTLETT AV, 1988, AM J EPIDEMIOL, V127, P808, DOI 10.1093/oxfordjournals.aje.a114863; BARTLETT AV, 1985, J PEDIATR-US, V107, P503, DOI 10.1016/S0022-3476(85)80005-6; BELL DM, 1989, AM J PUBLIC HEALTH, V79, P479, DOI 10.2105/AJPH.79.4.479; BITNER SO, 1964, J NURS EDUC, V19, P194; BLACK RE, 1981, AM J EPIDEMIOL, V113, P445, DOI 10.1093/oxfordjournals.aje.a113112; BLACK RE, 1977, PEDIATRICS, V60, P486; Braddy P K, 1989, Health Care Superv, V7, P33; CHANG A, 1989, PEDIATRICS, V83, P272; CHANG A, 1985, PEDIATRICS, V76, P425; CHORBA TL, 1987, AM J PUBLIC HEALTH, V77, P979, DOI 10.2105/AJPH.77.8.979; COL RD, 1978, 5000 AM FAMILIES PAT, V6, P10; DAVIS WS, 1988, AM J DIS CHILD, V142, P386; DAWSON DA, 1990, 187 NAT CTR HLTH STA; DENNY FW, 1986, REV INFECT DIS, V8, P527; DILKS SA, 1991, PEDIATR CLIN N AM, V38, P1529; DOYLE AB, 1976, PEDIATRICS, V58, P607; EICHELBERGER MR, 1990, AM J DIS CHILD, V144, P714, DOI 10.1001/archpedi.1990.02150300112029; ELARDO R, 1987, AM J ORTHOPSYCHIAT, V57, P60, DOI 10.1111/j.1939-0025.1987.tb03509.x; FERNANDEZ JP, 1986, CHILD CARE CORPORATE, P39; Finkelhor D., 1988, SEXUAL ABUSE DAY CAR; FLEMING DW, 1987, PEDIATRICS, V79, P55; FRENCK RW, 1990, SEMIN PEDIAT INFECT, V1, P234; FRIEDMAN DE, 1986, HARVARD BUS REV, V64, P28; GARRARD J, 1988, AM J DIS CHILD, V142, P643, DOI 10.1001/archpedi.1988.02150060077037; GUNN WJ, 1991, AM J DIS CHILD, V145, P779; HASKINS R, 1986, PEDIATRICS, V77, P951; HEDGES JN, 1977, MON LABOR REV, V100, P16; HENDERSON FW, 1986, REV INFECT DIS, V8, P533; HINMAN AR, 1986, REV INFECT DIS, V8, P573; HURWITZ ES, 1991, PEDIATRICS, V87, P62; JONES DS, 1990, SEMIN PEDIATR INFECT, V1, P280; JURANEK DD, 1985, CUTANEOUS INFESTATIO, P199; KELLEY SJ, 1990, NURS RES, V39, P25; KELLEY SJ, 1989, J INTERPERS VIOLENCE, V4, P501; LAMAURE SE, 1984, PERS ADMIN, V29, P53; LANDMAN PF, 1987, AM J DIS CHILD, V141, P292, DOI 10.1001/archpedi.1987.04460030070027; Lee E J, 1990, J Pediatr Health Care, V4, P18; LEGGIADRO RJ, 1989, PEDIATR INFECT DIS J, V8, P52, DOI 10.1097/00006454-198901000-00015; LEMP GF, 1984, AM J EPIDEMIOL, V120, P750, DOI 10.1093/oxfordjournals.aje.a113943; LODA FA, 1972, PEDIATRICS, V49, P428; MACDONALD KL, 1986, REV INFECT DIS, V8, P606; MARGOLIN L, 1990, CHILD ABUSE NEGLECT, V14, P365, DOI 10.1016/0145-2134(90)90008-H; NOLAN CM, 1987, PEDIATRICS, V79, P630; OCONNELL M, 1983, CURRENT POPULATI P23, V129; OSTERHOLM MT, 1990, SEMIN PEDIATR INFECT, V1, P222; Pass RF., 1990, SEMIN PEDIATR INFECT, V1, P245; Paulson J S, 1983, Child Abuse Negl, V7, P45, DOI 10.1016/0145-2134(83)90029-7; PICKERING LK, 1981, J PEDIATR-US, V99, P51, DOI 10.1016/S0022-3476(81)80956-0; PICKERING LK, 1986, REV INFECT DIS, V8, P539; PICKERING LK, 1990, SEMIN PEDIATR INFECT, V1, P263; POLIS MA, 1986, AM J PUBLIC HEALTH, V76, P1142, DOI 10.2105/AJPH.76.9.1142; RASSIN GM, 1991, CLIN PEDIATR, V30, P344, DOI 10.1177/000992289103000602; REICHELDERFER TE, 1979, PEDIATRICS, V64, P962; RIVARA FP, 1989, PEDIATRICS, V84, P1011; RUSSELL SD, 1987, CHILD WELFARE, V66, P149; SACKS JJ, 1990, AM J PUBLIC HEALTH, V80, P986, DOI 10.2105/AJPH.80.8.986; SACKS JJ, 1989, JAMA-J AM MED ASSOC, V262, P1641, DOI 10.1001/jama.262.12.1641; SACKS JJ, 1992, AM J PUBLIC HEALTH, V82, P429, DOI 10.2105/AJPH.82.3.429; SHAPIRO CN, 1989, PEDIATR INFECT DIS J, V8, P870, DOI 10.1097/00006454-198912000-00009; SHAPIRO CN, 1990, SEMIN PEDIATR INFECT, V1, P270; SOLOMONS HC, 1982, CHILD HEALTH CARE, V10, P90; SOLOMONS HC, 1989, EARLY CHILD RES Q, V4, P89; STAAT MA, 1991, PEDIATR INFECT DIS J, V10, P282, DOI 10.1097/00006454-199104000-00003; SULLIVAN P, 1984, AM J PUBLIC HEALTH, V74, P987, DOI 10.2105/AJPH.74.9.987; SWEENEY TB, 1979, PEDIATRICS, V64, P961; TAUXE RV, 1986, AM J PUBLIC HEALTH, V76, P627, DOI 10.2105/AJPH.76.6.627; WALD ER, 1991, J PEDIATR-US, V118, P509, DOI 10.1016/S0022-3476(05)83370-0; WASSERMAN RC, 1989, J PEDIATR-US, V114, P591, DOI 10.1016/S0022-3476(89)80700-0; WEISSMAN JB, 1974, J PEDIATR-US, V84, P797, DOI 10.1016/S0022-3476(74)80750-X; 1987, CURRENT POPULATI P70, V9; 1983, PHS831471 US DEP HLT; 1985, STATISTICAL ABSTRACT; 1992, NATIONAL HLTH SAFETY; 1991, RHETORIC NEW AM AGEN	79	57	57	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1720	1726		10.1001/jama.268.13.1720	http://dx.doi.org/10.1001/jama.268.13.1720			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1527882				2022-12-28	WOS:A1992JQ37600035
J	HECHT, SR; BERGER, M				HECHT, SR; BERGER, M			RIGHT-SIDED ENDOCARDITIS IN INTRAVENOUS-DRUG-USERS - PROGNOSTIC FEATURES IN 102 EPISODES	ANNALS OF INTERNAL MEDICINE			English	Article						ENDOCARDITIS, BACTERIAL; SUBSTANCE ABUSE, INTRAVENOUS; STAPHYLOCOCCUS-AUREUS; PULMONARY VALVE; TRICUSPID VALVE	TRICUSPID-VALVE ENDOCARDITIS; STAPHYLOCOCCUS-AUREUS ENDOCARDITIS; ACTIVE INFECTIVE ENDOCARDITIS; VEGETATION SIZE; ECHOCARDIOGRAPHIC FINDINGS; PROSTHETIC REPLACEMENT; CLINICAL IMPLICATIONS; COMBINATION THERAPY; ADDICTS; DIAGNOSIS	Objective: To describe the clinical, laboratory, and echocardiographic findings in a large group of patients with right-sided endocarditis and to determine whether any of these findings is predictive of prognosis. Design: Retrospective survey of medical records to evaluate the course of hospitalization with follow-up on 6-month survival. Review of two-dimensional echocardiograms by an observer blinded to clinical information. Setting: Large, metropolitan, voluntary hospital. Patients: One hundred twenty-one intravenous drug users with clinical and bacteriologic evidence of 132 episodes of endocarditis. The presence ot a right-sided valvular vegetation detected by two-dimensional echocardiography was required for entry into the study. Measurements and Results: Staphylococcus aureus was the most common infecting organism (82%, 108 of 132). Vegetations involved the tricuspid valve in 127 episodes, the pulmonic in 4, and both in 1; they ranged in size from 0.4 to 4.3 cm (mean, 1.5 +/- 0.7 cm). Vegetations greater than 1.0 cm were present in 106 cases (80%). Among patients with isolated native right-sided endocarditis who reached a definite end point in treatment, mortality was 7% (7 of 98). Vegetations greater than 2.0 cm were associated with a significantly higher mortality compared with vegetations of 2.0 cm or less (33% compared with 1.3%, P < 0.001). Conclusions: Overall, right-sided endocarditis has a favorable prognosis. Although complications and prolonged fever are common, most cases respond to medical therapy. Our findings suggest that vegetation size may be an important predictor of outcome and that vegetations greater than 2.0 cm are associated with increased mortality.	CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	HECHT, SR (corresponding author), BETH ISRAEL MED CTR, 1ST AVE & 16TH ST, NEW YORK, NY 10003 USA.							ABRAMS B, 1979, ANN INTERN MED, V90, P789, DOI 10.7326/0003-4819-90-5-789; ANDY JJ, 1977, AM J CARDIOL, V40, P17, DOI 10.1016/0002-9149(77)90094-7; ARBULU A, 1981, J THORAC CARDIOV SUR, V82, P684; BARBOUR DJ, 1986, AM J CARDIOL, V57, P475, DOI 10.1016/0002-9149(86)90776-9; BAYER AS, 1988, CHEST, V93, P247, DOI 10.1378/chest.93.2.247; BERGER M, 1984, AM HEART J, V107, P391, DOI 10.1016/0002-8703(84)90393-4; BERGER M, 1980, CIRCULATION, V61, P855, DOI 10.1161/01.CIR.61.4.855; CHAMBERS HF, 1983, MEDICINE, V62, P170, DOI 10.1097/00005792-198305000-00004; CHAMBERS HF, 1988, ANN INTERN MED, V109, P619, DOI 10.7326/0003-4819-109-8-619; CHAN PK, 1989, AM HEART J, V117, P1140, DOI 10.1016/0002-8703(89)90874-0; DINUBILE M, 1987, AM J MED, V82, P811, DOI 10.1016/0002-9343(87)90019-2; GINZTON LE, 1982, AM J CARDIOL, V49, P1853, DOI 10.1016/0002-9149(82)90202-8; HUBBELL G, 1981, AM HEART J, V102, P85, DOI 10.1016/0002-8703(81)90418-X; JAFFE WM, 1990, J AM COLL CARDIOL, V15, P1227, DOI 10.1016/S0735-1097(10)80005-1; LEVINE DP, 1986, REV INFECT DIS, V8, P374; LUTAS EM, 1986, AM HEART J, V112, P107, DOI 10.1016/0002-8703(86)90687-3; MANOLIS AS, 1988, ARCH INTERN MED, V148, P2461, DOI 10.1001/archinte.148.11.2461; MUGGE A, 1989, J AM COLL CARDIOL, V14, P631; OBRIEN JT, 1984, AM HEART J, V108, P386, DOI 10.1016/0002-8703(84)90630-6; RACKLEY CE, 1990, HEART ARTERIES VEINS, P855; REISBERG BE, 1979, PROG CARDIOVASC DIS, V22, P193, DOI 10.1016/0033-0620(79)90023-9; ROBBINS MJ, 1986, AM J MED, V80, P165, DOI 10.1016/0002-9343(86)90004-5; ROBIN E, 1975, AM J CARDIOL, V35, P481, DOI 10.1016/0002-9149(75)90830-9; SANABRIA TJ, 1990, ARCH INTERN MED, V150, P1305, DOI 10.1001/archinte.150.6.1305; SHEIKH MU, 1979, AM J MED, V66, P283, DOI 10.1016/0002-9343(79)90546-1; SHENOY MM, 1984, AM J CARDIOL, V54, P1374, DOI 10.1016/S0002-9149(84)80106-X; SHIVELY BK, 1991, J AM COLL CARDIOL, V18, P391, DOI 10.1016/0735-1097(91)90591-V; SKEHAN JD, 1988, BRIT HEART J, V59, P62; STAFFORD A, 1979, AM J CARDIOL, V44, P754, DOI 10.1016/0002-9149(79)90298-4; STAFFORD WJ, 1985, BRIT HEART J, V53, P310; STEWART JA, 1980, CIRCULATION, V61, P374, DOI 10.1161/01.CIR.61.2.374; TAAMS MA, 1990, BRIT HEART J, V63, P109; WONG D, 1983, ARCH INTERN MED, V143, P1874, DOI 10.1001/archinte.143.10.1874; YEE ES, 1988, J THORAC CARDIOV SUR, V96, P133	34	182	190	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					560	566		10.7326/0003-4819-117-7-560	http://dx.doi.org/10.7326/0003-4819-117-7-560			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524330				2022-12-28	WOS:A1992JQ22600003
J	BELLANNECHANTELOT, C; LACROIX, B; OUGEN, P; BILLAULT, A; BEAUFILS, S; BERTRAND, S; GEORGES, I; GLIBERT, F; GROS, I; LUCOTTE, G; SUSINI, L; CODANI, JJ; GESNOUIN, P; POOK, S; VAYSSEIX, G; LUKUO, J; RIED, T; WARD, D; CHUMAKOV, I; LEPASLIER, D; BARILLOT, E; COHEN, D				BELLANNECHANTELOT, C; LACROIX, B; OUGEN, P; BILLAULT, A; BEAUFILS, S; BERTRAND, S; GEORGES, I; GLIBERT, F; GROS, I; LUCOTTE, G; SUSINI, L; CODANI, JJ; GESNOUIN, P; POOK, S; VAYSSEIX, G; LUKUO, J; RIED, T; WARD, D; CHUMAKOV, I; LEPASLIER, D; BARILLOT, E; COHEN, D			MAPPING THE WHOLE HUMAN GENOME BY FINGERPRINTING YEAST ARTIFICIAL CHROMOSOMES	CELL			English	Article							PHYSICAL MAP; CAENORHABDITIS-ELEGANS; DNA; CONSTRUCTION; SEQUENCE; STRATEGY; LIBRARY; CLONES; HYBRIDIZATION; GENES	Physical mapping of the human genome has until now been envisioned through single chromosome strategies. We demonstrate that by using large insert yeast artificial chromosomes (YACs) a whole genome approach becomes feasible. YACs (22,000) of 810 kb mean size (5 genome equivalents) have been fingerprinted to obtain individual patterns of restriction fragments detected by a LINE-1 (L1) probe. More than 1000 contigs were assembled. Ten randomly chosen contigs were validated by metaphase chromosome fluorescence in situ hybridization, as well as by analyzing the inter-Alu PCR patterns of their constituent YACs. We estimate that 15% to 20% of the human genome, mainly the L1-rich regions, is already covered with contigs larger than 3 Mb.	GENETHON, F-91000 EVRY, FRANCE; INST NATL RECH INFORMAT & AUTOMAT, F-78153 LE CHESNAY, FRANCE; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA	Yale University; Yale University	BELLANNECHANTELOT, C (corresponding author), CTR ETUD POLYMORPHISME HUMAIN, F-75010 PARIS, FRANCE.		susini, laurent/N-7913-2019; Susini, Laurent/O-4227-2016	Susini, Laurent/0000-0002-5164-2770; Le Paslier, Denis/0000-0003-4335-9956; BARILLOT, Emmanuel/0000-0003-2724-2002				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANAND R, 1989, NUCLEIC ACIDS RES, V17, P3425, DOI 10.1093/nar/17.9.3425; ARNOLD N, 1992, IN PRESS TECHNIQUES; BALDING DJ, 1991, B MATH BIOL, V53, P853, DOI 10.1016/S0092-8240(05)80411-2; BATES GP, 1992, NAT GENET, V1, P180, DOI 10.1038/ng0692-180; BELLANNECHANTELOT C, 1991, NUCLEIC ACIDS RES, V19, P505, DOI 10.1093/nar/19.3.505; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CANGIANO G, 1990, NUCLEIC ACIDS RES, V18, P5077, DOI 10.1093/nar/18.17.5077; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COLLEAUX L, 1992, YEAST, V8, P325, DOI 10.1002/yea.320080410; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; CRAIG AG, 1990, NUCLEIC ACIDS RES, V18, P2653; EVANS GA, 1989, P NATL ACAD SCI USA, V86, P5030, DOI 10.1073/pnas.86.13.5030; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; JEFFREYS AJ, 1987, BIOCHEM SOC T, V15, P309, DOI 10.1042/bst0150309; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORENBERG JR, 1992, TRENDS BIOTECHNOL, V10, P27, DOI 10.1016/0167-7799(92)90163-P; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; LACROIX B, 1992, IN PRESS WORLD SCI; LANDER E S, 1988, Genomics, V2, P231; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; MATERA AG, 1990, NUCLEIC ACIDS RES, V18, P6019, DOI 10.1093/nar/18.20.6019; MONTANARO V, 1991, AM J HUM GENET, V48, P183; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; RIED T, 1992, GENE CHROMOSOME CANC, V4, P69, DOI 10.1002/gcc.2870040109; SHAFITZAGARDO B, 1982, NUCLEIC ACIDS RES, V10, P3175, DOI 10.1093/nar/10.10.3175; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609	33	169	175	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					1059	1068		10.1016/0092-8674(92)90254-A	http://dx.doi.org/10.1016/0092-8674(92)90254-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525822				2022-12-28	WOS:A1992JN78100019
J	GEORGIADIS, MM; KOMIYA, H; CHAKRABARTI, P; WOO, D; KORNUC, JJ; REES, DC				GEORGIADIS, MM; KOMIYA, H; CHAKRABARTI, P; WOO, D; KORNUC, JJ; REES, DC			CRYSTALLOGRAPHIC STRUCTURE OF THE NITROGENASE IRON PROTEIN FROM AZOTOBACTER-VINELANDII	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; MAGNESIUM ADENOSINE 5'-TRIPHOSPHATE; ELECTRON-PARAMAGNETIC RESONANCE; CLOSTRIDIUM-PASTEURIANUM; FE-PROTEIN; KLEBSIELLA-PNEUMONIAE; NUCLEOTIDE-BINDING; MACROMOLECULAR CRYSTALLOGRAPHY; MOLYBDENUM COFACTOR; CRYSTAL-STRUCTURE	The nitrogenase enzyme system catalyzes the ATP (adenosine triphosphate)-dependent reduction of dinitrogen to ammonia during the process of nitrogen fixation. Nitrogenase consists of two proteins: the iron (Fe)-protein, which couples hydrolysis of ATP to electron transfer, and the molybdenum-iron (MoFe)-protein, which contains the dinitrogen binding site. In order to address the role of ATP in nitrogen fixation, the crystal structure of the nitrogenase Fe-protein from Azotobacter vinelandii has been determined at 2.9 angstrom (angstrom) resolution. Fe-protein is a dimer of two identical subunits that coordinate a single 4Fe:4S cluster. Each subunit folds as a single alpha/beta-type domain, which together symmetrically ligate the surface exposed 4Fe:4S cluster through two cysteines from each subunit. A single bound ADP (adenosine diphosphate) molecule is located in the interface region between the two subunits. Because the phosphate groups of this nucleotide are approximately 20 angstrom from the 4Fe:4S cluster, it is unlikely that ATP hydrolysis and electron transfer are directly coupled. Instead, it appears that interactions between the nucleotide and cluster sites must be indirectly coupled by allosteric changes occurring at the subunit interface. The coupling between protein conformation and nucleotide hydrolysis in Fe-protein exhibits general similarities to the H-Ras p21 and recA proteins that have been recently characterized structurally. The Fe-protein structure may be relevant to the functioning of other biochemical energy-transducing systems containing two nucleotide-binding sites, including membrane transport proteins.	CALTECH,DEPT CHEM & CHEM ENGN,147-75CH,PASADENA,CA 91125	California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045162, R37GM045162] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ANDERSON GL, 1984, BIOCHEMISTRY-US, V23, P2118, DOI 10.1021/bi00305a002; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BETHGE PH, CCP4 DAR LAB PROJ; Bishop P. E., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P71; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; Burgess B. K., 1984, Advances in nitrogen fixation research, P103; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURKE DG, UNPUB; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CORK C, 1985, METHOD ENZYMOL, V114, P452; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DAESCH G, 1968, J BACTERIOL, V96, P346, DOI 10.1128/JB.96.2.346-351.1968; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEITS TL, 1989, J BIOL CHEM, V264, P6619; DRENTH J, 1975, J BIOL CHEM, V250, P5268; EMERICH DW, 1976, P NATL ACAD SCI USA, V73, P4369, DOI 10.1073/pnas.73.12.4369; GAVINI N, 1992, IN PRESS J BIOL CHEM; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GEORGIADIS M, UNPUB; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HAGEMAN RV, 1978, BIOCHEMISTRY-US, V17, P4117, DOI 10.1021/bi00613a002; HAGEMAN RV, 1980, BIOCHEMISTRY-US, V19, P2333, DOI 10.1021/bi00552a009; HAGEN WR, 1985, FEBS LETT, V189, P250, DOI 10.1016/0014-5793(85)81033-4; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HAUSINGER RP, 1982, J BIOL CHEM, V257, P2483; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; HOWARD KS, 1986, J BIOL CHEM, V261, P772; JACOBSON MR, 1990, J BIOL CHEM, V265, P19429; JOERGER RD, 1991, J BACTERIOL, V173, P4440, DOI 10.1128/JB.173.14.4440-4446.1991; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LINDAHL PA, 1985, J BIOL CHEM, V260, P1160; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; MEYER J, 1988, BIOCHEMISTRY-US, V27, P6150, DOI 10.1021/bi00416a048; MORGAN TV, 1986, FEBS LETT, V206, P4, DOI 10.1016/0014-5793(86)81329-1; MORGAN TV, 1990, BIOCHEMISTRY-US, V29, P3077, DOI 10.1021/bi00464a026; MURRELL SA, 1988, BIOCHEM J, V251, P609, DOI 10.1042/bj2510609; NELSON MJ, 1983, P NATL ACAD SCI-BIOL, V80, P147, DOI 10.1073/pnas.80.1.147; NORMAND P, 1989, J MOL EVOL, V29, P436, DOI 10.1007/BF02602914; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PAUL W, 1989, EUR J BIOCHEM, V178, P675, DOI 10.1111/j.1432-1033.1989.tb14497.x; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; POPE MR, 1985, P NATL ACAD SCI USA, V82, P3173, DOI 10.1073/pnas.82.10.3173; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; REES DC, 1983, J BIOL CHEM, V258, P2733; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; Rossmann M. G., 1972, MOL REPLACEMENT METH; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHULZ GE, 1974, NATURE, V250, P120, DOI 10.1038/250120a0; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SIMPSON FB, 1984, SCIENCE, V224, P1095, DOI 10.1126/science.6585956; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; STIEFEL EI, 1988, ACS SYM SER, V372, P372; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TAL S, 1991, J BIOL CHEM, V266, P10654; TANAKA M, 1977, J BIOL CHEM, V252, P7093; TANAKA M, 1977, J BIOL CHEM, V252, P7089; TANAKA M, 1977, J BIOL CHEM, V252, P7081; THORNELEY RNF, 1984, BIOCHEM J, V224, P887, DOI 10.1042/bj2240887; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; THORNELEY RNF, 1992, PHILOS T R SOC B, V336, P73, DOI 10.1098/rstb.1992.0046; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALKER GA, 1973, BIOCHEM BIOPH RES CO, V53, P904, DOI 10.1016/0006-291X(73)90177-0; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG ZC, 1985, BIOCHEMISTRY-US, V24, P214, DOI 10.1021/bi00322a031; WATT GD, 1986, BIOCHEMISTRY-US, V25, P8156, DOI 10.1021/bi00373a005; WATT GD, 1985, BIOCHEMISTRY-US, V24, P7226, DOI 10.1021/bi00346a031; WILLING A, 1990, J BIOL CHEM, V265, P6596; WILLING AH, 1989, J BIOL CHEM, V264, P8499; WOLLE D, 1992, J BIOL CHEM, V267, P3667; WOLLE D, IN PRESS SCIENCE; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9	91	573	587	2	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1653	1659		10.1126/science.1529353	http://dx.doi.org/10.1126/science.1529353			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529353				2022-12-28	WOS:A1992JN50100022
J	HE, ZJ; NAKAYAMA, K				HE, ZJ; NAKAYAMA, K			SURFACES VERSUS FEATURES IN VISUAL-SEARCH	NATURE			English	Article							DISCRIMINATION; PARALLEL; SERIAL; MOTION; DEPTH	OFTEN implicit in the interpretation of visual search tasks is the assumption that the detection of targets is determined by the feature-coding properties of low-level visual processing1,2. But higher level processes have also been implicated as visual search ability is enhanced in a depth plane3 of when two-dimensional shapes are interpreted as three-dimensional forms4,5. Here we manipulate binocular disparity to degrade visual search, so that otherwise identical features become parts of surfaces through perceptual completion, rendering them less clearly distinguishable as targets and distractors. Our results indicate that visual search has little or no access to the processing level of feature extraction but must have as an input a higher level process of surface representation.			HE, ZJ (corresponding author), HARVARD UNIV,DEPT PSYCHOL,VIS SCI LAB,CAMBRIDGE,MA 02138, USA.							BECK J, 1966, PERCEPT PSYCHOPHYS, V1, P300, DOI 10.3758/BF03215792; BERGEN JR, 1983, NATURE, V303, P696, DOI 10.1038/303696a0; ENNS JT, 1990, PSYCHOL SCI, V1, P323, DOI 10.1111/j.1467-9280.1990.tb00227.x; FOX R, 1981, PERCEPT PSYCHOPHYS, V30, P513, DOI 10.3758/BF03202004; JULESZ B, 1981, NATURE, V290, P91, DOI 10.1038/290091a0; KLEFFNER DA, 1992, PERCEPT PSYCHOPHYS, V52, P18, DOI 10.3758/BF03206757; MALIK J, 1990, J OPT SOC AM A, V7, P923, DOI 10.1364/JOSAA.7.000923; NAKAYAMA K, 1990, COLD SPRING HARB SYM, V55, P911; NAKAYAMA K, 1986, NATURE, V320, P264, DOI 10.1038/320264a0; NAKAYAMA K, 1989, PERCEPTION, V18, P55, DOI 10.1068/p180055; SHIMOJO S, 1989, VISION RES, V29, P619, DOI 10.1016/0042-6989(89)90047-3; SHIMOJO S, 1990, PERCEPTION, V19, P285, DOI 10.1068/p190285; TREISMAN A, 1985, J EXP PSYCHOL GEN, V114, P285, DOI 10.1037/0096-3445.114.3.285; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; [No title captured]	15	259	264	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					231	233		10.1038/359231a0	http://dx.doi.org/10.1038/359231a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JN944	1528263				2022-12-28	WOS:A1992JN94400059
J	DELATTRE, O; ZUCMAN, J; PLOUGASTEL, B; DESMAZE, C; MELOT, T; PETER, M; KOVAR, H; JOUBERT, I; DEJONG, P; ROULEAU, G; AURIAS, A; THOMAS, G				DELATTRE, O; ZUCMAN, J; PLOUGASTEL, B; DESMAZE, C; MELOT, T; PETER, M; KOVAR, H; JOUBERT, I; DEJONG, P; ROULEAU, G; AURIAS, A; THOMAS, G			GENE FUSION WITH AN ETS DNA-BINDING DOMAIN CAUSED BY CHROMOSOME-TRANSLOCATION IN HUMAN TUMORS	NATURE			English	Article							EWINGS-SARCOMA; RECIPROCAL TRANSLOCATION; MYXOID CHONDROSARCOMA; PROTEINS; ERYTHROLEUKEMIA; REARRANGEMENTS; CONSISTENCY; T(11-22); VIRUS	EWING'S sarcoma and related subtypes of primitive neuroectodermal tumours share a recurrent and specific t(11; 22) (q24; q12) chromosome translocation1-8, the breakpoints of which have recently been cloned9. Phylogenetically conserved restriction fragments in the vicinity of EWSR1 and EWSR2, the genomic regions where the breakpoints of chromosome 22 and chromosome 11 are, respectively, have allowed identification of transcribed sequences from these regions and has indicated that a hybrid transcript might be generated by the translocation9. Here we use these fragments to screen human complementary DNA libraries to show that the translocation alters the open reading frame of an expressed gene on chromosome 22 gene by substituting a sequence encoding a putative RNA-binding domain for that of the DNA-binding domain of the human homologue of murine Fli-1.	INST CURIE,GENET TUMEURS LAB,26 RUE ULM,F-75231 PARIS 05,FRANCE; ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,A-1090 VIENNA,AUSTRIA; MCGILL UNIV,CTR RECH NEUROSCI,MONTREAL H3G 1A4,QUEBEC,CANADA; LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,LIVERMORE,CA 94550; INST CURIE,CNRS,URA 620,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Saint Anna Children's Hospital; McGill University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			j, zucman-rossi/AAV-3594-2021; Plougastel-Douglas, Beatrice/Q-3186-2019; zucman-rossi, Jessica/B-5098-2009	j, zucman-rossi/0000-0002-5687-0334; Plougastel-Douglas, Beatrice/0000-0002-6389-561X; zucman-rossi, Jessica/0000-0002-5687-0334; Desmaze, Chantal/0000-0003-0777-8854; Kovar, Heinrich/0000-0001-6873-9109; delattre, olivier/0000-0002-8730-2276				AURIAS A, 1983, NEW ENGL J MED, V309, P496; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BAUD V, 1991, GENOMICS, V11, P223, DOI 10.1016/0888-7543(91)90124-W; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BIAMONTI G, 1989, J MOL BIOL, V207, P491, DOI 10.1016/0022-2836(89)90459-2; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CAVAZZANA AO, 1988, ADV NEUROBLASTOMA RE, V2, P463; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DECHADAREVIAN JP, 1984, NEW ENGL J MED, V311, P1702; DOUGLASS EC, 1986, J NATL CANCER I, V77, P1211; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; HAYNES SR, 1987, P NATL ACAD SCI USA, V84, P1819, DOI 10.1073/pnas.84.7.1819; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUMAR A, 1990, J BIOL CHEM, V265, P17094; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; ROULEAU GA, 1990, AM J HUM GENET, V46, P323; SHEN WPV, 1990, CANCER GENET CYTOGEN, V45, P207, DOI 10.1016/0165-4608(90)90084-N; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10173; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V30, P145, DOI 10.1016/0165-4608(88)90103-3; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VIGFUSSON NV, 1986, CANCER GENET CYTOGEN, V22, P211, DOI 10.1016/0165-4608(86)90157-3; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; WHANGPENG J, 1987, CANCER GENET CYTOGEN, V29, P155, DOI 10.1016/0165-4608(87)90043-4; ZUCMAN J, IN PRESS GENES CHROM	34	1477	1508	5	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					162	165		10.1038/359162a0	http://dx.doi.org/10.1038/359162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522903				2022-12-28	WOS:A1992JM49400058
J	SALMI, M; JALKANEN, S				SALMI, M; JALKANEN, S			A 90-KILODALTON ENDOTHELIAL-CELL MOLECULE MEDIATING LYMPHOCYTE BINDING IN HUMANS	SCIENCE			English	Article							GRANULE MEMBRANE-PROTEIN; TUMOR-NECROSIS-FACTOR; LEUKOCYTE ADHESION; RECEPTOR; INFLAMMATION; EXPRESSION; ACTIVATION; INTERFERON; INDUCTION; INCAM-110	Interactions between leukocyte surface receptors and their ligands on vascular endothelial cells control lymphocyte traffic between the blood and various lymphoid organs, as well as extravasation of leukocytes into sites of inflammation. A heretofore undescribed 90-kilodalton human endothelial cell adhesion molecule (VAP-1) defined by a monoclonal antibody 1B2 is described. The expression pattern, molecular mass, functional properties, and an amino-terminal amino acid sequence define VAP-1 as an endothelial ligand for lymphocytes. VAP-1 helps to elucidate the complex heterotypic cell interactions that direct tissue-selective lymphocyte migration in man.	UNIV TURKU, DEPT MED MICROBIOL, SF-20520 TURKU 52, FINLAND	University of Turku	SALMI, M (corresponding author), UNIV TURKU, NATL PUBL HLTH INST, KIINAMYLLYNKATU 13, SF-20520 TURKU 52, FINLAND.							BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BUTCHER EC, 1986, CURR TOP MICROBIOL, V128, P85; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DUSTIN ML, 1986, J IMMUNOL, V137, P245; HATTORI R, 1989, J BIOL CHEM, V264, P7768; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; JALKANEN ST, 1985, BLOOD, V66, P577; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POBER JS, 1986, J IMMUNOL, V137, P1893; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1991, AM J PATHOL, V138, P385; SALMI M, UNPUB; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; WELLICOME SM, 1990, J IMMUNOL, V144, P2558	24	275	286	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1992	257	5075					1407	1409		10.1126/science.1529341	http://dx.doi.org/10.1126/science.1529341			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529341				2022-12-28	WOS:A1992JL61200036
J	GOSTIN, LO				GOSTIN, LO			HEALTH LAW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											GOSTIN, LO (corresponding author), AMER SOC LAW & MED,BOSTON,MA 02215, USA.							Barnes M, 1990, Law Med Health Care, V18, P311; CAPRON AM, 1992, HASTINGS CTR REP JAN, P43; GOSTIN L, 1991, MILBANK Q, V69, P143, DOI 10.2307/3350124; 1991, OTABPH90 OFF TECHN A; 1991, MMWR SRR8, V40, P1; 1991, FED REG         1206, V56, P64004	6	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					364	366						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JC352	1535384				2022-12-28	WOS:A1992JC35200033
J	LEW, DJ; MARINI, NJ; REED, SI				LEW, DJ; MARINI, NJ; REED, SI			DIFFERENT G1 CYCLINS CONTROL THE TIMING OF CELL-CYCLE COMMITMENT IN MOTHER AND DAUGHTER CELLS OF THE BUDDING YEAST SACCHAROMYCES-CEREVISIAE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; FISSION YEAST; MATING-PHEROMONE; GENE; DIVISION; MITOSIS; HOMOLOG; GROWTH; COMPLEX	Growth of S. cerevisiae cells by budding gives rise to asymmetric progeny cells: a larger "mother" cell and a smaller "daughter" cell. The mother cell transits a brief G1 phase before forming a new bud and beginning DNA replication. The daughter cell stays in G1 for a longer period, growing in size before initiating a new cell cycle. We show that the timing of cell cycle initiation in mother and daughter cells is governed by different G1 cyclins. In daughter cells, transcription of CLN1 and CLN2 is induced in a size-dependent manner, and these cyclins are necessary for the normal timing of cell cycle initiation. CLN3 is not required in daughter cells, but is crucial for mother cells, in which the G1 phase is much longer in the absence of this cyclin.			LEW, DJ (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, MB7, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NIGMS NIH HHS [GM13991, GM38382] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013991] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BLOCK DE, 1990, BIOTECHNOL PROGR, V6, P504, DOI 10.1021/bp00006a015; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; Chant J, 1991, CURR OPIN GENET DEV, V1, P342, DOI 10.1016/S0959-437X(05)80298-9; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; Fantes P.A., 1984, CELL CYCLE CLOCKS, P233; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; HICKS JB, 1976, GENETICS, V83, P245; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MITCHISON JM, 1958, EXP CELL RES, V15, P214, DOI 10.1016/0014-4827(58)90077-6; MOORE SA, 1984, EXP CELL RES, V151, P542, DOI 10.1016/0014-4827(84)90402-6; MOORE SA, 1988, J BIOL CHEM, V263, P9674; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1982, MOL CELL BIOL, V2, P412, DOI 10.1128/MCB.2.4.412; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1980, GENETICS, V95, P561; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sambrook J, 1989, MOL CLONING LABORATO; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	57	92	93	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					317	327		10.1016/0092-8674(92)90412-6	http://dx.doi.org/10.1016/0092-8674(92)90412-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1533176				2022-12-28	WOS:A1992HQ18300011
J	SCHWARTZ, DA; LANDAS, SK; LASSISE, DL; BURMEISTER, LF; HUNNINGHAKE, GW; MERCHANT, JA				SCHWARTZ, DA; LANDAS, SK; LASSISE, DL; BURMEISTER, LF; HUNNINGHAKE, GW; MERCHANT, JA			AIRWAY INJURY IN SWINE CONFINEMENT WORKERS	ANNALS OF INTERNAL MEDICINE			English	Article						AGRICULTURAL WORKERS DISEASES; AGROCHEMICALS; SWINE; ASTHMA; BRONCHITIS; OCCUPATIONAL MEDICINE	COTTON DUST; RESPIRATORY SYMPTOMS; INHALED ENDOTOXIN; LUNG-FUNCTION; BUILDINGS; EXPOSURE; FARMERS; ASTHMA	Objective: To determine whether work-related respiratory symptoms are indicative of underlying lung disease among swine confinement workers and, if so, to identify whether respiratory changes were more indicative of airway or of interstitial lung injury. Design: Nested case-control study within a population-based longitudinal study. Setting: University hospital. Participants: Study participants were randomly selected from a group of 207 swine confinement workers followed longitudinally. Of these, 43 workers with respiratory symptoms were identified, and 31 were randomly selected for inclusion in this study. Three control groups (swine confinement workers, neighbor farmers, and blue collar workers) without work-related respiratory symptoms were frequency-matched by age, sex, and smoking status to the symptomatic swine confinement workers. Measurements: Spirometry and lung volumes, diffusing capacity of carbon monoxide, chest radiograph, methacholine airway challenge, and bronchoalveolar lavage were done. An endobronchial biopsy was done in the last 27 participants evaluated. Results: Although spirometric measures of airflow were similar between the symptomatic swine confinement workers and the three control groups, swine confinement cases were found to have significant elevations in residual volume (126.5 +/- 28.2 L) when compared to swine confinement controls (115.4 +/- 38.4 L; P less-than-or-equal-to 0.05), neighborhood farmer controls (101.1 +/- 29.4 L; P less-than-or-equal-to 0.005), and blue collar controls (106.4 +/- 30.4 L; P less-than-or-equal-to 0.05). Swine confinement cases also had an enhanced airway response to inhaled methacholine and had thickening of the epithelial basement membrane of the lobar bronchi. No parenchymal injury was observed in the swine confinement cases. Conclusions: Our findings suggest that swine confinement workers who have work-related respiratory symptoms are at risk for airway, but not parenchymal, lung injury, and that spirometry may not accurately reflect the extent of airway injury.	UNIV IOWA, COLL MED, DEPT VET AFFAIRS MED CTR, IOWA CITY, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	SCHWARTZ, DA (corresponding author), UNIV IOWA, COLL MED, DEPT INTERNAL MED, DIV PULM DIS, IOWA CITY, IA 52242 USA.				NHLBI NIH HHS [HL-37121] Funding Source: Medline; NIEHS NIH HHS [ES-00203] Funding Source: Medline; NIOSH CDC HHS [OH-00093] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [K01OH000093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES000203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIOSH CDC HHS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; ATTWOOD P, 1987, AM IND HYG ASSOC J, V48, P745, DOI 10.1080/15298668791385507; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CASTELLAN RM, 1984, ANN INTERN MED, V101, P157, DOI 10.7326/0003-4819-101-2-157; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DONHAM K, 1989, BRIT J IND MED, V46, P31; DONHAM KJ, 1984, AM J IND MED, V5, P367, DOI 10.1002/ajim.4700050505; DONHAM KJ, 1984, ARCH ENVIRON HEALTH, V39, P96, DOI 10.1080/00039896.1984.10545842; DONHAM KJ, 1986, AM IND HYG ASSOC J, V47, P404, DOI 10.1080/15298668691389955; DONHAM KJ, 1986, AM J IND MED, V10, P294, DOI 10.1002/ajim.4700100318; DOSMAN JA, 1988, J OCCUP ENVIRON MED, V30, P715; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; HAGLIND P, 1987, J OCCUP ENVIRON MED, V29, P904; HOLNESS DL, 1987, AM J IND MED, V11, P571, DOI 10.1002/ajim.4700110509; IVERSEN M, 1988, THORAX, V43, P872, DOI 10.1136/thx.43.11.872; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KENNEDY SM, 1987, AM REV RESPIR DIS, V135, P194; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PAGGIARO P, 1990, CHEST, V98, P536, DOI 10.1378/chest.98.3.536; ROCHE WR, 1989, LANCET, V1, P520; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; SCHWARTZ DA, 1987, OCCUP MED, V2, P297; THELIN A, 1984, EUR J RESPIR DIS, V65, P266; VANGANSE WF, 1972, AM REV RESPIR DIS, V105, P30; VONESSEN SG, 1988, AM REV RESPIR DIS, V138, P921, DOI 10.1164/ajrccm/138.4.921; ZAVALA D, 1983, RECENT ADV RESPIRATO, V3, P21	32	61	61	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					630	635		10.7326/0003-4819-116-8-630	http://dx.doi.org/10.7326/0003-4819-116-8-630			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546862				2022-12-28	WOS:A1992HN84400004
J	GELLERT, GA				GELLERT, GA			INTERNATIONAL HEALTH ASSISTANCE FOR EURASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AIDS				GELLERT, GA (corresponding author), ORANGE CTY HLTH CARE AGCY,SANTA ANA,CA 92702, USA.							CHAZOV YI, 1988, CURRENT DIGEST SOVIE, V40, P8; CHAZOV YI, 1989, PEOPLES HLTH SOC WEA; FORSTER DP, 1990, LANCET, V335, P458, DOI 10.1016/0140-6736(90)90678-X; GELLERT G, 1990, NEW ENGL J MED, V323, P1844, DOI 10.1056/NEJM199012273232616; GELLERT G A, 1989, Journal of Public Health Policy, V10, P421, DOI 10.2307/3342515; GELLERT GA, 1990, JAMA-J AM MED ASSOC, V264, P610; GELLERT GA, 1991, BRIT MED J, V302, P633, DOI 10.1136/bmj.302.6777.633; GOLDSMITH MF, 1988, JAMA-J AM MED ASSOC, V259, P1917, DOI 10.1001/jama.259.13.1917; KNOW JDE, 1989, LANCET, V2, P732; MCKEE M, 1991, INT J EPIDEMIOL COMM, V45, P260; MEDVEDEV ZA, 1985, GERONTOLOGIST, V25, P201, DOI 10.1093/geront/25.2.201; MOZHAROVA G, 1991, 7TH INT C AIDS FLOR, P413; NARKEVICH MI, 1989, ZH MIKROBIOL EPIDEMI, V2, P49; POKROVSKY V, 1991, 7TH INT C AIDS FLOR, V1, P419; RICH V, 1991, LANCET, V338, P1323; RICH V, 1990, INT MIGR REV, V337, P420; RICH V, 1991, LANCET, V337, P420; ROBBINS A, 1990, JAMA-J AM MED ASSOC, V264, P1097, DOI 10.1001/jama.264.9.1097; ROWLAND D, 1991, HEALTH AFFAIR, V10, P71, DOI 10.1377/hlthaff.10.3.71; SCHIEBER GJ, 1989, HLTH CARE FINANCIN S, P1; SEALE JR, 1987, J ROY SOC MED, V80, P301, DOI 10.1177/014107688708000515; SHEARS P, 1987, INT MIGR REV, V21, P783, DOI 10.2307/2546622; TRIMBLE J, 1990, US NEWS WORLD R 1119, P34; 1989, LANCET, V2, P1208; 1990, NATIONAL EC USSR 198; 1991, NEWSWEEK        0909, P33; 1990, ECONOMIST       0217, P62; 1991, 97 CTR DIS CONTR ADV; 1991, ALASKA MED, V33, P4	29	10	10	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1992	326	15					1021	1024		10.1056/NEJM199204093261512	http://dx.doi.org/10.1056/NEJM199204093261512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM285	1545840				2022-12-28	WOS:A1992HM28500012
J	HULL, RD; RASKOB, GE; PINEO, GF; GREEN, D; TROWBRIDGE, AA; ELLIOTT, CG; LERNER, RG; HALL, J; SPARLING, T; BRETTELL, HR; NORTON, J; CARTER, CJ; GEORGE, R; MERLI, G; WARD, J; MAYO, W; ROSENBLOOM, D; BRANT, R				HULL, RD; RASKOB, GE; PINEO, GF; GREEN, D; TROWBRIDGE, AA; ELLIOTT, CG; LERNER, RG; HALL, J; SPARLING, T; BRETTELL, HR; NORTON, J; CARTER, CJ; GEORGE, R; MERLI, G; WARD, J; MAYO, W; ROSENBLOOM, D; BRANT, R			SUBCUTANEOUS LOW-MOLECULAR-WEIGHT HEPARIN COMPARED WITH CONTINUOUS INTRAVENOUS HEPARIN IN THE TREATMENT OF PROXIMAL-VEIN THROMBOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP VENOUS THROMBOSIS; ACUTE PULMONARY-EMBOLISM; LONG-TERM TREATMENT; IMPEDANCE PLETHYSMOGRAPHY; HEMORRHAGIC COMPLICATIONS; ANTICOAGULANT-THERAPY; VENTILATION-PERFUSION; PROSPECTIVE TRIAL; INITIAL TREATMENT; WARFARIN SODIUM	Background. Low-molecular-weight heparin has a high bioavailability and a prolonged half-life in comparison with conventional unfractionated heparin. Limited data are available for low-molecular-weight heparin as compared with unfractionated heparin for the treatment of deep-vein thrombosis. Methods. In a multicenter, double-blind clinical trial, we compared fixed-dose subcutaneous low-molecular-weight heparin given once daily with adjusted-dose intravenous heparin given by continuous infusion for the initial treatment of patients with proximal-vein thrombosis, using objective documentation of clinical outcomes. Results. Six of 213 patients who received low-molecular-weight heparin (2.8 percent) and 15 of 219 patients who received intravenous heparin (6.9 percent) had new episodes of venous thromboembolism (P = 0.07; 95 percent confidence interval for the difference, 0.02 percent to 8.1 percent). Major bleeding associated with initial therapy occurred in 1 patient receiving low-molecular-weight heparin (0.5 percent) and in 11 patients receiving intravenous heparin (5.0 percent), a reduction in risk of 91 percent (P = 0.006). This apparent protection against major bleeding was lost during long-term therapy. Minor hemorrhagic complications were infrequent. Ten patients receiving low-molecular-weight heparin (4.7 percent) died, as compared with 21 patients receiving intravenous heparin (9.6 percent), a risk reduction of 51 percent (P = 0.049). Conclusions. Low-molecular-weight heparin is at least as effective and as safe as classic intravenous heparin therapy under the conditions of this study and more convenient to administer. The simplified therapy provided by low-molecular-weight heparin may allow patients with uncomplicated proximal deep-vein thrombosis to be cared for in an outpatient setting.	UNIV BRITISH COLUMBIA, VANCOUVER V6T 1W5, BC, CANADA; LIONS GATE HOSP, VANCOUVER, BC, CANADA; NORTHWESTERN UNIV, REHABIL INST CHICAGO, CHICAGO, IL 60611 USA; TEXAS A&M UNIV SYST, SCOTT & WHITE CLIN, TEMPLE, TX USA; UNIV UTAH, LATTER DAY ST HOSP, SALT LAKE CITY, UT 84143 USA; NEW YORK MED COLL, WESTCHESTER CTY MED CTR, VALHALLA, NY 10595 USA; METHODIST HOSP INDIANA, INDIANAPOLIS, IN 46202 USA; UNIV COLORADO HOSP, DENVER, CO USA; PENROSE COMMUNITY HOSP, COLORADO SPRINGS, CO USA; MERCY HOSP & MED CTR, SAN DIEGO, CA 92103 USA; JEFFERSON MED CTR, PHILADELPHIA, PA USA	University of British Columbia; Northwestern University; Shirley Ryan AbilityLab; Scott & White Medical Center; Texas A&M University System; Utah System of Higher Education; University of Utah; New York Medical College; Westchester Medical Center; Indiana University System; University of Colorado System; University of Colorado Hospital; Jefferson University	HULL, RD (corresponding author), UNIV CALGARY, DEPT MED, DIV GEN INTERNAL MED, CLIN TRIALS UNIT, 3330 HOSP DR NW, CALGARY T2N 4N1, ALBERTA, CANADA.			Brant, Rollin/0000-0002-8026-2451				AIACH M, 1983, THROMB RES, V31, P611, DOI 10.1016/0049-3848(83)90458-9; ALBADA J, 1989, CIRCULATION, V80, P935, DOI 10.1161/01.CIR.80.4.935; BARA L, 1985, THROMB RES, V39, P631, DOI 10.1016/0049-3848(85)90244-0; BERGQVIST D, 1983, THROMB RES, V32, P381, DOI 10.1016/0049-3848(83)90091-9; BOOKSTEIN JJ, 1974, RADIOLOGY, V110, P25, DOI 10.1148/110.1.25; BRATT G, 1985, THROMB HAEMOSTASIS, V54, P813; BRATT G, 1990, THROMB HAEMOSTASIS, V64, P506; BRATT G, 1986, THROMB RES, V42, P613, DOI 10.1016/0049-3848(86)90340-3; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CARTER CJ, 1982, BLOOD, V59, P1239; COON WW, 1969, ANN SURG, V170, P559, DOI 10.1097/00000658-196910000-00007; DALEN JE, 1971, AM HEART J, V81, P175, DOI 10.1016/0002-8703(71)90128-1; DOYLE DJ, 1987, ANN INTERN MED, V107, P441, DOI 10.7326/0003-4819-107-4-441; DUROUX P, 1991, THROMB HAEMOSTASIS, V65, P251; FRYDMAN AM, 1988, J CLIN PHARMACOL, V28, P609, DOI 10.1002/j.1552-4604.1988.tb03184.x; GALLUS A, 1986, LANCET, V2, P1293; GERHART TN, 1991, J BONE JOINT SURG AM, V73A, P494, DOI 10.2106/00004623-199173040-00003; GLAZIER RL, 1976, JAMA-J AM MED ASSOC, V236, P1365, DOI 10.1001/jama.236.12.1365; GREEN D, 1990, ANN INTERN MED, V113, P571, DOI 10.7326/0003-4819-113-8-571; HANDELAND GF, 1990, EUR J CLIN PHARMACOL, V39, P107, DOI 10.1007/BF00280041; HARENBERG J, 1990, HAEMOSTASIS, V20, P205; HARENBERG J, 1986, THROMB RES, V44, P549, DOI 10.1016/0049-3848(86)90333-6; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HIRSH J, 1990, ACTA CHIR SCAND, P42; HOLM HA, 1986, HAEMOSTASIS, V16, P30; HOLMER E, 1982, THROMB RES, V25, P475, DOI 10.1016/0049-3848(82)90089-5; HUET Y, 1990, ACTA CHIR SCAND, P116; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; HULL R, 1977, NEW ENGL J MED, V296, P1497, DOI 10.1056/NEJM197706302962604; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL R, 1982, NEW ENGL J MED, V306, P189, DOI 10.1056/NEJM198201283060401; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL R, 1978, CIRCULATION, V58, P898, DOI 10.1161/01.CIR.58.5.898; HULL RD, 1990, CIRCULATION, V82, P604; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; HULL RD, 1991, ANN INTERN MED, V115, P231, DOI 10.7326/0003-4819-115-3-231; HYERS TM, 1989, CHEST, V95, pS37, DOI 10.1378/chest.95.2.37S; JANVIER G, 1987, HAEMOSTASIS, V17, P49; KAKKAR VV, 1985, BRIT J SURG, V72, P786, DOI 10.1002/bjs.1800721006; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LEVINE MN, 1986, SEMIN THROMB HEMOST, V12, P39, DOI 10.1055/s-2007-1003533; LOCKNER D, 1986, HAEMOSTASIS, V16, P25; MANT MJ, 1977, LANCET, V1, P1133; MATZSCH T, 1987, THROMB HAEMOSTASIS, V57, P97; MCNEIL BJ, 1980, J NUCL MED, V21, P319; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; PRANDONI P, 1990, HAEMOSTASIS, V20, P220; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; ROOKE TW, 1986, MAYO CLIN PROC, V61, P198, DOI 10.1016/S0025-6196(12)61849-7; ROSENDAAL FR, 1991, THROMB HAEMOSTASIS, V65, P927; SALZMAN EW, 1975, NEW ENGL J MED, V292, P1046, DOI 10.1056/NEJM197505152922002; SALZMAN EW, 1986, NEW ENGL J MED, V315, P957, DOI 10.1056/NEJM198610093151509; SIEGBAHN A, 1989, THROMB RES, V55, P767, DOI 10.1016/0049-3848(89)90307-1; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; VASDEV S, 1991, SCAND J CLIN LAB INV, V51, P321, DOI 10.3109/00365519109091622; VERSTRAETE M, 1990, DRUGS, V40, P498, DOI 10.2165/00003495-199040040-00003; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WHEELER AP, 1988, ARCH INTERN MED, V148, P1321, DOI 10.1001/archinte.148.6.1321; WHEELER HB, 1974, PROG CARDIOVASC DIS, V17, P199; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297; WILLIAMSON DF, 1989, ANN INTERN MED, V110, P916, DOI 10.7326/0003-4819-110-11-916; WILSON JR, 1979, AM HEART J, V97, P155, DOI 10.1016/0002-8703(79)90349-1	69	709	714	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 9	1992	326	15					975	982		10.1056/NEJM199204093261502	http://dx.doi.org/10.1056/NEJM199204093261502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM285	1545850				2022-12-28	WOS:A1992HM28500002
J	IJSSELMUIDEN, CB; FADEN, RR				IJSSELMUIDEN, CB; FADEN, RR			RESEARCH AND INFORMED CONSENT IN AFRICA - ANOTHER LOOK	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEPATITIS-B VACCINE; DEVELOPING-COUNTRIES; CLINICAL RESEARCH; ENDEMIC AREA; HEALTH; AIDS; INFANTS; TRIALS; ETHICS		JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21205 USA	Johns Hopkins University	IJSSELMUIDEN, CB (corresponding author), MED UNIV S AFRICA, MEDUNSA 0204, SOUTH AFRICA.							AJAYI OO, 1980, J MED ETHICS, V6, P61, DOI 10.1136/jme.6.2.61; ANGELL M, 1988, NEW ENGL J MED, V319, P1081, DOI 10.1056/NEJM198810203191608; ANKRAH EM, 1989, SOC SCI MED, V29, P265, DOI 10.1016/0277-9536(89)90275-X; ANKRAH EM, 1991, SOC SCI MED, V32, P967, DOI 10.1016/0277-9536(91)90155-6; [Anonymous], 1986, HIST THEORY INFORM C; [Anonymous], 1982, PROPOSED INT GUIDELI; BARRY M, 1988, NEW ENGL J MED, V319, P1083, DOI 10.1056/NEJM198810203191609; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; BEAUCHAMP TL, 1982, PHILOS ETHICS, P39; BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; BERGH KD, 1990, TXB FAMILY PRACTICE, P285; CHAMBERS R, 1985, RURAL DEV PUTTING LA, P18; CHRISTAKIS NA, 1988, HASTINGS CENT REP, V18, P31, DOI 10.2307/3562201; CLELAND JG, 1988, SOC SCI MED, V27, P1357, DOI 10.1016/0277-9536(88)90201-8; COURSAGET P, 1986, LANCET, V2, P1143; DEBEER C, 1984, S AFRICAN DISEASE AP; DECRAEMER W, 1983, MILBANK FUND Q, V61, P19; DUROJAIYE MOA, 1979, INT J PSYCHOL, V14, P137, DOI 10.1080/00207597908246725; EKUNWE EO, 1984, HASTINGS CENT REP, V14, P23; GILLICK MR, 1985, NEW ENGL J MED, V313, P700, DOI 10.1056/NEJM198509123131120; GRANT JP, 1989, STATE WORLDS CHILDRE; HALL AJ, 1989, LANCET, V1, P1057; INGELFINGER FJ, 1972, NEW ENGL J MED, V287, P465, DOI 10.1056/NEJM197208312870912; JONES JH, 1981, BAD BLOOD; KATZ RL, 1977, WESTERN J MED, V126, P426; KIATBOONSRI P, 1988, LANCET, V2, P1491; MAYNARD JE, 1989, REV INFECT DIS, V11, pS574; Naipaul Shiva, 1980, N S AFRICAN JOURNEY; OYUGI WO, 1988, DEMOCRATIC THEORY PR; PRICE DH, 1989, ATLAS WORLD CULTURES; RAIKES A, 1989, SOC SCI MED, V28, P447, DOI 10.1016/0277-9536(89)90100-7; SCHOUB BD, 1991, BMJ-BRIT MED J, V302, P313, DOI 10.1136/bmj.302.6772.313; SERWADDA D, 1990, LANCET, V335, P842, DOI 10.1016/0140-6736(90)90946-3; SETILOANE GM, 1986, ETHICAL MORAL ISSUES, P32; SMITH HL, 1987, SOC SCI MED, V25, P705, DOI 10.1016/0277-9536(87)90098-0; SMITH HL, 1979, ETHICS SCI MED, V6, P167; Susser MW, 1985, SOCIOLOGY MED; TAYLOR CE, 1979, AM J PUBLIC HEALTH, V69, P981, DOI 10.2105/AJPH.69.10.981; VEATCH RM, 1984, HASTINGS CENT REP, V14, P38, DOI 10.2307/3561097; WILLETT WC, 1979, AM J PUBLIC HEALTH, V69, P987, DOI 10.2105/AJPH.69.10.987; YVONNET B, 1987, J MED VIROL, V22, P315, DOI 10.1002/jmv.1890220404; ZULU P, 1984, 2ND CARN INQ POV DEV; 1983, APARTHEID HLTH; 1978, DHEW OS780012 NAT CO	44	92	94	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1992	326	12					830	834		10.1056/NEJM199203193261212	http://dx.doi.org/10.1056/NEJM199203193261212			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ592	1538731				2022-12-28	WOS:A1992HJ59200012
J	JURIVICH, DA; SISTONEN, L; KROES, RA; MORIMOTO, RI				JURIVICH, DA; SISTONEN, L; KROES, RA; MORIMOTO, RI			EFFECT OF SODIUM-SALICYLATE ON THE HUMAN HEAT-SHOCK RESPONSE	SCIENCE			English	Article							AMINO-ACID-ANALOGS; ASPIRIN-LIKE DRUGS; DNA-BINDING; TRANSCRIPTION FACTOR; HUMAN-CELLS; PROTEIN; SEQUENCE; INHIBITION; EXPRESSION; ACTIVATION	Sodium salicylate, an anti-inflammatory agent, was examined for its effects on the heat shock response in cultured human cells. Salicylate activation of DNA binding by the heat shock transcription factor (HSF) was comparable to activation attained during heat shock. However, sodium salicylate did not induce heat shock gene transcription even though the HSF was bound in vivo to the heat shock elements upstream of the heat shock protein 70 (Hsp 70) gene. These results reveal that activation of the heat shock transcriptional response is a multistep process. Modulation of extracellular pH augments sensitivity to salicylate-induced activation of HSF.	NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT MED,EVANSTON,IL 60208	Northwestern University; Northwestern University			Kroes, Roger A/B-7620-2009	Sistonen, Lea/0000-0003-1341-2867	NIA NIH HHS [AG00509] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; ADRIAN C, 1957, J PHARMACOL EXP THER, V120, P540; AMICI C, UNPUB; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; GALLO GJ, 1991, MOL CELL BIOL, V11, P281, DOI 10.1128/MCB.11.1.281; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HIGGS GA, 1987, P NATL ACAD SCI USA, V84, P1417, DOI 10.1073/pnas.84.5.1417; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; JAMES MJ, 1990, J RHEUMATOL, V17, P579; JAMES MJ, 1990, J RHEUMATOL, V17, P529; JURIVICH D, UNPUB; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; KUBO T, 1985, ARTHRITIS RHEUM, V28, P1140, DOI 10.1002/art.1780281010; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; MORIMOTO RI, 1990, STRESS PROTEINS BIOL, P21; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; OHNO K, 1988, J BIOL CHEM, V263, P19764; Ritossa F, 1963, DROSOPHILA INFORMATI, V37, P122, DOI 10.1016/0014-4827(64)90147-8; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SARGENT CA, 1989, P NATL ACAD SCI USA, V86, P1968, DOI 10.1073/pnas.86.6.1968; SIEGEL MI, 1979, P NATL ACAD SCI USA, V76, P3774, DOI 10.1073/pnas.76.8.3774; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WATOWICH SS, 1990, THESIS NW U EVANSTON; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	42	343	357	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1243	1245		10.1126/science.1546322	http://dx.doi.org/10.1126/science.1546322			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546322				2022-12-28	WOS:A1992HG67700039
J	FEELY, J; BARRY, M; KEELING, PWN; WEIR, DG; COOKE, T				FEELY, J; BARRY, M; KEELING, PWN; WEIR, DG; COOKE, T			LIPOPROTEIN(A) IN CIRRHOSIS	BRITISH MEDICAL JOURNAL			English	Article							LP(A)		ST JAMES HOSP,TRINITY COLL MED SCH,DEPT CLIN MED,DUBLIN 8,IRELAND; DUBLIN INST TECHNOL,DEPT BIOL SCI,DUBLIN,IRELAND	Trinity College Dublin; Technological University Dublin	FEELY, J (corresponding author), ST JAMES HOSP,TRINITY COLL MED SCH,DEPT PHARMACOL & THERAPEUT,DUBLIN 8,IRELAND.			Barry, Michael/0000-0002-6232-3003				CARLSON LA, 1989, J INTERN MED, V226, P271, DOI 10.1111/j.1365-2796.1989.tb01393.x; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; MARTH E, 1982, ANN NUTR METAB, V26, P56, DOI 10.1159/000176544; SHERLOCK S, 1989, DIS LIVER BILIARY SY, P418; Utermann G, 1990, CURR OPIN LIPIDOL, V1, P404	5	51	51	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					545	546		10.1136/bmj.304.6826.545	http://dx.doi.org/10.1136/bmj.304.6826.545			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1532756	Bronze, Green Published			2022-12-28	WOS:A1992HG59900022
J	FRANCKLYN, C; SHI, JP; SCHIMMEL, P				FRANCKLYN, C; SHI, JP; SCHIMMEL, P			OVERLAPPING NUCLEOTIDE DETERMINANTS FOR SPECIFIC AMINOACYLATION OF RNA MICROHELICES	SCIENCE			English	Article							MOLECULAR RECOGNITION; SYNTHETASE; IDENTITY; PARAMETERS; PAIR; END; POLYMERASE; GENES; SITE; BASE	A seven-base pair microhelix that recapitulates a glycine transfer RNA (tRNA) acceptor helix can be specifically aminoacylated with glycine. A single base pair and the single-stranded discriminator base near the attachment site are essential for aminoacylation. These nucleotide sequence elements, and those in microhelices that can be charged with histidine and alanine, occur in the same positions and therefore overlap. Studies on a systematic set of sequence variants showed that no microhelix could be charged with more than one amino acid. Also, none of the three cognate aminoacyl-tRNA synthetases (aaRSs) gave a detectable amount of aminoacylation of the CCA trinucleotide that is common to the 3' ends of all tRNAs, showing that the specific acceptor stem nucleotide bases confer aminoacylation. An analysis of the relative contributions of these microhelices to overall tRNA recognition indicates that their interaction with aaRSs constitutes a substantial part of the recognition of the whole tRNAs.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					PHS HHS [15539] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CARBON J, 1974, J MOL BIOL, V85, P371, DOI 10.1016/0022-2836(74)90439-2; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; FERSHT A, 1977, ENZYME STRUCTURE MEC, P33; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAMMES GC, 1982, ENZYME CATALYSIS REG, P76; HASEGAWA T, 1989, BIOCHEM BIOPH RES CO, V163, P1534, DOI 10.1016/0006-291X(89)91154-6; HILL K, 1989, BIOCHEMISTRY-US, V28, P2577, DOI 10.1021/bi00432a035; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; MARTINIS SA, 1992, P NATL ACAD SCI USA, V89, P65, DOI 10.1073/pnas.89.1.65; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P6147, DOI 10.1073/pnas.88.14.6147; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PARK SJ, 1989, BIOCHEMISTRY-US, V28, P2740, DOI 10.1021/bi00432a056; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; ROBERTS JW, 1974, NATURE, V250, P412, DOI 10.1038/250412a0; ROGERS MJ, 1988, P NATL ACAD SCI USA, V85, P6627, DOI 10.1073/pnas.85.18.6627; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMPSON JR, 1989, SCIENCE, V243, P1363; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SHI JP, 1991, J BIOL CHEM, V266, P2705; SHI JP, 1989, BIOCHEMISTRY-US, V29, P361; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; TOTH MJ, 1990, J BIOL CHEM, V265, P1005	38	130	131	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 28	1992	255	5048					1121	1125		10.1126/science.1546312	http://dx.doi.org/10.1126/science.1546312			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546312				2022-12-28	WOS:A1992HF63200039
J	GORE, SM; CABLE, DJ; HOLLAND, AJ				GORE, SM; CABLE, DJ; HOLLAND, AJ			ORGAN DONATION FROM INTENSIVE-CARE UNITS IN ENGLAND AND WALES - 2 YEAR CONFIDENTIAL AUDIT OF DEATHS IN INTENSIVE-CARE	BRITISH MEDICAL JOURNAL			English	Article							TRANSPLANTATION	Objectives - Quantify possible increases in cadaveric organ donation from intensive care units; identify major sources of regional variation. Design - Confidential audit of all deaths in intensive care units in England in 1989 and 1990 and in Wales in 1990. Setting - 15 regional and special health authorities in England; Wales. Patients - 24023 audited deaths in England; 682 in Wales. Main outcome measures - Solid organ and corneal donor rates per 100 deaths; solid organ donor rate per 100 confirmed brain stem deaths; regional variation in (a) whether brain stem death was possible diagnosis, (b) general medical contraindications to donation, (c) relatives' refusal. Results - Confirmed brain stem death accounted for 2389 (10%) audited deaths in England. In 438 (18%) there was a general medical contraindication to organ donation, and of 1829 (94%) families asked about donation, 557 (30%) refused. Data for England suggested that among potential donors the heart is suitable for transplantation in 65% of cases, the kidneys in 95%, the liver in 71%, the lungs in 31%, and the corneas in 92%. Reasons for any shortfall in achievement of transplantation varied with organ type. Solid organ and corneal donor rates per 100 deaths were 5.0 and 3.9 respectively in England and 4.3 and 2.1 respectively in Wales. The solid organ donor rate per 100 confirmed brain stem deaths was 50 in England and 41 in Wales. Conclusions - A 20% increase in number of cadaveric kidney donors from intensive care could be achieved by prompt testing for brain stem death and a quarter reduction in relatives' refusals.			GORE, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2BW,ENGLAND.							COHEN AT, 1989, BRIT MED J, V299, P1463, DOI 10.1136/bmj.299.6713.1463-c; COLLINS C, 1989, BRIT MED J, V299, P1463, DOI 10.1136/bmj.299.6713.1463-b; Diagnosis of brain death, 1976, BMJ-BRIT MED J, V2, P1187; FEEST TG, 1990, LANCET, V335, P1133, DOI 10.1016/0140-6736(90)91134-V; GENTLEMAN D, 1990, BMJ-BRIT MED J, V301, P1203, DOI 10.1136/bmj.301.6762.1203; GORE SM, 1991, BRIT MED J, V302, P149, DOI 10.1136/bmj.302.6769.149; GORE SM, 1989, BRIT MED J, V299, P1193, DOI 10.1136/bmj.299.6709.1193; GORE SM, 1991, BRIT MED J, V302, P52, DOI 10.1136/bmj.302.6767.52-b; PAYNE JN, 1989, BRIT MED J, V299, P1463; SALIH MAM, 1991, BRIT MED J, V302, P1053, DOI 10.1136/bmj.302.6784.1053; WALLWORK J, 1989, BRIT MED J, V299, P1291, DOI 10.1136/bmj.299.6711.1291; 1979, BMJ, V1, P332; 1989, 1989 EUR F ANN REP, P21; 1987, REPORT	14	95	95	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					349	355		10.1136/bmj.304.6823.349	http://dx.doi.org/10.1136/bmj.304.6823.349			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540732	Bronze, Green Published			2022-12-28	WOS:A1992HD38700023
J	JONES, KP; BAIN, DJG; MIDDLETON, M; MULLEE, MA				JONES, KP; BAIN, DJG; MIDDLETON, M; MULLEE, MA			CORRELATES OF ASTHMA MORBIDITY IN PRIMARY CARE	BRITISH MEDICAL JOURNAL			English	Article							PRESSURIZED AEROSOL INHALERS; PEAK EXPIRATORY FLOW; GENERAL-PRACTICE; INTERNATIONAL TRENDS; MANAGEMENT; MORTALITY; PATIENT; PREVALENCE; EDUCATION; CHILDREN	Objectives - To explore the morbidity of patients diagnosed as asthmatic in general practice, to examine the determinants of this morbidity, and to derive a simple morbidity screening tool for use in primary care. Design - Patient interviews, lung function measurements, and data extraction from general practice case notes. Subjects - 300 asthmatic patients aged 5 to 65 years randomly selected from the repeat prescribing registers of three general practices in the Southampton area. Main outcome measures - Reported morbidity using a calculated index based on three questions (Are you in a wheezy or asthmatic condition at least once per week; Have you had time off work or school in the past year because of your asthma; Do you suffer from attacks of wheezing during the night?); mean forced expiratory volume in one second and mean peak expiratory flow (over a seven day period); diurnal variation in peak flow; and the relation of the morbidity index to lung function. Results - Mean forced expiratory volume in one second was 67% predicted (SD 18.4), mean peak expiratory flow was 80% predicted (SD 18.9), and mean diurnal variation was 10% (SD 7.7). 76 subjects were classified as having low morbidity, 95 medium, and 125 high. The morbidity index was significantly associated with forced expiratory volume in one second, mean peak expiratory flow rate, and diurnal variation (p < 0.05); it was not significantly associated with inhaler technique or use of prophylaxis. Conclusions - There was a large burden of persisting morbidity across all ages of patients diagnosed as asthmatic in the three well resourced practices studied. The use of the morbidity index may help to target the asthmatic patients needing more attention by concentrating on those reporting medium to high morbidity.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton	JONES, KP (corresponding author), UNIV SOUTHAMPTON,ALDERMOOR HLTH CTR,FAC MED,PRIMARY MED CARE GRP,SOUTHAMPTON SO1 6SY,ENGLAND.							ALLEN SC, 1986, BRIT J DIS CHEST, V80, P45, DOI 10.1016/0007-0971(86)90008-2; ANDERSON HR, 1990, THORAX, V45, P431, DOI 10.1136/thx.45.6.431; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BOSANQUET N, 1988, BRIT MED J, V296, P1576, DOI 10.1136/bmj.296.6636.1576; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; EVANS R, 1987, CHEST S, V91, P65; GELLERT AR, 1990, BRIT J GEN PRACT, V40, P197; GONAWARDENA KA, 1987, THORAX, V42, P689; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368; HILTON S, 1982, J ROY SOC MED, V75, P625; HILTON S, 1990, BRIT J GEN PRACT, V40, P505; HILTON S, 1986, LANCET, V1, P26; HOLGATE ST, 1988, Q J MED, V66, P5; HORN CR, 1989, RESP MED, V83, P71, DOI 10.1016/S0954-6111(89)80063-0; HORSLEY MG, 1988, J CLIN PHARM THER, V13, P139, DOI 10.1111/j.1365-2710.1988.tb00170.x; JACKSON R, 1988, CHEST, V94, P914, DOI 10.1378/chest.94.5.914; JENKINSON D, 1988, BRIT MED J, V297, P267, DOI 10.1136/bmj.297.6643.267; JONES K, 1989, J ROY COLL GEN PRACT, V39, P254; Jones K, 1989, UPDATE, V38, P1399; JONES KP, 1990, BRIT MED J, V300, P1629, DOI 10.1136/bmj.300.6740.1629; MAO Y, 1987, CAN MED ASSOC J, V137, P620; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; NEVILLE R, 1990, PRACTITIONER, V234, P417; NORUSIS MJ, 1983, SPSSX INTRO STATISTI; NORUSIS MJ, 1989, SPSS GUIDE DATA ANAL; PEDERSEN S, 1986, ALLERGY, V41, P118, DOI 10.1111/j.1398-9995.1986.tb00287.x; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STRUNK RC, 1987, J ALLERGY CLIN IMMUN, V80, P455, DOI 10.1016/0091-6749(87)90073-X; TURNERWARWICK M, 1989, J ROY COLL GEN PRACT, V39, P239; WHITE PT, 1989, J ROY COLL GEN PRACT, V39, P182; 1989, LANCET, V2, P199; 1982, BMJ, V285, P1251	36	53	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					361	364		10.1136/bmj.304.6823.361	http://dx.doi.org/10.1136/bmj.304.6823.361			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540736	Bronze, Green Published			2022-12-28	WOS:A1992HD38700027
J	BROWN, DA; ROSE, JK				BROWN, DA; ROSE, JK			SORTING OF GPI-ANCHORED PROTEINS TO GLYCOLIPID-ENRICHED MEMBRANE SUBDOMAINS DURING TRANSPORT TO THE APICAL CELL-SURFACE	CELL			English	Article							POLARIZED EPITHELIAL-CELLS; VESICULAR STOMATITIS-VIRUS; GLYCOSYL-PHOSPHATIDYLINOSITOL; PLASMA-MEMBRANE; TRYPANOSOMA-BRUCEI; MDCK CELLS; INTRACELLULAR-TRANSPORT; CHOLERA-TOXIN; ORGANIZATION; GLYCOPROTEINS	We show that a protein with a glycosylphosphatidyl inositol (GPI) anchor can be recovered from lysates of epithelial cells in a low density, detergent-insoluble form. Under these conditions, the protein is associated with detergent-resistant sheets and vesicles that contain other GPI-anchored proteins and are enriched in glycosphingolipids, but do not contain a basolateral marker protein. The protein is recovered in this complex only after it has been transported to the Golgi complex, suggesting that protein-sphingolipid microdomains form in the Golgi apparatus and plasma membrane and supporting the model proposed by Simons and colleagues for sorting of certain membrane proteins to the apical surface after intracellular association with glycosphingolipids.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University; Yale University					NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; PHS HHS [A124345] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		APGAR JR, 1986, J CELL BIOL, V103, P351, DOI 10.1083/jcb.103.2.351; ARIGA T, 1988, BIOCHEMISTRY-US, V27, P52, DOI 10.1021/bi00401a010; BERGER J, 1987, P NATL ACAD SCI USA, V84, P4885, DOI 10.1073/pnas.84.14.4885; BOOTHROYD JC, 1981, NUCLEIC ACIDS RES, V9, P4735, DOI 10.1093/nar/9.18.4735; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DAVIES AA, 1984, BIOCHEM J, V219, P301, DOI 10.1042/bj2190301; DOERING TL, 1990, J BIOL CHEM, V265, P611; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GONZALEZ A, 1987, P NATL ACAD SCI USA, V84, P3738, DOI 10.1073/pnas.84.11.3738; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HAGMANN J, 1982, BIOCHIM BIOPHYS ACTA, V720, P181, DOI 10.1016/0167-4889(82)90010-6; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOESSLI D, 1985, EXP CELL RES, V156, P239, DOI 10.1016/0014-4827(85)90278-2; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LETARTEMUIRHEAD M, 1974, BIOCHEM J, V143, P51, DOI 10.1042/bj1430051; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MACALA LJ, 1983, J LIPID RES, V24, P1243; McRoberts J. A., 1981, FUNCTIONALLY DIFFERE, P117; MENON AK, 1988, J BIOL CHEM, V263, P1970; MESCHER MF, 1981, NATURE, V289, P139, DOI 10.1038/289139a0; MESCHER MF, 1986, ADV EXP MED, V184, P387; NELSON WJ, 1987, J CELL BIOL, V104, P1527, DOI 10.1083/jcb.104.6.1527; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; NICHOLS GE, 1988, J LIPID RES, V29, P1205; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1982, CELL, V30, P753, DOI 10.1016/0092-8674(82)90280-X; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; STREULI CH, 1981, EXP CELL RES, V136, P247, DOI 10.1016/0014-4827(81)90002-1; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; THIELE HG, 1986, IMMUNOLOGY, V59, P195; THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.biophys.14.1.361; VAN MEER G, 1982, EMBO J, V1, P847, DOI 10.1002/j.1460-2075.1982.tb01258.x; VITETTA ES, 1973, EUR J IMMUNOL, V3, P446, DOI 10.1002/eji.1830030714; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	54	2577	2630	3	157	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					533	544		10.1016/0092-8674(92)90189-J	http://dx.doi.org/10.1016/0092-8674(92)90189-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1531449	hybrid			2022-12-28	WOS:A1992HD39800013
J	DEVOS, AM; ULTSCH, M; KOSSIAKOFF, AA				DEVOS, AM; ULTSCH, M; KOSSIAKOFF, AA			HUMAN GROWTH-HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR - CRYSTAL-STRUCTURE OF THE COMPLEX	SCIENCE			English	Article							X-RAY-DIFFRACTION; MACROMOLECULAR CRYSTALLOGRAPHY; SCANNING MUTAGENESIS; PROLACTIN RECEPTOR; HUMAN CD4; BINDING; SUPERFAMILY; RESOLUTION; FRAGMENT; DETECTOR	Binding of human growth hormone (hGH) to its receptor is required for regulation of normal human growth and development. Examination of the 2.8 angstrom crystal structure of the complex between the hormone and the extracellular domain of its receptor (hGHbp) showed that the complex consists of one molecule of growth hormone per two molecules of receptor. The hormone is a four-helix bundle with an unusual topology. The binding protein contains two distinct domains, similar in some respects to immunoglobulin domains. The relative orientation of these domains differs from that found between constant and variable domains in immunoglobulin Fab fragments. Both hGHbp domains contribute residues that participate in hGH binding. In the complex both receptors donate essentially the same residues to interact with the hormone, even though the two binding sites on hGH have no structural similarity. Generally, the hormone-receptor interfaces match those identified by previous mutational analyses. In addition to the hormone-receptor interfaces, there is also a substantial contact surface between the carboxyl-terminal domains of the receptors. The relative extents of the contact areas support a sequential mechanism for dimerization that may be crucial for signal transduction.			DEVOS, AM (corresponding author), GENENTECH INC, DEPT PROT ENGN, 460 POINT SAN BRUNO BLVD, SAN FRANCISCO, CA 94080 USA.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEWLEY TA, 1984, ARCH BIOCHEM BIOPHYS, V233, P219, DOI 10.1016/0003-9861(84)90620-9; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLARK RD, UNPUB; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUH G, 1990, J BIOL CHEM, V265, P3111; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LAMBERT G, 1989, J BIOL CHEM, V264, P12730; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MULKERRIN MG, UNPUB; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; STEIGEMANN W, 1974, THESIS TU MUNCHEN; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULTSCH M, IN PRESS J MOL BIOL; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	2073	2636	1	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 17	1992	255	5042					306	312		10.1126/science.1549776	http://dx.doi.org/10.1126/science.1549776			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1549776				2022-12-28	WOS:A1992GZ69500035
J	MADDEN, DR; GORGA, JC; STROMINGER, JL; WILEY, DC				MADDEN, DR; GORGA, JC; STROMINGER, JL; WILEY, DC			THE 3-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROM RESOLUTION SUGGESTS A GENERAL MECHANISM FOR TIGHT PEPTIDE BINDING TO MHC	CELL			English	Article							I HISTOCOMPATIBILITY ANTIGENS; SELF-PEPTIDES; HLA-A; ALPHA-3 DOMAIN; ANKYLOSING-SPONDYLITIS; LYMPHOCYTES-T; MOLECULES; RECOGNITION; PROTEIN; SITE	Cell surface complexes of class I MHC molecules and bound peptide antigens serve as specific recognition elements controlling the cytotoxic immune response. The 2.1 angstrom structure of the human class I MHC molecule HLA-B27 provides a detailed composite image of a co-crystallized collection of HLA-B27-bound peptides, indicating that they share a common main-chain structure and length. It also permits direct visualization of the conservation of arginine as an "anchor" side chain at the second peptide position, which is bound in a potentially HLA-B27-specific pocket and may therefore have a role in the association of HLA-B27 with several diseases. Tight peptide binding to class I MHC molecules appears to result from the extensive contacts found at the ends of the cleft between peptide main-chain atoms and conserved MHC side chains, which also involve the peptide in stabilizing the three-dimensional fold of HLA-B27. The concentration of binding interactions at the peptide termini permits extensive sequence (and probably some length) variability in the center of the peptide, where it is exposed for T cell recognition.	HARVARD UNIV,COMM HIGHER DEGREES BIOPHYS,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Howard Hughes Medical Institute	MADDEN, DR (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLU M, 1990, THESIS HARVARD U CAM; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BREURVRIESENDORP BS, 1987, ANN RHEUM DIS, V46, P353, DOI 10.1136/ard.46.5.353; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, X PLOR; BUXTON SE, 1992, J EXP MED, V175, P809, DOI 10.1084/jem.175.3.809; CALVO V, 1990, J IMMUNOL, V144, P4038; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHOO SY, 1991, J IMMUNOL, V147, P174; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; DAVIS MM, 1990, ANNU REV BIOCHEM, V59, P475, DOI 10.1146/annurev.biochem.59.1.475; DECASTRO JAL, 1989, IMMUNOL TODAY, V10, P239, DOI 10.1016/0167-5699(89)90261-2; DECASTRO JAL, 1984, METHOD ENZYMOL, V108, P582; DeMars R, 1992, Trends Cell Biol, V2, P81, DOI 10.1016/0962-8924(92)90077-Z; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; EZQUERRA A, 1985, BIOCHEMISTRY-US, V24, P1733, DOI 10.1021/bi00328a025; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; FREMONT DH, 1992, IN PRESS SCIENCE; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GORGA JC, 1992, PROTEINS, V12, P87, DOI 10.1002/prot.340120110; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HEDRICK PW, 1991, P NATL ACAD SCI USA, V88, P5897, DOI 10.1073/pnas.88.13.5897; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HERMANS J, 1974, ACTA CRYSTALLOGR A, VA 30, P730, DOI 10.1107/S056773947400180X; HILL AVS, 1991, LANCET, V337, P640, DOI 10.1016/0140-6736(91)92452-8; HUET SH, 1990, INT IMMUNOL, V4, P311; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Johnson CK, 1965, 3794 ONRL; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KHAN MA, 1987, ANKYLOSING SPONDYLIT, V1, P23; KRISHNA S, 1992, NATURE, V357, P164, DOI 10.1038/357164a0; LATRON F, 1992, IN PRESS SCIENCE; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOPEZ D, 1992, J IMMUNOL, V148, P996; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MATSUMURA M, 1992, IN PRESS SCIENCE; MCLACHLAN AD, 1979, J MOL BIOL, V128, P49, DOI 10.1016/0022-2836(79)90308-5; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; PARHAM P, 1977, J BIOL CHEM, V252, P7555; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHULZ GE, 1979, PRINCIPALS PROTEIN S, P3; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TILTON RF, 1992, BIOCHEMISTRY-US, V31, P2469, DOI 10.1021/bi00124a006; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TURNER MJ, 1975, J BIOL CHEM, V250, P4512; VANBLEEK GM, 1991, P NATL ACAD SCI USA, V88, P11032, DOI 10.1073/pnas.88.24.11032; VILLADANGOS JA, 1992, J IMMUNOL, V149, P505; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; ZHANG W, 1992, IN PRESS P NATL ACAD	75	643	663	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					1035	1048		10.1016/0092-8674(92)90252-8	http://dx.doi.org/10.1016/0092-8674(92)90252-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525820				2022-12-28	WOS:A1992JN78100017
J	FURLONG, TE				FURLONG, TE			MYOBLAST TRANSPLANTATION	SCIENCE			English	Letter																			0	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1329	1329		10.1126/science.1529325	http://dx.doi.org/10.1126/science.1529325			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529325				2022-12-28	WOS:A1992JL61200003
J	HOFFMANN, KK; WEBER, DJ; SAMSA, GP; RUTALA, WA				HOFFMANN, KK; WEBER, DJ; SAMSA, GP; RUTALA, WA			TRANSPARENT POLYURETHANE FILM AS AN INTRAVENOUS CATHETER DRESSING - A METAANALYSIS OF THE INFECTION RISKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OP-SITE; GAUZE DRESSINGS; NUTRITION; CULTURES; CARE	Objective. - To obtain a quantitative estimate of the impact on infectious complications of using transparent dressings with intravenous catheters. Data Sources. - Meta-analysis of all studies published in the English literature, including abstracts, letters, and reports that examined the primary research question of infection risks associated with transparent compared with gauze dressings for use on central and peripheral venous catheters. Studies were identified by use of the MEDLINE database using the indexing terms occlusive dressings, transparent dressings, and infection and by review of referenced bibliographies. Study Selection. - Seven of the 15 studies (47%) of central venous catheters and seven of 12 studies (58%) of peripheral catheters met our inclusion criteria for analysis. All studies used a prospective cohort design, utilized hospitalized patients, and reported at least one of our defined outcomes. Extraction. - Data for each study were abstracted independently by three investigators. At least three studies were used in the analysis of each outcome. Data Synthesis. - Applying a Mantel-Haenszel chi-2 analysis, use of transparent dressings on central venous catheters was significantly associated with an elevated relative risk (RR) of catheter tip infection (RR = 1.78; 95% confidence interval [Cl], 1.38 to 2.30). Catheter-related sepsis (RR = 1.69; 95% Cl, 0.97 to 2.95) and bacteremia (RR = 1.63; 95% Cl, 0.76 to 3.47) were both associated with an elevated RR. Use of transparent dressings on peripheral catheters was associated with an elevated RR of catheter-tip infection (RR = 1.53; 95% Cl, 1.18 to 1.99) but not phlebitis(RR = 1.02; 95% Cl, 0.86 to 1.20), infiltration (RR = 1.12; 95% Cl, 0.92 to 1.37), or skin colonization (RR = 0.99; 95% Cl, 0.90 to 1.09). Conclusion. - The results demonstrated a significantly increased risk of catheter-tip infection with the use of transparent compared with gauze dressings when used with either central or peripheral catheters. An increased risk of bacteremia and catheter sepsis associated with the use of transparent compared with gauze dressings for use on central venous catheters was suggested.	UNIV N CAROLINA HOSP,DEPT HOSP EPIDEMIOL,CHAPEL HILL,NC; DUKE UNIV,DEPT COMMUNITY & FAMILY MED,DIV BIOMETRY & MED INFORMAT,DURHAM,NC 27706	University North Carolina Hospital; Duke University	HOFFMANN, KK (corresponding author), UNIV N CAROLINA,DIV INFECT DIS,CB 7030,BURNETT WOMACK 547,CHAPEL HILL,NC 27599, USA.							ALY R, 1978, J INVEST DERMATOL, V71, P378, DOI 10.1111/1523-1747.ep12556778; ANDERSEN PT, 1986, J HOSP INFECT, V7, P161, DOI 10.1016/0195-6701(86)90059-9; BERRY R, 1986, MAY NAT INTR THER AS; BULPITT CJ, 1988, LANCET, V2, P93; CONLY JM, 1989, J INFECT DIS, V159, P310, DOI 10.1093/infdis/159.2.310; CRAVEN DE, 1985, INFECT CONT HOSP EP, V6, P361, DOI 10.1017/S0195941700063323; DICKERSON N, 1989, J INFECT DIS, V160, P720, DOI 10.1093/infdis/160.4.720; DOWNING JW, 1987, S AFR MED J, V72, P191; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; EINARSON TR, 1988, DRUG INTEL CLIN PHAR, V22, P813, DOI 10.1177/106002808802201021; GANTZ NM, 1984, DIAGN MICR INFEC DIS, V2, P325, DOI 10.1016/0732-8893(84)90064-6; GERBARG ZB, 1988, J CLIN EPIDEMIOL, V41, P503, DOI 10.1016/0895-4356(88)90053-4; GUGLIOTTI R, 1985, 12TH ANN ED C AS PRA; HAMPTON AA, 1988, SURG CLIN N AM, V68, P57; HOFFMANN KK, 1988, AM J INFECT CONTROL, V16, P101, DOI 10.1016/0196-6553(88)90046-6; JARRARD M, 1980, 4TH AM SOC PAR ENT N; JOSEPH P, 1985, 85TH ANN M AM SOC MI; KATICH M, 1985, J INFECT DIS, V151, P971, DOI 10.1093/infdis/151.5.971-a; KELSEY MC, 1984, J HOSP INFECT, V5, P313, DOI 10.1016/0195-6701(84)90081-1; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; Lawson M, 1986, J NATL INTRAVENOUS T, V9, P40; LITTENBERG B, 1987, J GEN INTERN MED, V2, P411, DOI 10.1007/BF02596369; MAKI D, 1984, JUN ASS PRACT INF CO; MAKI DG, 1987, JAMA-J AM MED ASSOC, V258, P2396, DOI 10.1001/jama.258.17.2396; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MAKI DG, 1986, 26TH INT C ANT AG CH; MAKI DG, 1986, HOSPITAL INFECTIONS, P561; MAKI DG, 24TH INT C ANT AG CH; NICOLA M, 1984, J NATL INTRAVENOUS T, V7, P139; PALIDAR PJ, 1982, JPEN-PARENTER ENTER, V6, P150, DOI 10.1177/0148607182006002150; PERKINS CM, 1990, PROB CRIT CARE, V4, P21; PETERSON PJ, 1982, J NATL INTRAVENOUS T, V5, P387; PETTIGREW RA, 1985, BRIT J SURG, V72, P52, DOI 10.1002/bjs.1800720121; POWELL CR, 1985, JPEN-PARENTER ENTER, V9, P443, DOI 10.1177/0148607185009004443; POWERS DL, 1982, J GRAPH THEOR, V6, P43, DOI 10.1002/jgt.3190060106; RICHET H, 1990, J CLIN MICROBIOL, V28, P2520, DOI 10.1128/JCM.28.11.2520-2525.1990; RIGHTER J, 1983, DIAGN MICR INFEC DIS, V1, P89, DOI 10.1016/0732-8893(83)90037-8; THOMAS MA, 1977, JPEN J PARENTER ENTE, V1, P41; YOUNG GP, 1988, JPEN-PARENTER ENTER, V12, P365, DOI 10.1177/0148607188012004365	40	164	171	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2072	2076		10.1001/jama.267.15.2072	http://dx.doi.org/10.1001/jama.267.15.2072			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1532429	Green Submitted			2022-12-28	WOS:A1992HM65000034
J	SINGER, DE; NATHAN, DM; FOGEL, HA; SCHACHAT, AP				SINGER, DE; NATHAN, DM; FOGEL, HA; SCHACHAT, AP			SCREENING FOR DIABETIC-RETINOPATHY	ANNALS OF INTERNAL MEDICINE			English	Review						DIABETIC RETINOPATHY; LIGHT COAGULATION; OPHTHALMOSCOPY; PHOTOGRAMMETRY; COST SAVINGS	MYDRIATIC FUNDUS PHOTOGRAPHY; NON-HISPANIC WHITES; RISK-FACTORS; MACULAR EDEMA; BLOOD-PRESSURE; PIMA-INDIANS; PROLIFERATIVE RETINOPATHY; 4-YEAR INCIDENCE; PROGRESSION; DIAGNOSIS	Purpose: To determine the appropriate patients, methods, and timing for screening for diabetic retinopathy. Data Sources: Relevant articles were identified through prominent review articles, the authors' files, recommendations from experts, and a MEDLINE search (1 986 to the present); additional references were selected from the bibliographies of identified articles. Study Selection: Selection of articles on the natural history of retinopathy was limited to large clinical series and formal epidemiologic studies of defined populations. Selection of articles on the therapeutic effect of photocoagulation and of glycemic control was limited to randomized trials. Sources bearing on the accuracy of screening modalities were necessarily more varied. Data Extraction: For important variables, individual estimates from multiple studies are presented rather than a single meta-analytic summary estimate. Results: Screening for retinopathy is justifiable if early detection leads to less vision loss at an acceptable cost. The evidence shows that 1) laser therapy reduces the rate of vision loss by 50% among patients with proliferative retinopathy and macular edema, conditions that are often asymptomatic; 2) duration of diabetes is the main risk factor for retinopathy; and 3) standard ophthalmoscopic examination has only moderate sensitivity (about 80% in research settings) and specificity (> 90% for proliferative retinopathy but lower for macular edema), making seven-field stereo-photography a more accurate method. Estimates of cost effectiveness indicate that screening for retinopathy not only saves years of vision but may be cost saving from a societal perspective. Conclusions: Screening for retinopathy in patients with diabetes, and subsequent photocoagulation therapy for those who have high risk macular edema or proliferative retinopathy, is clearly beneficial.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV HOSP, BALTIMORE, MD 21205 USA	Harvard University; Harvard Medical School; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	SINGER, DE (corresponding author), MASSACHUSETTS GEN HOSP, GEN INTERNAL MED UNIT, BULLFINCH 1, BOSTON, MA 02114 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006665] Funding Source: NIH RePORTER; AHRQ HHS [1 RO1 HS06665] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1991, Ophthalmology, V98, P757; [Anonymous], 1991, OPHTHALMOLOGY, V98, P741; [Anonymous], 1978, Ophthalmology, V85, P82; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; BALLARD DJ, 1986, DIABETES CARE, V9, P334, DOI 10.2337/diacare.9.4.334; BARRIE T, 1986, BRIT MED J, V293, P1304, DOI 10.1136/bmj.293.6557.1304; BAUDOIN C, 1989, DIABETES, V38, P491; BLANKENSHIP GW, 1979, OPHTHALMOLOGY, V86, P69; BRINCHMANNHANSEN O, 1988, ARCH OPHTHALMOL-CHIC, V106, P1242; DASBACH EJ, 1991, MED CARE, V29, P20, DOI 10.1097/00005650-199101000-00003; DCCT Res Grp, 1987, ARCH OPHTHALMOL-CHIC, V105, P1344; DWYER MS, 1985, DIABETES CARE, V8, P316, DOI 10.2337/diacare.8.4.316; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; ENGERMAN RL, 1987, INT OPHTHALMOL CLIN, V27, P225, DOI 10.1097/00004397-198702740-00002; FORREST RD, 1987, DIABETES RES CLIN EX, V5, P39; Foulds W S, 1983, Health Bull (Edinb), V41, P318; FRNAK RN, 1989, RETINA, V2, P301; GROOP LC, 1986, DIABETES, V35, P1397, DOI 10.2337/diabetes.35.12.1397; HAFFNER SM, 1988, DIABETES, V37, P878, DOI 10.2337/diabetes.37.7.878; HAMMAN RF, 1989, DIABETES, V38, P1231, DOI 10.2337/diabetes.38.10.1231; HARRIS M, 1979, DIABETES, V28, P1039; HOWARDWILLIAMS J, 1984, DIABETOLOGIA, V27, P198; ISHIHARA M, 1987, DIABETES CARE, V10, P20, DOI 10.2337/diacare.10.1.20; JANKA HU, 1989, DIABETES, V38, P460, DOI 10.2337/diabetes.38.4.460; JAVITT JC, 1990, OPHTHALMOLOGY, V97, P483, DOI 10.1016/S0161-6420(90)32573-3; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; JONES D, 1988, BRIT MED J, V296, P1029, DOI 10.1136/bmj.296.6628.1029; Karma A, 1987, Acta Ophthalmol Suppl, V182, P136; KINYOUN J, 1989, OPHTHALMOLOGY, V96, P746; KLEIN BEK, 1990, DIABETES CARE, V13, P34, DOI 10.2337/diacare.13.1.34; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P244, DOI 10.1001/archopht.1989.01070010250031; KLEIN R, 1984, OPHTHALMOLOGY, V91, P1; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464; KLEIN R, 1985, OPHTHALMOLOGY, V92, P485; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864; KLEIN R, 1989, ARCH INTERN MED, V149, P2427, DOI 10.1001/archinte.149.11.2427; KLEIN R, 1987, INT OPHTHALMOL CLIN, V27, P230, DOI 10.1097/00004397-198702740-00003; KLEIN R, 1989, OPHTHALMOLOGY, V96, P1501; KLENISTEIN RN, 1987, J AM OPTOM ASSOC, V58, P879; KNATTERUD GL, 1978, JAMA-J AM MED ASSOC, V240, P37, DOI 10.1001/jama.240.1.37; KNOWLER WC, 1980, NEW ENGL J MED, V302, P645, DOI 10.1056/NEJM198003203021201; KOHNER EM, 1983, DIABETES, V32, P1010; KROLEWSKI AS, 1986, DIABETES CARE, V9, P443, DOI 10.2337/diacare.9.5.443; LAURITZEN T, 1983, LANCET, V1, P200; MONSON JP, 1986, J ROY SOC MED, V79, P274, DOI 10.1177/014107688607900506; MOSS SE, 1985, OPHTHALMOLOGY, V92, P62; NATHAN DM, 1986, DIABETES, V35, P797, DOI 10.2337/diabetes.35.7.797; NATHAN DM, 1991, DIABETES CARE, V14, P26, DOI 10.2337/diacare.14.1.26; NELSON RG, 1989, DIABETES, V38, P435, DOI 10.2337/diabetes.38.4.435; PAETKAU ME, 1977, DIABETES, V26, P46, DOI 10.2337/diabetes.26.1.46; PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015; PETTITT DJ, 1980, LANCET, V2, P1050; RAND LI, 1985, INVEST OPHTH VIS SCI, V26, P983; RAND LI, 1985, NEW ENGL J MED, V313, P1433, DOI 10.1056/NEJM198512053132302; SAVOLAINEN EA, 1982, DIABETOLOGIA, V23, P138, DOI 10.1007/BF01271176; SHERWIN RS, 1984, NEW ENGL J MED, V311, P365, DOI 10.1056/NEJM198408093110604; SINGER DE, 1988, ANN INTERN MED, V109, P639, DOI 10.7326/0003-4819-109-8-639; SUSSMAN EJ, 1982, JAMA-J AM MED ASSOC, V247, P3231, DOI 10.1001/jama.247.23.3231; The Diabetic Retinopathy Study Research Group, 1987, INT OPHTHALMOL CLIN, V27, P239, DOI DOI 10.1097/00004397-198702740-00004; VELEZ R, 1987, CLIN RES, V35, pA363; WEST KM, 1980, DIABETES, V29, P501, DOI 10.2337/diab.29.7.501; WILLIAMS R, 1986, BRIT MED J, V293, P1140, DOI 10.1136/bmj.293.6555.1140; WITKIN SR, 1984, JAMA-J AM MED ASSOC, V251, P2534, DOI 10.1001/jama.251.19.2534; 1989, ARCH INTERN MED, V149, P769; 1983, PREVENTION TREATMENT, P3; 1981, INVEST OPHTHALMOL VI, V21, P149; 1987, INFORMATION CARE DIA; 1980, VISION PROBLEMS US; 1988, DIABETES CARE, V11, P745; 1989, COMPREHENSIVE ADULT; 1989, DIABETIC RETINOPATHY	74	173	174	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					660	671		10.7326/0003-4819-116-8-660	http://dx.doi.org/10.7326/0003-4819-116-8-660			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546868				2022-12-28	WOS:A1992HN84400010
J	FALK, RJ; SCHEINMAN, J; PHILLIPS, G; ORRINGER, E; JOHNSON, A; JENNETTE, JC				FALK, RJ; SCHEINMAN, J; PHILLIPS, G; ORRINGER, E; JOHNSON, A; JENNETTE, JC			PREVALENCE AND PATHOLOGICAL FEATURES OF SICKLE-CELL NEPHROPATHY AND RESPONSE TO INHIBITION OF ANGIOTENSIN-CONVERTING ENZYME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNE-COMPLEX NEPHRITIS; REDUCED RENAL MASS; GLOMERULAR INJURY; ANEMIA; DISEASE; HYPERTENSION; FILTRATION; ABLATION; RATS	Background. Nephropathy may develop in patients with sickle cell disease. We determined the prevalence of proteinuria and renal insufficiency in a group of patients with sickle cell disease and investigated the renal pathologic changes and the effects of an angiotensin-converting-enzyme inhibitor (enalapril) on protein excretion in patients found to have nephropathy. Methods. We prospectively screened 381 patients with sickle cell disease for the presence of proteinuria and renal insufficiency. Renal biopsy and measurements of glomerular filtration rate, effective renal plasma flow, and urinary protein excretion were performed in 10 patients with mild nephropathy before and after the administration of enalapril, and again two to three weeks after its discontinuation. Results. Of the 381 patients with sickle cell disease, 26 (7 percent) had serum creatinine concentrations above the normal range and 101 (26 percent) had proteinuria of at least 1+. The renal lesions in the 10 patients who had biopsies consisted of glomerular enlargement and perihilar focal segmental glomerulosclerosis. The mean (+/- SD) glomerular area in these patients was 28.7 +/- 4.1 x 10(3)-mu-m2, as compared with 15.8 +/- 4.3 x 10(3)-mu-m2 in 10 control patients without renal disease who had died of trauma (P < 0.001). During the administration of enalapril, the mean 24-hour urinary protein excretion decreased 57 percent (range, 23 to 79 percent) below the base-line value (P < 0.001), and it increased to 25 percent below the base-line value after enalapril was discontinued. The glomerular filtration rate and effective renal plasma flow did not change significantly. Conclusions. Approximately 25 percent of patients with sickle cell disease have proteinuria. Treatment with ena!april reduces the degree of proteinuria in these patients, suggesting that glomerular capillary hypertension may be a pathogenic factor in sickle cell nephropathy.	UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; DUKE UNIV, DEPT PEDIAT, DURHAM, NC 27706 USA; DUKE UNIV, DEPT MED, DURHAM, NC 27706 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University	FALK, RJ (corresponding author), UNIV N CAROLINA, DEPT MED, DIV NEPHROL, CB 7155, 3034 OLD CLIN BLDG, CHAPEL HILL, NC 27599 USA.			Jennette, John Charles/0000-0002-8081-6565	NCRR NIH HHS [RR00046, M01-RR30] Funding Source: Medline; NHLBI NIH HHS [5P60 HL28391-09] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL028391] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013; BAKIR AA, 1987, AM J NEPHROL, V7, P110, DOI 10.1159/000167444; BAUER WC, 1960, AM J PATHOL, V37, P695; BERGER EY, 1948, J CLIN INVEST, V27, P710, DOI 10.1172/JCI102020; BERNSTEIN J, 1960, ARCH PATHOL, V70, P407; BHATHENA DB, 1991, J AM SOC NEPHROL, V1, P1241; CHATTERJEE SN, 1980, NEPHRON, V25, P199, DOI 10.1159/000181781; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DAVIDSON WD, 1963, J LAB CLIN MED, V62, P351; DEJONG PE, 1981, NEPHRON, V29, P138, DOI 10.1159/000182331; DEJONG PE, 1985, KIDNEY INT, V27, P711, DOI 10.1038/ki.1985.70; ELFENBEIN IB, 1974, AM J PATHOL, V77, P357; ETTELDORF JN, 1955, AM J MED, V18, P243, DOI 10.1016/0002-9343(55)90239-4; ETTELDORF JN, 1952, AMA AM J DIS CHILD, V83, P185, DOI 10.1001/archpedi.1952.02040060051005; GARCIA DL, 1988, P NATL ACAD SCI USA, V85, P6142, DOI 10.1073/pnas.85.16.6142; GONZALEZCARRILLO M, 1982, CLIN NEPHROL, V18, P209; HALANKAR A, 1974, DHEW75723 PUBL, P311; HATCH FE, 1970, J LAB CLIN MED, V76, P632; HORNE MK, 1981, AM J MED, V70, P288, DOI 10.1016/0002-9343(81)90764-6; HOSTETTER TH, 1981, AM J PHYSIOL, V241, pF85, DOI 10.1681/ASN.V1261315; JENNETTE JC, 1983, KIDNEY INT, V24, P377, DOI 10.1038/ki.1983.170; JENNETTE JC, 1987, AM J KIDNEY DIS, V10, P470, DOI 10.1016/S0272-6386(87)80196-8; KEANE WF, 1989, ANN INTERN MED, V111, P503, DOI 10.7326/0003-4819-111-6-503; MCCOY RC, 1969, LAB INVEST, V21, P85; MORGAN AG, 1987, W INDIAN MED J, V36, P241; MURTHY VK, 1981, J CHRON DIS, V34, P313, DOI 10.1016/0021-9681(81)90069-2; NICHOLSON GD, 1980, W INDIAN MED J, V29, P239; OLSON JL, 1982, KIDNEY INT, V22, P112, DOI 10.1038/ki.1982.143; PARDO V, 1975, AM J MED, V59, P650, DOI 10.1016/0002-9343(75)90226-0; REMUZZI A, 1991, KIDNEY INT, V39, P1267, DOI 10.1038/ki.1991.160; RODICIO JL, 1990, KIDNEY INT, V38, P590, DOI 10.1038/ki.1990.247; ROMANELLI G, 1990, DIABETES, V39, P1333, DOI 10.2337/diabetes.39.11.1333; ROY S, 1976, AM J CLIN PATHOL, V66, P986; SMITH HW, 1945, J CLIN INVEST, V24, P388, DOI 10.1172/JCI101618; SPEAR GS, 1960, B JOHNS HOPKINS HOSP, V106, P347; STRAUSS J, 1974, ANN INTERN MED, V81, P114, DOI 10.7326/0003-4819-81-1-114; STRAUSS J, 1975, AM J MED, V58, P382, DOI 10.1016/0002-9343(75)90604-X; SUSMANO S, 1969, AM J DIS CHILD, V118, P615, DOI 10.1001/archpedi.1969.02100040617015; TEJANI A, 1985, NEPHRON, V39, P352, DOI 10.1159/000183404; THOMAS AN, 1982, BRIT MED J, V285, P633, DOI 10.1136/bmj.285.6342.633; YOUNG MK, 1952, P SOC EXP BIOL MED, V80, P771	41	224	228	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					910	915		10.1056/NEJM199204023261402	http://dx.doi.org/10.1056/NEJM199204023261402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1542341				2022-12-28	WOS:A1992HL26100002
J	BOICE, JD; HARVEY, EB; BLETTNER, M; STOVALL, M; FLANNERY, JT				BOICE, JD; HARVEY, EB; BLETTNER, M; STOVALL, M; FLANNERY, JT			CANCER IN THE CONTRALATERAL BREAST AFTER RADIOTHERAPY FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RADIATION-THERAPY; IRRADIATION; RISK; SURGERY; CERVIX; WOMEN	Background. Patients with breast cancer have a threefold increase in the risk that a second breast cancer will develop. Radiation treatment for the initial cancer can result in moderately high doses to the contralateral breast, possibly contributing to this heightened risk. Methods. We conducted a case-control study in a cohort of 41,109 women diagnosed with breast cancer between 1935 and 1982 in Connecticut. We reviewed the medical records of 655 women in whom a second breast cancer developed five or more years after the initial tumor and compared their radiation exposure with that of 1189 matched controls from the cohort who did not have a second cancer. The dose of radiation to the contralateral breast was estimated from the original radiotherapy records. Among the exposed women, the average radiation dose to the contralateral breast was 2.82 Gy (maximum, 7.10). Results. Overall, 23 percent of the women who had a second breast cancer and 20 percent of the controls had received radiotherapy (relative risk of a second breast cancer associated with radiotherapy, 1.19). Among women who survived for at least 10 years, radiation treatment was associated with a small but marginally significant elevation in the risk of a second breast cancer (relative risk, 1.33); the risk increased significantly with the dose of radiation. An increase in risk in association with radiotherapy was evident only among women who were under 45 years of age when they were treated (relative risk, 1.59) and not among older women (relative risk, 1.01). Conclusions. Radiotherapy for breast cancer contributes little to the already high risk of a second cancer in the opposite breast. Fewer than 3 percent of all second breast cancers in this study could be attributed to previous radiation treatment; the risk, however, was significantly increased among women who underwent irradiation at a relatively young age (< 45 years). Radiation exposure after the age of 45 entails little, if any, risk of radiation-induced breast cancer.	CONNECTICUT TUMOR REGISTRY,HARTFORD,CT; UNIV TEXAS,CTR CANC,HOUSTON,TX 77025	University of Texas System	BOICE, JD (corresponding author), NCI,RADIAT EPIDEMIOL BRANCH,EXECUT PLAZA N,RM 408,6130 EXECUT BLVD,ROCKVILLE,MD 20852, USA.				NCI NIH HHS [N01-CP0-5609, N01-CP8-5604, N01-CP9-5614] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP085604, N01CP005609, N01CP095614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		BARAL E, 1977, CANCER, V40, P2905, DOI 10.1002/1097-0142(197712)40:6<2905::AID-CNCR2820400621>3.0.CO;2-Y; BASCO VE, 1985, BRIT J CANCER, V52, P319, DOI 10.1038/bjc.1985.196; BOICE JD, 1989, INT J CANCER, V44, P7, DOI 10.1002/ijc.2910440103; BOICE JD, 1991, RADIAT RES, V125, P214, DOI 10.2307/3577890; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BURNS PE, 1984, CAN MED ASSOC J, V130, P881; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FRAASS BA, 1985, INT J RADIAT ONCOL, V11, P485, DOI 10.1016/0360-3016(85)90179-8; HANKEY BF, 1983, J NATL CANCER I, V70, P797; HARRIS JR, 1990, CANCER-AM CANCER SOC, V66, P1427, DOI 10.1002/1097-0142(19900915)66:14+<1427::AID-CNCR2820661420>3.0.CO;2-W; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; HENDERSON IC, 1989, CANCER PRINCIPLES PR, V2, P1197; HORN PL, 1988, CANCER-AM CANCER SOC, V62, P412, DOI 10.1002/1097-0142(19880715)62:2<412::AID-CNCR2820620228>3.0.CO;2-3; KURTZ JM, 1988, INT J RADIAT ONCOL, V15, P277, DOI 10.1016/S0360-3016(98)90005-0; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; MCCREDIE JA, 1975, CANCER, V35, P1472, DOI 10.1002/1097-0142(197505)35:5<1472::AID-CNCR2820350536>3.0.CO;2-M; MELLINK WAM, 1991, CANCER-AM CANCER SOC, V67, P1844, DOI 10.1002/1097-0142(19910401)67:7<1844::AID-CNCR2820670705>3.0.CO;2-W; MILLER AB, 1989, NEW ENGL J MED, V321, P1285, DOI 10.1056/NEJM198911093211902; MONTAGUE ED, 1984, CANCER, V53, P700, DOI 10.1002/1097-0142(19840201)53:3+<700::AID-CNCR2820531318>3.0.CO;2-2; PARKER RG, 1989, AM J CLIN ONCOL-CANC, V12, P213, DOI 10.1097/00000421-198906000-00007; SCHELL SR, 1982, CANCER, V50, P1191, DOI 10.1002/1097-0142(19820915)50:6<1191::AID-CNCR2820500628>3.0.CO;2-F; SHELLABARGER CJ, 1986, RAD CARCINOGENESIS, P169; SHORE RE, 1986, J NATL CANCER I, V77, P689, DOI 10.1093/jnci/77.3.689; STOVALL M, 1989, MED PHYS, V16, P726, DOI 10.1118/1.596331; TERCILLA O, 1989, INT J RADIAT ONCOL, V17, P205, DOI 10.1016/0360-3016(89)90390-8; TOKUNAGA M, 1987, RADIAT RES, V112, P243, DOI 10.2307/3577254; WHITTEMORE AS, 1983, AM J EPIDEMIOL, V117, P76, DOI 10.1093/oxfordjournals.aje.a113518; ZUCALI R, 1987, EUR J SURG ONCOL, V13, P413; 1991, JAMA-J AM MED ASSOC, V265, P391	29	316	320	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1992	326	12					781	785		10.1056/NEJM199203193261201	http://dx.doi.org/10.1056/NEJM199203193261201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ592	1538720				2022-12-28	WOS:A1992HJ59200001
J	CORINA, DP; VAID, J; BELLUGI, U				CORINA, DP; VAID, J; BELLUGI, U			THE LINGUISTIC BASIS OF LEFT-HEMISPHERE SPECIALIZATION	SCIENCE			English	Article								In humans the two cerebral hemispheres of the brain are functionally specialized with the left hemisphere predominantly mediating language skills. The basis of this lateralization has been proposed to be differential localization of the linguistic, the motoric, or the symbolic properties of language. To distinguish among these possibilities, lateralization of spoken language, signed language, and nonlinguistic gesture have been compared in deaf and hearing individuals. This analysis, plus additional clinical findings, support a linguistic basis of left hemisphere specialization.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037; TEXAS A&M UNIV SYST,COLLEGE STN,TX 77843	Salk Institute; Texas A&M University System; Texas A&M University College Station			Hsu, Oscar LiJen/C-3754-2009		NICHD NIH HHS [HD12349] Funding Source: Medline; NIDCD NIH HHS [DC00146, DC00201] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012349] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BELLUGI U, 1980, SIGNED SPOKEN LANGUA, P115; BELLUGI U, 1989, TRENDS NEUROSCI, V12, P10; BROWN J, 1977, MIND BRAIN CONSCIOUS; Brown J. W., 1991, SELF PROCESS; CORINA DP, 1989, INVEST PSYCHOL, V7, P31; CORINA DP, IN PRESS BRAIN LANG; GREEN A, 1990, BRAIN LANG, V39, P107, DOI 10.1016/0093-934X(90)90007-4; KIMURA D, 1982, PHILOS T ROY SOC B, V298, P135, DOI 10.1098/rstb.1982.0077; KIMURA D, 1974, BRAIN, V97, P337, DOI 10.1093/brain/97.1.337; KIMURA D, 1976, STUDIES NEUROLINGUIS, P145; KIMURA D, 1989, READINGS ENCY NEUROS; KINSBOURNE M, 1971, Q J EXP PSYCHOL, V23, P34; Kinsbourne M., 1978, ATTENTION PERFORM, VVII, P345; Klima E. S., 1988, SIGNS LANGUAGE; NEVILLE HJ, 1987, BRAIN RES, V405, P268, DOI 10.1016/0006-8993(87)90296-4; Padden CarolA., 1983, INTERACTION MORPHOLO; Poizner H., 1987, LANGUAGE, DOI [10.2307/414579, DOI 10.2307/414579]; Stokoe W. C., 1965, DICT AM SIGN LANGUAG; Supalla T.R., 1982, THESIS U SAN DIEGO S; [No title captured]	20	61	61	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1258	1260		10.1126/science.1546327	http://dx.doi.org/10.1126/science.1546327			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HG677	1546327	Green Submitted			2022-12-28	WOS:A1992HG67700044
J	PANKRATZ, MJ; BUSCH, M; HOCH, M; SEIFERT, E; JACKLE, H				PANKRATZ, MJ; BUSCH, M; HOCH, M; SEIFERT, E; JACKLE, H			SPATIAL CONTROL OF THE GAP GENE KNIRPS IN THE DROSOPHILA EMBRYO BY POSTERIOR MORPHOGEN SYSTEM	SCIENCE			English	Article							HEAD DEVELOPMENT; HUNCHBACK; PATTERN; KRUPPEL; SEGMENTATION; EXPRESSION; ANTERIOR; INFORMATION; POLARITY; GRADIENT	The gap genes of Drosophila are the first zygotic genes to respond to the maternal positional signals and establish the body pattern along the anterior-posterior axis. The gap gene knirps, required for patterning in the posterior region of the embryo, can be activated throughout the wild-type embryo and is normally repressed from the anterior and posterior sides. These results provide direct molecular evidence that the posterior morphogen system interacts in a fundamentally different manner than do hunchback and bicoid, which are responsible for anterior pattern formation.	INST GENET & MIKROBIOL, W-8000 MUNICH 19, GERMANY		PANKRATZ, MJ (corresponding author), MAX PLANCK INST BIOPHYS CHEM, MOLEK ENTWICKLUNGSBIOL ABT, W-3400 GOTTINGEN, GERMANY.							AKAM M, 1987, DEVELOPMENT, V101, P1; ANDERSON DT, 1972, DEV SYSTEMS INSECTS, V2; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; ELDON ED, 1991, DEVELOPMENT, V111, P367; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAUL U, 1989, DEVELOPMENT, V107, P651; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HOCH M, UNPUB; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KRAUT R, 1991, DEVELOPMENT, V111, P601; LEHMANN R, 1988, DEVELOPMENT, V104, P17; LEHMANN R, 1991, DEVELOPMENT, V112, P679; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PANKRATZ MJ, UNPUB; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; ROTHE M, UNPUB; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; Sander K., 1983, DEV EVOLUTION; SCHAFFNER G, 1988, J MOL BIOL, V201, P81, DOI 10.1016/0022-2836(88)90440-8; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K	40	67	67	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1992	255	5047					986	989		10.1126/science.1546296	http://dx.doi.org/10.1126/science.1546296			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546296				2022-12-28	WOS:A1992HE60500041
J	SMITH, GD; PEKKANEN, J				SMITH, GD; PEKKANEN, J			FOR DEBATE - SHOULD THERE BE A MORATORIUM ON THE USE OF CHOLESTEROL LOWERING DRUGS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BLOOD LIPID CONCENTRATIONS; MIDDLE-AGED MEN; PRIMARY-PREVENTION; SERUM-CHOLESTEROL; RISK-FACTORS; CARDIOVASCULAR RISK; CLINICAL-TRIALS; MORTALITY; DIET		NATL PUBL HLTH INST, DEPT EPIDEMIOL, SF-00280 HELSINKI 28, FINLAND	Finland National Institute for Health & Welfare	SMITH, GD (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BRADFORD RH, 1990, AM J CARDIOL, V66, pB44, DOI 10.1016/0002-9149(90)90440-C; BROWNER WS, 1991, JAMA-J AM MED ASSOC, V265, P3285, DOI 10.1001/jama.265.24.3285; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; DAYTON S, 1969, CIRCULATION       S2, V40, P1; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GORDON D C JR, 1990, Canadian Industry Report of Fisheries and Aquatic Sciences, P45; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HOLME I, 1985, PREV MED, V14, P279, DOI 10.1016/0091-7435(85)90057-X; JONES PH, 1990, AM J CARDIOL, V66, pB39, DOI 10.1016/0002-9149(90)90439-8; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KORNITZER M, 1985, PREV MED, V14, P272, DOI 10.1016/0091-7435(85)90056-8; KRISTIANSEN IS, 1991, BRIT MED J, V302, P1119, DOI 10.1136/bmj.302.6785.1119; LAW MR, 1991, CANCER CAUSE CONTROL, V2, P253, DOI 10.1007/BF00052142; LEWIS B, 1987, EUR HEART J, V8, P77; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MIETTINEN M, 1972, LANCET, V2, P835; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1984, LANCET, V2, P600; OLIVER MF, 1988, J AM COLL CARDIOL, V12, P814, DOI 10.1016/0735-1097(88)90327-0; OLIVER MF, 1991, LANCET, V337, P1529, DOI 10.1016/0140-6736(91)93208-Q; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SCHMIEDER RE, 1991, JAMA-J AM MED ASSOC, V265, P1566, DOI 10.1001/jama.265.12.1566; SHEPHERD J, 1987, BRIT MED J, V295, P1245, DOI 10.1136/bmj.295.6608.1245; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; SMITH GD, 1990, BRIT MED J, V301, P552; SPECTOR TD, 1991, J EPIDEMIOL COMMUN H, V45, P89, DOI 10.1136/jech.45.2.89; STRANDBERG TE, 1991, JAMA-J AM MED ASSOC, V266, P1225, DOI 10.1001/jama.266.9.1225; TAYLOR WC, 1987, ANN INTERN MED, V106, P605, DOI 10.7326/0003-4819-106-4-605; THELLE DS, 1983, BRIT HEART J, V49, P205, DOI 10.1136/hrt.49.3.205; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99; WYSOWSKI DK, 1990, JAMA-J AM MED ASSOC, V263, P2185, DOI 10.1001/jama.263.16.2185; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259; 1984, JAMA-J AM MED ASSOC, V231, P351; 1991, KEY ANSWERS VITAL QU; 1987, BRIT HEART J, V57, P188; 1990, BRIT NATIONAL FORMUL	45	308	309	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 15	1992	304	6824					431	434		10.1136/bmj.304.6824.431	http://dx.doi.org/10.1136/bmj.304.6824.431			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1532138	Bronze, Green Published			2022-12-28	WOS:A1992HE38900025
J	WHYTE, RK				WHYTE, RK			1ST DAY NEONATAL-MORTALITY SINCE 1935 - REEXAMINATION OF THE CROSS HYPOTHESIS	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To describe the change in first day infant mortality during 1935-87. To examine the hypothesis that excess first day mortality in the 1950s and 1960s was attributable to restricting oxygen for sick newborn infants. Design - Time series analysis of first day infant mortality and stillbirth rates. Setting - England and Wales and the United States of America. Subjects - All first day infant deaths, all neonatal deaths, and all stillbirths. Main outcome measures - Rate of fall in mortality, dates of deviation of mortality from established fall, and correlation with stillbirths. Results - In England and Wales first day infant mortality fell by 3.1% a year, except between 1951 (95% confidence interval 1951 to 1954) and 1980 (confidence interval < 1 year). During these years there were 37000 excess deaths. In the United States an annual fall of 2.7% was interrupted in 1955 (1951 to 1954) and resumed in 1980 (1978 to 1980), resulting in 195000 excess deaths. A similar pattern was observed in stillbirth rates. Conclusions - Restriction of oxygen in sick newborn infants cannot be the sole cause of the interruption in fall of first day neonatal mortality as stillbirth rates were also affected. The timing of onset and the course of the deviation is not consistent with the oxygen restriction hypothesis. Further investigation is needed to identify a factor affecting both fetal and newborn survival between 1950 and 1980.	MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8S 4L8,ONTARIO,CANADA	McMaster University								ASHTON N, 1953, BRIT J OPHTHALMOL, V37, P513, DOI 10.1136/bjo.37.9.513; BARRIE H, 1973, LANCET, V2, P1320; BOLTON DPG, 1974, LANCET, V1, P445; COHEN NM, 1974, LANCET, V1, P747; CROSS KW, 1973, LANCET, V2, P954; DURBIN J, 1950, BIOMETRIKA, V37, P409, DOI 10.1093/biomet/37.3-4.409; GROSS TL, 1985, PRINCIPLES MED THERA, P332; HACK M, 1989, NEW ENGL J MED, V321, P1642, DOI 10.1056/NEJM198912143212405; KENNEDY P, 1985, GUIDE ECONOMETRICS, P67; KINSEY VE, 1956, ARCH OPHTHALMOL-CHIC, V56, P481, DOI 10.1001/archopht.1956.00930040489001; KLEINBAUM DG, 1988, APPLIED REGRESSION A; LEWIS AF, 1974, LANCET, V1, P746; LUNING G, 1989, LANCET, V2, P1081; ROBERTON NRC, 1979, ARCH DIS CHILD, V54, P838, DOI 10.1136/adc.54.11.838; SILVERMAN WA, 1980, RETROLENTAL FIBROPLA, P59; SILVERMAN WA, 1980, RETROLENTAL FIBROPLA, P37; SILVERMAN WA, 1980, RETROLENTAL FIBROPLA, P53; SILVERMAN WA, 1980, RETROLENTAL FIBROPLA, P25; STERNGLASS EJ, 1969, 9TH P ANN HANF BIOL, P693; 1985, MORTALITY STATIS DH3; 1976, EPDIATRICS S, V57, P591; 1984, MORTALITY STATIS DH3; 1980, VITAL STATISTICS US; 1970, VITAL STATISTICS US; 1974, LANCET, V1, P437; 1990, VITAL STATISTICS US; 1989, MINITAB REFERENCE MA, V7; 1985, HDB VITAL STATISTICS, V2	28	17	17	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					343	346		10.1136/bmj.304.6823.343	http://dx.doi.org/10.1136/bmj.304.6823.343			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540730	Green Published, Bronze			2022-12-28	WOS:A1992HD38700021
J	CUNNINGHAM, CC; GORLIN, JB; KWIATKOWSKI, DJ; HARTWIG, JH; JANMEY, PA; BYERS, HR; STOSSEL, TP				CUNNINGHAM, CC; GORLIN, JB; KWIATKOWSKI, DJ; HARTWIG, JH; JANMEY, PA; BYERS, HR; STOSSEL, TP			ACTIN-BINDING PROTEIN REQUIREMENT FOR CORTICAL STABILITY AND EFFICIENT LOCOMOTION	SCIENCE			English	Article							DICTYOSTELIUM MUTANT; HUMAN-PLATELETS; ALPHA-ACTININ; MEMBRANE; ASSOCIATION; MACROPHAGES; HEPATOCYTES; GELATION; LINKING; FILAMIN	Three unrelated tumor cell lines derived from human malignant melanomas lack actin-binding protein (ABP), which cross-links actin filaments in vitro and connects these filaments to plasma membrane glycoproteins. The ABP-deficient cells have impaired locomotion and display circumferential blebbing of the plasma membrane. Expression of A.BP in one of the lines after transfection restored translocational motility and reduced membrane blebbing. These findings establish that ABP functions to stabilize cortical actin in vivo and is required for efficient cell locomotion.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,CHILDRENS HOSP,DEPT HEMATOL ONCOL,DIV PEDIAT ONCOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	CUNNINGHAM, CC (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV EXPTL MED,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 19429] Funding Source: Medline; NIAID NIH HHS [AI 08051] Funding Source: Medline; NIAMS NIH HHS [AR 38910] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRINK M, 1990, J CELL BIOL, V111, P1477, DOI 10.1083/jcb.111.4.1477; BROTSCHI EA, 1978, J BIOL CHEM, V253, P8988; BYERS HR, 1991, AM J PATHOL, V139, P423; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES WA, 1977, J CELL BIOL, V75, P941, DOI 10.1083/jcb.75.3.941; Eicke H.-F., 1990, PHYSICAL NETWORKS PO, P169; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARTWIG JH, 1980, J CELL BIOL, V87, P841, DOI 10.1083/jcb.87.3.841; HARTWIG JH, 1989, J CELL BIOL, V109, P1571, DOI 10.1083/jcb.109.4.1571; HARTWIG JH, 1975, J BIOL CHEM, V250, P5696; HARTWIG JH, 1991, LUNG SCI F, P141; JANMEY PA, 1991, J BIOCHEM BIOPH METH, V22, P41, DOI 10.1016/0165-022X(91)90080-G; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; LUBYPHELPS K, 1988, ANNU REV BIOPHYS BIO, V17, P369; MESLAND DAM, 1981, EXP CELL RES, V135, P431, DOI 10.1016/0014-4827(81)90184-1; MORROW J, 1985, BIOCHIM BIOPHYS ACTA, V830, P147; NARVANEN O, 1987, FEBS LETT, V224, P156, DOI 10.1016/0014-5793(87)80440-4; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SCHLEICHER M, 1988, J CELL SCI, V90, P59; Stossel T.P., 1987, P131; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STOSSEL TP, 1984, J CELL BIOL, V99, pS15, DOI 10.1083/jcb.99.1.15s; WANG K, 1975, P NATL ACAD SCI USA, V72, P4483, DOI 10.1073/pnas.72.11.4483; WEISS E, 1973, BEITR PATHOL, V150, P345	30	490	500	2	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1992	255	5042					325	327		10.1126/science.1549777	http://dx.doi.org/10.1126/science.1549777			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1549777				2022-12-28	WOS:A1992GZ69500040
J	BROWN, EY; VISCOLI, CM; HORWITZ, RI				BROWN, EY; VISCOLI, CM; HORWITZ, RI			PREVENTIVE HEALTH STRATEGIES AND THE POLICY MAKERS PARADOX	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						HEALTH POLICY; PUBLIC HEALTH; CHOLESTEROL; MAMMOGRAPHY; PREVENTIVE MEDICINE	CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; RISK-FACTORS; FRAMINGHAM	The likelihood of developing many diseases is predicted by levels of risk factors. Many public health strategies have been created to apply interventions (for example, drugs, diets, exercise) intended to lower levels of these factors and thereby prevent disease. Often, these strategies are based on the interpretation of incomplete evidence for the effectiveness of the interventions. The reason this evidence is and will likely remain incomplete is explained by the policy makers' paradox. The paradox occurs when evidence for an intervention's effectiveness is obtained in persons with the highest levels of a risk factor, but the application of the intervention may have the greatest potential for reducing disease burden in persons with lower levels. Resolution of the paradox requires consideration of the type and quality of evidence, the society's time preference for risk, and the society's choice about allocation of scarce resources.			BROWN, EY (corresponding author), YALE UNIV, SCH MED,DEPT INTERNAL MED,NEPHROL SECT, 333 CEDAR ST, 2073 LMP, NEW HAVEN, CT 06510 USA.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; FEINSTEIN AR, 1988, SCIENCE, V242, P1257, DOI 10.1126/science.3057627; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GARBER AM, 1989, ANN INTERN MED, V111, P625, DOI 10.7326/0003-4819-111-8-625; GARBER AM, 1989, ANN INTERN MED, V110, P622, DOI 10.7326/0003-4819-110-8-622; GOLDMAN L, 1989, CIRCULATION, V80, P254, DOI 10.1161/01.CIR.80.2.254; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; HIATT HH, 1975, NEW ENGL J MED, V293, P235, DOI 10.1056/NEJM197507312930506; KANNEL WB, 1976, AM J CARDIOL, V38, P46, DOI 10.1016/0002-9149(76)90061-8; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; KELSEY JL, 1986, METHODS OBSERVATIONA, P33; KOTTKE TE, 1988, J CLIN EPIDEMIOL, V41, P1083, DOI 10.1016/0895-4356(88)90078-9; Morris W., 1969, AM HERITAGE DICT ENG; PETRAKIS NL, 1977, CANCER, V39, P2709, DOI 10.1002/1097-0142(197706)39:6<2709::AID-CNCR2820390658>3.0.CO;2-Z; RHODES SE, 1985, EC VIEW WORLD CAMBRI; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROSS R, 1986, HEART, P801; Russell LB., 1986, IS PREVENTION BETTER; SACKETT DL, 1975, LANCET, V2, P357, DOI 10.1016/S0140-6736(75)92790-7; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; 1979, CAN MED ASS J, V121, P1193	25	19	19	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					593	597		10.7326/0003-4819-116-7-593	http://dx.doi.org/10.7326/0003-4819-116-7-593			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543315				2022-12-28	WOS:A1992HL25800012
J	LILLIE, SH; BROWN, SS				LILLIE, SH; BROWN, SS			SUPPRESSION OF A MYOSIN DEFECT BY A KINESIN-RELATED GENE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; HEAVY-CHAIN; PROTEIN; DROSOPHILA; MICROTUBULES; CYTOSKELETON; SEQUENCE	MOTOR proteins in cells include myosin 1, which is actin-based, and kinesin, dynein and dynamin 2, which are microtubule based. Several proteins have recently been identified that have amino-acid sequences with similarity to the motor domains of either myosin 3 or kinesin 4-9, but are otherwise dissimilar. This has led to the suggestion that these may all be motor proteins, but that they are specialized for moving different cargos. Genetic analysis can address the question of the different functions of these new proteins. Studies of a temperature-sensitive mutation (myo2-66) in a gene of the myosin superfamily (MYO2) have implicated the Myo2 protein (Myo2p) in the process of polarized secretion in yeast (Saccharomyces cerevisiae) 10. To understand more about the role of Myo2p, we have looked for 'multicopy suppressors' (heterologous genes that, when overexpressed, can correct the temperature sensitivity of the myo2-66 mutant). Here we report the identification of such a suppressor (SMY1) that (surprisingly) encodes a predicted polypeptide sharing sequence similarity with the motor portion of proteins in the kinesin superfamily.			LILLIE, SH (corresponding author), UNIV MICHIGAN,SCH MED,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48109, USA.							CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRUBIN D, 1989, CELL MOTIL CYTOSKEL, V14, P42, DOI 10.1002/cm.970140110; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; POLLARD TD, 1991, REV PHYSL, V53, P653; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	27	179	181	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					358	361		10.1038/356358a0	http://dx.doi.org/10.1038/356358a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549181	Green Published			2022-12-28	WOS:A1992HK79400071
J	SUCHETA, A; ACKRELL, BAC; COCHRAN, B; ARMSTRONG, FA				SUCHETA, A; ACKRELL, BAC; COCHRAN, B; ARMSTRONG, FA			DIODE-LIKE BEHAVIOR OF A MITOCHONDRIAL ELECTRON-TRANSPORT ENZYME	NATURE			English	Article							SUCCINATE-DEHYDROGENASE	IN mitochondria, electrons derived from the oxidation of succinate by the tricarboxylic acid cycle enzyme succinate-ubiquinone oxido-reductase are transferred directly to the quinone pool. Here we provide evidence that the soluble form of this enzyme (succinate dehydrogenase) behaves as a diode that essentially allows electron flow in one direction only. The gating effect is observed when electrons are exchanged rapidly and directly between fully active succinate dehydrogenase and a graphite electrode. Turnover is therefore measured under conditions of continuously variable electrochemical potential. The otherwise rapid and efficient reduction of fumarate (the reverse reaction) is severely retarded as the driving force (overpotential) is increased. Such behaviour can arise if a rate-limiting chemical step like substrate binding or product release depends on the oxidation state of a redox group on the enzyme. The observation provides, for a biological electron-transport system, a simple demonstration of directionality that is enforced by kinetics as opposed to that which is assumed from thermodynamics.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,DIV MOLEC BIOL,SAN FRANCISCO,CA 94143; VET ADM MED CTR,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	SUCHETA, A (corresponding author), UNIV CALIF IRVINE,DEPT CHEM,IRVINE,CA 92717, USA.							Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ARMSTRONG FA, 1990, STRUCT BOND, V72, P137; BARD AJ, 1980, ELECTROCHEMICAL METH, pCH8; BEINERT H, 1977, ARCH BIOCHEM BIOPHYS, V182, P95, DOI 10.1016/0003-9861(77)90287-9; COLLMAN JP, 1986, J AM CHEM SOC, V108, P7847, DOI 10.1021/ja00284a067; DAVIS KA, 1971, BIOCHEMISTRY-US, V10, P2509; MACKENROTH DR, 1984, ILLUSTRATED ENCY SOL, pCH1; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; SINGER TP, 1973, ADV ENZYMOL RAMB, V37, P189; ZEIJLEMAKER WP, 1968, BIOCHIM BIOPHYS ACTA, V178, P213	10	170	170	4	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					361	362		10.1038/356361a0	http://dx.doi.org/10.1038/356361a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549182				2022-12-28	WOS:A1992HK79400072
J	PFANNER, N; RASSOW, J; VANDERKLEI, IJ; NEUPERT, W				PFANNER, N; RASSOW, J; VANDERKLEI, IJ; NEUPERT, W			A DYNAMIC-MODEL OF THE MITOCHONDRIAL PROTEIN IMPORT MACHINERY	CELL			English	Review							TRANSLOCATION CONTACT SITES; PRECURSOR PROTEINS; YEAST MITOCHONDRIA; OUTER-MEMBRANE; RECEPTOR; CARRIER				PFANNER, N (corresponding author), UNIV MUNICH,INST PHYSIOL CHEM,W-8000 MUNICH 2,GERMANY.		van der Klei, Ida J/D-1919-2012; Pfanner, Nikolaus/AAV-7878-2021	Van der Klei, Ida J./0000-0001-7165-9679				BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; Bayer M E, 1981, Int Rev Cytol Suppl, V12, P39; BRDICZKA D, 1990, BIOCHIM BIOPHYS ACTA, V1018, P234, DOI 10.1016/0005-2728(90)90256-4; FILLOUX A, 1990, EMBO J, V9, P4323, DOI 10.1002/j.1460-2075.1990.tb07881.x; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; HWANG ST, 1991, J BIOL CHEM, V266, P21083; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KORONAKIS V, 1991, EMBO J, V10, P3263, DOI 10.1002/j.1460-2075.1991.tb04890.x; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MARTIN J, 1991, J BIOL CHEM, V266, P18051; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PUGSLEY AP, 1991, MOL MICROBIOL, V5, P865, DOI 10.1111/j.1365-2958.1991.tb00760.x; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SEN K, 1990, P NATL ACAD SCI USA, V87, P743, DOI 10.1073/pnas.87.2.743; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; VANVENETIE R, 1982, BIOCHIM BIOPHYS ACTA, V692, P397, DOI 10.1016/0005-2736(82)90390-X; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	25	127	128	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					999	1002		10.1016/0092-8674(92)90069-O	http://dx.doi.org/10.1016/0092-8674(92)90069-O			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547510	Green Published, Green Submitted			2022-12-28	WOS:A1992HK67400002
J	FROGUEL, P; VAXILLAIRE, M; SUN, F; VELHO, G; ZOUALI, H; BUTEL, MO; LESAGE, S; VIONNET, N; CLEMENT, K; FOUGEROUSSE, F; TANIZAWA, Y; WEISSENBACH, J; BECKMANN, JS; LATHROP, GM; PASSA, P; PERMUTT, MA; COHEN, D				FROGUEL, P; VAXILLAIRE, M; SUN, F; VELHO, G; ZOUALI, H; BUTEL, MO; LESAGE, S; VIONNET, N; CLEMENT, K; FOUGEROUSSE, F; TANIZAWA, Y; WEISSENBACH, J; BECKMANN, JS; LATHROP, GM; PASSA, P; PERMUTT, MA; COHEN, D			CLOSE LINKAGE OF GLUCOKINASE LOCUS ON CHROMOSOME-7P TO EARLY-ONSET NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NATURE			English	Article							YOUNG; GLUCOSE; GENE; MODY	NON-INSULIN-DEPENDENT diabetes mellitus (NIDDM) is a major health problem, affecting 5% of the world population. Genetic factors are important in NIDDM, but the mechanisms leading to glucose intolerance are unknown 1,2. Genetic linkage has been investigated in multigeneration families to localize, and ultimately identify, the gene(s) predisposing to NIDDM. Here we report linkage between the glucokinase locus on chromosome 7p and diabetes in 16 French families with maturity-onset diabetes of the young, a form of NIDDM characterized by monogenic autosomal dominant transmission and early age of onset 3. Statistical evidence of genetic heterogeneity was significant, with an estimated 45-95% of the 16 families showing linkage to glucokinase. Because glucokinase is a key enzyme of blood glucose homeostasis 4, these results are evidence that a gene involved in glucose metabolism could be implicated in the pathogenesis of NIDDM.	HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE; GENETHON,F-91000 EVRY,FRANCE; INST PASTEUR,CNRS,F-75724 PARIS 15,FRANCE; INSERM,U358,F-75010 PARIS,FRANCE; WASHINGTON UNIV,SCH MED,DIV METAB,ST LOUIS,MO 63110	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Washington University (WUSTL)	FROGUEL, P (corresponding author), CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.		Vionnet, Nathalie/N-6302-2017; FROGUEL, Philippe/O-6799-2017; Velho, Gilberto/Q-6724-2017; Clément, karine/R-1120-2017; Beckmann, Jacques S/A-9772-2008	FROGUEL, Philippe/0000-0003-2972-0784; Velho, Gilberto/0000-0001-8811-363X; Beckmann, Jacques S/0000-0002-9741-1900				BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; CHANSON P, 1991, J MED SCI, V7, P336; DEFRONZO RA, 1988, DIABETES, V37, P6667; ECONOMOU EP, 1990, P NATL ACAD SCI USA, V87, P2951, DOI 10.1073/pnas.87.8.2951; FAJANS SS, 1990, DIABETES CARE, V13, P49, DOI 10.2337/diacare.13.1.49; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FROGUEL P, 1991, DIABETOLOGIA, V34, P685, DOI 10.1007/BF00401001; FROGUEL P, 1991, NUCLEIC ACIDS RES, V19, P5799, DOI 10.1093/nar/19.20.5799; FROGUEL P, 1991, NUCLEIC ACIDS RES, V19, P3754, DOI 10.1093/nar/19.13.3754-a; HAZAN J, IN PRESS J GENOMICS; LATHROP GM, 1985, AM J HUM GENET, V37, P482; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MATSUTANI A, 1992, GENOMICS, V12, P319, DOI 10.1016/0888-7543(92)90380-B; MATSUTANI A, 1990, DIABETES, V39, P534; MEGLASSON MA, 1984, AM J PHYSIOL, V246, P1; MISHRA SK, 1992, GENOMICS, V12, P326, DOI 10.1016/0888-7543(92)90381-2; ORAHILLY S, 1988, DIABETOLOGIA, V31, P792; RAHILLY SO, 1988, DIABETOLOGIA, V31, P407; RAHILLY SO, 1988, DIAB MED, V5, P224; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; TATTERSALL RB, 1975, DIABETES, V24, P44, DOI 10.2337/diabetes.24.1.44; TURNER RC, 1983, DIABETOLOGIA, V24, P404; TZALL S, 1989, AM J HUM GENET, V44, P864; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; [No title captured]	27	528	557	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					162	164		10.1038/356162a0	http://dx.doi.org/10.1038/356162a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545870				2022-12-28	WOS:A1992HH73100063
J	PORTER, DG				PORTER, DG			ETHICAL SCORES FOR ANIMAL-EXPERIMENTS	NATURE			English	Editorial Material											PORTER, DG (corresponding author), UNIV GUELPH,DEPT BIOMED SCI,GUELPH N1G 2W1,ONTARIO,CANADA.							MANN MD, 1991, LAB ANIM SCI, V41, P6; MCLAUGHLIN RM, 1990, ANIMAL RESEARCH, ANIMAL RIGHTS, ANIMAL LEGISLATION, P11; MORTON DB, 1985, VET REC, V116, P431, DOI 10.1136/vr.116.16.431; PRENTICE ED, 1990, INVEST RADIOL, V25, P271, DOI 10.1097/00004424-199003000-00012; SHARPE R, 1989, CRUEL DECEPTION USE; 1983, SCI PROCEDURES LIVIN; 1990, ANIMALS, V24, P97	7	85	86	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					101	102		10.1038/356101a0	http://dx.doi.org/10.1038/356101a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HH731	1545854				2022-12-28	WOS:A1992HH73100021
J	SMITH, FW; FEIGON, J				SMITH, FW; FEIGON, J			QUADRUPLEX STRUCTURE OF OXYTRICHA TELOMERIC DNA OLIGONUCLEOTIDES	NATURE			English	Article							PROTON RESONANCES; H-1-NMR SPECTRA; NMR; ASSIGNMENT; FRAGMENT; SPECTROSCOPY; PHASE	THE telomeres of most eukaryotes contain a repeating G-rich sequence with the consensus d(T/A)1-4G1-8, of which 12-16 bases form a 3' single-strand overhang beyond the telomeric duplex 1. It has been proposed that these G-rich oligonucleotides associate to form four-stranded structures from one 2-4, two 2,5 or four 6,7 individual strands and that these structures may be relevant in vivo. The proposed structures contain Hoogsteen base-paired G-quartets, precedent for which has been in the literature for many years 8. Here we use H-1 NMR spectroscopy to study the conformations of the DNA oligonucleotides d(G4T4G4) (Oxy-1.5) and d(G4T4G4T4G4T4G4) (Oxy-3.5) which contain the Oxytricha telomere repeat (T4G4). We find that these molecules fold to form a symmetrical bimolecular and an intramolecular quadruplex, respectively. Both structures have four G-quartets formed from nucleotides that are alternately syn and anti along each strand. This arrangement differs from earlier models in which the strands are alternately all syn or all anti 2,3,5 . The T4 loops in Oxy-1.5 are on opposite ends of the quadruplex and loop diagonally across the G-quartet, resulting in adjacent strands being alternately parallel and antiparallel.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								BOELENS R, 1985, J MAGN RESON, V62, P378, DOI 10.1016/0022-2364(85)90207-0; BORZO M, 1978, CR ACAD SCI C CHIM, V287, P475; BRUNGER AT, 1990, MANUAL, P1; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DELEEUW FAAM, 1983, J COMPUT CHEM, V4, P428, DOI 10.1002/jcc.540040319; FEIGON J, 1984, NUCLEIC ACIDS RES, V12, P1243, DOI 10.1093/nar/12.2.1243; FEIGON J, IN PRESS DNA STRUCTU; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; JIN R, 1990, SCIENCE, V250, P543, DOI 10.1126/science.2237404; KINTANAR A, 1987, NUCLEIC ACIDS RES, V15, P5845, DOI 10.1093/nar/15.14.5845; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MACAYA RF, 1992, J AM CHEM SOC, V114, P781, DOI 10.1021/ja00028a067; MARION D, 1988, J MAGN RESON, V80, P528, DOI 10.1016/0022-2364(88)90250-8; NILGES M, 1991, J MOL BIOL, V219, P499, DOI 10.1016/0022-2836(91)90189-D; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PATEL DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1413, DOI 10.1073/pnas.79.5.1413; PINNAVAIA TJ, 1978, J AM CHEM SOC, V100, P3625, DOI 10.1021/ja00479a070; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WANG Y, 1991, NUCLEIC ACIDS RES, V19, P4619, DOI 10.1093/nar/19.17.4619; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	27	534	572	1	84	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					164	168		10.1038/356164a0	http://dx.doi.org/10.1038/356164a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545871				2022-12-28	WOS:A1992HH73100064
J	KEYES, LN; CLINE, TW; SCHEDL, P				KEYES, LN; CLINE, TW; SCHEDL, P			THE PRIMARY SEX DETERMINATION SIGNAL OF DROSOPHILA ACTS AT THE LEVEL OF TRANSCRIPTION	CELL			English	Article							DOSAGE COMPENSATION; DETERMINATION GENE; X-CHROMOSOME; LETHAL GENE; MELANOGASTER; ELEMENT; DAUGHTERLESS; SEQUENCE; PROTEINS; BINDING	For Drosophila, the choice between male and female development is made by the switch gene, Sxl, in response to the X:A ratio. Once Sxl is turned on in females, it actively maintains the determined state, independent of the X:A signal, by a positive autoregulatory feedback loop in which Sxl proteins direct the female-specific splicing of Sxl transcripts. In this paper we have investigated the mechanism controlling pathway initiation. Our results suggest a two-step model for the initial activation of Sxl in females. In the first step, a special class of Sxl mRNAs is expressed in female embryos from an early promoter that responds to the genes signaling the X:A ratio. The proteins produced from these early mRNAs then initiate the autoregulatory loop by directing the female-specific processing of transcripts from the late Sxl promoter.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	KEYES, LN (corresponding author), PRINCETON UNIV, DEPT BIOL, PRINCETON, NJ 08544 USA.							BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; CLINE TW, 1986, GENETICS, V113, P641; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1976, GENETICS, V84, P723; CLINE TW, 1980, GENETICS, V96, P903; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; CLINE TW, 1986, GENETICS, V114, P345; CRONMILLER C, 1987, CELL, V48, P479, DOI 10.1016/0092-8674(87)90198-X; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; GELIEBTER J, 1986, P NATL ACAD SCI USA, V83, P3371, DOI 10.1073/pnas.83.10.3371; GERGEN JP, 1987, GENETICS, V117, P477; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; HOOPES BC, 1985, P NATL ACAD SCI USA, V82, P3134, DOI 10.1073/pnas.82.10.3134; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; LYTTLE TW, 1989, GENETICS, V121, P751; MAINE EM, 1985, COLD SPRING HARB SYM, V50, P595, DOI 10.1101/SQB.1985.050.01.072; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; ROBERTSON HM, 1988, GENETICS, V118, P461; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SALZ HK, 1987, GENETICS, V117, P221; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SANCHEZ L, 1983, EMBO J, V2, P485, DOI 10.1002/j.1460-2075.1983.tb01451.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; WALKER ES, 1989, GENETICS, V122, P81	41	190	195	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					933	943		10.1016/0092-8674(92)90036-C	http://dx.doi.org/10.1016/0092-8674(92)90036-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547493				2022-12-28	WOS:A1992HH74800012
J	WHITE, JG; SOUTHGATE, E; THOMSON, JN				WHITE, JG; SOUTHGATE, E; THOMSON, JN			MUTATIONS IN THE CAENORHABDITIS-ELEGANS UNC-4 GENE ALTER THE SYNAPTIC INPUT TO VENTRAL CORD MOTOR NEURONS	NATURE			English	Article							DROSOPHILA; NEMATODE	IDENTIFICATION of the genes orchestrating neurogenesis would greatly enhance our understanding of this process. Genes have been identified that specify neuron type (for example cut 1 and numb 2 in Drosophila and mec-3 in Caenorhabditis elegans 3) and process guidance (for example, unc-5, unc-6 and unc-40 in C. elegans 4 and the fas-1 gene of Drosophila 5). We sought genes defining synaptic specificity by identifying mutations that alter synaptic connectivity in the motor circuitry in the nematode C. elegans. We used electron microscopy of serial sections 6 to reconstruct the ventral nerve-cords of uncoordinated (unc) mutants 7,8 that have distinctive locomotory choreographies. Here we describe the phenotype of mutations in the unc-4 gene in which a locomotory defect is correlated with specific changes in synaptic input to a subset of the excitatory VA motor neurons, normally used in reverse locomotion. The circuitry alterations do not arise because of the inaccessibility of the appropriate synaptic partners, but are a consequence of changes in synaptic specificity. The VA motor neurons with altered synaptic inputs are all lineal sisters of VB motor neurons; the VA motor neurons without VB sisters have essentially the same synaptic inputs as in wild-type animals. The normal function of the wild-type allele of unc-4 may thus be to invoke the appropriate synaptic specificities to VA motor neurons produced in particular developmental contexts.			WHITE, JG (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1985, J NEUROSCI, V5, P956; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DURBIN R, 1987, THESIS CAMBRIDGE U; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; HEDGECOCK EM, 1990, NEURON, V2, P61; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wood WB, 1988, NEMATODE CAENORHABDI	14	106	115	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					838	841		10.1038/355838a0	http://dx.doi.org/10.1038/355838a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538764				2022-12-28	WOS:A1992HF63600060
J	MANSFIELD, AO; WOLFE, JHN				MANSFIELD, AO; WOLFE, JHN			ABC OF VASCULAR DISEASES - TRAUMA	BRITISH MEDICAL JOURNAL			English	Article											MANSFIELD, AO (corresponding author), ST MARYS HOSP,LONDON,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1992	304	6824					439	442		10.1136/bmj.304.6824.439	http://dx.doi.org/10.1136/bmj.304.6824.439			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1547396	Bronze, Green Published			2022-12-28	WOS:A1992HE38900028
J	SMITH, A				SMITH, A			LEADING FOR HEALTH .2. SETTING A STRATEGY FOR HEALTH	BRITISH MEDICAL JOURNAL			English	Article											SMITH, A (corresponding author), LANCASTER MOOR HOSP,LANCASTER HLTH AUTHOR,LANCASTER LA1 3JR,ENGLAND.							1991, LEADING HLTH BMA AGE	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					376	378		10.1136/bmj.304.6823.376	http://dx.doi.org/10.1136/bmj.304.6823.376			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540740	Green Published, Bronze			2022-12-28	WOS:A1992HD38700032
J	NOVELLO, AC; SHOSKY, J				NOVELLO, AC; SHOSKY, J			HEALTHY-CHILDREN READY TO LEARN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US PHS,WASHINGTON,DC	United States Public Health Service									0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1643	1643						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1527862				2022-12-28	WOS:A1992JQ37600003
J	GILL, TM				GILL, TM			WHAT HAVE I DONE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						RESUSCITATION; HEART ARREST; ETHICS, MEDICAL		This short tale deals with a timely subject of general concern to internists and to most clinicians-that awful moment of hesitation when embarking on the urgent resuscitation of a patient whose previous health status is unknown. The exhilaration of a successful effort is supplanted by the dismay of a dismal outcome.			GILL, TM (corresponding author), YALE UNIV, SCH MED, RM IE-61 SHM, POB 3333, NEW HAVEN, CT 06510 USA.			Gill, Thomas/0000-0002-6450-0368				MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199	1	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					691	691		10.7326/0003-4819-116-8-691	http://dx.doi.org/10.7326/0003-4819-116-8-691			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546871				2022-12-28	WOS:A1992HN84400014
J	DUPONT, HL; ERICSSON, CD; MATHEWSON, JJ; DELACABADA, FJ; CONRAD, DA				DUPONT, HL; ERICSSON, CD; MATHEWSON, JJ; DELACABADA, FJ; CONRAD, DA			ORAL AZTREONAM, A POORLY ABSORBED YET EFFECTIVE THERAPY FOR BACTERIAL DIARRHEA IN UNITED-STATES TRAVELERS TO MEXICO	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRIMETHOPRIM-SULFAMETHOXAZOLE; HEALTHY-VOLUNTEERS; SQ 26,776; NORFLOXACIN; MONOBACTAM; SHIGELLOSIS; AZTHREONAM; DYSENTERY; ADULTS	Objective. - To evaluate a poorly absorbed antimicrobial with in vitro activity against all major bacterial enteropathogens in oral therapy for bacterial diarrhea. Design. - One hundred ninety-one US students with diarrhea acquired in Mexico received 100 mg of aztreonam or matching placebo three times a day for 5 days. Stools were cultured for bacterial enteropathogens before and after therapy. Setting. - We studied US students who acquired diarrhea in Mexico (travelers' diarrhea) in view of the high frequency of bacterial agents in this setting. Main Outcome Measure. - We examined time of clinical recovery, treatment failures, adverse experiences, and microbiologic eradication from stool of the etiologic agent in subjects randomized to receive aztreonam or placebo. Results. - Aztreonam reduced the average duration of diarrhea compared with the placebo: for all cases, by 40 hours (P << .01); for those with enterotoxigenic Escherichia coli diarrhea, by 50 hours (P < .01); for those with shigellosis, by 90 hours (P, not significant [small sample size]); for all bacterial agents, by 57 hours (P << .01). Clinical failures during the 5 days of therapy were seen in six patients (6%) receiving aztreonam and 25 (27%) receiving placebo (P < .01). Pathogen eradication occurred in 95% of those receiving aztreonam and in 70% of those receiving the placebo (P < .01). All bacterial enteropathogens were susceptible in vitro to aztreonam. The drug was well tolerated. Conclusions. - Oral aztreonam, which is poorly absorbed, was well tolerated and was an effective therapy for bacterial diarrhea in US adults in Mexico.	HOSP GEN OCCIDENTE SEGURO SOCIAL,GUADALAJARA,JALISCO,MEXICO; BRISTOL MYERS SQUIBB,PRINCETON,NJ	Bristol-Myers Squibb	DUPONT, HL (corresponding author), UNIV TEXAS,SCH MED,SCH PUBL HLTH,CTR INFECT DIS,6431 FANNIN,ROOM 1729 JFB,HOUSTON,TX 77025, USA.		DuPont, Herbert/AAH-6776-2021		NIAID NIH HHS [R01 AI 23049] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023049] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON S, 1980, STATISTICAL METHODS; BANDRES JC, IN PRESS AM J MED SC; BENNISH ML, 1990, J INFECT DIS, V161, P500, DOI 10.1093/infdis/161.3.500; DEVRIESHOSPERS HG, 1984, J INFECT DIS, V150, P636, DOI 10.1093/infdis/150.5.636; DUPONT HL, 1987, AM J MED, V82, P79, DOI 10.1016/0002-9343(87)90624-3; DUPONT HL, 1982, NEW ENGL J MED, V307, P841, DOI 10.1056/NEJM198209303071401; DUPONT HL, 1986, AM CLIN CLIMATOL ASS, V97, P32; EBRIGHT JR, 1984, AM J TROP MED HYG, V33, P1192, DOI 10.4269/ajtmh.1984.33.1192; ERICSSON CD, 1990, JAMA-J AM MED ASSOC, V263, P257, DOI 10.1001/jama.263.2.257; ERICSSON CD, 1983, ANN INTERN MED, V98, P20, DOI 10.7326/0003-4819-98-1-20; ERICSSON CD, 1988, J CLIN MICROBIOL, V26, P1047, DOI 10.1128/JCM.26.5.1047-1049.1988; GOOSSENS H, 1985, ANTIMICROB AGENTS CH, V27, P388, DOI 10.1128/AAC.27.3.388; GOTUZZO E, 1989, ANTIMICROB AGENTS CH, V33, P1101, DOI 10.1128/AAC.33.7.1101; GOUGH A, 1979, TOXICOL APPL PHARM, V51, P177, DOI 10.1016/0041-008X(79)90020-6; HALTALIN KC, 1968, J PEDIATR-US, V72, P708, DOI 10.1016/S0022-3476(68)80021-6; HARRIS JC, 1972, ANN INTERN MED, V76, P697, DOI 10.7326/0003-4819-76-5-697; JACOBUS NV, 1982, ANTIMICROB AGENTS CH, V22, P832, DOI 10.1128/AAC.22.5.832; MATA L, 1984, CHRONIC DIARRHEA CHI, P237; MATHEWSON JJ, 1985, J INFECT DIS, V151, P471, DOI 10.1093/infdis/151.3.471; MATTILA L, 1992, J INFECT DIS, V165, P385, DOI 10.1093/infdis/165.2.385; MURRAY BE, 1986, REV INFECT DIS, V8, pS172; NEILL MA, 1991, ANN INTERN MED, V114, P195, DOI 10.7326/0003-4819-114-3-195; NELSON JD, 1976, JAMA-J AM MED ASSOC, V235, P1239, DOI 10.1001/jama.235.12.1239; OBERHELMAN RA, 1987, J PEDIATR-US, V110, P960, DOI 10.1016/S0022-3476(87)80425-0; ROGERIE F, 1986, ANTIMICROB AGENTS CH, V29, P883, DOI 10.1128/AAC.29.5.883; SWABB EA, 1983, ANTIMICROB AGENTS CH, V23, P548, DOI 10.1128/AAC.23.4.548; SYKES RB, 1982, ANTIMICROB AGENTS CH, V21, P85, DOI 10.1128/AAC.21.1.85; SYKES RB, 1985, AM J MED, V78, P2, DOI 10.1016/0002-9343(85)90196-2; THORNTON SA, 1983, AM J CLIN PATHOL, V80, P858, DOI 10.1093/ajcp/80.6.858; WELLING GW, 1987, INFECTION, V15, P188, DOI 10.1007/BF01646046	30	56	57	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1932	1935		10.1001/jama.267.14.1932	http://dx.doi.org/10.1001/jama.267.14.1932			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL677	1548825				2022-12-28	WOS:A1992HL67700026
J	BALDI, MI; MATTOCCIA, E; BUFARDECI, E; FABBRI, S; TOCCHINIVALENTINI, GP				BALDI, MI; MATTOCCIA, E; BUFARDECI, E; FABBRI, S; TOCCHINIVALENTINI, GP			PARTICIPATION OF THE INTRON IN THE REACTION CATALYZED BY THE XENOPUS TRANSFER-RNA SPLICING ENDONUCLEASE	SCIENCE			English	Article							YEAST TRANSFER-RNA; INTERVENING SEQUENCES; TRANSCRIPTION; PRECURSORS; SECONDARY; SUBSTRATE; EXCISION; LAEVIS; PROBES; GENE	Introns have generally been assumed to be passive in the transfer RNA splicing reaction. Experiments have now been done showing that the endonuclease is able to cut a precursor provided that a base in the single-stranded loop of the intron can pair with the base of the 5' exon situated at the position that immediately follows the anticodon stem (position 33 in the yeast tRNA isoacceptor pre-tRNA3Leu, position 32 in yeast pre-tRNA(Phe). The elucidation of the role of the intron reveals that in addition to the conserved bases, there are positions in the mature domain which, although not necessarily occupied by the same base in all pre-tRNA's, nevertheless have a fundamental role in the splicing reaction. These positions are termed cardinal positions.	CNR,INST CELL BIOL,VIALE MARX 43,I-00137 ROME,ITALY; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; ENICHEM,DIPARTIMENTO BIOTECHNOL,I-00015 MONTEROTONDO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Chicago								BALDI MI, 1986, CELL, V47, P965, DOI 10.1016/0092-8674(86)90811-1; DZEKELY E, 1988, J BIOL CHEM, V263, P13839; FAHNESTOCK SR, 1972, P NATL ACAD SCI USA, V69, P363, DOI 10.1073/pnas.69.2.363; GANDINIATTARDI D, 1989, METHOD ENZYMOL, V181, P510; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; JOHNSON JD, 1980, P NATL ACAD SCI-BIOL, V77, P2564, DOI 10.1073/pnas.77.5.2564; LEE MC, 1985, J BIOL CHEM, V260, P3108; MATTOCCIA E, 1983, CELL, V32, P67, DOI 10.1016/0092-8674(83)90497-X; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OTSUKA A, 1981, MOL CELL BIOL, V1, P269, DOI 10.1128/MCB.1.3.269; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; RAYMOND GJ, 1983, NUCLEIC ACIDS RES, V11, P5969, DOI 10.1093/nar/11.17.5969; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SWERDLOW H, 1984, J BIOL CHEM, V259, P5197; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; ULBRICH N, 1978, J BIOL CHEM, V253, P9049; WICKENS MP, 1987, CELL, V51, P339, DOI 10.1016/0092-8674(87)90629-5; WREDE P, 1979, J BIOL CHEM, V254, P9608	20	66	69	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1404	1408		10.1126/science.1542788	http://dx.doi.org/10.1126/science.1542788			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542788				2022-12-28	WOS:A1992HH74400045
J	MELLMAN, I; SIMONS, K				MELLMAN, I; SIMONS, K			THE GOLGI-COMPLEX - INVITRO VERITAS	CELL			English	Review							ASPARAGINE-LINKED OLIGOSACCHARIDES; CELL-FREE SYSTEM; ROUGH ENDOPLASMIC-RETICULUM; VESICULAR STOMATITIS-VIRUS; PLASMA-MEMBRANE PROTEINS; BREFELDIN-A; CIS-GOLGI; SUCCESSIVE COMPARTMENTS; INTRACELLULAR-TRANSPORT; N-ACETYLGLUCOSAMINE		EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAM, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)	MELLMAN, I (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.		Mellman, Ira/ABG-5896-2020	Simons, Kai/0000-0002-9231-9996				ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BENNETT MK, 1988, EMBO J, V7, P4075, DOI 10.1002/j.1460-2075.1988.tb03301.x; BERGMANN JE, 1983, J CELL BIOL, V97, P1777, DOI 10.1083/jcb.97.6.1777; BONATTI S, 1989, J BIOL CHEM, V264, P12590; BRAELL WA, 1984, CELL, V39, P511, DOI 10.1016/0092-8674(84)90458-6; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; COLLEY KJ, 1989, J BIOL CHEM, V257, P14011; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; FRIES E, 1981, J CELL BIOL, V90, P697, DOI 10.1083/jcb.90.3.697; GEUZE HJ, 1991, J ELECTRON MICR TECH, V17, P24, DOI 10.1002/jemt.1060170105; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFFITHS G, 1989, J CELL BIOL, V108, P277, DOI 10.1083/jcb.108.2.277; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1984, J CELL BIOL, V98, P2133, DOI 10.1083/jcb.98.6.2133; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HELMS JB, 1990, J BIOL CHEM, V265, P20027; HERMO L, 1980, AM J ANAT, V157, P357, DOI 10.1002/aja.1001570405; HO WC, 1989, EUR J CELL BIOL, V48, P250; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; Huttner WB, 1989, CURR OPIN CELL BIOL, V1, P648, DOI 10.1016/0955-0674(89)90029-X; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KLAUSNER RD, 1992, IN PRESS J CELL BIOL; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LINDSEY JD, 1985, J NEUROSCI, V5, P3124; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; LOTTI L, 1992, IN PRESS J CELL BIOL; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MARSH M, 1986, P NATL ACAD SCI USA, V83, P2899, DOI 10.1073/pnas.83.9.2899; MELKONIAN M, 1991, J ELECTRON MICROSC, V17, P65; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NEEFJES JJ, 1988, J CELL BIOL, V107, P79, DOI 10.1083/jcb.107.1.79; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; ROTHMAN JE, 1984, J CELL BIOL, V99, P248, DOI 10.1083/jcb.99.1.248; ROTHMAN JE, 1984, J CELL BIOL, V99, P260, DOI 10.1083/jcb.99.1.260; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SARASTE J, 1991, IN PRESS J CELL SCI; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SLOT JW, 1983, J HISTOCHEM CYTOCHEM, V31, P1049, DOI 10.1177/31.8.6863900; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; THYBERG J, 1985, EXP CELL RES, V159, P1, DOI 10.1016/S0014-4827(85)80032-X; TOOZE J, 1984, EUR J CELL BIOL, V33, P281; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; ULMER JB, 1991, J BIOL CHEM, V266, P9173; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; YAMAMOTO K, 1987, J CELL BIOL, V105, P713, DOI 10.1083/jcb.105.2.713	123	440	443	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					829	840		10.1016/0092-8674(92)90027-A	http://dx.doi.org/10.1016/0092-8674(92)90027-A			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547485	Green Published, Bronze			2022-12-28	WOS:A1992HH74800003
J	MARGOLIS, B; HU, P; KATZAV, S; LI, W; OLIVER, JM; ULLRICH, A; WEISS, A; SCHLESSINGER, J				MARGOLIS, B; HU, P; KATZAV, S; LI, W; OLIVER, JM; ULLRICH, A; WEISS, A; SCHLESSINGER, J			TYROSINE PHOSPHORYLATION OF VAV PROTOONCOGENE PRODUCT CONTAINING SH2 DOMAIN AND TRANSCRIPTION FACTOR MOTIFS	NATURE			English	Article							PHOSPHOLIPASE C-II; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; KINASE-ACTIVITY; RECEPTOR; CELLS; PROTEINS; RELEASE; BINDING; PDGF	ACTIVATION of receptor-linked and cytoplasmic protein tyrosine kinases is crucial in the control of normal and abnormal cell growth and differentiation 1,2. Some substrates of protein tyrosine kinases such as phospholipase C-gamma and ras GTPase-activating protein (GAP) contain sequences homologous to the src protein domains SH2 and SH3 (refs 3-9). The proto-oncogene Vav is expressed in haematopoietic cells and its product Vav contains sequence motifs commonly found in transcription factors, such as helix-loop-helix, leucine-zipper and zinc-finger motifs and nuclear localization signals 10-12, as well as a single SH2 and two SH3 domains. Here we show that stimulation of T-cell antigen receptor on normal human peripheral blood lymphocytes or on human leukaemic T cells, and the crosslinking of IgE receptors on rat basophilic leukaemia cells, both promote the phosphorylation of tyrosine residues in Vav. Moreover, activation of the receptor for epidermal growth factor leads to marked tyrosine phosphorylation of Vav in cells transiently expressing vav, and Vav associates with the receptor through its SH2 domain. We propose that vav encodes a new class of substrates whose tyrosine phosphorylation may provide a mechanism for direct signal transduction linking receptors at the cell surface to transcriptional control.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV NEW MEXICO, DEPT PATHOL, ALBUQUERQUE, NM 87131 USA; MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DIV RHEUMATOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	St Jude Children's Research Hospital; University of New Mexico; Max Planck Society; Howard Hughes Medical Institute; University of California System; University of California San Francisco	MARGOLIS, B (corresponding author), NYU MED CTR, DEPT PHARMACOL, 550 1ST AVE, NEW YORK, NY 10016 USA.		Hu, Patrick/I-2902-2019	Hu, Patrick/0000-0002-5611-8062				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOLEN J, 1991, CELL GROWTH DIFFER, V2, P365; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; HARA T, 1985, J EXP MED, V161, P641, DOI 10.1084/jem.161.4.641; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KAPLAN DR, 1990, CELL, V61, P121; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; OLIVER JM, 1988, PROG ALLERGY, V42, P195; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUH PG, 1988, J BIOL CHEM, V263, P14497; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	37	381	389	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					71	74		10.1038/356071a0	http://dx.doi.org/10.1038/356071a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1531699				2022-12-28	WOS:A1992HG60200059
J	YEDNOCK, TA; CANNON, C; FRITZ, LC; SANCHEZMADRID, F; STEINMAN, L; KARIN, N				YEDNOCK, TA; CANNON, C; FRITZ, LC; SANCHEZMADRID, F; STEINMAN, L; KARIN, N			PREVENTION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS BY ANTIBODIES AGAINST ALPHA-4-BETA-1 INTEGRIN	NATURE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; ADHESION MOLECULES; HOMING RECEPTORS; CELL-ADHESION; LYMPHOCYTE-T; ANTIGEN; ENDOTHELIUM; BINDING; DEMYELINATION	EXPERIMENTAL autoimmune encephalomyelitis (EAE) is an inflammatory condition of the central nervous system with similarities to multiple sclerosis 1,2. In both diseases circulating leukocytes penetrate the blood-brain barrier and damage myelin, resulting in impaired nerve conduction and paralysis 3-5 . We sought to identify the adhesion receptors that mediate the attachment of circulating leukocytes to inflamed brain endothelium in EAE, because this interaction is the first step in leukocyte entry into the central nervous system. Using an in vitro adhesion assay on tissue sections, we found that lymphocytes and monocytes bound selectively to inflamed EAE brain vessels. Binding was inhibited by antibodies against the integrin molecule alpha-4-beta-1, but not by antibodies against numerous other adhesion receptors. When tested in vivo, anti-alpha-4 integrin effectively prevented the accumulation of leukocytes in the central nervous system and the development of EAE. Thus, therapies designed to interfere with alpha-4-beta-1 integrin may be useful in treating inflammatory diseases of the central nervous system, such as multiple sclerosis.	UNIV AUTONOMA MADRID,MADRID 34,SPAIN; STANFORD UNIV,STANFORD,CA 94305	Autonomous University of Madrid; Stanford University	YEDNOCK, TA (corresponding author), ATHENA NEUROSCI,S SAN FRANCISCO,CA, USA.		Sanchez-Madrid, Francisco/M-7889-2016	Sanchez-Madrid, Francisco/0000-0001-5303-0762; Steinman, Lawrence/0000-0002-2437-2250				ALVORD EC, 1984, EXPT ALLERGIC ENCEPH, P1; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BRISCOE DM, 1991, TRANSPLANTATION, V51, P537; CANNELLA B, 1990, J EXP MED, V172, P1521, DOI 10.1084/jem.172.5.1521; CHIN YH, 1990, J IMMUNOL, V145, P3669; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KOCH AE, 1991, LAB INVEST, V64, P313; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; PATERSON PY, 1976, TXB IMMUNOPATHOLOGY, P179; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RAINE CS, 1990, LAB INVEST, V63, P476; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; STAMPER HB, 1976, J EXP MED, V144, P828, DOI 10.1084/jem.144.3.828; TRAUGOTT U, 1986, CELL IMMUNOL, V99, P395, DOI 10.1016/0008-8749(86)90248-0; WILCOX CE, 1990, J NEUROIMMUNOL, V30, P43, DOI 10.1016/0165-5728(90)90051-N; WISNIEWSKI HM, 1977, ANN NEUROL, V1, P144, DOI 10.1002/ana.410010207; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	30	1476	1618	2	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					63	66		10.1038/356063a0	http://dx.doi.org/10.1038/356063a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538783				2022-12-28	WOS:A1992HG60200056
J	HAGLER, J; SHUMAN, S				HAGLER, J; SHUMAN, S			A FREEZE-FRAME VIEW OF EUKARYOTIC TRANSCRIPTION DURING ELONGATION AND CAPPING OF NASCENT MESSENGER-RNA	SCIENCE			English	Article							VACCINIA VIRUS; POLYMERASE; PURIFICATION; GUANYLYLTRANSFERASE; TERMINATION; INVITRO	Ribonuclease footprinting of nascent messenger RNA within ternary complexes of vaccinia RNA polymerase revealed an RNA binding site that encompasses an 18-nucleotide RNA segment. The dimensions of the binding site did not change as the polymerase moved along the template. Capping of the 5' end of the RNA was cotranscriptional and was confined to nascent chains 31 nucleotides or greater in length. Purified capping enzyme formed a binary complex with RNA polymerase in solution in the absence of nucleic acid. These findings suggest a mechanism for cotranscriptional establishment of messenger RNA identity in eukaryotes.			HAGLER, J (corresponding author), SLOAN KETTERING MEM CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; EDERY I, 1985, P NATL ACAD SCI USA, V82, P7590, DOI 10.1073/pnas.82.22.7590; HAGLER J, UNPUB; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; LUO Y, 1991, J BIOL CHEM, V266, P13303; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; MOSS B, 1991, J BIOL CHEM, V266, P1355; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; SPENCER E, 1980, J BIOL CHEM, V255, P5388; VENKATESAN S, 1980, J BIOL CHEM, V255, P903	20	82	82	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					983	986		10.1126/science.1546295	http://dx.doi.org/10.1126/science.1546295			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546295				2022-12-28	WOS:A1992HE60500040
J	KELLY, A; POWIS, SH; KERR, LA; MOCKRIDGE, I; ELLIOTT, T; BASTIN, J; UCHANSKAZIEGLER, B; ZIEGLER, A; TROWSDALE, J; TOWNSEND, A				KELLY, A; POWIS, SH; KERR, LA; MOCKRIDGE, I; ELLIOTT, T; BASTIN, J; UCHANSKAZIEGLER, B; ZIEGLER, A; TROWSDALE, J; TOWNSEND, A			ASSEMBLY AND FUNCTION OF THE 2 ABC TRANSPORTER PROTEINS ENCODED IN THE HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX	NATURE			English	Article							TOXIC LYMPHOCYTES-T; CLASS-II REGION; HLA-B ANTIGENS; MONOCLONAL-ANTIBODY; INFLUENZA NUCLEOPROTEIN; MULTIDRUG RESISTANCE; MOLECULAR ANALYSIS; CYSTIC-FIBROSIS; HEAVY-CHAINS; MHC	PRESENTATION Of Cytoplasmic antigens to class I-restricted cytotoxic T cells implied the existence of a specialized peptide transporter 1-3 (reviewed in ref. 4). For most class I heavy chains, association with peptides of the appropriate length is required for stable assembly with beta-2-microglobulin 5-11. Mutant cells RMA-S (ref. 12) and .174/T2 (refs 13, 14) neither assemble stable class I molecules nor present intracellular antigens, and we have suggested that they have lost a function required for the transport of short peptides from the cytosol to the endoplasmic reticulum 5-7. The genetic defect in .174 has been localized to a large deletion in the class II region of the major histocompatibility complex 6,15,16, within which two genes (RING4 and RING11) have been identified that code for 'ABC' (ATP-binding cassette) transporters 15,17-21. We report here that the protein products of these two genes assemble to form a complex. Defects in either protein result in the formation of unstable class I molecules and loss of presentation of intracellular antigens. The molecular defect in a new mutant, BM36.1, is shown to be in the ATP-binding domain of the RING11/PSF2 protein. This is in contrast to the mutant .134 (ref. 15), which lacks the RING4/PSF1 protein.	JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,INST EXPTL ONKOL & TRANSPLANTAT MED,W-1000 BERLIN 19,GERMANY	University of Oxford; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	KELLY, A (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Townsend, Alain/0000-0002-3702-0107				BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; ERLICH H, 1986, HUM IMMUNOL, V16, P205, DOI 10.1016/0198-8859(86)90049-2; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; GOULD K, 1989, J EXP MED, V170, P1051, DOI 10.1084/jem.170.3.1051; HAYNES BF, 1982, HUM IMMUNOL, V4, P273, DOI 10.1016/0198-8859(82)90001-5; HIGGINS CF, 1990, PHILOS T R SOC B, V326, P353, DOI 10.1098/rstb.1990.0017; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LJUNGGREN HG, 1989, J IMMUNOL, V142, P2911; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; PARHAM P, 1979, J IMMUNOL, V123, P342; POWIS SH, IN PRESS P NATN ACAD; RADKA SF, 1982, J IMMUNOL, V128, P2804; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SMITH MEF, 1989, P NATL ACAD SCI USA, V86, P5557, DOI 10.1073/pnas.86.14.5557; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SPRING B, 1985, IMMUNOGENETICS, V21, P277, DOI 10.1007/BF00375380; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VOLZ A, IN PRESS CYTOGENET C; WHITTON JL, 1989, J EXP MED, V170, P1033, DOI 10.1084/jem.170.3.1033; ZIEGLER A, 1985, IMMUNOBIOLOGY, V169, P455, DOI 10.1016/S0171-2985(85)80001-2	33	403	407	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					641	644		10.1038/355641a0	http://dx.doi.org/10.1038/355641a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538751				2022-12-28	WOS:A1992HD54700057
J	ZAMORE, PD; PATTON, JG; GREEN, MR				ZAMORE, PD; PATTON, JG; GREEN, MR			CLONING AND DOMAIN-STRUCTURE OF THE MAMMALIAN SPLICING FACTOR U2AF	NATURE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; DROSOPHILA-MELANOGASTER; SNRNP BINDING; 70K PROTEIN; RNA; GENE; PURIFICATION; EXPRESSION; INTRONS; IDENTIFICATION	A complementary DNA clone encoding the large subunit of the essential mammalian pre-messenger RNA splicing component U2 snRNP auxiliary factor (U2AF65) has been isolated and expressed in vitro. It contains two functional domains: a sequence-specific RNA-binding region composed of three ribonucleoprotein-consensus sequence domains, and an arginine/serine-rich motif necessary for splicing but not for binding to pre-mRNA.	HARVARD UNIV, SCH MED, MOLEC & CELLULAR PHYSIOL LAB, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	ZAMORE, PD (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.		Zamore, Phillip D/A-8941-2013	Zamore, Phillip/0000-0002-4505-9618				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; ETZERODT M, 1988, EMBO J, V7, P4311, DOI 10.1002/j.1460-2075.1988.tb03330.x; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MANCEBO R, 1990, MOL CELL BIOL, V10, P2492, DOI 10.1128/MCB.10.6.2492; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; QUERY CC, 1987, CELL, V51, P211, DOI 10.1016/0092-8674(87)90148-6; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; VOELKER RA, 1991, MOL CELL BIOL, V11, P894, DOI 10.1128/MCB.11.2.894; ZAMORE PD, 1990, NATURE, V348, P485, DOI 10.1038/348485a0; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814	39	499	507	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1992	355	6361					609	614		10.1038/355609a0	http://dx.doi.org/10.1038/355609a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538748				2022-12-28	WOS:A1992HD54700043
J	ENG, C; FARRAYE, FA; SHULMAN, LN; PEPPERCORN, MA; KRAUSS, CM; CONNORS, JM; STONE, RM				ENG, C; FARRAYE, FA; SHULMAN, LN; PEPPERCORN, MA; KRAUSS, CM; CONNORS, JM; STONE, RM			THE ASSOCIATION BETWEEN THE MYELODYSPLASTIC SYNDROMES AND CROHN DISEASE	ANNALS OF INTERNAL MEDICINE			English	Note						MYELODYSPLASTIC SYNDROMES; CROHN DISEASE; BONE MARROW CELLS; CHROMOSOME ABNORMALITIES; CHROMOSOMES, HUMAN, PAIR-20	INFLAMMATORY BOWEL-DISEASE	The cases of four patients who had both a myelodysplastic syndrome and Crohn disease are reported. The association of these two disorders has not been reported previously. Bone marrow cells from three of the patients showed abnormalities in chromosome 20; in two cases, the abnormalities involved band 20q11. Potential relations between the myelodysplastic syndromes and Crohn disease are discussed.	HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DIV MED ONCOL, 44 BINNEY ST, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV HEMATOL & ONCOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DIV GASTROENTEROL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, CTR INFLAMMATORY BOWEL DIS, DEPT MED, BOSTON, MA 02215 USA; HARVARD COMMUNITY HLTH PLAN, DIV GASTROENTEROL, BOSTON, MA 02116 USA; HARVARD COMMUNITY HLTH PLAN, DIV MED GENET, BOSTON, MA 02116 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Connors, Joseph/AAF-5284-2019	Connors, Joseph/0000-0002-1361-7531; Eng, Charis/0000-0002-3693-5145; Farraye, Francis/0000-0001-6371-2441				BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; GREEN AR, 1990, BRIT J HAEMATOL, V74, P364, DOI 10.1111/j.1365-2141.1990.tb02597.x; GREENSTEIN AJ, 1985, CANCER, V56, P2914, DOI 10.1002/1097-0142(19851215)56:12<2914::AID-CNCR2820561232>3.0.CO;2-J; KONSTANTINOVA B, 1969, Digestion, V2, P329; LIST AF, 1990, J CLIN ONCOL, V8, P1424, DOI 10.1200/JCO.1990.8.8.1424; MADJLESSI SHM, 1986, DIGEST DIS SCI, V31, P1025, DOI 10.1007/BF01300254; MCKUSICK VA, 1988, MENDELIAN INHERITANC, pR98; MITELMAN F, 1985, CATALOG CHROMOSOME A, P538; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P1008, DOI 10.1056/NEJM199110033251406; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; POMEROY C, 1991, AM J MED, V90, P338, DOI 10.1016/0002-9343(91)90574-H	11	37	38	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					661	662		10.7326/0003-4819-117-8-661	http://dx.doi.org/10.7326/0003-4819-117-8-661			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530197				2022-12-28	WOS:A1992JR86100006
J	ENYEDI, AJ; YALPANI, N; SILVERMAN, P; RASKIN, I				ENYEDI, AJ; YALPANI, N; SILVERMAN, P; RASKIN, I			SIGNAL MOLECULES IN SYSTEMIC PLANT-RESISTANCE TO PATHOGENS AND PESTS	CELL			English	Review							SALICYLIC-ACID; ACQUIRED-RESISTANCE; METHYL JASMONATE; VIRUS-INFECTION; ARABIDOPSIS-THALIANA; BIOLOGICAL FUNCTION; POLYACRYLIC-ACID; TOMATO PLANTS; FUNGAL GROWTH; TOBACCO GENES				ENYEDI, AJ (corresponding author), RUTGERS STATE UNIV, COOK COLL, AGBIOTECH CTR, NEW BRUNSWICK, NJ 08903 USA.							ANDERSON J M, 1985, Plant Physiology (Rockville), V77, P75; [Anonymous], 1989, GENETIC ENG PRINCIPL; ANTONIW JF, 1986, PLANT MOL BIOL, V6, P145, DOI 10.1007/BF00021483; BAARDSETH P, 1978, FOOD CHEM, V3, P43, DOI 10.1016/0308-8146(78)90046-8; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BOL JF, 1990, ANNU REV PHYTOPATHOL, V28, P113, DOI 10.1146/annurev.py.28.090190.000553; BOLLER T, 1983, PLANTA, V157, P22, DOI 10.1007/BF00394536; Boller T., 1991, PLANT HORMONE ETHYLE; BOWLER C, 1989, EMBO J, V8, P31, DOI 10.1002/j.1460-2075.1989.tb03345.x; BREDERODE FT, 1991, PLANT MOL BIOL, V17, P1117, DOI 10.1007/BF00028729; BROGLIE K, 1991, SCIENCE, V254, P1194, DOI 10.1126/science.254.5035.1194; CARR JP, 1987, MOL CELL BIOL, V7, P1580, DOI 10.1128/MCB.7.4.1580; CHADHA KC, 1974, CAN J BOT, V52, P2041, DOI 10.1139/b74-262; Chester KS, 1933, Q REV BIOL, V8, P275, DOI 10.1086/394440; CLELAND CF, 1974, PLANT PHYSIOL, V54, P904, DOI 10.1104/pp.54.6.904; CURTIS RW, 1984, J PLANT GROWTH REGUL, V3, P157, DOI 10.1007/BF02042000; DELAAT AMM, 1981, PLANT PHYSIOL, V68, P256, DOI 10.1104/pp.68.1.256; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; ECKER JR, 1987, P NATL ACAD SCI USA, V84, P5202, DOI 10.1073/pnas.84.15.5202; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; ESQUERRETUGAYE MT, 1979, PLANT PHYSIOL, V64, P320, DOI 10.1104/pp.64.2.320; FALKENSTEIN E, 1991, PLANTA, V185, P316, DOI 10.1007/BF00201050; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; FARMER EE, 1992, PLANT PHYSIOL, V98, P995, DOI 10.1104/pp.98.3.995; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; GILPATRICK JD, 1952, SCIENCE, V115, P701, DOI 10.1126/science.115.3000.701; GRAHAM JS, 1986, PLANTA, V169, P399, DOI 10.1007/BF00392137; GROSSKOPF DG, 1991, J PLANT PHYSIOL, V138, P741, DOI 10.1016/S0176-1617(11)81325-8; GUEDES MEM, 1980, PHYSIOL PLANT PATHOL, V17, P229, DOI 10.1016/0048-4059(80)90056-9; GUNDLACH H, 1992, P NATL ACAD SCI USA, V89, P2389, DOI 10.1073/pnas.89.6.2389; HUGHES RK, 1991, PLANT CELL PHYSIOL, V32, P853; Hyodo H., 1991, PLANT HORMONE ETHYLE; JOHNSON R, 1990, PLANT MOL BIOL, V14, P527, DOI 10.1007/BF00027498; KAUFFMANN S, 1987, EMBO J, V6, P3209, DOI 10.1002/j.1460-2075.1987.tb02637.x; KE DY, 1988, PLANT PHYSIOL, V88, P1136, DOI 10.1104/pp.88.4.1136; KUC J, 1982, BIOSCIENCE, V32, P854, DOI 10.2307/1309008; LEGRAND M, 1987, P NATL ACAD SCI USA, V84, P6750, DOI 10.1073/pnas.84.19.6750; LINTHORST HJM, 1991, CRIT REV PLANT SCI, V10, P123, DOI 10.1080/07352689109382309; Madamanchi N. R., 1991, The fungal spore and disease initiation in plants and animals., P347; MALAMY J, 1992, PLANT CELL, V4, P359, DOI 10.1105/tpc.4.3.359; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MAUCH F, 1984, PLANT PHYSIOL, V76, P607, DOI 10.1104/pp.76.3.607; MAUCH F, 1988, PLANT PHYSIOL, V88, P936, DOI 10.1104/pp.88.3.936; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; MEMELINK J, 1990, PLANT MOL BIOL, V14, P119, DOI 10.1007/BF00018553; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MILLS PR, 1984, PHYTOPATHOL Z, V111, P209; OELLER PW, 1991, SCIENCE, V254, P437, DOI 10.1126/science.1925603; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PENNAZIO S, 1987, PHYSIOL MOL PLANT P, V30, P347, DOI 10.1016/0885-5765(87)90016-6; RASKIN I, 1990, ANN BOT-LONDON, V66, P369, DOI 10.1093/oxfordjournals.aob.a088037; RASKIN I, 1992, ANNU REV PLANT PHYS, V43, P439, DOI 10.1146/annurev.pp.43.060192.002255; RASMUSSEN JB, 1991, PLANT PHYSIOL, V97, P1342, DOI 10.1104/pp.97.4.1342; Raupp M. J., 1991, PHYTOCHEMICAL INDUCT; RHODES MJC, 1973, PHYTOCHEMISTRY, V12, P107, DOI 10.1016/S0031-9422(00)84631-2; Ross A., 1966, VIRUSES OF PLANTS, P127; ROSS AF, 1961, VIROLOGY, V14, P329, DOI 10.1016/0042-6822(61)90318-X; ROSS AF, 1961, VIROLOGY, V14, P340, DOI 10.1016/0042-6822(61)90319-1; ROSS AF, 1972, PHYTOPATHOLOGY, V62, P786; SAMAC DA, 1990, PLANT PHYSIOL, V93, P907, DOI 10.1104/pp.93.3.907; SANIEWSKI M, 1985, EXPERIENTIA, V41, P256, DOI 10.1007/BF02002624; SCHLUMBAUM A, 1986, NATURE, V324, P365, DOI 10.1038/324365a0; SHINSHI H, 1987, P NATL ACAD SCI USA, V84, P89, DOI 10.1073/pnas.84.1.89; STASWICK PE, 1992, PLANT PHYSIOL, V99, P804, DOI 10.1104/pp.99.3.804; SWAIN AR, 1985, J AM DIET ASSOC, V85, P950; TAKEUCHI Y, 1990, PLANT PHYSIOL, V93, P673, DOI 10.1104/pp.93.2.673; UEDA J, 1980, PLANT PHYSIOL, V66, P246, DOI 10.1104/pp.66.2.246; VANDERHEE MD, 1990, PLANT CELL, V2, P357, DOI 10.1105/tpc.2.4.357; VANLOON LC, 1977, VIROLOGY, V80, P417, DOI 10.1016/S0042-6822(77)80016-0; VICK BA, 1986, PLANT PHYSIOL, V80, P202, DOI 10.1104/pp.80.1.202; VICK BA, 1984, PLANT PHYSIOL, V75, P458, DOI 10.1104/pp.75.2.458; VOGELI U, 1988, PLANTA, V174, P364, DOI 10.1007/BF00959522; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WEIDHASE RA, 1987, PLANT SCI, V51, P177, DOI 10.1016/0168-9452(87)90191-9; WHITE RF, 1991, CRIT REV PLANT SCI, V9, P443, DOI 10.1080/07352689109382300; WHITE RF, 1983, PHYTOPATHOL Z, V107, P224; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809; YALPANI N, 1992, IN PRESS PLANT PHYSL; YE XS, 1989, PHYSIOL MOL PLANT P, V35, P161, DOI 10.1016/0885-5765(89)90086-6	79	220	236	5	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					879	886		10.1016/0092-8674(92)90239-9	http://dx.doi.org/10.1016/0092-8674(92)90239-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525827				2022-12-28	WOS:A1992JN78100004
J	PEHRSON, JR; FRIED, VA				PEHRSON, JR; FRIED, VA			MACROH2A, A CORE HISTONE CONTAINING A LARGE NONHISTONE REGION	SCIENCE			English	Article							DNA-BINDING PROTEINS; LEUCINE ZIPPER; GEL-ELECTROPHORESIS; CHROMATIN; NUCLEOSOMES; FOS; SEQUENCE; GENE; CENTROMERE; DIGESTION	A histone, macroH2A, nearly three times the size of conventional H2A histone, was found in rat liver nucleosomes. Its N-terminal third is 64 percent identical to a full-length mouse H2A. However, it also contains a large nonhistone region. This region has a segment that resembles a leucine zipper, a structure known to be involved in dimerization of some transcription factors. Nucleosomes containing macroH2A may have novel functions, possibly involving interactions with other nuclear proteins.	NEW YORK MED COLL,DEPT CELL BIOL & ANAT,VALHALLA,NY 10595; FOX CHASE CANC INST,INST CANC RES,PHILADELPHIA,PA 19111	New York Medical College; Fox Chase Cancer Center					NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024019] Funding Source: NIH RePORTER; NCI NIH HHS [CA 06927] Funding Source: Medline; NCRR NIH HHS [RR 05539] Funding Source: Medline; NIGMS NIH HHS [GM 24019] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLIS CD, 1982, CELL, V31, P131, DOI 10.1016/0092-8674(82)90412-3; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; BLOOM KS, 1978, CELL, V15, P141, DOI 10.1016/0092-8674(78)90090-9; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; CLARK DJ, 1988, EMBO J, V7, P69, DOI 10.1002/j.1460-2075.1988.tb02784.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Cohen L., UNPUB; ECKERSKORN C, 1989, CHROMATOGRAPHIA, V28, P92, DOI 10.1007/BF02290390; GABRIELLI F, 1981, EUR J BIOCHEM, V120, P363, DOI 10.1111/j.1432-1033.1981.tb05713.x; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; HATCH CL, 1988, NUCLEIC ACIDS RES, V16, P1113, DOI 10.1093/nar/16.3.1113; HURT MM, 1989, NUCLEIC ACIDS RES, V17, P8876, DOI 10.1093/nar/17.21.8876; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KINGWELL B, 1987, CHROMOSOMA, V95, P403, DOI 10.1007/BF00333991; KNOWLES JA, 1987, MOL CELL BIOL, V7, P478, DOI 10.1128/MCB.7.1.478; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; PEHRSON JR, 1989, P NATL ACAD SCI USA, V86, P9149, DOI 10.1073/pnas.86.23.9149; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; SUBRAMANIAN IV, 1991, MOL CELL BIOL, V11, P4863; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WELLS D, 1991, NUCLEIC ACIDS RES, V19, P2173, DOI 10.1093/nar/19.suppl.2173; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	37	267	276	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1398	1400						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529340				2022-12-28	WOS:A1992JL61200033
J	SHIBUYA, H; YONEYAMA, M; NINOMIYATSUJI, J; MATSUMOTO, K; TANIGUCHI, T				SHIBUYA, H; YONEYAMA, M; NINOMIYATSUJI, J; MATSUMOTO, K; TANIGUCHI, T			IL-2 AND EGF RECEPTORS STIMULATE THE HEMATOPOIETIC-CELL CYCLE VIA DIFFERENT SIGNALING PATHWAYS - DEMONSTRATION OF A NOVEL ROLE FOR C-MYC	CELL			English	Article							BETA-CHAIN; MESSENGER-RNA; ERYTHROPOIETIN RECEPTOR; GROWTH-FACTORS; T-CELLS; V-ABL; GENE; ONCOGENE; LINE; EXPRESSION	Stimulation via cytokine receptors such as IL-2 and IL-3 receptors, but not by the EGF receptor (EGFR), induces cells of the BAF-B03 hematopoietic cell line to transit the cell cycle. We demonstrate that the IL-2 receptor beta-chain (IL-2R-beta) is linked to at least two intracellular signaling pathways. One pathway may involve a protein tyrosine kinase of the src family, which leads to the induction of the c-jun and c-fos genes, among others. A second pathway, involving an as yet unknown mechanism, leads to c-myc gene induction. Stimulation of the EGFR, expressed following transfection of an appropriate recombinant construct, can activate the former, but not the latter, pathway in this cell line and cause the cells to enter S phase but not progress further. This deficiency can be rescued by ectopic expression of the c-myc gene, indicating a novel role for this proto-oncogene in the S to G2/M transition of the cell cycle.	NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN	Nagoya University	SHIBUYA, H (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN.		Yoneyama, Mitsutoshi/D-8244-2017	Yoneyama, Mitsutoshi/0000-0001-9512-0408; Ninomiya-Tsuji, Jun/0000-0002-5584-0176				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLACKWOOD EM, 1992, IN PRESS CURR OPIN G; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DEAN M, 1987, ONCOGENE RES, V1, P279; DEAN M, 1986, J BIOL CHEM, V261, P9161; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOI T, 1989, EMBO J, V8, P1953, DOI 10.1002/j.1460-2075.1989.tb03600.x; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HATAKEYAMA M, 1992, IN PRESS EUR J BIOCH; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MINAMOTO S, 1990, J IMMUNOL, V145, P2177; MORI H, 1991, INT IMMUNOL, V3, P149, DOI 10.1093/intimm/3.2.149; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REED JC, 1987, ONCOGENE, V1, P223; ROUSSELMF, 1991, NATURE, V353, P361; RUDEN TV, 1988, EMBO J, V7, P2749; SATO C, 1985, J CELL BIOL, V100, P748, DOI 10.1083/jcb.100.3.748; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TANAKA T, 1991, INT IMMUNOL, V3, P105, DOI 10.1093/intimm/3.1.105; TROUCHE D, 1991, J IMMUNOL, V147, P2398; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUDO M, 1989, J IMMUNOL, V143, P4039; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WANG HM, 1989, EMBO J, V8, P3677, DOI 10.1002/j.1460-2075.1989.tb08542.x; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	70	261	265	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					57	67		10.1016/0092-8674(92)90533-I	http://dx.doi.org/10.1016/0092-8674(92)90533-I			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1535827				2022-12-28	WOS:A1992JC95700008
J	MOMAND, J; ZAMBETTI, GP; OLSON, DC; GEORGE, D; LEVINE, AJ				MOMAND, J; ZAMBETTI, GP; OLSON, DC; GEORGE, D; LEVINE, AJ			THE MDM-2 ONCOGENE PRODUCT FORMS A COMPLEX WITH THE P53 PROTEIN AND INHIBITS P53-MEDIATED TRANSACTIVATION	CELL			English	Article							CELLULAR TUMOR-ANTIGEN; AMINO-ACID-SEQUENCE; HEAT-SHOCK PROTEINS; TRANSFORMED-CELLS; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; MAMMALIAN-CELLS; T-ANTIGEN; GENE	A cellular phosphoprotein with an apparent molecular mass of 90 kd (p90) that forms a complex with both mutant and wild-type p53 protein has been characterized, purified, and identified. The protein was identified as a product of the murine double minute 2 gene (mdm-2). The mdm-2 gene enhances the tumorigenic potential of cells when it is overexpressed and encodes a putative transcription factor. To determine if mdm-2 could modulate p53 transactivation, a p53-responsive element from the muscle creatine kinase gene was employed. A wild-type p53-expressing plasmid enhanced the expression of the p53-responsive element when cotransfected into cells that contain no endogenous p53. When a cosmid expressing mdm-2 was transfected with this p53-expressing plasmid, the transactivation of the p53-responsive element was inhibited. Thus, a product of the mdm-2 oncogene forms a tight complex with the p53 protein, and the mdm-2 oncogene can inhibit p53-mediated transactivation.	UNIV PENN,DEPT HUMAN GENET,PHILADELPHIA,PA 19104	University of Pennsylvania	MOMAND, J (corresponding author), PRINCETON UNIV,LEWIS THOMAS LAB,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.		Momand, Jamil/F-8154-2012; Zambetti, Gerard/N-8093-2018	Zambetti, Gerard/0000-0002-0929-5007	NCI NIH HHS [5 F32 CA08771, CA09258-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KAWASAKI E, 1989, AMPLIFICATIONS, P4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, IN PRESS GENES DEV	53	2861	2959	3	118	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1237	1245		10.1016/0092-8674(92)90644-R	http://dx.doi.org/10.1016/0092-8674(92)90644-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1535557				2022-12-28	WOS:A1992JA43100017
J	DAVIS, KM; FISH, LC; ELAHI, D; CLARK, BA; MINAKER, KL				DAVIS, KM; FISH, LC; ELAHI, D; CLARK, BA; MINAKER, KL			ATRIAL-NATRIURETIC-PEPTIDE LEVELS IN THE PREDICTION OF CONGESTIVE-HEART-FAILURE RISK IN FRAIL ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTRICULAR EJECTION FRACTION; SUPRAVENTRICULAR TACHYCARDIA; BLOOD; PRESSURE; HOSPITALIZATION; POLYPEPTIDE; RELIABILITY; HORMONE; DISEASE; INDEX	Objective. - To develop a noninvasive clinical predictive model for acute congestive heart failure (CHF) in a frail elderly cohort using bedside clinical assessment (medical history and physical examination) and venous atrial natriuretic peptide (ANP) levels. Design. - One-year prospective blinded cohort study. Setting. - Life care facility. Participants. - Three hundred thirty-one frail, elderly volunteers free of acute illness at study entry (mean +/- SD age, 88 +/- 7 years; 23% male, 77% female). Main Outcome Measure. - Clinical episodes of CHF with confirmation of acute pulmonary edema by chest roentgenogram. Results. - Fifteen percent of the elderly cohort developed at least one episode of CHF during the 1-year follow-up period. Those developing CHF had significantly higher mean +/- SE ANP values at study entry: 493 +/- 55 vs 207 +/- 15 pmol/L. The risk for development of CHF rose progressively with increasing ANP levels at study entry. In multivariate analysis, only two independent variables significantly predicted CHF: ANP value greater than 200 pmol/L (adjusted odds ratio [OR], 7.9; 95% confidence interval [Cl], 3.2 to 19.2) and history of CHF in the previous year (adjusted OR, 7.0; 95% Cl, 2.9 to 17). Stratifying the cohort by these two variables results in three CHF risk groups: 55% of the population at 3% annual risk of CHF, 37% of the population at 20% to 24% annual risk of CHF, and 8% of the population at 66% annual risk of CHF. Conclusions. - This simple clinical prediction model identifies elderly subjects at risk for CHF and allows appropriate focusing of medical resources for prevention, early detection, and treatment of this highly morbid clinical syndrome.	HEBREW REHABIL CTR AGED, BOSTON, MA USA; HARVARD UNIV, BETH ISRAEL HOSP, THORNDIKE LAB, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DIV NEPHROL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA 02115 USA; BROCKTON W ROXBURY DEPT VET ADM VET ADM MED CTR, GERIATR RES EDUC CLIN CTR, BOSTON, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Geriatric Research Education & Clinical Center	DAVIS, KM (corresponding author), BETH ISRAEL HOSP, DEPT MED, DIV GERONTOL, SL-435, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NCRR NIH HHS [RR-0132] Funding Source: Medline; NIA NIH HHS [AG-00599, AG04390] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004390] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JV, 1988, BRIT HEART J, V59, P207; ARONOW WS, 1986, AM J CARDIOL, V58, P651, DOI 10.1016/0002-9149(86)90295-X; BATES ER, 1986, CIRCULATION, V73, P1155, DOI 10.1161/01.CIR.73.6.1155; BORST JGG, 1973, NETH J MED, V16, P66; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHAKKO S, 1991, AM J MED, V90, P353, DOI 10.1016/0002-9343(91)90576-J; CLARK BA, 1990, J CLIN ENDOCR METAB, V70, P349, DOI 10.1210/jcem-70-2-349; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; DOUGHERTY AH, 1984, AM J CARDIOL, V54, P778, DOI 10.1016/S0002-9149(84)80207-6; EAGLE KA, 1988, ARCH INTERN MED, V148, P882, DOI 10.1001/archinte.148.4.882; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; GOETZ KL, 1988, AM J PHYSIOL, V254, pE1, DOI 10.1152/ajpendo.1988.254.1.E1; GOLDBERGER JJ, 1986, ARCH INTERN MED, V146, P489, DOI 10.1001/archinte.146.3.489; GOLDSTEIN RL, 1984, MED CARE, V22, P854, DOI 10.1097/00005650-198409000-00010; GOTTLIEB SS, 1989, J AM COLL CARDIOL, V13, P1534, DOI 10.1016/0735-1097(89)90344-6; GRAVES EJ, 1990, ADV DATA VITAL HLTH, V185; HARA H, 1987, CLIN CARDIOL, V10, P437, DOI 10.1002/clc.4960100806; Hennekens CH., 1987, EPIDEMIOLOGY MED CHA, P54; HIRATA Y, 1987, AM HEART J, V113, P1463, DOI 10.1016/0002-8703(87)90663-6; HIRSCH AT, 1989, AM J CARDIOL, V63, P211, DOI 10.1016/0002-9149(89)90287-7; IRVINE PW, 1984, J AM GERIATR SOC, V32, P103, DOI 10.1111/j.1532-5415.1984.tb05848.x; KLAINER LM, 1965, J CHRON DIS, V18, P797, DOI 10.1016/0021-9681(65)90019-6; LUCHI RJ, 1991, J AM GERIATR SOC, V39, P810, DOI 10.1111/j.1532-5415.1991.tb02705.x; MATTLEMAN SJ, 1983, J AM COLL CARDIOL, V1, P417, DOI 10.1016/S0735-1097(83)80068-0; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; NEEDLEMAN P, 1986, NEW ENGL J MED, V314, P828; NGO L, 1989, AM HEART J, V118, P893, DOI 10.1016/0002-8703(89)90220-2; PLOTNICK GD, 1982, SOUTH MED J, V75, P565, DOI 10.1097/00007611-198205000-00015; RAINE AEG, 1986, NEW ENGL J MED, V315, P533, DOI 10.1056/NEJM198608283150901; ROY D, 1987, J AM COLL CARDIOL, V9, P509, DOI 10.1016/S0735-1097(87)80042-6; SHANNON RP, 1988, ANN THORAC SURG, V46, P430, DOI 10.1016/S0003-4975(10)64659-0; SOLDO BJ, 1980, POPULATION B, V35, P1; SOUFER R, 1985, AM J CARDIOL, V55, P1032, DOI 10.1016/0002-9149(85)90741-6; STEVENSON LW, 1989, JAMA-J AM MED ASSOC, V261, P884, DOI 10.1001/jama.261.6.884; TSAI RC, 1988, AM J CARDIOL, V61, P1260; TSUTAMOTO T, 1989, AM HEART J, V117, P599, DOI 10.1016/0002-8703(89)90734-5; WEGNER NK, 1986, CORONARY HEART DISEA; WEIDMANN P, 1988, AM J NEPHROL, V8, P1, DOI 10.1159/000167546; WIENER RS, 1987, AM J CARDIOL, V60, P33, DOI 10.1016/0002-9149(87)90979-9; YAMAJI T, 1987, JPN J MED, V26, P207, DOI 10.2169/internalmedicine1962.26.207; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1990, SPSS RELEASE 3 0 VAX; 1989, SAS RELEASE 6 03; 1984, CURRENT POPULATI P25, V952	44	74	78	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2625	2629		10.1001/jama.267.19.2625	http://dx.doi.org/10.1001/jama.267.19.2625			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1533427				2022-12-28	WOS:A1992HT82300029
J	AUSTIN, HA; ANTONOVYCH, TT; MACKAY, K; BOUMPAS, DT; BALOW, JE				AUSTIN, HA; ANTONOVYCH, TT; MACKAY, K; BOUMPAS, DT; BALOW, JE			MEMBRANOUS NEPHROPATHY	ANNALS OF INTERNAL MEDICINE			English	Article						GLOMERULONEPHRITIS, MEMBRANOUS; NEPHROTIC SYNDROME; KIDNEY FAILURE, CHRONIC; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE AGENTS	PASSIVE HEYMANN NEPHRITIS; SYSTEMIC LUPUS-ERYTHEMATOSUS; GLOMERULAR EPITHELIAL-CELLS; CORONARY HEART-DISEASE; NEPHROTIC SYNDROME; CONTROLLED TRIAL; URINARY-EXCRETION; ATTACK COMPLEX; RENAL-FUNCTION; B-CELLS	Membranous nephropathy is a worldwide problem that accounts for about 20% of the cases of the adult-onset nephrotic syndrome. This disease places many patients at risk for both end-stage renal failure and the complications of hyperlipidemia. Immune-mediated injury to the glomerular capillary wall in patients with membranous nephropathy is characterized by subepithelial immune complex formation and generation of the membrane attack complex of complement. Glomerular capillary hypertension, hyperlipidemia, and possibly cytokines could contribute to the glomerular sclerosis seen in the advanced stages of the disorder. In some cases, production of pathogenic antibody can be suppressed by treating the underlying condition. The mechanisms of action of immunosuppressive agents are being investigated and treatments are being tested in clinical trials to optimize the balance of efficacy and toxicity. Alternate-day treatment with corticosteroids is often recommended for nephrotic patients with idiopathic membranous nephropathy, but this approach has not been proved beneficial. Ongoing studies are evaluating whether cytotoxic drugs or cyclosporin A combined with prednisone is more effective than treatment with corticosteroids alone. Lipid-lowering drug therapy is warranted in cases of the persistent nephrotic syndrome to avert the cardiovascular sequelae of hyperlipidemia.			AUSTIN, HA (corresponding author), NIH, BLDG 10, ROOM 3N112, BETHESDA, MD 20892 USA.							ADAMS F, 1986, GENUINE WORKS HIPPOC, P311; ALEXANDER JH, 1974, MED J AUSTRALIA, V2, P119, DOI 10.5694/j.1326-5377.1974.tb93641.x; ANTONOVYCH TT, 1981, ANN CLIN LAB SCI, V11, P386; APPEL G, 1991, KIDNEY INT, V39, P169, DOI 10.1038/ki.1991.22; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BAKER PJ, 1989, AM J PATHOL, V135, P185; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER DM, 1988, AM J MED, V85, P632; Bell ET, 1946, RENAL DISEASES, P141; BERGER J, 1961, J UROL NEPHROL PARIS, V67, P52; BERLYNE GM, 1969, LANCET, V2, P399; BHORADE MS, 1971, J AMER MED ASSOC, V216, P1159, DOI 10.1001/jama.216.7.1159; BORDER WA, 1990, KIDNEY INT, V37, P689, DOI 10.1038/ki.1990.35; BOUMPAS DT, 1991, J CLIN INVEST, V87, P1739, DOI 10.1172/JCI115192; BOUMPAS DT, 1991, CLIN EXP RHEUMATOL, V9, P413; BRUNS FJ, 1991, ANN INTERN MED, V114, P725, DOI 10.7326/0003-4819-114-9-725; BUTLER WT, 1973, J CLIN INVEST, V52, P2629, DOI 10.1172/JCI107455; CAMERON JS, 1979, KIDNEY INT, V15, P88; CAMERON JS, 1990, Q J MED, V74, P133, DOI 10.1093/oxfordjournals.qjmed.a068422; CAMERON JS, 1987, AM J KIDNEY DIS, V10, P157, DOI 10.1016/S0272-6386(87)80170-1; Cameron JS, 1988, DISEASES KIDNEY, P2127; CATTRAN DC, 1989, NEW ENGL J MED, V320, P210, DOI 10.1056/NEJM198901263200403; COGGINS CH, 1979, NEW ENGL J MED, V301, P1301; CORITSIDIS G, 1991, KIDNEY INT, V39, P858, DOI 10.1038/ki.1991.108; COUSER WG, 1981, NEW ENGL J MED, V304, P1230, DOI 10.1056/NEJM198105143042011; CUPPS TR, 1985, J CLIN INVEST, V75, P754, DOI 10.1172/JCI111757; CURRY RC, 1977, AM J MED, V63, P183, DOI 10.1016/0002-9343(77)90231-5; CYBULSKY AV, 1986, J CLIN INVEST, V77, P1096, DOI 10.1172/JCI112408; DAVIES DR, 1977, HISTOPATHOLOGY, V1, P39, DOI 10.1111/j.1365-2559.1977.tb01643.x; DESANTO NG, 1987, AM J NEPHROL, V7, P74, DOI 10.1159/000167436; DONADIO JV, 1974, KIDNEY INT, V6, P431, DOI 10.1038/ki.1974.129; EDGINGTON TS, 1969, J IMMUNOL, V103, P528; Ehrenreich T., 1968, PATHOL ANNU, V3, P145; ERICKSON LC, 1980, P NATL ACAD SCI-BIOL, V77, P467, DOI 10.1073/pnas.77.1.467; FAUCI AS, 1974, J CLIN INVEST, V53, P240, DOI 10.1172/JCI107544; GARCIA DL, 1987, J CLIN INVEST, V80, P867, DOI 10.1172/JCI113145; GERMUTH FG, 1973, IMMUNOPATHOLOGY RENA, P81; GLUCK MC, 1973, ANN INTERN MED, V78, P1, DOI 10.7326/0003-4819-78-1-1; GONZALEZDETTONI H, 1985, ADV NEPHROL, P347; GRONHAGENRISKA C, 1990, CLIN EXP IMMUNOL, V79, P266; GRUNDY SM, 1990, KIDNEY INT, V37, P847, DOI 10.1038/ki.1990.57; GRUNDY SM, 1990, JAMA-J AM MED ASSOC, V264, P3053, DOI 10.1001/jama.264.23.3053; GUERRA IL, 1987, AM J KIDNEY DIS, V10, P385, DOI 10.1016/S0272-6386(87)80107-5; HEYMANN W, 1959, P SOC EXP BIOL MED, V100, P660; HILL L L, 1972, Pediatrics, V49, P260; HIRATA F, 1980, P NATL ACAD SCI-BIOL, V77, P2533, DOI 10.1073/pnas.77.5.2533; HONIG C, 1980, LAB INVEST, V42, P427; JINDAL K, 1992, AM J KIDNEY DIS, V19, P61, DOI 10.1016/S0272-6386(12)70204-4; JONES DB, 1957, AM J PATHOL, V33, P313; JOVEN J, 1990, NEW ENGL J MED, V323, P579, DOI 10.1056/NEJM199008303230905; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KAYSEN GA, 1991, KIDNEY INT, V39, pS8; KEANE WF, 1991, KIDNEY INT, V39, pS41; KERJASCHKI D, 1987, J EXP MED, V166, P109, DOI 10.1084/jem.166.1.109; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KERJASCHKI D, 1989, J IMMUNOL, V143, P546; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KERJASCHKI D, 1990, VIRCHOWS ARCH B, V58, P253; KERN JA, 1988, J CLIN INVEST, V81, P237, DOI 10.1172/JCI113301; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; KUPIECWEGLINSKI JW, 1984, TRANSPLANTATION, V38, P97, DOI 10.1097/00007890-198408000-00001; LAI KN, 1991, NEW ENGL J MED, V324, P1457, DOI 10.1056/NEJM199105233242103; MACKAY K, 1989, J CLIN INVEST, V83, P1160, DOI 10.1172/JCI113996; MACKAY K, 1990, KIDNEY INT, V38, P1095, DOI 10.1038/ki.1990.318; MAKKER SP, 1989, J IMMUNOL, V142, P3406; MALLICK NP, 1983, NEPHRON, V34, P209, DOI 10.1159/000183018; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHIESON PW, 1988, LANCET, V2, P869; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCUNE WJ, 1988, NEW ENGL J MED, V318, P1423, DOI 10.1056/NEJM198806023182203; MOVAT HZ, 1959, AM J CLIN PATHOL, V32, P109; NOEL LH, 1979, AM J MED, V66, P82, DOI 10.1016/0002-9343(79)90486-8; OGARRA A, 1986, J IMMUNOL, V137, P2220; ORDONEZ JD, 1990, KIDNEY INT, V37, P243; PALESTINE AG, 1986, NEW ENGL J MED, V314, P1293, DOI 10.1056/NEJM198605153142005; PIEPER RO, 1989, CARCINOGENESIS, V10, P1307, DOI 10.1093/carcin/10.7.1307; PONTICELLI C, 1989, NEW ENGL J MED, V320, P8, DOI 10.1056/NEJM198901053200102; PRUCHNO CJ, 1989, KIDNEY INT, V36, P65, DOI 10.1038/ki.1989.162; PRUCHNO CJ, 1991, AM J PATHOL, V138, P203; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RONCO P, 1989, Applied Pathology, V7, P85; ROSEN S, 1971, HUM PATHOL, V2, P209, DOI 10.1016/S0046-8177(71)80035-7; ROSTOKER G, 1989, LANCET, V2, P975; SALANT DJ, 1980, J CLIN INVEST, V66, P1339, DOI 10.1172/JCI109987; SCHMITZ PG, 1989, SEMIN NEPHROL, V9, P354; SCHULZE M, 1989, KIDNEY INT, V35, P60, DOI 10.1038/ki.1989.8; SCHULZE M, 1991, KIDNEY INT, V40, P533, DOI 10.1038/ki.1991.242; SCHWARTZ MM, 1984, AM J NEPHROL, V4, P301, DOI 10.1159/000166828; SHORT CD, 1987, Q J MED, V65, P929; SHORT CD, 1989, TXB NEPHROLOGY, P638; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; SUZUKI T, 1990, J BIOL CHEM, V265, P1274; THAISS F, 1989, LAB INVEST, V61, P661; TORNROTH T, 1983, PATHOLOGY GLOMERULAR, P125; WARWICK G, 1988, LANCET, V2, P1361; WARWICK GL, 1991, KIDNEY INT, V40, P129, DOI 10.1038/ki.1991.190; WASS VJ, 1979, LANCET, V2, P664; WETZELS JFM, 1989, LANCET, V1, P211; WHITE RHR, 1969, LANCET, V2, P746; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHU LP, 1987, J CLIN INVEST, V79, P1082, DOI 10.1172/JCI112922	102	34	36	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					672	682		10.7326/0003-4819-116-8-672	http://dx.doi.org/10.7326/0003-4819-116-8-672			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546869				2022-12-28	WOS:A1992HN84400011
J	BATES, DW; LEE, TH				BATES, DW; LEE, TH			RAPID CLASSIFICATION OF POSITIVE BLOOD CULTURES - PROSPECTIVE VALIDATION OF A MULTIVARIATE ALGORITHM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IDENTIFICATION; ASSOCIATION; BACTEREMIA; SLIME	Objective. - To develop and validate a model predicting whether a positive blood culture represents a true positive or a contaminant in hospitalized patients, using only information available when the initial culture result becomes available. Design. - Prospective cohort study with derivation and validation sets. Setting. - Urban tertiary care hospital. Patients. - Clinical data were collected within 24 hours of the initial culture from a random sample of inpatients who had blood cultures performed, and data from the episodes in which growth was reported were included. There were 219 episodes in the derivation set and 129 episodes in the validation set. Main Outcome Measure. - True bacteremia. Reviewers blinded to potential clinical predictors and initial laboratory results classified 115 (53%) of the episodes in the derivation set and 57 (44%) of the episodes in the validation set as true positives. Results. - Independent multivariate predictors of bacteremia were organism type, days until the blood culture became positive, multiple positive cultures, and clinical risk score. These factors were used to develop a model stratifying patients into four risk groups. In the derivation set's lowest-risk group, 92% (65/71) of positives represented contaminants, and in the highest-risk group, 97% (86/89) of positives represented true positives. In the validation set, the misclassification rates were 14% (8/59) in the low-risk group, and 11% (5/44) in the high-risk group. These two groups together comprised 76% of all episodes. Conclusion. - This model can help clinicians quantify the likelihood that a given positive blood culture represents a true positive when the laboratory first calls, which may be helpful in subsequent decision making.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	BATES, DW (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED, 75 FRANCIS ST, BOSTON, MA 02115 USA.				AHRQ HHS [1 F32 HS00040-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ARONSON MD, 1987, ANN INTERN MED, V106, P246, DOI 10.7326/0003-4819-106-2-246; BATES DW, 1990, ANN INTERN MED, V113, P495, DOI 10.7326/0003-4819-113-7-495; BATES DW, 1991, JAMA-J AM MED ASSOC, V265, P365, DOI 10.1001/jama.265.3.365; DOERN GV, 1982, ANTIMICROB AGENTS CH, V21, P1023, DOI 10.1128/AAC.21.6.1023; EDMISTON CE, 1989, INFECT CONT HOSP EP, V10, P111; EPSTEIN PE, 1990, ANN INTERN MED, V113, P646, DOI 10.7326/0003-4819-113-9-646; HARTZ A, 1986, MED DECIS MAKING, V6, P149, DOI 10.1177/0272989X8600600304; ISHAK MA, 1985, J CLIN MICROBIOL, V22, P1025, DOI 10.1128/JCM.22.6.1025-1029.1985; KOCKA FE, 1975, J INFECT DIS, V131, P456, DOI 10.1093/infdis/131.4.456; KOTILAINEN P, 1990, J CLIN MICROBIOL, V28, P2779, DOI 10.1128/JCM.28.12.2779-2785.1990; MACGREGOR RR, 1972, ARCH INTERN MED, V130, P84, DOI 10.1001/archinte.130.1.84; MADISON BM, 1983, J CLIN MICROBIOL, V18, P722, DOI 10.1128/JCM.18.3.722-724.1983; MOORE DF, 1981, J CLIN MICROBIOL, V13, P934, DOI 10.1128/JCM.13.5.934-939.1981; TRENHOLME GM, 1989, J CLIN MICROBIOL, V27, P1342, DOI 10.1128/JCM.27.6.1342-1345.1989; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P35, DOI 10.1093/clinids/5.1.35	15	71	73	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1962	1966		10.1001/jama.267.14.1962	http://dx.doi.org/10.1001/jama.267.14.1962			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL677	1548830				2022-12-28	WOS:A1992HL67700032
J	NIGHTINGALE, SL				NIGHTINGALE, SL			WARNING ABOUT USE OF PROTECTIVE RESTRAINT DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1442	1442						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1538524				2022-12-28	WOS:A1992HH48800004
J	SGANGA, MW; BAUER, CE				SGANGA, MW; BAUER, CE			REGULATORY FACTORS CONTROLLING PHOTOSYNTHETIC REACTION CENTER AND LIGHT-HARVESTING GENE-EXPRESSION IN RHODOBACTER-CAPSULATUS	CELL			English	Article							REACTION CENTER POLYPEPTIDES; RHODOPSEUDOMONAS-CAPSULATA; BACTERIOCHLOROPHYLL BIOSYNTHESIS; CAROTENOID BIOSYNTHESIS; NUCLEOTIDE-SEQUENCE; 3A RESOLUTION; R-CAPSULATA; PUF OPERON; OXYGEN; BACTERIA	Most species of photosynthetic bacteria synthesize their photosynthetic apparatus only under conditions of reduced oxygen tension. To a large extent, this phenomenon is dependent upon anaerobic induction of photosynthesis gene expression. Here we report an example of a regulatory gene, regA, that is involved in transactivating anaerobic expression of the photosynthetic apparatus. We show that RegA is itself responsible for differential induction of light-harvesting and reaction center gene expression relative to operons for photopigment biosynthesis. Surprisingly, strains disrupted for regA were found to retain normal photosynthetic growth capabilities under high light intensities. We further show that photosynthetic growth in the absence of transactivating structural gene expression is a consequence of the superoperonal organization of the photosynthetic gene cluster.			SGANGA, MW (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.				NIGMS NIH HHS [GM40941, R01 GM040941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040941, R01GM040941, R37GM040941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; BARANY F, 1985, GENE, V37, P111, DOI 10.1016/0378-1119(85)90263-X; BAUER CE, 1991, MOL GEN GENET, V228, P433, DOI 10.1007/BF00260637; BAUER CE, 1988, J BIOL CHEM, V263, P4820; BAUER CE, 1988, P NATL ACAD SCI USA, V85, P7074, DOI 10.1073/pnas.85.19.7074; BECK J, 1982, Z NATURFORSCH C, V37, P199; BELASCO JG, 1985, CELL, V40, P171, DOI 10.1016/0092-8674(85)90320-4; BIEL AJ, 1983, J BACTERIOL, V156, P686, DOI 10.1128/JB.156.2.686-694.1983; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHEN CYA, 1988, CELL, V52, P609, DOI 10.1016/0092-8674(88)90473-4; CLARK WG, 1984, J BACTERIOL, V157, P945, DOI 10.1128/JB.157.3.945-948.1984; Clayton R.K., 1966, PHOTOCHEM PHOTOBIOL, V5, P669, DOI [10.1111/j.1751-1097.1966.tb05813.x, DOI 10.1111/J.1751-1097.1966.TB05813.X]; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; DALE RMK, 1987, METHOD ENZYMOL, V155, P204; DAVISON J, 1987, GENE, V51, P275, DOI 10.1016/0378-1119(87)90316-7; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; DREWS G, 1981, ADV MICROB PHYSIOL, V22, P1, DOI 10.1016/S0065-2911(08)60325-2; GEST H, 1983, ARCH MICROBIOL, V136, P11, DOI 10.1007/BF00415602; KLUG G, 1991, P NATL ACAD SCI USA, V88, P1765, DOI 10.1073/pnas.88.5.1765; KLUG G, 1987, EMBO J, V6, P3315; MADIGAN M, 1982, J BACTERIOL, V150, P1422, DOI 10.1128/JB.150.3.1422-1429.1982; MARRS B, 1981, J BACTERIOL, V146, P1003, DOI 10.1128/JB.146.3.1003-1012.1981; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MINTON NP, 1984, GENE, V31, P269, DOI 10.1016/0378-1119(84)90220-8; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOLNIK PA, 1984, NATURE, V307, P289, DOI 10.1038/307289a0; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TAYLOR DP, 1983, J BACTERIOL, V154, P580, DOI 10.1128/JB.154.2.580-590.1983; TICHY HV, 1991, EMBO J, V10, P2949, DOI 10.1002/j.1460-2075.1991.tb07845.x; WEAVER PF, 1975, ARCH MICROBIOL, V105, P207, DOI 10.1007/BF00447139; WELLINGTON CL, 1991, J BACTERIOL, V173, P2954, DOI 10.1128/JB.173.9.2954-2961.1991; WELLINGTON CL, 1989, GENE, V83, P251, DOI 10.1016/0378-1119(89)90111-X; WELLINGTON CL, 1991, J BACTERIOL, V173, P1432, DOI 10.1128/jb.173.4.1432-1443.1991; WELLINGTON CL, 1992, CAN J MICROBIOL, V38, P20, DOI 10.1139/m92-003; YANG ZY, 1990, J BACTERIOL, V126, P619; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558; YOUVAN DC, 1985, P NATL ACAD SCI USA, V82, P58, DOI 10.1073/pnas.82.1.58; ZHU YS, 1986, P NATL ACAD SCI USA, V83, P7613, DOI 10.1073/pnas.83.20.7613; ZHU YS, 1986, J BACTERIOL, V168, P1180, DOI 10.1128/jb.168.3.1180-1188.1986; ZSEBO KM, 1984, CELL, V37, P937, DOI 10.1016/0092-8674(84)90428-8; ZUCCONI AP, 1988, J BACTERIOL, V170, P877, DOI 10.1128/jb.170.2.877-882.1988	50	154	157	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					945	954		10.1016/0092-8674(92)90037-D	http://dx.doi.org/10.1016/0092-8674(92)90037-D			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547494				2022-12-28	WOS:A1992HH74800013
J	CHROUSOS, GP; GOLD, PW				CHROUSOS, GP; GOLD, PW			THE CONCEPTS OF STRESS AND STRESS SYSTEM DISORDERS - OVERVIEW OF PHYSICAL AND BEHAVIORAL HOMEOSTASIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORTICOTROPIN-RELEASING-FACTOR; PITUITARY-ADRENAL AXIS; HORMONE-SECRETION INVITRO; LOCUS COERULEUS NEURONS; CENTRAL NERVOUS-SYSTEM; ACTIVATES NORADRENERGIC NEURONS; FACTOR-LIKE IMMUNOREACTIVITY; HYPOTHALAMIC BETA-ENDORPHIN; GROWTH-HORMONE; ANOREXIA-NERVOSA	Objective.-This article defines stress and related concepts and reviews their historical development. The notion of a stress system as the effector of the stress syndrome is suggested, and its physiologic and pathophysiologic manifestations are described. A new perspective on human disease states associated with dysregulation of the stress system is provided. Data Sources.-Published original articles from human and animal studies and selected reviews. Literature was surveyed utilizing MEDLINE and the Index Medicus. Study Selection.-Original articles from the basic science and human literature consisted entirely of controlled studies based on verified methodologies and, with the exception of the most recent studies, replicated by more than one laboratory. Many of the basic science and clinical studies had been conducted in our own laboratories and clinical research units. Reviews cited were written by acknowledged leaders in the fields of neurobiology, endocrinology, and behavior. Data Extraction.-Independent extraction and cross-referencing by the authors. Data Synthesis.-Stress and related concepts can be traced as far back as written science and medicine. The stress system coordinates the generalized stress response, which takes place when a stressor of any kind exceeds a threshold. The main components of the stress system are the corticotropin-releasing hormone and locus ceruleus-norepinephrine/autonomic systems and their peripheral effectors, the pituitary-adrenal axis, and the limbs of the autonomic system, Activation of the stress system leads to behavioral and peripheral changes that improve the ability of the organism to adjust homeostasis and increase its chances for survival. There has been an exponential increase in knowledge regarding the interactions among the components of the stress system and between the stress system and other brain elements involved in the regulation of emotion, cognitive function, and behavior, as well as with the axes responsible for reproduction, growth, and immunity. This new knowledge has allowed association of stress system dysfunction, characterized by sustained hyperactivity and/or hypoactivity, to various pathophysiologic states that cut across the traditional boundaries of medical disciplines. These include a range of psychiatric, endocrine, and inflammatory disorders and/or susceptibility to such disorders. Conclusions.-We hope that knowledge from apparently disparate fields of science and medicine integrated into a working theoretical framework will allow generation and testing of new hypotheses on the pathophysiology and diagnosis of, and therapy for, a variety of human illnesses reflecting systematic alterations in the principal effectors of the generalized stress response. We predict that pharmacologic agents capable of altering the central apparatus that governs the stress response will be useful in the treatment of many of these illnesses.	NIMH, CLIN NEUROENDOCRINOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	CHROUSOS, GP (corresponding author), NICHHD, DEV ENDOCRINOL BRANCH, BLDG 10, ROOM 10N262, BETHESDA, MD 20892 USA.							ADAM K, 1984, PSYCHOPHARMACOLOGY, V82, P389, DOI 10.1007/BF00427692; AGHAJANIAN GK, 1982, SCIENCE, V215, P1394, DOI 10.1126/science.6278591; AGHAJANIAN GK, 1980, BRAIN RES, V186, P492, DOI 10.1016/0006-8993(80)90997-X; AGHAJANIAN GK, 1977, BRAIN RES, V136, P570, DOI 10.1016/0006-8993(77)90083-X; Aston-Jones G., 1984, FRONT CLIN NEUROSCI, V2, P92; BAGDY G, 1989, ENDOCRINOLOGY, V125, P2664, DOI 10.1210/endo-125-5-2664; BARDELEBEN V, 1989, PSYCHONEUROENDOCRINO, V14, P441; BENKER G, 1990, CLIN ENDOCRINOL, V33, P777, DOI 10.1111/j.1365-2265.1990.tb03915.x; BERNARDINI R, 1990, ENDOCRINOLOGY, V126, P2876, DOI 10.1210/endo-126-6-2876; BERNARDINI R, 1989, ENDOCRINOLOGY, V125, P1067, DOI 10.1210/endo-125-2-1067; BERNARDINI R, 1989, NEUROENDOCRINOLOGY, V50, P708, DOI 10.1159/000125303; BERNASCONI S, 1988, ACTA ENDOCRINOL-COP, V119, P7, DOI 10.1530/acta.0.1190007; BERNINI GP, 1989, HORM RES, V31, P133, DOI 10.1159/000181102; BIRD SJ, 1977, BRAIN RES, V122, P523, DOI 10.1016/0006-8993(77)90462-0; BOUCHARD TJ, 1990, SCIENCE, V250, P223, DOI 10.1126/science.2218526; BRITTON DR, 1982, LIFE SCI, V31, P363, DOI 10.1016/0024-3205(82)90416-7; BROWN MR, 1982, ENDOCRINOLOGY, V111, P928, DOI 10.1210/endo-111-3-928; BROWN MR, 1991, STRESS NEUROPEPTIDES, P73; BURGUERA B, 1990, NEUROENDOCRINOLOGY, V51, P51, DOI 10.1159/000125315; BURNS G, 1989, ENDOCRINOLOGY, V125, P1365, DOI 10.1210/endo-125-3-1365; BUTLER RW, 1990, AM J PSYCHIAT, V147, P1308; CALOGERO AE, 1988, J CLIN INVEST, V82, P839, DOI 10.1172/JCI113687; CALOGERO AE, 1989, PEPTIDES, V10, P189, DOI 10.1016/0196-9781(89)90096-X; CALOGERO AE, 1988, BRAIN RES, V463, P28, DOI 10.1016/0006-8993(88)90523-9; CALOGERO AE, 1988, J CLIN INVEST, V82, P767, DOI 10.1172/JCI113677; CALOGERO AE, 1988, NEUROENDOCRINOLOGY, V47, P303, DOI 10.1159/000124929; CALOGERO AE, 1990, ENDOCRINOLOGY, V126, P1888, DOI 10.1210/endo-126-4-1888; CALOGERO AE, 1989, ENDOCRINOLOGY, V125, P2445, DOI 10.1210/endo-125-5-2445; CANTWELL DP, 1977, ARCH GEN PSYCHIAT, V34, P1087; CASANUEVA FF, 1990, J CLIN ENDOCR METAB, V70, P234, DOI 10.1210/jcem-70-1-234; CHRISTENSEN NJ, 1980, ACTA PSYCHIAT SCAND, V61, P178, DOI 10.1111/j.1600-0447.1980.tb00577.x; Chrousos GP, 1988, ADV EXPT MED BIOL, V245; COLE BJ, 1991, STRESS NEUROPEPTIDES, P119; CUMMINGS S, 1983, J NEUROSCI, V3, P1355; CUNNINGHAM ET, 1990, J COMP NEUROL, V292, P651, DOI 10.1002/cne.902920413; CUNNINGHAM ET, 1988, J COMP NEUROL, V274, P60, DOI 10.1002/cne.902740107; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; DESOUZA EB, 1985, J NEUROSCI, V5, P3189; DEUTCH AY, 1986, BRAIN RES, V363, P307, DOI 10.1016/0006-8993(86)91016-4; DEUTCH AY, 1990, BRAIN RES, V521, P311, DOI 10.1016/0006-8993(90)91557-W; DEWIED D, 1984, TRENDS NEUROSCI, V7, P62; DIEGUEZ C, 1988, CLIN ENDOCRINOL, V28, P109; DUICK DS, 1979, ARCH INTERN MED, V139, P767, DOI 10.1001/archinte.139.7.767; DUNN AJ, 1990, BRAIN RES REV, V15, P71, DOI 10.1016/0165-0173(90)90012-D; ELGEROT A, 1978, J CLIN PSYCHOL, V34, P759, DOI 10.1002/1097-4679(197807)34:3<759::AID-JCLP2270340338>3.0.CO;2-Y; ELKABIR DR, 1990, REGUL PEPTIDES, V28, P199, DOI 10.1016/0167-0115(90)90018-R; FOOTE SL, 1983, PHYSIOL REV, V63, P844, DOI 10.1152/physrev.1983.63.3.844; GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738; GOLD PW, 1986, NEW ENGL J MED, V314, P1335, DOI 10.1056/NEJM198605223142102; GOLD PW, 1986, NEW ENGL J MED, V314, P1329, DOI 10.1056/NEJM198605223142101; GOLD PW, 1988, PSYCHIAT CLIN N AM, V11, P327; GOLD PW, 1988, NEW ENGL J MED, V319, P348, DOI 10.1056/NEJM198808113190606; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; GOLD PW, 1984, NEUROBIOLOGY MOOD DI, P323; Gray T., 1989, NEUROPEPTIDES STRESS, P92; GRAY TS, 1991, STRESS NEUROPEPTIDES, P37; GUYENET PG, 1979, EUR J PHARMACOL, V53, P319, DOI 10.1016/0014-2999(79)90455-2; HERMAN JP, 1989, J NEUROSCI, V9, P3072; IMPERATO A, 1991, BRAIN RES, V538, P111, DOI 10.1016/0006-8993(91)90384-8; INSEL TR, 1982, PSYCHIAT RES, V6, P153, DOI 10.1016/0165-1781(82)90003-8; KACHATURIAN H, 1985, HDB CHEM NEUROANATOM, V4, P216; KAGAN J, 1988, SCIENCE, V240, P167, DOI 10.1126/science.3353713; KAGAN J, 1988, MECHANISMS PHYSICAL, P319; KALOGERAS KT, 1990, J CLIN ENDOCR METAB, V70, P1462, DOI 10.1210/jcem-70-5-1462; KAMILARIS TC, 1987, J CLIN ENDOCR METAB, V65, P994, DOI 10.1210/jcem-65-5-994; KAMILARIS TC, 1989, CLIN RES, V37, pA360; KAYE WH, 1987, J CLIN ENDOCR METAB, V64, P203, DOI 10.1210/jcem-64-2-203; KLING MA, 1991, J CLIN ENDOCR METAB, V72, P260, DOI 10.1210/jcem-72-2-260; KOPELMAN PG, 1988, CLIN ENDOCRINOL, V28, P15, DOI 10.1111/j.1365-2265.1988.tb01197.x; LAMBERTS SWJ, 1984, J CLIN ENDOCR METAB, V58, P298, DOI 10.1210/jcem-58-2-298; LIPOSITS Z, 1987, HISTOCHEMISTRY, V86, P541, DOI 10.1007/BF00489545; LOUGHLIN SE, 1986, NEUROSCIENCE, V18, P307, DOI 10.1016/0306-4522(86)90156-9; LUGER A, 1987, NEW ENGL J MED, V316, P1309, DOI 10.1056/NEJM198705213162105; MACADAMS MR, 1986, ANN INTERN MED, V104, P648, DOI 10.7326/0003-4819-104-5-648; MACCONNIE SE, 1986, NEW ENGL J MED, V315, P411, DOI 10.1056/NEJM198608143150702; MAGNUSON D J, 1988, Society for Neuroscience Abstracts, V14, P1288; MALOZOWSKI S, 1990, CLIN ENDOCRINOL, V32, P461, DOI 10.1111/j.1365-2265.1990.tb00886.x; MASON JW, 1986, J NERV MENT DIS, V174, P145, DOI 10.1097/00005053-198603000-00003; McEwen BS, 1987, PROG BRAIN RES <D>, V72, P11; MCFALL ME, 1990, BIOL PSYCHIAT, V27, P1165, DOI 10.1016/0006-3223(90)90053-5; Medvei Victor Cornelius, 1982, HIST ENDOCRINOLOGY; MELLMAN TA, 1986, AM J PSYCHIAT, V143, P1464; MENDELSON JH, 1988, AM J PSYCHIAT, V145, P1094; MILLAN MH, 1984, NEUROSCI LETT, V48, P149, DOI 10.1016/0304-3940(84)90011-9; Munck A, 1986, Adv Exp Med Biol, V196, P81; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; NAITOH Y, 1988, BIOCHEM BIOPH RES CO, V155, P1459, DOI 10.1016/S0006-291X(88)81305-6; Nauta W., 1986, FUNDAMENTAL NEUROANA; NEMEROFF CB, 1984, SCIENCE, V226, P1342, DOI 10.1126/science.6334362; NIKOLARAKIS KE, 1986, BRAIN RES, V399, P152, DOI 10.1016/0006-8993(86)90610-4; OLPE HR, 1981, EUR J PHARMACOL, V73, P377, DOI 10.1016/0014-2999(81)90243-0; ONO N, 1984, LIFE SCI, V35, P1117, DOI 10.1016/0024-3205(84)90077-8; OVERTON JM, 1989, BRAIN RES, V488, P233, DOI 10.1016/0006-8993(89)90713-0; PALKOVITS M, 1987, NEUROPEPTIDES, V9, P123, DOI 10.1016/0143-4179(87)90051-5; PEPPER CM, 1980, SCIENCE, V209, P394, DOI 10.1126/science.7384811; PIAZZA PV, 1991, P NATL ACAD SCI USA, V88, P2088, DOI 10.1073/pnas.88.6.2088; PLOTSKY PM, 1986, REGUL PEPTIDES, V16, P235, DOI 10.1016/0167-0115(86)90022-4; PUDDEY IB, 1984, CLIN EXP PHARMACOL P, V11, P423, DOI 10.1111/j.1440-1681.1984.tb00292.x; Rabin D, 1988, Adv Exp Med Biol, V245, P377; RABIN DS, 1990, J CLIN ENDOCR METAB, V71, P1158, DOI 10.1210/jcem-71-5-1158; RABIN DS, 1990, BIOL REPROD, V42, P74, DOI 10.1095/biolreprod42.1.74; RISHER-FLOWERS D, 1988, Advances in Alcohol and Substance Abuse, V7, P37; RITTMASTER RS, 1987, J CLIN ENDOCR METAB, V64, P371, DOI 10.1210/jcem-64-2-371; RIVIER C, 1984, ENDOCRINOLOGY, V114, P914, DOI 10.1210/endo-114-3-914; RIVIER C, 1986, SCIENCE, V231, P607, DOI 10.1126/science.3003907; RIVIER C, 1985, ENDOCRINOLOGY, V117, P2478, DOI 10.1210/endo-117-6-2478; ROCK JP, 1984, BRAIN RES, V323, P365, DOI 10.1016/0006-8993(84)90315-9; ROTH KA, 1983, SCIENCE, V219, P189, DOI 10.1126/science.6129700; ROTH RH, 1988, ANN NY ACAD SCI, V537, P138, DOI 10.1111/j.1749-6632.1988.tb42102.x; ROY A, 1987, PSYCHIAT RES, V20, P229, DOI 10.1016/0165-1781(87)90083-7; ROYBYRNE PP, 1986, AM J PSYCHIAT, V143, P396; SAKANAKA M, 1986, BRAIN RES, V382, P213, DOI 10.1016/0006-8993(86)91332-6; SAPER CB, 1980, BRAIN RES, V197, P291, DOI 10.1016/0006-8993(80)91117-8; SAPER CB, 1976, BRAIN RES, V117, P305, DOI 10.1016/0006-8993(76)90738-1; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; Selye H., 1950, STRESS; SILVERMAN AJ, 1989, NEUROENDOCRINOLOGY, V49, P291, DOI 10.1159/000125131; SINGER C, 1941, SHORT HIST SCI; SIRINATHSINGHJI DJS, 1983, NATURE, V305, P232, DOI 10.1038/305232a0; Smelik PG, 1987, PROG BRAIN RES <D>, V72, P3; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P2374, DOI 10.1073/pnas.86.7.2374; STERNBERG EM, 1992, BRAIN RES, V570, P54, DOI 10.1016/0006-8993(92)90563-O; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; STOCK G, 1981, J AUTONOM NERV SYST, V3, P503, DOI 10.1016/0165-1838(81)90083-7; SUTTON RE, 1982, NATURE, V297, P331, DOI 10.1038/297331a0; SWANSON LW, 1983, NEUROENDOCRINOLOGY, V36, P165, DOI 10.1159/000123454; SWANSON LW, 1983, ANNU REV NEUROSCI, V6, P269, DOI 10.1146/annurev.ne.06.030183.001413; SWERDLOW NR, 1986, PSYCHOPHARMACOLOGY, V88, P147, DOI 10.1007/BF00652231; SZEMEREDI K, 1988, ENDOCRINOLOGY, V123, P2585, DOI 10.1210/endo-123-5-2585; TASSIN JP, 1979, NEUROSCIENCE, V4, P1569, DOI 10.1016/0306-4522(79)90020-4; Taylor HO, 1922, GREEK BIOL MED; THOMAN E B, 1968, Developmental Psychobiology, V1, P21, DOI 10.1002/dev.420010105; UNTERMAN TG, 1985, J CLIN ENDOCR METAB, V61, P618; VALENTINO RJ, 1988, J NEUROSCI, V8, P1016; VALENTINO RJ, 1988, NEUROENDOCRINOLOGY, V48, P674, DOI 10.1159/000125081; VALENTINO RJ, 1983, BRAIN RES, V270, P363, DOI 10.1016/0006-8993(83)90615-7; Vanderpool J, 1991, J CLIN ENDOCRINOL ME, V72, P1382; VILLANUEVA AL, 1986, J CLIN ENDOCR METAB, V63, P133, DOI 10.1210/jcem-63-1-133; WALLACE DM, 1989, NEUROSCI LETT, V97, P252, DOI 10.1016/0304-3940(89)90606-X; WAND GS, 1991, J CLIN ENDOCR METAB, V72, P1290, DOI 10.1210/jcem-72-6-1290; WATSON SJ, 1982, SCIENCE, V216, P85, DOI 10.1126/science.6121376; WERNER EE, 1989, SCI AM, V260, P106, DOI 10.1038/scientificamerican0489-106; WEST RJ, 1984, PSYCHOPHARMACOLOGY, V84, P141, DOI 10.1007/BF00432045; WILLIAMSON DF, 1991, NEW ENGL J MED, V324, P739, DOI 10.1056/NEJM199103143241106; WINOKUR A, 1980, AM J PSYCHIAT, V137, P695; WITZMANN RF, 1981, STEROIDS KEYS LIFE; WYATT RJ, 1971, ARCH GEN PSYCHIAT, V24, P65; YAJIMA F, 1986, LIFE SCI, V39, P181, DOI 10.1016/0024-3205(86)90453-4; YATES A, 1983, NEW ENGL J MED, V308, P251, DOI 10.1056/NEJM198302033080504; YEHUDA R, 1990, J NERV MENT DIS, V178, P366, DOI 10.1097/00005053-199006000-00004; ZHANG JX, 1986, BRAIN RES, V386, P136, DOI 10.1016/0006-8993(86)90150-2	151	2742	2864	10	590	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1244	1252		10.1001/jama.267.9.1244	http://dx.doi.org/10.1001/jama.267.9.1244			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1538563				2022-12-28	WOS:A1992HF43900028
J	RADER, DJ; BREWER, HB				RADER, DJ; BREWER, HB			LIPOPROTEIN(A) - CLINICAL APPROACH TO A UNIQUE ATHEROGENIC LIPOPROTEIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; LP(A) LIPOPROTEIN; APOLIPOPROTEIN-B; HEART-DISEASE; ATHEROSCLEROSIS; ASSOCIATION; PLASMA; LIPIDS; MEN											ALBERS JJ, 1990, CLIN CHEM, V36, P2019; ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; Brewer Jr HB, 1990, LIPOPROTEIN A, P211; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CARLSON LA, 1989, J INTERN MED, V226, P271, DOI 10.1111/j.1365-2796.1989.tb01393.x; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; GURAKAR A, 1985, ATHEROSCLEROSIS, V57, P293, DOI 10.1016/0021-9150(85)90041-3; HELLSTEN G, 1989, ATHEROSCLEROSIS, V75, P93, DOI 10.1016/0021-9150(89)90211-6; HOEG JM, 1986, JAMA-J AM MED ASSOC, V255, P512, DOI 10.1001/jama.255.4.512; HOFF HF, 1988, CIRCULATION, V77, P1238, DOI 10.1161/01.CIR.77.6.1238; HOFMANN SL, 1990, J CLIN INVEST, V85, P1542, DOI 10.1172/JCI114602; JENKINS AJ, 1991, DIABETES, V40, P787, DOI 10.2337/diabetes.40.6.787; KERVINEN K, 1991, LIFE SCI, V48, P2183, DOI 10.1016/0024-3205(91)90152-2; Kostner G. M., 1990, LIPOPROTEIN A, P183; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P672, DOI 10.1161/01.ATV.10.5.672; MANN WA, 1989, CIRCULATION, V80, P181; MBEWU AD, 1990, ATHEROSCLEROSIS, V85, P1, DOI 10.1016/0021-9150(90)90177-K; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MEILAHN EN, 1991, CIRCULATION, V84, P456; MILES LA, 1990, THROMB HAEMOSTASIS, V63, P331; MOSCA L, 1991, CIRCULATION, V84, P546; NACHMAN RL, 1991, ARTERIOSCLER THROMB, V11, P32, DOI 10.1161/01.ATV.11.1.32; PARRA HJ, 1987, CLIN CHEM, V33, P721; RADER D, 1991, CIRCULATION S2, V84, P565; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; Sandkamp M, 1990, LIPOPROTEIN A, P205; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; SOMA M, 1991, LANCET, V337, P612, DOI 10.1016/0140-6736(91)91674-J; SOUTAR AK, 1991, J CLIN INVEST, V88, P483, DOI 10.1172/JCI115329; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1989, P NATL ACAD SCI USA, V86, P4171, DOI 10.1073/pnas.86.11.4171; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; ZENKER G, 1986, STROKE, V17, P942, DOI 10.1161/01.STR.17.5.942	38	85	86	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1109	1112		10.1001/jama.267.8.1109	http://dx.doi.org/10.1001/jama.267.8.1109			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE391	1531241				2022-12-28	WOS:A1992HE39100028
J	HOBBS, FDR; CHERRY, RC; FIELDING, JWL; PIKE, L; HOLDER, R				HOBBS, FDR; CHERRY, RC; FIELDING, JWL; PIKE, L; HOLDER, R			ACCEPTABILITY OF OPPORTUNISTIC SCREENING FOR OCCULT GASTROINTESTINAL BLOOD-LOSS	BRITISH MEDICAL JOURNAL			English	Article							COLORECTAL-CANCER; CONTROLLED TRIAL; GENERAL-PRACTICE	Objective - To test patient compliance for faecal occult blood testing in suburban and inner city general practice. Design - Prospective opportunistic trial using the Haemoccult test kit. Tests were offered during routine surgery attendance. Setting - Three group general practices in Birmingham. Subjects - All patients aged 40 years or older on the start date who routinely attended surgery during two years. Main outcome measures - Numbers of patients approached for testing and the numbers refusing, accepting, and returning the test kits. Results - Only 26.3% (1230/4677) of the potential target population had been screened within the two years, although 988 (39.3%) of the suburban practice target were screened. However, 55.7% (1230/2207) of patients actually offered a test returned completed kits, with only 6% (133) refusing the kit. 683 (61.6%) patients aged 50-69 returned kits, compared with 343 (54.3%) aged 70 or over and 204 (43.8%) aged 40-49. These differences were significant (p < 0.001). Patients from the inner city practice were significantly less likely to be offered the test than those in suburban practice (242 (11.2%) v 988 (39.9%), p < 0.001) and return the samples (242 (38.8%) v 988 (62.4%), p < 0.001). Patients from the inner city practice were also more likely to refuse the test (78 (12.5%) v 55 (3.5%), p < 0.001). Conclusions - Opportunistic testing for occult faecal blood in asymptomatic patients was reasonably acceptable to patients, especially those in a suburban practice. If the test is shown to reduce mortality from colorectal cancer then formal screening would probably achieve acceptable target rates, especially among patients aged 50-69, who represent the prime risk group.	UNIV BIRMINGHAM,STAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; GREENBANK MED CTR,BIRMINGHAM B28 8BG,ENGLAND; QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TJ,ENGLAND; BIRMINGHAM FAMILY HLTH SERV AUTHOR,BIRMINGHAM B6 5RQ,ENGLAND	University of Birmingham; University of Birmingham	HOBBS, FDR (corresponding author), UNIV BIRMINGHAM,GEN PRACT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			hobbs, richard/0000-0001-7976-7172				BLALOCK SJ, 1987, PREV MED, V16, P9, DOI 10.1016/0091-7435(87)90002-8; BOX V, 1984, PUBLIC HEALTH, V98, P16, DOI 10.1016/S0033-3506(84)80055-4; Farrands P A, 1984, Community Med, V6, P12; FARRANDS PA, 1981, LANCET, V1, P1231; FULLARD E, 1987, BRIT MED J, V294, P1080, DOI 10.1136/bmj.294.6579.1080; GILL PG, 1978, BRIT J SURG, V65, P17, DOI 10.1002/bjs.1800650105; HARDCASTLE JD, 1980, LANCET, V1, P791; HARDCASTLE JD, 1989, LANCET, V1, P1160; HARDCASTLE JD, 1983, LANCET, V2, P1; HOLLIDAY HW, 1979, LANCET, V1, P309; KELLY MH, 1990, GASTROENTEROLOGY TRE; LALLEMAND RC, 1984, BRIT MED J, V288, P31, DOI 10.1136/bmj.288.6410.31; LOVE R, 1981, LANCET, P489; MANT D, 1990, BRIT J GEN PRACT, V40, P423; MANT D, 1990, BMJ, V300, P1318; MCCRAE FA, 1982, GASTROENTEROLOGY, V82, P891; NICHOLS S, 1986, BRIT MED J, V293, P107, DOI 10.1136/bmj.293.6539.107; PAYNE CD, 1987, GLIM SYSTEM RELEASE; PIERCE M, 1989, BMJ-BRIT MED J, V299, P160, DOI 10.1136/bmj.299.6692.160; Silman A, 1984, Community Med, V6, P8; STOATE HG, 1989, J ROY COLL GEN PRACT, V39, P193; WEATHERALL DJ, 1983, OXFORD TXB MED, V1; WILSON JMG, 1968, WHO34 PUBL HLTH PAP; 1989, COMPENDIUM HLTH STAT	24	32	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					483	486		10.1136/bmj.304.6825.483	http://dx.doi.org/10.1136/bmj.304.6825.483			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547423	Green Published, Bronze			2022-12-28	WOS:A1992HF55500026
J	KAINZ, M; ROBERTS, J				KAINZ, M; ROBERTS, J			STRUCTURE OF TRANSCRIPTION ELONGATION COMPLEXES INVIVO	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; TERNARY COMPLEXES; PROMOTER DNA; ANTITERMINATION; INITIATION; METHYLATION; MECHANISM; PROTEIN	The opening of duplex DNA in the elongation phase of transcription by Escherichia coli RNA polymerase in vivo was detected at a regulatory site where a prolonged pause in transcription occurs. Single-stranded DNA in the transcription bubble was identified by its reactivity with potassium permanganate (KMnO4). The elongation structure in vivo was similar to that of transcription complexes made in vitro with some differences. The observed reactivity to KMnO4 of the DNA template strand was consistent with the existence of an RNA-DNA hybrid of about 12 nucleotides.			KAINZ, M (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,BIOTECHNOL BLDG,ITHACA,NY 14853, USA.				NIGMS NIH HHS [GM 21941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021941, R37GM021941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK S, 1987, CELL, V50, P885; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GUO HC, 1991, J BACTERIOL, V173, P1554, DOI 10.1128/jb.173.4.1554-1560.1991; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; KAINZ M, UNPUB; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; WAGNER LA, 1990, NUCLEIC ACIDS RES, V18, P3529, DOI 10.1093/nar/18.12.3529; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG X, 1988, THESIS CORNELL U; YANG XJ, 1989, J MOL BIOL, V210, P453, DOI 10.1016/0022-2836(89)90122-8; YANG XJ, 1987, GENE DEV, V1, P217, DOI 10.1101/gad.1.3.217	22	90	90	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					838	841		10.1126/science.1536008	http://dx.doi.org/10.1126/science.1536008			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1536008				2022-12-28	WOS:A1992HD54800034
J	SOLLNER, T; RASSOW, J; WIEDMANN, M; SCHLOSSMANN, J; KEIL, P; NEUPERT, W; PFANNER, N				SOLLNER, T; RASSOW, J; WIEDMANN, M; SCHLOSSMANN, J; KEIL, P; NEUPERT, W; PFANNER, N			MAPPING OF THE PROTEIN IMPORT MACHINERY IN THE MITOCHONDRIAL OUTER-MEMBRANE BY CROSS-LINKING OF TRANSLOCATION INTERMEDIATES	NATURE			English	Article							PRECURSOR PROTEINS; RECEPTOR; IDENTIFICATION; RECOGNITION; INSERTION; CARRIER; SITE	MITOCHONDRIA Contain a complex machinery for the import of nuclear-encoded proteins 1,2. Receptor proteins exposed on the outer membrane surface are required for the specific binding of precursor proteins to mitochondria, either by binding of cytosolic signal recognition factors or by direct recognition of the precursor polypeptides 1-5. Subsequently, the precursors are inserted into the outer membrane at the general insertion site GIP (general insertion protein) 6-10. Here we report the analysis of receptors and GIP by crosslinking of translocation intermediates and by coimmunoprecipitation. Surface-accumulated precursors were crosslinked to the receptors MOM19 and MOM72, suggesting a direct interaction of preproteins with surface receptors. We identified three novel mitochondrial outer membrane proteins, MOM7, MOM8, and MOM30 that, together with the previously identified MOM38, seem to form the GIP site and are present in the mitochondrial receptor com lex.	UNIV MUNICH, INST PHYSIOL CHEM, GOETHESTR 33, W-8000 MUNICH 2, GERMANY; AKAD WISSENSCH DDR, ZENT INST MOLEK BIOL, O-1115 BERLIN, GERMANY	University of Munich			Schlossmann, Jens/I-7743-2016; Pfanner, Nikolaus/AAV-7878-2021	Schlossmann, Jens/0000-0002-2550-6839; 				BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BECKER K, IN PRESS J BIOL CHEM, V267; FONT B, 1991, FEBS LETT, V279, P105, DOI 10.1016/0014-5793(91)80262-2; GILLESPIE LL, 1987, J BIOL CHEM, V262, P7939; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; MARTIN J, 1991, J BIOL CHEM, V266, P18051; ONO H, 1990, J BIOCHEM-TOKYO, V107, P840, DOI 10.1093/oxfordjournals.jbchem.a123135; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; RASSOW J, IN PRESS FEBS LETT; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SOLLNER T, 1988, FEBS LETT, V229, P25, DOI 10.1016/0014-5793(88)80790-7; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	24	153	156	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1992	355	6355					84	87		10.1038/355084a0	http://dx.doi.org/10.1038/355084a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1530986	Green Published			2022-12-28	WOS:A1992GY22800057
J	CHRISCHILLES, EA; SEGAR, ET; WALLACE, RB				CHRISCHILLES, EA; SEGAR, ET; WALLACE, RB			SELF-REPORTED ADVERSE DRUG-REACTIONS AND RELATED RESOURCE USE - A STUDY OF COMMUNITY-DWELLING PERSONS 65 YEARS OF AGE AND OLDER	ANNALS OF INTERNAL MEDICINE			English	Article						ADVERSE DRUG REACTION REPORTING SYSTEMS; GERIATRICS; HEALTH RESOURCES; DRUG TOXICITY; HEALTH STATUS	GENERAL-PRACTICE	Objective: To describe the incidence and health resource consequences of self-reported adverse drug reactions (ADRs) and their relation to self-perceived health, number of medications used, and age in a geographically based population 65 years of age and older. Design: A survey of a defined population. Participants: Three thousand, one hundred seventy noninstitutionalized persons 65 years of age and older residing in two Iowa counties. Measurements: Reports of ADRs (elicited using an open-ended questionnaire); names of drugs involved; descriptions of reactions and related health resource use; self-perceived health status (at the first annual follow-up); and number of medications (from the baseline interview). Results: Ten percent (95% Cl, 8.97 to 11.09) of respondents reported one or more ADRs. Three quarters of respondents who reported ADRs contacted a physician. Of these, half indicated that a laboratory test had been ordered, and 7% reported a hospitalization due to the reaction. Advanced age alone was associated with decreased risk in women; a similar trend in men was not statistically significant. However, persons with poorer health status and those who reported the greatest prior use of medications were most likely to report reactions. Conclusions: In this study of noninstitutionalized elderly persons, advanced age did not appear to be associated with increased risk for self-reported ADRs. We could not determine whether the decrease in ADR reports among the oldest respondents represented true diminished ADR occurrence or altered ADR detection and reporting capabilities. When projected to the elderly community-dwelling U.S. population, 2.2 million annual physician visits, 1.1 million laboratory tests, and 146 000 hospitalizations may result from ADRs.			CHRISCHILLES, EA (corresponding author), UNIV IOWA, COLL MED, DEPT PREVENT MED & ENVIRONM HLTH, IOWA CITY, IA 52242 USA.			Chrischilles, Elizabeth/0000-0002-1843-1955				Campbell W H, 1978, J Community Health, V3, P205, DOI 10.1007/BF01349383; CHRISCHILLES EA, 1989, PHARMACOEPIDEMIOLOGY; CHRISCHILLES EA, 1992, IN PRESS J GERONTOL; CICCOLUNGHI SN, 1975, J CLIN PHARMACOL, V15, P496, DOI 10.1002/j.1552-4604.1975.tb01471.x; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; Colsher Patricia L., 1991, Annals of Epidemiology, V1, P215; Cornoni-Huntley J., 1986, ESTABLISHED POPULATI; CURB J D, 1985, American Journal of Preventive Medicine, V1, P36; DOWNING RW, 1970, J CLIN PHARM     SEP, P289; German P S, 1989, J Aging Health, V1, P4, DOI 10.1177/089826438900100102; GRYMONPRE RE, 1988, J AM GERIATR SOC, V36, P1092, DOI 10.1111/j.1532-5415.1988.tb04395.x; HALLAS J, 1990, J INTERN MED, V228, P83, DOI 10.1111/j.1365-2796.1990.tb00199.x; HELLING DK, 1987, J AM GERIATR SOC, V35, P4, DOI 10.1111/j.1532-5415.1987.tb01312.x; HURWITZ N, 1969, BMJ-BRIT MED J, V1, P531, DOI 10.1136/bmj.1.5643.531; HUSKISSON EC, 1974, BRIT MED J, V29, P698; HUTCHINSON TA, 1986, J CHRON DIS, V39, P533, DOI 10.1016/0021-9681(86)90198-0; IREY NS, 1976, AM J PATHOL, V82, P617; KARCH FE, 1977, CLIN PHARMACOL THER, V21, P247; KELLAWAY GS, 1973, NEW ZEAL MED J, V78, P525; KLEIN LE, 1984, ARCH INTERN MED, V144, P1185, DOI 10.1001/archinte.144.6.1185; KOCH H, 1987, PHS871250 US DEP HLT; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; LIPTON HL, 1988, DRUGS ELDERLY CLIN S; LUMLEY C E, 1986, Pharmaceutical Medicine (London), V1, P205; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARTYS CR, 1979, BMJ-BRIT MED J, V2, P1194, DOI 10.1136/bmj.2.6199.1194; MCEVOY GK, 1990, AHFS DRUG INFORMATIO; MICHOCKI RJ, 1988, J AM GERIATR SOC, V36, P79, DOI 10.1111/j.1532-5415.1988.tb03439.x; MOELLER J, 1989, PHS893448 US DEP HLT; MULROY R, 1973, BRIT MED J, V2, P407, DOI 10.1136/bmj.2.5863.407; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; NOLAN L, 1988, J AM GERIATR SOC, V36, P142, DOI 10.1111/j.1532-5415.1988.tb01785.x; SEIDL LG, 1966, B JOHNS HOPKINS HOSP, V119, P299; SMIDT NA, 1972, NEW ZEAL MED J, V76, P397; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; STEWART RB, 1971, JOHNS HOPKINS MED J, V129, P319; STEWART RB, 1988, THERAPEUTICS ELDERLY; VENULET J, 1980, INT J CLIN PHARM TH, V18, P381; WILLIAMSON J, 1980, AGE AGEING, V9, P73, DOI 10.1093/ageing/9.2.73; 1990, PHYSICIANS DESK REFE; 1979, HLTH INTERVIEW SURVE	41	104	106	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					634	640		10.7326/0003-4819-117-8-634	http://dx.doi.org/10.7326/0003-4819-117-8-634			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530194				2022-12-28	WOS:A1992JR86100002
J	NELSON, KE; DONAHUE, JG; MUNOZ, A; COHEN, ND; NESS, PM; TEAGUE, A; STAMBOLIS, VA; YAWN, DH; CALLICOTT, B; MCALLISTER, H; REITZ, BA; LEE, H; FARZADEGAN, H; HOLLINGSWORTH, CG				NELSON, KE; DONAHUE, JG; MUNOZ, A; COHEN, ND; NESS, PM; TEAGUE, A; STAMBOLIS, VA; YAWN, DH; CALLICOTT, B; MCALLISTER, H; REITZ, BA; LEE, H; FARZADEGAN, H; HOLLINGSWORTH, CG			TRANSMISSION OF RETROVIRUSES FROM SERONEGATIVE DONORS BY TRANSFUSION DURING CARDIAC-SURGERY - A MULTICENTER STUDY OF HIV-1 AND HTLV-I/II INFECTIONS	ANNALS OF INTERNAL MEDICINE			English	Article						HTLV-I; HTLV-II; BLOOD TRANSFUSION; HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME	IMMUNODEFICIENCY-VIRUS TYPE-1; LYMPHOTROPIC VIRUS; HOMOSEXUAL MEN; BLOOD-DONORS; ACQUIRED IMMUNODEFICIENCY; SCREENED BLOOD; NEGATIVE BLOOD; DRUG-ABUSERS; I INFECTION; ANTIBODY	Objective: To evaluate the effectiveness of serologic testing of blood donors for human immunodeficiency virus type 1 (HIV-1) and human T-cell lymphotropic virus types I and II (HTLV-I/II) infections and to estimate the risk for transmission of HIV-1 and HTLV-I/II by transfusion of seronegative blood from screened donors. Design: A prospective multicenter cohort study of cardiac surgery patients who received multiple transfusions between 1985 and 1991. Setting: Cardiac surgery services of three large tertiary care hospitals. Patients: The study included 11 532 patients in three hospitals who had cardiovascular surgery. Measurements: Incident HIV-1 and HTLV-I or HTLV-II infection. Results: We detected two new HIV-1 infections among patients transfused with 120 312 units of blood components from seronegative donors. In each case a donor was detected on follow-up who had seroconverted since the donation. The HIV-1 infection rate was 0.0017% with an upper limit of the 95% Cl of 0.0053%. Before donor screening for HTLV-I, transfusion of 51 026 units resulted in two HTLV-I infections (0.0039%) and four HTLV-II infections (0.0078%). After HTLV-I screening was instituted, one recipient was infected with HTLV-II among participants exposed to 69 272 units, a rate of 0.0014%. A corresponding HTLV-I/II-infected donor was found for this patient. Conclusion: Serologic screening of donors for antibodies to HIV-1 and HTLV-I coupled with exclusion of donors from groups having a relatively high risk for infection has led to a low incidence of transfusion-transmitted HIV-1 and HTLV-I/II infection in the United States. A small risk remains, however, despite these measures. We estimate the residual risk for HIV-1 and HTLV-II infection from transfusion of screened blood during the time of this study to be about 1 in 60 000 units.	JOHNS HOPKINS UNIV HOSP, BALTIMORE, MD 21205 USA; ST LUKES EPISCOPAL HOSP, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; METHODIST HOSP, HOUSTON, TX 77030 USA; ABBOTT LABS, N CHICAGO, IL USA; NHLBI, BETHESDA, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; Saint Lukes Episcopal Hospital; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Abbott Laboratories; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	NELSON, KE (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, 624 N BROADWAY, ROOM 886, BALTIMORE, MD 21205 USA.			Cohen, Noah/0000-0002-0384-2903	NCRR NIH HHS [5M01RR00722] Funding Source: Medline; NHLBI NIH HHS [1-HB-6-7025] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB067025] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMMANN AJ, 1983, LANCET, V1, P956; ANDERSON DW, 1989, BLOOD, V74, P2585; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; CANN AJ, 1992, T CELL LEUKEMIA VIRU, P1501; COHEN ND, 1989, NEW ENGL J MED, V320, P1172, DOI 10.1056/NEJM198905043201803; CONLEY LJ, 1992, NEW ENGL J MED, V326, P1499, DOI 10.1056/NEJM199205283262213; Cox DR., 1989, ANAL BINARY DATA; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; CURRAN JW, 1984, NEW ENGL J MED, V310, P69, DOI 10.1056/NEJM198401123100201; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; HJELLE B, 1992, LANCET, V339, P645, DOI 10.1016/0140-6736(92)90797-7; HORSBURGH CR, 1989, LANCET, V2, P637; IMAGAWA D, 1991, NEW ENGL J MED, V325, P1250, DOI 10.1056/NEJM199110243251713; IMAGAWA DT, 1989, NEW ENGL J MED, V320, P1458, DOI 10.1056/NEJM198906013202205; IRANI MS, 1991, NEW ENGL J MED, V325, P1174, DOI 10.1056/NEJM199110173251613; JULLIEN AM, 1988, LANCET, V2, P1248; KLEINMAN S, 1988, TRANSFUSION, V28, P499, DOI 10.1046/j.1537-2995.1988.28588337347.x; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEE HH, 1990, J INFECT DIS, V162, P347, DOI 10.1093/infdis/162.2.347; LEE HH, 1992, IMMUNOBLOTTING LABOR, P195; LEITMAN SF, 1989, NEW ENGL J MED, V321, P917, DOI 10.1056/NEJM198910053211401; MENITOVE JE, 1989, NEW ENGL J MED, V321, P966, DOI 10.1056/NEJM198910053211409; NELSON KE, 1990, JAMA-J AM MED ASSOC, V263, P2194, DOI 10.1001/jama.263.16.2194; NESS PM, 1990, TRANSFUSION, V30, P201, DOI 10.1046/j.1537-2995.1990.30390194337.x; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; OPERSKALSKI EA, 1989, TRANSFUSION, V29, P746, DOI 10.1046/j.1537-2995.1989.29890020448.x; PETRICCIANI JC, 1985, ANN INTERN MED, V103, P726, DOI 10.7326/0003-4819-103-5-726; RANKI A, 1987, LANCET, V2, P589; SARIN PS, 1988, ANN NEUROL, V23, pS181, DOI 10.1002/ana.410230740; WARD JW, 1986, JAMA-J AM MED ASSOC, V256, P357, DOI 10.1001/jama.256.3.357; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; WILLIAMS AE, 1988, SCIENCE, V240, P643, DOI 10.1126/science.2896386; WOLINSKY SM, 1989, ANN INTERN MED, V111, P961, DOI 10.7326/0003-4819-111-12-961; ZUCK TF, 1987, TRANSFUSION, V27, P447, DOI 10.1046/j.1537-2995.1987.27688071691.x	35	75	77	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					554	559		10.7326/0003-4819-117-7-554	http://dx.doi.org/10.7326/0003-4819-117-7-554			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524329				2022-12-28	WOS:A1992JQ22600002
J	NAKAYAMA, K; SHIMOJO, S				NAKAYAMA, K; SHIMOJO, S			EXPERIENCING AND PERCEIVING VISUAL SURFACES	SCIENCE			English	Article							SUBJECTIVE CONTOURS; STEREOPSIS; DEPTH; ILLUSION	A theoretical framework is proposed to understand binocular visual surface perception based on the idea of a mobile observer sampling images from random vantage points in space, Application of the generic sampling principle indicates that the visual system acts as if it were viewing surface layouts from generic not accidental vantage points. Through the observer's experience of optical sampling, which can be characterized geometrically, the visual system makes associative connections between images and surfaces, passively internalizing the conditional probabilities of image sampling from surfaces. This in turn enables the visual system to determine which surface a given image most strongly indicates. Thus, visual surface perception can be considered as inverse ecological optics based on learning through ecological optics. As such, it is formally equivalent to a degenerate form of Bayesian inference where prior probabilities are neglected.	UNIV TOKYO,DEPT PSYCHOL,MEGURO KU,TOKYO 153,JAPAN	University of Tokyo	NAKAYAMA, K (corresponding author), HARVARD UNIV,DEPT PSYCHOL,VIS SCI LAB,CAMBRIDGE,MA 02138, USA.							ANDERSON J A, 1972, Mathematical Biosciences, V14, P197, DOI 10.1016/0025-5564(72)90075-2; BARLOW H, 1990, VISION RES, V30, P1561, DOI 10.1016/0042-6989(90)90144-A; BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; BIEDERMAN I, 1985, COMPUT VISION GRAPH, V32, P29, DOI 10.1016/0734-189X(85)90002-7; Brunswik E., 1981, PERCEPTUAL ORG, P255, DOI [DOI 10.4324/9781315512372-9, 10.4324/9781315512372-9]; Gibson J.J., 1966, SENSES CONSIDERED PE; Gibson JJ, 1950, PERCEPTION VISUAL WO; Gregory, 1970, INTELLIGENT EYE; Guzman A., 1969, AUTOMATIC INTERPRETA, P243; Helmholtz H. L., 1910, HDB PHYSL OPTIK; Huffman D. A., 1971, Machine Intelligence Volume 6, P295; Ittelson W. H., 1960, VISUAL SPACE PERCEPT; JONES DG, 1990, J INVEST OPHTHALMO S, V31, P529; JULESZ B, 1960, AT&T TECH J, V39, P1125, DOI 10.1002/j.1538-7305.1960.tb03954.x; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; KOENDERINK JJ, 1976, BIOL CYBERN, V24, P51, DOI 10.1007/BF00365595; KOHONEN T, 1972, IEEE T COMPUT, VC 21, P353, DOI 10.1109/TC.1972.5008975; MALIK J, 1987, INT J COMPUT VISION, V1, P73, DOI 10.1007/BF00128527; Marr D., 1980, VISION; METELLI F, 1974, SCI AM, V230, P90; NAKAYAMA K, 1990, VISION RES, V30, P1811, DOI 10.1016/0042-6989(90)90161-D; NAKAYAMA K, 1990, COLD SPRING HARB SYM, V55, P911; NAKAYAMA K, 1990, PERCEPTION, V19, P497, DOI 10.1068/p190497; POGGIO GF, 1984, ANNU REV NEUROSCI, V7, P379, DOI 10.1146/annurev.ne.07.030184.002115; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; POGGIO T, 1985, NATURE, V317, P314, DOI 10.1038/317314a0; RAMACHANDRAN VS, 1985, NATURE, V317, P527, DOI 10.1038/317527a0; RAMACHANDRAN VS, 1986, PERCEPT PSYCHOPHYS, V39, P3361; REDIES C, 1981, PERCEPTION, V10, P667, DOI 10.1068/p100667; RESCORLA RA, 1982, ANNU REV PSYCHOL, V33, P265, DOI 10.1146/annurev.ps.33.020182.001405; RICHARDS WA, 1987, J OPT SOC AM A, V4, P1168, DOI 10.1364/JOSAA.4.001168; Rock I., 1983, LOGIC PERCEPTION; SHIMOJO S, 1990, PERCEPTION, V19, P285, DOI 10.1068/p190285; Southall J.P.C., 1962, HELMHOLTZS TREATISE; VANTUIJL HFJM, 1975, ACTA PSYCHOL, V39, P441, DOI 10.1016/0001-6918(75)90042-6; [No title captured]	36	250	253	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1357	1363		10.1126/science.1529336	http://dx.doi.org/10.1126/science.1529336			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JL612	1529336				2022-12-28	WOS:A1992JL61200022
J	GIMBLE, FS; THORNER, J				GIMBLE, FS; THORNER, J			HOMING OF A DNA ENDONUCLEASE GENE BY MEIOTIC GENE CONVERSION IN SACCHAROMYCES-CEREVISIAE	NATURE			English	Article							SITE-SPECIFIC ENDONUCLEASE; INTRON-ENCODED PROTEINS; DOUBLE-STRAND-BREAK; RIBOSOMAL-RNA GENE; ADENOSINE-TRIPHOSPHATASE; YEAST; SUBUNIT; RECOMBINATION; TRANSCRIPTION; PURIFICATION	An unusual protein splicing reaction joins the N-terminal segment (A) and the C-terminal segment (C) of the 119K primary translation product (ABC) of the yeast VMA1 gene to yield a 69K vacuolar H+-ATPase subunit (AC) and an internal 50K polypeptide (B). This 50K protein is a site-specific DNA endonuclease that shares 34% identity with the homothallic switching endonuclease. The site cleaved by the VMA1-derived endonuclease exists in a VMA1 allele that lacks the derived endonuclease segment of the open reading frame. Cleavage at this site only occurs during meiosis and initiates 'homing', a genetic event that converts a VMA1 allele lacking the endonuclease coding sequence into one that contains it.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, ROOM 401, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019; Wood, David W/B-2992-2012	THORNER, Jeremy/0000-0002-2583-500X; 				BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BELFORT M, 1990, ANNU REV GENET, V24, P363; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; COLLEAUX L, 1988, P NATL ACAD SCI USA, V85, P6022, DOI 10.1073/pnas.85.16.6022; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DUJON B, 1980, CELL, V20, P185, DOI 10.1016/0092-8674(80)90246-9; FOGEL S, 1981, MOL BIOL YEAST SACCH, P289; HENIGENS LAM, 1980, CELL, P185; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HSU MT, 1978, BIOCHEMISTRY-US, V17, P131, DOI 10.1021/bi00594a019; JACQUIER A, 1985, CELL, V41, P383, DOI 10.1016/S0092-8674(85)80011-8; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; KAWASAKI K, 1991, J BIOL CHEM, V266, P5342; KLAR AJS, 1984, COLD SPRING HARB SYM, V49, P77, DOI 10.1101/SQB.1984.049.01.011; KOSTRIKEN R, 1984, COLD SPRING HARB SYM, V49, P89, DOI 10.1101/SQB.1984.049.01.012; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; KRONSTAD JW, 1987, CELL, V50, P369, DOI 10.1016/0092-8674(87)90491-0; LEMIEUX B, 1988, MOL GEN GENET, V212, P48, DOI 10.1007/BF00322443; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MURRAY JAH, 1986, EMBO J, V5, P3391, DOI 10.1002/j.1460-2075.1986.tb04655.x; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; NAKAGAWA K, 1988, EUR J BIOCHEM, V171, P23, DOI 10.1111/j.1432-1033.1988.tb13753.x; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PERLMAN PS, 1989, SCIENCE, V246, P1106, DOI 10.1126/science.2479980; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SARWAR G, 1985, J FOOD SCI, V50, P353, DOI 10.1111/j.1365-2621.1985.tb13400.x; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; Sherman F., 1986, METHODS YEAST GENETI; SHIBATA T, 1984, J BIOL CHEM, V259, P499; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; VANARSDELL SW, 1987, TRANSCRIPTIONAL CONT, P325; WARING RB, 1982, P NATL ACAD SCI-BIOL, V79, P6332, DOI 10.1073/pnas.79.20.6332; WATABE H, 1983, J BIOL CHEM, V258, P4663; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WERNETTE C, 1992, MOL CELL BIOL, V12, P716, DOI 10.1128/MCB.12.2.716; WERNETTE CM, 1990, J BIOL CHEM, V265, P18976; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; ZINN AR, 1985, CELL, V40, P887, DOI 10.1016/0092-8674(85)90348-4	50	245	252	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1992	357	6376					301	306		10.1038/357301a0	http://dx.doi.org/10.1038/357301a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1534148				2022-12-28	WOS:A1992HW13200037
J	LAPUMA, J; PRIEST, ER				LAPUMA, J; PRIEST, ER			IS THERE A DOCTOR IN THE HOUSE - AN ANALYSIS OF THE PRACTICE OF PHYSICIANS TREATING THEIR OWN FAMILIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE		LUTHERAN GEN HOSP,DEPT MED,PK RIDGE,IL 60068; UNIV CHICAGO,GEN INTERNAL MED SECT,CHICAGO,IL 60637	University of Chicago	LAPUMA, J (corresponding author), LUTHERAN GEN HOSP,CTR CLIN ETH,1775 DEMPSTER ST,PK RIDGE,IL 60068, USA.		La Puma, John/M-5558-2019	La Puma, John/0000-0002-0514-720X				BASS LW, 1980, PEDIATRICS, V65, P751; BASS LW, 1978, NEW ENGL J MED, V299, P772, DOI 10.1056/NEJM197810052991410; CRANFORD RE, 1990, ETHICS BEDSIDE, P194; GOLDMAN B, 1985, CAN MED ASSOC J, V132, P422; Gorlin Rena., 1990, CODES PROFESSIONAL R; KASS LR, 1985, MORE NATURAL SCI BIO, P224; LAPUMA J, 1991, NEW ENGL J MED, V325, P1290, DOI 10.1056/NEJM199110313251806; LAPUMA J, 1988, ANN INTERN MED, V108, P121, DOI 10.7326/0003-4819-108-1-121; LAPUMA J, IN PRESS ETHICS CONS; MCSHERRY J, 1988, CAN MED ASSOC J, V139, P420; QUILL TE, 1991, ARCH INTERN MED, V151, P463; Rang M, 1972, Can Med Assoc J, V106, P122; REICH WT, 1978, ENCY BIOETHICS, P162; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; SPOCK BM, 1962, PEDIATRICS, V30, P109; TOLSTOY L, 1961, ANNA KARENINA, P17; TUMULTY PA, 1970, NEW ENGL J MED, V283, P20, DOI 10.1056/NEJM197007022830105; Turner J C, 1991, Va Med Q, V118, P6; WHITE RB, 1963, DIS NERV SYST, V24, P304; 1981, NY STATE J MED, V81, P709; 1991, PHYSICIAN PSYCHOACTI, P8; 1977, OPINIONS REPORTS AMA; 1966, JAMA-J AM MED ASSOC, V195, P159; 1990, MEDICARE B B, V12, P10; 1847, CODE ETHICS, pCH2	25	35	35	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1810	1812		10.1001/jama.267.13.1810	http://dx.doi.org/10.1001/jama.267.13.1810			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545466				2022-12-28	WOS:A1992HK67200032
J	GOLDBERG, KC; HARTZ, AJ; JACOBSEN, SJ; KRAKAUER, H; RIMM, AA				GOLDBERG, KC; HARTZ, AJ; JACOBSEN, SJ; KRAKAUER, H; RIMM, AA			RACIAL AND COMMUNITY FACTORS INFLUENCING CORONARY-ARTERY BYPASS GRAFT-SURGERY RATES FOR ALL 1986 MEDICARE PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUPPLIER-INDUCED DEMAND; SMALL-AREA VARIATIONS; HOSPITAL SERVICES; HEART-DISEASE; CARE; DELIVERY; ENGLAND; BLACKS; RACE	Objective. - This study examines the differences in the rates of coronary artery bypass grafting (CABG) between white and black Medicare patients. Design. - This is a cross-sectional study with data from the 1986 Health Care Financing Administration hospital claims records on all Medicare patients, the 1988 update of the Bureau of Health Professions area resource file, and the 1985 Census Bureau's county population estimates file. Setting. - Data are from all Medicare patients in the United States in 1986. Main Outcome Measures. - Sex- and age-adjusted CABG rates for whites and blacks over the age of 65 year's were computed for each of 50 states and 305 Standard Metropolitan Statistical Areas (SMSAs). Results. - Nationally the CABG rate was 27.1 per 10 000 for whites (40.4 for white men and 16.2 for white women), but only 7.6 for blacks (9.3 for black men and 6.4 for black women). Racial differences were greater in the Southeast, particularly in nonmetropolitan areas, than in other regions. Neither white nor black SMSA rates were associated with the rate of admission for acute myocardial infarction (an indication of the amount of coronary artery disease). White rates, but not black rates, were associated with the number of thoracic surgeons per 100000 people. Conclusions. - For patients insured by Medicare, race is strongly associated with CABG rates, and this association is greater for men than for women and greater in the Southeast than in other parts of the country. Physician supply may relate to the CABG rates for whites.	MED COLL WISCONSIN,DIV BIOSTAT & EPIDEMIOL,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,CLIN EPIDEMIOL SECT,ROCHESTER,MN 55905; HLTH CARE FINANCING ADM,BALTIMORE,MD	Medical College of Wisconsin; Mayo Clinic				Jacobsen, Steven/0000-0002-8174-8533				BUNKER JP, 1970, NEW ENGL J MED, V282, P135, DOI 10.1056/NEJM197001152820306; CALLENDER CO, 1987, TRANSPLANT P, V19, P1551; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; FISHER ES, 1990, AM J PUBLIC HEALTH, V80, P1487, DOI 10.2105/AJPH.80.12.1487; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; FORD E, 1989, AM J PUBLIC HEALTH, V79, P37; Glover J A, 1938, Proc R Soc Med, V31, P1219; HAYWARD RA, 1988, NEW ENGL J MED, V318, P1507, DOI 10.1056/NEJM198806093182305; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; LEMBCKE PA, 1952, AJPH, V42, P276; LEWIS CE, 1969, NEW ENGL J MED, V281, P880, DOI 10.1056/NEJM196910162811606; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; OBERMAN A, 1984, AM HEART J, V108, P688, DOI 10.1016/0002-8703(84)90656-2; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; RICE TH, 1989, J HEALTH POLIT POLIC, V14, P587, DOI 10.1215/03616878-14-3-587; RICHMOND GM, 1989, NEW YORK STATE J MED, V89, P63; ROOS NP, 1988, AM J PUBLIC HEALTH, V13, P239; TUSSIG AD, 1986, SOC SCI MED, V9, P851; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1982, SOC SCI MED, V16, P811, DOI 10.1016/0277-9536(82)90234-9; WENNBERG JE, 1985, MED CARE, V23, P512, DOI 10.1097/00005650-198505000-00012; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1989, PHS891260 US DEP HLT; 1980, DHHS HRA819 US DEP H; 1989, COUNTY POPULATION ES; 1990, MEDICARE STATISTICAL; 1989, STATISTICAL ABSTRACT	31	220	220	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1473	1477		10.1001/jama.267.11.1473	http://dx.doi.org/10.1001/jama.267.11.1473			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH488	1538537				2022-12-28	WOS:A1992HH48800026
J	HUNT, DF; HENDERSON, RA; SHABANOWITZ, J; SAKAGUCHI, K; MICHEL, H; SEVILIR, N; COX, AL; APPELLA, E; ENGELHARD, VH				HUNT, DF; HENDERSON, RA; SHABANOWITZ, J; SAKAGUCHI, K; MICHEL, H; SEVILIR, N; COX, AL; APPELLA, E; ENGELHARD, VH			CHARACTERIZATION OF PEPTIDES BOUND TO THE CLASS-I MHC MOLECULE HLA-A2.1 BY MASS-SPECTROMETRY	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANTIGEN PRESENTATION; LYMPHOCYTE-T; PROTEIN; PATHWAY; GENE	Antigens recognized by T cells are expressed as peptides bound to major histocompatibility complex (MHC) molecules. Microcapillary high-performance liquid chromatography - electrospray ionization-tandem mass spectrometry was used to fractionate and sequence subpicomolar amounts of peptides isolated from the MHC molecule HLA-A2.1. Of 200 different species quantitated, eight were sequenced and four were found in cellular proteins. All were nine residues long and shared a distinct structural motif. The sensitivity and speed of this approach should enhance the analysis of peptides from small quantities of virally infected and transformed cells as well as those associated with autoimmune disease states.	UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908; NCI,CELL BIOL LAB,BETHESDA,MD 20892	University of Virginia; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HUNT, DF (corresponding author), UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22903, USA.			Sakaguchi, Kazuyasu/0000-0002-8434-4171; Engelhard, Victor/0000-0002-1741-0925; Cox, Andrea/0000-0002-9331-2462	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020963, R37AI020963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20963] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; CRUMPACKER DB, UNPUB; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; ENGELHARD VH, 1991, J IMMUNOL, V146, P1226; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; HEATH WR, 1991, EUR J IMMUNOL, V21, P153, DOI 10.1002/eji.1830210123; HEATH WR, 1991, P NATL ACAD SCI USA, V88, P5101, DOI 10.1073/pnas.88.12.5101; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; HUNT DJ, UNPUB; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MAN S, IN PRESS INT IMMUNOL; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669	30	1088	1191	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1261	1263		10.1126/science.1546328	http://dx.doi.org/10.1126/science.1546328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546328				2022-12-28	WOS:A1992HG67700045
J	HAGAN, I; YANAGIDA, M				HAGAN, I; YANAGIDA, M			KINESIN-RELATED CUT7 PROTEIN ASSOCIATES WITH MITOTIC AND MEIOTIC SPINDLES IN FISSION YEAST	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; MONOCLONAL-ANTIBODIES; ELECTRON-MICROSCOPY; NUCLEAR DIVISION; CULTURED-CELLS; DROSOPHILA; GENE; MUTATION; MITOSIS; IDENTIFICATION	SEVERAL mitotic and meiotic gene products are related to the microtubule motor kinesin, providing insight into the molecular basis of the complex motile events responsible for spindle formation and function 1. Of these genes, three have been shown to affect spindle structure when mutated 2-6. The most severe phenotype is seen in Aspergillus nidulans bimC and Schizosaccharomyces pombe cut7 mutants. In both fungi the intranuclear spindle is bipolar, with microtubules that emanate from spindle pole bodies at either pole, interdigitating in a central overlap zone. In bimC and cut7 mutants, microtubule interdigitation does not appear to take place, instead two unconnected half spindles form and chromosome separation fails 2,6,7. Here we report that cut7 protein concentrates on or near the spindle pole bodies throughout mitotic and meiotic nuclear division and associates with mitotic spindle microtubules in a stage-specific manner, associating with the mid-anaphase B midzone. In cut7ts mutants, spindle pole bodies stain but mitotic microtubules do not.			HAGAN, I (corresponding author), KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYO KU, KYOTO 606, JAPAN.			Hagan, Iain/0000-0002-5858-9415				AIST JR, 1991, J CELL SCI, V100, P279; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; Gutz H, 1974, HDB GENETICS, P395, DOI 10.1007/978-1-4899-1710-2_25; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HAGAN IM, 1988, J CELL SCI, V89, P343; HARLOW E, 1988, ANTIBODIES; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HORIO T, 1991, J CELL SCI, V99, P693; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KIMBLE M, 1983, J CELL SCI, V62, P301; MASUDA H, 1990, J CELL BIOL, V110, P417, DOI 10.1083/jcb.110.2.417; MCCULLY EK, 1971, J CELL SCI, V9, P475; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NEIGHBORS BW, 1988, J CELL BIOL, V106, P1193, DOI 10.1083/jcb.106.4.1193; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; ROBINOW CF, 1977, GENETICS, V87, P491; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA K, 1986, J CELL SCI, V80, P253; TODA T, 1981, J CELL SCI, V52, P271; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WOODS A, 1989, J CELL SCI, V93, P491; WORDEMAN L, 1989, J CELL SCI, V93, P279; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817	32	222	224	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1992	356	6364					74	76		10.1038/356074a0	http://dx.doi.org/10.1038/356074a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538784				2022-12-28	WOS:A1992HG60200060
J	UDVARHELYI, IS; COLDITZ, GA; RAI, A; EPSTEIN, AM				UDVARHELYI, IS; COLDITZ, GA; RAI, A; EPSTEIN, AM			COST-EFFECTIVENESS AND COST-BENEFIT ANALYSES IN THE MEDICAL LITERATURE - ARE THE METHODS BEING USED CORRECTLY	ANNALS OF INTERNAL MEDICINE			English	Review						COST BENEFIT ANALYSIS; ECONOMICS, MEDICAL; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); SENSITIVITY AND SPECIFICITY; COST CONTROL	MYOCARDIAL-INFARCTION; CHLAMYDIA-TRACHOMATIS; EFFECTIVENESS MODEL; SCREENING-PROGRAM; COLORECTAL-CANCER; DECISION-ANALYSIS; BREAST BIOPSY; THERAPY; HEALTH; MANAGEMENT	Objective: To determine whether published cost-effectiveness and cost-benefit analyses have adhered to basic analytic principles. Design: Structured methodologic review of published articles. Study Sample: Seventy-seven articles published either from 1978 to 1980 or from 1985 to 1987 in general medical, general surgical, and medical subspecialty journals. Main Outcome Measurements: Articles were reviewed to assess the use and reporting of six fundamental principles of analysis. These principles were derived by reviewing widely cited textbooks and articles describing the methods for performing economic analyses and by selecting the methods universally recommended. Main Results: Overall performance was only fair. Three articles adhered to all six principles, and the median number of principles to which articles adhered was three. Among the problems noted were failure to make underlying assumptions explicit and, therefore, verifiable, and failure to test assumptions with sensitivity analyses. No improvement in performance was observed between 1978 and 1987. Articles in general medical journals, however, were more likely to use analytic methods appropriately than articles in the general surgical or medical subspecialty literature. Conclusions: Greater attention should be devoted to ensuring the appropriate use of analytic methods for economic analyses, and readers should make note of the methods used when interpreting the results of economic analyses.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED, DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291				ANDERSON JP, 1985, JAMA-J AM MED ASSOC, V253, P2229; BABIKIAN G, 1986, SURG GYNECOL OBSTET, V163, P483; BARRY MJ, 1987, GASTROENTEROLOGY, V93, P301, DOI 10.1016/0016-5085(87)91019-5; BECK JR, 1987, J AM COLL CARDIOL, V9, P920; BENNION RS, 1987, SURG GYNECOL OBSTET, V165, P95; BENTON GS, 1985, SURG GYNECOL OBSTET, V161, P523; BERWICK DM, 1985, JAMA-J AM MED ASSOC, V254, P1492, DOI 10.1001/jama.254.11.1492; BROOTEN D, 1986, NEW ENGL J MED, V315, P934, DOI 10.1056/NEJM198610093151505; CEBUL RD, 1986, JAMA-J AM MED ASSOC, V256, P3353, DOI 10.1001/jama.256.24.3353; CENTERWALL BS, 1978, NEW ENGL J MED, V299, P285, DOI 10.1056/NEJM197808102990605; CLAIBORNE RA, 1987, AM REV RESPIR DIS, V136, P1095, DOI 10.1164/ajrccm/136.5.1095; COCHI SL, 1985, JAMA-J AM MED ASSOC, V253, P521, DOI 10.1001/jama.253.4.521; CROSBY IK, 1980, CIRCULATION, V62, P79; CROUCH M, 1979, DIABETES CARE, V2, P418, DOI 10.2337/diacare.2.5.418; DAVIS H, 1980, JAMA-J AM MED ASSOC, V243, P43; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; DETWILER RP, 1980, ARCH SURG-CHICAGO, V115, P1096; DEVEREUX RB, 1987, HYPERTENSION, V9, P69; DITTUS RS, 1987, J AM COLL CARDIOL, V10, P869, DOI 10.1016/S0735-1097(87)80282-6; DOBERNECK RC, 1980, ANN SURG, V192, P152, DOI 10.1097/00000658-198008000-00003; DOUBILET P, 1986, NEW ENGL J MED, V314, P253, DOI 10.1056/NEJM198601233140421; DRUMMOND M, 1987, ANN INTERN MED, V107, P88, DOI 10.7326/0003-4819-107-1-88; Drummond M F, 1985, World Health Stat Q, V38, P383; EDIS AJ, 1978, SURGERY, V84, P384; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; EPSTEIN SE, 1978, AM J CARDIOL, V42, P667, DOI 10.1016/0002-9149(78)90639-2; EPSTEIN SE, 1986, J AM COLL CARDIOL, V7, P220, DOI 10.1016/S0735-1097(86)80285-6; ERICKSON RA, 1987, GASTROENTEROLOGY, V93, P835, DOI 10.1016/0016-5085(87)90448-3; EVANS RW, 1987, CIRCULATION, V75, P63, DOI 10.1161/01.CIR.75.1.63; FARBER ME, 1979, NEW ENGL J MED, V300, P856, DOI 10.1056/NEJM197904123001512; FELMAN YM, 1978, JAMA-J AM MED ASSOC, V240, P459, DOI 10.1001/jama.240.5.459; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; FOX W, 1979, AM REV RESPIR DIS, V120, P503; FULCHIERO A, 1978, NEW ENGL J MED, V299, P574, DOI 10.1056/NEJM197809142991104; GOITEIN M, 1980, JAMA-J AM MED ASSOC, V244, P1347, DOI 10.1001/jama.244.12.1347; GRANDE P, 1980, CIRCULATION, V61, P723, DOI 10.1161/01.CIR.61.4.723; GREEN RM, 1985, ANN SURG, V201, P785, DOI 10.1097/00000658-198506000-00017; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; HERZ JH, 1980, JAMA-J AM MED ASSOC, V244, P586; JASPER AC, 1987, CHEST, V91, P614, DOI 10.1378/chest.91.4.614; JOHNSON MG, 1987, AM J SURG, V154, P261, DOI 10.1016/0002-9610(89)90605-3; KESTER DE, 1986, SURG GYNECOL OBSTET, V162, P337; KIRZ HL, 1986, JAMA-J AM MED ASSOC, V256, P734, DOI 10.1001/jama.256.6.734; KOPLAN JP, 1979, NEW ENGL J MED, V301, P906, DOI 10.1056/NEJM197910253011703; KOPLAN JP, 1980, JAMA-J AM MED ASSOC, V244, P2736, DOI 10.1001/jama.244.24.2736; KREIS DJ, 1986, SURG GYNECOL OBSTET, V163, P1; LAFFEL GL, 1987, J AM COLL CARDIOL, V10, pB79, DOI 10.1016/S0735-1097(87)80432-1; LANNIN DR, 1986, ANN SURG, V203, P474, DOI 10.1097/00000658-198605000-00005; LARSON EB, 1980, JAMA-J AM MED ASSOC, V243, P359, DOI 10.1001/jama.243.4.359; LAYDE PM, 1979, JAMA-J AM MED ASSOC, V241, P2290, DOI 10.1001/jama.241.21.2290; Lazenby H C, 1990, Health Care Financ Rev, V12, P1; LEA MS, 1987, AM J SURG, V154, P651, DOI 10.1016/0002-9610(87)90236-4; LEAF A, 1989, NEW ENGL J MED, V321, P898, DOI 10.1056/NEJM198909283211311; LIANG MH, 1986, ARTHRITIS RHEUM, V29, P937, DOI 10.1002/art.1780290801; MACKEY WC, 1986, SURGERY, V99, P26; MAKI DG, 1987, JAMA-J AM MED ASSOC, V258, P1777, DOI 10.1001/jama.258.13.1777; NIGHTINGALE CH, 1987, ARCH SURG-CHICAGO, V122, P451; ODONNELL TF, 1980, SURGERY, V88, P693; ORLANDO R, 1986, ARCH SURG-CHICAGO, V121, P470; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203; PAGE CP, 1979, AM J SURG, V138, P939, DOI 10.1016/0002-9610(79)90326-X; PITT HA, 1985, ANN SURG, V201, P545, DOI 10.1097/00000658-198505000-00002; Rios J, 1978, Am J Cardiol, V41, P175, DOI 10.1016/0002-9149(78)90152-2; ROSENSHEIN MS, 1980, NEW ENGL J MED, V302, P1058, DOI 10.1056/NEJM198005083021904; SAKSENA S, 1985, AM J CARDIOL, V55, P963, DOI 10.1016/0002-9149(85)90727-1; SALVATIERRA O, 1979, JAMA-J AM MED ASSOC, V241, P1469; SALZMAN EW, 1987, ANN SURG, V206, P636; SALZMAN EW, 1980, ANN SURG, V191, P207, DOI 10.1097/00000658-198002000-00013; SCHOENBERGER JA, 1986, AM HEART J, V112, P872, DOI 10.1016/0002-8703(86)90496-5; SKILLINGS JC, 1979, AM J SURG, V137, P26, DOI 10.1016/0002-9610(79)90006-0; SMITH TJ, 1985, AM J SURG, V149, P540, DOI 10.1016/S0002-9610(85)80053-2; SNIDER DE, 1986, JAMA-J AM MED ASSOC, V255, P1579, DOI 10.1001/jama.255.12.1579; SPITAL R, 1987, AM J KIDNEY DIS, V9, P396, DOI 10.1016/S0272-6386(87)80142-7; STODDART GL, 1984, CAN MED ASSOC J, V130, P1428; STODDART GL, 1984, CAN MED ASSOC J, V130, P1542; THIBAULT GE, 1985, AM J CARDIOL, V56, pC35, DOI 10.1016/S0002-9149(85)80007-2; TIEP BL, 1987, CHEST, V91, P15, DOI 10.1378/chest.91.1.15; Torrance GW, 1987, METHODS EC EVALUATIO; VOGELER DM, 1978, AM REV RESPIR DIS, V117, P227; WALKER GM, 1978, ARCH SURG-CHICAGO, V113, P942; WARNER KE, 1980, MED CARE, V18, P1069, DOI 10.1097/00005650-198011000-00001; Warner KE, 1982, COST BENEFIT COST EF; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2056, DOI 10.1001/jama.257.15.2056; WEINER CP, 1986, DIABETES CARE, V9, P255, DOI 10.2337/diacare.9.3.255; WEINSTEIN MC, 1980, NEW ENGL J MED, V303, P308, DOI 10.1056/NEJM198008073030604; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WELLER AC, 1990, JAMA-J AM MED ASSOC, V263, P1344; WILLEMS JS, 1980, NEW ENGL J MED, V303, P553, DOI 10.1056/NEJM198009043031004; WOLSON AH, 1978, JAMA-J AM MED ASSOC, V240, P2073, DOI 10.1001/jama.240.19.2073	92	293	296	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					238	244		10.7326/0003-4819-116-3-238	http://dx.doi.org/10.7326/0003-4819-116-3-238			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1530808				2022-12-28	WOS:A1992HB35600010
J	NOSSAL, GJV				NOSSAL, GJV			THE MOLECULAR AND CELLULAR BASIS OF AFFINITY MATURATION IN THE ANTIBODY-RESPONSE	CELL			English	Review							MUTATION				NOSSAL, GJV (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA.							BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; LINTON PJ, 1991, IMMUNOLOGY, V146, P4099; LIU YJ, 1991, EUR J IMMUNOL, V21, P1107, DOI 10.1002/eji.1830210504; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MCHEYZERWILLIAMS MG, 1991, NATURE, V350, P502, DOI 10.1038/350502a0; NOSSAL GJV, 1968, J EXP MED, V127, P263, DOI 10.1084/jem.127.2.263; NOSSAL GJV, 1990, P NATL ACAD SCI USA, V87, P1615, DOI 10.1073/pnas.87.4.1615; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; WEISS U, 1992, IN PRESS EUR J IMMUN	14	127	128	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					1	2		10.1016/0092-8674(92)90198-L	http://dx.doi.org/10.1016/0092-8674(92)90198-L			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1531039				2022-12-28	WOS:A1992GZ58300001
J	WEGENER, AMK; LETOURNEUR, F; HOEVELER, A; BROCKER, T; LUTON, F; MALISSEN, B				WEGENER, AMK; LETOURNEUR, F; HOEVELER, A; BROCKER, T; LUTON, F; MALISSEN, B			THE T-CELL RECEPTOR/CD3 COMPLEX IS COMPOSED OF AT LEAST 2 AUTONOMOUS TRANSDUCTION MODULES	CELL			English	Article							MEDIATED SIGNAL TRANSDUCTION; NATURAL-KILLER CELLS; ANTIGEN RECEPTOR; TYROSINE PHOSPHORYLATION; ZETA-CHAIN; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; SUBUNIT INTERACTIONS; TRANSFECTED CELLS; MESSENGER-RNA	Recent studies have demonstrated that the CD3-zeta subunit of the T cell antigen receptor (TCR) complex is involved in signal transduction. However, the function of the remaining invariant subunits, CD3-gamma, -delta, and epsilon, is still poorly understood. To examine their role in TCR function, we have constructed TCR/CD3 complexes devoid of functional zeta-subunit and showed that they are still able to trigger the production of interleukin-2 in response to antigen or superantigen. These data, together with previous results, indicate that the TCR/CD3 complex is composed of at least two parallel transducing units, made of the gamma-delta-epsilon and zeta-chains, respectively, Furthermore, the analysis of partially truncated zeta-chains has led us to individualize a functional domain that may have constituted the building block of most of the transducing subunits associated with antigen receptors and some Fc receptors.			WEGENER, AMK (corresponding author), CNRS MARSEILLE LUMINY, INSERM, CTR IMMUNOL, CASE 906, F-13288 MARSEILLE 9, FRANCE.		Luton, Frederic/N-7673-2017; Malissen, Bernard/AAK-4659-2020	Letourneur, Francois/0000-0003-2232-6127; Malissen, Bernard/0000-0003-1340-9342				ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; BANIYASH M, 1989, J BIOL CHEM, V264, P13252; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BERKHOUT B, 1988, J BIOL CHEM, V263, P8528; BERNOT A, 1991, P NATL ACAD SCI USA, V88, P2550, DOI 10.1073/pnas.88.6.2550; BILL J, 1989, J EXP MED, V169, P115, DOI 10.1084/jem.169.1.115; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; CLEVERS H, 1988, P NATL ACAD SCI USA, V85, P8623, DOI 10.1073/pnas.85.22.8623; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GASCOIGNE NRJ, 1991, P NATL ACAD SCI USA, V88, P613, DOI 10.1073/pnas.88.2.613; GILLIS S, 1978, J IMMUNOL, V120, P2027; GODING JW, 1986, HDB EXPT IMMUNOLOGY, V1; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P7649, DOI 10.1073/pnas.84.21.7649; GREEN NM, 1991, NATURE, V351, P349, DOI 10.1038/351349a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HASER WG, 1987, J EXP MED, V166, P1186, DOI 10.1084/jem.166.4.1186; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KRISSANSEN GW, 1987, J IMMUNOL, V138, P3513; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LABIT C, 1984, HYBRIDOMA, V3, P163, DOI 10.1089/hyb.1984.3.163; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LETOURNEUR F, 1989, IMMUNOGENETICS, V29, P265, DOI 10.1007/BF00717911; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MERCEP M, 1988, J IMMUNOL, V140, P324; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; ORTEGA G, 1986, J IMMUNOL, V137, P3240; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RA C, 1989, J BIOL CHEM, V264, P15323; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; VANDENELSEN P, 1986, P NATL ACAD SCI USA, V83, P2944; VIVIER E, 1991, J IMMUNOL, V146, P206; VIVIER E, 1991, J IMMUNOL, V146, P1142; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WHITE J, 1989, J IMMUNOL, V143, P1822; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0	81	433	444	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					83	95		10.1016/0092-8674(92)90208-T	http://dx.doi.org/10.1016/0092-8674(92)90208-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1531041	Green Published			2022-12-28	WOS:A1992GZ58300011
J	ECKMAN, MH; WONG, JB; SALEM, DN; PAUKER, SG				ECKMAN, MH; WONG, JB; SALEM, DN; PAUKER, SG			DIRECT ANGIOPLASTY FOR ACUTE MYOCARDIAL-INFARCTION - A REVIEW OF OUTCOMES IN CLINICAL SUBSETS	ANNALS OF INTERNAL MEDICINE			English	Review						MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; SHOCK, CARDIOGENIC; CORONARY ARTERY BYPASS	LUMINAL CORONARY ANGIOPLASTY; TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; THROMBOLYTIC THERAPY; INTRAVENOUS STREPTOKINASE; AORTOCORONARY BYPASS; REPERFUSION THERAPY; CARDIOGENIC-SHOCK; RANDOMIZED TRIAL; ARTERY DISEASE	Purpose: To review the usefulness of angioplasty done early in the course of an acute myocardial infarction without preceding thrombolytic therapy. Data Sources: The English-language literature was searched from 1983 through October 1991 using MEDLINE; bibliographies from selected articles were searched by hand. Study Selection: Series reporting results for direct angioplasty without preceding thrombolytic therapy were reviewed. Twenty-three articles describing a total of 4368 patients were found. Data Extraction: After duplicate patient series were eliminated, weighted average short- and long-term mortality rates were calculated for the remaining 2073 patients in 10 series and for selected clinical subsets. Results of Data Synthesis: Average hospital mortality for patients with acute myocardial infarction having direct angioplasty was 8.3% (95% Cl, 7.1% to 9.5%). Patients in cardiogenic shock had the highest mortality (44.2%; Cl, 35.9% to 52.5%); patients with one-vessel disease had the lowest (1%; Cl, 0% to 2.3%). For patients in cardiogenic shock, data on direct angioplasty appeared superior to data for similar patients receiving thrombolytic therapy. Although few data exist, a survival advantage was also suggested for patients with a history of previous bypass surgery (hospital mortality, 11.1% [Cl, 4.4% to 17.8%]). Conclusions: Direct angioplasty has an overall mortality similar to that of thrombolytic therapy. Patients who may benefit more from mechanical revascularization than from thrombolytic therapy include those at increased risk for thrombolytic therapy (uncontrolled hypertension, recent major surgery, cerebrovascular accident, prolonged cardiopulmonary resuscitation, or bleeding diathesis), and those with cardiogenic shock. The efficacy in several other patient subsets (age > 65 years, previous coronary artery bypass grafting, prolonged delay before reperfusion) warrants further study.	NEW ENGLAND MED CTR, DIV CARDIOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University	ECKMAN, MH (corresponding author), NEW ENGLAND MED CTR, DIV CLIN DECIS MAKING, BOX 302, 750 WASHINGTON ST, BOSTON, MA 02111 USA.			Wong, John/0000-0003-4203-9010; Eckman, Mark/0000-0001-8253-269X	AHRQ HHS [HS-06503] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AHNVE S, 1988, AM HEART J, V116, P925, DOI 10.1016/0002-8703(88)90142-1; [Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BEAUCHAMP GD, 1990, AM HEART J, V120, P237, DOI 10.1016/0002-8703(90)90064-5; BITTL JA, 1991, CHEST, V99, pS150, DOI 10.1378/chest.99.4.150S; BRODIE BR, 1991, AM J CARDIOL, V67, P7, DOI 10.1016/0002-9149(91)90090-8; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHATTERJEE S, 1977, REGRESSION ANAL EXAM, P101; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; DEFEYTER PJ, 1982, CIRCULATION, V66, P527, DOI 10.1161/01.CIR.66.3.527; ELLIS SG, 1989, J AM COLL CARDIOL, V13, P1251, DOI 10.1016/0735-1097(89)90296-9; ELLIS SG, 1991, J AM COLL CARDIOL, V17, P752, DOI 10.1016/S0735-1097(10)80195-0; ELLIS SG, 1989, J AM COLL CARDIOL, V13, P1122, DOI 10.1016/0735-1097(89)90272-6; FLAKER GC, 1989, AM HEART J, V118, P1154, DOI 10.1016/0002-8703(89)90003-3; GACIOCH GM, 1992, J AM COLL CARDIOL, V19, P647, DOI 10.1016/S0735-1097(10)80286-4; GIBBONS RJ, 1991, CIRCULATION S2, V84, P536; GREENE MA, 1991, ANN THORAC SURG, V51, P194, DOI 10.1016/0003-4975(91)90781-K; GRINES CL, 1991, J AM COLL CARDIOL, V17, P1382, DOI 10.1016/S0735-1097(10)80151-2; GRINES CL, 1991, CIRCULATION, V84, P540, DOI 10.1161/01.CIR.84.2.540; GRINES CL, 1990, AM J CARDIOL, V65, P1292, DOI 10.1016/0002-9149(90)91315-W; GRUENTZIG AR, 1977, CIRCULATION, V56, P84; HARTMANN JR, 1991, J AM COLL CARDIOL, V18, P1517, DOI 10.1016/0735-1097(91)90684-2; HARTZLER GO, 1983, AM HEART J, V106, P965, DOI 10.1016/0002-8703(83)90639-7; HENNING H, 1979, CIRCULATION, V59, P1124, DOI 10.1161/01.CIR.59.6.1124; HIBBARD MD, 1992, J AM COLL CARDIOL, V19, P639, DOI 10.1016/S0735-1097(10)80285-2; HILBORNE LH, 1991, PERCUTANEOUS TRANSLU, P89; HILLIS LD, 1990, J AM COLL CARDIOL, V16, P313, DOI 10.1016/0735-1097(90)90579-E; HOLLAND KJ, 1989, AM J CARDIOL, V63, P399, DOI 10.1016/0002-9149(89)90307-X; KAHN JK, 1990, AM J CARDIOL, V65, P698, DOI 10.1016/0002-9149(90)91373-E; KAHN JK, 1990, AM J CARDIOL, V66, P1045, DOI 10.1016/0002-9149(90)90502-R; KAHN JK, 1990, J AM COLL CARDIOL, V16, P1089, DOI 10.1016/0735-1097(90)90537-Y; KANDER NH, 1989, AM HEART J, V118, P228, DOI 10.1016/0002-8703(89)90180-4; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KLEIN LW, 1992, J AM COLL CARDIOL, V19, P654, DOI 10.1016/S0735-1097(10)80287-6; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; KUHN LA, 1967, AM HEART J, V74, P578, DOI 10.1016/0002-8703(67)90019-1; LANDIN RJ, 1988, CIRCULATION S2, V78, P9; LATTING CA, 1980, AM HEART J, V100, P311, DOI 10.1016/0002-8703(80)90144-1; LEE L, 1991, J AM COLL CARDIOL, V17, P599, DOI 10.1016/S0735-1097(10)80171-8; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; LEE TC, 1990, AM J CARDIOL, V66, P663, DOI 10.1016/0002-9149(90)91126-Q; MARCO J, 1987, INT J CARDIOL, V15, P55, DOI 10.1016/0167-5273(87)90292-0; MARK DB, 1991, CIRCULATION S2, V84, P257; MARX M, 1989, AM J ROENTGENOL, V153, P167, DOI 10.2214/ajr.153.1.167; MEYER J, 1985, INT J CARDIOL, V7, P281, DOI 10.1016/0167-5273(85)90053-1; MIDGETTE AS, 1990, ANN INTERN MED, V113, P961, DOI 10.7326/0003-4819-113-12-961; MULLER DWM, 1991, AM HEART J, V121, P1042, DOI 10.1016/0002-8703(91)90661-Z; NOTO TJ, 1991, CATHETER CARDIO DIAG, V24, P75, DOI 10.1002/ccd.1810240202; O'Neill WW, 1991, CIRCULATION S2, V84, pII; OKEEFE JH, 1989, AM J CARDIOL, V64, P1221, DOI 10.1016/0002-9149(89)90558-4; OLMSTED WL, 1987, AM J CARDIOL, V60, P971, DOI 10.1016/0002-9149(87)90335-3; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; Rothbaum D A, 1989, Cardiol Clin, V7, P837; ROTHBAUM DA, 1987, J AM COLL CARDIOL, V10, P264, DOI 10.1016/S0735-1097(87)80006-2; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P177; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P338; RYAN TJ, 1990, CIRCULATION, V82, P110; SALEM DN, 1989, AM J MED, V86, P259, DOI 10.1016/0002-9343(89)90292-1; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1988, LANCET, V1, P199; STONE GW, 1990, J AM COLL CARDIOL, V15, P534, DOI 10.1016/0735-1097(90)90621-U; TAYLOR GJ, 1980, CIRCULATION, V62, P960, DOI 10.1161/01.CIR.62.5.960; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; VANDEWERF F, 1990, LANCET, V336, P71; VAUGHAN DE, 1988, J AM COLL CARDIOL, V11, P1343, DOI 10.1016/0735-1097(88)90302-6; WALLER BF, 1987, J AM COLL CARDIOL, V9, P785, DOI 10.1016/S0735-1097(87)80234-6; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WILCOX RG, 1988, LANCET, V2, P525; WILLIAMS DO, 1991, J AM COLL CARDIOL, V17, pA337; WISEMAN A, 1988, J AM COLL CARDIOL, V12, P873, DOI 10.1016/0735-1097(88)90447-0; ZIJLSTRA F, 1991, CIRCULATION S2, V84, P536; 1990, VITAL STATISTICS US	76	42	43	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					667	676		10.7326/0003-4819-117-8-667	http://dx.doi.org/10.7326/0003-4819-117-8-667			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530199				2022-12-28	WOS:A1992JR86100008
J	GOLDHABER, SZ; MORPURGO, M				GOLDHABER, SZ; MORPURGO, M			DIAGNOSIS, TREATMENT, AND PREVENTION OF PULMONARY-EMBOLISM - REPORT OF THE WHO/INTERNATIONAL-SOCIETY-AND-FEDERATION-OF-CARDIOLOGY-TASK-FORCE .1.	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; COST-EFFECTIVENESS ANALYSIS; ELECTIVE HIP-SURGERY; VENOUS THROMBOSIS; COMPRESSION STOCKINGS; RANDOMIZED TRIAL; UNFRACTIONATED HEPARIN; PNEUMATIC COMPRESSION; SURGICAL PATIENTS	To assess the state of the art of venous thrombosis and pulmonary embolism for the medical and other health-related professions, the World Health Organization (WHO) and the International Society and Federation of Cardiology (ISFC) convened a task force in Geneva, Switzerland. Members of the task force prepared position papers and presented brief oral presentations. A report was subsequently prepared by the task force members, who contributed sections in their areas of expertise. Revisions of the report occurred both during the task force meeting itself in Geneva and during the ensuing months. The final report was approved by the WHO-ISFC Task Force on Pulmonary Embolism Steering Committee. More quantitative information is needed on the frequency of venous thrombosis and pulmonary embolism in hospitalized medical patients as well as in outpatients at high risk. Population studies should focus on incidence, survival, and long-term complications in different parts of the world with respect to gender and race. Further educational efforts are needed to increase awareness about venous thrombosis and pulmonary embolism prophylaxis. Finally, research into effective techniques for changing physician practice would be useful.			GOLDHABER, SZ (corresponding author), WHO,CARDIOVASC DIS,CH-1211 GENEVA 27,SWITZERLAND.							ANDERSON FA, 1991, ANN INTERN MED, V115, P591, DOI 10.7326/0003-4819-591; [Anonymous], 1975, LANCET, V2, P45; BARRITT DW, 1960, LANCET, V1, P1309; BERGQVIST D, 1985, BRIT J SURG, V72, P105, DOI 10.1002/bjs.1800720211; BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; BOUNAMEAUX H, 1991, LANCET, V337, P196, DOI 10.1016/0140-6736(91)92158-X; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278; CLARKEPEARSON DL, 1984, AM J OBSTET GYNECOL, V148, P1051, DOI 10.1016/0002-9378(84)90632-X; COLDITZ GA, 1986, LANCET, V2, P143; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; DAILY PO, 1990, J THORAC CARDIOV SUR, V99, P670; DAVIDSON BL, IN PRESS ANN INTERN; FOLEY M, 1989, RADIOLOGY, V172, P481, DOI 10.1148/radiology.172.2.2748830; FRANCIS CW, 1992, JAMA-J AM MED ASSOC, V267, P2911, DOI 10.1001/jama.267.21.2911; GOLDHABER SZ, 1991, PROG CARDIOVASC DIS, V34, P113, DOI 10.1016/0033-0620(91)90009-B; GRASSI CJ, 1989, HERZ, V14, P182; HIRSH J, 1992, ARCH INTERN MED, V152, P257, DOI 10.1001/archinte.152.2.257; HUBER O, 1992, ARCH SURG-CHICAGO, V127, P310; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; JEFFERY PC, 1990, BRIT J SURG, V77, P380, DOI 10.1002/bjs.1800770407; KAKKAR VV, 1984, NOUV REV FR HEMATOL, V26, P277; KARWINSKI B, 1989, J CLIN PATHOL, V42, P135, DOI 10.1136/jcp.42.2.135; KIERKEGAARD A, 1987, ACTA MED SCAND, V222, P409; KNIGHT MTN, 1976, LANCET, V2, P1265; LECLERC JR, 1991, VENOUS THROMBOEMBOLI, P176; LENSING AWA, 1990, ANN INTERN MED, V113, P9, DOI 10.7326/0003-4819-113-1-9; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LEYVRAZ PF, 1991, BRIT MED J, V303, P543, DOI 10.1136/bmj.303.6802.543; LINDBLAD B, 1991, BRIT MED J, V302, P709, DOI 10.1136/bmj.302.6778.709; MEYER G, 1991, ANN THORAC SURG, V51, P232, DOI 10.1016/0003-4975(91)90792-O; MOSER KM, 1990, CIRCULATION, V81, P1735, DOI 10.1161/01.CIR.81.6.1735; NEUHAUS A, 1978, CHEST, V73, P460, DOI 10.1378/chest.73.4.460; NICOLAIDES AN, 1980, SURGERY, V87, P69; OSTER G, 1987, AM J MED, V82, P889, DOI 10.1016/0002-9343(87)90149-5; OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203; Paiement G, 1987, J Arthroplasty, V2, P23, DOI 10.1016/S0883-5403(87)80027-X; PAIEMENT GD, 1991, AM J SURG, V161, P519, DOI 10.1016/0002-9610(91)91124-2; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309; POWERS PJ, 1989, ARCH INTERN MED, V149, P771, DOI 10.1001/archinte.149.4.771; QUINN DA, 1992, JAMA-J AM MED ASSOC, V268, P1689, DOI 10.1001/jama.268.13.1689; RICOU F, 1991, AM J CARDIOL, V67, P749, DOI 10.1016/0002-9149(91)90534-R; ROSENDAAL FR, 1991, THROMB HAEMOSTASIS, V65, P927; SCURR JH, 1988, BRIT MED J, V297, P28, DOI 10.1136/bmj.297.6640.28; SCURR JH, 1987, SURGERY, V102, P816; SHURE D, 1985, ANN INTERN MED, V103, P844, DOI 10.7326/0003-4819-103-6-844; STEIN PD, 1991, CHEST, V100, P598, DOI 10.1378/chest.100.3.598; STEIN PD, 1992, CIRCULATION, V85, P462, DOI 10.1161/01.CIR.85.2.462; The UKEP Study, 1987, EUR HEART J, V8, P2; TIMSIT JF, 1991, CHEST, V100, P655, DOI 10.1378/chest.100.3.655; TORNGREN S, 1980, BRIT J SURG, V67, P482, DOI 10.1002/bjs.1800670710; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; VERSTRAETE M, 1990, DRUGS, V40, P498, DOI 10.2165/00003495-199040040-00003; VERSTRAETE M, 1988, CIRCULATION, V77, P353, DOI 10.1161/01.CIR.77.2.353; WILLEJORGENSEN P, 1985, BRIT J SURG, V72, P579, DOI 10.1002/bjs.1800720726; 1991, MMWR, V40, P1; 1990, JAMA-J AM MED ASSOC, V263, P2753	57	113	117	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1727	1733		10.1001/jama.268.13.1727	http://dx.doi.org/10.1001/jama.268.13.1727			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1527883				2022-12-28	WOS:A1992JQ37600036
J	MALLABIABARRENA, A; FRESNO, M; ALARCON, B				MALLABIABARRENA, A; FRESNO, M; ALARCON, B			AN ENDOPLASMIC-RETICULUM RETENTION SIGNAL IN THE CD3-EPSILON CHAIN OF THE T-CELL RECEPTOR	NATURE			English	Article							ANTIGEN RECEPTOR; CD3 COMPLEX; EPSILON-SUBUNITS; DEGRADATION; PROTEINS; LOCALIZATION	ISOLATED polypeptide chains of the T-cell antigen receptor complex are degraded or retained in the endoplasmic reticulum (ER) 1-4. Assembly of the multisubunit complex allows the individual chains to escape retention in the ER and to be expressed on the cell surface. We engineered a series of deletions in the CD3-epsilon subunit of the human T-cell receptor in order to find the sequences responsible for its retention in the ER. Deletion of amino acids 171 to 180 in the cytosolic tail resulted in the cell-surface expression of the isolated chain. This sequence also promotes retention when it is appended to CD4, a plasma membrane protein. Mutagenesis of the 10-amino-acid CD3-epsilon sequence established that the tyrosine and serine residues are important for ER retention. This and other ER retention signals must be hidden when a complete T-cell receptor complex is assembled in order to allow its expression on the cell surface.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC, CANTOBLANCO, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Alarcon, Balbino/N-9648-2016; SANZ, MAGDALENA/L-4825-2013	Alarcon, Balbino/0000-0001-7820-1070; SANZ, MAGDALENA/0000-0002-3106-2680; Fresno Escudero, Manuel/0000-0002-9223-5477				ALARCON B, 1988, J BIOL CHEM, V263, P2953; ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; CARRERA AC, 1987, EUR J IMMUNOL, V17, P179, DOI 10.1002/eji.1830170205; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; INOUYE S, 1991, DIRECTED MUTAGENESIS, P71; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P10619, DOI 10.1073/pnas.88.23.10619; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NASH RA, 1991, IMMUNOGENETICS, V33, P396, DOI 10.1007/BF00216700; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SALMERON A, 1991, J IMMUNOL, V147, P3047; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	24	66	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1992	357	6379					593	596		10.1038/357593a0	http://dx.doi.org/10.1038/357593a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1535117				2022-12-28	WOS:A1992HZ11200055
J	KELLEY, WN; STROSS, JK				KELLEY, WN; STROSS, JK			FACULTY TRACKS AND ACADEMIC-SUCCESS	ANNALS OF INTERNAL MEDICINE			English	Article						FACULTY, MEDICAL; CLINICAL MEDICINE; ACADEMIC MEDICAL CENTERS; CAREER MOBILITY		In 1977, the Department of Internal Medicine at the University of Michigan implemented two specific faculty career tracks, the physician-scientist and clinician-scholar, to define more clearly the goals and expectations to which individuals should strive to achieve academic success. In response to the changing environment, a leadership track and a full-time clinical track were added. Although concerns about comparability, transfer between tracks, and research productivity were raised initially, they were alleviated as it became apparent that the ability to achieve tenure was similar in the physician-scientist and clinician-scholar tracks. The development of well-defined faculty tracks has facilitated the alignment of talents, training, and effort with career goals. It has also enabled us to protect the time of young investigators to pursue their research activities and to define the expectations for promotion for clinicians with a major commitment to patient care.			STROSS, JK (corresponding author), UNIV MICHIGAN, MED CTR, SCH MED, DEPT INTERNAL MED, 3110 TAUBMAN CTR, ANN ARBOR, MI 49109 USA.							GENTILE NO, 1987, RES ACTIVITY FULLTIM; KELLEY WN, 1988, J LAB CLIN MED, V111, P365; PARRIS M, 1984, J MED EDUC, V59, P465	3	44	44	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					654	659		10.7326/0003-4819-116-8-654	http://dx.doi.org/10.7326/0003-4819-116-8-654			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546867				2022-12-28	WOS:A1992HN84400009
J	FELSON, DT; ZHANG, YQ; ANTHONY, JM; NAIMARK, A; ANDERSON, JJ				FELSON, DT; ZHANG, YQ; ANTHONY, JM; NAIMARK, A; ANDERSON, JJ			WEIGHT-LOSS REDUCES THE RISK FOR SYMPTOMATIC KNEE OSTEOARTHRITIS IN WOMEN - THE FRAMINGHAM-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						OSTEOARTHRITIS; KNEE INJURIES; WEIGHT LOSS; OBESITY	OSTEO-ARTHRITIS; OBESITY	Objective: To evaluate the effect of weight loss in preventing symptomatic knee osteoarthritis in women. Design: Cohort analytic study. Setting: The Framingham Study, based on a sample of a defined population. Patients: Women who participated in the Framingham Knee Osteoarthritis Study (1983 to 1985): Sixty-four out of 796 women studied had recent-onset symptomatic knee osteoarthritis (knee symptoms plus radiographically confirmed osteoarthritis) were compared with women without disease. Measurements: Recalled date of symptom onset was used as the incident date of disease. Historical weight was defined as baseline body mass index up to 12 years before symptom onset. Change in body mass index was assessed at several intervals before the current examination. Odds ratios assessing the association between weight change and knee osteoarthritis were adjusted for age, baseline body mass index, history of previous knee injury, habitual physical activity level, occupational physical labor, smoking status, and attained education. Results: Weight change significantly affected the risk for the development of knee osteoarthritis. For example, a decrease in body mass index of 2 units or more (weight loss, approximately 5.1 kg) over the 10 years before the current examination decreased the odds for developing osteoarthritis by over 50% (odds ratio, 0.46; 95% CI, 0.24 to 0.86; P = 0.02). Among those women with a high risk for osteoarthritis due to elevated baseline body mass index (greater-than-or-equal-to 25), weight loss also decreased the risk (for 2 units of body mass index, odds ratio, 0.41; P = 0.02). Weight gain was associated with a slightly increased risk for osteoarthritis, which was not statistically significant. Conclusion: Weight loss reduces the risk for symptomatic knee osteoarthritis in women.	BOSTON UNIV HOSP, DEPT RADIOL, BOSTON, MA 02218 USA	Boston University	FELSON, DT (corresponding author), BOSTON UNIV, BOSTON CITY HOSP, CTR ARTHRIT, A203, 80 E CONCORD ST, BOSTON, MA 02118 USA.			Zhang, Yuqing/0000-0001-7954-1149; Felson, David/0000-0002-2668-2447	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR20613] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHESON RM, 1975, ANN RHEUM DIS, V34, P379, DOI 10.1136/ard.34.5.379; ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; Ball J, 1963, ATLAS STANDARD RADIO, V2; DAVIS MA, 1988, AM J EPIDEMIOL, V127, P1019, DOI 10.1093/oxfordjournals.aje.a114878; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; FELSON DT, 1988, EPIDEMIOL REV, V10, P1; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; FELSON DT, 1989, ARTHRITIS RHEUM, V32, P166, DOI 10.1002/anr.1780320209; FELSON DT, 1991, J RHEUMATOL, V18, P1587; HANNAN MT, 1992, IN PRESS J CLIN EPID; KANNEL WB, 1985, AM HEART J, V109, P876, DOI 10.1016/0002-8703(85)90653-2; KELLGREN JH, 1958, ANN RHEUM DIS, V17, P388, DOI 10.1136/ard.17.4.388; LEACH RE, 1973, CLIN ORTHOP RELAT R, V93, P271; TRAUT EF, 1969, J AM GERIATR SOC, V17, P710, DOI 10.1111/j.1532-5415.1969.tb02326.x; VANSAASE JLCM, 1988, J RHEUMATOL, V15, P1152	15	648	686	0	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					535	539		10.7326/0003-4819-116-7-535	http://dx.doi.org/10.7326/0003-4819-116-7-535			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543306				2022-12-28	WOS:A1992HL25800002
J	KOVAR, PA; ALLEGRANTE, JP; MACKENZIE, CR; PETERSON, MGE; GUTIN, B; CHARLSON, ME				KOVAR, PA; ALLEGRANTE, JP; MACKENZIE, CR; PETERSON, MGE; GUTIN, B; CHARLSON, ME			SUPERVISED FITNESS WALKING IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE - A RANDOMIZED, CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						WALKING; OSTEOARTHRITIS; KNEE INJURIES; EXERCISE THERAPY; PATIENT EDUCATION	CONTROLLED LONG-TERM; ALL-CAUSE MORTALITY; RHEUMATOID-ARTHRITIS; OSTEO-ARTHRITIS; PHYSICAL-ACTIVITY; AEROBIC EXERCISE; HEART-DISEASE; HEALTHY-MEN; WOMEN; EPIDEMIOLOGY	Objective: To assess the effect of a program of supervised fitness walking and patient education on functional status, pain, and use of medication in patients with osteoarthritis of the knee. Design: An 8-week randomized, controlled trial. Setting: Inpatient and outpatient services of an orthopedic hospital in an academic medical center. Patients: A total of 102 patients with a documented diagnosis of primary osteoarthritis of one or both knees participated in the study. Data were obtained on 47 of 51 intervention patients and 45 of 51 control patients. Interventions: An 8-week program of supervised fitness walking and patient education or standard routine medical care. Measurements: Patients were evaluated and outcomes assessed before and after the intervention using a 6-minute test of walking distance and scores on the physical activity, arthritis impact, pain, and medication subscales of the Arthritis Impact Measurement Scale (AIMS). Results: Patients randomly assigned to the walking program had a 70-meter increase in walking distance relative to their baseline assessment, which represents an improvement of 18.4% (95% CI, 9.8% to 27.0%). In contrast, controls showed a 17-meter decrease in walking distance relative to their baseline assessment (P < 0.001). Improvements in functional status as measured by the AIMS physical activity subscale were also observed in the walking group but not in the control group (P < 0.001); patients assigned to the walking program improved 39% (CI, 15.6% to 60.4%). Although changes in scores on the arthritis impact subscale were similar in the two groups (P = 0.093), the walking group experienced a decrease in arthritis pain of 27% (CI, 9.6% to 41.4%) (P = 0.003). Medication use was less frequent in the walking group than in the control group at the post-test (P = 0.08). Conclusions: A program of supervised fitness walking and patient education can improve functional status without worsening pain or exacerbating arthritis-related symptoms in patients with osteoarthritis of the knee.	HOSP SPECIAL SURG, CORNELL ARTHRIT & MUSCULOSKELETAL DIS CTR, 535 E 70TH ST, NEW YORK, NY 10021 USA; COLUMBIA UNIV, NEW YORK, NY 10027 USA; MED COLL GEORGIA, DEPT PEDIAT, AUGUSTA, GA 30912 USA; MED COLL GEORGIA, GEORGIA PREVENT INST, AUGUSTA, GA 30912 USA	Columbia University; University System of Georgia; Augusta University; University System of Georgia; Augusta University				Allegrante, John/0000-0002-6281-3037	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR038520] Funding Source: NIH RePORTER; NIAMS NIH HHS [1 P60 AR38520-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHTERBERGLAWLIS J, 1982, J CONSULT CLIN PSYCH, V50, P984, DOI 10.1037/0022-006X.50.6.984; ALLEGRANTE JP, IN PRESS HLTH ED Q; ALLEN ME, 1990, RHEUMATIC DISEASES C, P887; ALOIA JF, 1978, ANN INTERN MED, V89, P356, DOI 10.7326/0003-4819-89-3-356; BEALS CA, 1985, J RHEUMATOL, V12, P458; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; EKBLOM B, 1974, SCAND J RHEUMATOL, V3, P121, DOI 10.3109/03009747409097136; EKBLOM B, 1975, SCAND J RHEUMATOL, V4, P87, DOI 10.3109/03009747509095620; EKBLOM B, 1975, J SCAND J RHEUMATOL, V41, P80; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; FELSON DT, 1988, EPIDEMIOL REV, V10, P1; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HARKCOM TM, 1985, ARTHRITIS RHEUM, V28, P32, DOI 10.1002/art.1780280106; IKE RW, 1989, PHYSICIAN SPORTSMED, V17, P128, DOI 10.1080/00913847.1989.11709710; KELLEY WN, 1978, TXB RHEUMATOLOGY, V89, P356; KOHL HW, 1988, SPORTS MED, V6, P222, DOI 10.2165/00007256-198806040-00004; LUBECK DP, 1982, 1982 ANN M AM PUBL H; Mason J H, 1989, Arthritis Care Res, V2, P89, DOI 10.1002/anr.1790020303; MEENAN RF, 1982, J RHEUMATOL, V9, P785; MINOR MA, 1989, ARTHRITIS RHEUM, V32, P1396, DOI 10.1002/anr.1780321108; MINOR MA, 1988, J RHEUMATOL, V15, P905; MOSCOWITZ RW, 1986, ARTHRITIS ELDERLY; MOSKOWITZ RW, 1987, AM J MED, V83, P5, DOI 10.1016/0002-9343(87)90844-8; NORDEMAR R, 1976, SCAND J RHEUMATOL, V5, P233, DOI 10.3109/03009747609099911; NORDEMAR R, 1981, SCAND J RHEUMATOL, V10, P25; NORDEMAR R, 1981, SCAND J RHEUMATOL, V10, P17; NORDESJO LO, 1983, SCAND J RHEUMATOL, V12, P152, DOI 10.3109/03009748309102902; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; POLLOCK ML, 1971, J APPL PHYSIOL, V30, P126, DOI 10.1152/jappl.1971.30.1.126; PORCARI J, 1987, PHYSICIAN SPORTSMED, V15, P119, DOI 10.1080/00913847.1987.11709285; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; PRICE LG, 1988, ARTHRIT CARE RES, V1, P33; RIPPE JM, 1988, JAMA-J AM MED ASSOC, V259, P2720, DOI 10.1001/jama.259.18.2720; RIPPE JM, 1989, PRAC CARDIOL, V15, P66; SHOENFELD Y, 1980, JAMA-J AM MED ASSOC, V243, P2062, DOI 10.1001/jama.243.20.2062; SISCOVICK DS, 1985, PUBLIC HEALTH REP, V100, P180; SPIEGEL D, 1989, LANCET, V2, P888; STERN MJ, 1981, ARCH INTERN MED, V141, P1463, DOI 10.1001/archinte.141.11.1463; SUMMERS MN, 1988, ARTHRITIS RHEUM, V31, P204, DOI 10.1002/art.1780310208; TAYLOR CB, 1985, PUBLIC HEALTH REP, V100, P195; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; VANSAASE JLCM, 1989, ANN RHEUM DIS, V48, P271, DOI 10.1136/ard.48.4.271	43	377	382	3	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					529	534		10.7326/0003-4819-116-7-529	http://dx.doi.org/10.7326/0003-4819-116-7-529			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543305				2022-12-28	WOS:A1992HL25800001
J	GREENFIELD, S; NELSON, EC; ZUBKOFF, M; MANNING, W; ROGERS, W; KRAVITZ, RL; KELLER, A; TARLOV, AR; WARE, JE				GREENFIELD, S; NELSON, EC; ZUBKOFF, M; MANNING, W; ROGERS, W; KRAVITZ, RL; KELLER, A; TARLOV, AR; WARE, JE			VARIATIONS IN RESOURCE UTILIZATION AMONG MEDICAL SPECIALTIES AND SYSTEMS OF CARE - RESULTS FROM THE MEDICAL OUTCOMES STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-MAINTENANCE ORGANIZATIONS; PREPAID GROUP-PRACTICE; FINANCIAL INCENTIVES; GENERAL INTERNISTS; FAMILY PHYSICIANS; CONTROLLED TRIAL; FEE; MODELS	Objective. - To examine whether specialty and system of care exert independent effects on resource utilization. Study Design. - Cross-sectional analysis of just over 20 000 patients (greater-than-or-equal-to 18 years of age) who visited providers' offices during 9-day periods in 1986. Patient- and physician-provided information was obtained by self-administered questionnaires. Setting. - Offices of 349 physicians practicing family medicine, internal medicine, endocrinology, and cardiology within health maintenance organizations, large multispecialty groups, and solo practices or small single-specialty group practices in three major US cities. Outcome Measures. - Indicators of the intensity of resource utilization were examined among four medical specialties (family practice, general internal medicine, cardiology, and endocrinology) and five systems of care (health maintenance organization, multispecialty group-fee-for-service, multispecialty group-prepaid; solo practice and single-specialty group-fee-for-service, and solo practice and single-specialty group-prepaid) before and after controlling for the mix of patients seen in these offices. The indicators of resource utilization were hospitalizations, annual office visits, prescription drugs, and common tests and procedures, with rates estimated on both a per-visit and per-year basis. Results. - Variation in patient mix was a major determinant of the large variations in resource use. However, increased utilization was also independently related to specialty (cardiology and endocrinology), fee-for-service payment plan, and solo and single-specialty group practice arrangements. After adjusting for patient mix, solo practice/single-specialty groups-fee-for-service had 41 % more hospitalizations than health maintenance organizations. General internists had utilization rates somewhat greater than family physicians on some indicators. Conclusion. - Although variations in patient mix should be a major determinant of variations in resource use, the independent effects of specialty training, payment system, and practice organization on utilization rates need further explication. The 2- and 4-year outcomes now being analyzed will provide information critical to interpretation of the variations reported herein.	TUFTS UNIV,DEPT MED,BOSTON,MA 02111; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; HOSP CORP AMER,NASHVILLE,TN; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03756; UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455; RAND CORP,SANTA MONICA,CA 90406	Tufts University; Harvard University; Harvard T.H. Chan School of Public Health; Hospital Corporation of America; Dartmouth College; University of Minnesota System; University of Minnesota Twin Cities; RAND Corporation	GREENFIELD, S (corresponding author), NEW ENGLAND MED CTR HOSP,INST HLTH,750 WASHINGTON ST,BOX 345,BOSTON,MA 02111, USA.		Kravitz, Richard/AAF-7425-2021	Kravitz, Richard/0000-0001-5575-529X; Greenfield, Sheldon/0000-0003-4628-1998				ADAMSON TE, 1989, J FAM PRACTICE, V29, P93; BERTAKIS KD, 1975, J MED EDUC, V50, P264; CHERKIN DC, 1987, MED CARE, V25, P455, DOI 10.1097/00005650-198706000-00001; CLEARY PD, 1991, JAMA-J AM MED ASSOC, V266, P73, DOI 10.1001/jama.266.1.73; CRAGG JG, 1971, ECONOMETRICA, V39, P829, DOI 10.2307/1909582; Duan N., 1983, J BUS STAT, V1, P115, DOI DOI 10.2307/1391852; EGDAHL RH, 1986, NEW ENGL J MED, V315, P59, DOI 10.1056/NEJM198607033150111; ENTHOVEN AC, 1978, NEW ENGL J MED, V299, P1229; FELDMAN R, 1989, DHHS PHS893434 US DE; FINKEL A, 1977, PHYSICIANS CURRENT P; FRANCIS AM, 1984, MED CARE, V22, P418, DOI 10.1097/00005650-198405000-00006; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREENWALD HP, 1984, MED CARE, V22, P14, DOI 10.1097/00005650-198401000-00002; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1990, ANN INTERN MED, V112, P891, DOI 10.7326/0003-4819-112-12-891; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; KULKARNI PR, 1981, MED CARE, V27, P608; LEVIT KR, 1990, HEALTH AFFAIR, V9, P171, DOI 10.1377/hlthaff.9.2.171; LUFT HS, 1978, NEW ENGL J MED, V298, P1336, DOI 10.1056/NEJM197806152982404; LUFT HS, 1981, HLTH MAINTENANCE ORG; MANNING WG, 1987, J ECONOMETRICS, V35, P59, DOI 10.1016/0304-4076(87)90081-9; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MURRAY JP, IN PRESS MED CARE; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; NOREN J, 1980, NEW ENGL J MED, V302, P11, DOI 10.1056/NEJM198001033020103; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; SUNSHINE JH, 1987, 8720215 DEP HLTH HUM; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; WARE JE, 1986, LANCET, V1, P1017; WELCH WP, 1984, ADV HLTH EC HLTH SER, P95; Wilensky G R, 1986, Health Aff (Millwood), V5, P66, DOI 10.1377/hlthaff.5.1.66; YELIN EH, 1986, MED CARE, V24, P236, DOI 10.1097/00005650-198603000-00006; 1990, STATISTICAL ABSTRACT	33	534	537	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1624	1630		10.1001/jama.267.12.1624	http://dx.doi.org/10.1001/jama.267.12.1624			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HJ597	1542172				2022-12-28	WOS:A1992HJ59700029
J	MCCULLOUGH, DJ				MCCULLOUGH, DJ			1ST ENCOUNTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1197	1197						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1538552				2022-12-28	WOS:A1992HF43900009
J	HALL, JV; WINER, AM; KLEINMAN, MT; LURMANN, FW; BRAJER, V; COLOME, SD				HALL, JV; WINER, AM; KLEINMAN, MT; LURMANN, FW; BRAJER, V; COLOME, SD			VALUING THE HEALTH BENEFITS OF CLEAN-AIR	SCIENCE			English	Article							SPECIFICATION TEST; PERSONAL EXPOSURE; INDOOR AIR; POLLUTION; OZONE; MORTALITY; EXERCISE; QUALITY; RATES; MODEL	An assessment of health effects due to ozone and particulate matter (PM10) suggests that each of the 12 million residents of the South Coast Air Basin of California experiences ozone-related symptoms on an average of up to 17 days each year and faces an increased risk of death in any year of 1/10,000 as a result of elevated PM10 exposure. The estimated annual economic value of avoiding these effects is nearly $10 billion. Attaining air pollution standards may save 1600 lives a year in the region.	UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT ENVIRONM HLTH SCI,ENVIRONM SCI & ENGN PROGRAM,LOS ANGELES,CA 90024; SONOMA TECHNOL INC,SANTA ROSA,CA 95403; INTEGRATED ENVIRONM SERV,IRVINE,CA 92715; UNIV CALIF IRVINE,DEPT COMMUNITY & ENVIRONM MED,AIR POLLUT HLTH EFFECTS LAB,IRVINE,CA 92715	University of California System; University of California Los Angeles; University of California System; University of California Irvine	HALL, JV (corresponding author), CALIF STATE UNIV FULLERTON,DEPT ECON,FULLERTON,CA 92634, USA.		Hall, Jane/A-7046-2009					BAKER PE, 1988, SEP AIR POLL CONTR A; BRAJER V, 1991, CONTEMP POLICY ISSUE, V9, P81; CHAN CC, 1989, NOV TOT EXP ASS METH; COLOME SD, 1982, ENVIRON INT, V8, P197; DENNY M, 1978, PRODUCTION EC DUAL A, P249; DICKIE MT, 1987, IMPROVING ACCURACY R; DOCKERY DW, 1981, JAPCA J AIR WASTE MA, V31, P153, DOI 10.1080/00022470.1981.10465205; DRUZIK JR, 1990, ATMOS ENVIRON A-GEN, V24, P1813, DOI 10.1016/0960-1686(90)90513-M; EVANS JS, 1984, ENVIRON INT, V10, P55, DOI 10.1016/0160-4120(84)90233-2; FISHER A, 1989, J POLICY ANAL MANAG, V8, P88, DOI 10.2307/3324426; Freeman A. M, 1982, AIR WATER POLLUT; GAREN J, 1988, REV ECON STAT, V70, P9, DOI 10.2307/1928145; GEGAX D, 1985, PERCEIVED RISK MARGI; GREEN CL, 1988, IN VEHICLE AIR TOXIC; HALL JV, 1989, EC ASSESSMENT HLTH B; HAMMER DI, 1974, ARCH ENVIRON HEALTH, V28, P255, DOI 10.1080/00039896.1974.10666482; HAYES SR, 1989, JAPCA J AIR WASTE MA, V39, P1453, DOI 10.1080/08940630.1989.10466640; IMAI M, 1985, JAPCA J AIR WASTE MA, V35, P103, DOI 10.1080/00022470.1985.10465891; JONES-LEE MW, 1985, ECON J, V95, P49, DOI 10.2307/2233468; Kahn S., 1986, IEEE Technology and Society Magazine, V5, P24, DOI 10.1109/MTAS.1986.5010011; Kleinman M T, 1991, J Expo Anal Environ Epidemiol, V1, P309; KLEINMAN MD, 1989, EFFECTS HUMAN HLTH P; KLINGER D, 1986, PERSOAL TRAVEL US 19; KRUPNICK AJ, 1991, SCIENCE, V252, P522, DOI 10.1126/science.1902322; KRUPNICK AJ, 1989, HLTH AGR BENEFITS RE; KULLE TJ, 1985, AM REV RESPIR DIS, V132, P35; LAVE LB, 1970, SCIENCE, V169, P723, DOI 10.1126/science.169.3947.723; Lave LB, 1977, AIR POLLUTION HUMAN; LEIGH JP, 1984, Q REV ECON BUS, V24, P56; LIPPMANN M, 1989, JAPCA J AIR WASTE MA, V39, P672, DOI 10.1080/08940630.1989.10466554; LOEHMAN ET, 1979, J ENVIRON ECON MANAG, V6, P222, DOI 10.1016/0095-0696(79)90006-8; LURMANN F, 1989, COMMUNICATION; LURMANN FW, 1989, 1989 C TOT EXP ASS M; LURMANN FW, 1989, SENSITIVITY ANAL REG; MAKINO K, 1975, NIPPON KOSHU ISEI ZA, V2, P421; MCDONNELL WF, 1983, J APPL PHYSIOL, V54, P1345, DOI 10.1152/jappl.1983.54.5.1345; MOORE MJ, 1988, J POLICY ANAL MANAG, V7, P476, DOI 10.2307/3323726; NAZAROFF WW, 1986, ENVIRON SCI TECHNOL, V20, P924, DOI 10.1021/es00151a012; OSTRO BD, 1987, J ENVIRON ECON MANAG, V14, P87, DOI 10.1016/0095-0696(87)90008-8; OTT W, 1988, ATMOS ENVIRON, V22, P2101, DOI 10.1016/0004-6981(88)90122-9; OTT WR, 1985, ENVIRON SCI TECHNOL, V19, P880, DOI 10.1021/es00140a001; OZKAYNAK H, 1987, RISK ANAL, V7, P449, DOI 10.1111/j.1539-6924.1987.tb00482.x; PAUL RRA, 1986, EPA68024309WA32 REP; PORTNEY PR, 1986, J URBAN ECON, V20, P21, DOI 10.1016/0094-1190(86)90013-6; ROWE R, 1987, SANTA CLARA COUNTY A; SABERSKY RH, 1973, ENVIRON SCI TECHNOL, V7, P347, DOI 10.1021/es60076a001; SCHWAB M, 1990, TOXICOL IND HEALTH, V6, P517; SCHWARTZ J, 1990, AM J EPIDEMIOL, V131, P185, DOI 10.1093/oxfordjournals.aje.a115473; Sexton K., 1988, AIR POLLUTION AUTOMO; SHAIR FH, 1974, ENVIRON SCI TECHNOL, V8, P444, DOI 10.1021/es60090a006; SPEKTOR DM, 1988, AM REV RESPIR DIS, V137, P313, DOI 10.1164/ajrccm/137.2.313; Szalai A., 1972, USE TIME; THOMAS J, 1988, 1988 P RES PLANN C H; THURSTON GD, 1989, ENVIRON HEALTH PERSP, V79, P73, DOI 10.2307/3430532; TOLLEY G, 1986, VALUATION REDUCTIONS; Viscusi WK, 1986, BENEFITS ASSESSMENT, P193; WESCHLER CJ, 1989, JAPCA J AIR WASTE MA, V39, P1562, DOI 10.1080/08940630.1989.10466650; WHITE CC, 1987, AM J PREV MED, V3, P304; WINER AM, 1989, CHARACTERIZATION AIR; 1988, ACCIDENT FACTS	60	103	103	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					812	817		10.1126/science.1536006	http://dx.doi.org/10.1126/science.1536006			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HD548	1536006				2022-12-28	WOS:A1992HD54800027
J	POTAMI, AR				POTAMI, AR			INDIRECT COSTS AT THE UNIVERSITY-OF-MINNESOTA	SCIENCE			English	Editorial Material											POTAMI, AR (corresponding author), UNIV MINNESOTA,RES & TECHNOL TRANSFER,MINNEAPOLIS,MN 55455, USA.								0	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					779	780		10.1126/science.1535999	http://dx.doi.org/10.1126/science.1535999			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HD548	1535999				2022-12-28	WOS:A1992HD54800003
J	ALBERTS, B; MIAKELYE, R				ALBERTS, B; MIAKELYE, R			UNSCRAMBLING THE PUZZLE OF BIOLOGICAL MACHINES - THE IMPORTANCE OF THE DETAILS	CELL			English	Review							SIGNAL-RECOGNITION PARTICLE; PROTEINS; SEQUENCE; ROTATION; MUSCLE; MODEL; ACTIN; FORCE; ACID; DNA		CELL,CAMBRIDGE,MA 02138		ALBERTS, B (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; Hammer J A, 1991, Trends Cell Biol, V1, P50, DOI 10.1016/0962-8924(91)90089-R; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; HUXLEY A, 1980, REFLECTIONS MUSCLE, P97; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; KRUMMEL B, 1992, IN PRESS J MOL BIOL; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MEISTER M, 1989, BIOPHYS J, V55, P905, DOI 10.1016/S0006-3495(89)82889-9; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STORY RM, 1992, IN PRESS NATURE; THOMAS DD, 1987, ANNU REV PHYSIOL, V49, P691, DOI 10.1146/annurev.ph.49.030187.003355; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; YANAGIDA T, 1985, J MUSCLE RES CELL M, V6, P43, DOI 10.1007/BF00712310	26	97	99	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					415	420		10.1016/0092-8674(92)90179-G	http://dx.doi.org/10.1016/0092-8674(92)90179-G			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1531448				2022-12-28	WOS:A1992HD39800003
J	LANGLOIS, AJ; WEINHOLD, KJ; MATTHEWS, TJ; GREENBERG, ML; BOLOGNESI, DP				LANGLOIS, AJ; WEINHOLD, KJ; MATTHEWS, TJ; GREENBERG, ML; BOLOGNESI, DP			THE ABILITY OF CERTAIN SIV VACCINES TO PROVOKE REACTIONS AGAINST NORMAL-CELLS	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY VIRUS-INFECTION; PROTECTION; ANTIGENS; MACAQUES		DUKE UNIV,MED CTR,CTR AIDS RES,DEPT SURG,DURHAM,NC 27710	Duke University								ANDERSON C, 1991, NATURE, V353, P287, DOI 10.1038/353287b0; AZOCAR J, 1979, CANCER RES, V39, P3388; BOLOGNESI DP, 1970, COMP LEUKEMIA RES 19, P126; BROWN P, 1991, NEW SCI, V21, P14; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CELADA F, 1990, J EXP MED, V172, P1143, DOI 10.1084/jem.172.4.1143; DESROSIERS R, COMMUNICATION; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; DESROSIERS RC, 1989, 21ST C AIDS ANN; GARDNER MB, IN PRESS AIDS; GIRARD M P, 1990, AIDS (London), V4, pS143; HENDERSON LE, 1987, J VIROL, V61, P629, DOI 10.1128/JVI.61.2.629-632.1987; HILDRETH JEK, 1989, SCIENCE, V244, P1075, DOI 10.1126/science.2543075; HILLEMAN MR, 1985, J INFECT DIS, V151, P407, DOI 10.1093/infdis/151.3.407; HOXIE JA, 1987, HUM IMMUNOL, V18, P39, DOI 10.1016/0198-8859(87)90111-X; HU SL, IN PRESS SCIENCE; JAVAHERIAN K, UNPUB P NATL ACAD SC; LANGLOIS AJ, 1991, AIDS RES HUM RETROV, V7, P713, DOI 10.1089/aid.1991.7.713; LINDENMANN J, 1977, VIRUS INFECTION CELL, P291; MADDOX J, 1991, NATURE, V353, P297, DOI 10.1038/353297a0; MONTEFIORE DC, IN PRESS NATURE; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; WATANABE M, 1991, P NATL ACAD SCI USA, V88, P4616, DOI 10.1073/pnas.88.11.4616	24	87	89	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1992	255	5042					292	293		10.1126/science.1549775	http://dx.doi.org/10.1126/science.1549775			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1549775				2022-12-28	WOS:A1992GZ69500032
J	MECLEY, M; ROSENFIELD, K; KAUFMAN, J; LANGEVIN, RE; RAZVI, S; ISNER, JM				MECLEY, M; ROSENFIELD, K; KAUFMAN, J; LANGEVIN, RE; RAZVI, S; ISNER, JM			ATHEROSCLEROTIC PLAQUE HEMORRHAGE AND RUPTURE ASSOCIATED WITH CRESCENDO CLAUDICATION	ANNALS OF INTERNAL MEDICINE			English	Note						INTERMITTENT CLAUDICATION; PERIPHERAL VASCULAR DISEASES; ATHEROSCLEROSIS; THROMBOSIS; PLAQUE, ATHEROSCLEROTIC	ATHERECTOMY; THROMBOSIS	Atherosclerotic plaque rupture with intraluminal thrombus formation has not been previously described in patients with peripheral vascular disease who have accelerated symptoms of claudication. We describe a patient in whom claudication progressed from the occurrence of symptoms only after 100 yards of level walking to the occurrence of symptoms at rest, requiring narcotic analgesia. Intravascular ultrasound examination showed evidence of plaque hemorrhage. Examination of the plaque specimen obtained by directional atherectomy confirmed intraplaque hemorrhage, plaque rupture, and intraluminal thrombus. The findings in this patient document that plaque hemorrhage, plaque rupture, and luminal thrombosis may cause a crescendo pattern of lower-extremity claudication.	ST ELIZABETH HOSP, DEPT MED, 736 CAMBRIDGE ST, BOSTON, MA 02135 USA; ST ELIZABETH HOSP, DEPT RADIOL, BOSTON, MA 02135 USA; ST ELIZABETH HOSP, DEPT VASC SURG, BOSTON, MA 02135 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040518, K07HL002824] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40518, 1 K07 HL02824-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBANO EF, 1989, ATHEROSCLEROSIS, V78, P183, DOI 10.1016/0021-9150(89)90222-0; DAVIES MJ, 1985, BRIT HEART J, V53, P363; FALK E, 1983, BRIT HEART J, V50, P127; FISHER M, 1987, ARCH NEUROL-CHICAGO, V44, P1086, DOI 10.1001/archneur.1987.00520220082022; FUSTER V, 1990, CIRCULATION, V82, P47; JOHNSON DE, 1990, J AM COLL CARDIOL, V15, P419, DOI 10.1016/S0735-1097(10)80071-3; LUSBY RJ, 1982, ARCH SURG-CHICAGO, V117, P1479; ODONNELL TF, 1985, ARCH SURG-CHICAGO, V120, P443; RAHILLY GT, 1981, AM HEART J, V101, P237, DOI 10.1016/0002-8703(81)90677-3; ROSENFIELD K, 1991, CIRCULATION, V84, P1938, DOI 10.1161/01.CIR.84.5.1938	10	7	8	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					663	666		10.7326/0003-4819-117-8-663	http://dx.doi.org/10.7326/0003-4819-117-8-663			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530198				2022-12-28	WOS:A1992JR86100007
J	BREO, DL				BREO, DL			JFK DEATH .3. FINCK SPEAKS OUT - 2 BULLETS, FROM THE REAR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1992, JAMA-J AM MED ASSOC, V267, P2794	1	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1748	1754		10.1001/jama.268.13.1748	http://dx.doi.org/10.1001/jama.268.13.1748			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1527887				2022-12-28	WOS:A1992JQ37600041
J	TRICHOPOULOS, D; MOLLO, F; TOMATIS, L; AGAPITOS, E; DELSEDIME, L; ZAVITSANOS, X; KALANDIDI, A; KATSOUYANNI, K; RIBOLI, E; SARACCI, R				TRICHOPOULOS, D; MOLLO, F; TOMATIS, L; AGAPITOS, E; DELSEDIME, L; ZAVITSANOS, X; KALANDIDI, A; KATSOUYANNI, K; RIBOLI, E; SARACCI, R			ACTIVE AND PASSIVE SMOKING AND PATHOLOGICAL INDICATORS OF LUNG-CANCER RISK IN AN AUTOPSY STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIR-POLLUTION; CIGARETTE-SMOKING; TOBACCO-SMOKE; BRONCHIAL EPITHELIUM; SMALL AIRWAYS; COUNTY; ASSOCIATION; EXPOSURE; DISEASE; WOMEN	Objective.-The association between involuntary smoking and lung cancer has been supported by most epidemiologic studies, but a number of authors and interest groups claim that the possibility of bias has not been excluded. Few autopsy-based studies have explored the role of active smoking and other exposures in lung carcinogenesis, and none has been previously done to examine the role of passive smoking. We have undertaken such an autopsy-based study in Athens, Greece. Design.-Lung specimens were taken at autopsy from 400 persons 35 years of age or older, of both genders, who had died within 4 hours from a cause other than respiratory or cancer in Athens or the surrounding area. For each person at least seven tissue blocks were taken from the main and lobar bronchi and at least five blocks from the parenchyma, including an average of about 20 smaller cartilaginous bronchi and membranous bronchioles. The specimens were examined without knowledge of the exposures of the particular subject in Turin, Italy. For 283 (71%) of the subjects the preservation of the bronchial epithelium was satisfactory for pathological examination, and for 206 among them (73%) an interview could be arranged with their next of kin, focusing on smoking habits of the deceased and their spouses, as well as other variables. The interviewers were not aware of the results of the pathological examinations. Main Outcome Measure.-Specimens were examined for basal cell hyperplasia, squamous cell metaplasia, cell atypia, and (in membranous bronchioles and bronchiolo-alveolar airways) mucous cell metaplasia, ie, pathological entities that may be lung cancer risk indicators or epithelial, possibly precancerous, lesions (EPPL). The gland and wall thicknesses were also measured and their ratio calculated (Reid Index). Results.-In comparison with nonsmokers, EPPL values were significantly higher among current smokers and higher, but not significantly so, among former smokers. Furthermore, EPPL values were significantly higher among deceased nonsmoking women married to smokers rather than to nonsmokers. In this set of data neither occupation nor residence was associated with EPPL, but this could be due to the poor correlation of residential history with exposure to air pollution and the lack of adequate standardization of contemporary Greek occupations. The Reid Index was higher among smokers and former smokers in comparison with nonsmokers, among subjects with mainly urban residence in comparison with those with mainly rural residence, and among nonsmoking women married to smokers in comparison with those married to nonsmokers, but none of these differences was statistically significant. Conclusion.-These results provide support to the body of evidence linking passive smoking to lung-cancer, even though they are based on a study methodologically different from those that have previously examined this association.	UNIV ATHENS,SCH MED,DEPT PATHOL,ATHENS,GREECE; UNIV ATHENS,SCH MED,DEPT HYG & EPIDEMIOL,ATHENS,GREECE; WHO,INT AGCY RES CANC,LYON,FRANCE; UNIV TURIN,DEPT BIOMED SCI & HUMAN ONCOL,I-10124 TURIN,ITALY	Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens; World Health Organization; International Agency for Research on Cancer (IARC); University of Turin	TRICHOPOULOS, D (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Katsouyanni, Klea/D-4856-2014	Katsouyanni, Klea/0000-0002-0132-9575; Riboli, Elio/0000-0001-6795-6080				AGAPITOS E, 1991, AUTOPSY EPIDEMIOLOGY, P263; [Anonymous], 1986, IARC MONOGRAPHS EVAL; [Anonymous], 1985, EPIDEMIOLOGY AIR POL; AUERBACH O, 1962, NEW ENGL J MED, V267, P111, DOI 10.1056/NEJM196207192670301; AUERBACH O, 1962, NEW ENGL J MED, V267, P119, DOI 10.1056/NEJM196207192670302; AUERBACH O, 1957, NEW ENGL J MED, V256, P97, DOI 10.1056/NEJM195701172560301; AUERBACH O, 1956, CANCER, V9, P76, DOI 10.1002/1097-0142(195601/02)9:1<76::AID-CNCR2820090106>3.0.CO;2-D; AUERBACH O, 1979, NEW ENGL J MED, V300, P381, DOI 10.1056/NEJM197902223000801; BLOT WJ, 1976, AM J EPIDEMIOL, V103, P539, DOI 10.1093/oxfordjournals.aje.a112258; BOSKEN CH, 1990, AM REV RESPIR DIS, V142, P563, DOI 10.1164/ajrccm/142.3.563; BUFFLER PA, 1988, AM J EPIDEMIOL, V128, P683, DOI 10.1093/oxfordjournals.aje.a115022; CANVOW BW, 1978, ENV HLTH PERSPECT, V22, P17; CARROLL R, 1961, BRIT J CANCER, V15, P215, DOI 10.1038/bjc.1961.27; COSIO MG, 1980, AM REV RESPIR DIS, V122, P265; Cosio MG, 1977, NEW ENGL J MED, V298, P1277; EVERINGHAM R, 1991, TOBACCO LITIGATION A; Field W E, 1966, Br J Dis Chest, V60, P66, DOI 10.1016/S0007-0971(66)80002-5; FORD AB, 1980, ARCH ENVIRON HEALTH, V35, P350; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HAMMOND EC, 1980, PREV MED, V9, P206, DOI 10.1016/0091-7435(80)90077-8; HENDERSON BE, 1975, AM J EPIDEMIOL, V101, P477, DOI 10.1093/oxfordjournals.aje.a112118; HIRAYAMA T, 1981, BRIT MED J, V282, P183, DOI 10.1136/bmj.282.6259.183; JANERICH DT, 1990, NEW ENGL J MED, V323, P632, DOI 10.1056/NEJM199009063231003; KALANDIDI A, 1990, CANCER CAUSE CONTROL, V1, P15, DOI 10.1007/BF00053179; KATSOUYANNI K, 1991, PREV MED, V20, P271, DOI 10.1016/0091-7435(91)90026-Z; LEE PN, 1987, TOXICOL LETT, V35, P157, DOI 10.1016/0378-4274(87)90102-0; LEE PN, 1987, HUM TOXICOL, V6, P517, DOI 10.1177/096032718700600612; MATANOSKI GM, 1981, ENVIRON RES, V25, P8, DOI 10.1016/0013-9351(81)90076-1; Mollo F, 1981, Pathologica, V73, P185; MULLEN JBM, 1986, AM REV RESPIR DIS, V133, P120, DOI 10.1164/arrd.1986.133.1.120; Pershagen G, 1990, EUROPEAN SCH ONCOLOG, P63; REID LYNNE, 1960, THORAX, V15, P132, DOI 10.1136/thx.15.2.132; RIBOLI E, 1990, CANCER CAUSE CONTROL, V1, P243, DOI 10.1007/BF00117476; SARACCI R, 1989, MUTAT RES, V22, P117; SOLOMON MD, 1990, MODERN PATHOL, V3, P684; TANNENBAUM A, 1970, INT J CANCER, V5, P282, DOI 10.1002/ijc.2910050217; THURLBECK WM, 1988, PATHOLOGY LUNG, P529; TRICHOPOULOS D, 1981, INT J CANCER, V27, P1, DOI 10.1002/ijc.2910270102; TRICHOPOULOS D, 1988, SCAND J SOC MED, V16, P75, DOI 10.1177/140349488801600203; VENA JE, 1982, AM J EPIDEMIOL, V116, P42, DOI 10.1093/oxfordjournals.aje.a113401; VINE MF, 1990, AM J EPIDEMIOL, V131, P781, DOI 10.1093/oxfordjournals.aje.a115569; VUTUC C, 1984, PREV MED, V13, P698, DOI 10.1016/S0091-7435(84)80019-5; WALD NJ, 1986, BMJ-BRIT MED J, V293, P1217, DOI 10.1136/bmj.293.6556.1217; WEINBERG GB, 1982, AM J EPIDEMIOL, V115, P40, DOI 10.1093/oxfordjournals.aje.a113278; WELLS AJ, 1991, AM J EPIDEMIOL, V133, P208, DOI 10.1093/oxfordjournals.aje.a115859; WHIMSTER W F, 1988, Applied Pathology, V6, P241; WRIGHT JL, 1984, AM REV RESPIR DIS, V129, P989; WRIGHT JL, 1985, ARCH PATHOL LAB MED, V109, P163; ZU ZY, 1989, J NATL CANCER I, V81, P1800; 1985, PHS DHHS CDC87839833	50	48	49	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1697	1701		10.1001/jama.268.13.1697	http://dx.doi.org/10.1001/jama.268.13.1697			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1527879				2022-12-28	WOS:A1992JQ37600031
J	TANG, WJ; GILMAN, AG				TANG, WJ; GILMAN, AG			ADENYLYL CYCLASES	CELL			English	Review							MOLECULAR-CLONING; G-PROTEINS; EXPRESSION; SEQUENCE				TANG, WJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.			Tang, Wei-Jen/0000-0002-8267-8995				BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; INIGUEZLLUHI JA, 1992, IN PRESS J BIOL CHEM; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KATSUSHIKA S, 1992, IN PRESS P NATL ACAD; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NEER EJ, 1980, J BIOL CHEM, V255, P9782; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PREMONT RT, 1992, IN PRESS P NATL ACAD; SATTIN A, 1975, J PHARMACOL EXP THER, V192, P22; SCHULTZ JE, 1992, SCIENCE, V255, P600, DOI 10.1126/science.1371017; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TANG WJ, 1992, IN PRESS COLD SPRING, V57; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957	24	454	460	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					869	872		10.1016/0092-8674(92)90236-6	http://dx.doi.org/10.1016/0092-8674(92)90236-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525824				2022-12-28	WOS:A1992JN78100001
J	DEBOER, P; CROSSLEY, R; ROTHFIELD, L				DEBOER, P; CROSSLEY, R; ROTHFIELD, L			THE ESSENTIAL BACTERIAL CELL-DIVISION PROTEIN FTSZ IS A GTPASE	NATURE			English	Article							ESCHERICHIA-COLI; GENE-FTSZ; BACILLUS-SUBTILIS; SEPTATION; CLONING; SITE	CYTOKINESIS defines the last stage in the division cycle, in which cell constriction leads to the formation of daughter cells. The biochemical mechanisms responsible for this process are poorly understood. In bacteria, the ftsZ gene product, FtsZ, is required for cell division1-3,17, playing a prominent role in cytokinesis. The cellular concentration of FtsZ regulates the frequency of division4 and genetic studies have indicated that it is the target of several endogenous division inhibitors5. At the time of onset of septal invagination, the FtsZ protein is recruited from the cytoplasm to the division site, where it assembles into a ring that remains associated with the leading edge of the invaginating septum until septation is completed 6. Here we report that FtsZ specifically binds and hydrolyses GTP. The reaction can be dissociated into a GTP-dependent activation stage that is markedly affected by the concentration of FtsZ, and a hydrolysis stage in which GTP is hydrolysed to GDP. The results indicate that GTP binding and hydrolysis are important in enabling FtsZ to support bacterial cytokinesis, either by facilitating the assembly of the FtsZ ring and/or by catalysing an essential step in the cytokinetic process itself.			DEBOER, P (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT MICROBIOL, FARMINGTON, CT 06030 USA.			de Boer, Piet/0000-0002-5375-6317				BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BEALL B, 1988, J BACTERIOL, V170, P4855, DOI 10.1128/jb.170.10.4855-4864.1988; BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447; BI E, 1990, J BACTERIOL, V172, P5602, DOI 10.1128/jb.172.10.5602-5609.1990; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; CARLIER MF, 1989, INT REV CYTOL, V115, P139; DAI K, 1991, J BACTERIOL, V173, P3500, DOI 10.1128/jb.173.11.3500-3506.1991; DEBOER PAJ, 1990, ANNU REV GENET, V24, P249, DOI 10.1146/annurev.genet.24.1.249; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; HESSE J, 1987, J BIOL CHEM, V262, P15472; LUTKENHAUS JF, 1980, J BACTERIOL, V142, P615, DOI 10.1128/JB.142.2.615-620.1980; MARGOLIN W, 1991, J BACTERIOL, V173, P5822, DOI 10.1128/jb.173.18.5822-5830.1991; PLA J, 1991, MOL MICROBIOL, V5, P1681, DOI 10.1111/j.1365-2958.1991.tb01915.x; STERNLICHT H, 1987, FEBS LETT, V214, P226, DOI 10.1016/0014-5793(87)80061-3; WANG XD, 1991, EMBO J, V10, P3363, DOI 10.1002/j.1460-2075.1991.tb04900.x; WARD JE, 1985, CELL, V42, P941, DOI 10.1016/0092-8674(85)90290-9; YI QM, 1985, GENE, V36, P241	17	447	459	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1992	359	6392					254	256		10.1038/359254a0	http://dx.doi.org/10.1038/359254a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1528268				2022-12-28	WOS:A1992JN94400067
J	HWANG, C; SINSKEY, AJ; LODISH, HF				HWANG, C; SINSKEY, AJ; LODISH, HF			OXIDIZED REDOX STATE OF GLUTATHIONE IN THE ENDOPLASMIC-RETICULUM	SCIENCE			English	Article							PROTEIN-DISULFIDE-ISOMERASE; MICROSOMAL-MEMBRANES; RAT-LIVER; CATALYZED FORMATION; BOND FORMATION; SYSTEM; THIOL; TRANSLOCATION; RIBONUCLEASE; TRANSPORT	The redox state of the endoplasmic reticulum (ER) was measured with the peptide N-Ace-tyl-Asn-Tyr-Thr-Cys-NH2. The peptide diffused across cellular membranes; some became glycosylated and thus trapped within the secretory pathway, and its cysteine residue underwent reversible thiol-disulfide exchanges with the surrounding redox buffer. Glycosylated peptides from cells were disulfide-linked to glutathione, indicating that glutathione is the major redox buffer in the secretory pathway. The redox state of the secretory pathway was more oxidative than that of the cytosol; the ratio of reduced glutathione to the disulfide form (GSH/GSSG) within the secretory pathway ranged from 1:1 to 3:1, whereas the overall cellular GSH/GSSG ratio ranged from 30:1 to 100:1. Cytosolic glutathione was also transported into the lumen of microsomes in a cell-free system. Although how the ER maintains an oxidative environment is not known, these results suggest that the demonstrated preferential transport of GSSG compared to GSH into the ER lumen may contribute to this redox compartmentation.	MIT, WHITEHEAD INST BIOMED RES, DEPT BIOL, CAMBRIDGE, MA 02142 USA; MIT, CTR BIOTECH PROC ENGN, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)								ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; ANIYA Y, 1989, ARCH BIOCHEM BIOPHYS, V270, P330, DOI 10.1016/0003-9861(89)90035-0; BANNAI S, 1980, J CELL PHYSIOL, V104, P215, DOI 10.1002/jcp.1041040211; BISCHOFF J, 1983, J BIOL CHEM, V258, P7907; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; COTGREAVE IA, 1989, SULPHUR CONTAINING B, V2, P101; Dolphin D., 1990, GLUTATHIONE CHEM BIO, V3; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HOLMGREN A, 1968, EUR J BIOCHEM, V6, P475, DOI 10.1111/j.1432-1033.1968.tb00470.x; HWANG C, UNPUB; ISAACS J, 1977, BIOCHIM BIOPHYS ACTA, V497, P192, DOI 10.1016/0304-4165(77)90152-0; JANOLINO VG, 1987, ARCH BIOCHEM BIOPHYS, V258, P265, DOI 10.1016/0003-9861(87)90344-4; KADERBHAI MA, 1984, BIOCHEM J, V217, P145, DOI 10.1042/bj2170145; KADERBHAI MA, 1985, EUR J BIOCHEM, V153, P167, DOI 10.1111/j.1432-1033.1985.tb09283.x; KOIVU J, 1987, J BIOL CHEM, V262, P6159; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; KUROSAWA K, 1990, BIOCHEM BIOPH RES CO, V167, P367, DOI 10.1016/0006-291X(90)91774-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; NILSSON R, 1973, J CELL BIOL, V56, P762, DOI 10.1083/jcb.56.3.762; ONDARZA RN, 1989, BIOSCIENCE REP, V9, P593, DOI 10.1007/BF01119803; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PETERSEN JG, 1974, J BIOL CHEM, V249, P5633; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHEELE G, 1983, METHOD ENZYMOL, V96, P94; SCHEELE G, 1983, J BIOL CHEM, V258, P2005; Torchinsky Y, 1981, SULFUR PROTEINS; VERMEER C, 1990, BIOCHEM J, V266, P625, DOI 10.1042/bj2660625; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WETLAUFER DB, 1987, PROTEIN ENG, V1, P141, DOI 10.1093/protein/1.2.141; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	40	1599	1636	5	212	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1992	257	5076					1496	1502		10.1126/science.1523409	http://dx.doi.org/10.1126/science.1523409			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523409				2022-12-28	WOS:A1992JM57000021
J	HOLLENBERG, M; MANGANO, DT; BROWNER, WS; LONDON, MJ; TUBAU, JF; TATEO, IM				HOLLENBERG, M; MANGANO, DT; BROWNER, WS; LONDON, MJ; TUBAU, JF; TATEO, IM			PREDICTORS OF POSTOPERATIVE MYOCARDIAL-ISCHEMIA IN PATIENTS UNDERGOING NONCARDIAC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIABETES-MELLITUS; HEART-DISEASE; ANESTHESIA; FRAMINGHAM; RISK; REINFARCTION; INFARCTION; MORBIDITY; ONSET	Objective.-To identify predictors of postoperative myocardial ischemia in patients scheduled to undergo major noncardiac surgery. Design.-Historical, clinical, laboratory, and physiological data were obtained prospectively before and during surgery to identify potential univariate predictors of postoperative myocardial ischemia, which then were entered into multivariate logistic models. Continuous two-lead electrocardiograms before, during, and after surgery were used to identify episodes of myocardial ischemia. Setting.-Department of Veterans Affairs tertiary care hospital. Patients.-A consecutive sample of 474 men at high risk for or with coronary artery disease who were scheduled to undergo major noncardiac surgery (95% compliance rate). Main Outcome Measure.-Significant variables identified by multivariate logistic models that are associated with postoperative myocardial ischemia. Results.-Five major preoperative predictors of postoperative myocardial ischemia were identified: (1) left ventricular hypertrophy by electrocardiogram; (2) history of hypertension; (3) diabetes mellitus; (4) definite coronary artery disease; and (5) use of digoxin. The risk of postoperative myocardial ischemia increased progressively with the number of predictors present: in 22% of patients with no predictors, in 31% with one predictor, in 46% with two predictors, in 70% with three predictors, and in 77% with four predictors. Conclusion.-Patient subgroups who are at high risk for developing postoperative myocardial ischemia and who might benefit the most from intensive Holter monitoring in the postoperative period now can be identified preoperatively.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIA, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	HOLLENBERG, M (corresponding author), DEPT VET AFFAIRS MED CTR, 4150 CLEMENT ST 111C3, SAN FRANCISCO, CA 94121 USA.			Tice, Jeffrey/0000-0002-9857-2028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL36744] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Cox DR., 1970, ANAL BINARY DATA; DORTIMER AC, 1978, CIRCULATION, V57, P133, DOI 10.1161/01.CIR.57.1.133; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HOLLENBERG M, 1985, AM J CARDIOL, V56, P13, DOI 10.1016/0002-9149(85)90557-0; HOLLENBERG M, 1986, J AM COLL CARDIOL, V7, pA163; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8; KANNEL WB, 1980, CIRCULATION, V61, P1179, DOI 10.1161/01.CIR.61.6.1179; KANNEL WB, 1985, AM HEART J, V110, P1100, DOI 10.1016/0002-8703(85)90224-8; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; RAO TLK, 1983, ANESTHESIOLOGY, V59, P499, DOI 10.1097/00000542-198312000-00003; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; STEEN PA, 1978, JAMA-J AM MED ASSOC, V239, P2566, DOI 10.1001/jama.239.24.2566; STRAUER BE, 1985, J CARDIOVASC PHARM, V7, pS62, DOI 10.1097/00005344-198507002-00013; TARHAN S, 1972, J AMER MED ASSOC, V220, P1451, DOI 10.1001/jama.220.11.1451; VIGORITA VJ, 1980, AM J CARDIOL, V46, P535, DOI 10.1016/0002-9149(80)90500-7; WALLER BF, 1980, AM J MED, V69, P498, DOI 10.1016/S0149-2918(05)80002-5; 1979, NOMENCLATURE CRITERI, P94	25	122	129	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					205	209		10.1001/jama.268.2.205	http://dx.doi.org/10.1001/jama.268.2.205			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1535109				2022-12-28	WOS:A1992JB27900026
J	DUFFY, TP				DUFFY, TP			WHEN TO LET GO	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											DUFFY, TP (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,HEMATOL SECT,WWW4,POB 3333,NEW HAVEN,CT 06510, USA.							ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; Katz J., 1984, SILENT WORLD DOCTOR; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334	3	6	6	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					933	935		10.1056/NEJM199204023261406	http://dx.doi.org/10.1056/NEJM199204023261406			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1542343				2022-12-28	WOS:A1992HL26100006
J	ANGUIANO, A; OATES, RD; AMOS, JA; DEAN, M; GERRARD, B; STEWART, C; MAHER, TA; WHITE, MB; MILUNSKY, A				ANGUIANO, A; OATES, RD; AMOS, JA; DEAN, M; GERRARD, B; STEWART, C; MAHER, TA; WHITE, MB; MILUNSKY, A			CONGENITAL BILATERAL ABSENCE OF THE VAS-DEFERENS - A PRIMARILY GENITAL FORM OF CYSTIC-FIBROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; GRADIENT GEL-ELECTROPHORESIS; POLYMORPHIC DNA MARKER; SINGLE-BASE CHANGES; ABNORMAL DISTRIBUTION; POINT MUTATIONS; GENE; IDENTIFICATION; LOCALIZATION; MISMATCHES	Objective. - Almost all males with cystic fibrosis (CF) have absent vasa deferentia. It has been suggested that otherwise healthy males with congenital bilateral absence of the vas deferens (CBAVD), previously considered a distinct genetic entity, have an increased frequency of CF gene mutations. This study examined the genetic commonality of these two disorders. Design. -We typed six common CF gene mutations in 25 patients with CBAVD. Additional rare mutations were sought using single-stranded conformation polymorphisms and direct DNA sequencing. When rare mutations were found, they were sought in a large sample of both CF patients and obligate CF carriers to exclude them as polymorphisms. Setting. - All the patients presented to a male infertility clinic of a teaching hospital. Subjects.-Twenty-five unselected, unrelated azoospermic men with CBAVD, most of them of Northern European ancestry. Results. - Sixteen (64%) of the 25 men with CBAVD had at least one detectable CF mutation, 16 times the expected frequency (P < .001). Moreover, we have thus far determined that three of these 16 men are compound heterozygotes, one of whom has a mutation not previously described. Analyses continue on patients who have yet to yield a detectable mutation. Conclusions. - Some, if not all, otherwise healthy men with CBAVD reflect a newly recognized, primarily genital, phenotype of CF. Prior to sperm aspiration to remedy infertility, CF mutation analysis should be recommended for them and their partners, as well as for their relatives.	BOSTON UNIV, SCH MED, CTR HUMAN GENET, 80 E CONCORD ST, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT UROL, BOSTON, MA 02118 USA; BOSTON UNIV HOSP, BOSTON, MA 02218 USA; BOSTON CITY HOSP, BOSTON, MA 02118 USA; NCI, VIRAL CARCINOGENESIS LAB, BETHESDA, MD 20892 USA; PROGRAM RESOURCES INC, FREDERICK CANC RES & DEV CTR, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD USA	Boston University; Boston University; Boston University; Boston University; Boston University; Boston Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; Oates, Robert/0000-0003-2330-6697; Milunsky, Aubrey/0000-0003-2114-4823; Maher, Thomas/0000-0002-6083-9487	NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMOS JA, 1984, BIOCHIM BIOPHYS ACTA, V782, P247, DOI 10.1016/0167-4781(84)90059-9; BURGER J, 1991, LANCET, V337, P974, DOI 10.1016/0140-6736(91)91603-R; CAMPBELL MF, 1970, UROLOGY, V2, P1573; CHARNY CW, 1965, J UROLOGY, V93, P399, DOI 10.1016/S0022-5347(17)63787-X; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; DAVIES K, 1990, NATURE, V348, P110, DOI 10.1038/348110a0; DEAN M, 1991, BIOTECHNIQUES, V10, P332; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DEAN M, 1991, ADV EXP MED BIOL, V290, P45; DENNING CR, 1968, PEDIATRICS, V41, P7; di Sant'Agnese P A, 1968, N Engl J Med, V279, P103, DOI 10.1056/NEJM196807112790213; DUMUR V, 1990, LANCET, V336, P512, DOI 10.1016/0140-6736(90)92066-Q; DUMUR V, 1990, LANCET, V335, P1340, DOI 10.1016/0140-6736(90)91216-W; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HOLSCLAW DS, 1971, J UROLOGY, V106, P568, DOI 10.1016/S0022-5347(17)61343-0; KAPLAN E, 1968, NEW ENGL J MED, V279, P65, DOI 10.1056/NEJM196807112790203; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM BS, 1989, AM J HUM GENET, V44, P827; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KLECZKOWSKA A, 1989, CLIN GENET, V35, P268; KNOWLTON RG, 1985, NATURE, V318, P380, DOI 10.1038/318380a0; LAROCHE D, 1991, LANCET, V337, P55, DOI 10.1016/0140-6736(91)93377-L; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; LUCOTTE G, 1991, LANCET, V337, P988, DOI 10.1016/0140-6736(91)91634-7; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NELSON RE, 1950, J UROLOGY, V63, P176, DOI 10.1016/S0022-5347(17)68750-0; NG ISL, 1991, HUM GENET, V87, P613; OLSON JR, 1969, J CLIN PATHOL, V22, P725, DOI 10.1136/jcp.22.6.725; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSBORNE L, 1991, AM J HUM GENET, V48, P608; PETIT P, 1983, HUM GENET, V64, P303, DOI 10.1007/BF00279418; RIGOT JM, 1991, NEW ENGL J MED, V325, P64; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS J, 1990, AM J HUM GENET, V46, P395; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHELLEN TMCM, 1980, FERTIL STERIL, V34, P401; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SILBER SJ, 1990, NEW ENGL J MED, V323, P1788, DOI 10.1056/NEJM199012273232602; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TSUI LC, 1985, SCIENCE, V230, P1054, DOI 10.1126/science.2997931; VIDAUD M, 1990, HUM GENET, V85, P446, DOI 10.1007/BF02428305; WAINWRIGHT BJ, 1985, NATURE, V318, P384, DOI 10.1038/318384a0; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	54	428	434	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1794	1797		10.1001/jama.267.13.1794	http://dx.doi.org/10.1001/jama.267.13.1794			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545465				2022-12-28	WOS:A1992HK67200029
J	DAVIDSON, NE				DAVIDSON, NE			TAMOXIFEN - PANACEA OR PANDORA BOX	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BREAST-CANCER; ADJUVANT				DAVIDSON, NE (corresponding author), JOHNS HOPKINS UNIV HOSP,CTR ONCOL,BALTIMORE,MD 21205, USA.							Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FORNANDER T, 1989, LANCET, V1, P117; JORDAN VC, 1987, CANCER RES, V47, P624; JORDAN VC, 1991, J NATL CANCER I, V83, P1488, DOI 10.1093/jnci/83.20.1488; LOVE RR, 1991, ARCH INTERN MED, V151, P1842, DOI 10.1001/archinte.151.9.1842; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; SAPHNER T, 1991, J CLIN ONCOL, V9, P286, DOI 10.1200/JCO.1991.9.2.286; 1992, LANCET, V339, P71	11	36	36	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1992	326	13					885	886		10.1056/NEJM199203263261308	http://dx.doi.org/10.1056/NEJM199203263261308			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK523	1542327				2022-12-28	WOS:A1992HK52300008
J	GHOSH, A; SHATZ, CJ				GHOSH, A; SHATZ, CJ			INVOLVEMENT OF SUBPLATE NEURONS IN THE FORMATION OF OCULAR DOMINANCE COLUMNS	SCIENCE			English	Article							CAT VISUAL-CORTEX; EARLY POSTNATAL-DEVELOPMENT; LONG-TERM POTENTIATION; NMDA RECEPTORS; CORTICAL PLASTICITY; BLOCKADE PREVENTS; CEREBRAL-CORTEX; STRIATE CORTEX; CELLS; AFFERENTS	During development of the mammalian visual system, axon terminals of lateral geniculate nucleus (LGN) neurons, initially intermixed within layer 4 of the visual cortex, gradually segregate according to eye preference to form ocular dominance columns. In addition to LGN axons and layer 4 neurons, subplate neurons may also participate in interactions leading to column formation. Deletion of subplate neurons before the formation of ocular dominance columns prevents the segregation of LGN axons within layer 4. Thus, interactions between LGN axons and layer 4 neurons are not sufficient; subplate neurons are also required for formation of ocular dominance columns in the visual cortex.	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University					NATIONAL EYE INSTITUTE [R37EY002858, R01EY002858] Funding Source: NIH RePORTER; NEI NIH HHS [EY02858] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON PA, 1988, J NEUROSCI, V8, P2183; ANTONINI A, 1990, EUR J NEUROSCI, V2, P744, DOI 10.1111/j.1460-9568.1990.tb00465.x; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BEAR MF, 1990, J NEUROSCI, V10, P909; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; CAMPOCHIARO P, 1978, P NATL ACAD SCI USA, V75, P2025, DOI 10.1073/pnas.75.4.2025; CHUN JJM, 1989, J NEUROSCI, V9, P1648; CHUN JJM, 1988, J CELL BIOL, V106, P857, DOI 10.1083/jcb.106.3.857; CHUN JJM, 1989, J COMP NEUROL, V282, P555, DOI 10.1002/cne.902820407; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; FOX K, 1989, J NEUROSCI, V9, P2443; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; FRIAUF E, 1990, J NEUROSCI, V10, P2601; FRIAUF E, 1991, J NEUROPHYSIOL, V66, P2059, DOI 10.1152/jn.1991.66.6.2059; GHOSH A, 1992, J NEUROSCI, V12, P39; Ghosh A., UNPUB; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; MULLER CM, 1989, NATURE, V342, P427, DOI 10.1038/342427a0; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; REITER HO, 1986, EXP BRAIN RES, V65, P182; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; SHATZ CJ, 1977, BRAIN RES, V131, P103, DOI 10.1016/0006-8993(77)90031-2; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHATZ CJ, 1986, J NEUROSCI, V6, P3655; STRYKER MP, 1986, J NEUROSCI, V6, P2117; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0; VALVERDE F, 1987, DEV BRAIN RES, V32, P283, DOI 10.1016/0165-3806(87)90108-8; WAHLE P, 1987, J COMP NEUROL, V261, P165, DOI 10.1002/cne.902610202; WIESEL TN, 1974, BRAIN RES, V79, P273, DOI 10.1016/0006-8993(74)90416-8	33	204	205	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1441	1443		10.1126/science.1542795	http://dx.doi.org/10.1126/science.1542795			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542795				2022-12-28	WOS:A1992HH74400059
J	TLSTY, TD; WHITE, A; SANCHEZ, J				TLSTY, TD; WHITE, A; SANCHEZ, J			SUPPRESSION OF GENE AMPLIFICATION IN HUMAN CELL HYBRIDS	SCIENCE			English	Article							OUABAIN-RESISTANT; HELA-CELLS; EXPRESSION; TUMORIGENICITY; CHROMOSOME-11; MALIGNANCY; LINES	Gene amplification, one example of genetic instability, is of prognostic and clinical importance in neoplasia. In tumorigenic cells, gene amplification occurs at a very high frequency, whereas in normal diploid fibroblasts the event is undetectable by the clonogenic assay. To investigate genetic control of gene amplification, amplification frequency was measured in hybrids of tumorigenic cells and normal diploid cells. The ability to amplify an endogenous gene behaved as a recessive genetic trait, and control of gene amplification potential segregated independently of tumorigenicity and immortality.			TLSTY, TD (corresponding author), UNIV N CAROLINA,SCH MED,DEPT PATHOL & CURRICULUM GENET,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599, USA.							BENEDICT WF, 1984, CANCER RES, V44, P3471; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOYD JA, 1990, PHARMACOL THERAPEUT, V46, P469, DOI 10.1016/0163-7258(90)90028-Z; CHEN P, 1990, CARCINOGENESIS D, P13; DER CJ, 1978, CELL, V15, P1241, DOI 10.1016/0092-8674(78)90050-8; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1982, ONCODEV BIOL MED, V4, P161; FOULDS L, 1975, NEOPLASTIC DEV, V2; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; NICHOLSON GL, 1987, CANCER RES, V47, P1473; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OTTO E, 1989, J BIOL CHEM, V264, P3390; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; POSTE G, 1986, CANCER TREAT REP, V70, P183; ROBBINS AR, 1977, BIOCHEMISTRY-US, V16, P5163, DOI 10.1021/bi00642a600; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SRIVATSAN ES, 1986, CANCER RES, V46, P6174; STANBRIDGE EJ, 1978, P NATL ACAD SCI USA, V75, P1466, DOI 10.1073/pnas.75.3.1466; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; STARK GR, 1984, ANN REV BIOCH, V37, P705; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TLSTY TD, UNPUB; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WEISSMAN B, 1980, CYTOGENET CELL GENET, V28, P227, DOI 10.1159/000131536; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791	28	71	72	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1425	1427		10.1126/science.1542791	http://dx.doi.org/10.1126/science.1542791			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542791				2022-12-28	WOS:A1992HH74400053
J	MAHADEVAN, M; TSILFIDIS, C; SABOURIN, L; SHUTLER, G; AMEMIYA, C; JANSEN, G; NEVILLE, C; NARANG, M; BARCELO, J; OHOY, K; LEBLOND, S; EARLEMACDONALD, J; DEJONG, PJ; WIERINGA, B; KORNELUK, RG				MAHADEVAN, M; TSILFIDIS, C; SABOURIN, L; SHUTLER, G; AMEMIYA, C; JANSEN, G; NEVILLE, C; NARANG, M; BARCELO, J; OHOY, K; LEBLOND, S; EARLEMACDONALD, J; DEJONG, PJ; WIERINGA, B; KORNELUK, RG			MYOTONIC-DYSTROPHY MUTATION - AN UNSTABLE CTG REPEAT IN THE 3' UNTRANSLATED REGION OF THE GENE	SCIENCE			English	Article								Myotonic dystrophy (DM) is the most common inherited neuromuscular disease in adults, with a global incidence of 1 in 8000 individuals. DM is an autosomal dominant, multisystemic disorder characterized primarily by myotonia and progressive muscle weakness. Genomic and complementary DNA probes that map to a 10-kilobase Eco RI genomic fragment from human chromosome 19q13.3 have been used to detect a variable length polymorphism in individuals with DM. Increases in the size of the allele in patients with DM are now shown to be due to an increased number of trinucleotide CTG repeats in the 3' untranslated region of a DM candidate gene. An increase in the severity of the disease in successive generations (genetic anticipation) is accompanied by an increase in the number of trinucleotide repeats. Nearly all cases of DM (98 percent or 253 of 258 individuals) displayed expansion of the CTG repeat region. These results suggest that DM is primarily caused by mutations that generate an amplification of a specific CTG repeat.	UNIV OTTAWA,DEPT MICROBIOL & IMMUNOL,OTTAWA K1H 8L1,ONTARIO,CANADA; CHILDRENS HOSP EASTERN ONTARIO,RES INST,OTTAWA K1H 8L1,ONTARIO,CANADA; UNIV CALIF LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550; CATHOLIC UNIV NIJMEGEN,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,DEPT CELL BIOL & HISTOL,6500 HB NIJMEGEN,NETHERLANDS	University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Radboud University Nijmegen; Radboud University Nijmegen			Jansen, Gert/HCI-8852-2022; Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020; Jansen, Gert/0000-0002-7524-171X				ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; Harper P.S., 1989, MYOTONIC DYSTROPHY; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; JANSEN G, UNPUB; JANSEN G, IN PRESS GENOMICS; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PENROSE LS, 1948, ANN EUGENIC, V14, P125; SHUTLER G, IN PRESS GENOMICS; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	15	1414	1455	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1253	1255		10.1126/science.1546325	http://dx.doi.org/10.1126/science.1546325			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546325				2022-12-28	WOS:A1992HG67700042
J	KAPLAN, LJ; DAUM, RS; SMARON, M; MCCARTHY, CA				KAPLAN, LJ; DAUM, RS; SMARON, M; MCCARTHY, CA			SEVERE MEASLES IN IMMUNOCOMPROMISED PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN IMMUNODEFICIENCY VIRUS; INCLUSION-BODY ENCEPHALITIS; LIVE ATTENUATED MEASLES; GIANT-CELL PNEUMONIA; MALIGNANT DISEASE; CHILDREN; ENCEPHALOPATHY; IMMUNOSUPPRESSION; TRANSPLANT	Objectives.-To describe the severity of measles in immunocompromised. hosts and to assess preventive and therapeutic modalities. Data.-Patients admitted to two academic medical centers between September 1989 and December 1990 and English language references obtained by MEDLINE from 1963 to 1991. Bibliographies were used to identify reports prior to 1963. Study Selection.-We identified nine immunocompromised patients with measles. Further analysis was based on 35 patients from two cohort studies of measles in oncology patients and 24 reported cases of measles in human immunodeficiency virus (HIV)-infected patients. Data Extraction.-Clinical data are presented from the nine patients we treated. Information concerning measles complications, presence of rash, use of prophylactic immunoglobulin, and therapeutic measures was extracted from the literature. Data Synthesis.-Of our nine patients, eight developed severe complications and two died. Two patients had no rash. In combining our patients with those from the literature, severe complications occurred in about 80%. The case fatality rate for severe measles was about 70% for oncology patients and about 40% for HIV-infected patients. Rash was absent in about 30%. The efficacy of prophylactic or therapeutic measures could not be assessed due to the small number of patients. However, we observed a rapid defervescence following administration of ribavirin. Vaccinated, HIV-infected patients had a lower mortality rate than those not previously vaccinated (P = .06). Conclusions.-Measles is a severe illness in immunocompromised patients, and the absence of rash is frequent. While treatment is supportive, ribavirin requires further study. Measles vaccine may be efficacious in HIV-infected patients. Vaccination of oncology patients should be reassessed.	UNIV CHICAGO HOSP & CLIN, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO HOSP & CLIN, DEPT PEDIAT, CHICAGO, IL 60637 USA; UNIV CHICAGO HOSP & CLIN, CLIN MICROBIOL LAB, CHICAGO, IL 60637 USA	University of Chicago; University of Illinois System; University of Chicago; University of Illinois System; University of Chicago; University of Illinois System								AGAMANOLIS DP, 1979, ARCH NEUROL-CHICAGO, V36, P686, DOI 10.1001/archneur.1979.00500470056011; AICARDI J, 1977, PEDIATRICS, V59, P232; AKHTAR M, 1973, ARCH PATHOL, V96, P145; Banks G, 1984, CLIN APPLICATIONS RI, P203; BARAM TZ, 1987, PEDIATR NEUROSCI, V13, P52, DOI 10.1159/000120301; BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547; BLAND JD, 1982, BRIT MED J, V284, P82, DOI 10.1136/bmj.284.6309.82; BREITFELD V, 1973, LAB INVEST, V28, P279; CAMPBELL RHA, 1977, ARCH DIS CHILD, V52, P850, DOI 10.1136/adc.52.11.850; CHIEN LT, 1983, CLIN ELECTROENCEPHAL, V14, P214, DOI 10.1177/155005948301400405; COLAMARIA V, 1989, BRAIN DEV-JPN, V11, P322, DOI 10.1016/S0387-7604(89)80061-0; DRYSDALE HC, 1976, J CLIN PATHOL, V29, P865, DOI 10.1136/jcp.29.10.865; ENDERS JF, 1959, NEW ENGL J MED, V261, P875, DOI 10.1056/NEJM195910292611801; GRAHAM DG, 1983, J CLIN LAB IMMUNOL, V10, P117; GRAY MM, 1987, BRIT MED J, V295, P19, DOI 10.1136/bmj.295.6589.19; HALTIA M, 1977, J NEUROL SCI, V32, P323, DOI 10.1016/0022-510X(77)90015-6; HERVAS JA, 1990, PEDIATR INFECT DIS J, V9, P529, DOI 10.1097/00006454-199007000-00022; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; JOLIAT G, 1973, VIRCHOWS ARCH A, V358, P215, DOI 10.1007/BF00543229; JONES HE, 1969, LANCET, V2, P1255; KAY HEM, 1984, LANCET, V1, P901; KERNAHAN J, 1987, BRIT MED J, V295, P15, DOI 10.1136/bmj.295.6589.15; KRASINSKI K, 1989, JAMA-J AM MED ASSOC, V261, P2512, DOI 10.1001/jama.261.17.2512; LEWIS MJ, 1978, BRIT MED J, V1, P330, DOI 10.1136/bmj.1.6109.330; LIPSEY AI, 1967, PEDIATRICS, V39, P659; LJUNGMAN P, 1989, J INFECT DIS, V159, P610, DOI 10.1093/infdis/159.4.610; MARKOWITZ LE, 1988, J INFECT DIS, V158, P481, DOI 10.1093/infdis/158.2.480; MCLAUGHLIN M, 1988, PEDIATRICS, V82, P229; MEADOW SR, 1969, LANCET, V2, P876; MELLOR DH, 1976, NEUROPADIATRIE, V7, P423, DOI 10.1055/s-0028-1091642; MITUS A, 1959, NEW ENGL J MED, V261, P882, DOI 10.1056/NEJM195910292611802; MITUS A, 1962, AM J DIS CHILD, V103, P413, DOI 10.1001/archpedi.1962.02080020425051; MURPHY JV, 1976, J PEDIATR-US, V88, P937, DOI 10.1016/S0022-3476(76)81045-1; NINANE J, 1981, ARCH DIS CHILD, V56, P841, DOI 10.1136/adc.56.11.841; OLDINGSTENKVIST E, 1982, SCAND J INFECT DIS, V14, P1; PEARL PL, 1990, PEDIATR NEUROL, V6, P126, DOI 10.1016/0887-8994(90)90046-4; PEDERSEN FK, 1978, ACTA PAEDIATR SCAND, V67, P109, DOI 10.1111/j.1651-2227.1978.tb16286.x; PREBLUD SR, 1988, VACCINES, P182; PULLAN CR, 1976, BRIT MED J, V1, P1562, DOI 10.1136/bmj.1.6025.1562; ROOS RP, 1981, NEUROLOGY, V31, P1263, DOI 10.1212/WNL.31.10.1263; ROSS LA, 1990, AM J MED, V88, P313, DOI 10.1016/0002-9343(90)90162-7; SENSION MG, 1988, AM J DIS CHILD, V142, P1271, DOI 10.1001/archpedi.1988.02150120025021; SIEGEL C, 1990, AM J CLIN PATHOL, V94, P464, DOI 10.1093/ajcp/94.4.464; SIEGEL MM, 1977, PEDIATRICS, V60, P38; SILVESTRI F, 1979, TUMORI, V65, P459, DOI 10.1177/030089167906500406; SIMPSON R, 1984, SCAND J INFECT DIS, V16, P315, DOI 10.3109/00365548409070407; Sluga E, 1975, Acta Neuropathol Suppl, VSuppl 6, P267; SMARON MF, 1991, J VIROL METHODS, V33, P223, DOI 10.1016/0166-0934(91)90022-R; SMYTH D, 1976, LANCET, V2, P574; SPALKE G, 1979, J NEUROL, V220, P269, DOI 10.1007/BF00314151; TOKUNAGA O, 1980, ACTA PATHOL JAPON, V30, P483; TORIGOE S, 1981, BIKEN J, V24, P147; WOLINSKY JS, 1977, ANN NEUROL, V1, P452, DOI 10.1002/ana.410010508; 1990, MMWR, V39, P317; 1991, REPORT COMMITTEE INF, P308; 1988, MMWR, V37, P183; 1990, MMWR, V39, P325; 1989, MMWR, V38, P1	58	225	232	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1237	1241		10.1001/jama.267.9.1237	http://dx.doi.org/10.1001/jama.267.9.1237			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1538561				2022-12-28	WOS:A1992HF43900026
J	SALT, A; NOBLEJAMIESON, G; BARNES, ND; MOWAT, AP; ROLLES, K; JAMIESON, N; JOHNSTON, P; FRIEND, P; CALNE, RY				SALT, A; NOBLEJAMIESON, G; BARNES, ND; MOWAT, AP; ROLLES, K; JAMIESON, N; JOHNSTON, P; FRIEND, P; CALNE, RY			LIVER-TRANSPLANTATION IN 100 CHILDREN - CAMBRIDGE AND KINGS-COLLEGE-HOSPITAL SERIES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CYTOMEGALO-VIRUS DISEASE; BILIARY ATRESIA; EXPERIENCE; REJECTION; GRAFT; THROMBOSIS; DEFICIENCY; SURGERY; KIDNEY; DONOR	Objective - To review the results of the Addenbrooke's and King's College Hospital children's liver transplantation programme. Design - Retrospective analysis of the first 100 children to receive liver grafts at Addenbrooke's Hospital, Cambridge, from December 1983 to March 1990. Setting - Addenbrooke's Hospital, Cambridge, and King's College Hospital, London. Subjects - 153 children assessed for liver transplantation, of whom 22 died before a donor became available and 31 were considered unsuitable. 100 children received grafts, of whom 27 had second grafts. Results - One year actuarial patient survival was 71%, with 57% one year graft survival. In the last two years survival rates had improved considerably, with 86% of patients and 63% of grafts surviving for at least one year. Sixty five children were alive 12 to 86 months after transplantation; 63 were well and leading normal active lives and 56 had entirely normal liver function. Children's growth and development were essentially normal, with many showing remarkable catch up growth. Conclusions - Liver transplantation offers children with terminal liver disease a high chance of a return to full quality life and normal development. Improved surgical and medical care have progressively improved survival. The timing of transplantation is critical but has been constrained particularly by the availability of donors and resources.	ADDENBROOKES HOSP, DEPT PAEDIAT, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV LONDON KINGS COLL HOSP, PAEDIAT HEPATOL, LONDON SE5 8RX, ENGLAND; ADDENBROOKES HOSP, DEPT SURG, CAMBRIDGE CB2 2QQ, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Friend, Peter/AAH-6512-2019					ANDREWS WS, 1989, J PEDIATR SURG, V24, P77, DOI 10.1016/S0022-3468(89)80306-9; BISMUTH H, 1984, SURGERY, V95, P367; BROELSCH CE, 1988, TRANSPLANTATION, V45, P519, DOI 10.1097/00007890-198803000-00003; CALNE R, 1987, LIVER TRANSPLANTATIO; CALNE RY, 1976, ANN SURG, V184, P605, DOI 10.1097/00000658-197611000-00012; COULDEN RA, 1990, LANCET, V336, P273, DOI 10.1016/0140-6736(90)91804-J; DEHEMPTINNE B, 1987, TRANSPLANT P, V19, P3317; FOEGH ML, 1990, TRANSPL P, V22, P119; GARTNER JC, 1984, PEDIATRICS, V74, P140; HARPER PL, 1988, LANCET, V2, P924; HUBSCHER SG, 1991, TRANSPL P, V23, P1415; KALAYOGLU M, 1989, J PEDIATR SURG, V24, P70, DOI 10.1016/S0022-3468(89)80305-7; MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011; MCDONALD JA, 1989, TRANSPLANT P, V21, P3792; MIELIVERGANI G, 1989, LANCET, V1, P421; NOBLEJAMIESON G, 1990, ARCH DIS CHILD, V65, P1217, DOI 10.1136/adc.65.11.1217; OGUMA S, 1989, HEPATOLOGY, V9, P204, DOI 10.1002/hep.1840090207; OHI R, 1990, J PEDIATR SURG, V25, P442, DOI 10.1016/0022-3468(90)90390-U; OTTE JB, 1987, TRANSPLANT P, V19, P3289; PETT S, 1987, TRANSPLANT P, V19, P3256; ROLLES K, 1984, HEPATOLOGY, V4, pS50, DOI 10.1002/hep.1840040715; SALMELA K, 1990, TRANSPLANT P, V22, P238; SALT A, 1990, J CLIN PATHOL, V43, P63, DOI 10.1136/jcp.43.1.63; SAMUEL D, 1989, TRANSPLANT P, V21, P2225; SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703; SOKAL EM, 1990, J PEDIATR-US, V117, P205, DOI 10.1016/S0022-3476(05)80531-1; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, 1979, PEDIATRICS, V63, P825; STARZL TE, 1968, ANN SURG, V168, P392, DOI 10.1097/00000658-196809000-00009; STRATTA RJ, 1989, ARCH SURG-CHICAGO, V124, P1443; WEIMAR W, 1990, TRANSPLANT P, V22, P229; 1984, HEPATOLOGY S, V4, P107	32	57	57	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 15	1992	304	6824					416	421		10.1136/bmj.304.6824.416	http://dx.doi.org/10.1136/bmj.304.6824.416			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1547389	Green Published, Bronze			2022-12-28	WOS:A1992HE38900019
J	ROBINSON, DS; HAMID, Q; YING, S; TSICOPOULOS, A; BARKANS, J; BENTLEY, AM; CORRIGAN, C; DURHAM, SR; KAY, AB				ROBINSON, DS; HAMID, Q; YING, S; TSICOPOULOS, A; BARKANS, J; BENTLEY, AM; CORRIGAN, C; DURHAM, SR; KAY, AB			PREDOMINANT TH2-LIKE BRONCHOALVEOLAR LYMPHOCYTE-T POPULATION IN ATOPIC ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN EOSINOPHILS; PULMONARY SARCOIDOSIS; HUMAN INTERLEUKIN-5; BRONCHIAL BIOPSIES; IMMUNE REGULATION; CELL CLONE; TH2 CLONES; IFN-GAMMA; RELEASE; RNA	Background. In atopic asthma, activated T helper lymphocytes are present in bronchial-biopsy specimens and bronchoalveolar-lavage (BAL) fluid, and their production of cytokines may be important in the pathogenesis of this disorder. Different patterns of cytokine release are characteristic of certain subgroups of T helper cells, termed T(H1) and T(H2), the former mediating delayed-type hypersensitivity and the latter mediating IgE synthesis and eosinophilia. The pattern of cytokine production in atopic asthma is unknown. Methods. We assessed cells obtained by BAL in subjects with mild atopic asthma and in normal control subjects for the expression of messenger RNA (mRNA) for interleukin-2, 3, 4, and 5, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon gamma by in situ hybridization with P-32-labeled complementary RNA. Localization of mRNA to BAL T cells was assessed by simultaneous in situ hybridization and immunofluorescence and by in situ hybridization after immunomagnetic enrichment or depletion of T cells. Results. As compared with the control subjects, the subjects with asthma had more BAL cells per 1000 cells that were positive for mRNA for interleukin-2 (P < 0.05), 3 (P < 0.01), 4 (P < 0.001), and 5 (P < 0.001) and GM-CSF (P < 0.001). There was no significant difference between the two groups in the number of cells expressing mRNA for interferon gamma. In the subjects with asthma, mRNA for interleukin-4 and 5 was expressed predominantly by T lymphocytes. Conclusions. Atopic asthma is associated with activation in the bronchi of the interleukin-3, 4, and 5 and GM-CSF gene cluster, a pattern compatible with predominant activation of the T(H2)-like T-cell population.	NATL HEART & LUNG INST,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND	Imperial College London			Tsicopoulos, Anne/C-2260-2019	Tsicopoulos, Anne/0000-0002-1579-2763; Bentley, Andrew/0000-0002-6883-9246; Corrigan, Chris/0000-0002-0706-6534				AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BEVERLEY PCL, 1990, IMMUNOL TODAY, V11, P203, DOI 10.1016/0167-5699(90)90083-L; BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; CHANG TL, 1990, J IMMUNOL, V145, P2803; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; CORRIGAN CJ, 1988, LANCET, V1, P1129; DELPOZO V, 1990, J IMMUNOL, V144, P3117; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FONG TAT, 1989, J IMMUNOL, V143, P2887; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; GIAID A, 1989, HISTOCHEMISTRY, V93, P191, DOI 10.1007/BF00315974; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; HOWELL CJ, 1989, AM REV RESPIR DIS, V140, P1340, DOI 10.1164/ajrccm/140.5.1340; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LEA T, 1985, SCAND J IMMUNOL, V22, P207, DOI 10.1111/j.1365-3083.1985.tb01873.x; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; ROBINSON BWS, 1985, J CLIN INVEST, V75, P1488, DOI 10.1172/JCI111852; ROBINSON DS, 1991, 3RD INT C BRONCH LAV; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SALTINI C, 1986, J CLIN INVEST, V77, P1962, DOI 10.1172/JCI112525; STREET NE, 1990, J IMMUNOL, V144, P1629; SWAIN SL, 1990, J IMMUNOL, V145, P3796; WALKER C, 1991, J IMMUNOL, V146, P1829; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673	38	2526	2606	3	150	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					298	304		10.1056/NEJM199201303260504	http://dx.doi.org/10.1056/NEJM199201303260504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1530827				2022-12-28	WOS:A1992HA99100004
J	KEELER, EB; RUBENSTEIN, LV; KAHN, KL; DRAPER, D; HARRISON, ER; MCGINTY, MJ; ROGERS, WH; BROOK, RH				KEELER, EB; RUBENSTEIN, LV; KAHN, KL; DRAPER, D; HARRISON, ER; MCGINTY, MJ; ROGERS, WH; BROOK, RH			HOSPITAL CHARACTERISTICS AND QUALITY OF CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE PAYMENT SYSTEM; MORTALITY-RATES; IMPLEMENTATION; SEVERITY; ILLNESS	Objective.-To compare quality of care measured by explicit criteria, implicit review, and sickness-adjusted outcomes at different types of hospitals. Design.-Further analysis of data retrospectively abstracted from medical records to evaluate the effects of prospective payment on quality of care for hospitalized Medicare patients. Setting.-Hospitals in five states were sampled to represent the national Medicare admissions along many dimensions. Patients.-A total of 14 008 elderly patients with one of the following five diseases: congestive heart failure, acute myocardial infarction, pneumonia, stroke, or hip fracture. These patients were randomly sampled from those with these diseases in 297 hospitals in two time periods, 1981 to 1982 and 1985 to 1986. Outcome Measures.-Explicit criteria, implicit review, and mortality within 30 days of admission adjusted for sickness at admission. Results.-Quality of care ratings for hospital types are similar using explicit criteria, implicit review, and outcomes adjusted for sickness at admission. Quality differences between types of hospitals were large, with the lowest group estimated to have four percentage points higher mortality than major teaching hospitals in a cohort of patients with average mortality of 16%. Quality varies from state to state, but teaching, larger, and more urban hospitals have better quality in general than nonteaching, small, and rural hospitals. Hospital quality persists overtime, but small nonteaching hospitals narrowed the gap with better quality hospitals between 1981 and 1986. Conclusions.-The different measures led to consistent and plausible relationships between quality and hospital characteristics. Thus, valid information about hospital quality can be obtained. We need to develop ways to use such information to improve care.	SEPULVEDA VET AFFAIRS HOSP,SEPULVEDA,CA; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT HLTH SERV,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MATH,LOS ANGELES,CA 90024; CALIF ASSOC PUBLIC HOSP,BERKELEY,CA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	KEELER, EB (corresponding author), RAND CORP,HLTH PROGRAM,SANTA MONICA,CA 90406, USA.		Kahn, Katherine/AAE-2857-2020	Kahn, Katherine/0000-0002-6605-1455	AHRQ HHS [1 R01-HSO-6546] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		CLARK LA, 1991, STATISTICAL MODELS S; DRAPER D, 1990, JAMA-J AM MED ASSOC, V264, P1956, DOI 10.1001/jama.264.15.1956; Ermann D A, 1990, Med Care Rev, V47, P33, DOI 10.1177/107755879004700104; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; IEZZONI LI, 1990, JAMA-J AM MED ASSOC, V264, P1426, DOI 10.1001/jama.264.11.1426; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1953, DOI 10.1001/jama.264.15.1953; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KAHN KL, 1988, RAND N2798HCFA PUBL; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; Kelly J V, 1990, Int J Technol Assess Health Care, V6, P239; KOSECOFF J, 1988, RAND N2799HCFA PUBL; LUFT HS, 1990, HOSPITAL VOLUME PHYS; NIGHTINGALE F, 1863, NOTES NURSING ENLARG; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; RICHARDS T, 1988, MED CARE S, V26, P1; ROTH CP, 1988, RAND N2801HCFA PUBL; RUBENSTEIN LV, 1990, JAMA-J AM MED ASSOC, V264, P1974, DOI 10.1001/jama.264.15.1974; RUBENSTEIN LV, 1988, RAND N2802HCFA PUBL; Scheffe H, 1959, ANAL VARIANCE; SHERWOOD MJ, 1988, RAND N2800HCFA PUBL; SHORTELL SM, 1988, NEW ENGL J MED, V318, P1100, DOI 10.1056/NEJM198804283181705; 1990, MED HLTH, V44, P2	24	307	308	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1709	1714		10.1001/jama.268.13.1709	http://dx.doi.org/10.1001/jama.268.13.1709			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1527880				2022-12-28	WOS:A1992JQ37600033
J	DERAY, G; BENHMIDA, M; LEHOANG, P; MAKSUD, P; AUPETIT, B; BAUMELOU, A; JACOBS, C				DERAY, G; BENHMIDA, M; LEHOANG, P; MAKSUD, P; AUPETIT, B; BAUMELOU, A; JACOBS, C			RENAL-FUNCTION AND BLOOD-PRESSURE IN PATIENTS RECEIVING LONG-TERM, LOW-DOSE CYCLOSPORINE THERAPY FOR IDIOPATHIC AUTOIMMUNE UVEITIS	ANNALS OF INTERNAL MEDICINE			English	Article						CYCLOSPORINE; UVEITIS; AUTOIMMUNE DISEASES; KIDNEY DISEASES; HYPERTENSION	GLOMERULAR-FILTRATION RATE; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; INTERSTITIAL NEPHRITIS; TRANSPLANT RECIPIENTS; ANTERIOR UVEITIS; CONTROLLED TRIAL; HYPERTENSION; PLACEBO; NEPHROTOXICITY	Objective: To determine the renal side effects of long-term, low-dose cyclosporine therapy (initial dose, 5 mg/kg body weight per day) in patients with autoimmune idiopathic uveitis. Design: Cohort study with at least 2 years of follow-up. Setting: A teaching hospital in Paris, France (Hospital Pitie-Salpetriere). Patients: Sixteen patients with idiopathic autoimmune uveitis who were normotensive and had normal renal function before treatment. Cyclosporine was administered orally for at least 2 years at an initial dosage of 5 mg/kg body weight per day. Results: After 2 years of treatment, the serum creatinine level increased by 35 +/- 5 mumol/L (0.40 +/- 0.06 mg/dL) (95% Cl, 25 to 46 mumol/L, [73 +/- 4 to 108 +/- 4 mumol/L]). Creatinine clearance decreased significantly from 120 +/- 5 mL/min to 75 +/- 4 mL/min. Glomerular filtration rate decreased from 116 +/- 8 mL/min to 75 +/- 3 mL/min, and effective renal plasma flow decreased from 455 +/- 24 mL/min to 338 +/- 30 mL/min (P < 0.05). Cyclosporine induced a significant increase in serum uric acid, total cholesterol, and serum potassium levels. Blood pressure was normal in all patients before treatment; 81% (95% Cl, 64% to 98%) of these patients developed hypertension after 24 months of treatment. Blood pressure was controlled with a single drug in all but two patients. Conclusions: In patients with healthy native kidneys, long-term cyclosporine therapy, even at a low dose (5 mg/kg per day), is nephrotoxic and is associated with a high incidence of hypertension.			DERAY, G (corresponding author), HOP PITIE, SERV NEPHROL, 83 BLVD HOP, F-75013 PARIS, FRANCE.			Ben Hmida, Mohamed/0000-0002-0997-6136				BENNETT WM, 1988, AM J MED, V85, P131, DOI 10.1016/S0002-9343(88)80330-9; BRYNSKOV J, 1989, NEW ENGL J MED, V321, P845, DOI 10.1056/NEJM198909283211301; COHEN SL, 1989, NEPHROL DIAL TRANSPL, V4, P201, DOI 10.1093/oxfordjournals.ndt.a091856; CURTIS JJ, 1988, AM J MED, V85, P134; DERAY G, 1988, EUR J CLIN PHARMACOL, V34, P601, DOI 10.1007/BF00615224; DERAY G, 1987, LANCET, V1, P158; DERAY G, 1989, CLIN NEPHROL, V32, P47; DIETERLE A, 1988, TRANSPLANT P, V20, P349; DOBRIN RS, 1975, AM J MED, V59, P325, DOI 10.1016/0002-9343(75)90390-3; DOUGADOS M, 1988, ANN RHEUM DIS, V47, P127, DOI 10.1136/ard.47.2.127; GAFTER U, 1986, NEPHRON, V42, P249, DOI 10.1159/000183675; GURECKI J, 1985, TRANSPLANT P, V17, P1997; LAMB FS, 1987, LIFE SCI, V40, P2571, DOI 10.1016/0024-3205(87)90080-4; LEVEY AS, 1988, ANNU REV MED, V39, P465, DOI 10.1146/annurev.me.39.020188.002341; LIN HY, 1989, NEW ENGL J MED, V321, P287, DOI 10.1056/NEJM198908033210504; LUDWIN D, 1988, TRANSPLANT P, V20, P367; MCDIARMID SV, 1990, TRANSPLANTATION, V49, P81, DOI 10.1097/00007890-199001000-00018; MIHATSCH MJ, 1988, KLIN WOCHENSCHR, V66, P43, DOI 10.1007/BF01713009; MORGAN BJ, 1989, FASEB J, V3, pA1145; POWLES AV, 1990, BRIT J DERMATOL, V122, P665, DOI 10.1111/j.1365-2133.1990.tb07288.x; RAINE AEG, 1988, NEPHROL DIAL TRANSPL, V3, P458, DOI 10.1093/oxfordjournals.ndt.a091698; RUSSELL CD, 1985, J NUCL MED, V26, P1243; SCHERRER U, 1990, NEW ENGL J MED, V323, P693, DOI 10.1056/NEJM199009133231101; SCHMITZSCHUMANN M, 1986, PROG ALLERGY, V38, P436; SINCLAIR NR, 1986, NEW ENGL J MED, V314, P1219; STILLER CR, 1983, NEW ENGL J MED, V309, P809; TAUXE WN, 1982, EUR J NUCL MED, V7, P51; TAUXE WN, 1971, MAYO CLIN PROC, V46, P524; TINDALL RSA, 1987, NEW ENGL J MED, V316, P719, DOI 10.1056/NEJM198703193161205; TUGWELL P, 1987, J RHEUMATOL, V14, P1108; TUGWELL P, 1990, LANCET, V335, P1051, DOI 10.1016/0140-6736(90)92630-Z; VANRIJTHOVEN AWAM, 1991, J RHEUMATOL, V18, P19; WEIDLE PJ, 1988, DRUG INTEL CLIN PHAR, V22, P443, DOI 10.1177/106002808802200601; WIESNER RH, 1990, NEW ENGL J MED, V322, P1419, DOI 10.1056/NEJM199005173222003; WOLINSKY JS, 1990, ANN NEUROL, V27, P591; YOCUM DE, 1988, ANN INTERN MED, V109, P863, DOI 10.7326/0003-4819-109-11-863; ZACHARIAE H, 1990, BRIT J DERMATOL, V122, P677, DOI 10.1111/j.1365-2133.1990.tb07290.x	37	87	88	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					578	583		10.7326/0003-4819-117-7-578	http://dx.doi.org/10.7326/0003-4819-117-7-578			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524331				2022-12-28	WOS:A1992JQ22600006
J	HOGAN, BLM; THALLER, C; EICHELE, G				HOGAN, BLM; THALLER, C; EICHELE, G			EVIDENCE THAT HENSEN NODE IS A SITE OF RETINOIC ACID SYNTHESIS	NATURE			English	Article							DEVELOPING CHICK LIMB; LOCAL APPLICATION; XENOPUS EMBRYOS; NERVOUS-SYSTEM; MOUSE EMBRYOS; EXPRESSION; PATTERN; GENES; BUD; TRANSFORMATION	HENSEN'S node of amniotes, like the Spemann organizer of amphibians, can induce a second body axis when grafted into a host embryo1. The avian node, as well as several midline structures originating from it (notochord, floor plate), can also induce digit pattern duplications when grafted into the chick wing bud2,3. We report here that the equivalent of Hensen's node from mouse is an effective inducer of digits in the chick wing bud. Tissues anterior and posterior to the node also evoke pattern duplications, but with a significantly lower efficiency. The finding that the murine node operates in an avian wing bud suggests that the same inducing agent(s) function in both primary and secondary embryonic fields and have been conserved during vertebrate evolution. Digit pattern duplications are also evoked by local administration of all-transretinoic acid4,5. This similarity raises the possibility that Hensen's node is a source of retinoic acid. The mouse node is capable of synthesizing retinoic acid from its biosynthetic precursor all-transretinol at a substantially higher rate than either anterior or posterior tissues.	BAYLOR COLL MED,V&M MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232	Baylor College of Medicine; Vanderbilt University								ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; [Anonymous], 1952, EPIGENETICS BIRDS; CONLON RA, IN PRESS DEVELOPMENT; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; GAUNT SJ, 1990, TRENDS GENET, V6, P208; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAWSON KA, 1992, CIBA F SYMP, V165, P3; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY P, 1991, DEVELOPMENT, V111, P61; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; Romijn HJ, 1982, DEV BRAIN RES, V2, P583; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SCHOENWOLF GC, 1992, DEV DYNAM, V193, P235, DOI 10.1002/aja.1001930304; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; SHARPE CR, 1991, NEURON, V7, P239, DOI 10.1016/0896-6273(91)90262-X; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SMITH SM, 1991, DEVELOPMENT, V111, P245; STERN CD, 1979, ANAT EMBRYOL, V156, P319, DOI 10.1007/BF00299630; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; SUNDIN O, 1992, DEVELOPMENT, V114, P841; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THALLER C, 1988, DEVELOPMENT, V103, P473; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0	33	205	206	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					237	241		10.1038/359237a0	http://dx.doi.org/10.1038/359237a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1528265				2022-12-28	WOS:A1992JN94400062
J	VANTILBEURGH, H; SARDA, L; VERGER, R; CAMBILLAU, C				VANTILBEURGH, H; SARDA, L; VERGER, R; CAMBILLAU, C			STRUCTURE OF THE PANCREATIC LIPASE PROCOLIPASE COMPLEX	NATURE			English	Article							REFINEMENT; COLIPASE	INTERFACIAL adsorption of pancreatic lipase is strongly dependent on the physical chemical properties of the lipid surface. These properties are affected by amphiphiles such as phospholipids and bile salts. In the presence of such amphiphiles, lipase binding to the interface requires a protein cofactor, colipase1-3. We obtained crystals of the pancreatic lipase-procolipase complex and solved the structure at 3.04 angstrom resolution. Here we describe the structure of procolipase, which essentially consists of three 'fingers' and is topologically comparable to snake toxins4,5. The tips of the fingers contain most of the hydrophobic amino acids and presumably form the interfacial binding site. Lipase binding occurs at the opposite side to this site and involves polar interactions. Determination of the three-dimensional structure of pancreatic lipase has revealed the presence of two domains: an amino-terminal domain, at residues 1-336 containing the active site and a carboxy-terminal domain at residues 337-449 (ref. 6). Procolipase binds exclusively to the C-terminal domain of lipase. No conformational change in the lipase molecule is induced by the binding of procolipase.	FAC ST CHARLES,INST CHIM BIOL,F-13331 MARSEILLE 3,FRANCE; CNRS,CTR BIOCHIM & BIOL MOLEC,F-13402 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	VANTILBEURGH, H (corresponding author), FAC MED NORD,LCCMB,CNRS,F-13326 MARSEILLE 15,FRANCE.							ABOUSALHAM A, 1992, PROTEIN ENG, V5, P105, DOI 10.1093/protein/5.1.105; Borgstrom B., 1984, P151; BOURNE PE, 1985, EUR J BIOCHEM, V153, P521, DOI 10.1111/j.1432-1033.1985.tb09333.x; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; COZZONE PJ, 1984, EUR J BIOCHEM, V114, P119; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DONNER J, 1976, BIOCHEMISTRY-US, V15, P5413, DOI 10.1021/bi00669a031; ERLANSON C, 1974, BIOCHIM BIOPHYS ACTA, V259, P198; JANIN J, 1990, J BIOL CHEM, V265, P16027; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; MCINTYRE JC, 1987, BIOCHEM J, V245, P821, DOI 10.1042/bj2450821; RATHELOT J, 1981, BIOCHIMIE, V63, P227, DOI 10.1016/S0300-9084(81)80196-4; REES B, 1987, P NATL ACAD SCI USA, V84, P3132, DOI 10.1073/pnas.84.10.3132; ROUSSEL A, 1991, SILICON GRAPHICS DIR; SARDA L, 1991, LIPASES STRUCTURE ME, P145; Verger R., 1984, P83; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	18	303	318	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					159	162		10.1038/359159a0	http://dx.doi.org/10.1038/359159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522902				2022-12-28	WOS:A1992JM49400057
J	WHITE, PH; ANSELL, BM				WHITE, PH; ANSELL, BM			METHOTREXATE FOR JUVENILE RHEUMATOID-ARTHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											WHITE, PH (corresponding author), GEORGE WASHINGTON UNIV,CHILDRENS NATL MED CTR,WASHINGTON,DC 20010, USA.							ANSELL BM, 1990, PAEDIATRIC RHEUMATOL, P3; FERNANDEZVINA MA, 1990, ARTHRITIS RHEUM, V33, P1787, DOI 10.1002/art.1780331205; GIANNINI EH, 1992, NEW ENGL J MED, V326, P1043, DOI 10.1056/NEJM199204163261602; HALLE F, 1991, CLIN EXP RHEUMATOL, V9, P297; KEIM D, 1990, J RHEUMATOL, V17, P846; LOVELL DJ, 1992, J RHEUMATOL, V19, P28; TUGWELL P, 1990, ARCH INTERN MED, V150, P59, DOI 10.1001/archinte.150.1.59; WALLACE CA, 1989, ARTHRITIS RHEUM, V32, P677, DOI 10.1002/anr.1780320604; WALLACE CA, 1991, RHEUM DIS CLIN N AM, V17, P891; WEINBLATT ME, 1992, ARTHRITIS RHEUM, V35, P129, DOI 10.1002/art.1780350202	10	13	13	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1992	326	16					1077	1078		10.1056/NEJM199204163261608	http://dx.doi.org/10.1056/NEJM199204163261608			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN738	1549155				2022-12-28	WOS:A1992HN73800008
J	SCHUCHAT, A; DEAVER, KA; WENGER, JD; PLIKAYTIS, BD; MASCOLA, L; PINNER, RW; REINGOLD, AL; BROOME, CV				SCHUCHAT, A; DEAVER, KA; WENGER, JD; PLIKAYTIS, BD; MASCOLA, L; PINNER, RW; REINGOLD, AL; BROOME, CV			ROLE OF FOODS IN SPORADIC LISTERIOSIS .1. CASE-CONTROL STUDY OF DIETARY RISK-FACTORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIC LISTERIOSIS; INFECTION; OUTBREAK	Objective. - To identify dietary risk factors for sporadic listeriosis. Design. - Case-control study with blinded telephone interviews. Setting. - Multistate population of 18 million persons, November 1988 through December 1990. Participants. - One hundred sixty-five patients with culture-confirmed listeriosis and 376 control subjects matched for age, health care provider, and immunosuppressive condition. Results. - The annual incidence of invasive listeriosis was 7.4 cases per million population; 23% of the infections were fatal. Cases were more likely than matched controls to have eaten soft cheeses (odds ratio [OR], 2.6; 95% confidence interval [Cl], 1.4 to 4.8; P = .002) or food purchased from store delicatessen counters (OR, 1.6; 95% Cl, 1.0 to 2.5; P = .04); 32% of sporadic disease could be attributed to eating these foods. Sixty-nine percent of cases in men and nonpregnant women occurred in cancer patients, persons with the acquired immunodeficiency syndrome, organ transplant recipients, or those receiving corticosteroid therapy. Among these immunosuppressed patients, eating undercooked chicken also increased the risk of listeriosis (OR, 3.3; 95% Cl, 1.2 to 9.2; P = .02). Conclusions. - Foodborne transmission may account for a substantial portion of sporadic listeriosis. Prevention efforts should include dietary counseling of high-risk patients and continued monitoring of food production.	CTR DIS CONTROL, DIV BACTERIAL & MYCOT DIS, BIOSTAT & INFORMAT BRANCH, ATLANTA, GA 30333 USA; LOS ANGELES CTY DEPT HLTH SERV, BERKELEY, CA USA; UNIV CALIF BERKELEY, DEPT BIOMED & ENVIRONM HLTH SCI, BERKELEY, CA 94720 USA	Centers for Disease Control & Prevention - USA; University of California System; University of California Berkeley	SCHUCHAT, A (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA.				FDA HHS [FDA 224-88-2456] Funding Source: Medline	FDA HHS		BILLE J, 1990, T IND MICR, P71; FLEMING DW, 1985, NEW ENGL J MED, V312, P404, DOI 10.1056/NEJM198502143120704; GELLIN BG, 1991, AM J EPIDEMIOL, V133, P392, DOI 10.1093/oxfordjournals.aje.a115893; HO JL, 1986, ARCH INTERN MED, V146, P520, DOI 10.1001/archinte.146.3.520; HUMBLE CG, 1984, AM J EPIDEMIOL, V119, P86, DOI 10.1093/oxfordjournals.aje.a113729; Humphrey T. J., 1990, PHLS Microbiology Digest, V7, P57; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; MARSHALL J, 1980, AM J EPIDEMIOL, V112, P675, DOI 10.1093/oxfordjournals.aje.a113040; McLauchlin J., 1990, PHLS Microbiology Digest, V7, P54; MILLER JK, 1965, AM J CLIN PATHOL, V43, P248; Morbidity and Mortality Weekly Report (MMWR), 1988, MMWR-MORBID MORTAL W, V37, P764; NELSON LM, 1990, EPIDEMIOL REV, V12, P71, DOI 10.1093/oxfordjournals.epirev.a036063; PINNER RW, 1992, JAMA-J AM MED ASSOC, V267, P2046, DOI 10.1001/jama.267.15.2046; SCHLECH WF, 1990, T IND MICR, P51; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P221; SCHUCHAT A, 1991, P INT C LISTERIA FOO, P69; SCHWARTZ B, 1988, LANCET, V2, P779; WENGER JD, 1990, J FOOD PROTECT, V53, P1015, DOI 10.4315/0362-028X-53.12.1015; 1988, B WORLD HEALTH ORGAN, V66, P421; 1986, SUGI SUPPLEMENTAL LI, P307; 1989, MMWR, V38, P267	22	260	265	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2041	2045		10.1001/jama.267.15.2041	http://dx.doi.org/10.1001/jama.267.15.2041			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552639				2022-12-28	WOS:A1992HM65000028
J	ALMY, TP; COLBY, KK; ZUBKOFF, M; GEPHART, DS; MOOREWEST, M; LUNDQUIST, LL				ALMY, TP; COLBY, KK; ZUBKOFF, M; GEPHART, DS; MOOREWEST, M; LUNDQUIST, LL			HEALTH, SOCIETY, AND THE PHYSICIAN - PROBLEM-BASED LEARNING OF THE SOCIAL-SCIENCES AND HUMANITIES - 8 YEARS OF EXPERIENCE	ANNALS OF INTERNAL MEDICINE			English	Article						DECISION MAKING; EDUCATION, MEDICAL; SOCIAL SCIENCES; HUMANITIES; KNOWLEDGE, ATTITUDES, PRACTICE; SIMULATED PATIENTS	MEDICAL-EDUCATION; STUDENTS	We describe a required course for fourth-year medical students focusing on the application of the social sciences and the humanities of critical decisions in the practice of medicine. During 160 hours (70 with faculty contact) in a 7-week period, active, patient-centered, problem-based learning takes place in small collaborating groups, is facilitated by trained tutors, and uses computerized access to library materials plus reference files and resource persons. Major issues identified in the cases are clarified in complementary lectures and symposia. Formative evaluation is ongoing within tutorial groups. Summative evaluation is determined by the individual student's performance in a final complex management problem using a simulated patient. Evaluation of the course, and the basis for its ongoing revision, are provided by participating students and faculty, whose evaluations of the course have been favorable in 80% to 90% of cases.			ALMY, TP (corresponding author), DARTMOUTH COLL, SCH MED, DEPT COMMUNITY & FAMILY MED, HANOVER, NH 03755 USA.							BARROWS HS, 1983, JAMA-J AM MED ASSOC, V250, P3077, DOI 10.1001/jama.250.22.3077; BENSON JA, 1983, ANN INTERN MED, V99, P720, DOI 10.7326/0003-4819-99-5-720; BRANCH WT, 1991, ANN INTERN MED, V114, P482, DOI 10.7326/0003-4819-114-6-482; COLBY KK, 1986, J MED EDUC, V61, P413; FEIGHTNER JW, 1985, ASSESSING CLIN COMPE, P183; FLEXNER A, 1910, MED ED US CANADA, P26; GRODIN MA, 1986, J MED EDUC, V61, P613; HAM TH, 1976, MED ED EXPERIENCE CA; KAUFMAN A, 1989, ACAD MED, V64, P285, DOI 10.1097/00001888-198906000-00001; KEGELES SM, 1985, J MED EDUC, V60, P876; Knowles M.S., 1970, MODERN PRACTICE ADUL, P37; MULLER S, 1984, J MED EDUC, V59, P1; NEUFELD VR, 1974, J MED EDUC, V49, P1040; NEUFELD VR, 1989, ACAD MED, V64, P423, DOI 10.1097/00001888-198908000-00001; NEWBLE DI, 1986, MED EDUC, V20, P267, DOI 10.1111/j.1365-2923.1986.tb01365.x; Painvin C, 1979, Annu Conf Res Med Educ, V18, P73; ROGERS DE, 1988, CLIN ED DOCTOR TOMOR; TOSTESON DC, 1990, NEW ENGL J MED, V322, P234, DOI 10.1056/NEJM199001253220405; WERTHEIMER MD, 1985, J MED EDUC, V60, P804; WEST DA, 1985, IMPLEMENTING PROBLEM, P144; 1985, FUNCTION STRUCTURE M	21	18	18	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					569	574		10.7326/0003-4819-116-7-569	http://dx.doi.org/10.7326/0003-4819-116-7-569			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543312				2022-12-28	WOS:A1992HL25800009
J	BROGAN, WC; LANGE, RA; GLAMANN, DB; HILLIS, LD				BROGAN, WC; LANGE, RA; GLAMANN, DB; HILLIS, LD			RECURRENT CORONARY VASOCONSTRICTION CAUSED BY INTRANASAL COCAINE - POSSIBLE ROLE FOR METABOLITES	ANNALS OF INTERNAL MEDICINE			English	Article						COCAINE; CORONARY VASOSPASM; DEATH, SUDDEN; ANGINA PECTORIS; MYOCARDIAL INFARCTION	ACUTE MYOCARDIAL-INFARCTION; ECGONINE METHYL-ESTER; HUMANS; ABUSE; INTOXICATION; DISPOSITION; KINETICS; DISEASE	Objective: To define the temporal characteristics of cocaine-induced coronary vasoconstriction in humans and to assess the relation between cocaine-induced coronary vasoconstriction and the blood concentration of cocaine and its main metabolites. Design: Randomized, double-blind, controlled clinical trial. Setting: Cardiac catheterization laboratory of a large teaching hospital. Patients: Eighteen patients (16 men and 2 women, 37 to 65 years of age) having catheterization for evaluation of chest pain. Measurements: At catheterization, patients received intranasal saline (8 patients) or cocaine, 2 mg/kg body weight (10 patients). Cineangiographic examination of the left coronary artery and quantitation of the blood concentration of cocaine and its metabolites were done before (baseline) and 30, 60, and 90 minutes after administration of intranasal saline or cocaine. Results: In response to cocaine, proximal coronary arterial diameter decreased from 2.4 +/- 1.6 mm (mean +/- SD) at baseline to 2.0 +/- 1.4 mm at 30 minutes (P < 0.05). This change corresponded temporally to the peak blood concentration of cocaine. At 60 minutes, the cocaine concentration decreased and coronary artery diameter returned to baseline (2.3 +/- 1.6 mm) (P < 0.05 compared with baseline). At 90 minutes, all patients had recurrent vasoconstriction (1.9 +/- 1.4 mm, P < 0.05) despite a further decrease in the blood cocaine concentration. This vasoconstriction corresponded temporally with an increasing blood concentration of cocaine's main metabolites, benzoylecgonine and ethyl methyl ecgonine. No changes were observed in the control group. Conclusion: Intranasal cocaine causes recurrent coronary vasoconstriction, which may be due to its metabolites.	UNIV TEXAS, SW MED CTR, ROOM CS 7102, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; PARKLAND MEM HOSP & AFFILIATED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Lange, Richard/AAM-9594-2021					ADROUNY A, 1985, NEW ENGL J MED, V313, P48; ALLRED RJ, 1981, ANN EMERG MED, V10, P441; AMBRE J, 1985, J ANAL TOXICOL, V9, P241, DOI 10.1093/jat/9.6.241; AMBRE JJ, 1982, J ANAL TOXICOL, V6, P26, DOI 10.1093/jat/6.1.26; AMIN M, 1990, AM J CARDIOL, V66, P1434, DOI 10.1016/0002-9149(90)90529-A; BARTH CW, 1986, AM J CARDIOL, V57, P496, DOI 10.1016/0002-9149(86)90787-3; BENCHIMOL A, 1978, ANN INTERN MED, V88, P519, DOI 10.7326/0003-4819-88-4-519; BERTOLET BD, 1990, CLIN CARDIOL, V13, P323, DOI 10.1002/clc.4960130505; BROMLEY L, 1988, ANAESTHESIA, V43, P356, DOI 10.1111/j.1365-2044.1988.tb09011.x; CHAMBERS HF, 1987, ANN INTERN MED, V106, P833, DOI 10.7326/0003-4819-106-6-833; CHOKSHI SK, 1989, ANN INTERN MED, V111, P1039, DOI 10.7326/0003-4819-111-12-1039; FLORES ED, 1990, J AM COLL CARDIOL, V16, P74, DOI 10.1016/0735-1097(90)90459-3; HAWKS RL, 1974, LIFE SCI, V15, P2189, DOI 10.1016/0024-3205(74)90035-6; ISENSCHMID DS, 1988, J ANAL TOXICOL, V12, P242, DOI 10.1093/jat/12.5.242; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; JAVAID JI, 1983, BIOPHARM DRUG DISPOS, V4, P9, DOI 10.1002/bdd.2510040104; JAVAID JI, 1978, SCIENCE, V202, P227, DOI 10.1126/science.694530; JEFFCOAT AR, 1989, DRUG METAB DISPOS, V17, P153; KARCH SB, 1988, ARCH PATHOL LAB MED, V112, P225; LANGE RA, 1989, NEW ENGL J MED, V321, P1557, DOI 10.1056/NEJM198912073212301; MADDEN JA, 1990, LIFE SCI, V47, P1109, DOI 10.1016/0024-3205(90)90169-R; MISRA AL, 1975, J PHARM PHARMACOL, V27, P784, DOI 10.1111/j.2042-7158.1975.tb09404.x; SCHACHNE JS, 1984, NEW ENGL J MED, V310, P1665; SMITH HWB, 1987, ANN INTERN MED, V107, P13, DOI 10.7326/0003-4819-107-1-13; VANDYKE C, 1976, SCIENCE, V191, P859, DOI 10.1126/science.56036; VIRMANI R, 1988, AM HEART J, V115, P1068, DOI 10.1016/0002-8703(88)90078-6; WILKINSON P, 1980, CLIN PHARMACOL THER, V27, P386, DOI 10.1038/clpt.1980.52; YOUNG D, 1947, AM HEART J, V34, P272, DOI 10.1016/0002-8703(47)90296-2	28	97	107	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					556	561		10.7326/0003-4819-116-7-556	http://dx.doi.org/10.7326/0003-4819-116-7-556			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543310				2022-12-28	WOS:A1992HL25800006
J	LIBBY, DM; KLEIN, L; ALTORKI, NK				LIBBY, DM; KLEIN, L; ALTORKI, NK			ASPIRATION OF THE NASAL-SEPTUM - A NEW COMPLICATION OF COCAINE ABUSE	ANNALS OF INTERNAL MEDICINE			English	Note						NASAL SEPTUM; COCAINE; ASPIRATION; COUGH; FOREIGN BODIES	PNEUMOMEDIASTINUM	A 55-year-old man with a habit of nasal inhalation of cocaine developed a chronic cough. At bronchoscopy, a foreign body was discovered in the bronchus intermedius, which was histopathologically identified as bone. A DNA-print analysis showed that the bone was from the patient. Because the patient had nasal septum perforation, it was deduced that he had aspirated his own nasal septum. The observation of pulmonary auto-aspiration of the nasal septum is discussed in the context of known neuropsychiatric, otolaryngologic, and cardiopulmonary complications of cocaine abuse.			LIBBY, DM (corresponding author), CORNELL UNIV, MED CTR, NEW YORK HOSP, DIV PULM & CRIT CARE MED, 407 E 70TH ST, NEW YORK, NY 10021 USA.							BRODY SL, 1990, AM J MED, V88, P325, DOI 10.1016/0002-9343(90)90484-U; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; CUCCO RA, 1987, AM REV RESPIR DIS, V136, P179, DOI 10.1164/ajrccm/136.1.179; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HOLLINGER PH, 1962, T AM ACAD OPHTHALMOL, V66, P193; ITKONEN J, 1984, ARCH INTERN MED, V144, P2195, DOI 10.1001/archinte.144.11.2195; REBHUN J, 1988, ANN ALLERGY, V60, P339; SCHWEITZER VG, 1986, LARYNGOSCOPE, V96, P206; SHESSER R, 1981, ANN EMERG MED, V10, P213, DOI 10.1016/S0196-0644(81)80166-7	9	19	21	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					567	568		10.7326/0003-4819-116-7-567	http://dx.doi.org/10.7326/0003-4819-116-7-567			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543311				2022-12-28	WOS:A1992HL25800008
J	CONROY, GC; PICKFORD, M; SENUT, B; VANCOUVERING, J; MEIN, P				CONROY, GC; PICKFORD, M; SENUT, B; VANCOUVERING, J; MEIN, P			OTAVIPITHECUS-NAMIBIENSIS, 1ST MIOCENE HOMINOID FROM SOUTHERN AFRICA	NATURE			English	Article							MIDDLE MIOCENE; PRIMATE FOSSILS; WESTERN KENYA; EAST-AFRICA; ANTHROPOIDS; MORPHOLOGY; SPECIMENS; PAKISTAN; PASALAR; BEARING	WE report here the discovery of a Miocene hominoid from Berg Aukas, Namibia, the first known from the African continent south of equatorial East Africa. This represents a major range extension of Miocene Hominoidea in Africa to latitude 20-degrees-S. The holotype, a right mandibular corpus preserving the crowns of the P4-M3, partial crown and root of the P3, partial root of the canine, alveoli for all four incisors, and partial alveolus for the left canine, was found during paleontological explorations of karst-fill breccias in the Otavi region of northern Namibia. The mandible has unique characteristics that differentiate it from other middle Miocene hominoids of Africa and Eurasia and represents the only fossil evidence documenting a pre-australopithecine stage of hominoid evolution in southern Africa. Faunal analyses indicate that the breccia block containing the specimen accumulated during the latter part of the middle Miocene, about 13 +/- 1 Myr. Fauna from other breccia blocks at Berg Aukas are of diverse ages, including the earlier part of the middle Miocene, the upper Miocene, Plio-Pleistocene and Holocene.	WASHINGTON UNIV, SCH MED, DEPT ANTHROPOL, ST LOUIS, MO 63110 USA; COLL FRANCE, CHAIRE PALEOANTHROPOL & PREHIST, F-75231 PARIS 05, FRANCE; MUSEUM NATL HIST NAT, INST PALEONTOL, F-75231 PARIS 05, FRANCE; MUSEUM NATL HIST NAT, ANTHROPOL LAB, F-75231 PARIS 05, FRANCE; AMER MUSEUM NAT HIST, MICROPALEONTOL PRESS, NEW YORK, NY 10024 USA; UNIV LYON 1, CTR SCI TERRE, F-69622 VILLEURBANNE, FRANCE	Washington University (WUSTL); UDICE-French Research Universities; PSL Research University Paris; College de France; Museum National d'Histoire Naturelle (MNHN); Museum National d'Histoire Naturelle (MNHN); American Museum of Natural History (AMNH); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	CONROY, GC (corresponding author), WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, BOX 8108, ST LOUIS, MO 63110 USA.		Klein, Richard G/B-5910-2009					ALPAGUT B, 1990, J HUM EVOL, V19, P397, DOI 10.1016/0047-2484(90)90052-D; ANDREWS P, 1987, J HUM EVOL, V16, P101, DOI 10.1016/0047-2484(87)90062-5; Andrews P., 1985, P14; Andrews P.J., 1978, Bulletin of the British Museum (Natural History) Geology, V30, P85; Barry J.C., 1986, P93; BEGUN DR, 1990, J HUM EVOL, V19, P255, DOI 10.1016/0047-2484(90)90068-M; BEGUN DR, 1991, J HUM EVOL, V20, P521, DOI 10.1016/0047-2484(91)90025-Q; BENEFIT BR, 1989, J HUM EVOL, V18, P493, DOI 10.1016/0047-2484(89)90078-X; BERNOR RL, 1990, J HUM EVOL, V19, P551, DOI 10.1016/0047-2484(90)90064-I; COIFFAITMARTN B, 1991, CONTRIBUTION RONGEUR; CONROY G C, 1991, Palaeontologia Africana, V28, P53; CONROY GC, 1987, INT J PRIMATOL, V8, P115, DOI 10.1007/BF02735160; CONROY GC, 1991, AM J PHYS ANTHROPOL, V86, P243, DOI 10.1002/ajpa.1330860212; CONROY GC, 1991, AM J PHYS ANTHROPOL, V86, P137, DOI 10.1002/ajpa.1330860205; CONROY GC, 1991, AM J PHYS ANTHROPOL, V86, P121, DOI 10.1002/ajpa.1330860204; CORVINUS G, 1978, NEUES JB GEOLOGIE PA, V4, P193; Ginsburg L., 1986, P47; HARRISON T, 1991, J HUM EVOL, V21, P329, DOI 10.1016/0047-2484(91)90112-9; HARRISON T, 1991, J HUM EVOL, V20, P515, DOI 10.1016/0047-2484(91)90024-P; HARRISON T, 1986, AM J PHYS ANTHROPOL, V71, P265, DOI 10.1002/ajpa.1330710303; HARRISON T, 1988, FOLIA PRIMATOL, V50, P59, DOI 10.1159/000156334; HOPWOOD A. TINDELL, 1929, AMER MUS NOVITATES, V344, P1; HYLANDER WL, 1975, SCIENCE, V189, P1095, DOI 10.1126/science.808855; Ishida H., 1984, AFR STUD MONOGR, V2, P73; Jungers W.L., 1985, P345; KAPPELMAN J, 1991, J HUM EVOL, V21, P61, DOI 10.1016/0047-2484(91)90036-U; Kay R.F., 1984, P21; Kay R.F., 1983, P577; KEENE HJ, 1966, AM J PHYS ANTHROPOL, V25, P208; Kelley J., 1986, COMP PRIMATE BIOL, P361; LEAKEY RE, 1988, AM J PHYS ANTHROPOL, V76, P277, DOI 10.1002/ajpa.1330760302; LEAKEY RE, 1987, J HUM EVOL, V16, P369, DOI 10.1016/0047-2484(87)90067-4; LEAKEY RE, 1988, AM J PHYS ANTHROPOL, V76, P289, DOI 10.1002/ajpa.1330760303; LUCAS P W, 1986, Zeitschrift fuer Morphologie und Anthropologie, V76, P253; MASON R J, 1976, Annals of the South African Museum, V71, P215; MATSUZAKI T, 1986, CHEM IND-LONDON, P35; Mein P., 1986, P59; PICKFORD M, 1987, Annals of the South African Museum, V97, P283; Pickford M., 1986, P163; Pickford M., 1986, P19; PICKFORD M, 1982, AM J PHYS ANTHROPOL, V58, P1, DOI 10.1002/ajpa.1330580102; PICKFORD M, 1985, J HUM EVOL, V14, P113, DOI 10.1016/S0047-2484(85)80002-6; PICKFORD M, 1986, TER RES SPEC PAP, V7, P1; PILBEAM D, 1977, NATURE, V270, P689, DOI 10.1038/270689a0; PILBEAM DR, 1980, POSTILLA, V181, P1; RAZA SM, 1983, NATURE, V306, P52, DOI 10.1038/306052a0; SANDELOWSKY BH, 1983, AM SCI, V71, P606; SCHLENTHER K, 1987, PRIMARY ATLAS NAMIBI; SENUT B, IN PRESS CR HEBD ACA; SIMONS EL, 1965, FOLIA PRIMATOL, V3, P81, DOI 10.1159/000155026; STROMER E, 1926, DIAMANTENWUSTE SUDWE, P107; VANCOUVERING JA, 1983, 1975 NATL GEOGR SOC, P697	52	54	54	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					144	148		10.1038/356144a0	http://dx.doi.org/10.1038/356144a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545864				2022-12-28	WOS:A1992HH73100056
J	ROMEO, C; AMIOT, M; SEED, B				ROMEO, C; AMIOT, M; SEED, B			SEQUENCE REQUIREMENTS FOR INDUCTION OF CYTOLYSIS BY THE T-CELL ANTIGEN/FC RECEPTOR ZETA-CHAIN	CELL			English	Article							NATURAL-KILLER-CELLS; FC-GAMMA-RIII; TRIGGER MOLECULES; CYTO-TOXICITY; TUMOR-CELLS; COMPLEX; EXPRESSION; CD16; RECOGNITION; LYMPHOCYTES	The zeta-chain of the T cell antigen receptor is a dimeric transmembrane protein with a very short extracellular domain and an extended cytoplasmic tail that triggers T cell effector function when aggregated by extracellular stimuli. We have reduced the active site of zeta to an 18 residue motif that can be appended to the intracellular domain of other transmembrane proteins to endow them with receptor-like activity. The compact size of the motif appears to eliminate zeta-mechanisms based on enzymatic activity and suggests that one or at most a few cellular proteins interact with the zeta-intracellular domain to initiate signal transduction. Analysis of individual amino acids within the 18 residue element reveals two phylogenetically conserved tyrosines that are absolutely required for activity and other residues that are less essential but contribute to the efficacy of receptor-directed cytolysis.			ROMEO, C (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.				NIAID NIH HHS [AI27849] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027849, R37AI027849] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BOYLE DB, 1988, GENE, V65, P123, DOI 10.1016/0378-1119(88)90424-6; BREITMEYER JB, 1987, J IMMUNOL, V138, P726; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FANGER MW, 1989, IMMUNOL TODAY, V10, P92, DOI 10.1016/0167-5699(89)90234-X; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GRAZIANO RF, 1987, J IMMUNOL, V138, P945; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; OSTERGAARD HL, 1987, NATURE, V330, P71, DOI 10.1038/330071a0; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMUELSON LE, 1985, CELL, V43, P223; SANCHO J, 1989, J BIOL CHEM, V264, P20760; SHEN L, 1989, MOL IMMUNOL, V26, P959, DOI 10.1016/0161-5890(89)90114-4; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TRENN G, 1989, J IMMUNOL, V142, P3796; TRENN G, 1987, NATURE, V330, P72, DOI 10.1038/330072a0; WEISS A, 1984, J IMMUNOL, V133, P123; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; YOUNG JDE, 1987, J EXP MED, V166, P1894, DOI 10.1084/jem.166.6.1894	42	318	331	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					889	897		10.1016/0092-8674(92)90032-8	http://dx.doi.org/10.1016/0092-8674(92)90032-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547489				2022-12-28	WOS:A1992HH74800008
J	BAXTER, JN; ODWYER, PJ				BAXTER, JN; ODWYER, PJ			FOR DEBATE - LAPAROSCOPIC OR MINILAPAROTOMY CHOLECYSTECTOMY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INCISION		WESTERN INFIRM & ASSOCIATED HOSP, GLASGOW G11 6NT, SCOTLAND		BAXTER, JN (corresponding author), UNIV GLASGOW, GLASGOW ROYAL INFIRM, DEPT SURG, GLASGOW G31 2ER, SCOTLAND.							BERCI G, 1991, AM J SURG, V161, P355, DOI 10.1016/0002-9610(91)90597-7; CAMERON JL, 1991, ANN SURG, V213, P1; DUBOIS F, 1982, NOUV PRESSE MED, V11, P1139; FLOWERS JL, 1991, AM J SURG, V161, P388, DOI 10.1016/0002-9610(91)90604-C; LAMBERT ME, 1991, BRIT J SURG, V78, P473, DOI 10.1002/bjs.1800780427; LEDET WP, 1990, ARCH SURG-CHICAGO, V125, P1434; MCDERMOTT EWM, IN PRESS BR J SURG; MERRILL JR, 1988, AM SURGEON, V54, P256; NEUGEBAUER E, 1991, BRIT J SURG, V78, P150, DOI 10.1002/bjs.1800780207; ODWYER PJ, 1990, BRIT J SURG, V77, P1189, DOI 10.1002/bjs.1800771034; PETERS JH, 1991, ANN SURG, V213, P3, DOI 10.1097/00000658-199101000-00002; REDDICK E J, 1989, Surgical Endoscopy, V3, P131, DOI 10.1007/BF00591357; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; RUSSELL RCG, 1987, BRIT J SURG, V74, P826, DOI 10.1002/bjs.1800740925; WOLFE BM, 1991, JAMA-J AM MED ASSOC, V265, P1573, DOI 10.1001/jama.265.12.1573	15	23	23	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 29	1992	304	6826					559	560		10.1136/bmj.304.6826.559	http://dx.doi.org/10.1136/bmj.304.6826.559			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1532758	Bronze, Green Published			2022-12-28	WOS:A1992HG59900031
J	EWEN, ME; FAHA, B; HARLOW, E; LIVINGSTON, DM				EWEN, ME; FAHA, B; HARLOW, E; LIVINGSTON, DM			INTERACTION OF P107 WITH CYCLIN-A INDEPENDENT OF COMPLEX-FORMATION WITH VIRAL ONCOPROTEINS	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; LARGE T-ANTIGEN; SV40 LARGE-T; CELL-CYCLE; SUSCEPTIBILITY GENE; BINDING; PROTEIN; PHOSPHORYLATION; ADENOVIRUS-E1A; REGIONS	The p107 protein and the retinoblastoma protein (R-B) both bind specifically to two viral oncoproteins, the SV40 T antigen (T) and adenoviral protein E1A (E1A). Like RB, p107 contains a segment (the pocket) that, alone, can bind specifically to T, EIA, and multiple cellular proteins. Cyclin A bound to the p107 pocket, but not the R-B pocket. Although both pockets contain two, related collinear subsegments (A and B), the unique sequence in the p107 pocket that occupies the space between A and B is required for the interaction with cyclin A.	MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital	EWEN, ME (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.							BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; EWEN ME, UNPUB; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, UNPUB; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SHIRODKAR S, COMMUNICATION; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807	33	226	233	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					85	87		10.1126/science.1532457	http://dx.doi.org/10.1126/science.1532457			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1532457				2022-12-28	WOS:A1992GX79100043
J	KIM, JS; REES, DC				KIM, JS; REES, DC			STRUCTURAL MODELS FOR THE METAL CENTERS IN THE NITROGENASE MOLYBDENUM-IRON PROTEIN	SCIENCE			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; KLEBSIELLA-PNEUMONIAE NITROGENASE; SUBSTRATE REDUCTION PROPERTIES; CONSERVED CYSTEINE RESIDUES; MOFE PROTEIN; ALPHA-SUBUNIT; FEMO-COFACTOR; BETA-SUBUNIT; MACROMOLECULAR CRYSTALLOGRAPHY; CLUSTER	Structural models for the nitrogenase FeMo-cofactor and P-clusters are proposed based on crystallographic analysis of the nitrogenase molybdenum-iron (MoFe)-protein from Azotobacter vinelandii at 2.7 angstrom resolution. Each center consists of two bridged clusters; the FeMo-cofactor has 4Fe:3S and 1Mo:3Fe:3S clusters bridged by three non-protein ligands, and the P-clusters contain two 4Fe:4S clusters bridged by two cysteine thiol ligands. Six of the seven Fe sites in the FeMo-cofactor appear to have trigonal coordination geometry, including one ligand provided by a bridging group. The remaining Fe site has tetrahedral geometry and is liganded to the side chain of Cys(alpha-275). The Mo site exhibits approximate octahedral coordination geometry and is liganded by three sulfurs in the cofactor, two oxygens from homocitrate, and the imidazole side chain of His(alpha-442). The P-clusters are liganded by six cysteine thiol groups, two which bridge the two clusters, alpha-88 and beta-95, and four which singly coordinate the remaining Fe sites, alpha-62, alpha-154, beta-70, and beta-153. The side chain of Ser(beta-188) may also coordinate one iron. The polypeptide folds of the homologous alpha and beta-subunits surrounding the P-clusters are approximately related by a twofold rotation that may be utilized in the binding interactions between the MoFe-protein and the nitrogenase Fe-protein. Neither the FeMo-cofactor nor the P-clusters are exposed to the surface, suggesting that substrate entry, electron transfer, and product release must involve a carefully regulated sequence of interactions between the MoFe-protein and Fe-protein of nitrogenase.	CALTECH,DIV CHEM & CHEM ENGN 14775CH,PASADENA,CA 91125	California Institute of Technology								ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ARBER JM, 1988, BIOCHEM J, V252, P421, DOI 10.1042/bj2520421; BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BRIGLE KE, 1985, GENE, V37, P37, DOI 10.1016/0378-1119(85)90255-0; Burgess B. K., 1984, Advances in nitrogen fixation research, P103; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; CHU CTW, 1977, INORG CHEM, V16, P3245, DOI 10.1021/ic50178a052; CONRADSON SD, 1987, J AM CHEM SOC, V109, P7507, DOI 10.1021/ja00258a042; COUCOUVANIS D, 1991, ACCOUNTS CHEM RES, V24, P1, DOI 10.1021/ar00001a001; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; DEAN DR, 1990, MOL MICROBIOL, V4, P1505, DOI 10.1111/j.1365-2958.1990.tb02061.x; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DRENTH J, 1975, J BIOL CHEM, V250, P5268; EIDSNESS MK, 1986, J AM CHEM SOC, V108, P2746, DOI 10.1021/ja00270a039; GEORGIADIS M, UNPUB; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEN WR, 1987, EUR J BIOCHEM, V169, P457, DOI 10.1111/j.1432-1033.1987.tb13633.x; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HEDMAN B, 1988, J AM CHEM SOC, V110, P3798, DOI 10.1021/ja00220a013; HERSKOVITZ T, 1972, P NATL ACAD SCI USA, V69, P2437, DOI 10.1073/pnas.69.9.2437; Holm R. H., 1985, MOLYBDENUM ENZYMES; HOLMES S, 1990, COMPOS SCI TECHNOL, V38, P1, DOI 10.1016/0266-3538(90)90068-G; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUYNH BH, 1980, BIOCHIM BIOPHYS ACTA, V623, P124, DOI 10.1016/0005-2795(80)90015-X; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KENT HM, 1990, MOL MICROBIOL, V4, P1497, DOI 10.1111/j.1365-2958.1990.tb02060.x; KENT HM, 1989, BIOCHEM J, V264, P257, DOI 10.1042/bj2640257; KURTZ DM, 1979, P NATL ACAD SCI USA, V76, P4986, DOI 10.1073/pnas.76.10.4986; LAMMERS PJ, 1983, P NATL ACAD SCI-BIOL, V80, P4723, DOI 10.1073/pnas.80.15.4723; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LINDAHL PA, 1988, J BIOL CHEM, V263, P19412; LINDAHL PA, 1987, J BIOL CHEM, V262, P12900; MADDEN MS, 1990, P NATL ACAD SCI USA, V87, P6517, DOI 10.1073/pnas.87.17.6517; MARCUS RN, 1992, SCIENCE, V256, P1007; MAY HD, 1991, BIOCHEM J, V277, P457, DOI 10.1042/bj2770457; NELSON MJ, 1983, P NATL ACAD SCI-BIOL, V80, P147, DOI 10.1073/pnas.80.1.147; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; POWER PP, 1991, ANGEW CHEM INT EDIT, V30, P330, DOI 10.1002/anie.199103301; RAWLINGS J, 1978, J BIOL CHEM, V253, P1001; Rossmann M. G., 1972, MOL REPLACEMENT METH; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SCOTT DJ, 1990, NATURE, V343, P188, DOI 10.1038/343188a0; SCOTT DJ, 1990, NITROGEN FIXATION AC, P169; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; STIEFEL EI, 1988, ACS SYM SER, V372, P372; SURERUS KK, IN PRESS J AM CHEM S; THOMANN H, 1987, J AM CHEM SOC, V109, P7913, DOI 10.1021/ja00259a067; THOMANN H, 1991, P NATL ACAD SCI USA, V88, P6620, DOI 10.1073/pnas.88.15.6620; THORNELEY RNF, 1984, BIOCHEM J, V224, P887, DOI 10.1042/bj2240887; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TRUE AE, 1988, J AM CHEM SOC, V110, P1935, DOI 10.1021/ja00214a045; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG SZ, 1988, BIOCHEMISTRY-US, V27, P2800, DOI 10.1021/bi00408a021; WEININGER MS, 1982, P NATL ACAD SCI-BIOL, V79, P378, DOI 10.1073/pnas.79.2.378; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4	61	744	770	0	211	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1677	1682		10.1126/science.1529354	http://dx.doi.org/10.1126/science.1529354			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529354				2022-12-28	WOS:A1992JN50100030
J	LEESMILLER, JP; HELFMAN, DM; SCHROER, TA				LEESMILLER, JP; HELFMAN, DM; SCHROER, TA			A VERTEBRATE ACTIN-RELATED PROTEIN IS A COMPONENT OF A MULTISUBUNIT COMPLEX INVOLVED IN MICROTUBULE-BASED VESICLE MOTILITY	NATURE			English	Article							CYTOPLASMIC DYNEIN; MUSCLE ACTIN; SEQUENCE; FLAGELLA; DNA	ACTIN is a cytoskeletal protein which is highly conserved across eukaryotic phyla. Actin filaments, in association with a family of myosin motor proteins, are required for cellular motile processes as diverse as vesicle transport, cell locomotion and cytokinesis1,2. Many organisms have several closely related actin isoforms3,4. In addition to conventional actins, yeasts contain actin-related proteins that are essential for viability5,6. We show here that vertebrates also contain an actin-related protein (actin-RPV). Actin-RPV is a major component of the dynactin complex, an activator of dynein-driven vesicle movement7,8, indicating that unlike conventional actins which work in conjunction with myosin motors, actin-RPV may be involved in cytoplasmic movements via a microtubule-based system.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University	LEESMILLER, JP (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Schroer, Trina/0000-0002-5065-1835	NIGMS NIH HHS [R01 GM044589] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JOHANNES FJ, 1991, EMBO J, V10, P3951, DOI 10.1002/j.1460-2075.1991.tb04965.x; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KELLEY KA, 1992, GENOMICS, V13, P381, DOI 10.1016/0888-7543(92)90257-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1992, P NATL ACAD SCI USA, V89, P80, DOI 10.1073/pnas.89.1.80; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; MEAGHER RB, 1990, CELL MOTIL CYTOSKEL, V16, P164, DOI 10.1002/cm.970160303; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PIPERNO G, 1979, J BIOL CHEM, V254, P2187; PIPERNO G, 1981, CELL, V27, P331, DOI 10.1016/0092-8674(81)90416-5; RUBENSTEIN PA, 1990, BIOESSAYS, V12, P309, DOI 10.1002/bies.950120702; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANDEKERCKHOVE J, 1978, EUR J BIOCHEM, V90, P451, DOI 10.1111/j.1432-1033.1978.tb12624.x	27	166	171	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					244	246		10.1038/359244a0	http://dx.doi.org/10.1038/359244a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1528266				2022-12-28	WOS:A1992JN94400064
J	FUH, G; CUNNINGHAM, BC; FUKUNAGA, R; NAGATA, S; GOEDDEL, DV; WELLS, JA				FUH, G; CUNNINGHAM, BC; FUKUNAGA, R; NAGATA, S; GOEDDEL, DV; WELLS, JA			RATIONAL DESIGN OF POTENT ANTAGONISTS TO THE HUMAN GROWTH-HORMONE RECEPTOR	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; PURIFICATION; MUTAGENESIS; SUPERFAMILY; EXPRESSION; PROLACTIN; CLONING; DOMAIN	A hybrid receptor was constructed that contained the extracellular binding domain of the human growth hormone (hGH) receptor linked to the transmembrane and intracellular domains of the murine granulocyte colony-stimulating factor receptor. Addition of hGH to a myeloid leukemia cell line (FDC-P1) that expressed the hybrid receptor caused proliferation of these cells. The mechanism for signal transduction of the hybrid receptor required dimerization because monoclonal antibodies to the hGH receptor were agonists whereas their monovalent fragments were not. Receptor dimerization occurs sequentially-a receptor binds to site 1 on hGH, and then a second receptor molecule binds to site 2 on hGH. On the basis of this sequential mechanism, which may occur in many other cytokine receptors, inactive hGH analogs were designed that were potent antagonists to hGH-induced cell proliferation. Such antagonists could be useful for treating clinical conditions of hGH excess, such as acromegaly.	GENENTECH INC,DEPT PROT ENGN,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN	Roche Holding; Genentech; Roche Holding; Genentech			Nagata, Shigekazu/AAG-3203-2019; Fukunaga, Rikiro/CAG-2891-2022; Wells, Jim A/O-9854-2016	Nagata, Shigekazu/0000-0001-9758-8426; 				BARNARD R, 1985, BIOCHEM J, V231, P459, DOI 10.1042/bj2310459; BAS SH, 1991, P NATL ACAD SCI USA, V88, P4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FROHMAN LA, 1991, J CLIN ENDOCR METAB, V72, P1175, DOI 10.1210/jcem-72-6-1175; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, UNPUB; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; HIGUCHI R, 1989, PCR PROTOCOLS GUIDE, P177; ISHIZAKAIKEDA E, UNPUB; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MELMED S, 1990, NEW ENGL J MED, V322, P966, DOI 10.1056/NEJM199004053221405; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; WELLS JA, IN PRESS RECENT PROG	23	585	652	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1677	1680		10.1126/science.256.5064.1677	http://dx.doi.org/10.1126/science.256.5064.1677			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1535167				2022-12-28	WOS:A1992HZ17400044
J	BIRNBAUMER, M; SEIBOLD, A; GILBERT, S; ISHIDO, M; BARBERIS, C; ANTARAMIAN, A; BRABET, P; ROSENTHAL, W				BIRNBAUMER, M; SEIBOLD, A; GILBERT, S; ISHIDO, M; BARBERIS, C; ANTARAMIAN, A; BRABET, P; ROSENTHAL, W			MOLECULAR-CLONING OF THE RECEPTOR FOR HUMAN ANTIDIURETIC-HORMONE	NATURE			English	Article							EXPRESSION; DNA; PROTEIN; PROBES; GENE; CDNA	ANTIDIURESIS, the recovery of water from the lumen of the renal collecting tubule, is regulated by the hypothalamic release of antidiuretic hormone (ADH), which binds to specific receptors on renal collecting tubule cells, stimulates adenylyl cyclase and promotes the cyclic AMP-mediated incorporation of water pores into the luminal surface of these cells 1-3. We report here the isolation of the human ADH receptor gene using a genomic expression cloning approach 4. The gene was used to clone the complementary DNA from a human renal library. The deduced amino-acid sequence of the receptor yields a hydropathy profile characteristic of receptors with seven putative transmembrane regions. This and the comparison with other cloned receptors indicates that the ADH receptor is a member of the superfamily of G-protein-coupled receptors.			BIRNBAUMER, M (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.		Brabet, Philippe/AAO-8522-2020	Brabet, Philippe/0000-0003-2739-1622				BIRNBAUMER L, 1974, J BIOL CHEM, V249, P7857; BIRNBAUMER M, 1990, MOL ENDOCRINOL, V4, P245, DOI 10.1210/mend-4-2-245; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HARRIS HW, 1990, AM J PHYSIOL, V258, P237; JARD S, 1983, CURR TOP MEMBR TRANS, V18, P255; JARD S, 1987, AM J PHYSIOL, V253, P41; KAISER K, 1985, DNA CLONING PRACTICA, V1, P1; KENNELLY PJ, 1991, J BIOL CHEM, V266, P1555; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWRENCE CB, 1989, MOL BIOL INFORM RESO; LEVY FO, IN PRESS J BIOL CHEM; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Michell R H, 1979, Biochem Soc Trans, V7, P861; ORLOFF J, 1967, AM J MED, V42, P757, DOI 10.1016/0002-9343(67)90093-9; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	23	480	486	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					333	335		10.1038/357333a0	http://dx.doi.org/10.1038/357333a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1534149				2022-12-28	WOS:A1992HW13200049
J	MANSON, JE; TOSTESON, H; RIDKER, PM; SATTERFIELD, S; HEBERT, P; OCONNOR, GT; BURING, JE; HENNEKENS, CH				MANSON, JE; TOSTESON, H; RIDKER, PM; SATTERFIELD, S; HEBERT, P; OCONNOR, GT; BURING, JE; HENNEKENS, CH			MEDICAL PROGRESS - THE PRIMARY PREVENTION OF MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORONARY HEART-DISEASE; HIGH-DENSITY-LIPOPROTEIN; FACTOR INTERVENTION TRIAL; NON-CONTRACEPTIVE ESTROGENS; TIME PHYSICAL-ACTIVITY; ALL-CAUSE MORTALITY; RISK FACTOR; CARDIOVASCULAR-DISEASE; UNITED-STATES; FOLLOW-UP		BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PREVENT MED, BOSTON, MA 02115 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT MED, HANOVER, NH 03756 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Dartmouth College					NHLBI NIH HHS [HL-34594, HL-34595] Funding Source: Medline; NIDDK NIH HHS [DK-36798] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595, R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1984, LANCET, V2, P600; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BARRETTCONNOR E, 1983, AM J EPIDEMIOL, V118, P489, DOI 10.1093/oxfordjournals.aje.a113654; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BIERMAN EL, 1981, TXB ENDOCRINOLOGY, V1, P906; BJORNTORP P, 1985, ANN INTERN MED, V103, P994, DOI 10.7326/0003-4819-103-6-994; BJORNTORP P, 1992, OBESITY, P708; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BLUM A, 1986, JAMA-J AM MED ASSOC, V255, P1049; BONADONNA RC, 1992, OBESITY, P474; BOSTICK R M, 1991, Archives of Internal Medicine, V151, P478, DOI 10.1001/archinte.151.3.478; BRUNNER D, 1974, J CHRON DIS, V27, P217, DOI 10.1016/0021-9681(74)90047-2; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; BURKE GL, 1991, NEW ENGL J MED, V324, P941, DOI 10.1056/NEJM199104043241402; BUSH TL, 1987, MENOPAUSE PHYSL PHAR, P187; BUTLER WJ, 1985, AM J EPIDEMIOL, V121, P541; CANO A, 1991, MATURITAS, V13, P35, DOI 10.1016/0378-5122(91)90283-V; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CHAKRABARTI R, 1976, DIABETOLOGIA, V12, P383; CHANG WC, 1980, BIOCHIM BIOPHYS ACTA, V620, P472; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CHRISTIANSEN C, 1984, MATURITAS, V5, P193, DOI 10.1016/0378-5122(84)90052-5; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOKSEY JD, 1978, AM J CARDIOL, V42, P372, DOI 10.1016/0002-9149(78)90930-X; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DAYTON S, 1969, CIRCULATION S2, V39, P1; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; DeFronzo R A, 1983, Am J Med, V74, P52, DOI 10.1016/0002-9343(83)90654-X; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DOYLE JT, 1964, JAMA-J AM MED ASSOC, V190, P886; DWYER JT, 1992, OBESITY, P662; EAKER ED, 1987, CORONARY HEART DISEA, P122; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; FIORE M, 1988, SMOKING HLTH 1987, P189; FISCHER GM, 1981, ATHEROSCLEROSIS, V39, P463, DOI 10.1016/0021-9150(81)90004-6; FLEISCHER N, 1990, HEART, P1497; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GORDON T, 1974, LANCET, V2, P1345; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GORDON T, 1974, J CHRON DIS, V27, P329, DOI 10.1016/0021-9681(74)90013-7; HAARBO J, 1991, AM J MED, V90, P584, DOI 10.1016/S0002-9343(05)80009-9; HAMMER RL, 1989, AM J CLIN NUTR, V49, P77, DOI 10.1093/ajcn/49.1.77; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; HARLAN WR, 1988, AM J EPIDEMIOL, V128, P1065; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HEBERT PR, 1988, AM J EPIDEMIOL, V127, P581, DOI 10.1093/oxfordjournals.aje.a114833; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HENDERSON BE, 1986, AM J OBSTET GYNECOL, V154, P1181, DOI 10.1016/0002-9378(86)90696-4; HENNEKENS CH, 1979, JAMA-J AM MED ASSOC, V242, P1973, DOI 10.1001/jama.242.18.1973; HENNEKENS CH, 1978, AM J EPIDEMIOL, V107, P196, DOI 10.1093/oxfordjournals.aje.a112525; HENNEKENS CH, 1988, NEW ENGL J MED, V318, P923; HENNEKENS CH, 1988, TRENDS CORONARY HEAR, P103; HENNEKENS CH, 1979, BR J FAM PLANN, V5, P66; HEYDEN S, 1980, J CHRON DIS, V33, P265, DOI 10.1016/0021-9681(80)90021-1; HJERMANN I, 1981, LANCET, V2, P1303; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; Hypertension Prevention Trial Research Group, 1990, ARCH INTERN MED, V150, P153, DOI [10.1001/archinte.1990.00390130131021, DOI 10.1001/ARCHINTE.1990.00390130131021]; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JARRETT RJ, 1982, DIABETOLOGIA, V22, P79, DOI 10.1007/BF00254833; JARRETT RJ, 1984, DIABETES HEART DISEA, P00001; JICK H, 1978, JAMA-J AM MED ASSOC, V239, P1407, DOI 10.1001/jama.239.14.1407; KABLE WT, 1990, J REPROD MED, V35, P512; Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120; KANNEL WB, 1980, CIRCULATION, V61, P1179, DOI 10.1161/01.CIR.61.6.1179; KANNEL WB, 1985, AM HEART J, V110, P1100, DOI 10.1016/0002-8703(85)90224-8; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KANNEL WB, 1970, SOME CHARACTERISTICS; KANNEL WB, 1986, HEART ARTERIES VEINS, P557; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KLATSKY AL, 1974, ANN INTERN MED, V81, P294, DOI 10.7326/0003-4819-81-3-294; KROLEWSKI AS, 1985, JOSLINS DIABETES MEL, P251; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LANGFORD HG, 1985, JAMA-J AM MED ASSOC, V253, P657, DOI 10.1001/jama.253.5.657; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LAUG WE, 1983, JAMA-J AM MED ASSOC, V250, P772, DOI 10.1001/jama.250.6.772; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LIE H, 1985, EUR HEART J, V6, P147, DOI 10.1093/oxfordjournals.eurheartj.a061829; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; LOBO RA, 1990, ANN NY ACAD SCI, V592, P286; LUNDBERG GD, 1986, JAMA-J AM MED ASSOC, V255, P1051; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANN GV, 1974, NEW ENGL J MED, V291, P178, DOI 10.1056/NEJM197407252910405; MANN GV, 1974, NEW ENGL J MED, V291, P226, DOI 10.1056/NEJM197408012910504; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MASKIN CS, 1986, CARDIOPULMONARY EXER, P317; MAYNE EE, 1970, DIABETOLOGIA, V6, P436, DOI 10.1007/BF01212078; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NABULSI A, 1991, AM J EPIDEMIOL, V134, P752; OBERMAN A, 1988, HEART DISEASE TXB CA, P1395; OCKENE JK, 1990, AM J PUBLIC HEALTH, V80, P954, DOI 10.2105/AJPH.80.8.954; OTTOSSON UB, 1985, AM J OBSTET GYNECOL, V151, P746, DOI 10.1016/0002-9378(85)90509-5; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1983, AM J EPIDEMIOL, V117, P245, DOI 10.1093/oxfordjournals.aje.a113537; PALMER JR, 1989, NEW ENGL J MED, V320, P1569, DOI 10.1056/NEJM198906153202401; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; PETERS RK, 1983, JAMA-J AM MED ASSOC, V249, P3052, DOI 10.1001/jama.249.22.3052; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PIKE MC, 1989, LANCET, V2, P1034; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROBERTSON TL, 1977, AM J CARDIOL, V39, P239, DOI 10.1016/S0002-9149(77)80197-5; ROGOT E, 1980, PUBLIC HEALTH REP, V95, P213; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; ROSE G, 1982, J EPIDEMIOL COMMUN H, V36, P102, DOI 10.1136/jech.36.2.102; ROSENBERG L, 1990, NEW ENGL J MED, V322, P213, DOI 10.1056/NEJM199001253220401; ROSENBERG L, 1976, NEW ENGL J MED, V294, P1256, DOI 10.1056/NEJM197606032942302; ROSENBERG L, 1985, NEW ENGL J MED, V313, P1511, DOI 10.1056/NEJM198512123132404; ROSENBERG L, 1980, JAMA-J AM MED ASSOC, V244, P339, DOI 10.1001/jama.244.4.339; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; ROSSOUW JE, 1991, NEW ENGL J MED, V325, P1813; Rothman K, 1986, MODERN EPIDEMIOLOGY, P7; RUDERMAN NB, 1984, PROG CARDIOVASC DIS, V26, P373, DOI 10.1016/0033-0620(84)90011-2; SCHUCKER B, 1991, ARCH INTERN MED, V151, P666, DOI 10.1001/archinte.151.4.666; SCHWARTZ J, 1987, NIH872940 PUBL; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SHAPIRO S, 1979, LANCET, V1, P743; SHERWIN R W, 1987, Journal of the American Medical Association, V257, P943, DOI 10.1001/jama.257.7.943; SILFVERSTOLPE G, 1982, MATURITAS, V4, P103, DOI 10.1016/0378-5122(82)90036-6; SIMOPOULOS AP, 1984, ANN INTERN MED, V100, P285, DOI 10.7326/0003-4819-100-2-285; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; SOBOLSKI J, 1987, AM J EPIDEMIOL, V125, P601, DOI 10.1093/oxfordjournals.aje.a114573; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; STAMLER R, 1989, ARCH INTERN MED, V149, P661, DOI 10.1001/archinte.149.3.661; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; SUAREZ L, 1984, AM J EPIDEMIOL, V120, P670, DOI 10.1093/oxfordjournals.aje.a113933; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; THANAVARO S, 1980, CIRCULATION, V61, P29, DOI 10.1161/01.CIR.61.1.29; THORNTON J, 1983, LANCET, V2, P819; TIKKANEN MJ, 1982, J CLIN ENDOCR METAB, V54, P1113, DOI 10.1210/jcem-54-6-1113; TOIVANEN J, 1984, THROMB RES, V33, P1, DOI 10.1016/0049-3848(84)90149-X; VANITALLIE TB, 1979, AM J CLIN NUTR, V32, P2723, DOI 10.1093/ajcn/32.12.2723; WAHL P, 1983, NEW ENGL J MED, V308, P862, DOI 10.1056/NEJM198304143081502; Warner K E, 1986, Circulation, V73, p381A; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; WEST KM, 1978, EPIDEMIOLOGY DIABETE; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WILLIAMS GH, 1980, HARRISONS PRINCIPLES, V2, P1167; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; YANCEY MK, 1990, FERTIL STERIL, V54, P778; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259; 1968, VITAL STATISTICS US; 1992, BMJ, V304, P405; [No title captured]; 1987, MMWR, V3, P195; 1986, PREV MED, V15, P254; 1990, DHHS CDC908416 DEP H; 1989, DHHS CDC898411 DEP H; 1988, ARCH INTERN MED, V148, P36; 1989, GUIDE CLIN PREVENTIV, P375; 1989, GUIDE CLIN PREVENTIV, P305; [No title captured]; 1986, JAMA-J AM MED ASSOC, V256, P70; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1989, GUIDE CLIN PREVENTIV, P300; 1988, ARCH INTERN MED, V148, P1023; 1987, JAMA-J AM MED ASSOC, V257, P937; 1973, VITAL HLTH STATI 10A, V1; 1985, ADV DATA VITAL HLTH, V113, P2; 1981, VITAL HLTH STATIS 15, V1; 1989, GUIDE CLIN PREVENTIV, P27; [No title captured]	182	449	477	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 21	1992	326	21					1406	1416		10.1056/NEJM199205213262107	http://dx.doi.org/10.1056/NEJM199205213262107			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU890	1533273				2022-12-28	WOS:A1992HU89000007
J	HERSH, BS; MARKOWITZ, LE; MAES, EF; FUNKHOUSER, AW; BAUGHMAN, AL; SIROTKIN, BI; HADLER, SC				HERSH, BS; MARKOWITZ, LE; MAES, EF; FUNKHOUSER, AW; BAUGHMAN, AL; SIROTKIN, BI; HADLER, SC			THE GEOGRAPHIC-DISTRIBUTION OF MEASLES IN THE UNITED-STATES, 1980 THROUGH 1989	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGHLY VACCINATED POPULATION; RISK-FACTORS; SCHOOL POPULATION; OUTBREAK; TRANSMISSION; EPIDEMIOLOGY; DISEASE; FAILURE; CARE	Objective. - To describe the geographic distribution of measles cases in the United States by county for the 10-year period from 1980 through 1989. Design. - Ecological analysis of national measles surveillance data. Methods. - Measles cases reported to the Morbidity and Mortality Weekly Report from 1980 through 1989 were analyzed. Data from the 1980 and 1990 US censuses were used to produce demographic profiles for each of the 3137 counties. Outcome variables examined included mean annual incidence and number of years reporting measles, with use of Spearman's rank correlation coefficients to examine the association between the demographic and the two outcome variables. Results. - A total of 56 775 measles cases were reported during the decade. Of the nation's 3137 counties, 1690 (53.9%) did not report any cases; only 17 (0.5%) reported measles in all 10 years. Counties reporting measles more frequently during the decade had higher median populations, population densities, and percentage of black and Hispanic populations than those counties reporting less frequently. Population size, Population density, and percentage of Hispanic population were associated with number of years reporting measles and mean annual measles incidence rate. Measles cases in counties reporting measles every year predominately occurred in unvaccinated preschoolers; cases in counties reporting less frequently predominately occurred in vaccinated school-aged children. Conclusions. - This analysis illustrates the focal nature of measles in the United States during the past decade. Most counties have not reported a single case of measles during the entire decade, and only 17 counties reported measles every year. Targeted strategies are needed to improve age-appropriate immunization levels among preschool-aged children living in large inner-city areas.	CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								Anderson R M, 1984, IMA J Math Appl Med Biol, V1, P233; CHEN RT, 1989, AM J EPIDEMIOL, V129, P173, DOI 10.1093/oxfordjournals.aje.a115106; DAVIS RM, 1987, AM J EPIDEMIOL, V126, P438, DOI 10.1093/oxfordjournals.aje.a114675; FRANK JA, 1985, AM J DIS CHILD, V139, P881, DOI 10.1001/archpedi.1985.02140110035024; GINZBERG E, 1991, JAMA-J AM MED ASSOC, V265, P238, DOI 10.1001/jama.265.2.238; GRIFFITH.DA, 1973, J ROY STAT SOC A STA, V136, P441, DOI 10.2307/2344999; GUSTAFSON TL, 1987, NEW ENGL J MED, V316, P771, DOI 10.1056/NEJM198703263161303; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; Hinman A R, 1980, Epidemiol Rev, V2, P153; HULL HF, 1985, PEDIATRICS, V76, P518; HUTCHINS SS, 1990, AM J EPIDEMIOL, V132, P157, DOI 10.1093/oxfordjournals.aje.a115627; HUTCHINS SS, 1989, PEDIATRICS, V83, P369; MARKOWITZ LE, 1989, NEW ENGL J MED, V320, P75, DOI 10.1056/NEJM198901123200202; NKOWANE BM, 1987, AM J PUBLIC HEALTH, V77, P434, DOI 10.2105/AJPH.77.4.434; ORENSTEIN WA, 1990, PEDIATR CLIN N AM, V37, P709; SHASBY DM, 1977, NEW ENGL J MED, V296, P585, DOI 10.1056/NEJM197703172961102; SOLIS JM, 1990, AM J PUBLIC HEALTH, V80, P11, DOI 10.2105/AJPH.80.Suppl.11; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; 1991, MMWR, V40, P369; 1990, MMWR, V39, P317; 1990, MMWR, V39, P23; 1991, REPORT COMMITTEE INF, P308; 1990, MMWR, V39, P3; 1988, MMWR, V37, P527; 1990, MMWR, V39, P473; 1989, MMWR, V38, P49; 1989, MMWR, V38, pS9; 1988, MMWR, V38, P601; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1986, MMWR, V35, P213; 1989, MMWR, V38, P591; 1990, MMWR, V39, P361; 1978, MMWR, V27, P391; 1989, 1040RD1 CURR POP P25; 1990, MMWR, V39, P353; 1991, MMWR, V40, P36	36	27	28	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1936	1941		10.1001/jama.267.14.1936	http://dx.doi.org/10.1001/jama.267.14.1936			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HL677	1548826				2022-12-28	WOS:A1992HL67700027
J	RODEWALD, HR; MOINGEON, P; LUCICH, JL; DOSIOU, C; LOPEZ, P; REINHERZ, EL				RODEWALD, HR; MOINGEON, P; LUCICH, JL; DOSIOU, C; LOPEZ, P; REINHERZ, EL			A POPULATION OF EARLY FETAL THYMOCYTES EXPRESSING FC-GAMMA-RII/III CONTAINS PRECURSORS OF LYMPHOCYTES-T AND NATURAL-KILLER-CELLS	CELL			English	Article							AFFINITY IGE RECEPTOR; MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; BONE-MARROW; ZETA-CHAIN; NK CELLS; DEVELOPMENTAL BIOLOGY; ACTIVATION PATHWAYS; TRANSFECTED CELLS; B-CELLS	We have identified a dominant fetal thymocyte population at day 14.5 of gestation in the mouse that lacks CD4 and CD8 but expresses Fc-gamma-RII/III+ several days prior to acquisition of the T cell receptor (TCR) in vivo. If maintained in a thymic microenvironment, this population of CD4-CD8-TCR-Fc-gamma-RII/III+ thymocytes differentiates first into CD4+CD8+TCR(low)Fc-gamma-RII/III- thymocytes and subsequently CD4+CD8-TCR(high)Fc-gamma-RII/III- and CD4-CD8+TCR(high)Fc-gamma-RII/III mature Ti alpha-beta lineage T cells. However, if removed from the thymus, the CD4-CD8-TCR-Fc-gamma-RII/III+ thymocyte population selectively generates functional natural killer (NK) cells in vivo as well as in vitro. These findings show that a cellular pool of Fc-gamma-RII/III+ precursors gives rise to T and NK lineages in a microenvironment-dependent manner. Moreover, they suggest a hitherto unrecognized role for Fc receptors on primitive T cells.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, FLOW CYTOMETRY FACIL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	RODEWALD, HR (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, IMMUNOBIOL LAB, 44 BINNEY ST, BOSTON, MA 02115 USA.		Lopez, Peter/AAP-7234-2020	Moingeon, Philippe/0000-0002-2380-9983; Lopez, Peter/0000-0002-8587-7148; Dosiou, Chrysoula/0000-0001-6609-5135	NIAID NIH HHS [AI21226, AI 19807] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021226, R37AI019807, R01AI019807] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACUTO O, 1983, CELL, V34, P717, DOI 10.1016/0092-8674(83)90528-7; ADKINS B, 1987, ANNU REV IMMUNOL, V5, P325, DOI 10.1146/annurev.iy.05.040187.001545; ALCOVER A, 1988, EMBO J, V7, P1973, DOI 10.1002/j.1460-2075.1988.tb03035.x; ALLISON JP, 1982, J IMMUNOL, V129, P2293; ANDERSON CL, 1974, J EXP MED, V139, P1175, DOI 10.1084/jem.139.5.1175; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; [Anonymous], IMMUNOBIOLOGY NATURA; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BOCKENSTEDT LK, 1988, J IMMUNOL, V141, P1904; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BRENNER MB, 1986, NATURE, V322, P145, DOI 10.1038/322145a0; BRUCE J, 1981, J IMMUNOL, V127, P2496; BUDD RC, 1986, J IMMUNOL, V137, P3734; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER MD, 1966, J EXP MED, V123, P75, DOI 10.1084/jem.123.1.75; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; FAURE F, 1990, IMMUNOL TODAY, V11, P108, DOI 10.1016/0167-5699(90)90041-7; FONTAINEPERUS JC, 1981, J IMMUNOL, V126, P2310; FOWLKES BJ, 1985, J EXP MED, V162, P802, DOI 10.1084/jem.162.3.802; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARNIWAGNER BA, 1990, J IMMUNOL, V144, P796; GOLDSCHNEIDER I, 1986, J EXP MED, V163, P1, DOI 10.1084/jem.163.1.1; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; HACKETT J, 1986, P NATL ACAD SCI USA, V83, P3427, DOI 10.1073/pnas.83.10.3427; HACKETT J, 1985, J IMMUNOL, V134, P3731; HALLER O, 1977, J EXP MED, V145, P1411, DOI 10.1084/jem.145.5.1411; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HERBERMAN RB, 1978, J IMMUNOL, V121, P304; HERBERMAN RB, 1986, ANNU REV IMMUNOL, V4, P651, DOI 10.1146/annurev.iy.04.040186.003251; HERBERMAN RB, 1975, INT J CANCER, V16, P216, DOI 10.1002/ijc.2910160204; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HOGAN B, 1986, MANIPULATING MOUSE E, P271; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P7706, DOI 10.1073/pnas.82.22.7706; HORI T, 1991, J IMMUNOL, V146, P2116; HOWARD FD, 1990, P NATL ACAD SCI USA, V87, P7015, DOI 10.1073/pnas.87.18.7015; JOHNSON GD, 1986, HDB EXPT IMMUNOLOGY, V4, P1; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; JOTEREAU F, 1987, J IMMUNOL, V138, P1026; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; KOO GC, 1986, J IMMUNOL, V137, P3742; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUZIEL WA, 1991, EUR J IMMUNOL, V21, P1563, DOI 10.1002/eji.1830210635; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOHMANNMATTHES ML, 1979, J IMMUNOL, V123, P1883; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; MATHIESON BJ, 1984, IMMUNOL REV, V82, P141, DOI 10.1111/j.1600-065X.1984.tb01121.x; MELLMAN IS, 1980, J EXP MED, V152, P1048, DOI 10.1084/jem.152.4.1048; MICHON JM, 1988, J IMMUNOL, V140, P3660; MILLER JF, 1961, LANCET, V2, P748; MINGARI MC, 1991, J EXP MED, V174, P21, DOI 10.1084/jem.174.1.21; MOINGEON P, 1988, J EXP MED, V168, P2077, DOI 10.1084/jem.168.6.2077; MOINGEON P, 1992, P NATL ACAD SCI USA, V89, P1492, DOI 10.1073/pnas.89.4.1492; NAKANISHI N, 1987, NATURE, V325, P720, DOI 10.1038/325720a0; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; ORTALDO JR, 1984, ANNU REV IMMUNOL, V2, P359, DOI 10.1146/annurev.iy.02.040184.002043; OWEN JJT, 1969, J EXP MED, V129, P431, DOI 10.1084/jem.129.2.431; PARDOLL DM, 1987, NATURE, V326, P79, DOI 10.1038/326079a0; PERUSSIA B, 1989, J EXP MED, V170, P73, DOI 10.1084/jem.170.1.73; PETER HH, 1983, J IMMUNOL, V131, P2332; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PHILLIPS JH, 1987, J IMMUNOL, V139, P683; PLUM J, 1990, J IMMUNOL, V144, P3710; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RA C, 1989, J BIOL CHEM, V264, P15323; RAMSDELL FJ, 1987, J IMMUNOL, V139, P1446; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RITZ J, 1985, SCIENCE, V228, P1540, DOI 10.1126/science.2409597; RODEWALD HR, 1991, J BIOL CHEM, V266, P15974; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITTVERHULST AM, 1987, NATURE, V325, P628, DOI 10.1038/325628a0; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; SHEN FW, 1981, MONOCLONAL ANTIBODIE, P25; SKINNER M, 1987, J EXP MED, V165, P1481, DOI 10.1084/jem.165.6.1481; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; SPANGRUDE GJ, 1988, J EXP MED, V167, P1671, DOI 10.1084/jem.167.5.1671; STOUT RD, 1975, J EXP MED, V142, P611, DOI 10.1084/jem.142.3.611; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; YAGITA H, 1989, EUR J IMMUNOL, V19, P2211, DOI 10.1002/eji.1830191206; YAGITA H, 1989, P NATL ACAD SCI USA, V86, P645, DOI 10.1073/pnas.86.2.645	97	275	285	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					139	150		10.1016/0092-8674(92)90125-V	http://dx.doi.org/10.1016/0092-8674(92)90125-V			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1532536				2022-12-28	WOS:A1992HM44500013
J	KUNIN, CM				KUNIN, CM			SURVEILLANCE CULTURES OF THE URINE AND CATHETER PLACEMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KUNIN, CM (corresponding author), OHIO STATE UNIV,COLUMBUS,OH 43210, USA.							GIVENS CD, 1980, J UROLOGY, V124, P646, DOI 10.1016/S0022-5347(17)55596-2; HARDING GKM, 1991, ANN INTERN MED, V114, P713, DOI 10.7326/0003-4819-114-9-713; KUNIN CM, 1987, DETECTION PREVENTION, P245; PLATT R, 1982, NEW ENGL J MED, V307, P637, DOI 10.1056/NEJM198209093071101	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1677	1677						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1542181				2022-12-28	WOS:A1992HJ59700039
J	BLOCK, PC				BLOCK, PC			PERCUTANEOUS MITRAL BALLOON VALVOTOMY BY MEANS OF THE DOUBLE-BALLOON TECHNIQUE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note																			0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1992	326	12					799	799						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ592	1538723				2022-12-28	WOS:A1992HJ59200004
J	CROSS, SJ; EVANS, SA; THOMSON, LF; LEE, HS; JENNINGS, KP; SHIELDS, TG				CROSS, SJ; EVANS, SA; THOMSON, LF; LEE, HS; JENNINGS, KP; SHIELDS, TG			SAFETY OF SUBAQUA DIVING WITH A PATENT FORAMEN OVALE	BRITISH MEDICAL JOURNAL			English	Article							DECOMPRESSION-SICKNESS; DIVERS		ABERDEEN ROYAL INFIRM,HYPERBAR MED UNIT,ABERDEEN AB9 2ZB,SCOTLAND	University of Aberdeen	CROSS, SJ (corresponding author), ABERDEEN ROYAL INFIRM,DEPT CARDIOL,ABERDEEN AB9 2ZD,SCOTLAND.							HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; MOON RE, 1989, LANCET, V1, P513; SHUB C, 1976, MAYO CLIN PROC, V51, P81; WILMSHURST PT, 1989, LANCET, V2, P1302	5	33	33	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					481	482		10.1136/bmj.304.6825.481	http://dx.doi.org/10.1136/bmj.304.6825.481			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547421	Green Published, Bronze			2022-12-28	WOS:A1992HF55500024
J	PIMM, SL; GITTLEMAN, JL				PIMM, SL; GITTLEMAN, JL			BIOLOGICAL DIVERSITY - WHERE IS IT	SCIENCE			English	Editorial Material									UNIV TENNESSEE,GRAD PROGRAM ECOL,KNOXVILLE,TN 37996	University of Tennessee System; University of Tennessee Knoxville	PIMM, SL (corresponding author), UNIV TENNESSEE,DEPT ZOOL,KNOXVILLE,TN 37996, USA.							JARVINEN O, 1978, OIKOS, V30, P496, DOI 10.2307/3543345; MARES MA, 1992, SCIENCE, V255, P976, DOI 10.1126/science.255.5047.976; MAY RM, 1988, SCIENCE, V241, P1441, DOI 10.1126/science.241.4872.1441; PAGEL MD, 1991, AM NAT, V137, P791, DOI 10.1086/285194; PRESTON FW, 1962, ECOLOGY, V43, P185, DOI 10.2307/1931976; RICE B, 1983, VEGETATIO, V52, P129, DOI 10.1007/BF00044988; ROSENZWEIG ML, IN PRESS HIST GEOGRP; SCHALL JJ, 1978, SCIENCE, V201, P679, DOI 10.1126/science.201.4357.679; TOBIN RJ, 1990, EXPENDABLE FUTURE; WALLACE AR, 1876, GEOGRPAHICAL DISTRIB	10	45	49	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					940	940		10.1126/science.1546290	http://dx.doi.org/10.1126/science.1546290			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546290				2022-12-28	WOS:A1992HE60500030
J	RISCH, N				RISCH, N			GENETIC-LINKAGE - INTERPRETING LOD SCORES	SCIENCE			English	Editorial Material							FAMILIAL ALZHEIMERS-DISEASE; BREAST-CANCER; ONSET		YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Yale University	RISCH, N (corresponding author), YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510, USA.				NHGRI NIH HHS [HG00348] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000348] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BISHOP DT, 1988, GENET EPIDEMIOL, V5, P151, DOI 10.1002/gepi.1370050303; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059; ELSTON RC, 1975, ANN HUM GENET, V38, P341, DOI 10.1111/j.1469-1809.1975.tb00619.x; FAJANS SS, 1990, DIABETES CARE, V13, P49, DOI 10.2337/diacare.13.1.49; GOATE AM, 1989, LANCET, V1, P352; GREENBERG DA, 1989, GENET EPIDEMIOL, V6, P259, DOI 10.1002/gepi.1370060145; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HALL JM, 1989, AM J HUM GENET, V44, P577; MORTON NE, 1955, AM J HUM GENET, V7, P277; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P1; OTT J, 1985, ANAL HUMAN GENETIC L; RISCH N, 1990, GENET EPIDEMIOL, V7, P3, DOI 10.1002/gepi.1370070103; RISCH N, 1990, AM J HUM GENET, V46, P222; RISCH N, 1991, AM J HUM GENET, V48, P1058; RISCH N, IN PRESS HUM HERED; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; TATTERSALL RB, 1975, DIABETES, V24, P44, DOI 10.2337/diabetes.24.1.44; WILLIAMS W R, 1984, Genetic Epidemiology, V1, P7, DOI 10.1002/gepi.1370010104	22	65	83	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					803	804		10.1126/science.1536004	http://dx.doi.org/10.1126/science.1536004			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1536004				2022-12-28	WOS:A1992HD54800025
J	LOSICK, R; STRAGIER, P				LOSICK, R; STRAGIER, P			CRISSCROSS REGULATION OF CELL-TYPE-SPECIFIC GENE-EXPRESSION DURING DEVELOPMENT IN BACILLUS-SUBTILIS	NATURE			English	Review							DUPLICATED SPORULATION GENES; SIGMA-FACTOR SIGMA-29; BACILLUS-SUBTILIS; TRANSCRIPTION FACTOR; RNA-POLYMERASE; ENDOSPORE FORMATION; SPATIAL CONTROL; SPORE COAT; PROTEIN; IDENTIFICATION	Sporulation in Bacillus subtilis is a model for how cells of one type generate other differentiated cell types. During sporulation two cellular compartments arise that differ from each other and from the progenitor cell. Differential gene expression between the two is governed by the successive appearance of four transcription factors whose activities are coordinated in crisscross fashion between the two cells.	INST BIOL PHYSICOCHEM,F-75005 PARIS,FRANCE		LOSICK, R (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,BIOL LABS,CAMBRIDGE,MA 02138, USA.			STRAGIER, Patrick/0000-0003-0849-3025				ADAMS LF, 1991, J BACTERIOL, V173, P3846, DOI 10.1128/JB.173.12.3846-3854.1991; BEALL B, 1991, J GENES DEV, V5, P447; BUIKEMA WJ, 1991, GENE DEV, V5, P321, DOI 10.1101/gad.5.2.321; CARLSON HC, 1989, J BACTERIOL, V171, P2216, DOI 10.1128/jb.171.4.2216-2218.1989; CLARKE S, 1986, J GEN MICROBIOL, V132, P2987; CUTTING S, 1989, J MOL BIOL, V207, P393, DOI 10.1016/0022-2836(89)90262-3; CUTTING S, 1991, J MOL BIOL, V221, P1237; CUTTING S, 1991, GENE DEV, V5, P456, DOI 10.1101/gad.5.3.456; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DELENCASTRE H, 1979, J GEN MICROBIOL, V114, P377, DOI 10.1099/00221287-114-2-377; DRIKS A, 1991, P NATL ACAD SCI USA, V88, P9934, DOI 10.1073/pnas.88.22.9934; ERRINGTON J, 1991, P ROY SOC B-BIOL SCI, V244, P117, DOI 10.1098/rspb.1991.0059; ERRINGTON J, 1985, FEBS LETT, V188, P184, DOI 10.1016/0014-5793(85)80368-9; ERRINGTON J, 1990, GENETICS BIOTECHNOLO, V3, P257; FORT P, 1984, J GEN MICROBIOL, V130, P2147; FRANCESCONI SC, 1988, J BACTERIOL, V170, P5963, DOI 10.1128/jb.170.12.5963-5967.1988; GHOLAMHOSEINIAN A, 1989, J BACTERIOL, V171, P5747, DOI 10.1128/jb.171.10.5747-5749.1989; GOBER JW, 1991, CELL, V64, P381, DOI 10.1016/0092-8674(91)90646-G; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; ILLING N, 1991, J BACTERIOL, V173, P3159, DOI 10.1128/JB.173.10.3159-3169.1991; ILLING N, 1991, J MOL MICROBIOL, V5, P1927; JONAS RM, 1990, J BACTERIOL, V172, P4178, DOI 10.1128/jb.172.8.4178-4186.1990; JONAS RM, 1989, J BACTERIOL, V171, P5226, DOI 10.1128/jb.171.9.5226-5228.1989; JONAS RM, 1988, J BACTERIOL, V170, P507, DOI 10.1128/jb.170.2.507-511.1988; KARMAZYNCAMPELLI C, 1989, GENE DEV, V3, P150, DOI 10.1101/gad.3.2.150; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; KUNKEL B, 1990, GENE DEV, V4, P525, DOI 10.1101/gad.4.4.525; KUNKEL B, 1988, J BACTERIOL, V170, P3513, DOI 10.1128/jb.170.8.3513-3522.1988; KUNKEL B, 1989, GENE DEV, V3, P1735, DOI 10.1101/gad.3.11.1735; LABELL TL, 1987, P NATL ACAD SCI USA, V84, P1784, DOI 10.1073/pnas.84.7.1784; LOSICK R, 1986, ANNU REV GENET, V20, P625, DOI 10.1146/annurev.ge.20.120186.003205; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MORAN CP, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P167; PARTRIDGE SR, 1991, MOL MICROBIOL, V5, P757, DOI 10.1111/j.1365-2958.1991.tb00746.x; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; PIGGOT PJ, 1984, J GEN MICROBIOL, V130, P2123; RATHER PN, 1990, J BACTERIOL, V172, P709, DOI 10.1128/jb.172.2.709-715.1990; RONG S, 1986, J BACTERIOL, V165, P771, DOI 10.1128/jb.165.3.771-779.1986; SANDMAN K, 1988, J MOL BIOL, V200, P461, DOI 10.1016/0022-2836(88)90536-0; SATO T, 1990, J BACTERIOL, V172, P1092, DOI 10.1128/jb.172.2.1092-1098.1990; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; SETLOW P, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P211; STEVENS CM, 1990, MOL MICROBIOL, V4, P543, DOI 10.1111/j.1365-2958.1990.tb00622.x; STRAGIER P, 1990, MOL MICROBIOL, V4, P1801, DOI 10.1111/j.1365-2958.1990.tb02028.x; STRAGIER P, 1984, NATURE, V312, P376, DOI 10.1038/312376a0; STRAGIER P, 1989, SCIENCE, V243, P507, DOI 10.1126/science.2536191; STRAGIER P, 1986, FEBS LETT, V195, P9, DOI 10.1016/0014-5793(86)80119-3; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STRAGIER P, 1992, PROKARYOTIC STRUCTUR, P297; SUN DX, 1991, J BACTERIOL, V173, P2977, DOI 10.1128/JB.173.9.2977-2984.1991; SUN DX, 1989, GENE DEV, V3, P141, DOI 10.1101/gad.3.2.141; SUSSMAN MD, 1991, J BACTERIOL, V173, P291, DOI 10.1128/jb.173.1.291-300.1991; TREMPY JE, 1985, P NATL ACAD SCI USA, V82, P4189, DOI 10.1073/pnas.82.12.4189; TREMPY JE, 1985, J BACTERIOL, V161, P340, DOI 10.1128/JB.161.1.340-346.1985; ZHENG LB, 1990, J MOL BIOL, V212, P645, DOI 10.1016/0022-2836(90)90227-D	57	349	356	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					601	604		10.1038/355601a0	http://dx.doi.org/10.1038/355601a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538747				2022-12-28	WOS:A1992HD54700041
J	CHESHIRE, NJW; WOLFE, JHN				CHESHIRE, NJW; WOLFE, JHN			ABC OF VASCULAR DISEASES - CRITICAL LEG ISCHEMIA - AMPUTATION OR RECONSTRUCTION	BRITISH MEDICAL JOURNAL			English	Article											CHESHIRE, NJW (corresponding author), ST MARYS HOSP,LONDON,ENGLAND.								0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					312	314		10.1136/bmj.304.6822.312	http://dx.doi.org/10.1136/bmj.304.6822.312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1531431	Green Published, Bronze			2022-12-28	WOS:A1992HC70800029
J	WALD, A; COYLE, MB; CARLSON, LC; THOMPSON, RL; HOOTON, TM				WALD, A; COYLE, MB; CARLSON, LC; THOMPSON, RL; HOOTON, TM			INFECTION WITH A FASTIDIOUS MYCOBACTERIUM RESEMBLING MYCOBACTERIUM-SIMIAE IN 7 PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Note								We report the clinical features of seven patients with the acquired immunodeficiency syndrome (AIDS) who were infected with a new, fastidious mycobacterium, and we describe the microbiologic properties of the isolates. All patients but one had had a previous AIDS-defining illness; the median CD4 lymphocyte count was 7/muL. Fevers and wasting were the most common signs and symptoms, followed by abdominal pain and diarrhea. The mycobacterium grew fastidiously on solid media and resembled Mycobacterium simiae on chromatography. We conclude that this mycobacterium infects profoundly immunosuppressed patients with AIDS. The clinical features at presentation are comparable to those reported in patients with disseminated Mycobacterium avium complex infection.	UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA; GRP HLTH COOPERAT PUGET SOUND, SEATTLE, WA USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative			Wald, Anna/B-6272-2012	Wald, Anna/0000-0003-3486-6438				AGY MB, 1989, DIAGN MICR INFEC DIS, V12, P303, DOI 10.1016/0732-8893(89)90094-1; BOTTGER EC, 1991, 31ST P INT C ANT AG; BUTLER WR, 1991, J CLIN MICROBIOL, V29, P2468, DOI 10.1128/JCM.29.11.2468-2472.1991; HIRSCHEL B, 1990, NEW ENGL J MED, V323, P109, DOI 10.1056/NEJM199007123230207; MINNIKIN DE, 1985, ZBL BAKT-INT J MED M, V259, P446	5	37	37	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					586	589		10.7326/0003-4819-117-7-586	http://dx.doi.org/10.7326/0003-4819-117-7-586			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524333				2022-12-28	WOS:A1992JQ22600008
J	NERI, D; BILLETER, M; WIDER, G; WUTHRICH, K				NERI, D; BILLETER, M; WIDER, G; WUTHRICH, K			NMR DETERMINATION OF RESIDUAL STRUCTURE IN A UREA-DENATURED PROTEIN, THE 434-REPRESSOR	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; DNA-BINDING DOMAIN; PHAGE-434 REPRESSOR; PROTON; SPECTROSCOPY; CONFORMATIONS; FILTERS; LEUCINE; VALINE	A nuclear magnetic resonance (NMR) structure determination is reported for the polypeptide chain of a globular protein in strongly denaturing solution. Nuclear Overhauser effect (NOE) measurements with a 7 molar urea solution of the amino-terminal 63-residue domain of the 434-repressor and distance geometry calculations showed that the polypeptide segment 54 to 59 forms a hydrophobic cluster containing the side chains of Val54, Val56, Trp58, and Leu59. This residual structure in the urea-unfolded protein is related to the corresponding region of the native, folded protein by simple rearrangements of the residues 58 to 60. Based on these observations a model for the early phase of refolding of the 434-repressor(1-63) is proposed.	SWISS FED INST TECHNOL,INST MOLEK BIOL & BIOPHYS,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Neri, Dario/P-4368-2016; Billeter, Martin/A-8293-2010	Neri, Dario/0000-0001-5234-7370; Wider, Gerhard/0000-0001-9366-7645				ANDERSON J, 1984, P NATL ACAD SCI-BIOL, V81, P1307, DOI 10.1073/pnas.81.5.1307; BILLETER M, 1990, BIOPOLYMERS, V29, P695, DOI 10.1002/bip.360290404; BRAUN W, 1981, BIOCHIM BIOPHYS ACTA, V667, P377, DOI 10.1016/0005-2795(81)90205-1; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CHAN HS, 1990, P NATL ACAD SCI USA, V87, P6388, DOI 10.1073/pnas.87.16.6388; Dobson CM, 1991, CURR OPIN STRUC BIOL, V1, P22, DOI 10.1016/0959-440X(91)90006-F; FESIK SW, 1988, NATURE, V332, P865, DOI 10.1038/332865a0; GRIFFEY RH, 1987, Q REV BIOPHYS, V19, P51, DOI 10.1017/S0033583500004029; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; MONDRAGON A, 1989, J MOL BIOL, V205, P189, DOI 10.1016/0022-2836(89)90375-6; NERI D, 1992, J MOL BIOL, V223, P743, DOI 10.1016/0022-2836(92)90987-U; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NERI D, 1992, P NATL ACAD SCI USA, V89, P4397, DOI 10.1073/pnas.89.10.4397; NERI D, 1992, FEBS LETT, V303, P129, DOI 10.1016/0014-5793(92)80504-A; OTTING G, 1988, J MAGN RESON, V76, P569, DOI 10.1016/0022-2364(88)90361-7; OTTING G, 1986, J MAGN RESON, V70, P500, DOI 10.1016/0022-2364(86)90144-7; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083; RICHARDS FM, 1991, SCI AM, V264, P54, DOI 10.1038/scientificamerican0191-54; RODER H, 1986, Proteins Structure Function and Genetics, V1, P34, DOI 10.1002/prot.340010107; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SENN H, 1989, FEBS LETT, V249, P113, DOI 10.1016/0014-5793(89)80027-4; SINGH UC, 1986, AMBER30 U CAL; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WIDER G, 1991, J AM CHEM SOC, V113, P4676, DOI 10.1021/ja00012a044; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC	28	494	498	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 11	1992	257	5076					1559	1563		10.1126/science.1523410	http://dx.doi.org/10.1126/science.1523410			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523410				2022-12-28	WOS:A1992JM57000036
J	SKINNER, MH; FUTTERMAN, A; MORRISSETTE, D; THOMPSON, LW; HOFFMAN, BB; BLASCHKE, TF				SKINNER, MH; FUTTERMAN, A; MORRISSETTE, D; THOMPSON, LW; HOFFMAN, BB; BLASCHKE, TF			ATENOLOL COMPARED WITH NIFEDIPINE - EFFECT ON COGNITIVE FUNCTION AND MOOD IN ELDERLY HYPERTENSIVE PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						ATENOLOL; NIFEDEPINE; HYPERTENSION; COGNITION DISORDERS; AFFECTIVE DISORDERS	BETA-BLOCKERS; ANTIHYPERTENSIVE THERAPY; BEHAVIORAL CONSEQUENCES; BLOOD-PRESSURE; MEMORY; PERFORMANCE; TOLERANCE; PROPRANOLOL; IMPAIRMENT; NIMODIPINE	Objective: To compare the effects of atenolol an nifedipine on mood and cognitive function in elderly hypertensive patients. Design: Randomized, double-blind, crossover trial. Patients: Thirty-one elderly volunteers (7 women and 24 men) 60 to 81 years of age with mild to moderate hypertension were recruited from the general community and a Veterans Affairs hospital hypertension clinic. Six volunteers withdrew at early phases of the study for reasons unrelated to adverse drug effects. Interventions: Participants had 2 weeks of placebo, 2 to 6 weeks of titration with atenolol or nifedipine, and 4 weeks of treatment followed by similar periods with the other drug. Measurements: Psychometric tests designed to assess mood and cognitive function. Results: In the group first treated with nifedipine, the summed recall score on the Buschke selective reminding test (a test of verbal learning and memory) decreased by 9.3 words (95% Cl, 2.8 to 15.6 words), or 9%, during nifedipine treatment compared with placebo (P = 0.031). The group first treated with atenolol showed no improvement in summed recall scores when results seen during atenolol therapy and placebo administration were compared (P = 0.10); however, this group had an improvement of 16.1 words (Cl, 5.6 to 26.5 words), or of 16%, when the atenolol score was compared with the nifedipine score (P = 0.026). In the group first treated with nifedipine, 6 of 11 patients (55%) showed a decrease of 5 words or more during nifedipine therapy compared with placebo, whereas only 1 of the 14 patients (7%) in the group first treated with atenolol showed a similar decrease (P < 0.01). On the digit symbol test (a psychomotor test), patients treated first with atenolol tended to improve, whereas patients treated first with nifedipine tended to decline. The difference between nifedipine and atenolol, in terms of the change from the score seen during placebo, was 4.3 codings (Cl, 0.7 to 7.9 codings) or 10% (P = 0.043). No statistically significant differences were seen between nifedipine and atenolol therapy regarding the other measures of psychomotor ability, sustained attention, motor performance, verbal fluency, or reasoning, and no effects of either drug on mood or psychopathologic symptoms were noted. Conclusions: Although atenolol and nifedipine are generally free of gross effects on cognition or mood, nifedipine may subtly impair learning and memory in some elderly hypertensive patients.	STANFORD UNIV, MED CTR, STANFORD, CA 94305 USA; VET AFFAIRS MED CTR, PALO ALTO, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Blaschke, Terrence/0000-0001-5307-2620	NIA NIH HHS [AG05627] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTURA BT, 1981, SCIENCE, V212, P1051, DOI 10.1126/science.7195070; ANDERSON GC, 1990, NATURE, V344, P368, DOI 10.1038/344368b0; BANKS PG, 1987, EXP AGING RES, V13, P203; BARNES DM, 1988, SCIENCE, V239, P254, DOI 10.1126/science.2447649; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BOLLER F, 1977, ARCH NEUROL-CHICAGO, V34, P701, DOI 10.1001/archneur.1977.00500230071012; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; DAVIES ADM, 1968, J CLIN PSYCHOL, V24, P98; Derogatis L.R., 1982, BRIEF SYMPTOM INDEX; DEYO RA, 1989, SCIENCE, V243, P809, DOI 10.1126/science.2916127; DIMSDALE JE, 1989, ARCH INTERN MED, V149, P514, DOI 10.1001/archinte.149.3.514; DOLIN SJ, 1989, ANESTHESIOLOGY, V70, P91, DOI 10.1097/00000542-198901000-00018; DOLIN SJ, 1989, J PHARMACOL EXP THER, V250, P985; Drachman DA, 1986, DEV NEUROPSYCHOL, V2, P277, DOI 10.1080/87565648609540349; ERBER JT, 1981, J GERONTOL, V36, P586, DOI 10.1093/geronj/36.5.586; Fleiss JL, 1986, DESIGN ANAL CLIN EXP, P263; FRANCESCHI M, 1982, HYPERTENSION, V4, P226, DOI 10.1161/01.HYP.4.2.226; FULD PA, 1982, ANN NEUROL, V11, P155, DOI 10.1002/ana.410110208; FULD PA, 1976, NEUROPSYCHOLOGIA, V14, P225, DOI 10.1016/0028-3932(76)90052-X; GANZ PA, 1990, DRUG SAFETY, V5, P233, DOI 10.2165/00002018-199005040-00001; GENGO FM, 1988, ARCH INTERN MED, V148, P779, DOI 10.1001/archinte.148.4.779; Goldman H, 1974, Dis Nerv Syst, V35, P571; GOREN JY, 1968, 76TH P ANN CONV AM P, V3, P469; Halstead WC., 1947, BRAIN INTELLIGENCE; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; HAYNES RB, 1980, NIH812102 US DEP HLT; IZQUIERDO I, 1990, TRENDS PHARMACOL SCI, V11, P309, DOI 10.1016/0165-6147(90)90229-2; KAZNIAK AW, 1986, HDB CLIN MEMORY ASSE, P168; KRAEMER HC, 1983, PSYCHOL BULL, V94, P367, DOI 10.1037/0033-2909.94.2.367; LANDAUER AA, 1979, PSYCHOPHARMACOLOGY, V60, P211, DOI 10.1007/BF00432296; LASSER NL, 1989, AM J MED, V86, P98, DOI 10.1016/0002-9343(89)90142-3; Levin H. S., 1982, NEUROBEHAVIORAL CONS; Lezak MD, 2012, NEUROPSYCHOLOGICAL A, V5; LICHTER I, 1986, BRIT J CLIN PHARMACO, V21, P641, DOI 10.1111/j.1365-2125.1986.tb05228.x; MADDEN DJ, 1988, HYPERTENSION, V11, P470, DOI 10.1161/01.HYP.11.5.470; MCENTEE WJ, 1990, NEUROLOGY, V40, P526, DOI 10.1212/WNL.40.3_Part_1.526; MILLER RE, 1984, HYPERTENSION, V6, P202, DOI 10.1161/01.HYP.6.2_Pt_1.202; MINTZER J, 1989, ARCH INTERN MED, V149, P1223, DOI 10.1001/archinte.1989.00390050167044; PARKER ES, 1977, J STUD ALCOHOL, V38, P1224, DOI 10.15288/jsa.1977.38.1224; PAYKEL ES, 1982, J CLIN PSYCHOPHARM, V2, P14, DOI 10.1097/00004714-198202000-00004; PETERS BH, 1977, ARCH NEUROL-CHICAGO, V34, P215, DOI 10.1001/archneur.1977.00500160029004; Raven J.C., 1960, GUIDE STANDARD PROGR; Raven J.C., 1965, GUIDE USING COLOURED; REITAN RM, 1955, ARCH NEUROL PSYCHIAT, V73, P338; SALEM SA, 1983, CLIN PHARMACOL THER, V33, P52, DOI 10.1038/clpt.1983.7; SHAPIRO AP, 1982, HYPERTENSION, V4, P355, DOI 10.1161/01.HYP.4.3.355; SOLOMON S, 1983, ARCH GEN PSYCHIAT, V40, P1109; Speilberger C.D., 1970, MANUAL STATE TRAIT A; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; SPITZER RL, 1978, NIMH CLIN RES BRANCH; Spreen O., 1991, PROFILE TEST RESULTS; Steinfatt T. M., 1979, HUMAN COMMUNICATION, V5, P366, DOI DOI 10.1111/J.1468-2958.1979.TB00650.X; STREUFERT S, 1988, AM HEART J, V116, P311, DOI 10.1016/0002-8703(88)90106-8; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Thompson L W, 1987, Annu Rev Gerontol Geriatr, V7, P295; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; WENGER NK, 1984, ASSESSMENT QUALITY L; WILKIE FL, 1990, ARCH NEUROL-CHICAGO, V47, P433, DOI 10.1001/archneur.1990.00530040085022; WOODS JR, 1989, ANN INTERN MED, V110, P560, DOI 10.7326/0003-4819-110-7-560; WU PH, 1987, EUR J PHARMACOL, V139, P233, DOI 10.1016/0014-2999(87)90256-1; YESAVAGE JA, 1985, AM J PSYCHIAT, V142, P600	65	40	41	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					615	623		10.7326/0003-4819-116-8-615	http://dx.doi.org/10.7326/0003-4819-116-8-615			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546860				2022-12-28	WOS:A1992HN84400002
J	NIEMIRA, DA				NIEMIRA, DA			A TIME TO DECIDE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1913	1913		10.1001/jama.267.14.1913	http://dx.doi.org/10.1001/jama.267.14.1913			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL677	1548814				2022-12-28	WOS:A1992HL67700007
J	HUME, SE				HUME, SE			MASS VOLUNTARY IMMUNIZATION CAMPAIGNS FOR MENINGOCOCCAL DISEASE IN CANADA - MEDIA HYSTERIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1992, VANCOUVER SUN   0115, pA1; 1992, PROVINCE        0126, pA9; 1992, VANCOUVER SUN   0203, pB1; 1992, PROVINCE        0119, pA1; 1992, GLOBE MAIL      0114, pA14; 1992, VANCOUVER SUN   0121, pA1; 1992, PROVINCE        0121, pA1	7	26	26	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1833	&		10.1001/jama.267.13.1833	http://dx.doi.org/10.1001/jama.267.13.1833			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545470				2022-12-28	WOS:A1992HK67200039
J	TORRES, A; SERRABATLLES, J; ROS, E; PIERA, C; DELABELLACASA, JP; COBOS, A; LOMENA, F; RODRIGUEZROISIN, R				TORRES, A; SERRABATLLES, J; ROS, E; PIERA, C; DELABELLACASA, JP; COBOS, A; LOMENA, F; RODRIGUEZROISIN, R			PULMONARY ASPIRATION OF GASTRIC CONTENTS IN PATIENTS RECEIVING MECHANICAL VENTILATION - THE EFFECT OF BODY POSITION	ANNALS OF INTERNAL MEDICINE			English	Article						RESPIRATION, ARTIFICIAL; PNEUMONIA; SUPINE POSITION; SUCRALFATE; HISTAMINE-H2 RECEPTOR; BLOCKADERS	NOSOCOMIAL PNEUMONIA; GASTROESOPHAGEAL REFLUX; ARTIFICIAL-VENTILATION; RESPIRATORY-TRACT; RISK; COLONIZATION; SUCRALFATE; CIMETIDINE; PROGNOSIS; BACTERIA	Objective: To determine if the semirecumbent position (45-degree angle) decreases aspiration of gastric contents to the airways in intubated and mechanically ventilated patients. Design: A randomized, two-period crossover trial. Setting: Respiratory intensive care unit. Patients: Nineteen patients requiring intubation and mechanical ventilation. Interventions: Patients were studied in the supine and semirecumbent positions on two separate days. Measurements: After technetium (Tc)-99m sulphur colloid labeling of gastric contents, sequential radioactive counts in endobronchial secretions were measured at 30-minute intervals over a 5-hour period. Samples of endobronchial secretions, gastric juice, and pharyngeal contents were obtained for qualitative bacterial cultures. Results: Mean radioactive counts in endobronchial secretions were higher in samples obtained while patients were in the supine position than in those obtained while patients were in the semirecumbent position (4154 cpm compared with 954 cpm; P = 0.036). Moreover, the aspiration pattern was time-dependent for each position: For the supine position, radioactivity was 298 cpm at 30 min and 2592 cpm at 300 min (P = 0.013); for the semirecumbent position, radioactivity was 103 cpm at 30 min and 216 cpm at 300 min (P = 0.04). The same microorganisms were isolated from stomach, pharynx, and endobronchial samples in 32% of studies done while patients were semirecumbent and in 68% of studies done while patients were in the supine position. Conclusions: We conclude that the supine position and length of time the patient is kept in this position are potential risk factors for aspiration of gastric contents. Elevating the head of the bed for patients who can tolerate the semirecumbent position may be a simple, no-cost prophylactic measure.	UNIV BARCELONA, FAC MED REUS, UNITAT BIOESTADIST, E-08036 BARCELONA, SPAIN	University of Barcelona			Torres, Antoni/H-6128-2017	Torres, Antoni/0000-0002-8643-2167; Ros, Emilio/0000-0002-2573-1294				ANDREWS CP, 1981, CHEST, V80, P254, DOI 10.1378/chest.80.3.254; ATHERTON ST, 1978, LANCET, V2, P968; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CHERNOW B, 1979, DIGEST DIS SCI, V24, P839, DOI 10.1007/BF01324899; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; CRAVEN DE, 1989, EUR J CLIN MICROBIOL, V8, P40, DOI 10.1007/BF01964119; DONOWITZ LG, 1986, INFECT CONT HOSP EP, V7, P23, DOI 10.1017/S0195941700063748; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; DUMOULIN GC, 1982, LANCET, V1, P242; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FISHER RS, 1976, GASTROENTEROLOGY, V70, P301; GOULARTE TA, 1986, AM J INFECT CONTROL, V14, P88; HARDY JF, 1988, CAN J ANAESTH, V35, P162, DOI 10.1007/BF03010658; HELM JF, 1983, GASTROENTEROLOGY, V85, P607; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; Ibanez J, 1988, INTENS CARE MED, V14, P296; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; LAGGNER AN, 1989, AM J MED, V86, P81, DOI 10.1016/0002-9343(89)90164-2; NACHTKAMP J, 1989, LANCET, V1, P160; NORUSIS MJ, 1986, STATISTICAL PACKAGE; REICH SB, 1977, J NUCL MED, V18, P1079; RUDDELL WSJ, 1980, LANCET, V1, P672; SATIANI B, 1978, ARCH SURG-CHICAGO, V113, P721; SCHULZEDELRIEU K, 1982, DISEASES ESOPHAGUS, P35; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; TORRES A, 1988, AM REV RESPIR DIS, V138, P117, DOI 10.1164/ajrccm/138.1.117; TRYBA M, 1987, AM J MED, V83, P117, DOI 10.1016/0002-9343(87)90840-0; WINTERBAUER RH, 1981, ANN INTERN MED, V95, P67, DOI 10.7326/0003-4819-95-1-67	28	455	478	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					540	543		10.7326/0003-4819-116-7-540	http://dx.doi.org/10.7326/0003-4819-116-7-540			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543307				2022-12-28	WOS:A1992HL25800003
J	PARVIN, JD; TIMMERS, HTM; SHARP, PA				PARVIN, JD; TIMMERS, HTM; SHARP, PA			PROMOTER SPECIFICITY OF BASAL TRANSCRIPTION FACTORS	CELL			English	Article							RNA POLYMERASE-II; ACCURATE TRANSCRIPTION; INITIATION-FACTOR; BINDING-PROTEIN; GENE-PRODUCTS; TATA; ACTIVATION; PURIFICATION; REQUIREMENT; COMPLEXES	Regulation of expression of protein-encoding genes in eukaryotes is frequently mediated by sequence-specific transcription factors that control the activities of the basal factors and RNA polymerase II. Basal factors have been considered to be essential for all polymerase II promoters. Studies of the basal factor requirements for transcription from the immunoglobulin heavy chain gene (IgH) core promoter and the adenovirus major late gene core promoter (MLP) suggest that this paradigm is too simple. Basal transcription from the IgH promoter was reconstituted by TFIID, TFIIB, TFIIF, and polymerase, whereas basal transcription from the MLP is highly dependent upon TFIIE in addition to the above factors. Two novel protein activities, referred to as 700 kd and 90 kd, further stimulated the basal reaction from the MLP. Thus, these data indicate that not all basal factors are in fact general.	MIT,DEPT BIOL,CAMBRIDGE,MA 02138	Massachusetts Institute of Technology (MIT)	PARVIN, JD (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02138, USA.		Parvin, Jeffrey D/C-8955-2009		NCI NIH HHS [P30-CA14051, P01-CA42063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARTHEW RW, 1988, J BIOL CHEM, V263, P17128; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1988, J BIOL CHEM, V263, P10812; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KINGSTON RE, 1984, MOL CELL BIOL, V4, P1970, DOI 10.1128/MCB.4.10.1970; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0	36	108	108	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1135	1144		10.1016/0092-8674(92)90084-P	http://dx.doi.org/10.1016/0092-8674(92)90084-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547507				2022-12-28	WOS:A1992HK67400016
J	JOHNSON, J; WEISSMAN, MM; KLERMAN, GL				JOHNSON, J; WEISSMAN, MM; KLERMAN, GL			SERVICE UTILIZATION AND SOCIAL MORBIDITY ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN THE COMMUNITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAGNOSTIC INTERVIEW SCHEDULE; GENERAL-POPULATION; DISORDERS	Objective. - To estimate service utilization and social morbidity in the community associated with depressive symptoms. Estimates were made using an epidemiologic measure, population attributable risk. Population attributable risk is a compound measure reflecting both the morbid risk to an individual with a disorder and the prevalence of the disorder in the community. Design. - Epidemiologic survey. Participants. - Eighteen thousand five hundred seventy-one adults in the Epidemiologic Catchment Area Study interviewed from a complex random sample in five US communities. Outcome Measures. - Suicide attempts, use of psychoactive medications, self-reported physical and emotional health, time lost from work, and general medical services or use of emergency departments for emotional problems. Results. - Major depression-dysthymia (lifetime prevalence, 6.1%) and depressive symptoms (lifetime prevalence, 23.1%) were associated with increased service utilization and social morbidity as measured by the outcome variables. On a population basis, however, as much or more service burden and impairment was associated with depressive symptoms as with the clinical conditions of depression or dysthymia. The equal association results from the greater prevalence of depressive symptoms. Population attributable risk percentages associated with depressive symptoms (not disorder) were as follows: emergency department use (11.8%) or medical consultations for emotional problems (21.5%); use of tranquilizers 14.6%), sleeping pills (21.0%), or antidepressants (22.2%); fair or poor self-reported emotional health (15.3%); days lost from work (17.8%); and suicide attempts (25.0%). Conclusions. - Estimates of population attributable risk indicated that physicians actually provided services to more persons with depressive symptoms than to persons with formally defined conditions of depressive disorders. Subclinical depression, as a consequence of high prevalence, is a clinical and public health problem. Attention to diagnostic and treatment issues is indicated.	NEW YORK STATE PSYCHIAT INST & HOSP, DIV CLIN & GENET EPIDEMIOL, BOX 14, 722 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PSYCHIAT, NEW YORK, NY 10032 USA; CORNELL UNIV, MED CTR, DEPT PSYCHIAT, ITHACA, NY 14853 USA; NEW YORK HOSP, PAYNE WHITNEY CLIN, NEW YORK, NY 10021 USA	New York State Psychiatry Institute; Columbia University; Cornell University; NewYork-Presbyterian Hospital				Weissman, Myrna/0000-0003-3490-3075	NIMH NIH HHS [5R01 MH43525-02] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043525] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BLAZER D, 1991, CURRENT OPINION PSYC, V4, P596; BOYD JH, 1981, ARCH GEN PSYCHIAT, V38, P1039; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; COHEN P, 1984, ARCH GEN PSYCHIAT, V41, P1178; DOHRENWEND BP, 1980, ARCH GEN PSYCHIAT, V37, P1229; Eaton W.M., 1985, EPIDEMIOLOGIC FIELD; GREENLAND S, 1988, AM J EPIDEMIOL, V128, P1185, DOI 10.1093/oxfordjournals.aje.a115073; GREENLAND S, 1984, STAT MED, V3, P131, DOI 10.1002/sim.4780030206; HELZER JE, 1985, ARCH GEN PSYCHIAT, V42, P657; JANERICH DT, 1990, NEW ENGL J MED, V323, P632, DOI 10.1056/NEJM199009063231003; JULIUS S, 1990, JAMA-J AM MED ASSOC, V264, P354; KELSEY JL, 1986, METHODS OBSERVATIONA, P39; KLERMAN G L, 1988, P309; Maser J.D., 1990, COMORBIDITY MOOD ANX; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; REGIER DA, 1984, ARCH GEN PSYCHIAT, V41, P934; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rothman K, 1986, MODERN EPIDEMIOLOGY; SARGEANT JK, 1990, ARCH GEN PSYCHIAT, V47, P519; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; WEISSMAN MM, 1988, AM J PSYCHIAT, V145, P815; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; 1991, INT CLASSIFICATION D; 1980, DIAGNOSTIC STATISTIC; 1987, DIAGNOSTIC STATISTIC	25	589	597	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1478	1483		10.1001/jama.267.11.1478	http://dx.doi.org/10.1001/jama.267.11.1478			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1538538				2022-12-28	WOS:A1992HH48800027
J	KANNEL, WB; ANDERSON, K; WILSON, PWF				KANNEL, WB; ANDERSON, K; WILSON, PWF			WHITE BLOOD-CELL COUNT AND CARDIOVASCULAR-DISEASE - INSIGHTS FROM THE FRAMINGHAM-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; LEUKOCYTE COUNTS; CORONARY; PREDICTOR; MORTALITY; RISK	Objective.-To examine the relation of white blood cell (WBC) count to the development of cardiovascular disease (CVD), including coronary heart disease, stroke, peripheral arterial disease, and cardiac failure. Traditional CVD risk factors, hematocrit, and vital capacity were considered. Design.-Prospective cohort analysis with one baseline examination of relevant risk factors and 12 years of follow-up for CVD. Participants and Methods.-A community-based sample (Framingham Offspring Study) of 1393 men and 1401 women who were free of CVD at the onset of the study and who were between the ages of 30 and 59 years at baseline. Time-dependent multiple variable logistic regression methods were used. Results.-There were 180 CVD events in men and 80 in women. The WBC count was correlated most strongly with the number of cigarettes smoked per day, hematocrit, and vital capacity. Among nonsmoking men with WBC counts within the normal range, the age-adjusted WBC count was significantly associated with CVD and coronary heart disease incidence. For each 1.0 x 10(9)/L-cell difference in WBC count, the CVD risk increased 32%. In women, each 1.0 x 10(9)/L-cell increment in WBC count was associated with a 17% increase in CVD risk, but only in smokers, and the relationship was not statistically significant after adjustment for relevant risk factors. Conclusions.-The degree of elevation of WBC count within the normal range is a marker for increased risk of CVD that is partially explained by cigarette smoking. Future-studies should include differential WBC determinations to assess their association with CVD.	NHLBI,FRAMINGHAM HEART STUDY,5 THURBER ST,FRAMINGHAM,MA 01701; BOSTON UNIV,SCH MED,EVANS MEM RES FDN,DEPT MED,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA 02118; CENTOCOR INC,MALVERN,PA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc			Wilson, Peter W.F./J-2455-2016		NHLBI NIH HHS [N01-HV-92922, N01-HV-52971] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DELABRY LO, 1990, J CLIN EPIDEMIOL, V43, P153, DOI 10.1016/0895-4356(90)90178-R; DESERVI S, 1991, AM J CARDIOL, V68, pB64, DOI 10.1016/0002-9149(91)90386-Y; ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318; FRIEDMAN GD, 1974, NEW ENGL J MED, V290, P1275, DOI 10.1056/NEJM197406062902302; GRIMM RH, 1985, JAMA-J AM MED ASSOC, V254, P1932, DOI 10.1001/jama.254.14.1932; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LOWE GDO, 1985, THROMB HAEMOSTASIS, V54, P700; PRENTICE RL, 1982, AM J EPIDEMIOL, V116, P496, DOI 10.1093/oxfordjournals.aje.a113434; PRENTICE RL, 1982, J CHRON DIS, V35, P703, DOI 10.1016/0021-9681(82)90094-7; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P234; STUART J, 1981, J CLIN PATHOL, V34, P464, DOI 10.1136/jcp.34.5.464; WILSON PWF, 1983, ARTERIOSCLEROSIS, V3, P273, DOI 10.1161/01.ATV.3.3.273; ZALOKAR JB, 1981, NEW ENGL J MED, V304, P402	13	338	348	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1253	1256		10.1001/jama.267.9.1253	http://dx.doi.org/10.1001/jama.267.9.1253			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1538564				2022-12-28	WOS:A1992HF43900029
J	WOOD, B				WOOD, B			ORIGIN AND EVOLUTION OF THE GENUS HOMO	NATURE			English	Review							PLIO-PLEISTOCENE HOMINID; EAST RUDOLF; CLADISTIC-ANALYSIS; FOSSIL HOMINIDS; OLDUVAI-GORGE; LAKE TURKANA; BED-I; HABILIS; KENYA; MORPHOLOGY	It is remarkable that the taxonomy and phylogenetic relationships of the earliest known representatives of our own genus, Homo, remain obscure. Advances in techniques for absolute dating and reassessments of the fossils themselves have rendered untenable a simple unilineal model of human evolution, in which Homo habilis succeeded the australopithecines and then evolved via H. erectus into H. sapiens-but no clear alternative consensus has yet emerged.			WOOD, B (corresponding author), UNIV LIVERPOOL, DEPT HUMAN ANAT & CELL BIOL, HOMINID PALAEONTOL RES GRP, POB 147, LIVERPOOL L69 3BX, ENGLAND.		Klein, Richard G/B-5910-2009					AIELLO L, IN PRESS J HUM EVOL; Alexeev V.P., 1986, ORIGIN HUMAN RACE; [Anonymous], 2012, NAT METHODS; BOAZ NT, 1977, AM J PHYS ANTHROPOL, V46, P93, DOI 10.1002/ajpa.1330460113; BRACE CL, 1972, YEARB PHYS ANTHROPOL, V16, P50; Broom R., 1950, STERKFONTEIN APE MAN, V4, P7; Chamberlain A.T., 1989, P175; Chamberlain A.T., 1987, THESIS U LIVERPOOL; CHAMBERLAIN AT, 1987, J HUM EVOL, V16, P119, DOI 10.1016/0047-2484(87)90063-7; CLARK WEL, 1964, DISCOVERY, V25, P49; Clarke R.J., 1977, THESIS U WITWATERSRA; CLARKE RJ, 1977, S AFR J SCI, V73, P46; CLARKE RJ, 1972, AM J PHYS ANTHROPOL, V37, P319, DOI 10.1002/ajpa.1330370302; Coppens Y., 1979, Bulletin de la Societe Geologique de France, V21, P313; Coppens Y., 1980, CURRENT ARGUMENT EAR, P207; DAVIS PR, 1964, NATURE, V201, P967, DOI 10.1038/201967a0; DAY MH, 1964, NATURE, V201, P969, DOI 10.1038/201969a0; DELSON E, 1986, NATURE, V322, P496, DOI 10.1038/322496b0; DELSON E, 1977, J HUM EVOL, V6, P263, DOI 10.1016/S0047-2484(77)80051-1; ELDREDGE N, 1975, CONTRIB PRIMATOL, V5, P218; FALK D, 1983, SCIENCE, V221, P1072, DOI 10.1126/science.221.4615.1072; FEIBEL CS, 1989, AM J PHYS ANTHROPOL, V78, P595, DOI 10.1002/ajpa.1330780412; GRINE FE, IN PRESS; Groves C., 1989, THEORY HUMAN PRIMATE; Groves CP, 1975, CASOPIS PROMINERALOG, V20, P225; HARRIS JM, 1988, SCIENCE, V239, P27, DOI 10.1126/science.239.4835.27; HARTWIGSCHERER S, 1991, J HUM EVOL, V21, P439, DOI 10.1016/0047-2484(91)90094-C; HARTWIGSCHRERER S, IN PRESS COUR FORSCH; Hay R.L., 1976, GEOLOGY OLDUVAI GORG; HILL A, 1992, NATURE, V355, P719, DOI 10.1038/355719a0; Holloway R.L., 1985, P47; HOLLOWAY RL, 1965, NATURE, V208, P205, DOI 10.1038/208205b0; Howell F.C., 1978, P154; HOWELL FC, 1987, J HUM EVOL, V16, P665; HUGHES AR, 1977, NATURE, V265, P310, DOI 10.1038/265310a0; JOHANSON DC, 1987, NATURE, V327, P205, DOI 10.1038/327205a0; JOHANSON DC, 1979, SCIENCE, V203, P321, DOI 10.1126/science.104384; JOHANSON DC, 1976, NATURE, V260, P293, DOI 10.1038/260293a0; JOHANSON DC, 1978, KIRTLANDIA, V28, P1; KENNEDY GE, 1983, AM J PHYS ANTHROPOL, V61, P429, DOI 10.1002/ajpa.1330610405; KENNEDY GE, 1983, J HUM EVOL, V12, P587, DOI 10.1016/S0047-2484(83)80001-3; Le Gros Clark W.E., 1955, FOSSIL EVIDENCE HUMA; LEAKEY LSB, 1966, NATURE, V209, P1279, DOI 10.1038/2091279a0; LEAKEY LSB, 1964, NATURE, V202, P7, DOI 10.1038/202007a0; LEAKEY MD, 1971, NATURE, V232, P308, DOI 10.1038/232308a0; LEAKEY MD, 1976, NATURE, V262, P460, DOI 10.1038/262460a0; LEAKEY RE, 1989, 2ND P IN C HUM PAL J, P167; LEAKEY REF, 1974, NATURE, V248, P653, DOI 10.1038/248653a0; LEAKEY REF, 1973, NATURE, V242, P447, DOI 10.1038/242447a0; Lewis O.J., 1989, FUNCTIONAL MORPHOLOG; LEWIS OJ, 1972, AM J PHYS ANTHROPOL, V37, P13, DOI 10.1002/ajpa.1330370104; LIEBERMAN DE, 1988, J HUM EVOL, V17, P503, DOI 10.1016/0047-2484(88)90039-5; MARTYN J, 1967, NATURE, V215, P476, DOI 10.1038/215476a0; MAYR E, 1950, COLD SPRING HARB SYM, V15, P109, DOI 10.1101/SQB.1950.015.01.013; MCHENRY HM, 1980, SCIENCE, V207, P1103, DOI 10.1126/science.207.4435.1103; MCHENRY HM, 1978, AM J PHYS ANTHROPOL, V49, P473, DOI 10.1002/ajpa.1330490407; MILLER JA, 1991, AM J PHYS ANTHROPOL, V84, P385, DOI 10.1002/ajpa.1330840403; Napier J. R., 1964, Archo Biol Liege (Suppl), V75, P673; OLSON TR, 1978, J HUM EVOL, V7, P159, DOI 10.1016/S0047-2484(78)80008-6; PROST JH, 1980, AM J PHYS ANTHROPOL, V52, P175, DOI 10.1002/ajpa.1330520204; Robinson J. T., 1968, EVOLUTION HOMINISATI, P150; ROBINSON JT, 1966, NATURE, V209, P957, DOI 10.1038/209957a0; ROBINSON JT, 1972, NATURE, V240, P239, DOI 10.1038/240239a0; ROBINSON JT, 1965, NATURE, V205, P121, DOI 10.1038/205121a0; Rose M.D., 1984, P509; Simpson G.G., 1961, PRINCIPLES ANIMAL TA, DOI DOI 10.7312/SIMP92414; SKELTON RR, 1986, CURR ANTHROPOL, V27, P21, DOI 10.1086/203377; Stringer C.B., 1986, P266; STRINGER CB, 1987, J HUM EVOL, V16, P135, DOI 10.1016/0047-2484(87)90064-9; SUSMAN RL, 1982, SCIENCE, V217, P931, DOI 10.1126/science.217.4563.931; Tobias P.V., 1989, P141; Tobias P.V., 1980, Palaeontologia Africana, V23, P1; Tobias P.V., 1985, P94; Tobias P.V., 1991, OLDUVAI GORGE, V4; TOBIAS PV, 1987, J HUM EVOL, V16, P741, DOI 10.1016/0047-2484(87)90022-4; TOBIAS PV, 1965, CURR ANTHROPOL, V6, P391, DOI 10.1086/200622; TOBIAS PV, 1964, NATURE, V204, P515, DOI 10.1038/204515a0; TRINKAUS E, 1984, AM J PHYS ANTHROPOL, V64, P137, DOI 10.1002/ajpa.1330640206; TRINKAUS E, 1989, AM J PHYS ANTHROPOL, V80, P411, DOI 10.1002/ajpa.1330800402; VANDEBROEK G, 1969, EVOLUTION VERTEBRES, P450; WALKER A, 1978, SCI AM, V239, P54, DOI 10.1038/scientificamerican0878-54; WHITE TD, 1981, S AFR J SCI, V77, P445; WOOD B, 1987, NATURE, V327, P187, DOI 10.1038/327187a0; Wood B., 1985, P206; Wood B., 1984, Courier Forschungsinstitut Senckenberg, V69, P99; Wood B., 1991, HOMINID CRANIAL REMA, V4; Wood B.A., 1986, P220; Wood B. A., 1986, VARIATION CULTURE EV, P101; WOOD BA, 1991, J ANAT, V174, P185; WOOD BA, 1974, J HUM EVOL, V3, P373, DOI 10.1016/0047-2484(74)90199-7; WOOD BA, 1974, NATURE, V251, P135, DOI 10.1038/251135a0; [No title captured]	92	270	275	1	123	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 27	1992	355	6363					783	790		10.1038/355783a0	http://dx.doi.org/10.1038/355783a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538759				2022-12-28	WOS:A1992HF63600043
J	JONES, PDE; HUDSON, N; HAWKEY, CJ				JONES, PDE; HUDSON, N; HAWKEY, CJ			DEPRESSION OF SALIVARY EPIDERMAL GROWTH-FACTOR BY SMOKING	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								BENOWITZ NL, 1986, ANNU REV MED, V37, P21; JONES PDE, 1990, EUR J GASTROEN HEPAT, V2, P203; MACCINI DM, 1990, AM J GASTROENTEROL, V85, P1102; OLSEN PS, 1986, GUT, V27, P1443, DOI 10.1136/gut.27.12.1443; SONTAG S, 1984, NEW ENGL J MED, V311, P689, DOI 10.1056/NEJM198409133111101	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					480	480		10.1136/bmj.304.6825.480	http://dx.doi.org/10.1136/bmj.304.6825.480			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547420	Green Published, Bronze			2022-12-28	WOS:A1992HF55500023
J	KLEMI, PJ; JOENSUU, H; TOIKKANEN, S; TUOMINEN, J; RASANEN, O; TYRKKO, J; PARVINEN, I				KLEMI, PJ; JOENSUU, H; TOIKKANEN, S; TUOMINEN, J; RASANEN, O; TYRKKO, J; PARVINEN, I			AGGRESSIVENESS OF BREAST CANCERS FOUND WITH AND WITHOUT SCREENING	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; TRIAL	Objective - To examine how breast cancers found by mammographic screening differ from those found outside screening. Design - Comparative cohort study. Setting - Turku, southwestern Finland. Patients - 126 women aged 40-74 years with breast cancer detected during the first round of mammographic screening in 1987-90 and 125 women within the same age range with breast cancer-detected outside screening during the same period. Main outcome measures - Primary tumour size, axillary nodal status, histological features, oestrogen and progesterone receptor concentrations, ploidy, and S phase fraction. Results - Compared with the controls women with cancers detected by screening had a smaller primary tumour (57 (46%) screened v 11 (10%) controls had tumours less-than-or-equal-to 11 mm in diameter, p < 0.0001), and less often had axillary nodal metastases (104 (83%) screened v 71 (57%) controls node negative, p < 0.0001). After adjustment for the smaller size of the primary tumour compared with control cancers, those cancers detected by screening were less likely to have axillary nodal metastases (odds ratio 0.44, 95% confidence interval 0.23 to 0.84), poor histological differentiation (0.20, 0.08 to 0.49), high mitotic counts (0.38, 0.15 to 0.97), tumour necrosis (0.45, 0.22 to 0.93) or to be of the ductal histological type (0.46, 0.22 to 0.95). They had low oestrogen receptor (0.29, 0.12 to 0.70) and progesterone receptor (0.35, 0.17 to 0.92) concentrations less often and had smaller S phase fractions (0.72, 0.55 to 0.96) than control cancers. Conclusions - Even after adjustment for the smaller size of screen detected breast cancers, their histological and cytometric features suggest low malignant potential. They may also be less likely to metastasise to axillary lymph nodes than cancers found outside screening.	UNIV TURKU,SF-20500 TURKU 50,FINLAND; CANC SOC SW FINLAND,SF-20700 TURKU,FINLAND; FINNISH CANC SOC,SF-20100 TURKU,FINLAND; TURKU HEALTH CTR,SF-20700 TURKU,FINLAND	University of Turku	KLEMI, PJ (corresponding author), TURKU UNIV HOSP,DEPT PATHOL,SF-20520 TURKU,FINLAND.							Agresti A., 1990, CATEGORICAL DATA ANA, pXV; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; CAMPLEJOHN RS, 1989, CYTOMETRY, V10, P410, DOI 10.1002/cyto.990100408; CHAMBERLAIN J, 1988, LANCET, V2, P411; HEDLEY DW, 1983, J HISTOCHEM CYTOCHEM, V31, P1333, DOI 10.1177/31.11.6619538; JOENSUU H, 1991, BRIT J CANCER, V64, P588, DOI 10.1038/bjc.1991.355; KALLIONIEMI OP, 1988, INT J CANCER, V42, P697, DOI 10.1002/ijc.2910420511; KOSCIELNY S, 1984, BRIT J CANCER, V49, P709, DOI 10.1038/bjc.1984.112; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; ROBERTS MM, 1990, LANCET, V335, P241; Shapiro S, 1985, Natl Cancer Inst Monogr, V67, P65; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; TOIKKANEN S, 1990, APMIS, V98, P1005, DOI 10.1111/j.1699-0463.1990.tb05027.x; VERBEEK ALM, 1984, LANCET, V1, P1222; 1981, INT CLASSIFICATION T, V2; 1987, TNM CLASSIFICATION M	16	72	72	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					467	469		10.1136/bmj.304.6825.467	http://dx.doi.org/10.1136/bmj.304.6825.467			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547414	Bronze, Green Published			2022-12-28	WOS:A1992HF55500017
J	HUGHES, SM; BLAU, HM				HUGHES, SM; BLAU, HM			MUSCLE-FIBER PATTERN IS INDEPENDENT OF CELL LINEAGE IN POSTNATAL RODENT DEVELOPMENT	CELL			English	Article							HEAVY-CHAIN ISOFORMS; MYOSIN GENE-EXPRESSION; CEREBRAL-CORTEX; CLONAL ANALYSIS; NEURAL CONTROL; RAT; MYOBLASTS; DIFFERENTIATION; FAMILY; SLOW	Muscle fibers specialized for fast or slow contraction are arrayed in characteristic patterns within developing limbs. Clones of myoblasts analyzed in vitro express fast and slow myosin isoforms typical of the muscle from which they derive. As a result, it has been suggested that distinct myoblast lineages generate and maintain muscle fiber pattern. We tested this hypothesis in vivo by using a retrovirus to label myoblasts genetically so that the fate of individual clones could be monitored. Both myoblast clones labeled in muscle in situ and clones labeled in tissue culture and then injected into various muscles contribute progeny to all fiber types encountered. Thus, extrinsic signals override the intrinsic commitment of myoblast nuclei to particular programs of gene expression. We conclude that in postnatal development, pattern is not dictated by myoblast lineage.			HUGHES, SM (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT PHARMACOL, STANFORD, CA 94305 USA.		Hughes, Simon M/S-1073-2016	Hughes, Simon M/0000-0001-8227-9225	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009521, R37AG009521] Funding Source: NIH RePORTER; NIA NIH HHS [AG-09521] Funding Source: Medline; NICHD NIH HHS [HD-18179] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BONNER PH, 1974, DEV BIOL, V37, P317, DOI 10.1016/0012-1606(74)90152-3; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; BUTLER J, 1982, J EXP ZOOL, V224, P65, DOI 10.1002/jez.1402240108; CONDON K, 1990, DEV BIOL, V138, P275, DOI 10.1016/0012-1606(90)90197-Q; COSSU G, 1988, DEVELOPMENT, V102, P65; DANGOOR M, 1990, J MUSCLE RES CELL M, V11, P216, DOI 10.1007/BF01843575; DEROBERTIS EM, 1991, DEVELOPMENT, V112, P669; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; FELDMAN JL, 1991, DEV BIOL, V143, P320, DOI 10.1016/0012-1606(91)90083-F; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GUNDERSEN K, 1988, J PHYSIOL-LONDON, V398, P177, DOI 10.1113/jphysiol.1988.sp017037; HARRIS AJ, 1989, DEVELOPMENT, V107, P751; HOH JFY, 1988, J MUSCLE RES CELL M, V9, P59; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KELLY AM, 1986, MED SCI SPORT EXER, V18, P292, DOI 10.1249/00005768-198606000-00007; LAFRAMBOISE WA, 1991, DEV BIOL, V144, P1, DOI 10.1016/0012-1606(91)90473-G; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MILLER AD, 1990, BLOOD, V76, P271; MILLER JB, 1986, J CELL BIOL, V103, P2197, DOI 10.1083/jcb.103.6.2197; MILLER JB, 1985, J CELL BIOL, V101, P1643, DOI 10.1083/jcb.101.5.1643; MILLER JB, 1986, P NATL ACAD SCI USA, V83, P3860, DOI 10.1073/pnas.83.11.3860; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PAVLATH GK, 1989, NATURE, V337, P570, DOI 10.1038/337570a0; PEDROSA F, 1989, HISTOCHEMISTRY, V92, P185, DOI 10.1007/BF00500917; PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; PRICE J, 1988, DEVELOPMENT, V104, P473; Price J, 1989, CURR OPIN CELL BIOL, V1, P1071, DOI 10.1016/S0955-0674(89)80052-3; RALSTON E, 1989, SCIENCE, V244, P1066, DOI 10.1126/science.2543074; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SALVIATI G, 1986, NATURE, V322, P637, DOI 10.1038/322637a0; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHAFER DA, 1987, CELL, V48, P659, DOI 10.1016/0092-8674(87)90244-3; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SCHMALBRUCH H, 1985, SKELETAL MUSCLE, P440; SILBERSTEIN L, 1986, CELL, V46, P1075, DOI 10.1016/0092-8674(86)90707-5; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2; WEBSTER C, 1988, EXP CELL RES, V174, P252, DOI 10.1016/0014-4827(88)90159-0; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WESTGAARD RH, 1988, J NEUROSCI, V8, P4415	50	187	190	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1992	68	4					659	671		10.1016/0092-8674(92)90142-Y	http://dx.doi.org/10.1016/0092-8674(92)90142-Y			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1531450				2022-12-28	WOS:A1992HF44000007
J	JIRIKOWSKI, GF; SANNA, PP; MACIEJEWSKILENOIR, D; BLOOM, FE				JIRIKOWSKI, GF; SANNA, PP; MACIEJEWSKILENOIR, D; BLOOM, FE			REVERSAL OF DIABETES-INSIPIDUS IN BRATTLEBORO RATS - INTRAHYPOTHALAMIC INJECTION OF VASOPRESSIN MESSENGER-RNA	SCIENCE			English	Article							BRAIN RIBONUCLEASES; PITUITARY; MOUSE; GENE; HYPOTHALAMUS; EXPRESSION; TRANSPORT; OXYTOCIN	Messenger RNAs occur within the axons of magnocellular hypothalamic neurons known to secrete oxytocin and vasopressin. In Brattleboro rats, which have a genetic mutation that renders them incapable of vasopressin expression and secretion and thus causes diabetes insipidus, injection into the hypothalamus of purified mRNAs from normal rat hypothalami or of synthetic copies of the vasopressin mRNA leads to selective uptake, retrograde transport, and expression of vasopressin exclusively in the magnocellular neurons. Temporary reversal of their diabetes insipidus (for up to 5 days) can be observed within hours of the injection. Intra-axonal mRNAs may represent an additional category of chemical signals for neurons.			JIRIKOWSKI, GF (corresponding author), Scripps Res Inst, RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH047680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022347] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 47680] Funding Source: Medline; NINDS NIH HHS [NS 22347-03] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOCH B, 1990, NEUROSCI LETT, V109, P259, DOI 10.1016/0304-3940(90)90004-S; BROOKS PJ, 1990, SOC NEUR ABSTR, V14; CARAZANNA EJ, 1988, MOL CELL BIOL, V8, P2267; CARTER DA, 1989, J BIOL CHEM, V264, P6601; DAVIS L, 1990, J NEUROSCI, V10, P3056; FRANZONI L, 1978, ACTA PHYSIOL LAT AM, V28, P185; HAUSSLER HU, 1990, J CHEM NEUROANAT, V3, P271; IVELL R, 1984, P NATL ACAD SCI USA, V81, P1216; JIRIKOWSKI GF, 1990, P NATL ACAD SCI USA, V87, P7400, DOI 10.1073/pnas.87.19.7400; LEHMANN E, 1990, NEUROSCI LETT, V111, P170, DOI 10.1016/0304-3940(90)90363-E; LENOIR D, 1986, J NEUROSCI, V6, P522; LEVY A, 1990, J NEUROENDOCRINOL, V2, P329, DOI 10.1111/j.1365-2826.1990.tb00413.x; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MCCABE JJ, 1985, IN SITU HYBRIDIZATIO, P73; MOHR E, 1991, EMBO J, V10, P2419, DOI 10.1002/j.1460-2075.1991.tb07781.x; MURPHY D, 1990, MOL ENDOCRINOL, V4, P1051, DOI 10.1210/mend-4-7-1051; MURPHY D, 1989, P NATL ACAD SCI USA, V86, P9002, DOI 10.1073/pnas.86.22.9002; POPICK FR, 1976, LIFE SCI, V18, P197, DOI 10.1016/0024-3205(76)90025-4; SCHIBLER U, 1980, J MOL BIOL, V142, P93, DOI 10.1016/0022-2836(80)90208-9; SCHMALE H, 1984, NATURE, V308, P705, DOI 10.1038/308705a0; SCHULZHARDER B, 1988, HISTOCHEMISTRY, V88, P587, DOI 10.1007/BF00570329; STERNBERGER LA, 1978, IMMUNOCYTOCHEMISTRY; TREMBLEAU A, 1991, NEUROCYTOCHEMICAL ME, P313; ZINGG HH, 1988, J BIOL CHEM, V263, P11041	24	156	192	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					996	998		10.1126/science.1546298	http://dx.doi.org/10.1126/science.1546298			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546298				2022-12-28	WOS:A1992HE60500045
J	HOMMES, DW; BURA, A; MAZZOLAI, L; BULLER, HR; TENCATE, JW				HOMMES, DW; BURA, A; MAZZOLAI, L; BULLER, HR; TENCATE, JW			SUBCUTANEOUS HEPARIN COMPARED WITH CONTINUOUS INTRAVENOUS HEPARIN ADMINISTRATION IN THE INITIAL TREATMENT OF DEEP-VEIN THROMBOSIS - A METAANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Article						METAANALYSIS; HEPARIN; THROMBOSIS; DRUG ADMINISTRATION ROUTES; COST CONTROL	RANDOMIZED TRIAL; THERAPY; MANAGEMENT	Objective: To quantitatively assess the efficacy and safety of published randomized trials comparing subcutaneous heparin with continuous intravenous heparin for the initial treatment of deep vein thrombosis. Data Identification: Studies published between January 1966 and April 1991 were identified through computer searches of the MEDLINE database and through reviews of the Science Citation Index, Current Contents, proceedings and abstract books, and references cited in the identified articles. Complete manuscripts were obtained from the authors if only abstracts were available. Study Selection: Eight clinical trials were identified that compared subcutaneous with intravenous heparin administration in patients with venographically confirmed deep vein thrombosis. Data Extraction: Each study was independently analyzed for the percentage distribution of thrombosis, the method of outcome measurement, and the heparin dose. The methodologic strength of each study was assessed using predefined standards for the proper evaluation of a therapeutic intervention with particular emphasis on the type of patient allocation and objective measurements. Results of Data Analysis: The overall relative risk for efficacy (defined as prevention of extension and recurrence of venous thromboembolism) of subcutaneous compared with intravenous heparin treatment was 0.62 (95% Cl, 0.39 to 0.98), whereas for safety (defined as major hemorrhage) it was 0.79 (Cl, 0.42 to 1.48). Conclusions: The results of our meta-analysis indicated that heparin administered subcutaneously twice daily in the initial treatment of deep vein thrombosis is more effective and at least as safe as continuous intravenous heparin administration. Administration of heparin subcutaneously may simplify patient treatment and could facilitate home treatment.	UNIV PERUGIA, IST SEMEIOT MED, CTR THROMBOSIS & HAEMOSTASIS, I-06100 PERUGIA, ITALY	University of Perugia	HOMMES, DW (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, CTR HAEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA, 1105 AZ AMSTERDAM, NETHERLANDS.							ANDERSSON G, 1982, THROMB RES, V27, P631, DOI 10.1016/0049-3848(82)90001-9; BARRITT DW, 1960, LANCET, V1, P1309; BAUER G, 1950, Angiology, V1, P161, DOI 10.1177/000331975000100205; BENTLEY PG, 1980, THROMB RES, V18, P177, DOI 10.1016/0049-3848(80)90182-6; DOYLE DJ, 1987, ANN INTERN MED, V107, P441, DOI 10.7326/0003-4819-107-4-441; GALLUS AS, 1989, SEMIN THROMB HEMOST, V15, P99, DOI 10.1055/s-2007-1002692; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; Kleinbaum DG, 1983, EPIDEMIOLOGIC RES; KRAHENBUHL B, 1979, SCHWEIZ MED WSCHR, V109, P1322; LOPACIUK S, 1989, 6TH P INT M DAN LEAG, P389; MANTEL N, 1959, J NATL CANCER I, V22, P719; PINI M, 1990, THROMB HAEMOSTASIS, V64, P222; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P300; SALZMAN EW, 1975, NEW ENGL J MED, V292, P1046, DOI 10.1056/NEJM197505152922002; WALKER MG, 1987, BRIT MED J, V294, P1189, DOI 10.1136/bmj.294.6581.1189; WILSON JR, 1979, AM HEART J, V97, P155, DOI 10.1016/0002-8703(79)90349-1; Zilliacus H, 1946, ACTA MED SCANDINAV S, V171, P1	18	194	195	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					279	284		10.7326/0003-4819-116-4-279	http://dx.doi.org/10.7326/0003-4819-116-4-279			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1531108				2022-12-28	WOS:A1992HD54600002
J	MARAHRENS, Y; STILLMAN, B				MARAHRENS, Y; STILLMAN, B			A YEAST CHROMOSOMAL ORIGIN OF DNA-REPLICATION DEFINED BY MULTIPLE FUNCTIONAL ELEMENTS	SCIENCE			English	Article							RIBOSOMAL-PROTEIN GENES; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATOR; CONSENSUS SEQUENCE; BINDING PROTEIN; SILENCER; ARS; PURIFICATION; PLASMIDS; INITIATION	Although it has been demonstrated that discrete origins of DNA replication exist in eukaryotic cellular chromosomes, the detailed organization of a eukaryotic cellular origin remains to bc determined. Linker substitution mutations were constructed across the entire Saccharomyces cerevisiae chromosomal origin, ARS1. Functional studies of these mutants revealed one essential clement (A), which includes a match to the ARS consensus sequence, and three additional elements (B1, B2, and B3), which collectively are also essential for origin function. These four elements arranged exactly as in ARS1, but surrounded by completely unrelated sequence, functioned as an efficient origin. Element B3 is the binding site for the transcription factor-origin binding protein ABF1. Other transcription factor binding sites substitute for the B3 element and a trans-acting transcriptional activation domain is required. The multipartite nature of a chromosomal replication origin and the role of transcriptional activators in its function present a striking similarity to the organization of eukaryotic promoters.	SUNY STONY BROOK, GRAD PROGRAM MOLEC & CELLULAR BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	MARAHRENS, Y (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091	NIAID NIH HHS [AI20460] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020460, R01AI020460] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BARU M, 1991, J VIROL, V65, P3496, DOI 10.1128/JVI.65.7.3496-3503.1991; BENNETTCOOK ER, 1991, EMBO J, V10, P959, DOI 10.1002/j.1460-2075.1991.tb08030.x; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; DANI GM, 1983, P NATL ACAD SCI-BIOL, V80, P3406, DOI 10.1073/pnas.80.11.3406; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DEVILLIERS J, 1984, NATURE, V312, P242, DOI 10.1038/312242a0; DIFFLEY JFX, 1990, TRENDS GENET, V6, P427, DOI 10.1016/0168-9525(90)90305-P; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DORSMAN JC, 1989, NUCLEIC ACIDS RES, V17, P4917, DOI 10.1093/nar/17.13.4917; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; EISENBERG S, 1988, P NATL ACAD SCI USA, V85, P743, DOI 10.1073/pnas.85.3.743; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FANGMAN WL, 1983, CELL, V32, P831, DOI 10.1016/0092-8674(83)90069-7; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HALFTER H, 1989, EMBO J, V8, P3029, DOI 10.1002/j.1460-2075.1989.tb08453.x; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HOLMES SG, 1989, MOL CELL BIOL, V9, P5464, DOI 10.1128/MCB.9.12.5464; HSIAO CL, 1979, P NATL ACAD SCI USA, V76, P3829, DOI 10.1073/pnas.76.8.3829; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; LONG CM, 1985, MOL CELL BIOL, V5, P3124, DOI 10.1128/MCB.5.11.3124; MARAHRENS Y, UNPUB; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MURRAY AW, 1983, NATURE, V305, P189, DOI 10.1038/305189a0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; ORRWEAVER TL, 1989, EMBO J, V8, P4153, DOI 10.1002/j.1460-2075.1989.tb08600.x; PALZKILL TG, 1988, CELL, V53, P441, DOI 10.1016/0092-8674(88)90164-X; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; SNYDER M, 1986, NATURE, V324, P87, DOI 10.1038/324087a0; SRIENC F, 1985, MOL CELL BIOL, V5, P1676, DOI 10.1128/MCB.5.7.1676; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; WALKER SS, 1991, NUCLEIC ACIDS RES, V19, P6255, DOI 10.1093/nar/19.22.6255; WALKER SS, 1990, P NATL ACAD SCI USA, V87, P4665, DOI 10.1073/pnas.87.12.4665; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	70	507	515	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1992	255	5046					817	823		10.1126/science.1536007	http://dx.doi.org/10.1126/science.1536007			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1536007				2022-12-28	WOS:A1992HD54800028
J	SPIES, T; CERUNDOLO, V; COLONNA, M; CRESSWELL, P; TOWNSEND, A; DEMARS, R				SPIES, T; CERUNDOLO, V; COLONNA, M; CRESSWELL, P; TOWNSEND, A; DEMARS, R			PRESENTATION OF VIRAL-ANTIGEN BY MHC CLASS-I MOLECULES IS DEPENDENT ON A PUTATIVE PEPTIDE TRANSPORTER HETERODIMER	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; TOXIC LYMPHOCYTES-T; HLA-B ANTIGENS; ASSOCIATION; PROTEIN; RECOGNITION; PATHWAY; INVITRO; REGION; CELLS	MAJOR histocompatibility complex (MHC) class I molecules present peptides derived from the endogenous protein pool to cytotoxic T lymphocytes, which can thus recognize intracellular antigen 1-3 . This pathway may depend on a transporter (PSF1) (refs 4-6) to mediate entry of the cytosolic peptides into a pre-Golgi compartment where they bind to class I heavy chains and promote their stable assembly with beta-2-microglobulin 7-12. There is, however, only indirect support for this function of PSF1 (ref. 6). Here we show that PSF1 is necessary for the efficient assembly of class I molecules and enables them to present a peptide epitope derived from endogenously synthesized viral antigen. Immunochemical and genetic data demonstrate that the PSF1 polypeptide is associated with a complementary transporter chain, which is polymorphic and is encoded by the PSF2 gene 13, which is closely linked to PSF1.	JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; IST NAZL RIC CANC,I-16132 GENOA,ITALY; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	University of Oxford; University of Genoa; IRCCS AOU San Martino IST; Yale University; University of Wisconsin System; University of Wisconsin Madison	SPIES, T (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,44 BINNEY ST,BOSTON,MA 02115, USA.			Cerundolo, Vincenzo/0000-0003-0040-3793; Colonna, Marco/0000-0001-5222-4987; Townsend, Alain/0000-0002-3702-0107				ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; HYDE SC, 1990, NATURE, V346, P263; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; LEACH R, 1986, P NATL ACAD SCI USA, V83, P3909, DOI 10.1073/pnas.83.11.3909; LJUNGGREN HG, 1990, NATURE, V346, P478; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; WAYS JP, 1986, J IMMUNOL, V137, P217; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	28	331	332	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					644	646		10.1038/355644a0	http://dx.doi.org/10.1038/355644a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538752				2022-12-28	WOS:A1992HD54700058
J	EDWARDS, IR; COULTER, DM; MACINTOSH, D				EDWARDS, IR; COULTER, DM; MACINTOSH, D			INTESTINAL EFFECTS OF CAPTOPRIL	BRITISH MEDICAL JOURNAL			English	Article									UNIV OTAGO,SCH MED,NATL TOXICOL GRP,DUNEDIN,NEW ZEALAND	University of Otago								BHASKAR RM, 1984, PEPTIDES, V5, P291; CHONG EKS, 1973, J PHARM PHARMACOL, V25, P170, DOI 10.1111/j.2042-7158.1973.tb10614.x; LEVENS NR, 1985, AM J PHYSIOL, V249, pG3, DOI 10.1152/ajpgi.1985.249.1.G3; PICARELLI ZP, 1954, CIRC RES, V2, P354, DOI 10.1161/01.RES.2.4.354; WALUS KM, 1981, DIGEST DIS SCI, V26, P1069, DOI 10.1007/BF01295970	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					359	360		10.1136/bmj.304.6823.359	http://dx.doi.org/10.1136/bmj.304.6823.359			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540734	Green Published, Bronze			2022-12-28	WOS:A1992HD38700025
J	GORE, SM; FONTAINE, O; PIERCE, NF				GORE, SM; FONTAINE, O; PIERCE, NF			IMPACT OF RICE BASED ORAL REHYDRATION SOLUTION ON STOOL OUTPUT AND DURATION OF DIARRHEA - METAANALYSIS OF 13 CLINICAL-TRIALS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLUCOSE ELECTROLYTE SOLUTION; ACUTE CHILDHOOD DIARRHEA; DEHYDRATING DIARRHEA; INFANTILE DIARRHEA; SALT SOLUTION; EFFICACY; CHILDREN; THERAPY; POWDER	Objective - To define the benefit of rice oral rehydration salts solution in relation to the glucose based World Health Organisation oral rehydration salts solution for treating and preventing dehydration in patients with severe dehydrating diarrhoea. Design-Meta-analysis using data from 13 available randomised trials that compared these two formulations. Subjects - The studies compared 1367 patients with cholera, severe cholera-like diarrhoea, or acute non-cholera diarrhoea. 668 received the standard WHO solution and 699 the rice based solution. Intervention - Each trial report was reviewed to determine patient eligibility, the number of patients who were randomised and the number of these excluded from analysis, details of the randomisation procedure, and the precise timing of the outcome measurements. Main outcome measures - Stool output during the first 24 hours; weighted estimates of the difference in mean stool output between treatments. Results - The rice solution significantly reduced the rate of stool output during the first 24 hours by 36% (95% confidence interval 28 to 44%) in adults with cholera and by 32% (19 to 45%) in children with cholera. The rate of stool loss in infants and children with acute non-cholera diarrhoea was reduced by only 18% (6 to 30%). Conclusions - The benefit of rice oral rehydration salts solution for patients with cholera is sufficiently great to warrant its use in such patients. The benefit is considerably smaller for children with acute, non-cholera diarrhoea and should be more precisely defined before its practical value can be judged.	WHO, DIARRHOEAL DIS CONTROL PROGRAMME, CH-1211 GENEVA 27, SWITZERLAND; MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND	World Health Organization; MRC Biostatistics Unit								ALAM AN, 1987, ARCH DIS CHILD, V62, P440, DOI 10.1136/adc.62.5.440; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BHAN MK, 1987, J PEDIATR GASTR NUTR, V6, P392, DOI 10.1097/00005176-198705000-00016; DUTTA P, 1988, INDIAN J MED RES, V87, P229; ELMOUGI M, 1988, J PEDIATR GASTR NUTR, V7, P572, DOI 10.1097/00005176-198807000-00016; HIRSCHHORN N, 1968, NEW ENGL J MED, V279, P176, DOI 10.1056/NEJM196807252790402; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; KENYA PR, 1989, ARCH DIS CHILD, V64, P1032, DOI 10.1136/adc.64.7.1032; LEBENTHAL E, 1983, J PEDIATR-US, V103, P29, DOI 10.1016/S0022-3476(83)80770-7; LEBENTHAL E, 1981, TXB GASTROENTEROLOGY, P149; LEPAGE P, 1989, LANCET, V2, P868; Mahalanabis D, 1974, J Trop Pediatr Environ Child Health, V20, P82; MOHAN M, 1986, J PEDIATR GASTR NUTR, V5, P423, DOI 10.1097/00005176-198605000-00015; MOHAN M, 1988, INDIAN J MED RES, V87, P234; MOLLA AM, 1989, LANCET, V2, P429; MOLLA AM, 1985, B WORLD HEALTH ORGAN, V63, P751; MOLLA AM, 1985, CHILD HLTH TROPICS, P65; PATRA F C, 1986, Journal of Diarrhoeal Diseases Research, V4, P16; PATRA FC, 1982, ARCH DIS CHILD, V57, P910, DOI 10.1136/adc.57.12.910; PATRA FC, 1984, ACTA PAEDIATR SCAND, V73, P18, DOI 10.1111/j.1651-2227.1984.tb09891.x; PIERCE NF, 1968, GASTROENTEROLOGY, V55, P333; SACK DA, 1978, LANCET, V2, P280; VESIKARI T, 1986, ARCH DIS CHILD, V61, P372, DOI 10.1136/adc.61.4.372; WAPNIR RA, 1990, J PEDIATR GASTR NUTR, V10, P213, DOI 10.1097/00005176-199002000-00012	24	144	150	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 1	1992	304	6822					287	291		10.1136/bmj.304.6822.287	http://dx.doi.org/10.1136/bmj.304.6822.287			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1531430	Green Published, Bronze			2022-12-28	WOS:A1992HC70800021
J	TREANOR, JJ; MATTISON, HR; DUMYATI, G; YINNON, A; ERB, S; OBRIEN, D; DOLIN, R; BETTS, RF				TREANOR, JJ; MATTISON, HR; DUMYATI, G; YINNON, A; ERB, S; OBRIEN, D; DOLIN, R; BETTS, RF			PROTECTIVE EFFICACY OF COMBINED LIVE INTRANASAL AND INACTIVATED INFLUENZA-A VIRUS-VACCINES IN THE ELDERLY	ANNALS OF INTERNAL MEDICINE			English	Article						ORTHOMYXOVIRUSES TYPE-A; INFLUENZA VACCINE; NURSING HOMES; ADMINISTRATION; INTRANASAL; INFLUENZA	ADAPTED REASSORTANT VIRUS; RESPIRATORY SYNCYTIAL VIRUS; WILD-TYPE VIRUS; NURSING-HOME; ANTIBODY-RESPONSES; CHRONICALLY ILL; ADULTS; POPULATION; PNEUMONIA; OUTBREAK	Objective: To evaluate the efficacy of adding intranasal live attenuated cold-adapted influenza A vaccine to inactivated influenza vaccine to prevent influenza A in elderly residents of long-term-care institutions. Design: Randomized, double-blind, placebo-controlled study conducted over 3 years. Setting: Three large nursing homes. Participants: A total of 523 residents of nursing homes (mean age, 84.2 years). Interventions: All participants received trivalent inactivated influenza vaccine parenterally and were randomly assigned to receive either live attenuated influenza A (H3N2) virus vaccine or placebo intranasally. Measurements: Laboratory-documented influenza A was defined as a respiratory illness plus isolation of influenza A virus from nasal secretions, significant serologic response, or both. Participants were considered to have been exposed to influenza A if they resided in an institution in which cases of influenza A were documented. Outbreak-associated illnesses were defined as those occurring between the first and last isolation of influenza virus from within the institution, +/- 3 days. Results: Participants who received intranasal vaccine and were subsequently exposed to influenza A had significantly lower rates of laboratory-documented influenza A (9 of 162 vaccine recipients compared with 24 of 169 placebo recipients; vaccine protective efficacy, 60.6%; 95% Cl, 18% to 82%), outbreak-associated respiratory illnesses (13 of 162 vaccine recipients compared with 34 of 169 placebo recipients; vaccine protective efficacy, 56.8%; Cl 23% to 76%), and outbreak-associated influenza-like illnesses (6 of 162 vaccine recipients compared with 18 of 169 placebo recipients; vaccine protective efficacy, 65.0%; Cl 17% to 86%). Conclusions: Intranasal immunization with live attenuated influenza A virus vaccine provided additional protection against influenza A when added to parenteral trivalent inactivated influenza vaccine among elderly nursing home residents.			TREANOR, JJ (corresponding author), UNIV ROCHESTER, INFECT DIS UNIT, BOX 689, 601 ELMWOOD AVE, ROCHESTER, NY 14642 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI005049] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-05049] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON EL, 1989, J CLIN MICROBIOL, V27, P909, DOI 10.1128/JCM.27.5.909-914.1989; ARDEN NH, 1986, OPTIONS CONTROL INFL, P155; ARROYO JC, 1984, AM J INFECT CONTROL, V12, P329, DOI 10.1016/0196-6553(84)90005-1; ATMAR RL, 1990, VACCINE, V8, P217, DOI 10.1016/0264-410X(90)90049-R; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BARKER WH, 1980, JAMA-J AM MED ASSOC, V244, P2547, DOI 10.1001/jama.244.22.2547; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; BARKER WH, 1986, OPTIONS CONTROL INFL, P169; BELSHE RB, 1984, J INFECT DIS, V150, P834, DOI 10.1093/infdis/150.6.834; BETTS RF, 1985, J INFECT DIS, V151, P744, DOI 10.1093/infdis/151.4.744; BETTS RF, 1984, 24TH INT C ANT AG CH; BUDNICK LD, 1984, NEW YORK STATE J MED, V84, P235; CARTER ML, 1986, INFECT CONT HOSP EP, V11, P473; CLEMENTS ML, 1984, LANCET, V1, P705; CLEMENTS ML, 1986, J CLIN MICROBIOL, V23, P73, DOI 10.1128/JCM.23.1.73-76.1986; CLEMENTS ML, 1990, J INFECT DIS, V161, P869, DOI 10.1093/infdis/161.5.869; COX NJ, 1988, VIROLOGY, V167, P554, DOI 10.1016/S0042-6822(88)90118-3; FALSEY AR, 1992, J AM GERIATR SOC, V40, P115, DOI 10.1111/j.1532-5415.1992.tb01929.x; FEERY BJ, 1979, J INFECT DIS, V139, P237, DOI 10.1093/infdis/139.2.237; GORSE GJ, 1988, J CLIN MICROBIOL, V26, P911, DOI 10.1128/JCM.26.5.911-918.1988; GORSE GJ, 1990, J CLIN MICROBIOL, V28, P2539, DOI 10.1128/JCM.28.11.2539-2550.1990; GORSE GJ, 1991, SCAND J INFECT DIS, V23, P7, DOI 10.3109/00365549109023368; GORSE GJ, 1986, J CLIN MICROBIOL, V24, P336, DOI 10.1128/JCM.24.3.336-342.1986; GROSS PA, 1988, ARCH INTERN MED, V148, P562, DOI 10.1001/archinte.148.3.562; GROSS PA, 1988, ARCH INTERN MED, V148, P559, DOI 10.1001/archinte.148.3.559; HALL CB, 1976, AM J DIS CHILD, V130, P615, DOI 10.1001/archpedi.1976.02120070041009; HORMAN JT, 1986, AM J PUBLIC HEALTH, V76, P501, DOI 10.2105/AJPH.76.5.501; JOHNSON PR, 1986, J INFECT DIS, V154, P121, DOI 10.1093/infdis/154.1.121; JOHNSON PR, 1985, J MED VIROL, V17, P325, DOI 10.1002/jmv.1890170405; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MAASSAB HF, 1985, VACCINE, V3, P355, DOI 10.1016/0264-410X(85)90124-0; MADORE HP, 1983, J CLIN MICROBIOL, V18, P1345, DOI 10.1128/JCM.18.6.1345-1350.1983; MATHUR U, 1980, ANN INTERN MED, V93, P49, DOI 10.7326/0003-4819-93-1-49; MURPHY BR, 1981, INFECT IMMUN, V32, P693, DOI 10.1128/IAI.32.2.693-697.1981; PATRIARCA PA, 1986, AM J EPIDEMIOL, V124, P114, DOI 10.1093/oxfordjournals.aje.a114355; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; POWERS DC, 1989, J CLIN MICROBIOL, V27, P2666, DOI 10.1128/JCM.27.12.2666-2671.1989; POWERS DC, 1991, J CLIN MICROBIOL, V29, P498, DOI 10.1128/JCM.29.3.498-505.1991; RUBEN FL, 1974, JAMA-J AM MED ASSOC, V230, P863; SAAH AJ, 1986, ARCH INTERN MED, V146, P2353, DOI 10.1001/archinte.146.12.2353; SEARS SD, 1988, J INFECT DIS, V158, P1209, DOI 10.1093/infdis/158.6.1209; SNYDER MH, 1989, J INFECT DIS, V160, P604, DOI 10.1093/infdis/160.4.604; SNYDER MH, 1988, J VIROL, V62, P488, DOI 10.1128/JVI.62.2.488-495.1988; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1990, MMWR, V39, P1	46	134	138	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					625	633		10.7326/0003-4819-117-8-625	http://dx.doi.org/10.7326/0003-4819-117-8-625			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530193				2022-12-28	WOS:A1992JR86100001
J	YOUNGERSHEPHERD, S; VAESSIN, H; BIER, E; JAN, LY; JAN, YN				YOUNGERSHEPHERD, S; VAESSIN, H; BIER, E; JAN, LY; JAN, YN			DEADPAN, AN ESSENTIAL PAN-NEURAL GENE ENCODING AN HLH PROTEIN, ACTS AS A DENOMINATOR IN DROSOPHILA SEX DETERMINATION	CELL			English	Article							ACHAETE-SCUTE COMPLEX; LOOP-HELIX PROTEINS; PERIPHERAL NERVOUS-SYSTEM; X-A RATIO; DOSAGE COMPENSATION; DNA-BINDING; DETERMINATION SIGNAL; NEGATIVE REGULATOR; PRONEURAL CLUSTERS; NUMERATOR ELEMENT	In Drosophila, sex is determined by the X:A ratio. One major numerator element on the X chromosome is sisterless-b (sis-b), also called scute, which encodes an HLH-type transcription factor. We report here that an essential pan-neural gene, the autosomal HLH gene deadpan (dpn), acts as a denominator element. As revealed by dosage-dependent dominant interactions, males die with too high a ratio of sc+ to dpn+, caused by misexpression of Sex lethal (Sxl) in embryos, and females die with too low a ratio of sc+ to dpn+, because of altered embryonic Sxl expression. In addition, we found that the HLH gene extramacrochaetae (emc), like daughterless (da), is needed maternally for proper communication of the X:A ratio, thus supporting the idea that a set of HLH genes comprises a functional cassette that makes a sensitive and stable genetic switch used in both neural determination and sex determination.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL & BIOCHEM, SAN FRANCISCO, CA 94143 USA; OHIO STATE UNIV, DEPT MOLEC GENET, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, OHIO STATE BIOTECHNOL CTR, COLUMBUS, OH 43210 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Francisco; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of California System; University of California San Diego; University of California System; University of California San Diego	YOUNGERSHEPHERD, S (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.			Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				BAKER BS, 1989, GENOME, V31, P638, DOI 10.1139/g89-117; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL AE, 1954, GENETICS, V39, P958; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BRAND M, 1988, ROUX ARCH DEV BIOL, V197, P457, DOI 10.1007/BF00385679; Bridges CB, 1925, AM NAT, V59, P127, DOI 10.1086/280023; Bridges CB, 1921, SCIENCE, V54, P252, DOI 10.1126/science.54.1394.252; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CARROLL SB, 1989, GENE DEV, V3, P905, DOI 10.1101/gad.3.6.905; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CAUDY M, 1988, GENE DEV, V2, P843, DOI 10.1101/gad.2.7.843; CLINE TW, 1986, GENETICS, V113, P641; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1976, GENETICS, V84, P723; CLINE TW, 1980, GENETICS, V96, P903; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CLINE TW, 1979, DEV BIOL, V72, P266, DOI 10.1016/0012-1606(79)90117-9; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; CLINE TW, 1983, GENETICS, V104, P516; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; CRONMILLER C, 1987, CELL, V48, P479, DOI 10.1016/0092-8674(87)90198-X; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; CRONMILLER C, 1986, DEV GENET, V7, P205, DOI 10.1002/dvg.1020070406; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; DAMBLYCHAUDIERE C, 1988, ROUX ARCH DEV BIOL, V197, P419, DOI 10.1007/BF00398993; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; Dobzhansky T, 1934, J GENET, V28, P349, DOI 10.1007/BF02981760; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; FOE VE, 1983, J CELL SCI, V61, P31; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GERGEN JP, 1987, GENETICS, V117, P477; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; INGHAM PW, 1985, GENETICS, V111, P463; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; LINDSLEY D, 1987, DROS INF SERV, V65; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; MANGE AP, 1973, GENETICS, V73, P73; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SANCHEZ L, 1983, EMBO J, V2, P485, DOI 10.1002/j.1460-2075.1983.tb01451.x; SCHUPBACH T, 1985, GENETICS, V109, P529; SCHUPBACH T, 1982, DEV BIOL, V89, P117, DOI 10.1016/0012-1606(82)90300-1; SIMPSON P, 1990, DEVELOPMENT, V110, P927; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; SLEE R, 1990, Q REV BIOL, V65, P175, DOI 10.1086/416718; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; TORRES M, 1991, DEVELOPMENT, V113, P715; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; VAESSIN H, 1990, COLD SH Q B, V55, P239; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8	76	112	114	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					911	922		10.1016/0092-8674(92)90242-5	http://dx.doi.org/10.1016/0092-8674(92)90242-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525829				2022-12-28	WOS:A1992JN78100007
J	CAVANAGH, P				CAVANAGH, P			ATTENTION-BASED MOTION PERCEPTION	SCIENCE			English	Article							GRATINGS; MODEL	Two "attentive" tracking tasks reveal the existence of an attention-based motion process. In the first task, oppositely rotating luminance and color gratings were superimposed. Because of masking from the color grating, the bars of the luminance grating were not visible; nevertheless, their motion was visible and it determined the perceived direction of the stimulus rotation. On the other hand, the bars of the color grating were visible but they could only be seen to move (in the opposite direction to the overall stimulus rotation) when they were tracked with attention. In a second task, the perceived velocity of a color grating, typically slow at equiluminance, speeded up when individual bars were attentively tracked. These findings demonstrate two independent motion processes: one that is "low-level" or automatic in that it signals motion even in the absence of attention to the stimulus, and one that is mediated by attention to visible features and provides accurate velocity judgments independently of the features being tracked.			CAVANAGH, P (corresponding author), HARVARD UNIV, DEPT PSYCHOL, CAMBRIDGE, MA 02138 USA.							ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; ANSTIS SM, 1980, PHILOS T ROY SOC B, V290, P153, DOI 10.1098/rstb.1980.0088; BRADDICK OJ, 1980, PHILOS T ROY SOC B, V290, P137, DOI 10.1098/rstb.1980.0087; BRENNER E, 1991, VISION RES, V31, P1893, DOI 10.1016/0042-6989(91)90184-7; CAVANAGH P, 1989, Spatial Vision, V4, P103, DOI 10.1163/156856889X00077; CAVANAGH P, 1984, J OPT SOC AM A, V1, P893, DOI 10.1364/JOSAA.1.000893; Cavanagh P, 1991, Spat Vis, V5, P303, DOI 10.1163/156856891X00065; CAVANAGH P, 1990, Investigative Ophthalmology and Visual Science, V31, P172; CHEUNG BSK, 1991, VISION RES, V31, P1327, DOI 10.1016/0042-6989(91)90054-9; DAWSON MRW, 1991, PSYCHOL REV, V98, P569, DOI 10.1037/0033-295X.98.4.569; DEVALOIS KK, 1983, J OPT SOC AM, V73, P11, DOI 10.1364/JOSA.73.000011; Helmholtz H, 1910, TREATISE PHYSL OPTIC, V3; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KAHNEMAN D, 1992, COGNITIVE PSYCHOL, V24, P175, DOI 10.1016/0010-0285(92)90007-O; KELLY DH, 1979, J OPT SOC AM, V69, P1340, DOI 10.1364/JOSA.69.001340; MORELAND JD, 1982, COLOUR DEFICIENCIES, V6, P61; NAKAYAMA K, 1985, VISION RES, V25, P625, DOI 10.1016/0042-6989(85)90171-3; PYLYSHYN Z, 1989, COGNITION, V32, P65, DOI 10.1016/0010-0277(89)90014-0; RAMACHANDRAN VS, 1983, NATURE, V304, P529, DOI 10.1038/304529a0; VANSANTEN JPH, 1985, J OPT SOC AM A, V2, P300, DOI 10.1364/JOSAA.2.000300; von Holst E, 1954, BRIT J ANIM BEHAV, V2, P89, DOI DOI 10.1016/S0950-5601(54)80044-X; WATSON AB, 1985, J OPT SOC AM A, V2, P322, DOI 10.1364/JOSAA.2.000322; WATSON AB, 1980, VISION RES, V20, P341, DOI 10.1016/0042-6989(80)90020-6; YANTIS S, 1992, COGNITIVE PSYCHOL, V24, P295, DOI 10.1016/0010-0285(92)90010-Y	25	389	392	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1992	257	5076					1563	1565		10.1126/science.1523411	http://dx.doi.org/10.1126/science.1523411			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523411				2022-12-28	WOS:A1992JM57000037
J	CRYER, B; LEE, E; FELDMAN, M				CRYER, B; LEE, E; FELDMAN, M			FACTORS INFLUENCING GASTRODUODENAL MUCOSAL PROSTAGLANDIN CONCENTRATIONS - ROLES OF SMOKING AND AGING	ANNALS OF INTERNAL MEDICINE			English	Article						SMOKING; AGING; PROSTAGLANDINS; GASTRIC MUCOSA; INTESTINAL MUCOSA	GASTRIC LUMINAL PROSTAGLANDIN-E2; ANTI-INFLAMMATORY DRUGS; SECRETION; ULCER; CYTOPROTECTION; INDOMETHACIN; INJURY; HUMANS; ACID; RAT	Objective: To evaluate behavioral, demographic, clinical, and histologic variables that independently influence gastroduodenal mucosal prostaglandin concentrations. Design: Prospective study. Setting: A clinical research laboratory located in a Department of Veterans Affairs hospital. Patients: Fifty-two healthy adults who had no history of peptic ulcer disease and who were not receiving nonsteroidal anti-inflammatory drugs. Measurements: Mucosal biopsy specimens were obtained endoscopically from the stomach (body and antrum) and the duodenum (bulb and postbulbar area). Mucosal extracts from each of these four regions were assessed by radioimmunoassay to determine prostaglandin E2 and prostaglandin F2-alpha concentrations. Specimens were also examined histologically for inflammation and the presence of Helicobacter pylori. A multivariate linear regression model was used to determine which behavioral, demographic, and histologic variables significantly and independently influenced gastroduodenal mucosal prostaglandin concentrations. Results: Smoking and older age were independently associated with lower prostaglandin concentrations in all four mucosal regions (P = 0.0001 to P = 0.05). Compared with results in young nonsmokers, mucosal prostaglandin concentrations were reduced by 70% to 80% in older smokers. Gender, alcohol use, endoscopic appearance, dyspeptic symptoms, mucosal inflammation, and the presence of H. pylori had no consistent effect on prostaglandin content. Conclusion: Smoking and older age are associated with significantly reduced gastric and duodenal prostaglandin concentrations. These observations may help explain the predisposition to ulcer disease in smokers and older persons.	DEPT VET AFFAIRS MED CTR, 4500 S LANCASTER RD, DALLAS, TX 75216 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75230 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK 16816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; BOCHENEK WJ, 1973, AM J DIG DIS, V18, P729; BODE C, 1988, DIGEST DIS SCI, V33, P814, DOI 10.1007/BF01550968; BODE C, 1989, ALCOHOL ALCOHOLISM, V24, P35; COHEN MM, 1989, GASTROENTEROLOGY, V96, P292, DOI 10.1016/0016-5085(89)91550-3; COLLIER DS, 1985, GUT, V26, P359, DOI 10.1136/gut.26.4.359; DOLL R, 1958, LANCET, V1, P657; ENDOH K, 1991, DIGEST DIS SCI, V36, P39, DOI 10.1007/BF01300085; GOTO H, 1991, GASTROENTEROLOGY, V100, P74; GREENBERG RE, 1988, GASTROENTEROLOGY, V94, pA155; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; Gunst R. F., 1980, REGRESSION ANAL ITS, DOI 10.1201/9780203741054; HAWKEY CJ, 1988, GASTROENTEROLOGY, V94, P948, DOI 10.1016/0016-5085(88)90552-5; ISENBERG JI, 1986, GASTROENTEROLOGY, V91, P370, DOI 10.1016/0016-5085(86)90571-8; KONTUREK SJ, 1982, DIGEST DIS SCI, V27, P967, DOI 10.1007/BF01391740; LANZA FL, 1984, AM J MED, V77, P19, DOI 10.1016/S0002-9343(84)80014-5; MALESCI A, 1988, SCAND J GASTROENTERO, V23, P602, DOI 10.3109/00365528809093919; MCCREADY DR, 1985, GUT, V26, P1192, DOI 10.1136/gut.26.11.1192; MILLER TA, 1983, AM J PHYSIOL, V245, pG601, DOI 10.1152/ajpgi.1983.245.5.G601; MOORE JG, 1991, GASTROENTEROLOGY, V100, P1626, DOI 10.1016/0016-5085(91)90661-4; MURTHY SNS, 1977, GASTROENTEROLOGY, V73, P758; PETERSON WL, 1988, GASTROENTEROLOGY, V95, P1185, DOI 10.1016/0016-5085(88)90349-6; QUIMBY GF, 1986, ANN INTERN MED, V104, P616, DOI 10.7326/0003-4819-104-5-616; REDFERN JS, 1987, GASTROENTEROLOGY, V92, P969, DOI 10.1016/0016-5085(87)90972-3; ROBERT A, 1983, AM J PHYSIOL, V245, pG113, DOI 10.1152/ajpgi.1983.245.1.G113; SILEN W, 1987, PHYSL GASTROINTESTIN, P1055; SOMERVILLE K, 1986, LANCET, V1, P462; STEEL RGD, 1960, PRINCIPLES PROCEDURE, P157; WALT R, 1986, LANCET, V1, P489; WHITFIELD PF, 1987, GUT, V28, P557, DOI 10.1136/gut.28.5.557; WHITTLE BJR, 1987, PHYSL GASTROINTESTIN, P143; WONG SH, 1986, J PHARM PHARMACOL, V38, P537, DOI 10.1111/j.2042-7158.1986.tb04633.x	32	58	59	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					636	640		10.7326/0003-4819-116-8-636	http://dx.doi.org/10.7326/0003-4819-116-8-636			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546863				2022-12-28	WOS:A1992HN84400005
J	HILLNER, BE; SMITH, TJ; DESCH, CE				HILLNER, BE; SMITH, TJ; DESCH, CE			EFFICACY AND COST-EFFECTIVENESS OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN METASTATIC BREAST-CANCER - ESTIMATES USING DECISION-ANALYSIS WHILE AWAITING CLINICAL-TRIAL RESULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-DOSE CHEMOTHERAPY; MANAGEMENT; PROGNOSIS; THERAPY; SUPPORT	Objective. - To assess the efficacy and cost-effectiveness of standard chemotherapy and high-dose chemotherapy with autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Design. - Decision analysis model using a Markov process. Setting. - Response and recurrence rates from the published literature for standard therapy and from case series of ABMT. Costs were based on local charges and on adjusted Medicare data. Patients. - Hypothetical cohorts of women with metastatic breast cancer who had no bone marrow involvement and no comorbid illness. Intervention. - The standard chemotherapy cohort received cyclophosphamide, doxorubicin, and fluorouracil. The ABMT cohort was treated with intense induction chemotherapy, then additional high-dose chemotherapy following a remission, with ABMT support. Main Outcome Measures. - Anticipated survival, incremental cost per year of life, and incremental cost per quality-adjusted year of life gained using a 5-year time horizon. Rigorous sensitivity analyses were done, including assessing a benefit "tail" of normal life expectancy for those free of disease after 5 years. Results. - ABMT was the preferred approach under almost all assumptions, but the size of the benefit varied greatly. ABMT had a survival benefit of 6.0 months at 5 years at an incremental cost of $115 800 per year of life saved. If patients who were free of disease after 5 years had normal survival, the benefit was 18.1 months at an incremental cost of $28 600 per year. The benefit of ABMT was primarily dependent on whether the recurrence risk was constant or decreases after a finite period of time. Conclusion. - Using reasonable assumptions, ABMT provided a substantial benefit but at a cost that may be untenable. Decision analysis highlights the limitations in the currently available data and the assumptions made for the emotional question of using ABMT in metastatic breast cancer. The model supports the need for randomized clinical trials.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,RICHMOND,VA 23298	Virginia Commonwealth University	HILLNER, BE (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT INTERNAL MED,DIV GEN MED,MCV STN,BOX 170,RICHMOND,VA 23298, USA.		Hillner, Bruce/A-6852-2009	Smith, Thomas/0000-0003-3040-6434	AHRQ HHS [R01 HS 0659-O1A1] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANTMAN K, 1988, ANN INTERN MED, V108, P570, DOI 10.7326/0003-4819-108-4-570; ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; ANTMAN K, 1991, NEW STRATEGIES BONE, P423; BAKER MS, 1991, MED CARE, V29, P40, DOI 10.1097/00005650-199101000-00004; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BELANGER D, 1991, J CLIN ONCOL, V9, P7, DOI 10.1200/JCO.1991.9.1.7; CLARK GM, 1987, J CLIN ONCOL, V5, P55, DOI 10.1200/JCO.1987.5.1.55; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; DJULBEGOVIC B, 1991, MED DECIS MAKING, V11, P1, DOI 10.1177/0272989X9101100101; DUNPHY FR, 1990, J CLIN ONCOL, V8, P1207, DOI 10.1200/JCO.1990.8.7.1207; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ELIAS A, 1990, BLOOD S, V76, pA536; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; FETTING JH, 1990, J CLIN ONCOL, V8, P1476, DOI 10.1200/JCO.1990.8.9.1476; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HENDERSON IC, 1991, J NATL CANCER I, V83, P894; HENDERSON IC, 1990, CANCER, V66, P1439, DOI 10.1002/1097-0142(19900915)66:14+<1439::AID-CNCR2820661421>3.0.CO;2-M; HENDERSON IC, 1991, BREAST DIS, P604; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; HOLLENBERG J, 1989, SMLTREE 2 9; JONES RB, 1990, CANCER, V66, P431, DOI 10.1002/1097-0142(19900801)66:3<431::AID-CNCR2820660305>3.0.CO;2-X; KENNEDY MJ, 1991, J NATL CANCER I, V83, P920, DOI 10.1093/jnci/83.13.920; LEVINE MN, 1991, EFFECT CANCER QUALIT, P205; MICK R, 1989, BREAST CANCER RES TR, V13, P33, DOI 10.1007/BF01806548; MULLEY AG, 1989, MED CARE, V27, pS269, DOI 10.1097/00005650-198903001-00021; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; NEWCOMER LN, 1990, NEW ENGL J MED, V323, P1702, DOI 10.1056/NEJM199012133232411; PENMAN DT, 1984, J CLIN ONCOL, V2, P849, DOI 10.1200/JCO.1984.2.7.849; Peters W P, 1991, Important Adv Oncol, P135; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; PETERS WP, 1991, JUN FOR EM TREATM BR; PETERS WP, 1991, 14TH ANN ANT TEX BRE; PETRU E, 1986, WIEN KLIN WOCHENSCHR, V98, P790; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SIMES RJ, 1989, P AM SOC CLIN ONCOL, V8, pA52; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; WIESEMAN T, 1991, ONCOL ISSUES, V6, P7; WILLIAMS SF, 1989, J CLIN ONCOL, V7, P1824, DOI 10.1200/JCO.1989.7.12.1824; 1990, NEWSWEEK        1210, P62; 1990, NY TIMES        1112, pA1; 1991, J NATL CANCER I, V83, P254; 1986, LANCET, V1, P786; 1991, MED LETT DRUGS THER, V33, P3940; 1990, STATISTICAL ABSTRACT, P469	47	142	143	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2055	2061		10.1001/jama.267.15.2055	http://dx.doi.org/10.1001/jama.267.15.2055			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552641				2022-12-28	WOS:A1992HM65000031
J	IGLEHART, JK				IGLEHART, JK			THE AMERICAN HEALTH-CARE SYSTEM - INTRODUCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICAL-CARE; INSURANCE; CHOICE											AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; American College of Physicians, 1990, ANN INTERN MED, V112, P641; BLENDON RJ, 1990, NEW ENGL J MED, V323, P208, DOI 10.1056/NEJM199007193230329; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; FOLEY J, 1992, SOURCES HLTH INSURAN; FREUDENHEIM M, 1990, NY TIMES        0205; Fuchs V R, 1982, Health Aff (Millwood), V1, P5, DOI 10.1377/hlthaff.1.3.5; FUCHS VR, 1991, HEALTH AFFAIR, V10, P7, DOI 10.1377/hlthaff.10.4.7; GINZBERG E, 1984, NEW ENGL J MED, V310, P1162, DOI 10.1056/NEJM198405033101806; Gray BH., 1989, CONTROLLING COSTS CH; Gray Bradford H., 1991, PROFIT MOTIVE PATIEN, P71; HIRSHFIELD DS, 1970, LOST REFORM CAMPAIGN; HOLLINGSWORTH JW, 1990, NEW ENGL J MED, V322, P1851, DOI 10.1056/NEJM199006283222605; HOY EW, 1991, HEALTH AFFAIR, V10, P18, DOI 10.1377/hlthaff.10.4.18; IGLEHART JK, 1985, NEW ENGL J MED, V313, P1552, DOI 10.1056/NEJM198512123132429; IGLEHART JK, 1991, NEW ENGL J MED, V324, P1750, DOI 10.1056/NEJM199106133242428; IGLEHART JK, 1991, NEW ENGL J MED, V325, P823, DOI 10.1056/NEJM199109123251126; JENCKS SF, 1992, HLTH CARE FINANCE RE, V14, P1; Levit K R, 1991, Health Care Financ Rev, V13, P29; LUNDBERG GD, 1991, JAMA-J AM MED ASSOC, V265, P2566; MARCHASIN S, 1991, WALL STREET J   1209; RELMAN AS, 1991, NEW ENGL J MED, V325, P854, DOI 10.1056/NEJM199109193251205; SCHIEBER GJ, 1991, HEALTH AFFAIR, V10, P22, DOI 10.1377/hlthaff.10.3.22; SCHWARTZ A, 1991, HEALTH AFFAIR, V10, P131, DOI 10.1377/hlthaff.10.1.131; Starr P, 1982, SOCIAL TRANSFORMATIO; STARR P, 1991, AM PROSPECT      SUM, P5; STEVENS R, 1991, J HEALTH POLIT POLIC, V16, P281, DOI 10.1215/03616878-16-2-281; VIBBERT S, 1991, DOCTOR WATCHERS; WALDO DR, 1991, HEALTH AFFAIR, V10, P231, DOI 10.1377/hlthaff.10.4.231; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; 1990, HASSLE FACTOR AM HLT; 1990, SOURCE BOOK HLTH INS; 1991, CRITICAL DISTINCTION	33	46	46	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					962	967		10.1056/NEJM199204023261426	http://dx.doi.org/10.1056/NEJM199204023261426			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HL261	1542360				2022-12-28	WOS:A1992HL26100032
J	MACHARIA, WM; LEON, G; ROWE, BH; STEPHENSON, BJ; HAYNES, RB				MACHARIA, WM; LEON, G; ROWE, BH; STEPHENSON, BJ; HAYNES, RB			AN OVERVIEW OF INTERVENTIONS TO IMPROVE COMPLIANCE WITH APPOINTMENT KEEPING FOR MEDICAL-SERVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							FAMILY-PRACTICE; FAILED APPOINTMENTS; RANDOMIZED TRIAL; HEALTH-CENTER; OUTPATIENT; REMINDERS; CANCER; ATTENDANCE; STRATEGIES; RECALL	Objective. - To determine, by a quantitative meta-analysis of randomized trials, the effectiveness of strategies to improve patient compliance with screening, referral, and clinic appointments for health services that are provided at the time of the visit. Data Sources.-Computerized searches of MEDLINE (1966 through 1990) were done using two search strategies: (1) (Patient Compliance OR Adhere* OR Dropout*) AND (Appointment*) AND (Screen* OR Follow* OR Refer*); and (2) (Patient Compliance OR Adhere* OR Dropout*) AND (Attend* OR Screen*) OR (Appointment*). A computerized search of PSYCHLIT was done with the terms Compliance AND Appointment*. In addition, the reference list of each retrieved article was reviewed and relevant citations retrieved. Study Selection. - Only randomized trials with quantitative data concerning the effect of interventions to improve attendance at appointments for supervised administration of care were considered for detailed review. Studies of appointment keeping for self-administered treatments or tests were excluded. Two independent reviewers assessed each article for inclusion (kappa, for agreement, 0.66 for MEDLINE; 0.95 for PSYCHLIT) and validity (kappa, 0.62) using a priori criteria. Twenty-three (26%) of 88 relevant articles met all criteria. Data Extraction. - Data on study populations, interventions, and outcomes were extracted and analyzed using pooled odds ratios (ORs). Data Synthesis.-The average rate of compliance with appointments was 58%. Mailed reminders and telephone prompts were consistently useful in reducing broken appointments (OR, 2.2; 95% confidence interval [Cl], 1.7 to 2.9; and OR, 2.9, Cl, 1.9 to 4.3, respectively). An "orientation statement" (OR, 2.9; Cl, 1.5 to 5.6), "contracting" with patients (OR, 1.9; Cl, 1.04 to 3.5), and prompts from physicians (OR, 1.6; Cl, 1.4 to 2.0) showed positive effects as well. Conclusions. - In clinic settings where kept appointments can be an accurate measure of patient compliance with health care interventions, broken appointments can be reduced by mail, telephone, or physician reminders; orienting patients to the clinic; or contracting with patients.	MCMASTER UNIV, FAC HLTH SCI,MED CTR, DESIGN MEASUREMENT & EVALUAT PROGRAM,ROOM 3H7, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA	McMaster University			macharia, william/Q-6042-2018	macharia, william/0000-0002-4428-862X; Haynes, Robert Brian/0000-0002-1453-3196				BARRY SP, 1984, J FAM PRACTICE, V18, P739; BRESLOW NE, 1980, STATISTICAL METHODS, P141; BRIGG EH, 1968, FAM COORD, V17, P41, DOI 10.2307/581971; BURGOYNE RW, 1983, AM J PSYCHIAT, V140, P345; CLEMENTZ GL, 1990, J FAM PRACTICE, V30, P537; DUNBAR JM, 1980, COMPREHENSIVE HDB BE, P225; FLETCHER SW, 1974, NEW ENGL J MED, V291, P385, DOI 10.1056/NEJM197408222910804; FRANKEL BS, 1978, BEHAV MODIF, V2, P435, DOI 10.1177/014544557824001; GATES SJ, 1976, MED CARE, V14, P263, DOI 10.1097/00005650-197603000-00007; HAGERMAN GA, 1978, J FAM PRACTICE, V7, P199; HAYNES RB, 1979, COMPLIANCE HLTH CARE, P121; HOEHNSARIC R, 1964, J PSYCHIAT RES, V2, P267, DOI 10.1016/0022-3956(64)90013-5; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; KLUGER MP, 1983, COMMUNITY MENT HLT J, V19, P137, DOI 10.1007/BF00877606; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LARSON EB, 1982, MED CARE, V20, P639, DOI 10.1097/00005650-198206000-00010; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEVENTHAL H, 1987, PATIENT EDUC COUNS, V10, P117, DOI 10.1016/0738-3991(87)90093-0; LEVY RL, 1980, J BEHAV THER EXP PSY, V11, P105, DOI 10.1016/0005-7916(80)90005-1; LOWE RH, 1982, J CONSULT CLIN PSYCH, V50, P602, DOI 10.1037/0022-006X.50.4.602; MAIMAN LA, 1974, HLTH BELIEF MODEL PE, P9; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCDOWELL I, 1989, J FAM PRACTICE, V28, P420; MCDOWELL I, 1989, MED CARE, V27, P297, DOI 10.1097/00005650-198903000-00008; NICHOLS S, 1986, BRIT MED J, V293, P107, DOI 10.1136/bmj.293.6539.107; NIRENBERG TD, 1980, AM J DRUG ALCOHOL AB, V7, P73; OPPENHEIM GL, 1979, J FAM PRACTICE, V8, P789; OSSIPKLEIN DJ, 1984, ADDICT BEHAV, V9, P85, DOI 10.1016/0306-4603(84)90010-8; PIERCE M, 1989, BMJ-BRIT MED J, V299, P160, DOI 10.1136/bmj.299.6692.160; PYE G, 1988, J EPIDEMIOL COMMUN H, V42, P66, DOI 10.1136/jech.42.1.66; ROTH H P, 1984, Controlled Clinical Trials, V5, P476, DOI 10.1016/0197-2456(84)90007-2; ROTH HP, 1971, AM J MED SCI, V262, P269, DOI 10.1097/00000441-197111000-00004; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA, P199; SHEPARD DS, 1976, MED CARE, V14, P268, DOI 10.1097/00005650-197603000-00008; SWENSON TR, 1988, COMMUNITY MENT HLT J, V24, P205, DOI 10.1007/BF00757138; WARZAK WJ, 1987, J COMPLIANCE HLTH CA, V2, P143; WILLIAMS EMI, 1989, BMJ-BRIT MED J, V299, P158, DOI 10.1136/bmj.299.6692.158; YUSUF S, 1987, STAT MED, V6, P281, DOI 10.1002/sim.4780060314	38	257	260	2	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1813	1817		10.1001/jama.267.13.1813	http://dx.doi.org/10.1001/jama.267.13.1813			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1532036				2022-12-28	WOS:A1992HK67200033
J	LOVE, RR; MAZESS, RB; BARDEN, HS; EPSTEIN, S; NEWCOMB, PA; JORDAN, VC; CARBONE, PP; DEMETS, DL				LOVE, RR; MAZESS, RB; BARDEN, HS; EPSTEIN, S; NEWCOMB, PA; JORDAN, VC; CARBONE, PP; DEMETS, DL			EFFECTS OF TAMOXIFEN ON BONE-MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADJUVANT CHEMOTHERAPY; OSTEOPOROSIS; RATS; ANTIESTROGENS; CLOMIPHENE; THERAPY; HORMONE; TRIAL	Background and Methods. Tamoxifen, a synthetic antiestrogen, increases disease-free and overall survival when used as adjuvant therapy for primary breast cancer. Because it is given for long periods, it is important to know whether tamoxifen affects the skeleton, particularly since it is used extensively in postmenopausal women who are at risk for osteoporosis. Using photon absorptiometry, we studied the effects of tamoxifen on the bone mineral density of the lumbar spine and radius and on biochemical measures of bone metabolism in 140 postmenopausal women with axillary-node-negative breast cancer, in a two-year randomized, double-blind, placebo-controlled trial. Results. In the women given tamoxifen, the mean bone mineral density of the lumbar spine increased by 0.61 percent per year, whereas in those given placebo it decreased by 1.00 percent per year (P < 0.001). Radial bone mineral density decreased to the same extent in both groups. In a subgroup randomly selected from each group, serum osteocalcin and alkaline phosphatase concentrations decreased significantly in women given tamoxifen (P < 0.001 for each variable), whereas serum parathyroid hormone and 1,25-dihydroxyvitamin D concentrations did not change significantly in either group. Conclusions. In postmenopausal women, treatment with tamoxifen is associated with preservation of the bone mineral density of the lumbar spine. Whether this favorable effect on bone mineral density is accompanied by a decrease in the risk of fractures remains to be determined.	UNIV WISCONSIN,DEPT HUMAN ONCOL,MADISON,WI 53706; UNIV WISCONSIN,DEPT MED PHYS,MADISON,WI 53706; ALBERT EINSTEIN MED CTR,NO DIV,DEPT MED,PHILADELPHIA,PA 19141	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Yeshiva University			Jordan, V. Craig/H-4491-2011; JORDAN, V.Craig/AAX-3562-2020		NCI NIH HHS [CA-50243] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, AM J EPIDEMIOL, V132, P877, DOI 10.1093/oxfordjournals.aje.a115730; BANKSON DD, 1989, BONE MINER, V6, P55, DOI 10.1016/0169-6009(89)90023-8; BRUNING PF, 1990, BRIT J CANCER, V61, P308, DOI 10.1038/bjc.1990.58; CIVITELLI R, 1988, J CLIN INVEST, V82, P1268, DOI 10.1172/JCI113725; DRAPER NR, 1981, APPLIED REGRESSION A; EPSTEIN S, 1984, LANCET, V1, P307; FALKSON HC, 1990, J CLIN ONCOL, V8, P599, DOI 10.1200/JCO.1990.8.4.599; FELDMANN S, 1989, BONE MINER, V7, P245, DOI 10.1016/0169-6009(89)90081-0; FENTIMAN IS, 1989, BRIT J CANCER, V60, P262, DOI 10.1038/bjc.1989.266; FISHER B, 1987, ANN INTERN MED, V106, P649, DOI 10.7326/0003-4819-106-5-649; FORNANDER T, 1990, J CLIN ONCOL, V8, P1019, DOI 10.1200/JCO.1990.8.6.1019; GOTFREDSEN A, 1984, CANCER, V53, P853, DOI 10.1002/1097-0142(19840215)53:4<853::AID-CNCR2820530406>3.0.CO;2-M; GOULDING A, 1990, BONE MINER, V8, P185, DOI 10.1016/0169-6009(90)90104-N; JORDAN VC, 1987, CANCER RES, V47, P624; JORDAN VC, 1987, BREAST CANCER RES TR, V10, P31, DOI 10.1007/BF01806132; LERNER LJ, 1990, CANCER RES, V50, P4177; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LOVE RR, 1988, BREAST CANCER RES TR, V12, P297, DOI 10.1007/BF01811242; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; LOVE RR, 1991, ARCH INTERN MED, V151, P1842, DOI 10.1001/archinte.151.9.1842; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; MAZESS RB, 1987, BONE MINER, V2, P211; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; RYAN WG, 1988, J BONE MINER RES, V3, pS130; STEWART PJ, 1986, ENDOCRINOLOGY, V118, P125, DOI 10.1210/endo-118-1-125; TURKEN S, 1989, J NATL CANCER I, V81, P1086, DOI 10.1093/jnci/81.14.1086; TURNER RT, 1987, J BONE MINER RES, V2, P449; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; WAHNER HW, 1986, CRIT REV CLIN LAB SC, V24, P2217; WAKLEY GK, 1988, CALCIFIED TISSUE INT, V43, P383, DOI 10.1007/BF02553283; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; 1987, LANCET, V2, P171; 1988, NEW ENGL J MED, V319, P1681	35	915	942	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1992	326	13					852	856		10.1056/NEJM199203263261302	http://dx.doi.org/10.1056/NEJM199203263261302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK523	1542321				2022-12-28	WOS:A1992HK52300002
J	BOWERMAN, B; EATON, BA; PRIESS, JR				BOWERMAN, B; EATON, BA; PRIESS, JR			SKN-1, A MATERNALLY EXPRESSED GENE REQUIRED TO SPECIFY THE FATE OF VENTRAL BLASTOMERES IN THE EARLY C-ELEGANS EMBRYO	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; DNA-BINDING; GERM-LINE; CELLULAR INTERACTIONS; NUCLEOTIDE-SEQUENCE; SPLICED LEADER; DORSAL PROTEIN; LOCUS; LOCALIZATION	By the 4-cell stage of C. elegans embryogenesis, a ventral blastomere, called EMS, is already committed to producing pharyngeal and intestinal cell types. Recessive, maternal-effect mutations in the gene skn-1 prevent EMS from producing both pharyngeal and intestinal cells. In skn-1 mutant embryos, EMS instead produces hypodermal cells and body wall muscle cells, much like its sister blastomere. Genetic analysis suggests that the skn-1 gene product is also required post-embryonically for development of the intestine. We have cloned and sequenced the skn-1 gene and describe sequence similarities to the basic regions of bZIP transcription factors. We propose that the maternally expressed skn-1 gene product acts to specify the fate of the EMS blastomere.			BOWERMAN, B (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104, USA.							ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ARTAVANISTSAKONAS S, 1983, P NATL ACAD SCI-BIOL, V80, P1977, DOI 10.1073/pnas.80.7.1977; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; Ausubel FM, 1988, MOL REPROD DEV; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BENSON M, 1987, EMBO J, V6, P1387, DOI 10.1002/j.1460-2075.1987.tb02379.x; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BRAND M, 1990, ROUX ARCH DEV BIOL, V198, P275, DOI 10.1007/BF00377394; BRENNER S, 1974, GENETICS, V77, P71; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON AR, 1986, P NATL ACAD SCI USA, V85, P4397; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DAVIDSON EH, 1991, DEVELOPMENT, V113, P1; DELACONCHA A, 1988, GENETICS, V118, P499; EPSTEIN HF, 1982, MUSCLE DEV MOL CELLU, P7; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GREENWALD IS, 1980, GENETICS, V96, P147; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GREENWALD IS, 1985, CELL, V45, P583; HARI T, 1989, GENE DEV, V3, P2083; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; LEHMANN R, 1991, DEVELOPMENT, V112, P679; MANSUKHANI A, 1988, MOL GEN GENET, V211, P121, DOI 10.1007/BF00338402; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MENEELY PM, 1979, GENETICS, V92, P99; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MUSSLEINVOLHARD C, 1991, DEVELOPMENT S, V1, P1; OBRIEN SJ, 1990, GENETIC MAPS, V5; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIERENBERG E, 1985, COLD SPRING HARB SYM, V50, P59, DOI 10.1101/SQB.1985.050.01.010; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VINSON CR, 1989, SCIENCE, V246, P991; WALLACE JC, 1991, IN PRESS CABIOS; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; Waterston R., 1988, NEMATODE C ELEGANS, P281; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	75	315	327	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1061	1075		10.1016/0092-8674(92)90078-Q	http://dx.doi.org/10.1016/0092-8674(92)90078-Q			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547503				2022-12-28	WOS:A1992HK67400010
J	FU, YH; PIZZUTI, A; FENWICK, RG; KING, J; RAJNARAYAN, S; DUNNE, PW; DUBEL, J; NASSER, GA; ASHIZAWA, T; DEJONG, P; WIERINGA, B; KORNELUK, R; PERRYMAN, MB; EPSTEIN, HF; CASKEY, CT				FU, YH; PIZZUTI, A; FENWICK, RG; KING, J; RAJNARAYAN, S; DUNNE, PW; DUBEL, J; NASSER, GA; ASHIZAWA, T; DEJONG, P; WIERINGA, B; KORNELUK, R; PERRYMAN, MB; EPSTEIN, HF; CASKEY, CT			AN UNSTABLE TRIPLET REPEAT IN A GENE RELATED TO MYOTONIC MUSCULAR-DYSTROPHY	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE	Synthetic oligonucleotides containing GC-rich triplet sequences were used in a scanning strategy to identify unstable genetic sequences at the myotonic dystrophy (DM) locus. A highly polymorphic GCT repeat was identified and found to be unstable, with an increased number of repeats occurring in DM patients. In the case of severe congenital DM, the paternal triplet allele was inherited unaltered while the maternal, DM-associated allele was unstable. These studies suggest that the mutational mechanism leading to DM is triplet amplification, similar to that occurring in the fragile X syndrome. The triplet repeat sequence is within a gene (to be referred to as myotonin-protein kinase), which has a sequence similar to protein kinases.	BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,CTR HUMAN GENOME,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; UNIV CALIF LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550; CATHOLIC UNIV NIJMEGEN,DEPT CELL BIOL & HISTOL,NIJMEGEN,NETHERLANDS; CHILDRENS HOSP EASTERN ONTARIO,DEPT GENET,OTTAWA K1H 8L1,ONTARIO,CANADA; BAYLOR COLL MED,DEPT CARDIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Radboud University Nijmegen; University of Ottawa; Children's Hospital of Eastern Ontario; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute			Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020; PIZZUTI, Antonio/0000-0003-3245-1925	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P30HG000210] Funding Source: NIH RePORTER; NCRR NIH HHS [5-M01-RR00350] Funding Source: Medline; NHGRI NIH HHS [P30-HG00210] Funding Source: Medline; NHLBI NIH HHS [P50HL42267-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; EDWARDS A, 1991, AM J HUM GENET, V49, P746; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; GOLDSTEIN JL, 1989, METABOLIC BASIS INHE, pCH48; HALL JG, 1990, AM J HUM GENET, V46, P357; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JANSEN G, IN PRESS GENOMICS; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LUPSKI JR, UNPUB; Myotonic Dystrophy Foundation, 2017, VOIC PAT REP MYOT DY; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RIDLEY RM, 1991, J MED GENET, V28, P224, DOI 10.1136/jmg.28.4.224; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SHUTLER G, IN PRESS GENOMICS; SMEETS HJM, 1991, GENOMICS, V9, P257, DOI 10.1016/0888-7543(91)90250-I; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; ZOGHBI HY, 1988, ANN NEUROL, V23, P580, DOI 10.1002/ana.410230609	21	1275	1329	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1256	1258		10.1126/science.1546326	http://dx.doi.org/10.1126/science.1546326			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546326				2022-12-28	WOS:A1992HG67700043
J	GAO, WQ; LIU, XL; HATTEN, ME				GAO, WQ; LIU, XL; HATTEN, ME			THE WEAVER GENE ENCODES A NONAUTONOMOUS SIGNAL FOR CNS NEURONAL DIFFERENTIATION	CELL			English	Article							GRANULE CELL MIGRATION; CEREBELLAR CORTEX; MOUSE CEREBELLUM; POSTNATAL-DEVELOPMENT; MUTANT MICE; RAT-BRAIN; INVITRO; DROSOPHILA; ASTROGLIA; ADHESION	In the neurological mutant mouse weaver, CNS precursor cells in the external germinal layer (EGL) of the cerebellar cortex proliferate normally, but fail to differentiate and die in the proliferative zone. To examine the autonomy of expression of the weaver gene, we carried out cell-mixing experiments in vitro. In homo-typic, reaggregate cultures, weaver EGL precursor cells expressed the general neuronal markers N-CAM, L1, and MAP2, but failed to express the late neuronal antigens TAG-1 and astrotactin, to extend neurites or to migrate on glial fibers. After reaggregation with wild-type EGL precursor cells, weaver precursor cells extended neurites equivalent in length to wild-type cells, migrated along astroglial fibers, and expressed TAG-1 and astrotactin. Rescue of neurite production was also achieved by the addition of membranes from, but not by medium conditioned by wild-type cells. These findings suggest that the weaver gene acts nonautonomously, encoding a membrane-associated ligand that induces EGL neuronal differentiation.			GAO, WQ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT PATHOL,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015429] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15429] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; BAIRD D, 1992, IN PRESS J NEUROSCI; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; Cajal S. R., 1911, HISTOLOGIE SYSTEME N; CAJAL SR, 1889, REV TRIM HISTOL NORM; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; EDMONDSON JC, 1988, J CELL BIOL, V106, P505, DOI 10.1083/jcb.106.2.505; FISHELL G, 1991, DEVELOPMENT, V113, P755; FUJITA S, 1966, J COMP NEUROL, V128, P191, DOI 10.1002/cne.901280206; FUJITA S, 1967, J CELL BIOL, V32, P277, DOI 10.1083/jcb.32.2.277; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GOLDOWITZ D, 1989, NEURON, V2, P1565, DOI 10.1016/0896-6273(89)90045-7; GOLDOWITZ D, 1982, J NEUROSCI, V2, P1474; GREGORY WA, 1988, J NEUROSCI, V8, P1728; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HATTEN ME, 1984, DEV BRAIN RES, V13, P309, DOI 10.1016/0165-3806(84)90166-4; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HATTEN ME, 1987, J CELL BIOL, V104, P1353, DOI 10.1083/jcb.104.5.1353; HATTEN ME, 1984, J CELL BIOL, V98, P193, DOI 10.1083/jcb.98.1.193; HATTEN ME, 1984, J NEUROSCI, V4, P1163; HATTEN ME, 1986, J NEUROSCI, V6, P2676; HATTEN ME, 1978, EXP CELL RES, V113, P111, DOI 10.1016/0014-4827(78)90092-7; HIS W, 1989, ABHANDL MATH PHYS KO, V26, P313; HORAN PK, 1989, NATURE, V340, P167, DOI 10.1038/340167a0; HUBER G, 1984, J NEUROSCI, V4, P151; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Le Douarin N.M., 1982, NEURAL CREST; LUND RD, 1985, NEUROSCI LETT, V61, P221, DOI 10.1016/0304-3940(85)90428-8; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MARTINEZARIAS A, 1988, NATURE, V336, P348; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; PATTERSON PH, 1978, ANNU REV NEUROSCI, V1, P1, DOI 10.1146/annurev.ne.01.030178.000245; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PERSOHN E, 1987, J CELL BIOL, V105, P569, DOI 10.1083/jcb.105.1.569; RAKIC P, 1973, J COMP NEUROL, V152, P103, DOI 10.1002/cne.901520202; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RATHJEN FG, 1984, EMBO J, V3, P1; REZAI Z, 1972, DEV BIOL, V29, P17, DOI 10.1016/0012-1606(72)90039-5; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SAUER FC, 1935, J COMP NEUROL, V63, P12; SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3; SMEYNE RJ, 1991, ANAT EMBRYOL, V183, P213; SOTELO C, 1974, BRAIN RES, V77, P484, DOI 10.1016/0006-8993(74)90636-2; STITT TN, 1990, NEURON, V5, P639, DOI 10.1016/0896-6273(90)90218-5; THIERY JP, 1977, J BIOL CHEM, V252, P6841; TRENKNER E, 1977, J CELL BIOL, V75, P915, DOI 10.1083/jcb.75.3.915; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WATANABE T, 1990, NEURON, V4, P461, DOI 10.1016/0896-6273(90)90058-N; WILLINGER M, 1985, DEV BIOL, V107, P156, DOI 10.1016/0012-1606(85)90384-7; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMAMOTO M, 1986, J NEUROSCI, V6, P3676; 1970, ANAT REC, V166, P257	60	103	105	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					841	854		10.1016/0092-8674(92)90028-B	http://dx.doi.org/10.1016/0092-8674(92)90028-B			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547486				2022-12-28	WOS:A1992HH74800004
J	CHOW, RH; VONRUDEN, L; NEHER, E				CHOW, RH; VONRUDEN, L; NEHER, E			DELAY IN VESICLE FUSION REVEALED BY ELECTROCHEMICAL MONITORING OF SINGLE SECRETORY EVENTS IN ADRENAL CHROMAFFIN CELLS	NATURE			English	Article							PATCH-CLAMP TECHNIQUES; TRANSMITTER RELEASE; CALCIUM DIFFUSION; CHANNELS; MEMBRANE; FACILITATION; VOLTAMMETRY; EXOCYTOSIS; ELECTRODES; SQUID	IN synapses, a rise in presynaptic intracellular calcium leads to secretory vesicle fusion in less than a millisecond, as indicated by the short delay from excitation to postsynaptic signal 1-4 . In nonsynaptic secretory cells, studies at high time resolution have been limited by the lack of a detector as fast and sensitive as the postsynaptic membrane. Electrochemical methods may be sensitive enough to detect catecholamines released from single vesicles 5,6. Here, we show that under voltage-clamp conditions, stochastically occurring signals can be recorded from adrenal chromaffin cells using a carbon-fibre electrode as an electrochemical detector. These signals obey statistics characteristic for quantal release; however, in contrast to neuronal transmitter release, secretion occurs with a significant delay after short step depolarizations. Furthermore, we identify a pedestal or 'foot' at the onset of unitary events which may represent the slow leak of catecholamine molecules out of a narrow 'fusion pore' before the pore dilates for complete exocytosis.	MAX PLANCK INST BIOPHYS CHEM,POSTFACH 2841,W-3400 GOTTINGEN,GERMANY	Max Planck Society			Chow, Robert/B-8155-2013; Neher, Erwin/A-2109-2013					ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; ARMSTRONGJAMES M, 1979, J NEUROSCI METH, V1, P279, DOI 10.1016/0165-0270(79)90039-6; AUGUSTINE GJ, 1985, J PHYSIOL-LONDON, V367, P163, DOI 10.1113/jphysiol.1985.sp015819; BAUR JE, 1988, ANAL CHEM, V60, P1268, DOI 10.1021/ac00164a006; Crank J., 1975, MATH DIFFUSION; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DETOLEDO GA, 1990, J GEN PHYSIOL, V95, P397, DOI 10.1085/jgp.95.3.397; DUCHEN MR, 1991, J PHYSIOL-LONDON, V426, P5; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; FOGELSON AL, 1985, BIOPHYS J, V48, P1003, DOI 10.1016/S0006-3495(85)83863-7; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Jackson J., 1975, CLASSICAL ELECTRODYN; KATZ B, 1965, J PHYSIOL-LONDON, V181, P656, DOI 10.1113/jphysiol.1965.sp007790; LESZCZYSZYN DJ, 1990, J BIOL CHEM, V265, P14736; LESZCZYSZYN DJ, 1991, J NEUROCHEM, V56, P1855, DOI 10.1111/j.1471-4159.1991.tb03441.x; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MARSDEN CA, 1988, NEUROSCIENCE, V25, P389, DOI 10.1016/0306-4522(88)90247-3; MARTY A, 1985, J PHYSIOL-LONDON, V367, P117, DOI 10.1113/jphysiol.1985.sp015817; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; PARNAS H, 1986, PFLUG ARCH EUR J PHY, V406, P121, DOI 10.1007/BF00586672; PHILLIPS JH, 1982, NEUROSCIENCE, V7, P1595, DOI 10.1016/0306-4522(82)90017-3; SALA F, 1990, BIOPHYS J, V57, P313, DOI 10.1016/S0006-3495(90)82533-9; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754	28	727	744	0	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					60	63		10.1038/356060a0	http://dx.doi.org/10.1038/356060a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538782				2022-12-28	WOS:A1992HG60200055
J	BURATOWSKI, S; ZHOU, H				BURATOWSKI, S; ZHOU, H			TRANSCRIPTION FACTOR-IID MUTANTS DEFECTIVE FOR INTERACTION WITH TRANSCRIPTION FACTOR-IIA	SCIENCE			English	Article							RNA POLYMERASE-II; TATA BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; INITIATION-FACTOR; SCHIZOSACCHAROMYCES-POMBE; PREINITIATION COMPLEX; PROMOTER INTERACTIONS; FUNCTIONAL DOMAINS; GENE; BOX	Transcription factor IID (TFIID) recognizes the TATA element of promoters transcribed by RNA polymerase II (RNAPII) and serves as the base for subsequent association by other general transcription factors and RNAPII. The carboxyl-terminal domain of TFIID is highly conserved and contains an imperfect repetition of a 60-amino acid sequence. These repeats are separated by a region rich in bask amino acids. Mutagenesis of the lysines in this region resulted in a conditional phenotype in vivo, and the mutant proteins were defective for interactions with transcription factor IIA in vitro. Binding of TFIID to DNA was unaffected. These results suggest that the basic domain of TFIID is important for protein-protein interactions.			BURATOWSKI, S (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NIGMS NIH HHS [R29-GM46498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURATOWSKI S, UNPUB; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; EISENMANN DM, 1989, CELL, V58, P1193; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RANISH JA, 1991, J BIOL CHEM, V266, P19320; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495	40	92	93	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1130	1132		10.1126/science.1546314	http://dx.doi.org/10.1126/science.1546314			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546314				2022-12-28	WOS:A1992HF63200042
J	GRENFELL, BT; PRICE, OF; ALBON, SD; CLUTTONBROCK, TH				GRENFELL, BT; PRICE, OF; ALBON, SD; CLUTTONBROCK, TH			OVERCOMPENSATION AND POPULATION-CYCLES IN AN UNGULATE	NATURE			English	Article							ECOLOGICAL-SYSTEMS; DENSITY DEPENDENCE; MODELS; CHAOS	ALTHOUGH theoretical studies show that overcompensatory density-dependent mechanisms can potentially generate regular or chaotic fluctuations in animal numbers, the majority of realistic single-species models of invertebrate populations are not overcompensatory enough to cause sustained population cycles 1-3. The possibility that overcompensation may generate cycles or chaos in vertebrate populations has seldom been considered. Here we show that highly overcompensating density-dependent mortality can generate recurrent population crashes consistent with those observed in a naturally limited population of Soay sheep. The observed interval of three or more years between crashes points to sharp 'focusing' of mortality over a narrow range of population density.			GRENFELL, BT (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		ALBON, Stephen D/C-6304-2011; Price, Owen F/H-4033-2012	ALBON, Stephen D/0000-0002-0811-1333; Price, Owen F/0000-0001-5327-568X				ATKIN M, 1989, STATISTICAL MODELLIN; BELLOWS TS, 1981, J ANIM ECOL, V50, P139, DOI 10.2307/4037; BULMER MG, 1974, J ANIM ECOL, V43, P701, DOI 10.2307/3532; CLARK CW, 1976, J MATH BIOL, V3, P381, DOI 10.1007/BF00275067; Clutton-Brock T. H., 1989, RED DEER HIGHLANDS; CLUTTONBROCK TH, 1985, J ANIM ECOL, V54, P831, DOI 10.2307/4381; CLUTTONBROCK TH, 1991, J ANIM ECOL, V60, P593, DOI 10.2307/5300; Fowler C.W., 1987, Current Mammalogy, V1, P401; FOWLER CW, 1981, ECOLOGY, V62, P602, DOI 10.2307/1937727; HASSELL MP, 1976, J ANIM ECOL, V45, P471, DOI 10.2307/3886; HASSELL MP, 1988, ECOLOGICAL CONCEPTS, P147; Holden AV., 1986, CHAOS; Hudson P.J., 1990, P5; LESLIE PH, 1948, BIOMETRIKA, V35, P213, DOI 10.2307/2332342; LESLIE PH, 1945, BIOMETRIKA, V33, P183, DOI 10.2307/2332297; PETERSON RO, 1984, SCIENCE, V224, P1350, DOI 10.1126/science.224.4655.1350; SCHAFFER WM, 1985, ECOLOGY, V66, P93, DOI 10.2307/1941309; SCHAFFER WM, 1986, TRENDS ECOL EVOL, V1, P58, DOI 10.1016/0169-5347(86)90018-2; SMITH JM, 1973, ECOLOGY, V54, P384, DOI 10.2307/1934346; Varley G.C., 1973, INSECT POPULATION EC; WATSON A, 1984, J ANIM ECOL, V53, P639, DOI 10.2307/4541; [No title captured]; [No title captured]	23	107	108	0	55	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 27	1992	355	6363					823	826		10.1038/355823a0	http://dx.doi.org/10.1038/355823a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538761				2022-12-28	WOS:A1992HF63600055
J	DAVISON, A; MULVEY, D; GREEN, M; CURRIE, D; DENISON, DM; CLARK, T; CHUNG, KF; GEDDES, D				DAVISON, A; MULVEY, D; GREEN, M; CURRIE, D; DENISON, DM; CLARK, T; CHUNG, KF; GEDDES, D			ROYAL BROMPTON GRAND ROUNDS - IDIOPATHIC DIAPHRAGMATIC WEAKNESS	BMJ-BRITISH MEDICAL JOURNAL			English	Discussion							SNIFF		ROYAL BROMPTON & NATL HEART HOSP, LONDON SW3 6HP, ENGLAND	Imperial College London								Billings R, 1975, Rheumatol Rehabil, V14, P260, DOI 10.1093/rheumatology/14.4.260; CAPE CA, 1965, NEUROLOGY, V15, P191, DOI 10.1212/WNL.15.2.191; KOULOURIS N, 1988, EUR RESPIR J, V1, P863; LAROCHE CM, 1988, AM REV RESPIR DIS, V138, P598, DOI 10.1164/ajrccm/138.3.598; MIER A, 1987, THORAX, V42, P885, DOI 10.1136/thx.42.11.885; MIER AK, 1986, BRIT MED J, V292, P1495, DOI 10.1136/bmj.292.6534.1495; MILLER JM, 1985, CLIN SCI, V69, P91, DOI 10.1042/cs0690091; PARSONAGE MJ, 1948, LANCET, V254, P973; PIETERS T, 1988, CLIN RHEUMATOL, V7, P402, DOI 10.1007/BF02239201; RILEY EA, 1962, AM J MED, V32, P404, DOI 10.1016/0002-9343(62)90130-4; Spillane JD, 1943, LANCET, V2, P532; SWEENEY PJ, 1982, CLEVELAND CLIN Q, V49, P145, DOI 10.3949/ccjm.49.3.145; TSAIRIS P, 1972, ARCH NEUROL-CHICAGO, V27, P109, DOI 10.1001/archneur.1972.00490140013004	13	21	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 22	1992	304	6825					492	494		10.1136/bmj.304.6825.492	http://dx.doi.org/10.1136/bmj.304.6825.492			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547426	Green Published, Bronze			2022-12-28	WOS:A1992HF55500029
J	MAHER, J; REILLY, M; DALY, L; HUTCHINSON, M				MAHER, J; REILLY, M; DALY, L; HUTCHINSON, M			PLANTAR POWER - REPRODUCIBILITY OF THE PLANTAR RESPONSE	BRITISH MEDICAL JOURNAL			English	Article							PURE MOTOR HEMIPLEGIA		ADELAIDE HOSP,DEPT NEUROL,DUBLIN 8,IRELAND; NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT PUBL HLTH MED & EPIDEMIOL,DUBLIN 4,IRELAND	Trinity College Dublin; University College Dublin			hutchinson, michael/H-3508-2019	Maher, John/0000-0001-8275-8488; hutchinson, michael/0000-0002-8675-1723				CHOKROVERTY S, 1975, ARCH NEUROL-CHICAGO, V32, P647, DOI 10.1001/archneur.1975.00490510103014; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; LEESTMA JE, 1976, J NEUROL NEUROSUR PS, V39, P877, DOI 10.1136/jnnp.39.9.877; MCCANCE C, 1968, J CHRON DIS, V21, P369, DOI 10.1016/0021-9681(68)90045-3; NATHAN PW, 1955, J NEUROL NEUROSUR PS, V18, P250, DOI 10.1136/jnnp.18.4.250	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					482	482		10.1136/bmj.304.6825.482	http://dx.doi.org/10.1136/bmj.304.6825.482			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547422	Bronze, Green Published			2022-12-28	WOS:A1992HF55500025
J	HU, SL; ABRAMS, K; BARBER, GN; MORAN, P; ZARLING, JM; LANGLOIS, AJ; KULLER, L; MORTON, WR; BENVENISTE, RE				HU, SL; ABRAMS, K; BARBER, GN; MORAN, P; ZARLING, JM; LANGLOIS, AJ; KULLER, L; MORTON, WR; BENVENISTE, RE			PROTECTION OF MACAQUES AGAINST SIV INFECTION BY SUBUNIT VACCINES OF SIV ENVELOPE GLYCOPROTEIN GP160	SCIENCE			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; EXPRESSION; LENTIVIRUS	Simian immunodeficiency virus (SIV) is a primate lentivirus related to human immunodeficiency viruses and is an etiologic agent for acquired immunodeficiency syndrome (AIDS)-like diseases in macaques. To date, only inactivated whole virus vaccines have been shown to protect macaques against SIV infection. Protective immunity was elicited by recombinant subunit vaccines. Four Macaca fascicularis were immunized with recombinant vaccinia virus expressing SIVmne gpl60 and were boosted with gpl60 produced in baculovirus-infected cells. All four animals were protected against an intravenous challenge of the homologous virus at one to nine animal-infectious doses. These results indicate that immunization with viral envelope antigens alone is sufficient to elicit protective immunity against a primate immunodeficiency virus. The combination immunization regimen, similar to one now being evaluated in humans as candidate human immunodeficiency virus (HIV)-1 vaccines, appears to be an effective way to elicit such immune responses.	UNIV WASHINGTON,SEATTLE,WA 98195; DUKE UNIV,MED CTR,DURHAM,NC 27710; NCI,FREDERICK,MD 21701	University of Washington; University of Washington Seattle; Duke University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HU, SL (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121, USA.		Hu, Shiu-Lok/A-3196-2008	Hu, Shiu-Lok/0000-0003-4336-7964	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028065] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [R01 AI28065, AI26503] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER GN, UNPUB; BENVENISTE RE, 1990, J MED PRIMATOL, V19, P351; BENVENISTE RE, 1986, J VIROL, V60, P483, DOI 10.1128/JVI.60.2.483-490.1986; BENVENISTE RE, 1988, J VIROL, V62, P2091, DOI 10.1128/JVI.62.6.2091-2101.1988; BENVENISTE RE, 1989, J MED PRIMATOL, V18, P287; BENVENISTE RE, UNPUB; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CHIN J, 1990, B WORLD HEALTH ORGAN, V68, P1; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; COONEY EL, 1990, 6TH INT C AIDS SAN F; CRANAGE MP, IN PRESS SCIENCE; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; GARDNER MB, IN PRESS AIDS; GRAHAM BS, 1991, 7TH INT C AIDS FLOR; HENDERSON LE, 1988, SCIENCE, V241, P199, DOI 10.1126/science.3388031; HU SL, 1988, J VIROL, V62, P176, DOI 10.1128/JVI.62.1.176-180.1988; HU SL, 1986, NATURE, V320, P537, DOI 10.1038/320537a0; HU SL, 1987, J VIROL, V61, P3617, DOI 10.1128/JVI.61.11.3617-3620.1987; HU SL, 1991, AIDS RES HUM RETROV, V7, P615, DOI 10.1089/aid.1991.7.615; HU SL, IN PRESS AIDS RES HU; HU SL, IN PRESS J MED PRIMA; KOFF WC, 1990, AIDS S1, V4, P179; KULLER LR, UNPUB; LANGLOIS AJ, 1991, AIDS RES HUM RETROV, V7, P713, DOI 10.1089/aid.1991.7.713; LANGLOIS AJ, 1992, SCIENCE, V255, P292, DOI 10.1126/science.1549775; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; MURPHEYCORB M, 1991, AIDS, V5, P655, DOI 10.1097/00002030-199106000-00003; MURPHEYCORB M, 1990, 3RD ANN M NAT COOP V; SHAFFERMAN A, 1991, P NATL ACAD SCI USA, V88, P7126, DOI 10.1073/pnas.88.16.7126; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0	32	327	350	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					456	459		10.1126/science.1531159	http://dx.doi.org/10.1126/science.1531159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1531159				2022-12-28	WOS:A1992HA59000038
J	FERRIS, JP; ERTEM, G				FERRIS, JP; ERTEM, G			OLIGOMERIZATION OF RIBONUCLEOTIDES ON MONTMORILLONITE - REACTION OF THE 5'-PHOSPHORIMIDAZOLIDE OF ADENOSINE	SCIENCE			English	Article							BOND FORMATION; RNA; TETRAHYMENA; NUCLEOTIDES; CATALYSIS; ENZYME	The regiospecific formation of oligomers from unblocked monomers in aqueous solution is one of the central tenets in research on the.origins of life on earth. Direct experimental support for this hypothesis has been obtained in studies of the condensation of the 5'-phosphorimidazolide of adenosine (ImpA) with itself and with P1,P2-diadenosine-5',5'-pyrophosphate (AppA) in water in the presence of a montmorillonite clay. Oligomers of up to ten nucleotides in length are formed. Analysis of the trimers, tetramers, and pentamers formed from a 9:1 ImpA:AppA mixture has shown that 85% of the bonds formed are 3',5'-linked and that any 2',5'-linkages present are at the phosphodiester bond next to the 3'-terminus of the oligomers.			FERRIS, JP (corresponding author), RENSSELAER POLYTECH INST,DEPT CHEM,TROY,NY 12180, USA.							ASHIRBEKOVA DT, 1989, BIOORG KHIM+, V15, P166; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BERNAL JD, 1949, P PHYS SOC LOND A, V62, P537, DOI 10.1088/0370-1298/62/9/301; CHEN CB, 1985, J MOL BIOL, V181, P271, DOI 10.1016/0022-2836(85)90091-9; ERTEM G, 1990, ORIGINS LIFE EVOL BI, V20, P279; FAKHRAI H, 1981, J MOL EVOL, V17, P295, DOI 10.1007/BF01795751; FERRIS JP, 1989, ORIGINS LIFE EVOL B, V19, P609, DOI 10.1007/BF01808121; FERRIS JP, 1989, ORIGINS LIFE EVOL B, V19, P165, DOI 10.1007/BF01808150; GRZESKOWIAK K, 1986, J MOL EVOL, V23, P287, DOI 10.1007/BF02100635; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; JOYCE GF, 1987, P NATL ACAD SCI USA, V84, P4398, DOI 10.1073/pnas.84.13.4398; KORNBERG A, 1991, DNA REPLICATION, P310; LOHRMANN R, 1979, J MOL EVOL, V14, P243, DOI 10.1007/BF01732491; LOHRMANN R, 1978, J MOL EVOL, V11, P17, DOI 10.1007/BF01768021; LUEBKE KJ, 1991, J AM CHEM SOC, V113, P7447, DOI 10.1021/ja00019a066; ORGEL LE, 1986, J THEOR BIOL, V123, P127, DOI 10.1016/S0022-5193(86)80149-7; PONNAMPERUMA C, 1982, ORIGINS LIFE, V12, P98; Reid T.W., 1971, ENZYMES, V4, P373; RODRIGUEZ L, 1991, J MOL EVOL, V32, P101, DOI 10.1007/BF02515382; SAWAI H, 1975, J AM CHEM SOC, V97, P3532, DOI 10.1021/ja00845a050; SAWAI H, 1989, B CHEM SOC JPN, V62, P2018, DOI 10.1246/bcsj.62.2018; SLEEPER HL, 1979, J MOL EVOL, V12, P357, DOI 10.1007/BF01732030; SOFFHILL R, 1970, J ORG CHEM, V35, P2881; STRIBLING R, 1991, J CHROMATOGR, V338, P474; SULSTON J, 1968, P NATL ACAD SCI USA, V59, P726, DOI 10.1073/pnas.59.3.726; YOUNG B, 1989, J MOL EVOL, V29, P480, DOI 10.1007/BF02602919; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	27	210	212	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1387	1389		10.1126/science.1529338	http://dx.doi.org/10.1126/science.1529338			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529338				2022-12-28	WOS:A1992JL61200029
J	YARNELL, WS; ROBERTS, JW				YARNELL, WS; ROBERTS, JW			THE PHAGE-LAMBDA GENE-Q TRANSCRIPTION ANTITERMINATOR BINDS DNA IN THE LATE GENE PROMOTER AS IT MODIFIES RNA-POLYMERASE	CELL			English	Article							ESCHERICHIA-COLI; TERNARY COMPLEXES; BACTERIOPHAGE-LAMBDA; Q-PROTEIN; 3' END; INITIATION; SITE; TERMINATION; ELONGATION; PRODUCT	The bacteriophage lambda-gene Q transcription antiterminator modifies RNA polymerase during an extended pause in elongation at nt +16 and +17 of the phage late gene promoter transcript. We show here that Q binds a specific DNA site between the -10 and -35 elements of the promoter as it interacts with the enzyme. We show that the pause must reflect a specialized elongation structure that is receptive to modification by Q, because Q does not bind to RNA polymerase stopped artificially after transcribing 16 nt of mutant DNA that does not encode the natural pause. Footprinting shows that RNA polymerase in the paused complex makes distinctive interactions with DNA in the region where Q binds; binding of Q, in turn, changes the footprint both at the Q-binding site and in the transcription bubble. Binding of Q to the paused transcription complex is stabilized by the transcription factor NusA, as expected from the dependence of lambda-Q-mediated antitermination on NusA.			YARNELL, WS (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,BIOTECHNOL BLDG,ITHACA,NY 14853, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021941, R37GM021941] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21941] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DEVEGVAR HEN, 1986, CELL, V47, P259; Friedman DI., 1983, LAMBDA 2, P21; GOLIGER JA, 1989, J MOL BIOL, V210, P461, DOI 10.1016/0022-2836(89)90123-X; GRAYHACK EJ, 1982, CELL, V30, P637, DOI 10.1016/0092-8674(82)90260-4; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GUO HC, 1991, J BACTERIOL, V173, P1554, DOI 10.1128/jb.173.4.1554-1560.1991; GUO HC, 1990, THESIS CORNELL U ITH; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HERNANDEZ N, 1986, CELL, V47, P249, DOI 10.1016/0092-8674(86)90447-2; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LANDOLFI NF, 1987, P NATL ACAD SCI USA, V84, P3851, DOI 10.1073/pnas.84.11.3851; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SPENCER CA, 1990, ONCOGENE, V5, P777; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; YANG X, 1988, THESIS CORNELL U ITH; YANG XJ, 1989, J MOL BIOL, V210, P453, DOI 10.1016/0022-2836(89)90122-8; YANG XJ, 1987, GENE DEV, V1, P217, DOI 10.1101/gad.1.3.217; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301	32	80	80	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1181	1189		10.1016/0092-8674(92)90639-T	http://dx.doi.org/10.1016/0092-8674(92)90639-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1535556				2022-12-28	WOS:A1992JA43100012
J	GAMER, J; BUJARD, H; BUKAU, B				GAMER, J; BUJARD, H; BUKAU, B			PHYSICAL INTERACTION BETWEEN HEAT-SHOCK PROTEINS DNAK, DNAJ, AND GRPE AND THE BACTERIAL HEAT-SHOCK TRANSCRIPTION FACTOR-SIGMA(32)	CELL			English	Article							ESCHERICHIA-COLI DNAK; METAL CHELATE ADSORBENT; BACTERIOPHAGE-LAMBDA; RNA-POLYMERASE; CELLULAR DEFECTS; REGULATORY GENE; SIGMA-32; REPLICATION; MUTANTS; INITIATION	Genetic evidence indicates central roles for Hsp70 chaperones in the regulation of heat shock gene expression. This regulatory function has been postulated for Escherichia coli to rely on the direct association of DnaK (Hsp70) with the heat shock transcription factor sigma-32. This report presents evidence for the physical association of DnaK, DnaJ, and GrpE chaperones with sigma-32 in vivo. Surprisingly, an interaction of DnaJ with sigma-32 exists that is distinguishable from an interaction of DnaK and GrpE with sigma-32: addition of ATP disrupts the association of DnaK and GrpE with sigma-32, but not the association of DnaJ with sigma-32. Furthermore, DnaJ-sigma-32 and DnaK-sigma-32 associations occur independent of DnaK and DnaJ, respectively. These results suggest distinct regulatory functions of DnaJ and DnaK/GrpE.			GAMER, J (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,INF 282,W-6900 HEIDELBERG,GERMANY.			Bukau, Bernd/0000-0003-0521-7199				ALFANO C, 1989, J BIOL CHEM, V264, P10699; ANATHAN J, 1986, SCIENCE, V232, P252; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; COWING DW, 1985, P NATL ACAD SCI USA, V82, P2679, DOI 10.1073/pnas.82.9.2679; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ERICKSON JW, 1987, GENE DEV, V1, P419, DOI 10.1101/gad.1.5.419; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; GROSSMAN AD, 1987, GENE DEV, V1, P179, DOI 10.1101/gad.1.2.179; GROSSMAN AD, 1984, CELL, V38, P383, DOI 10.1016/0092-8674(84)90493-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JOHNSON C, 1989, J BACTERIOL, V171, P1590, DOI 10.1128/jb.171.3.1590-1596.1989; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KRUGER JH, 1984, P NATL ACAD SCI USA, V81, P1499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZER M, 1988, THESIS U HEIDELBERG; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; Maniatis T, 1989, DECONTAMINATION DILU; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Miller J.H., 1972, EXPT MOL GENETICS; Morimoto RI, 1990, STRESS PROTEINS BIOL; NAGAI H, 1990, J BACTERIOL, V172, P2710, DOI 10.1128/jb.172.5.2710-2715.1990; NEIDHARDT FC, 1987, CELLULAR MOL BIOL, V2, P1334; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SELL SM, 1990, J BACTERIOL, V172, P4827, DOI 10.1128/jb.172.9.4827-4835.1990; Silhavy T. J., 1984, EXPT GENE FUSIONS; SKELLY S, 1988, P NATL ACAD SCI USA, V85, P5497, DOI 10.1073/pnas.85.15.5497; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1987, NATURE, V329, P348, DOI 10.1038/329348a0; STRAUS DB, 1989, GENE DEV, V3, P2003, DOI 10.1101/gad.3.12a.2003; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; TILLY K, 1983, CELL, V34, P641, DOI 10.1016/0092-8674(83)90396-3; TILLY K, 1989, J BACTERIOL, V171, P1585, DOI 10.1128/jb.171.3.1585-1589.1989; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P6176, DOI 10.1073/pnas.79.20.6176; YAMAMORI T, 1982, P NATL ACAD SCI-BIOL, V79, P860, DOI 10.1073/pnas.79.3.860	50	278	281	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					833	842		10.1016/0092-8674(92)90294-M	http://dx.doi.org/10.1016/0092-8674(92)90294-M			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1534276				2022-12-28	WOS:A1992HW83800013
J	TSIPOURAS, P; DELMASTRO, R; SARFARAZI, M; LEE, B; VITALE, E; CHILD, AH; GODFREY, M; DEVEREUX, RB; HEWETT, D; STEINMANN, B; VILJOEN, D; SYKES, BC; KILPATRICK, M; RAMIREZ, F				TSIPOURAS, P; DELMASTRO, R; SARFARAZI, M; LEE, B; VITALE, E; CHILD, AH; GODFREY, M; DEVEREUX, RB; HEWETT, D; STEINMANN, B; VILJOEN, D; SYKES, BC; KILPATRICK, M; RAMIREZ, F			GENETIC-LINKAGE OF THE MARFAN-SYNDROME, ECTOPIA LENTIS, AND CONGENITAL CONTRACTURAL ARACHNODACTYLY TO THE FIBRILLIN GENES ON CHROMOSOME-15 AND CHROMOSOME-5	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONNECTIVE-TISSUE; CLASSIFICATION; MICROFIBRILS; DIAGNOSIS; DISORDERS	Background. The large glycoprotein fibrillin is a structural component of elastin-containing microfibrils found in many tissues. The Marfan syndrome has been linked to the fibrillin gene on chromosome 15, but congenital contractural arachnodactyly, which shares some of the physical features of the syndrome, has been linked to the fibrillin gene on chromosome 5. Methods. Using specific markers for the fibrillin genes, we performed genetic linkage analysis in 28 families with the Marfan syndrome and 8 families with four phenotypically related disorders - congenital contractural arachnodactyly (3 families), ectopia lentis (2), mitral-valve prolapse syndrome (2), and annuloaortic ectasia (1). Results. Genetic linkage was established between the Marfan syndrome and only the fibrillin gene on chromosome 15, with a maximum lod score of 25.6 (odds for linkage, 10(25-6):1). Ectopia lentis was also linked to the fibrillin gene on chromosome 15, whereas congenital contractural arachnodactyly was linked to the fibrillin gene on chromosome 5. There was no linkage of mitral-valve prolapse to the fibrillin gene on chromosome 5; studies of chromosome 15 were not informative. Annuloaortic ectasia was not linked to either fibrillin gene. Conclusions. The Marfan syndrome appears to be caused by mutations in a single fibrillin gene on chromosome 15. Diagnosis of the Marfan syndrome by genetic linkage and analysis is now feasible in many families.	UNIV BIRMINGHAM,DEPT CLIN GENET,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; UNIV LONDON,ST GEORGES MED SCH,DEPT CARDIOL SCI,LONDON,ENGLAND; UNIV NEBRASKA,HOLLISTER RES LABS,OMAHA,NE 68182; CORNELL UNIV,MED CTR,DEPT MED,NEW YORK,NY 10021; UNIV OXFORD,INST MOLEC MED,OXFORD,ENGLAND; UNIV ZURICH,DEPT PEDIAT,CH-8006 ZURICH,SWITZERLAND; UNIV CAPE TOWN,DEPT HUMAN GENET,CAPE TOWN,SOUTH AFRICA	University of Birmingham; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; St Georges University London; University of London; University of Nebraska System; Cornell University; University of Oxford; University of Zurich; University of Cape Town	TSIPOURAS, P (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06030, USA.		vitale, emilia/A-5282-2011; Hayward, Caroline/M-8818-2016; Ramesar, Raj S/I-6941-2015	Hayward, Caroline/0000-0002-9405-9550; Ramesar, Raj S/0000-0001-5688-1634; Vitale, Emilia/0000-0003-4651-3875; Byers, Peter H./0000-0001-7786-7030	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR038648, R01AR038648] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-38648] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ARROYO MAR, 1985, CLIN GENET, V27, P570; BEALS RK, 1971, J BONE JOINT SURG AM, VA 53, P987, DOI 10.2106/00004623-197153050-00013; BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; DEVEREUX RB, 1987, AM HEART J, V113, P1265, DOI 10.1016/0002-8703(87)90955-0; DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MCKUSICK VA, 1988, MENDELIAN INHERITANC; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; OTT J, 1983, ANN HUM GENET, V47, P311, DOI 10.1111/j.1469-1809.1983.tb01001.x; OTT J, 1974, AM J HUM GENET, V26, P588; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; TSIPOURAS P, 1991, P NATL ACAD SCI USA, V88, P4486, DOI 10.1073/pnas.88.10.4486; WEIL D, 1988, J BIOL CHEM, V263, P8561; [No title captured]	22	230	235	1	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					905	909		10.1056/NEJM199204023261401	http://dx.doi.org/10.1056/NEJM199204023261401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1542340				2022-12-28	WOS:A1992HL26100001
J	KTISTAKIS, NT; LINDER, ME; ROTH, MG				KTISTAKIS, NT; LINDER, ME; ROTH, MG			ACTION OF BREFELDIN-A BLOCKED BY ACTIVATION OF A PERTUSSIS-TOXIN-SENSITIVE G-PROTEIN	NATURE			English	Article							INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; RAT HEPATOCYTES; CELLS; MASTOPARAN	IN many mammalian cells brefeldin A interferes with mechanisms that keep the Golgi apparatus separate from the endoplasmic reticulum 1-8. The earliest effect of brefeldin A is release of the coat protein beta-COP from the Golgi 9-11. This release is blocked by pretreatment with GTP-gamma-S or AlF4- (ref. 12). The AlF4- ion activates heterotrimeric C proteins 13 but not proteins of the ras superfamily 14, suggesting that a heterotrimeric G protein might control membrane transfer from the endoplasmic reticulum to the Golgi. We report here that mastoparan, a peptide that activates heterotrimeric G proteins 15,16, promotes binding of beta-COP to Golgi membranes in vitro and antagonizes the effect of brefeldin A on beta-COP in perforated cells and on isolated Golgi membranes. This inhibition is greatly diminished if cells are pretreated with pertussis toxin before perforation., Thus, a heterotrimeric G protein of the G(i)/G(o) subfamily regulates association of coat components with Golgi membranes.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	KTISTAKIS, NT (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712; Roth, Michael/0000-0002-9056-332X				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1991, CELL, V64, P1183; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIMONS K, 1987, EMBO J, V6, P2241, DOI 10.1002/j.1460-2075.1987.tb02496.x; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992	23	101	101	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 26	1992	356	6367					344	346		10.1038/356344a0	http://dx.doi.org/10.1038/356344a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549178				2022-12-28	WOS:A1992HK79400066
J	MELSKI, JW				MELSKI, JW			PRICE OF TECHNOLOGY - A BLIND SPOT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PROGRESSIVE SYSTEMIC-SCLEROSIS				MELSKI, JW (corresponding author), MARSHFIELD CLIN FDN MED RES & EDUC,DEPT DERMATOL 4K5,MARSHFIELD,WI 54449, USA.							ANGELL M, 1991, NEW ENGL J MED, V325, P1371, DOI 10.1056/NEJM199111073251910; BLACK CM, 1990, ANN RHEUM DIS, V49, P735, DOI 10.1136/ard.49.9.735; BLOOM BS, 1988, INQUIRY-J HEALTH CAR, V25, P383; CHARLEY MR, 1983, J INVEST DERMATOL, V80, pA328; EDELSON R, 1991, PROG DERMATOL, V25, P1; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; JAMPEL RM, 1991, ARCH DERMATOL, V127, P1673, DOI 10.1001/archderm.127.11.1673; JOHNSON HA, 1991, JAMA-J AM MED ASSOC, V265, P2229, DOI 10.1001/jama.265.17.2229; KALALEH MB, 1986, CLIN EXP RHEUMATOL, V4, P367; LOHR K, 1986, MED CARE, V24, pS72; RELMAN AS, 1989, NEW ENGL J MED, V320, P33; ROOK AH, 1989, YALE J BIOL MED, V62, P639; ROOK AH, 1992, ARCH DERMATOL, V128, P1517; STEEN VD, 1982, ANN INTERN MED, V97, P652, DOI 10.7326/0003-4819-97-5-652; STERN RS, 1991, JAMA-J AM MED ASSOC, V265, P74, DOI 10.1001/jama.265.1.74; WINSLOW R, 1991, WALL STREET J   1105, P73	18	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1516	1518						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1538542				2022-12-28	WOS:A1992HH48800034
J	BARINAGA, M				BARINAGA, M			PROFILE OF A FIELD - THE PIPELINE IS LEAKING	SCIENCE			English	Article																			0	20	20	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1366	1367		10.1126/science.1542786	http://dx.doi.org/10.1126/science.1542786			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542786				2022-12-28	WOS:A1992HH74400036
J	FUHRMAN, JA; MCCALLUM, K; DAVIS, AA				FUHRMAN, JA; MCCALLUM, K; DAVIS, AA			NOVEL MAJOR ARCHAEBACTERIAL GROUP FROM MARINE PLANKTON	NATURE			English	Article							RIBOSOMAL-RNA SEQUENCES; PHYLOGENETIC ANALYSIS; SARGASSO SEA; BACTERIOPLANKTON; BACTERIA; MICROORGANISMS; FILTRATION	MARINE bacteria often dominate the plankton biomass 1,2 and are responsible for much of the cycling of organic matter 3, but bacterial diversity is poorly understood because conventional identification methods (requiring culturing) miss about 99% of the organisms 4,5. Recent advances permit characterization of microbial communities by analysis of 16S ribosomal RNA gene sequences directly from biomass without the need to culture the organisms 6; such studies from surface ocean samples have found only eubacteria 7-10, not archaebacteria (or Archaea 11), which are profoundly different 12. Here we report 16S rRNA sequences obtained from Pacific Ocean bacterioplankton samples collected from depths of 100 m and 500 m. Among these we found sequences only distantly related to those of any organisms previously characterized by 16S rRNA sequences, with similarities to the nearest such relatives (extreme thermophiles) approximately the same as those between animals and plants. We suggest that these sequences are from a previously undescribed archaebacterial group that may have diverged from the ancestors of characterized organisms very early in evolution.			FUHRMAN, JA (corresponding author), UNIV SO CALIF, DEPT BIOL SCI, LOS ANGELES, CA 90089 USA.		Fuhrman, Jed A/C-6461-2013	Fuhrman, Jed A/0000-0002-2361-1985				AMANN R, 1991, NATURE, V351, P161, DOI 10.1038/351161a0; AZAM F, 1983, MAR ECOL PROG SER, V10, P257, DOI 10.3354/meps010257; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; BRITSCHGI TB, 1991, APPL ENVIRON MICROB, V57, P1707, DOI 10.1128/AEM.57.6.1707-1713.1991; CHO BC, 1988, NATURE, V332, P441, DOI 10.1038/332441a0; DISTEL DL, 1988, J BACTERIOL, V170, P2506, DOI 10.1128/jb.170.6.2506-2510.1988; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FERGUSON RL, 1984, APPL ENVIRON MICROB, V47, P49, DOI 10.1128/AEM.47.1.49-55.1984; FUHRMAN JA, 1988, APPL ENVIRON MICROB, V54, P1426, DOI 10.1128/AEM.54.6.1426-1429.1988; FUHRMAN JA, 1989, MAR ECOL PROG SER, V57, P207, DOI 10.3354/meps057207; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; GIOVANNONI SJ, 1990, APPL ENVIRON MICROB, V56, P2572, DOI 10.1128/AEM.56.8.2572-2575.1990; HOBBIE JE, 1977, APPL ENVIRON MICROB, V33, P1225, DOI 10.1128/AEM.33.5.1225-1228.1977; HOLM-HANSEN OSMUND, 1965, J CONS CONS PERMS INTE EXPLOR MER, V30, P3; JANNASCH HW, 1959, LIMNOL OCEANOGR, V4, P128, DOI 10.4319/lo.1959.4.2.0128; LANE DJ, 1985, P NATL ACAD SCI USA, V82, P6955, DOI 10.1073/pnas.82.20.6955; LEE S, 1990, APPL ENVIRON MICROB, V56, P739, DOI 10.1128/AEM.56.3.739-746.1990; LEE SH, 1991, LIMNOL OCEANOGR, V36, P1277, DOI 10.4319/lo.1991.36.7.1277; Maniatis T., 1982, MOL CLONING; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; PACE NR, 1986, ADV MICROB ECOL, V9, P1; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHMIDT TM, 1991, J BACTERIOL, V173, P4371, DOI 10.1128/JB.173.14.4371-4378.1991; WARD DM, 1990, NATURE, V345, P63, DOI 10.1038/345063a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	26	653	688	1	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1992	356	6365					148	149		10.1038/356148a0	http://dx.doi.org/10.1038/356148a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545865				2022-12-28	WOS:A1992HH73100057
J	KANG, C; ZHANG, XH; RATLIFF, R; MOYZIS, R; RICH, A				KANG, C; ZHANG, XH; RATLIFF, R; MOYZIS, R; RICH, A			CRYSTAL-STRUCTURE OF 4-STRANDED OXYTRICHA TELOMERIC DNA	NATURE			English	Article							POLYINOSINIC ACID; POLYGUANYLIC ACID; FIBER DIFFRACTION; 3' TERMINUS; X-RAY	The sequence d(GGGGTTTTGGGG) from the 3' over-hang of the Oxytricha telomere has been crystallized and its three-dimensional structure solved to 2.5 angstrom resolution. The oligonucleotide forms hairpins, two of which join to make a four-stranded helical structure with the loops containing four thymine residues at either end. The guanine residues are held together by cyclic hydrogen bonding and an ion is located in the centre. The four guanine residues in each segment have a glycosyl conformation that alternates between anti and syn. There are two four-stranded molecules in the asymmetric unit showing that the structure has some intrinsic flexibility.	UNIV CALIF LOS ALAMOS SCI LAB, CTR HUMAN GENOME STUDIES, LOS ALAMOS, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	KANG, C (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.			Kang, ChulHee/0000-0002-0693-7860				ARNOTT S, 1974, BIOCHEM J, V141, P537, DOI 10.1042/bj1410537; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1990, X PLOR MANUAL; CECH TR, 1988, NATURE, V332, P777, DOI 10.1038/332777a0; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; HARE DR, 1986, BIOCHEMISTRY-US, V25, P5341, DOI 10.1021/bi00366a053; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HOWARD FB, 1982, BIOCHEMISTRY-US, V21, P6736, DOI 10.1021/bi00269a019; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KUNG HJ, 1976, CELL, V7, P609, DOI 10.1016/0092-8674(76)90211-7; LIPPS HJ, 1980, P NATL ACAD SCI-BIOL, V77, P4104, DOI 10.1073/pnas.77.7.4104; LIPPS HJ, 1982, P NATL ACAD SCI-BIOL, V79, P2495, DOI 10.1073/pnas.79.8.2495; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PINNAVAIA TJ, 1978, J AM CHEM SOC, V100, P3625, DOI 10.1021/ja00479a070; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; RICH A, 1961, J MOL BIOL, V3, P71, DOI 10.1016/S0022-2836(61)80009-0; RICH A, 1958, BIOCHIM BIOPHYS ACTA, V29, P502, DOI 10.1016/0006-3002(58)90005-2; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SMITH FW, 1991, J BIOMOLEC STRUCT DY, V8, P201; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WANG Y, 1991, NUCLEIC ACIDS RES, V19, P4619, DOI 10.1093/nar/19.17.4619; WANG Y, IN PRESS J MOL BIOL; WILLIAMS LD, 1990, P NATL ACAD SCI USA, V87, P2225, DOI 10.1073/pnas.87.6.2225; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZIMMERMAN SB, 1976, J MOL BIOL, V106, P663, DOI 10.1016/0022-2836(76)90257-6; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	30	547	554	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1992	356	6365					126	131		10.1038/356126a0	http://dx.doi.org/10.1038/356126a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545863				2022-12-28	WOS:A1992HH73100049
J	NATHKE, IS; HEUSER, J; LUPAS, A; STOCK, J; TURCK, CW; BRODSKY, FM				NATHKE, IS; HEUSER, J; LUPAS, A; STOCK, J; TURCK, CW; BRODSKY, FM			FOLDING AND TRIMERIZATION OF CLATHRIN SUBUNITS AT THE TRISKELION HUB	CELL			English	Article							LIGHT-CHAINS; HEAVY-CHAIN; COATED VESICLES; BINDING; PROTEINS; INTERNALIZATION; SEQUENCE; RECEPTOR; PURIFICATION; INTERMEDIATE	The triskelion shape of the clathrin molecule enables it to form the polyhedral protein network that covers clathrin-coated pits and vesicles. Domains within the clathrin heavy chain that are responsible for maintaining triskelion shape and function were identified and localized. Sequences that mediate trimerization are distal to the carboxyl terminus and are adjacent to a domain that mediates both light chain binding and clathrin assembly. Structural modeling predicts that within this domain, the region of heavy chain-light chain interaction is a bundle of three or four a helices. These studies establish a low resolution model of clathrin subunit folding in the central portion (hub) of the triskelion, thus providing a basis for future mutagenesis experiments.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Washington University (WUSTL); Princeton University; Max Planck Society; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	NATHKE, IS (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARM,SAN FRANCISCO,CA 94143, USA.			Nathke, Inke/0000-0003-2420-4385; Brodsky, Frances/0000-0002-1334-9258	NIGMS NIH HHS [GM-29647, GM-38093, GM-26691] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038093, R01GM029647, P50GM026691] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1989, J BIOL CHEM, V264, P20089; BLANK GS, 1986, EMBO J, V5, P2087, DOI 10.1002/j.1460-2075.1986.tb04470.x; BLANK GS, 1987, J CELL BIOL, V105, P2011, DOI 10.1083/jcb.105.5.2011; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BRODSKY FM, 1991, TRENDS BIOCHEM SCI, V16, P208, DOI 10.1016/0968-0004(91)90087-C; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; BRODSKY FM, 1983, J CELL BIOL, V96, P911, DOI 10.1083/jcb.96.3.911; BRODSKY FM, 1987, NATURE, V326, P203, DOI 10.1038/326203a0; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; FERRIN TE, 1987, J MOL GRAPHICS, V6, P2; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; HEUSER J, 1985, J ULTRA MOL STRUCT R, V92, P1, DOI 10.1016/0889-1605(85)90123-5; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; JACKSON AP, 1988, J BIOL CHEM, V263, P16688; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON SK, 1991, J CELL BIOL, V112, P65, DOI 10.1083/jcb.112.1.65; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAKELA O, 1986, HDB EXPT IMMUNOLOGY, V1; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; OHALLORAN TJ, 1992, IN PRESS DNA CELL BI; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; SCARMATO P, 1990, J BIOL CHEM, V265, P3661; SCHMID SL, 1982, P NATL ACAD SCI-BIOL, V79, P91, DOI 10.1073/pnas.79.1.91; UNGEWICKELL E, 1991, J BIOL CHEM, V266, P12710; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x	45	135	136	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					899	910		10.1016/0092-8674(92)90033-9	http://dx.doi.org/10.1016/0092-8674(92)90033-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547490				2022-12-28	WOS:A1992HH74800009
J	MORGAN, A; BURGOYNE, RD				MORGAN, A; BURGOYNE, RD			EXO1 AND EXO2 PROTEINS STIMULATE CALCIUM-DEPENDENT EXOCYTOSIS IN PERMEABILIZED ADRENAL CHROMAFFIN CELLS	NATURE			English	Article							14-3-3 PROTEIN; KINASE-C; CATECHOLAMINE SECRETION; VESICULAR TRANSPORT; PHORBOL ESTER; MAST-CELLS; CALPACTIN; PURIFICATION; PHOSPHORYLATION; REQUIREMENT	IN many cell types an increase in cytosolic calcium is the main signal for the exocytotic release of stored secretory components such as hormones and neurotransmitters. The site of action of calcium in exocytosis is not known, neither are the participating molecules 1,2. In the case of the intracellular membrane fusions that occur during transport through early stages of the secretory pathway, several cytosolic and peripheral membrane proteins are necessary 3-6. Permeabilized cells have been useful in understanding the requirements for calcium and nucleotides in regulated exocytosis 7,8 and under certain conditions there is leakage of soluble protein components and run-down of the exocytotic response 9-14. This system can be used to identify the soluble proteins involved in exocytosis, one candidate in chromaffin cells being annexin II (calpactin) 9. Here we use this assay to identify two other cytosolic protein factors that regulate exocytosis in permeabilized adrenal chromaffin cells, which we term Exo1 and Exo2. Exo1 from brain cytosol resolves on electrophoresis in SDS-polyacrylamide gels as a group of polypeptides of relative molecular mass approximately 30,000 and shares sequence homology with the 14-3-3 family of proteins. The ability of Exol to reactivate exocytosis is potentiated by protein kinase C activation and therefore Exol may influence the protein kinase C-mediated control of Ca2+-dependent exocytosis.			MORGAN, A (corresponding author), UNIV LIVERPOOL,DEPT PHYSIOL,POB 147,LIVERPOOL L69 3BX,ENGLAND.		Burgoyne, Robert/C-6706-2008; Burgoyne, Robert D/P-6641-2019; Morgan, Alan/AAI-8875-2020	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387; Morgan, Alan/0000-0002-0346-1289	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AITKEN A, 1990, NATURE, V344, P594; ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; ALI SM, 1990, CELL SIGNAL, V2, P265, DOI 10.1016/0898-6568(90)90054-E; ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOSTON PF, 1982, J NEUROCHEM, V38, P1475, DOI 10.1111/j.1471-4159.1982.tb07928.x; BURGOYNE RD, 1988, FEBS LETT, V238, P151, DOI 10.1016/0014-5793(88)80246-1; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; BURGOYNE RD, 1990, BIOCHEM SOC T, V18, P1111; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; DUNN LA, 1983, J BIOL CHEM, V258, P4989; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; HOWELL TW, 1989, CELL SIGNAL, V1, P157, DOI 10.1016/0898-6568(89)90005-3; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; KNIGHT DE, 1989, TRENDS NEUROSCI, V12, P451, DOI 10.1016/0166-2236(89)90095-7; KNIGHT DE, 1983, FEBS LETT, V160, P98, DOI 10.1016/0014-5793(83)80944-2; KOFFER A, 1989, J CELL SCI, V94, P585; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; POCOTTE SL, 1985, P NATL ACAD SCI USA, V82, P930, DOI 10.1073/pnas.82.3.930; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; SCHAFER T, 1987, J NEUROCHEM, V49, P1696; SCHWEIZER FE, 1989, NATURE, V339, P709; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; WATTENBERG BW, 1990, J CELL BIOL, V110, P947, DOI 10.1083/jcb.110.4.947; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WU YN, 1991, FEBS LETT, V282, P197, DOI 10.1016/0014-5793(91)80476-J; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404	33	197	201	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					833	836		10.1038/355833a0	http://dx.doi.org/10.1038/355833a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538762				2022-12-28	WOS:A1992HF63600058
J	DOHRENWEND, BP; LEVAV, I; SHROUT, PE; SCHWARTZ, S; NAVEH, G; LINK, BG; SKODOL, AE; STUEVE, A				DOHRENWEND, BP; LEVAV, I; SHROUT, PE; SCHWARTZ, S; NAVEH, G; LINK, BG; SKODOL, AE; STUEVE, A			SOCIOECONOMIC-STATUS AND PSYCHIATRIC-DISORDERS - THE CAUSATION-SELECTION ISSUE	SCIENCE			English	Article							ADOPTED INDIVIDUALS; ECONOMIC STATUS; SOCIAL CLASS; SCHIZOPHRENIA; PSYCHOPATHOLOGY; INHERITANCE; RELIABILITY; SAMPLE; ABUSE; AGE	Are inverse relations between psychiatric disorders and socioeconomic status due more to social causation (adversity and stress) or social selection (downward mobility of genetically predisposed)? This classical epidemiological issue is tested by focusing on ethnic status in relation to socioeconomic status. Ethnic status cannot be an effect of disorder because it is present at birth whereas socioeconomic status depends on educational and occupational attainment. A birth cohort sample of 4914 young, Israel-born adults of European and North African background was selected from the country's population register, screened, and diagnosed by psychiatrists. Results indicate that social selection may be more important for schizophrenia and that social causation may be more important for depression in women and for antisocial personality and substance use disorders in men.	BROOKDALE INST,JEWISH DOCUMENTAT CTR ISRAEL,IL-91034 JERUSALEM,ISRAEL; HADASSAH UNIV HOSP,DEPT SOCIAL MED,JERUSALEM,ISRAEL; COLUMBIA UNIV,SCH PUBL HLTH,DEPT BIOSTAT,NEW YORK,NY 10032; COLUMBIA UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,NEW YORK,NY 10032	Hebrew University of Jerusalem; Columbia University; Columbia University	DOHRENWEND, BP (corresponding author), NEW YORK STATE PSYCHIAT INST & HOSP,722 W 168 ST,BOX 8,NEW YORK,NY 10032, USA.		Link, Bruce/AAO-9094-2021; Link, Bruce G/N-9087-2013; Skodol, Andrew/AAK-9646-2021	Link, Bruce/0000-0001-9980-7450	NIMH NIH HHS [MH14663, MH30710] Funding Source: Medline; PHS HHS [30906] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH014663, R01MH030710] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BROMET EJ, 1986, ARCH GEN PSYCHIAT, V43, P435; Brown G., 1978, SOCIAL ORIGINS DEPRE; Brown G. W., 1986, LIFE EVENTS PSYCHIAT, P107; BURKE KC, 1990, ARCH GEN PSYCHIAT, V47, P511; CADORET RJ, 1986, ARCH GEN PSYCHIAT, V43, P1131; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; CROWE RR, 1974, ARCH GEN PSYCHIAT, V31, P785; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; Dohrenwend B.P., 1979, STRESS MENTAL DISORD, P1; Dohrenwend B. P., 1981, AM J COMMUN PSYCHOL, V9, P129; Dohrenwend B. P., 1969, SOCIAL STATUS PSYCHO; DOHRENWEND BP, 1981, SCHIZOPHRENIA BULL, V7, P12, DOI 10.1093/schbul/7.1.12; DOHRENWEND BP, 1976, AM J SOCIOL, V81, P1447, DOI 10.1086/226229; DOHRENWEND BP, 1980, ARCH GEN PSYCHIAT, V37, P1229; DOHRENWEND BP, 1990, PSYCHOL MED, V20, P195, DOI 10.1017/S0033291700013374; DOHRENWEND BP, 1975, J HEALTH SOC BEHAV, V16, P365, DOI 10.2307/2136610; DOHRENWEND BP, 1966, SOCIAL THEORY SOCIAL, V31, P13; DOHRENWEND BP, 1980, MENTAL ILLNESS US; Dunham H. W., 1965, COMMUNITY SCHIZOPHRE; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; Faris Robert E.L, 1939, MENTAL DISORDERS URB; FOX JW, 1990, J HEALTH SOC BEHAV, V31, P344, DOI 10.2307/2136818; Fuller WA, 1975, SANKHYA C, V37, P117; GOTTES I, 1972, SCHIZOPHRENIA GENETI; GOTTESMAN II, 1976, SCHIZOPHRENIA BULL, V2, P360, DOI 10.1093/schbul/2.3.360; GUARNACCIA PJ, 1990, AM J PSYCHIAT, V147, P1449; HAFNER H, 1989, PSYCHOL MED, V19, P903, DOI 10.1017/S0033291700005626; HIDIROGLOU MA, 1980, SUPERCARP; Hollingshead August B., 1958, SOCIAL CLASS MENTAL; HOLZER CE, 1986, AM J SOCIAL PSYCHIAT, V0006; JARVIS E, 1971, INSANITY IDIOCY MASS; KETY SS, 1976, SCHIZOPHRENIA BULL, V2, P413, DOI 10.1093/schbul/2.3.413; KOHN ML, 1972, SOC FORCES, V50, P310, DOI 10.2307/2577035; KRAUS V, 1981, MEGAMOT, V26, P283; KRAUS V, 1990, PROMISES PROMISED LA; Leighton D, 1963, CHARACTER DANGER; LEVAV I, 1987, ACTA PSYCHIAT SCAND, V75, P183, DOI 10.1111/j.1600-0447.1987.tb02772.x; LINK BG, 1986, AM SOCIOL REV, V51, P242, DOI 10.2307/2095519; LINK BG, UNPUB; LORANGER AW, 1984, ARCH GEN PSYCHIAT, V41, P157; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; MECHANIC D, 1972, SOC FORCES, V50, P305, DOI 10.2307/2577034; MERIKANGAS KR, 1990, PSYCHOL MED, V20, P11, DOI 10.1017/S0033291700013192; PAYKEL ES, 1974, STRESSFUL LIFE EVENT, P135; PLOMIN R, 1990, SCIENCE, V248, P183, DOI 10.1126/science.2183351; PULVER AE, 1983, SCHIZOPHRENIA BULL, V9, P377, DOI 10.1093/schbul/9.3.377; ROBINS LN, 1990, PSYCHIATRIC DISORDER; SCHWARTZ S, 1991, SOC PSYCHOL QUART, V54, P287, DOI 10.2307/2786842; SHROUT PE, 1986, J CONSULT CLIN PSYCH, V54, P314, DOI 10.1037/0022-006X.54.3.314; SIGAL JJ, 1985, J ABNORM PSYCHOL, V94, P556; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; SROLE L, 1962, MENTAL HLTH METROPOL, V1; TORREY EF, 1991, SCHIZOPHRENIA BULL, V17, P15, DOI 10.1093/schbul/17.1.15; WENDER PH, 1986, ARCH GEN PSYCHIAT, V43, P923; WENDER PH, 1973, ARCH GEN PSYCHIAT, V28, P318; YUCHTMANYAAR E, 1979, AM J SOCIOL, V85, P576, DOI 10.1086/227050; 1980, DIAGNOSTIC STATISTIC, P3	58	792	799	3	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					946	952		10.1126/science.1546291	http://dx.doi.org/10.1126/science.1546291			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HE605	1546291				2022-12-28	WOS:A1992HE60500031
J	RAMOND, MJ; POYNARD, T; RUEFF, B; MATHURIN, P; THEODORE, C; CHAPUT, JC; BENHAMOU, JP				RAMOND, MJ; POYNARD, T; RUEFF, B; MATHURIN, P; THEODORE, C; CHAPUT, JC; BENHAMOU, JP			A RANDOMIZED TRIAL OF PREDNISOLONE IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLLAGEN GENE-EXPRESSION; MULTICENTER TRIAL; THERAPY; DEXAMETHASONE	Background. Controlled trials have yielded inconsistent results with regard to the efficacy of corticosteroids in the treatment of alcoholic hepatitis. Three meta-analyses suggest that they may be effective in patients with encephalopathy who have severe liver disease. Methods. We conducted a randomized, double-blind trial comparing 28 days of prednisolone treatment (40 mg per day) with placebo in 61 patients with biopsy-proved alcoholic hepatitis and either spontaneous hepatic encephalopathy (n = 19) or a discriminant-function value higher than 32. The discriminant function used was as follows: 4.6 (prothrombin time - control time [in seconds]) + serum bilirubin (in micromoles per liter)/17. Fifty-seven of the patients had evidence of cirrhosis on biopsy. The primary end point was death within two months. Results. One patient was lost to follow-up after 56 days. Treatment was discontinued in two patients because of drug toxicity. By the 66th day after randomization, 16 of 29 placebo recipients had died (mean [+/- SE] survival, 45 +/- 8 percent), as compared with 4 of 32 prednisolone recipients (survival, 88 +/- 5 percent) (log-rank test, 10.9; P = 0.001). The survival advantage for prednisolone persisted after stratification according to center and the presence of encephalopathy, and after adjustment for prognostic factors in a proportional-hazards model. Conclusions. Treatment with prednisolone improves the short-term survival of patients with severe biopsy-proved alcoholic hepatitis.	HOP BEAUJON,SERV TRAITEMENT AMBULATOIRE MALAD ALCOOL,F-92118 CLICHY,FRANCE; HOP ANTOINE BECLERE,SERV GASTROENTEROL,CLAMART,FRANCE; HOP FORCILLES,SERV GASTROENTEROL,FEROLLES ATTILLY,FRANCE; HOP BEAUJON,SERV HEPATOL,F-92118 CLICHY,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite			Mathurin, Philippe/A-9121-2018; Poynard, Thierry/C-1355-2010	Mathurin, Philippe/0000-0003-3447-2025; Poynard, Thierry/0000-0002-3726-7230; Poynard, Thierry/0000-0002-2050-640X				CARITHERS RL, 1989, ANN INTERN MED, V110, P685, DOI 10.7326/0003-4819-110-9-685; CONN HO, 1978, GASTROENTEROLOGY, V74, P319; DAURES JP, 1991, GASTROEN CLIN BIOL, V15, P223; HARDISON WG, 1966, NEW ENGL J MED, V275, P61, DOI 10.1056/NEJM196607142750201; HELMAN RA, 1971, ANN INTERN MED, V74, P311, DOI 10.7326/0003-4819-74-3-311; IMPERIALE TF, 1990, ANN INTERN MED, V113, P299, DOI 10.7326/0003-4819-113-4-299; JEFFERSON DM, 1985, HEPATOLOGY, V5, P14, DOI 10.1002/hep.1840050105; MADDREY WC, 1978, GASTROENTEROLOGY, V75, P193; MADDREY WC, 1986, HEPATOLOGY, V6, P1202; MADDREY WC, 1990, SCAND J GASTROENTE S, V175, P118; NOLAN JP, 1989, HEPATOLOGY, V10, P887, DOI 10.1002/hep.1840100523; Reynolds TB, 1989, GASTROENTEROL INT, V2, P208; WEINER FR, 1987, J BIOL CHEM, V262, P6955; ZETTERMAN RK, 1981, GASTROENTEROLOGY, V81, P616	14	292	296	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1992	326	8					507	512		10.1056/NEJM199202203260802	http://dx.doi.org/10.1056/NEJM199202203260802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD658	1531090				2022-12-28	WOS:A1992HD65800002
J	HENDRA, TJ; MARSHALL, AJ				HENDRA, TJ; MARSHALL, AJ			INCREASED PRESCRIPTION OF THROMBOLYTIC TREATMENT TO ELDERLY PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION ASSOCIATED WITH AUDIT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTRAVENOUS STREPTOKINASE; THERAPY; MORTALITY	Objectives - To assess prescription of thrombolytic treatment to elderly patients with suspected acute myocardial infarction and the incidence of side effects. Design - Retrospective analysis of prescriptions during five months (first audit) followed by prospective analysis of uptake of treatment during five months after interventions in clinical management; prospective assessment of adverse events during thrombolytic treatment. Setting - Coronary care unit of large district general hospital. Patients - 110 patients aged greater-than-or-equal-to 65 with subsequently proved acute myocardial infarction admitted in first audit and 119 admitted in the second. Main outcome measures - Site of infarct, prescription of thrombolysis treatment, reasons for nonprescription, complications. Results - Before intervention thrombolytic treatment was prescribed to 13/110 (12%) patients with subsequently confirmed myocardial infarction and after intervention to 55/119 (46%) patients (p < 0.01). In the first audit no patients with angina received thrombolytic treatment whereas 13/79 (16%) were treated in the second audit. Increased prescription of thrombolytic treatment in the second audit was associated with significantly fewer exclusions owing to dyspepsia (p < 0.05) and unstated or unsatisfactory reasons (p < 0.01) Streptokinase infusions were completed uneventfully in 75% (48/64) and 77% (10/13) of patients with infarction and angina respectively. Side effects of treatment were more common in patients with inferior than with anterior infarcts (16/42 (30%) v 3/24 (13%), p < 0.05). Conclusions - Low rates of prescription of thrombolytic treatment to elderly patients with suspected acute myocardial infarction were identified and corrected. Streptokinase treatment was associated with transient arrhythmias or hypotension in about a third of these patients with infarcts, particularly those with electrocardiographic changes in inferior leads.	DERRIFORD HOSP, DEPT CARDIOL, PLYMOUTH PL6 8DH, ENGLAND	Derriford Hospital								ALDRICH MS, 1985, JAMA-J AM MED ASSOC, V253, P1777, DOI 10.1001/jama.253.12.1777; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BURRELL CJ, 1990, BMJ-BRIT MED J, V300, P237, DOI 10.1136/bmj.300.6719.237; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; KENNEDY JW, 1990, ANN INTERN MED, V113, P907, DOI 10.7326/0003-4819-113-12-907; LEW AS, 1987, AM J CARDIOL, V59, P1, DOI 10.1016/S0002-9149(87)80059-0; LEW AS, 1985, CIRCULATION, V72, P1321, DOI 10.1161/01.CIR.72.6.1321; MIDGETTE AS, 1990, ANN INTERN MED, V113, P961, DOI 10.7326/0003-4819-113-12-961; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; MURRAY N, 1987, BRIT HEART J, V57, P144; PETCH MC, 1990, BMJ-BRIT MED J, V300, P483, DOI 10.1136/bmj.300.6723.483; SHAW C, 1990, MED AUDIT HOSPITAL H; SLEIGHT P, 1990, EUR HEART J, V11, P1; SMITH LDR, 1990, POSTGRAD MED J, V66, P263, DOI 10.1136/pgmj.66.774.263; TIMMIS AD, 1990, BMJ-BRIT MED J, V301, P941, DOI 10.1136/bmj.301.6758.941; WILCOX RG, 1988, LANCET, V2, P525; 1976, PUBLIC HLTH EUROPE, V5	18	22	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 15	1992	304	6824					423	425		10.1136/bmj.304.6824.423	http://dx.doi.org/10.1136/bmj.304.6824.423			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1547391	Green Published, Bronze			2022-12-28	WOS:A1992HE38900022
J	FITZPATRICK, A; SUTTON, R				FITZPATRICK, A; SUTTON, R			A GUIDE TO TEMPORARY PACING	BRITISH MEDICAL JOURNAL			English	Article							INFARCTION		WESTMINSTER MED SCH & HOSP,LONDON SW1P 2AP,ENGLAND; SOUTHAMPTON GEN HOSP,WESSEX REG CARDIOTHORAC CTR,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	Imperial College London; University of Southampton								ATKINS JM, 1973, NEW ENGL J MED, V288, P281, DOI 10.1056/NEJM197302082880603; GINKS W, 1977, BRIT HEART J, V196, P189; JULIAN DG, 1964, AM J MED, V37, P915, DOI 10.1016/0002-9343(64)90133-0; ROSEN M, 1988, BMJ, P88; SHAH PK, 1987, AM HEART J, V113, P194, DOI 10.1016/0002-8703(87)90029-9; WINNER S, 1989, J ROY COLL PHYS LOND, V23, P161; 1988, IONISING RAD REGULAT	7	21	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					365	369		10.1136/bmj.304.6823.365	http://dx.doi.org/10.1136/bmj.304.6823.365			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540737	Bronze, Green Published			2022-12-28	WOS:A1992HD38700029
J	YIN, YX; TAINSKY, MA; BISCHOFF, FZ; STRONG, LC; WAHL, GM				YIN, YX; TAINSKY, MA; BISCHOFF, FZ; STRONG, LC; WAHL, GM			WILD-TYPE P53 RESTORES CELL-CYCLE CONTROL AND INHIBITS GENE AMPLIFICATION IN CELLS WITH MUTANT P53 ALLELES	CELL			English	Article							CHINESE-HAMSTER CELLS; DNA POLYMERASE-ALPHA; MAMMALIAN-CELLS; T-ANTIGEN; COLORECTAL TUMORIGENESIS; HIGH-SENSITIVITY; CANCER SYNDROME; OVARY CELLS; CAD GENE; PROTEIN	Loss of cell cycle control and acquisition of chromosomal rearrangements such as gene amplification often occur during tumor progression, suggesting that they may be correlated. We show here that the wild-type p53 allele is lost when fibroblasts from patients with the Li-Fraumeni syndrome (LFS) are passaged in vitro. Normal and LFS cells containing wild-type p53 arrested in G1 when challenged with the uridine biosynthesis inhibitor PALA and did not undergo PALA-selected gene amplification. The converse occurred in cells lacking wild-type p53 expression. Expression of wild-type p53 in transformants of immortal and tumor cells containing mutant p53 alleles restored G1 control and reduced the frequency of gene amplification to undetectable levels. These studies reveal that p53 contributes to a metabolically regulated G1 checkpoint, and they provide a model for understanding how abnormal cell cycle progression leads to the genetic rearrangements involved in tumor progression.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT EXPTL PEDIAT, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	YIN, YX (corresponding author), SALK INST, SAN DIEGO, CA 92186 USA.			Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [P01CA34936] Funding Source: Medline; NIGMS NIH HHS [GM27754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027754] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, DNA REPAIR; ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; AYUSAWA D, 1983, J BIOL CHEM, V258, P2448; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BEISKER W, 1987, CYTOMETRY, V8, P235, DOI 10.1002/cyto.990080218; BIEDLER JL, 1988, CANCER RES, V48, P3179; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BROWN PC, 1983, MOL CELL BIOL, V3, P1097, DOI 10.1128/MCB.3.6.1097; CHEN KC, 1989, HUM GENET, V82, P40, DOI 10.1007/BF00288269; CHENG J, 1992, CANCER RES, V52, P222; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; Cleaver J E, 1989, Birth Defects Orig Artic Ser, V25, P61; DAVIDSON JN, 1990, DNA CELL BIOL, V9, P667, DOI 10.1089/dna.1990.9.667; DEAN PN, 1974, J CELL BIOL, V60, P523, DOI 10.1083/jcb.60.2.523; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EKI T, 1987, CANCER RES, V47, P5162; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLINTOFF WF, 1984, MOL CELL BIOL, V4, P69, DOI 10.1128/MCB.4.1.69; FULTS D, 1992, CANCER RES, V52, P674; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOZ B, 1989, MOL PHARMACOL, V36, P360; HAHN P, 1986, CANCER RES, V46, P4607; HAMLIN JL, 1984, INT REV CYTOL, V90, P31, DOI 10.1016/S0074-7696(08)61487-4; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HUNT JD, 1990, MOL CELL BIOL, V10, P823, DOI 10.1128/MCB.10.2.823; JAMES CD, 1988, CANCER RES, V48, P5546; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOYAMA H, 1982, MUTAT RES, V105, P433, DOI 10.1016/0165-7992(82)90190-7; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, J NATL CANCER I, V43, P1365; LITTLE JB, 1987, CANCER RES, V47, P4229; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGAN WE, 1986, CHROMOSOMA, V93, P191, DOI 10.1007/BF00292737; MOYER JD, 1982, CANCER RES, V42, P4525; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P1507; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1982, TUMOR CELL HETEROGEN, P351; OTTO E, 1989, J BIOL CHEM, V264, P3390; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RICE GC, 1987, P NATL ACAD SCI USA, V84, P9261, DOI 10.1073/pnas.84.24.9261; RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STARK GR, 1986, CANCER SURV, V5, P1; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; STEIN WD, 1991, ADV CANCER RES, V56, P161; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TISTY T, 1982, GENE AMPLIFICATION, P231; TIsty T.D., 1989, P NATL ACAD SCI USA, V86, P9441; TISTY TD, 1990, P NATL ACAD SCI USA, V87, P3132; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YEARGIN J, 1992, LEUKEMIA, V6, pS85; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	89	1172	1183	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					937	948		10.1016/0092-8674(92)90244-7	http://dx.doi.org/10.1016/0092-8674(92)90244-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525830				2022-12-28	WOS:A1992JN78100009
J	MACARTHUR, C; LEWIS, M; KNOX, EG				MACARTHUR, C; LEWIS, M; KNOX, EG			INVESTIGATION OF LONG-TERM PROBLEMS AFTER OBSTETRIC EPIDURAL-ANESTHESIA	BRITISH MEDICAL JOURNAL			English	Article							INTRAMUSCULAR PETHIDINE; MATERNAL OPINION; ANALGESIA; LABOR; ANESTHESIA; BLOCK	Objective-To examine the association between obstetric epidural anaesthesia and subsequent long term problems. Design -Postal questionnaire on heath problems after childbirth linked to maternity case note data. Setting-Maternity hospital in Birmingham. Subjects-11 701 women who delivered their most recent child during 1978-85 and who returned completed questionnaires. Main outcome measures-Frequencies of long term symptoms after childbirth. Results-Compared with the 6935 women who did Dot have epidural anaesthesia the 4766 women who did more commonly experienced backache (903 (18.9%) with epidural v 731 (10.5%) without epidural), frequent headaches 220 (4.6%) v 199 (2.9%)), migraine (92 (1.9%) v 73 (1.1%)), neckache (116 (2.4%) v 112 (1-6%)), and tingling in hands or fingers (143 (3.0%) v 150 (2.2%)). The results could not be explained by correlated social or obstetric factors. The associations with head, neck, and hand symptoms were found only in women who reported backache. An excess of visual disturbances among women who had epidural anaesthesia (83 (1.7%) v 91 (1.3%); was present only in association with migraine, but excess of dizziness or fainting (102 (2.1%) v 109 (1.6%)) was independent of other symptoms. 26 women had numbness or tingling in the lower back, buttocks, and leg, of whom 23 had had epidural anaesthesia. Of 34 women with spinal headache, nine (five after accidental dural puncture; four after spinal block) reported long term headaches. Conclusions-These associations may indicate a causal sequence, although this cannot be proved from this type of study. Randomised trials of epidural anaesthesia are required to determine whether causal relations exist.	BIRMINGHAM MATERN HOSP,DEPT ANAESTHET,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND		MACARTHUR, C (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT PUBL HLTH & EPIDEMIOL,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		MacArthur, Christine/ABA-8601-2021	MacArthur, Christine/0000-0003-0434-2158				BROWNRIDGE P, 1983, ANAESTH INTENS CARE, V11, P4, DOI 10.1177/0310057X8301100102; CRAWFORD JS, 1972, BRIT J ANAESTH, V44, P66, DOI 10.1093/bja/44.1.66; CRAWFORD JS, 1985, ANAESTHESIA, V40, P1219, DOI 10.1111/j.1365-2044.1985.tb10664.x; Crawford JS, 1985, PRINCIPLES PRACTICE; HIBBARD BM, 1990, BRIT J OBSTET GYNAEC, V97, P402, DOI 10.1111/j.1471-0528.1990.tb01826.x; KITZINGER S, 1987, SOME WOMENS EXPERIEN; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MACARTHUR C, 1991, HLTH AFTER CHILDBIRT; MOORE J, 1974, ANAESTHESIA, V29, P537, DOI 10.1111/j.1365-2044.1974.tb00716.x; MORGAN BM, 1982, LANCET, V2, P808; PHILIPSEN T, 1990, EUR J OBSTET GYN R B, V34, P205, DOI 10.1016/0028-2243(90)90072-9; RAMANATHAN S, 1988, OBSTETRIC ANAESTHESI; ROBINSON JO, 1980, ANAESTHESIA, V35, P1173, DOI 10.1111/j.1365-2044.1980.tb05074.x	13	46	46	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1279	1282		10.1136/bmj.304.6837.1279	http://dx.doi.org/10.1136/bmj.304.6837.1279			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1535010	Bronze, Green Published			2022-12-28	WOS:A1992HV08600020
J	THORNTON, JG; LILFORD, RJ; JOHNSON, N				THORNTON, JG; LILFORD, RJ; JOHNSON, N			DECISION-ANALYSIS IN MEDICINE	BRITISH MEDICAL JOURNAL			English	Article							COMPUTER-AIDED DIAGNOSIS; ACUTE ABDOMINAL-PAIN; CESAREAN-SECTION; MANAGEMENT; TERM		UNIV LEEDS,INST EPIDEMIOL & HLTH SERV RES,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds			Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; BALLA JI, 1989, BRIT MED J, V298, P579, DOI 10.1136/bmj.298.6673.579; BINGHAM P, 1987, OBSTET GYNECOL, V69, P965; DEDOMBAL FT, 1972, BMJ-BRIT MED J, V2, P9, DOI 10.1136/bmj.2.5804.9; ELSTEIN AS, 1986, AM J MED, V80, P246, DOI 10.1016/0002-9343(86)90016-1; ELSTEIN AS, 1988, PROFESSIONAL JUDGEME, P109; FELDMAN GB, 1985, NEW ENGL J MED, V312, P1264, DOI 10.1056/NEJM198505093121926; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; JOHNSON N, 1992, BRIT J CANCER, V65, P717, DOI 10.1038/bjc.1992.151; Keeney R.L., 1976, DECISIONS MULTIPLE O; Klein K, 1981, Med Decis Making, V1, P181, DOI 10.1177/0272989X8100100208; LILFORD RJ, 1990, LANCET, V335, P483; LILFORD RJ, 1990, LANCET, V336, P1303, DOI 10.1016/0140-6736(90)92977-P; Lindley D V, 1975, J R Coll Physicians Lond, V9, P225; MCNAMEE P, 1987, DECISION ANAL PROFES; NEUHAUSER D, 1975, NEW ENGL J MED, V293, P226, DOI 10.1056/NEJM197507312930504; NEUTRA R, 1977, COSTS BENEFITS RISKS; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; PAUKER SP, 1977, YALE J BIOL MED, V50, P275; PHILIPS C, 1988, LOGIC MED; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SIMES RJ, 1985, J CHRON DIS, V38, P171, DOI 10.1016/0021-9681(85)90090-6; THORNTON JG, 1988, LANCET, V2, P332; TOMPKINS RK, 1977, ANN INTERN MED, V86, P481, DOI 10.7326/0003-4819-86-4-481; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; VANCREVEL H, 1986, NEUROLOGY, V36, P1335, DOI 10.1212/WNL.36.10.1335; Weinstein MC, 1980, CLIN DECISION ANAL; WEINSTEIN MC, 1977, COSTS BENEFITS RISKS	28	87	87	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1099	1103		10.1136/bmj.304.6834.1099	http://dx.doi.org/10.1136/bmj.304.6834.1099			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1530694	Bronze, Green Published			2022-12-28	WOS:A1992HR13600023
J	MANOLIO, TA; FURBERG, CD; WAHL, PW; TRACY, RP; BORHANI, NO; GARDIN, JM; FRIED, LP; OLEARY, DH; KULLER, LH				MANOLIO, TA; FURBERG, CD; WAHL, PW; TRACY, RP; BORHANI, NO; GARDIN, JM; FRIED, LP; OLEARY, DH; KULLER, LH			ELIGIBILITY FOR CHOLESTEROL REFERRAL IN COMMUNITY-DWELLING OLDER ADULTS - THE CARDIOVASCULAR-HEALTH-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						LIPOPROTEINS; CORONARY DISEASE; HYPERCHOLESTEROLEMIA; ANTILIPEMIC AGENTS; GERIATRICS; HEALTH SERVICES FOR THE AGED	CORONARY HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; RISK-FACTORS; SERUM-CHOLESTEROL; EDUCATION-PROGRAM; SOCIAL-CLASS; PREVALENCE; LEVEL	Objectives: To assess the proportion of community-dwelling adults aged 65 years or older who are eligible for referral for lipoprotein analysis and intervention according to the National Cholesterol Education Program (NCEP) guidelines. Design: Cross-sectional study based on examinations and questionnaires collected in 1989 and 1990. Setting: Four communities in the U.S. in the Cardiovascular Health Study (CHS), a study of risk factors for heart disease and stroke in older adults. Participants: A sample of 4810 men and women ages 65 to 100 randomly selected and recruited from Health Care Financing Administration Medicare eligibility lists for the four communities; not institutionalized, not wheelchair-bound, not currently receiving therapy for cancer, not currently taking lipid-lowering medications, and not having eaten in the preceding 9 hours. Measurements: Total cholesterol and lipoprotein analysis measured in all participants. Results: Total cholesterol levels were less than 5.17 mmol/L (200 mg/dL) in 37% of participants, 5.17 to 6.19 mmol/L (200 to 239 mg/dL) in 39%, and 6.20 mmol/L (240 mg/dL) or greater in 24%. Compared with their counterparts, older participants, especially those over 80 years of age, were more likely to have levels below 5.17 mmol/L, as were men, nonwhites, and those with coronary heart disease or two or more coronary heart disease risk factors (P < 0.008 for all values). Based on this screening measurement, 2174 participants were eligible for lipoprotein analysis, 80% were eligible for dietary or drug therapy using NCEP guidelines. Overall, 46% of CHS participants were eligible for lipoprotein analysis and 36% for intervention by NCEP guidelines, based on a single cholesterol measurement. Conclusion: A substantial proportion of older adults in this community sample were eligible for lipoprotein analysis and intervention. Prospective studies of elderly persons are needed to determine the risk for incident coronary heart disease according to NCEP classifications and the benefits of lipid-lowering treatments in persons in this age group so that intervention strategies may best be targeted to an appropriately high-risk group.	NHLBI, BETHESDA, MD 20892 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, WINSTON SALEM, NC 27103 USA; UNIV VERMONT, BURLINGTON, VT 05405 USA; UNIV CALIF IRVINE, IRVINE, CA 92717 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA; GEISINGER MED CTR, DANVILLE, PA 17822 USA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University; Wake Forest Baptist Medical Center; University of Vermont; University of California System; University of California Irvine; Johns Hopkins University; Geisinger Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	MANOLIO, TA (corresponding author), UNIV WASHINGTON, CTR CARDIOVASC HLTH STUD COORDINAT, JD-30, 1107 NE 45TH ST, SUITE 530, SEATTLE, WA 98195 USA.				NHLBI NIH HHS [N01-HC-85079, N01-HC-85081, N01-HC-85080] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085080, N01HC085079, N01HC085081] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON AJ, 1979, PREV MED, V8, P419, DOI 10.1016/0091-7435(79)90019-7; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BOOKSTEIN L, 1990, ARCH INTERN MED, V150, P1653, DOI 10.1001/archinte.150.8.1653; BURTON BT, 1985, INT J OBESITY, V9, P155; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; Castelli W P, 1976, Hosp Pract, V11, P113; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; DONAHUE RP, 1989, ARTERIOSCLEROSIS, V9, P656, DOI 10.1161/01.ATV.9.5.656; DRURY TF, 1985, NIH851468 PUBL, pVII1; FEINLEIB M, 1989, CIRCULATION, V79, P13; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FULWOOD R, 1986, VITAL HLTH STATIS 11, V236; GARBER AM, 1991, ARCH INTERN MED, V151, P1089, DOI 10.1001/archinte.151.6.1089; GARBER AM, 1989, ANN INTERN MED, V110, P622, DOI 10.7326/0003-4819-110-8-622; GARBER AM, 1989, GPO052003011514 OFF; HARLAN WR, 1989, PHS7 US DEP HLTH HUM; HARRIS T, 1990, CIRCULATION, V81, P714; KANNEL WB, 1986, CORONARY HEART DISEA, P60; KITTNER SJ, 1986, J CHRON DIS, V39, P163, DOI 10.1016/0021-9681(86)90019-6; Kuller L H, 1978, Adv Neurol, V19, P281; LILLIENFELD AM, 1980, F EPIDEMIOLOGY, P76; LIU K, 1982, CIRCULATION, V66, P1308, DOI 10.1161/01.CIR.66.6.1308; MANOLIO TA, 1991, IN PRESS ANN EPIDEMI; MCCALL M, 1979, ACTA MED SCAND, V206, P477; MOGADAM M, 1990, ARCH INTERN MED, V150, P1645, DOI 10.1001/archinte.150.8.1645; PALUMBO PJ, 1988, MAYO CLIN PROC, V63, P88, DOI 10.1016/S0025-6196(12)62672-X; ROSE G, 1981, BRIT HEART J, V45, P13, DOI 10.1136/hrt.45.1.13; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; WONG ND, 1989, AM J EPIDEMIOL, V130, P469, DOI 10.1093/oxfordjournals.aje.a115360; 1990, VITAL STATISTICS U A, V2; 1980, NIH801257 NAT HEART, P76; 1989, DHHS PHS891232 NAT C, P102; 1989, DHHS PHS891232 NAT C, P96; 1959, STATISTICAL B METROP, V40, P1; 1987, VITAL HLTH STATIS 11, V238, P21	38	21	21	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					641	649		10.7326/0003-4819-116-8-641	http://dx.doi.org/10.7326/0003-4819-116-8-641			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546864				2022-12-28	WOS:A1992HN84400006
J	CUTTS, FT; ZELL, ER; MASON, D; BERNIER, RH; DINI, EF; ORENSTEIN, WA				CUTTS, FT; ZELL, ER; MASON, D; BERNIER, RH; DINI, EF; ORENSTEIN, WA			MONITORING PROGRESS TOWARD UNITED-STATES PRESCHOOL IMMUNIZATION GOALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ERADICATION; CHILDREN	The United States has achieved over 97% immunization of children by school age and has reduced the incidence of vaccine-preventable diseases by more than 90% since the prevaccination era. However, children often do not receive immunizations at the recommended age, and in densely populated urban areas this delay in immunization has led to epidemics of measles. Correctable deficiencies of the immunization delivery system have been identified in these areas. To respond to needs, the public health infrastructure must be strengthened, and active participation from the private sector must be obtained, both in delivery of immunizations and in assessment of performance. Appropriate action must be stimulated by the provision of timely information on immunization coverage and on indicators of program performance at the local level.	CTR DIS CONTROL, DIV IMMUNIZAT, ATLANTA, GA 30333 USA; GEORGIA STATE DEPT HUMAN RESOURCES, IMMUNIZAT PROGRAM, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA								BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547; BERNLER R, 1991, 25TH P NAT IMM C ATL, P27; BROOK RH, 1991, JAMA-J AM MED ASSOC, V265, P2998, DOI 10.1001/jama.265.22.2998; CUTTS FT, 1990, B WORLD HEALTH ORGAN, V68, P769; CUTTS FT, 1990, INT J HEALTH SERV, V20, P717, DOI 10.2190/61V1-220G-4A4D-K8KN; FARIZO KM, 1990, 39TH EP INT SERV ANN, P59; GOODWIN S, 1990, PEDIATRICS, V86, P1056; HADLER SC, 1991, 25TH P NAT IMM C WAS, P105; HANES A, 1988, 22ND P NAT IMM C SAN, P159; HENDERSON DA, 1987, B WORLD HEALTH ORGAN, V65, P535; HERSH BS, 1992, JAMA-J AM MED ASSOC, V267, P1936, DOI 10.1001/jama.267.14.1936; HOPKINS DR, 1982, LANCET, V1, P1396; HUTCHINS S, 1990, 24TH P NAT IMM C ORL, P87; JONES JE, 1988, 22ND P NAT IMM C SAN, P159; LINDEGREN ML, 1990, 39TH EP INT SERV ANN, P60; MARCUSE EK, 1991, 25TH NAT IMM C P WAS, P87; MCCONNOCHIE KM, IN PRESS PEDIATRICS; MOORE GT, 1991, JAMA-J AM MED ASSOC, V265, P2108; NOAH ND, 1987, BMJ-BRIT MED J, V294, P1270, DOI 10.1136/bmj.294.6582.1270; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; PAUNIO M, 1991, AM J EPIDEMIOL, V133, P1152, DOI 10.1093/oxfordjournals.aje.a115827; SABIN AB, 1986, BRIT MED J, V292, P531, DOI 10.1136/bmj.292.6519.531; SCHULTE JM, 1991, PEDIATRICS, V87, P204; SPITALNY K, 1991, 25TH P NAT IMM C WAS, P119; TIFFT CJ, 1988, AM J DIS CHILD, V142, P719, DOI 10.1001/archpedi.1988.02150070033019; VERBRUGGE HP, 1990, PEDIATRICS, V86, P1060; ZELL E, 1991, 25TH P NAT IMM C CTR, P35; ZIMMERMAN RK, 1991, 25TH P NAT IMM C WAS, P170; 1991, MMWR, V40, P369; 1991, HRSAM CH912 US DEP H; 1991, MMWR, V40, P36	31	67	67	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1952	1955		10.1001/jama.267.14.1952	http://dx.doi.org/10.1001/jama.267.14.1952			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL677	1548828				2022-12-28	WOS:A1992HL67700030
J	JOHNSON, CA; DENSEN, P; WETSEL, RA; COLE, FS; GOEKEN, NE; COLTEN, HR				JOHNSON, CA; DENSEN, P; WETSEL, RA; COLE, FS; GOEKEN, NE; COLTEN, HR			MOLECULAR HETEROGENEITY OF C2 DEFICIENCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							2ND COMPONENT; FACTOR-B; GENETIC DEFICIENCY; HUMAN-COMPLEMENT; HYBRIDIZATION; INTERFERON; EXPRESSION; MONOCYTES; DISEASE; DEFECT		WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; VET AFFAIRS MED CTR,DEPT INTERNAL MED,IOWA CITY,IA; UNIV IOWA,COLL MED,IOWA CITY,IA 52242	Washington University (WUSTL); US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa	JOHNSON, CA (corresponding author), WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110, USA.			Cole, F. Sessions/0000-0002-3797-9369	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024836, R01AI025011, R55AI025011] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24836, AI25011] Funding Source: Medline; NICHD NIH HHS [HD17461] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALPER CA, 1987, IMMUNOL LETT, V14, P175, DOI 10.1016/0165-2478(87)90098-8; AMOS DB, 1979, DHEW NIH80545 PUBL; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AWDEH ZL, 1981, J CLIN INVEST, V67, P581, DOI 10.1172/JCI110070; CARROLL MC, 1984, NATURE, V307, P237, DOI 10.1038/307237a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE FS, 1985, NEW ENGL J MED, V313, P11, DOI 10.1056/NEJM198507043130103; EINSTEIN LP, 1976, J EXP MED, V143, P114, DOI 10.1084/jem.143.1.114; EINSTEIN LP, 1975, NEW ENGL J MED, V292, P1169, DOI 10.1056/NEJM197505292922207; EZEKOWITZ RAB, 1988, NEW ENGL J MED, V319, P146, DOI 10.1056/NEJM198807213190305; FU SM, 1974, J EXP MED, V140, P1108, DOI 10.1084/jem.140.4.1108; GLASS D, 1976, J CLIN INVEST, V58, P853, DOI 10.1172/JCI108538; KATZ Y, 1988, J EXP MED, V167, P1, DOI 10.1084/jem.167.1.1; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NONAKA M, 1989, MOL CELL BIOCHEM, V89, P1; PERLMUTTER DH, 1985, J CLIN INVEST, V76, P1449, DOI 10.1172/JCI112123; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WOODS DE, 1984, J CLIN INVEST, V74, P634, DOI 10.1172/JCI111461	19	34	37	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1992	326	13					871	874		10.1056/NEJM199203263261306	http://dx.doi.org/10.1056/NEJM199203263261306			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK523	1542325				2022-12-28	WOS:A1992HK52300006
J	JOSHI, HC; PALACIOS, MJ; MCNAMARA, L; CLEVELAND, DW				JOSHI, HC; PALACIOS, MJ; MCNAMARA, L; CLEVELAND, DW			GAMMA-TUBULIN IS A CENTROSOMAL PROTEIN REQUIRED FOR CELL CYCLE-DEPENDENT MICROTUBULE NUCLEATION	NATURE			English	Article							LYSED MAMMALIAN-CELLS; HAMSTER OVARY CELLS; ALPHA-TUBULIN; ASPERGILLUS-NIDULANS; MITOTIC CENTERS; INITIATION; SPINDLE; IDENTIFICATION; FILAMENTS; ANTIBODY	Gamma-TUBULIN is a newly identified member of the tubulin family whose sequence is highly conserved from yeast to man. This minor microtubule protein is localized to the microtuble organizing centres 1-3 and a mutation in the gene encoding it produces a microtubuleless mitotic arrest in the filamentous fungus Aspergillus nidulans 4,5. Here we investigate the in vivo function of gamma-tubulin in mammalian cells using a synthetic peptide to generate a polyclonal antibody that binds to a highly conserved segment of gamma-tubulin. After microinjection into cultured mammalian cells, immunofluorescence localization revealed that this antibody binds to native centrosomes at all phases of the cell cycle. In the presence of the gamma-tubulin antibody, microtubules fail to regrow into cytoplasmic arrays after depolymerization induced by nocodazole or cold. Furthermore, cells injected immediately before or during mitosis fail to assemble a functional spindle. Thus in vivo gamma-tubulin is required for microtubule nucleation throughout the mammalian cell cycle.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University	JOSHI, HC (corresponding author), EMORY UNIV,SCH MED,DEPT ANAT & CELL BIOL,ATLANTA,GA 30322, USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682				BAJER A, 1969, CHROMOSOMA, V27, P448, DOI 10.1007/BF00325682; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; ELLIOTT EM, 1986, MOL CELL BIOL, V6, P906, DOI 10.1128/MCB.6.3.906; HORIO T, 1991, J CELL SCI, V99, P693; JOSHI HC, 1989, J CELL BIOL, V109, P663, DOI 10.1083/jcb.109.2.663; KURIYAMA R, 1981, J CELL BIOL, V91, P822, DOI 10.1083/jcb.91.3.822; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; MCGILL M, 1975, J CELL BIOL, V67, P189, DOI 10.1083/jcb.67.1.189; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; PEPPER DA, 1979, J CELL BIOL, V82, P585, DOI 10.1083/jcb.82.2.585; PONSTINGL H, 1981, P NATL ACAD SCI-BIOL, V78, P2757, DOI 10.1073/pnas.78.5.2757; SALMON ED, 1984, J CELL BIOL, V99, P2165, DOI 10.1083/jcb.99.6.2165; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNYDER JA, 1975, J CELL BIOL, V67, P744, DOI 10.1083/jcb.67.3.744; SOLOMON F, 1979, CELL, V18, P431, DOI 10.1016/0092-8674(79)90062-X; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; VENDRE DD, 1984, MOL BIOL CYTOSKELETO, P3; WEHLAND J, 1983, J CELL BIOL, V97, P1476, DOI 10.1083/jcb.97.5.1476; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	25	428	432	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					80	83		10.1038/356080a0	http://dx.doi.org/10.1038/356080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538786				2022-12-28	WOS:A1992HG60200062
J	LOMBARDI, V; PIAZZESI, G; LINARI, M				LOMBARDI, V; PIAZZESI, G; LINARI, M			RAPID REGENERATION OF THE ACTIN MYOSIN POWER STROKE IN CONTRACTING MUSCLE	NATURE			English	Article							STRIATED-MUSCLE; FIBERS; LENGTH; REFLECTIONS; DIFFRACTION; STIFFNESS; TENSION	AT the molecular level, muscle contraction is the result of cyclic interaction between myosin crossbridges, which extend from the thick filament, and the thin filament, which consists mainly of actin. The energy for work done by a single crossbridge during a cycle of attachment, generation of force, shortening and detachment is believed to be coupled to the hydrolysis of one molecule of ATP 1,2. The distance the actin filament slides relative to the myosin filament in one crossbridge cycle has been estimated as 12 nm by step-length perturbation studies on single fibres from frog muscle 3,4. The 'mechanical' power stroke of the attached crossbridge can therefore be defined as 12-nm shortening with a force profile like that shown by the quick recovery of force following a length perturbation. According to this definition, power strokes cannot be repeated faster than the overall ATPase rate. Here, however, we show that the power stroke can be regenerated much faster than expected from the ATPase rate. This contradiction can be resolved if, in the shortening muscle, the free energy of ATP hydrolysis is used in several actin-myosin interactions consisting of elementary power strokes each of 5-10 nm.			LOMBARDI, V (corresponding author), UNIV FLORENCE,DIPARTIMENTO SCI FISIOL,VIALE GB MORGAGNI 63,I-50134 FLORENCE,ITALY.			LINARI, MARCO/0000-0001-6512-4897				CECCHI G, 1987, PFLUG ARCH EUR J PHY, V409, P39, DOI 10.1007/BF00584747; Cecchi G, 1976, Boll Soc Ital Biol Sper, V52, P733; CECCHI G, 1983, J PHYSIOL-LONDON, V345, pP146; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; FORD LE, 1981, J PHYSIOL-LONDON, V311, P219, DOI 10.1113/jphysiol.1981.sp013582; GOLMAN YE, 1977, J PHYSIOL-LONDON, V269, pP55; HOMSHER E, 1984, CONTRACTILE MECH MUS, P865; HUXLEY AF, 1981, J PHYSIOL-LONDON, V317, pP12; HUXLEY AF, 1980, J PHYSIOL-LONDON, V305, pP15; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1980, NATURE, V284, P140, DOI 10.1038/284140a0; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; KUSHMERICK MJ, 1969, PROC R SOC SER B-BIO, V174, P315, DOI 10.1098/rspb.1969.0096; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P617; MATSUBARA I, 1975, NATURE, V255, P728, DOI 10.1038/255728a0; PIAZZESI G, 1992, J PHYSIOL-LONDON, V445, P659, DOI 10.1113/jphysiol.1992.sp018945; Woledge RC., 1985, ENERGETIC ASPECTS MU; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	20	183	185	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					638	641		10.1038/355638a0	http://dx.doi.org/10.1038/355638a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538750				2022-12-28	WOS:A1992HD54700056
J	HARLAND, RW; BECKER, CG; BRANDES, JC; FRITSCHE, C; ROSENZWEIG, DY				HARLAND, RW; BECKER, CG; BRANDES, JC; FRITSCHE, C; ROSENZWEIG, DY			IMMUNOGLOBULIN-A (IGA) IMMUNE-COMPLEX PNEUMONITIS IN A PATIENT WITH IGA NEPHROPATHY	ANNALS OF INTERNAL MEDICINE			English	Note						GLOMERULONEPHRITIS, IGA; PULMONARY FIBROSIS; IMMUNE COMPLEX DISEASE; IGA; DYSPNEA	PULMONARY	We describe a patient with biopsy-proven immunoglobulin A (IgA) nephropathy who developed a respiratory illness characterized by dyspnea on exertion, slight restrictive ventilatory impairment, reduced diffusing capacity, and hypoxemia. A lung biopsy showed an interstitial pneumonitis with immune complex deposition. The immune complexes consisted of IgA and C3 and closely resembled those found in the mesangium during renal biopsy. Treatment with corticosteroids resulted in resolution of pulmonary disease. To our knowledge, this is the first description of an IgA immune complex-mediated pneumonitis in a patient with documented IgA nephropathy.	MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin								BERGER J, 1969, TRANSPL P, V1, P939; BONNIN A, 1987, NEPHRON, V47, P229, DOI 10.1159/000184498; BORDER WA, 1979, ANN INTERN MED, V91, P21, DOI 10.7326/0003-4819-91-1-21; COHEN AJ, 1985, ARCH INTERN MED, V145, P554, DOI 10.1001/archinte.145.3.554; ENDO Y, 1986, KIDNEY INT, V29, P557, DOI 10.1038/ki.1986.34; KANAYAMA Y, 1982, SCAND J INFECT DIS, V14, P231, DOI 10.3109/inf.1982.14.issue-3.13; WOODROFFE AJ, 1980, KIDNEY INT, V18, P366, DOI 10.1038/ki.1980.147; YAMABE H, 1989, NEPHRON, V51, P499, DOI 10.1159/000185383; YUM MN, 1978, AM J MED, V64, P1056, DOI 10.1016/0002-9343(78)90461-8; ZIMMERMAN SW, 1975, ARCH INTERN MED, V135, P1217, DOI 10.1001/archinte.135.9.1217	10	17	17	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					220	222		10.7326/0003-4819-116-3-220	http://dx.doi.org/10.7326/0003-4819-116-3-220			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1530807				2022-12-28	WOS:A1992HB35600008
J	MENIKOFF, JA; SACHS, GA; SIEGLER, M				MENIKOFF, JA; SACHS, GA; SIEGLER, M			BEYOND ADVANCE DIRECTIVES - HEALTH-CARE SURROGATE LAWS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SELF-DETERMINATION ACT; LIVING WILLS; INTERVENTIONS; ATTITUDES; PROXY; LIFE				MENIKOFF, JA (corresponding author), UNIV CHICAGO, CHICAGO, IL 60637 USA.							ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; Areen J, 1991, Law Med Health Care, V19, P91; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; BRUNETTI LL, 1991, J GEN INTERN MED, V6, P323, DOI 10.1007/BF02597430; CAPLAN AL, 1991, GERONTOLOGIST, V31, P582; CAPRON AM, 1990, HASTINGS CENT REP, V20, P35, DOI 10.2307/3562537; CAPRON AM, 1991, HASTINGS CENT REP, V21, P26, DOI 10.2307/3562887; COHENMANSFIELD J, 1991, ARCH INTERN MED, V151, P289, DOI 10.1001/archinte.151.2.289; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; Goldman G M, 1989, Law Med Health Care, V17, P298; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; HARE J, 1991, J GEN INTERN MED, V6, P41, DOI 10.1007/BF02599390; HIGH DM, 1991, GERONTOLOGIST, V31, P611, DOI 10.1093/geront/31.5.611; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; Portman R M, 1991, J Health Hosp Law, V24, P311; RHODEN NK, 1988, HARVARD LAW REV, V102, P375, DOI 10.2307/1341384; Rouse F, 1991, Law Med Health Care, V19, P83; ROWLAND M, 1990, NY TIMES        1111, V3, P17; Sachs G.A., 1991, J CRIT ILLNESS, V6, P348; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334	23	60	60	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1992	327	16					1165	1169		10.1056/NEJM199210153271612	http://dx.doi.org/10.1056/NEJM199210153271612			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT153	1528214				2022-12-28	WOS:A1992JT15300012
J	STEGER, GG; LOCKER, G; RAINER, H; MADER, RM; SIEDER, AE; GNANT, MFX; ABERER, W; JAKESZ, R				STEGER, GG; LOCKER, G; RAINER, H; MADER, RM; SIEDER, AE; GNANT, MFX; ABERER, W; JAKESZ, R			CUTANEOUS REACTIONS TO GM-CSF IN INFLAMMATORY BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							COLONY-STIMULATING FACTOR				STEGER, GG (corresponding author), UNIV VIENNA,A-1090 VIENNA,AUSTRIA.		Gnant, Michael/AAN-7054-2020	Gnant, Michael/0000-0003-1002-2118; Mader, Robert/0000-0003-3017-8240				DIPERSIO JF, 1988, J IMMUNOL, V140, P4315; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; HORN TD, 1989, ARCH DERMATOL, V125, P1512, DOI 10.1001/archderm.125.11.1512; HORN TD, 1991, ARCH DERMATOL, V127, P49, DOI 10.1001/archderm.127.1.49; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; WEISBART RH, 1989, ANN INTERN MED, V110, P297, DOI 10.7326/0003-4819-110-4-297	6	14	14	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					286	286						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1535420				2022-12-28	WOS:A1992JE38100032
J	HOOK, EW; MARRA, CM				HOOK, EW; MARRA, CM			ACQUIRED SYPHILIS IN ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; 20 YEARS EXPERIENCE; SECONDARY SYPHILIS; TREPONEMA-PALLIDUM; CEREBROSPINAL-FLUID; HIV INFECTION; PENICILLIN CONCENTRATIONS; RISK-FACTORS; GENITAL ULCERS; HOMOSEXUAL MEN		JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA; BALTIMORE CITY DEPT HLTH, BALTIMORE, MD USA	Johns Hopkins University; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027727] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27727] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON J, 1989, GENITOURIN MED, V65, P239; ANDRUS JK, 1990, ANN INTERN MED, V112, P539, DOI 10.7326/0003-4819-112-7-539; BAKERZANDER SA, 1983, INFECT IMMUN, V42, P634, DOI 10.1128/IAI.42.2.634-638.1983; BAYNE LL, 1986, ARCH NEUROL-CHICAGO, V43, P137, DOI 10.1001/archneur.1986.00520020031012; BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; BLOUNT JH, 1976, BIOL PARASITIC SPIRO, P157; BRANDT A, 1987, NO MAGIC BULLET; BRANDT AM, 1988, SCIENCE, V239, P375, DOI 10.1126/science.3276007; BROWN ST, 1985, JAMA-J AM MED ASSOC, V253, P1296, DOI 10.1001/jama.253.9.1296; BURKE JM, 1985, NEUROLOGY, V35, P1368, DOI 10.1212/WNL.35.9.1368; CAMERON DW, 1989, LANCET, V2, P403; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; CHAPEL TA, 1980, SEX TRANSM DIS, V7, P161, DOI 10.1097/00007435-198010000-00002; Chesney AM, 1924, J AMER MED ASSOC, V83, P1725, DOI 10.1001/jama.1924.02660220001001; CLARK EG, 1964, MED CLIN N AM, V48, P613; COLLART P, 1964, BRIT J VENER DIS, V40, P81; DARROW WW, 1987, AM J PUBLIC HEALTH, V77, P479, DOI 10.2105/AJPH.77.4.479; DAVIS LE, 1989, ANN NEUROL, V25, P50, DOI 10.1002/ana.410250108; DAVIS LE, 1979, ANN NEUROL, V6, P68, DOI 10.1002/ana.410060116; DIAZMITOMA F, 1987, SEX TRANSM DIS, V14, P33, DOI 10.1097/00007435-198701000-00007; DUNCAN WC, 1974, ARCH DERMATOL, V110, P77, DOI 10.1001/archderm.110.1.77; EAGLE H, 1948, ANN INTERN MED, V28, P260, DOI 10.7326/0003-4819-28-2-260; FARLEY TA, 1990, SEX TRANSM DIS, V17, P163, DOI 10.1097/00007435-199010000-00003; FIUMARA NJ, 1980, SEX TRANSM DIS, V7, P111, DOI 10.1097/00007435-198007000-00003; FLEMING WL, 1970, J AMER MED ASSOC, V211, P1827, DOI 10.1001/jama.211.11.1827; GOH BT, 1984, BRIT J VENER DIS, V60, P371; GREGORY N, 1990, J AM ACAD DERMATOL, V22, P1061, DOI 10.1016/0190-9622(90)70153-9; GRIMPREL E, 1991, J CLIN MICROBIOL, V29, P1711, DOI 10.1128/JCM.29.8.1711-1718.1991; GRUHZIT O. M., 1950, AMER JOUR SYPHILIS GONORRHEA AND VENEREAL DIS, V34, P338; HAAS JS, 1990, J INFECT DIS, V162, P862, DOI 10.1093/infdis/162.4.862; HAHN R D, 1946, Am J Syph Gonorrhea Vener Dis, V30, P305; HAHN RD, 1956, ARCH DERMATOL, V74, P367, DOI 10.1001/archderm.1956.01550100035007; HANDSFIELD HH, 1990, SEX TRANSM DIS, V17, P211, DOI 10.1097/00007435-199010000-00011; HART G, 1986, ANN INTERN MED, V104, P368, DOI 10.7326/0003-4819-104-3-368; HASHISAKI P, 1983, SEX TRANSM DIS, V10, P36, DOI 10.1097/00007435-198301000-00008; HICKS CB, 1987, ANN INTERN MED, V107, P492, DOI 10.7326/0003-4819-107-4-492; HICKS CB, 1987, ANN INTERN MED, V107, P946, DOI 10.7326/0003-4819-107-6-946_4; HIRA SK, 1987, INT J DERMATOL, V26, P103, DOI 10.1111/j.1365-4362.1987.tb00532.x; HOOK EW, 1989, J INFECT DIS, V160, P530, DOI 10.1093/infdis/160.3.530; HOOK EW, 1985, J CLIN MICROBIOL, V22, P241, DOI 10.1128/JCM.22.2.241-244.1985; HOOK EW, 1988, J INFECT DIS, V158, P881, DOI 10.1093/infdis/158.4.881; HOTSON JR, 1981, WESTERN J MED, V135, P191; HUTCHINSON CM, 1990, MED CLIN N AM, V74, P1389, DOI 10.1016/S0025-7125(16)30487-4; HUTCHINSON CM, 1991, ARCH INTERN MED, V151, P511, DOI 10.1001/archinte.151.3.511; Idsoe O, 1972, Bull World Health Organ, V47 Suppl, P1; IZZAT NN, 1971, BRIT J VENER DIS, V47, P162; JACKMAN JD, 1989, AM J MED, V87, P425, DOI 10.1016/S0002-9343(89)80826-5; JAFFE HW, 1978, ARCH INTERN MED, V138, P252, DOI 10.1001/archinte.138.2.252; JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503; JOHNSON PDR, 1991, AIDS, V5, P419, DOI 10.1097/00002030-199104000-00010; KAMPMEIER RH, 1964, MED CLIN N AM, V48, P667, DOI 10.1016/S0025-7125(16)33449-6; KAMPMEIER RH, 1981, SEX TRANSM DIS, V8, P260, DOI 10.1097/00007435-198110000-00005; KATZ DA, 1989, ARCH NEUROL-CHICAGO, V46, P895, DOI 10.1001/archneur.1989.00520440085024; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; LEFEVRE JC, 1990, J CLIN MICROBIOL, V28, P1704, DOI 10.1128/JCM.28.8.1704-1707.1990; LUKEHART SA, 1981, J IMMUNOL, V127, P1361; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; Magnuson Harold J., 1948, AMER JOUR SYPHILIS GONORRHEA AND VENEREAL DIS, V32, P1; MAGNUSON HJ, 1956, MEDICINE, V35, P33, DOI 10.1097/00005792-195602000-00002; MARKOVITZ DM, 1986, JAMA-J AM MED ASSOC, V255, P1767, DOI 10.1001/jama.255.13.1767; MCLEISH WM, 1990, OPHTHALMOLOGY, V97, P196; Merritt HH, 1940, NEW ENGL J MED, V223, P446, DOI 10.1056/NEJM194009192231204; Merritt HH., 1946, NEUROSYPHILIS; MIAO RM, 1980, J BACTERIOL, V141, P427, DOI 10.1128/JB.141.1.427-429.1980; Mills C H, 1927, Br Med J, V2, P527; MINDEL A, 1989, GENITOURIN MED, V65, P1; MINKOFF HL, 1990, AM J OBSTET GYNECOL, V163, P521, DOI 10.1016/0002-9378(90)91188-I; MOHR JA, 1976, JAMA-J AM MED ASSOC, V236, P2208, DOI 10.1001/jama.236.19.2208; Moore JE, 1922, B JOHNS HOPKINS HOSP, V33, P231; Moore JE, 1930, J AMER MED ASSOC, V95, P1637, DOI 10.1001/jama.1930.02720220007003; MOORE JE, 1949, PUBLICATION PHS PRIN, V426, P1; MOORE MB, 1963, PUBLIC HEALTH REP, V78, P966, DOI 10.2307/4591989; MOORTHY TT, 1987, SEX TRANSM DIS, V14, P116, DOI 10.1097/00007435-198704000-00013; MUSHER DM, 1990, ANN INTERN MED, V113, P872, DOI 10.7326/0003-4819-113-11-872; NELSON KE, 1991, J INFECT DIS, V164, P457, DOI 10.1093/infdis/164.3.457; NICOLIS G, 1974, BRIT J VENER DIS, V50, P270; NOORDHOEK GT, 1990, J CLIN MICROBIOL, V28, P2853; NORGARD MV, 1981, SCIENCE, V213, P553, DOI 10.1126/science.6264606; OLANSKY S, 1964, MED CLIN N AM, V48, P653, DOI 10.1016/S0025-7125(16)33448-4; ONOA Y, 1979, J INT MED RES, V7, P539; PARKER JDJ, 1972, BRIT J VENER DIS, V48, P32; QUINN TC, 1990, ARCH INTERN MED, V150, P1297, DOI 10.1001/archinte.150.6.1297; RADOLF JD, 1988, J AM ACAD DERMATOL, V18, P423, DOI 10.1016/S0190-9622(88)70062-6; RAVAUT P, 1903, ANN DERMATOL SYPHIL, V4, P537; REIN M F, 1976, Journal of the American Venereal Disease Association, V3, P109; RICCI JM, 1989, OBSTET GYNECOL, V74, P687; ROLFS RT, 1990, AM J PUBLIC HEALTH, V80, P853, DOI 10.2105/AJPH.80.7.853; ROLFS RT, 1990, JAMA-J AM MED ASSOC, V264, P1432, DOI 10.1001/jama.264.11.1432; ROMANOWSKI B, 1991, ANN INTERN MED, V114, P1005, DOI 10.7326/0003-4819-114-12-1005; ROMPALO AM, IN PRESS J INFECT DI; ROY R. N., 1963, Journal of the Indian Medical Association, V40, P498; SCHOBER PC, 1983, BRIT J VENER DIS, V59, P217; SCHOTH PEM, 1987, NEUROLOGY, V37, P1214, DOI 10.1212/WNL.37.7.1214; SCHRIJVERS D, 1989, GENITOURIN MED, V65, P84; SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471; SCHROETER AL, 1971, J AMER MED ASSOC, V218, P711, DOI 10.1001/jama.218.5.711; SIMON RP, 1985, ARCH NEUROL-CHICAGO, V42, P606, DOI 10.1001/archneur.1985.04060060112021; SMIBERT RM, 1984, BERGEYS MANUAL SYSTE, V1, P50; SPARLING PF, 1971, NEW ENGL J MED, V284, P642, DOI 10.1056/NEJM197103252841205; Sparling PF., 1990, SEX TRANSM DIS, P213; STAMM WE, 1988, JAMA-J AM MED ASSOC, V260, P1429, DOI 10.1001/jama.260.10.1429; STAPLETON JT, 1985, REV INFECT DIS, V7, pS314; STOKES JH, 1944, MODERN CLIN SYPHILOL; TELZAK EE, 1991, AIDS, V5, P591, DOI 10.1097/00002030-199105000-00020; THORNBURG RW, 1983, INFECT IMMUN, V42, P623, DOI 10.1128/IAI.42.2.623-627.1983; TIKJOB G, 1991, J AM ACAD DERMATOL, V24, P506, DOI 10.1016/S0190-9622(08)80082-5; TRAMONT EC, 1976, JAMA-J AM MED ASSOC, V236, P2206, DOI 10.1001/jama.236.19.2206; TURNER TB, 1969, BRIT J VENER DIS, V45, P183; VANDERVALK PGM, 1988, GENITOURIN MED, V64, P223; Von Werssowetz A., 1948, JOUR VENEREAL DIS INFORM, V29, P132; Wile UJ, 1921, J AMER MED ASSOC, V76, P8; WILE UJ, 1914, J CUTAN DIS, V32, P607; YOBS AR, 1964, BRIT J VENER DIS, V40, P248; YOBS AR, 1964, ARCH PATHOL, V77, P220; 1991, MMWR, V40, P77; 1991, MMWR, V40, P323; 1989, MMWR, V38, P664; 1991, MMWR, V40, P314; 1988, MMWR, V37, P600; 1989, MMWR, V38, P825; 1991, SEXUALLY TRANSMITTED	121	346	364	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 16	1992	326	16					1060	1069		10.1056/NEJM199204163261606	http://dx.doi.org/10.1056/NEJM199204163261606			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN738	1549153				2022-12-28	WOS:A1992HN73800006
J	FRIED, RH; MURAKAMI, CS; FISHER, LD; WILLSON, RA; SULLIVAN, KM; MCDONALD, GB				FRIED, RH; MURAKAMI, CS; FISHER, LD; WILLSON, RA; SULLIVAN, KM; MCDONALD, GB			URSODEOXYCHOLIC ACID TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE OF THE LIVER	ANNALS OF INTERNAL MEDICINE			English	Article						URSODEOXYCHOLIC ACID; GRAFT VS HOST DISEASE; BONE MARROW TRANSPLANTATION; LIVER DISEASES; CHOLESTASIS	PRIMARY BILIARY-CIRRHOSIS; BILE-SALTS; MARROW TRANSPLANTATION; HUMAN HEPATOCYTES; CONSEQUENCE; PREDNISONE; ABSORPTION; INVITRO; TRIAL	Objective: To determine the safety and efficacy of ursodeoxycholic acid treatment in patients with chronic graft-versus-host disease (GVHD) of the liver. Design: Open-label study in which each patient served as his or her own control. Setting: Private practice and a university bone marrow transplant center. Patients: Twelve patients with refractory chronic GVHD of the liver were studied after allogeneic bone marrow transplantation. Interventions: After baseline data collection, patients were given ursodeoxycholic acid (UDCA, 10 to 15 mg/kg body weight per day) for 6 weeks. After discontinuation of the drug, patients were followed for an additional 6 weeks. Doses of immunosuppressive drugs were unchanged for these 12 weeks. Measurements: Signs, symptoms, Karnofsky performance scores, hematocrit, total leukocyte count, absolute neutrophil count, platelet count, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, gamma-glutamyltransferase (GGT), total serum bilirubin, prothrombin time, serum creatinine, and blood urea nitrogen were assessed. Results: Serum tests of cholestatic liver injury measured at 2, 4, and 6 weeks showed improvement compared with baseline. At 6 weeks, the percent decrease from baseline in total serum bilirubin was 33% (P < 0.005); in alkaline phosphatase the decrease was 32% (P < 0.038); and in AST the decrease was 37% (P < 0.007). After discontinuation of UDCA therapy, 11 patients were followed for 6 additional weeks. All showed significant worsening in liver function test results. Symptom scores were unchanged throughout the study. One patient with pruritus improved while receiving therapy with UDCA. No adverse effects were observed. Conclusion: Therapy with UDCA was safe, well-tolerated, and efficacious in the short-term treatment of refractory chronic GVHD of the liver. Further investigation is needed to evaluate the long-term effects of UDCA therapy.	FRED HUTCHINSON CANC RES CTR, GASTROENTEROL HEPATOL SECT SC114, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle					NCI NIH HHS [CA 18029, CA 18221] Funding Source: Medline; NHLBI NIH HHS [HL36444] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA018029, P01CA018221] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036444] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATTA AK, 1989, HEPATOLOGY, V10, P414, DOI 10.1002/hep.1840100404; CALMUS Y, 1990, HEPATOLOGY, V11, P12, DOI 10.1002/hep.1840110104; CHAZOUILLERES O, 1990, J HEPATOL, V11, P120, DOI 10.1016/0168-8278(90)90281-U; COLOMBO C, 1990, J PEDIATR-US, V117, P482, DOI 10.1016/S0022-3476(05)81103-5; DUMONT M, 1980, GASTROENTEROLOGY, V79, P82; EPSTEIN O, 1980, LANCET, V1, P1166; ERLINGER S, 1990, HEPATOLOGY, V11, P888, DOI 10.1002/hep.1840110527; GALLE PR, 1990, HEPATOLOGY, V12, P486, DOI 10.1002/hep.1840120307; GIANNI L, 1980, GASTROENTEROLOGY, V78, P231; HADZIYANNIS SJ, 1989, HEPATOLOGY, V10, P580; HEUMAN DM, 1989, HEPATOLOGY, V10, P728; HEUMAN DM, 1991, GASTROENTEROLOGY, V100, P203, DOI 10.1016/0016-5085(91)90602-H; HOFFMAN AF, 1990, STRATEGIES TREATMENT, P13; Karnofsky D., 1949, CLIN EVALUATION CHEM, P191; KEANE RM, 1984, SURGERY, V95, P439; KNAPP AB, 1987, GASTROENTEROLOGY, V92, P513, DOI 10.1016/0016-5085(87)90150-8; LAKE JR, 1987, AM J PHYSIOL, V252, pG163, DOI 10.1152/ajpgi.1987.252.2.G163; LEHMANN EL, 1975, NONPARAMETRICS STATI, P123; LEUSCHNER U, 1989, GASTROENTEROLOGY, V97, P1268, DOI 10.1016/0016-5085(89)91698-3; MARTEAU P, 1990, HEPATOLOGY, V12, P1206, DOI 10.1002/hep.1840120521; MATSUZAKI Y, 1990, AM J GASTROENTEROL, V85, P15; MIYAZAKI K, 1984, DIGEST DIS SCI, V29, P1123, DOI 10.1007/BF01317087; POUPON RE, 1991, NEW ENGL J MED, V324, P1548, DOI 10.1056/NEJM199105303242204; SCHMUCKER DL, 1990, HEPATOLOGY, V12, P1216, DOI 10.1002/hep.1840120523; SCHOLMERICH J, 1984, HEPATOLOGY, V4, P661, DOI 10.1002/hep.1840040416; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; SHULMAN HM, 1988, HEPATOLOGY, V8, P463, DOI 10.1002/hep.1840080305; SHULMAN HM, 1978, AM J PATHOL, V91, P545; STECHSCHULTE DJ, 1990, GASTROENTEROLOGY, V98, P223, DOI 10.1016/0016-5085(90)91315-W; STIEHL A, 1990, GASTROENTEROLOGY, V98, P424, DOI 10.1016/0016-5085(90)90834-N; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; SULLIVAN KM, 1981, BLOOD, V57, P267, DOI 10.1182/blood.V57.2.267.267; SULLIVAN KM, 1988, BLOOD, V72, P546; SULLIVAN KM, 1988, BLOOD, V72, P555; YAU JC, 1986, TRANSPLANTATION, V41, P129, DOI 10.1097/00007890-198601000-00029	35	84	87	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					624	629		10.7326/0003-4819-116-8-624	http://dx.doi.org/10.7326/0003-4819-116-8-624			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546861				2022-12-28	WOS:A1992HN84400003
J	GILL, TM				GILL, TM			ARE YOU SURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Gill, Thomas/0000-0002-6450-0368					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1750	1750						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545454				2022-12-28	WOS:A1992HK67200009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PARTICIPATES IN CLINICAL LABORATORY IMPROVEMENT REGULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1721	1721						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545450				2022-12-28	WOS:A1992HK67200004
J	WILENSKY, GR; MASON, JO				WILENSKY, GR; MASON, JO			ASSURING THE QUALITY OF LABORATORY TESTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US PHS,WASHINGTON,DC	United States Public Health Service	WILENSKY, GR (corresponding author), US HLTH CARE FINANCING ADM,BALTIMORE,MD 21207, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1722	1722						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545451				2022-12-28	WOS:A1992HK67200006
J	SATOH, MS; LINDAHL, T				SATOH, MS; LINDAHL, T			ROLE OF POLY(ADP-RIBOSE) FORMATION IN DNA-REPAIR	NATURE			English	Article							EXCISION REPAIR; ADP-RIBOSE; POLYMERASE; INVITRO; TRANSCRIPTION; INHIBITORS; MECHANISM; DOMAIN	THE abundant nuclear enzyme poly(ADP-ribose) polymerase catalyses the synthesis of poly(ADP-ribose) from nicotinamide adenine dinucleotide (NAD+) 1-5. This protein has an N-terminal DNA-binding domain containing two zinc-fingers, which is linked to the C-terminal NAD+-binding domain by a short region containing several glutamic acid residues that are sites of auto-poly(ADP-ribosyl)ation 6-8. The intracellular production of poly(ADP-ribose) is induced by agents that generate strand interruptions in DNA 7. The branched homopolymer chains may attain a size of 200-300 residues 9 but are rapidly degraded after synthesis. The function of poly(ADP-ribose) synthesis is not clear, although it seems to be required for DNA repair 10,11. Here we describe a human cell-free system that enables the role of poly(ADP-ribose) synthesis in DNA repair to be characterized. The results indicate that unmodified polymerase molecules bind tightly to DNA strand breaks; auto-poly(ADP-ribosyl)ation of the protein then effects its release and allows access to lesions for DNA repair enzymes.			SATOH, MS (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.							ALTHAUS FR, 1987, ADP RIBOSYLATION PRO, P1; BENHUR E, 1984, RADIAT RES, V97, P546, DOI 10.2307/3576146; CHAMBON P, 1966, BIOCHEM BIOPH RES CO, V25, P638, DOI 10.1016/0006-291X(66)90502-X; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; DESMARAIS Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P179, DOI 10.1016/0167-4838(91)99007-F; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; EKI T, 1991, J BIOL CHEM, V266, P3087; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MIWA M, 1984, METHOD ENZYMOL, V106, P441; NDUKA N, 1980, EUR J BIOCHEM, V105, P525, DOI 10.1111/j.1432-1033.1980.tb04528.x; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; Sugimura T, 1973, Prog Nucleic Acid Res Mol Biol, V13, P127, DOI 10.1016/S0079-6603(08)60102-6; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; WERNER E, 1984, EUR J BIOCHEM, V139, P81, DOI 10.1111/j.1432-1033.1984.tb07979.x; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; YOSHIHARA K, 1981, J BIOL CHEM, V256, P3471; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x; ZAHRADKA P, 1982, EUR J BIOCHEM, V127, P579	25	954	977	3	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					356	358		10.1038/356356a0	http://dx.doi.org/10.1038/356356a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549180				2022-12-28	WOS:A1992HK79400070
J	MARTYS, CR				MARTYS, CR			ASTHMA CARE IN DARLEY-DALE - GENERAL-PRACTITIONER AUDIT	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; PREVALENCE; ENGLAND; WALES	Objective - To complete a first audit cycle of asthma care in Darley Dale after starting an asthma clinic. Design - Pre-clinic (1989) and post-clinic (1990) analysis of medical records of patients with asthma. Setting - A group practice in Derbyshire. Patients - 161 pre-clinic, 238 post-clinic patients with asthma. Main outcome measures - Term "asthma" in the patient's computerised problem list, recording of peak expiratory flow rate, smoking history, clinical review, medication, and hospital admissions for asthma. Results - There were significant improvements post-clinic with respect to the term "asthma" in the computer file (1989, 93/161 (58%); 1990, 233/238 (98%) (difference 0.40; 95% confidence interval 0.32 to 0.48)); at least one peak flow measurement (1989, 24/161 (15%); 1990, 143/238 (60%) (0.45; 0.37 to 0- 53)); three or more peak flow measurements (1989, 15/161 (9%); 1990, 40/238 (17%) (0.08; 0.02 to 0.14)); and smoking history (1989, 24/161 (15%); 1990, 133/238 (56%) (0.41; 0.33 to 0.49)). There were no significant differences post-clinic with respect to asthma reviewed at least once (1989, 61/161 (38%); 1990, 74/238 (31%) (0.07; -0.03 to 0.17)); recording long term medication; treating acute asthma; or ratio of average to best peak flow rate of 38 patients who had one or more measurements (1989, 31/38 (82%); 1990, 34/38 (89%) (0.08; -0.08 to 0.24)). Conclusions - Setting up an asthma clinic resulted in better recording of data relevant to patients with asthma. However, objective improvement in patients' asthma could not be detected. Renewed emphasis on prophylactic measures may result in measurable improvement in these patients' asthma in the future.			MARTYS, CR (corresponding author), TWO DALES MED CTR,DARLEY DALE,MATLOCK DE4 2SA,DERBY,ENGLAND.							[Anonymous], 1990, BMJ, V301, P651; BELL D, 1991, BRIT MED J, V302, P1440, DOI 10.1136/bmj.302.6790.1440; BURNEY PGJ, 1986, LANCET, V2, P323; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P227; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; DENBAK JH, 1986, BRIT MED J, V292, P175, DOI 10.1136/bmj.292.6514.175; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; GELLERT AR, 1990, BRIT J GEN PRACT, V40, P197; JONES K, 1991, BRIT J GEN PRACT, V41, P224; TURNERWARWICK M, 1989, J ROY COLL GEN PRACT, V39, P239; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; 1990, BMJ, V301, P797	12	18	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					758	760		10.1136/bmj.304.6829.758	http://dx.doi.org/10.1136/bmj.304.6829.758			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1530691	Green Published, Bronze			2022-12-28	WOS:A1992HK80000024
J	KALASKA, JF; CRAMMOND, DJ				KALASKA, JF; CRAMMOND, DJ			CEREBRAL CORTICAL MECHANISMS OF REACHING MOVEMENTS	SCIENCE			English	Article							PRIMATE MOTOR CORTEX; NEURAL-NETWORK MODEL; FREE ARM MOVEMENTS; NEURONAL POPULATION VECTOR; POSTERIOR PARIETAL NEURONS; INSTRUCTED-DELAY PERIOD; VISUALLY GUIDED ARM; TRAJECTORY FORMATION; 3-DIMENSIONAL SPACE; PREMOTOR CORTEX	Because reaching movements have a clear objective-to bring the hand to the spatial location of an object-they are well suited to study how the central nervous system plans a purposeful act from sensory input to motor output. Most models of movement planning propose a serial hierarchy of analytic steps. However, the central nervous system is organized into densely interconnected populations of neurons. This paradox between the apparent serial order of central nervous system function and its complex internal organization is strikingly demonstrated by recent behavioral, modeling, and neurophysiological studies of reaching movements.			KALASKA, JF (corresponding author), UNIV MONTREAL, FAC MED, DEPT PHYSIOL, CP 6128, SUCCURSALE A, MONTREAL H3C 3J7, QUEBEC, CANADA.							ABEND W, 1982, BRAIN, V105, P331, DOI 10.1093/brain/105.2.331; ADAMS JA, 1971, J MOTOR BEHAV, V3, P111; ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P133, DOI 10.1152/jn.1990.64.1.133; ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P164, DOI 10.1152/jn.1990.64.1.164; ALEXANDER GE, IN PRESS BEHAV BRAIN; ALSTERMARK B, 1990, EXP BRAIN RES, V80, P96, DOI 10.1007/BF00228851; ANASTASIO TJ, 1990, BIOL CYBERN, V63, P161, DOI 10.1007/BF00195854; ANASTASIO TJ, 1991, BIOL CYBERN, V64, P187, DOI 10.1007/BF00201979; ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; [Anonymous], 1971, OXFORD ENGLISH DICT; Arbib M. A., 2011, HDB PHYSL NERVOUS SY, P1449, DOI [DOI 10.1016/J.JPHYSPARIS.2008.03.001, 10.1002/cphy.cp010233]; ARBIB MA, 1990, ATTENTION PERFORM, P111; ARNOLD DB, 1991, BIOL CYBERN, V64, P447, DOI 10.1007/BF00202608; BAUSWEIN E, 1989, BRAIN RES, V493, P198, DOI 10.1016/0006-8993(89)91018-4; Bernstein N, 1967, COORDINATION REGULAT; BIZZI E, 1991, SCIENCE, V253, P287, DOI 10.1126/science.1857964; BRUWER M, 1990, BIOL CYBERN, V62, P549, DOI 10.1007/BF00205117; BULLOCK D, 1988, PSYCHOL REV, V95, P49, DOI 10.1037/0033-295X.95.1.49; BULLOCK D, 1991, HUM MOVEMENT SCI, V10, P3, DOI 10.1016/0167-9457(91)90029-W; BURBAUD P, 1991, J NEUROPHYSIOL, V66, P429, DOI 10.1152/jn.1991.66.2.429; BURNOD Y, IN PRESS NEUROSCI; BUYS EJ, 1986, J PHYSIOL-LONDON, V381, P529, DOI 10.1113/jphysiol.1986.sp016342; CAMINITI R, 1990, J NEUROSCI, V10, P2039; CAMINITI R, 1991, J NEUROSCI, V11, P1182; Caminiti R., 1985, EXP BRAIN RES S, P175; CHENEY PD, 1985, J NEUROPHYSIOL, V53, P805, DOI 10.1152/jn.1985.53.3.805; CRAMMOND D J, 1989, Society for Neuroscience Abstracts, V15, P786; CRAMMOND D J, 1991, Society for Neuroscience Abstracts, V17, P308; CRAMMOND DJ, 1989, EXP BRAIN RES, V76, P458; CRAMMOND DJ, UNPUB; CRUTCHER MD, 1990, J NEUROPHYSIOL, V64, P151, DOI 10.1152/jn.1990.64.1.151; DIPELLEGRINO G, 1991, BRAIN, V114, P951; DONOGHUE JP, 1990, EXP BRAIN RES, V79, P492; DUM RP, 1991, J NEUROSCI, V11, P667; DUM RP, 1991, LIFE SCI R, V50, P383; FAVILLA M, 1989, EXP BRAIN RES, V75, P280; FELDMAN AG, 1966, BIOPHYS-USSR, V11, P565; FELDMAN AG, 1990, MULTIPLE MUSCLE SYST, P195, DOI DOI 10.1007/978-1-4613-9030-5_12; FETZ EE, 1980, J NEUROPHYSIOL, V44, P751, DOI 10.1152/jn.1980.44.4.751; FLANDERS M, 1990, J NEUROSCI, V10, P2420; FLANDERS M, 1991, J NEUROSCI, V11, P2680; Flash T., 1990, MULTIPLE MUSCLE SYST, P282; FREUND HJ, 1991, MOTOR CONTROL CONCEP, P349; FROMM C, 1983, ADV NEUROL, V739, P329; FUSTER JM, 1981, HDB PHYSL NERVOUS SY, V2, P1149; GAUDIANO P, 1991, NEURAL NETWORKS, V4, P147, DOI 10.1016/0893-6080(91)90002-M; GENTILUCCI M, 1988, EXP BRAIN RES, V71, P475, DOI 10.1007/BF00248741; GEORGOPOULOS AP, 1984, EXP BRAIN RES, V54, P446; GEORGOPOULOS AP, 1988, FASEB J, V2, P2849, DOI 10.1096/fasebj.2.13.3139485; GEORGOPOULOS AP, 1989, EXP BRAIN RES, V75, P183; GEORGOPOULOS AP, 1989, SCIENCE, V245, P1209, DOI 10.1126/science.2675307; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; GODSCHALK M, 1981, EXP BRAIN RES, V44, P113; HALSBAND U, 1990, BRAIN, V113, P207, DOI 10.1093/brain/113.1.207; HASAN Z, 1991, LIFE SCI R, V50, P75; HEIN A, 1974, BRAIN RES, V71, P259, DOI 10.1016/0006-8993(74)90969-X; HELD R, 1974, BRAIN RES, V71, P265, DOI 10.1016/0006-8993(74)90970-6; HEUER H, 1985, MOTOR BEHAVIOR PROGR; HILDRETH EC, 1987, HDB PHYSL NERVOUS SY, V5, P605; HOCHERMAN S, 1991, EXP BRAIN RES, V83, P285; HOGAN N, 1985, BIOL CYBERN, V52, P315, DOI 10.1007/BF00355754; Hogan N., 1990, MULTIPLE MUSCLE SYST, P149, DOI [10.1007/978-1-4613-9030-5_9, DOI 10.1007/978-1-4613-9030-5_9]; HOPFIELD JJ, 1984, P NATL ACAD SCI-BIOL, V81, P3088, DOI 10.1073/pnas.81.10.3088; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; HUMPHREY DR, 1986, FED PROC, V45, P2687; HUMPHREY DR, 1991, LIFE SCI R, V50, P413; HUNTLEY GW, 1991, J NEUROPHYSIOL, V66, P390, DOI 10.1152/jn.1991.66.2.390; Iberall T., 1990, VISION ACTION CONTRO, P204; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; JEANNEROD M, 1991, BRAIN SPACE, P49; JORDAN MI, 1990, ATTENTION PERFORM, P796; Kalaska J, 1991, SEMIN NEUROSCI, V3, P67; KALASKA J F, 1990, Society for Neuroscience Abstracts, V16, P423; KALASKA JF, 1991, LIFE SCI R, V50, P307; KALASKA JF, 1990, EXP BRAIN RES, V80, P351; KALASKA JF, 1989, J NEUROSCI, V9, P2080; KALASKA JF, 1983, EXP BRAIN RES, V51, P247; KALASKA JF, 1991, BRAIN SPACE, P133; KARST GM, 1991, J NEUROPHYSIOL, V66, P1579, DOI 10.1152/jn.1991.66.5.1579; KAWATO M, 1987, BIOL CYBERN, V57, P169, DOI 10.1007/BF00364149; KAWATO M, 1990, BIOL CYBERN, V62, P275, DOI 10.1007/BF00201442; KAWATO M, 1988, BIOL CYBERN, V59, P161, DOI 10.1007/BF00318008; Keele S. W., 1981, HDB PHYSL 1, P1391, DOI DOI 10.1002/CPHY.CP010231; KELLER A, 1990, J COMP NEUROL, V300, P47, DOI 10.1002/cne.903000105; KETTNER RE, 1988, J NEUROSCI, V8, P2938; KLAPP ST, 1977, J MOTOR BEHAV, V9, P301; KNUDSEN EI, 1987, ANNU REV NEUROSCI, V10, P41, DOI 10.1146/annurev.ne.10.030187.000353; Kuperstein M, 1990, IEEE Trans Neural Netw, V1, P137, DOI 10.1109/72.80213; KUPERSTEIN M, 1988, SCIENCE, V239, P1308, DOI 10.1126/science.3344437; KURATA K, 1988, EXP BRAIN RES, V72, P237; KWAN HC, 1990, CAN J PHYSIOL PHARM, V68, P126, DOI 10.1139/y90-019; KWAN HC, 1978, J NEUROPHYSIOL, V41, P1120, DOI 10.1152/jn.1978.41.5.1120; KWAN HC, 1987, BRAIN RES, V400, P259, DOI 10.1016/0006-8993(87)90625-1; LACQUANITI F, 1989, TRENDS NEUROSCI, V12, P287, DOI 10.1016/0166-2236(89)90008-8; LEMON R, 1988, TRENDS NEUROSCI, V11, P501, DOI 10.1016/0166-2236(88)90012-4; LOEB GE, 1983, TRENDS NEUROSCI, V6, P203, DOI 10.1016/0166-2236(83)90093-0; LOEB GE, 1990, COLD SH Q B, V55, P791; LUKASHIN AV, 1990, BIOL CYBERN, V63, P377, DOI 10.1007/BF00202754; LUPPINO G, 1991, J COMP NEUROL, V311, P463, DOI 10.1002/cne.903110403; Martinetz T M, 1990, IEEE Trans Neural Netw, V1, P131, DOI 10.1109/72.80212; MASSONE L, 1989, BIOL CYBERN, V61, P417, DOI 10.1007/BF02414903; Mel B. W., 1990, CONNECTIONIST ROBOT; MITZ AR, 1991, J NEUROSCI, V11, P1855; MORASSO P, 1981, EXP BRAIN RES, V42, P223; MORASSO P, 1986, NEUROSCIENCE, V17, P312; Mountcastle V.B., 1978, MINDFUL BRAIN CORTIC, P7; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; MUIR RB, 1983, BRAIN RES, V261, P312, DOI 10.1016/0006-8993(83)90635-2; NELSON ME, 1990, TRENDS NEUROSCI, V13, P403, DOI 10.1016/0166-2236(90)90119-U; NUDO RJ, 1990, SOMATOSENS MOT RES, V7, P463, DOI 10.3109/08990229009144720; OKANO K, 1987, EXP BRAIN RES, V66, P155; PARTRIDGE LD, 1982, BEHAV BRAIN SCI, V5, P561, DOI 10.1017/S0140525X0001356X; PELLIONISZ A, 1988, PROG BRAIN RES, V76, P341; POIZNER H, 1990, BRAIN, V113, P85, DOI 10.1093/brain/113.1.85; Poulton E.C., 1981, HDB PHYSL SECTION 1, V2, P1337; RIEHLE A, 1991, BRAIN RES, V540, P131, DOI 10.1016/0006-8993(91)90499-L; RIEHLE A, 1989, J NEUROPHYSIOL, V61, P534, DOI 10.1152/jn.1989.61.3.534; RIZZOLATTI G, 1988, EXP BRAIN RES, V71, P491, DOI 10.1007/BF00248742; ROBINSON DA, IN PRESS CAN J PHYSL; ROSENBAUM DA, 1980, J EXP PSYCHOL GEN, V109, P444, DOI 10.1037/0096-3445.109.4.444; Rumelhart D., 1986, PARALLEL DISTRIBUTED; SALTZMAN E, 1979, J MATH PSYCHOL, V20, P91, DOI 10.1016/0022-2496(79)90020-8; SATO KC, 1989, J NEUROPHYSIOL, V62, P959, DOI 10.1152/jn.1989.62.4.959; SCHIEBER MH, 1990, TRENDS NEUROSCI, V13, P440, DOI 10.1016/0166-2236(90)90093-P; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; SHIMA K, 1991, J NEUROPHYSIOL, V65, P188, DOI 10.1152/jn.1991.65.2.188; SHINODA Y, 1981, NEUROSCI LETT, V23, P7, DOI 10.1016/0304-3940(81)90182-8; Soechting J F, 1991, Exerc Sport Sci Rev, V19, P389; SOECHTING JF, 1981, J NEUROSCI, V1, P710, DOI 10.1523/JNEUROSCI.01-07-00710.1981; SOECHTING JF, 1989, J NEUROPHYSIOL, V62, P582, DOI 10.1152/jn.1989.62.2.582; SOECHTING JF, 1989, J NEUROPHYSIOL, V62, P595, DOI 10.1152/jn.1989.62.2.595; STEIN JF, 1989, Q J EXP PHYSIOL CMS, V74, P583, DOI 10.1113/expphysiol.1989.sp003314; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; VONHOFSTEN C, 1990, ATTENTION PERFORM, P739; WEINRICH M, 1982, J NEUROSCI, V2, P1329; WERNER W, 1991, EXP BRAIN RES, V86, P293; Wiesendanger M, 1981, HDB PHYSL 1, P1121; WISE SP, 1985, ANNU REV NEUROSCI, V8, P1, DOI 10.1146/annurev.ne.08.030185.000245; WISE SP, 1988, SCIENCE, V242, P736, DOI 10.1126/science.3187520; WISE SP, 1991, MOTOR CONTROL CONCEP, P463; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0; [No title captured]; [No title captured]	145	304	304	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1992	255	5051					1517	1523		10.1126/science.1549781	http://dx.doi.org/10.1126/science.1549781			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1549781				2022-12-28	WOS:A1992HJ80900028
J	FURIE, B; FURIE, BC				FURIE, B; FURIE, BC			MOLECULAR AND CELLULAR BIOLOGY OF BLOOD-COAGULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ORAL ANTICOAGULANT-THERAPY; HUMAN FACTOR-VIII; GAMMA-CARBOXYGLUTAMIC ACID; NATIVE PROTHROMBIN ANTIGEN; HUMAN-TISSUE FACTOR; VITAMIN-K; PROTEIN-C; FACTOR-IX; ANTIHEMOPHILIC-FACTOR; HEMOPHILIA-A		TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA	Tufts University; Tufts University	FURIE, B (corresponding author), NEW ENGLAND MED CTR HOSP, DIV HEMATOL ONCOL, CTR HEMOSTASIS & THROMBOSIS RES, 750 WASHINGTON ST, BOSTON, MA 02111 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443, R37HL038216, R37HL018834] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL18834, P01 HL42443, R37 HL38216] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1981, J BIOL CHEM, V256, P8324; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BLANCHARD RA, 1981, NEW ENGL J MED, V305, P242, DOI 10.1056/NEJM198107303050502; BROZE GJ, 1988, BLOOD, V71, P335; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; COMP PC, 1984, NEW ENGL J MED, V311, P1525, DOI 10.1056/NEJM198412133112401; CONWAY EM, 1987, J CLIN INVEST, V80, P1535, DOI 10.1172/JCI113239; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DAVIE EW, 1964, SCIENCE, V145, P1310, DOI 10.1126/science.145.3638.1310; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; EGEBERG O, 1965, THROMB DIATH HAEMOST, V13, P516, DOI 10.1055/s-0038-1656297; ESMON CT, 1975, J BIOL CHEM, V250, P4095; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; FULCHER CA, 1984, BLOOD, V63, P486; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1990, SEMIN HEMATOL, V27, P270; FURIE B, 1982, J BIOL CHEM, V257, P3875; FURIE B, 1984, BLOOD, V64, P445; FURIE B, 1990, BLOOD, V75, P344; GIANNELLI F, 1991, NUCLEIC ACIDS RES, V19, P2193, DOI 10.1093/nar/19.suppl.2193; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; GITSCHIER J, 1985, NATURE, V315, P427, DOI 10.1038/315427a0; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GUHA A, 1986, P NATL ACAD SCI USA, V83, P299, DOI 10.1073/pnas.83.2.299; HATHAWAY WE, 1965, BLOOD-J HEMATOL, V26, P521, DOI 10.1182/blood.V26.5.521.521; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; JONES ME, 1985, BIOCHEMISTRY-US, V24, P8064, DOI 10.1021/bi00348a034; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; MACFARLANE RG, 1964, NATURE, V202, P498, DOI 10.1038/202498a0; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MARCUM JA, 1984, BIOCHEMISTRY-US, V23, P1730, DOI 10.1021/bi00303a023; MCMILLAN CW, 1966, NEW ENGL J MED, V274, P1313, DOI 10.1056/NEJM196606092742309; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; NAITO K, 1991, J BIOL CHEM, V266, P7353; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; OREILLY RA, 1976, MEDICINE, V55, P389, DOI 10.1097/00005792-197609000-00003; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; RADCLIFFE R, 1976, J BIOL CHEM, V251, P4797; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1987, BLOOD, V69, P645; RATNOFF OD, 1955, J CLIN INVEST, V34, P602, DOI 10.1172/JCI103109; SCHWARTZ RS, 1990, NEW ENGL J MED, V323, P1800, DOI 10.1056/NEJM199012273232604; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WEITZEL JN, 1990, BLOOD, V76, P2555; WHITE GC, 1989, NEW ENGL J MED, V320, P166, DOI 10.1056/NEJM198901193200307; WHITE GC, 1989, BLOOD, V73, P1; ZUR M, 1982, J BIOL CHEM, V257, P5623	59	398	411	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1992	326	12					800	806						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ592	1538724				2022-12-28	WOS:A1992HJ59200005
J	HUBBARD, RC; MCELVANEY, NG; BIRRER, P; SHAK, S; ROBINSON, WW; JOLLEY, C; WU, M; CHERNICK, MS; CRYSTAL, RG				HUBBARD, RC; MCELVANEY, NG; BIRRER, P; SHAK, S; ROBINSON, WW; JOLLEY, C; WU, M; CHERNICK, MS; CRYSTAL, RG			A PRELIMINARY-STUDY OF AEROSOLIZED RECOMBINANT HUMAN DEOXYRIBONUCLEASE-I IN THE TREATMENT OF CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							SPUTUM; IDENTIFICATION; VISCOSITY; GENE		NHLBI, PULM BRANCH, BLDG 10, RM 6D03, BETHESDA, MD 20892 USA; GENENTECH INC, DEPT IMMUNOBIOL, S SAN FRANCISCO, CA USA; NIDDKD, PEDIAT METAB BRANCH, BETHESDA, MD USA; NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, BIOSTAT RES BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Roche Holding; Genentech; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			McElvaney, Noel/A-6809-2010	mcelvaney, Noel/0000-0002-0152-4370				Boat T.J., 1989, METABOLIC BASIS INHE, P2649; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; FULMER JD, 1979, J CLIN INVEST, V63, P665, DOI 10.1172/JCI109349; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KURNICK NB, 1950, ARCH BIOCHEM, V29, P41; LETHEM MI, 1990, EUR RESPIR J, V3, P19; MACLEAN GL, 1985, S AFR J WILDL RES, V15, P1; MATTHEWS LW, 1963, AM REV RESPIR DIS, V88, P199; NICKERSON BG, 1980, AM REV RESPIR DIS, V122, P859; PICOT R, 1978, THORAX, V33, P235, DOI 10.1136/thx.33.2.235; REGELMANN WE, 1990, AM REV RESPIR DIS, V141, P914, DOI 10.1164/ajrccm/141.4_Pt_1.914; RIORDAN JR, 1989, SCIENCE, V245, P1437; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; SMITH AL, 1988, J PEDIATR-US, V112, P547, DOI 10.1016/S0022-3476(88)80165-3; TAUSSIG LM, 1984, CYSTIC FIBROSIS, P115; WELSH MJ, 1987, J CLIN INVEST, V80, P1523, DOI 10.1172/JCI113237	17	176	188	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1992	326	12					812	815		10.1056/NEJM199203193261207	http://dx.doi.org/10.1056/NEJM199203193261207			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ592	1538726				2022-12-28	WOS:A1992HJ59200007
J	SMEETS, DFCM; HAMEL, BCJ; NELEN, MR; SMEETS, HJM; BOLLEN, JHM; SMITS, APT; ROPERS, HH; VANOOST, BA				SMEETS, DFCM; HAMEL, BCJ; NELEN, MR; SMEETS, HJM; BOLLEN, JHM; SMITS, APT; ROPERS, HH; VANOOST, BA			PRADER-WILLI SYNDROME AND ANGELMAN SYNDROME IN COUSINS FROM A FAMILY WITH A TRANSLOCATION BETWEEN CHROMOSOME-6 AND CHROMOSOME-15	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							PARENTAL ORIGIN; 15Q DELETIONS; DIAGNOSIS; DNA; ABNORMALITIES; INVERSIONS; 15Q11-13; PROBES; RISK		HOSP BETHESDA,HOOGEVEEN,NETHERLANDS		SMEETS, DFCM (corresponding author), UNIV HOSP NIJMEGEN,DEPT HUMAN GENET,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		Nelen, Marcel R./L-4542-2015; Smeets, D.F.C.M./L-4653-2015					ANGELMAN H, 1965, DEV MED CHILD NEUROL, V7, P681; BUTLER MG, 1986, AM J MED GENET, V23, P793, DOI 10.1002/ajmg.1320230307; BUTLER MG, 1990, AM J MED GENET, V35, P319, DOI 10.1002/ajmg.1320350306; Cassidy S B, 1984, Curr Probl Pediatr, V14, P1; DANIEL A, 1986, PRENATAL DIAG, V6, P315, DOI 10.1002/pd.1970060502; DONLON TA, 1988, HUM GENET, V80, P322, DOI 10.1007/BF00273644; DUNN HG, 1981, PRADER WILLI SYNDROM, P69; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRYBURG JS, 1991, AM J MED GENET, V38, P58, DOI 10.1002/ajmg.1320380114; GREENBERG F, 1987, AM J MED GENET, V28, P845, DOI 10.1002/ajmg.1320280409; GREENSWAG LR, 1987, DEV MED CHILD NEUROL, V29, P145; GREGORY CA, 1990, AM J MED GENET, V35, P536, DOI 10.1002/ajmg.1320350420; HALL JG, 1990, AM J HUM GENET, V46, P857; Hall JG, 1991, CURR OPIN GENET DEV, V1, P34, DOI 10.1016/0959-437X(91)80038-N; HULTEN M, 1991, LANCET, V338, P638, DOI 10.1016/0140-6736(91)90652-6; IMAIZUMI K, 1990, AM J MED GENET, V35, P314, DOI 10.1002/ajmg.1320350305; KAISER P, 1984, HUM GENET, V68, P1, DOI 10.1007/BF00293869; KNOLL JHM, 1991, AM J HUM GENET, V48, P16; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; LEDBETTER DH, 1982, AM J HUM GENET, V34, P278; LEDBETTER DH, 1981, NEW ENGL J MED, V304, P325, DOI 10.1056/NEJM198102053040604; MADAN K, 1984, J MED GENET, V21, P407, DOI 10.1136/jmg.21.6.407; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NICHOLLS RD, 1989, AM J MED GENET, V33, P66, DOI 10.1002/ajmg.1320330109; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; PEMBREY M, 1989, J MED GENET, V26, P73, DOI 10.1136/jmg.26.2.73; Prader A., 1956, SCHWEIZ MED WSCHR, V86, P1260, DOI DOI 10.1007/978-3-642-47669-3_24; RIVERA H, 1990, AM J MED GENET, V37, P311, DOI 10.1002/ajmg.1320370304; Sambrook J, 1989, MOL CLONING LABORATO; SCHERES JMJC, 1982, HUM GENET, V61, P8, DOI 10.1007/BF00291322; SCHINZEL AA, 1991, AM J HUM GENET, V48, P424; STENGELRUTKOWSK.S, 1988, MONOGRAPHIE ANN GENE; TANTRAVAHI U, 1989, AM J MED GENET, V33, P78, DOI 10.1002/ajmg.1320330110; WANG JCC, 1991, AM J HUM GENET, V48, P1069; WILLEMS PJ, 1987, AM J MED GENET, V27, P773, DOI 10.1002/ajmg.1320270405; WILLIAMS CA, 1982, AM J MED GENET, V11, P453, DOI 10.1002/ajmg.1320110411; WILLIAMS CA, 1990, AM J MED GENET, V35, P350, DOI 10.1002/ajmg.1320350308; WILLIAMS CA, 1989, AM J MED GENET, V32, P339, DOI 10.1002/ajmg.1320320313; 1991, LANCET, V338, P413	41	105	106	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1992	326	12					807	811		10.1056/NEJM199203193261206	http://dx.doi.org/10.1056/NEJM199203193261206			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ592	1538725				2022-12-28	WOS:A1992HJ59200006
J	COMAI, L; TANESE, N; TJIAN, R				COMAI, L; TANESE, N; TJIAN, R			THE TATA-BINDING PROTEIN AND ASSOCIATED FACTORS ARE INTEGRAL COMPONENTS OF THE RNA POLYMERASE-I TRANSCRIPTION FACTOR, SL1	CELL			English	Article							INITIATION FACTOR-IIB; RIBOSOMAL-RNA; PROMOTER INTERACTIONS; FUNCTIONAL-ANALYSIS; PURIFICATION; ACTIVATION; UPSTREAM; SPECIFICITY; MECHANISMS; COMPLEXES	We have previously shown that the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs) are required for regulated transcriptional initiation by RNA polymerase II. Here we report the biochemical properties of the RNA polymerase I promoter selectivity factor, SL1, and its relationship to TBP. Column chromatography and glycerol gradient sedimentation indicate that a subpopulation of TBP copurifies with SL1 activity. Antibodies directed against TBP efficiently deplete SL1 transcriptional activity, which can be restored with the SL1 fraction but not purified TBP. Thus, TBP is necessary but not sufficient to complement SL1 activity. Analysis of purified SL1 reveals a complex containing TBP and three distinct TAFs. Purified TAFs reconstituted with recombinant TBP complement SL1 activity, and this demonstrates that TBP plus novel associated factors are integral components of SL1. These findings suggest that TBP may be a universal transcription factor and that the TBP-TAF arrangement provides a unifying mechanism for promoter recognition in animal cells.			COMAI, L (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.		Comai, Lucio/H-9524-2019; Comai, Lucio/L-5905-2019	Comai, Lucio/0000-0003-3109-1841				BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; HALTINER MM, 1986, MOL CELL BIOL, V6, P227, DOI 10.1128/MCB.6.1.227; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOSICK R, 1976, RNA POLYMERASE, P227; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PIKAARD CS, 1989, GENE DEV, V3, P1779, DOI 10.1101/gad.3.11.1779; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REEDER RH, 1990, TRENDS GENET, V6, P390, DOI 10.1016/0168-9525(90)90298-K; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WHITE RJ, 1992, IN PRESS P NATL ACAD; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313	37	378	384	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					965	976		10.1016/0092-8674(92)90039-F	http://dx.doi.org/10.1016/0092-8674(92)90039-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547496				2022-12-28	WOS:A1992HH74800015
J	PINTO, I; WARE, DE; HAMPSEY, M				PINTO, I; WARE, DE; HAMPSEY, M			THE YEAST SUA7 GENE ENCODES A HOMOLOG OF HUMAN TRANSCRIPTION FACTOR TFIIB AND IS REQUIRED FOR NORMAL START SITE SELECTION INVIVO	CELL			English	Article							RNA POLYMERASE-II; TATA BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; INITIATION-FACTOR; MESSENGER-RNA; REGULATORY PROTEINS; FUNCTIONAL-ANALYSIS; DNA-SEQUENCE; PROMOTER; TRANSFORMATION	Mutations in the Saccharomyces cerevisiae SUA7 gene were isolated as suppressors of an aberrant ATG translation initiation codon in the leader region of the cyc1 gene. Molecular and genetic analysis of the cloned SUA7 gene demonstrated that SUA7 is a single copy, essential gene encoding a basic protein (calculated M(r) of 38,142) that is homologous to human transcription factor TFIIB. Analysis of cyc1 transcripts from sua7 strains revealed that suppression is a consequence of diminished transcription initiation at the normal start sites in favor of initiation at downstream sites, including a major site between the aberrant and normal ATG start codons. A similar effect was found at the ADH1 locus, establishing that this effect is not cyc1 gene-specific. Thus, SUA7 encodes a yeast TFIIB homolog and functions in transcription start site selection.			PINTO, I (corresponding author), LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, SHREVEPORT, LA 71130 USA.				NIGMS NIH HHS [GM39484] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039484, R01GM039484] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERROTERAN RW, 1991, ARCH BIOCHEM BIOPHYS, V288, P261, DOI 10.1016/0003-9861(91)90193-M; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CHEN W, 1985, EMBO J, V4, P3273, DOI 10.1002/j.1460-2075.1985.tb04077.x; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FURTERGRAVES EM, 1990, MOL GEN GENET, V223, P407, DOI 10.1007/BF00264447; FURTERGRAVES EM, 1991, MOL CELL BIOL, V11, P4121, DOI 10.1128/MCB.11.8.4121; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HAMPSEY M, 1991, GENETICS, V128, P59; HAMPSEY M, 1991, IN PRESS BIOCHIMIE; HAWLEY D, 1991, TRENDS BIOCHEM SCI, V16, P317, DOI 10.1016/0968-0004(91)90130-N; HEALY AM, 1987, MOL CELL BIOL, V7, P3785, DOI 10.1128/MCB.7.10.3785; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAEHNING JA, 1991, SCIENCE, V253, P859, DOI 10.1126/science.1876846; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALONE EA, 1991, MOL CELL BIOL, V11, P5710, DOI 10.1128/MCB.11.11.5710; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; Maniatis T., 1982, MOL CLONING; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCNEIL JB, 1986, J MOL BIOL, V187, P363, DOI 10.1016/0022-2836(86)90439-0; MCNEIL JB, 1985, MOL CELL BIOL, V5, P3545, DOI 10.1128/MCB.5.12.3545; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORTIMER RK, 1991, METHOD ENZYMOL, V194, P827; NAGAWA F, 1985, P NATL ACAD SCI USA, V82, P8557, DOI 10.1073/pnas.82.24.8557; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PERKINS DD, 1949, GENETICS, V34, P607; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PRENDERGAST JA, 1990, GENETICS, V124, P81; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROWLEY A, 1991, MOL CELL BIOL, V11, P5718, DOI 10.1128/MCB.11.11.5718; RUDOLPH H, 1987, P NATL ACAD SCI USA, V84, P1340, DOI 10.1073/pnas.84.5.1340; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SHERMAN F, 1991, METHOD ENZYMOL, V94, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH A, 1978, GENETICS, V89, P653; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STILES JI, 1981, CELL, V25, P277, DOI 10.1016/0092-8674(81)90253-1; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; SWANSON MS, 1990, MOL CELL BIOL, V10, P4935, DOI 10.1128/MCB.10.9.4935; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; ZHENG XM, 1990, NATURE, V344, P556, DOI 10.1038/344556a0; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	80	183	187	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					977	988		10.1016/0092-8674(92)90040-J	http://dx.doi.org/10.1016/0092-8674(92)90040-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547497				2022-12-28	WOS:A1992HH74800016
J	VINCENT, JP; OFARRELL, PH				VINCENT, JP; OFARRELL, PH			THE STATE OF ENGRAILED EXPRESSION IS NOT CLONALLY TRANSMITTED DURING EARLY DROSOPHILA DEVELOPMENT	CELL			English	Article							SEGMENT POLARITY GENES; PAIR-RULE GENES; FUSHI-TARAZU; CELL LINEAGE; REGULATORY INTERACTIONS; SPATIAL-DISTRIBUTION; WINGLESS GENE; MELANOGASTER; EMBRYOS; DISK	In Drosophila embryos, boundaries of lineage restriction separate groups of cells, or compartments. engrailed is essential for specification of the posterior compartment of each segment, and its expression is thought to mark this compartment. Using a new photo-activatable lineage tracer, we followed the progeny of single embryonic cells marked at the blastoderm stage. No clones straddled the anterior edges of engrailed stripes (the parasegment border). However, posterior cells of each stripe lose engrailed expression, producing mixed clones. We suggest that stable expression of engrailed by cells at the anterior edge of the stripe reflects, not cell-intrinsic mechanisms, but proximity to cells that produce Wingless, an extracellular signal needed for maintenance of engrailed expression. If control of posterior cell fate parallels control of engrailed expression, cell fate is initially responsive to cell environment and cell fate determination is a later event.			VINCENT, JP (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA.			O'Farrell, Patrick/0000-0003-0011-2734	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM037193-10, R01 GM037193] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1985, NATURE, V313, P639; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BROWER DL, 1984, NATURE, V310, P496, DOI 10.1038/310496a0; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; CARROLL SB, 1988, GENE DEV, V2, P350, DOI 10.1101/gad.2.3.350; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DiNardo S, 1990, Semin Cell Biol, V1, P173; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HARDING K, 1986, SCIENCE, V233, P953, DOI 10.1126/science.3755551; HARTENSTEIN V, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P213, DOI 10.1007/BF00848248; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; KORNBERG T, 1981, DEV BIOL, V86, P363, DOI 10.1016/0012-1606(81)90194-9; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1988, DEVELOPMENT, V104, P61; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; Lawrence PA, 1976, INSECT DEV, P132; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; PATEL NH, 1989, DEVELOPMENT, V107, P201; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SLACK JWM, 1983, DEV CELL BIOL SERIES; SZABAD J, 1979, DEV BIOL, V73, P256, DOI 10.1016/0012-1606(79)90066-6; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WEISBLAT DA, 1978, SCIENCE, V202, P1295, DOI 10.1126/science.725606; WIESCHAUS E, 1976, DEV BIOL, V50, P249, DOI 10.1016/0012-1606(76)90150-0	42	147	150	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					923	931		10.1016/0092-8674(92)90035-B	http://dx.doi.org/10.1016/0092-8674(92)90035-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547492	Green Accepted			2022-12-28	WOS:A1992HH74800011
J	VELLA, S; GIULIANO, M; PEZZOTTI, P; AGRESTI, MG; TOMINO, C; FLORIDIA, M; GRECO, D; MORONI, M; VISCO, G; MILAZZO, F; GIANNELLI, F; ANGARANO, G; ORTONA, L; ZANUSSI, C				VELLA, S; GIULIANO, M; PEZZOTTI, P; AGRESTI, MG; TOMINO, C; FLORIDIA, M; GRECO, D; MORONI, M; VISCO, G; MILAZZO, F; GIANNELLI, F; ANGARANO, G; ORTONA, L; ZANUSSI, C			SURVIVAL OF ZIDOVUDINE-TREATED PATIENTS WITH AIDS COMPARED WITH THAT OF CONTEMPORARY UNTREATED PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SAN-FRANCISCO; EXPERIENCE; COMPLEX; FOLLOW; TRENDS	Objective.-To assess the long-term effectiveness of zidovudine (AZT) in patients with acquired immunodeficiency syndrome (AIDS). This assessment has never been adequately done because controlled clinical trials were stopped early and survival comparisons were made with historical controls. Design.-Nonrandomized contemporary observational study of patients treated and not treated with zidovudine. Setting.-Twenty-three AIDS treatment centers throughout Italy that reported cases to the National Registry of AIDS Cases between July 1987 and March 1988. Patients.-One hundred fifty-nine zidovudine-treated and 112 untreated patients with AIDS, the majority of whom had acquired human immunodeficiency virus (HIV) infection through intravenous drug use. Outcome Measures.-Median survival and 1- and 2-year survival for treated and untreated groups, as estimated using the Kaplan-Meier method. Cox proportional hazards regression analysis was also used to identify independent predictors of survival among the variables studied. Results.-Patients were similar with respect to CD4/CD8 ratio, age, sex, clinical and immunological status at diagnosis, and source of HIV infection. After 24 months, survival was 45.9% (95% confidence interval [CI], 36.1% to 55.7%) in the treated group and 20.5% (95% CI, 12.6% to 28.3%) in the untreated group, with median survival of 21.2 and 9.6 months, respectively. Conclusions.-Possible biases of this study include imperfect matching for clinical status and better overall medical care of treated patients. Nevertheless, we believe that the observed differences in survival were primarily due to zidovudine treatment.	IST SUPER SANITA, CTR OPERAT AIDS, I-00161 ROME, ITALY; UNIV MILAN, OSPED SPALLANZANI, INST INFECT DIS, ROME, ITALY; OSPED L SACCO, MILAN, ITALY; OSPED NIGUARDA CA GRANDA, MILAN, ITALY; UNIV BARI, INST INTERNAL MED & INFECT DIS, I-70124 BARI, ITALY; UNIV CATTOLICA SACRO CUORE, I-00168 ROME, ITALY; UNIV MILAN, INST INTERNAL MED, I-20122 MILAN, ITALY	Istituto Superiore di Sanita (ISS); IRCCS Lazzaro Spallanzani; University of Milan; University of Milan; Luigi Sacco Hospital; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Universita degli Studi di Bari Aldo Moro; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Milan	VELLA, S (corresponding author), IST SUPER SANITA, VIROL LAB, VIALE REGINA ELENA 299, I-00161 ROME, ITALY.		Tomino, Carlo/AAA-7478-2021; Floridia, Marco/Q-6571-2017; Vella, Stefano/GZM-0519-2022; VELLA, STEFANO/ABI-3368-2020; Giuliano, Marina/V-8991-2017; PEZZOTTI, PATRIZIO/C-6480-2016; VELLA, STEFANO/D-4912-2015	Floridia, Marco/0000-0003-3971-0141; Giuliano, Marina/0000-0003-2789-7797; PEZZOTTI, PATRIZIO/0000-0002-0805-2927; VELLA, STEFANO/0000-0003-2347-5984; ANGARANO, Gioacchino/0000-0003-3207-7523				BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; COX DR, 1972, J R STAT SOC B, V34, P187; COX DR, 1984, ANAL SURVIVAL DATA, P91; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FATKENHEUER G, 1991, NEW ENGL J MED, V325, P1311, DOI 10.1056/NEJM199110313251812; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PEDERSEN C, 1990, AIDS, V4, P1111, DOI 10.1097/00002030-199011000-00009; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; 1987, NATIONAL PROTOCOL ZI; 1987, MMWR S1, V36, P3	18	82	84	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1232	1236		10.1001/jama.267.9.1232	http://dx.doi.org/10.1001/jama.267.9.1232			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1538560				2022-12-28	WOS:A1992HF43900025
J	FOWLER, GJS; VISSCHERS, RW; GRIEF, GG; VANGRONDELLE, R; HUNTER, CN				FOWLER, GJS; VISSCHERS, RW; GRIEF, GG; VANGRONDELLE, R; HUNTER, CN			GENETICALLY MODIFIED PHOTOSYNTHETIC ANTENNA COMPLEXES WITH BLUESHIFTED ABSORBENCY BANDS	NATURE			English	Article							RHODOPSEUDOMONAS-SPHAEROIDES; ENERGY-TRANSFER	LIGHT energy for photosynthesis is collected by the antenna system, creating an excited state which migrates energetically 'downhill'. To achieve efficient migration of energy the antenna is populated with a series of pigments absorbing at progressively redshifted wavelengths. This variety in absorbing species in vivo has been created in a biosynthetically economical fashion by modulating the absorbance behaviour of one kind of (bacterio) chlorophyll molecule. This modulation is poorly understood but has been ascribed to pigment-pigment and pigment-protein interactions. We have examined the relationship between aromatic residues in antenna polypeptides and pigment absorption, by studying the effects of site-directed mutagenesis on a bacterial antenna complex. A clear correlation was observed between the absorbance of bacteriochlorophyll a and the presence of two tyrosine residues, alpha-Tyr44 and alpha-Tyr45, in the alpha-subunit of the peripheral light-harvesting complex of Rhodobacter sphaeroides, a purple photosynthetic bacterium that provides a well characterized system for site-specific mutagenesis 1-3. By constructing single (alpha-Tyr44, alpha-Tyr45 --> PheTyr) and then double (alpha-Tyr44, alpha-Tyr45 --> PheLeu) site-specific mutants, the absorbance of bacteriochlorophyll was blueshifted by 11 and 24 nm at 77 K, respectively. The results suggest that there is a close approach of tyrosine residues to bacteriochlorophyll, and that this proximity may promote redshifts in vivo.	FREE UNIV AMSTERDAM,DEPT PHYS & ASTRON,1081 HV AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam	FOWLER, GJS (corresponding author), UNIV SHEFFIELD,DEPT MOLEC BIOL & BIOTECHNOL,KREBS INST,WESTERN BANK,SHEFFIELD S10 2UH,ENGLAND.			Fowler, Gregory/0000-0002-0420-7661				Brunisholz R., 1988, PHOTOSYNTHETIC LIGHT, P103; BURGESS JG, 1989, J GEN MICROBIOL, V135, P1809; COGDELL RJ, 1990, MOL BIOL MEMBRANE BO, P211; FEHER G, 1989, NATURE, V339, P11; GUDOWSKANOWAK E, 1990, J PHYS CHEM-US, V94, P5795, DOI 10.1021/j100378a036; HUNTER CN, 1989, TRENDS BIOCHEM SCI, V14, P72; HUNTER CN, 1988, J GEN MICROBIOL, V134; JONES MR, IN PRESS MOL MICROBI; KRAMER HJM, 1984, BIOCHIM BIOPHYS ACTA, V765, P156, DOI 10.1016/0005-2728(84)90009-4; PEARLSTEIN RM, 1988, PHOTOSYNTHETIC LIGHT, P555; SIMON R, 1983, BIOTECHNOLOGY, V1, P748; SUNDSTROM V, 1990, J OPT SOC AM B, V7, P1595, DOI 10.1364/JOSAB.7.001595; VANGRONDELLE R, 1982, BIOCHIM BIOPHYS ACTA, V682, P208, DOI 10.1016/0005-2728(82)90100-1; VANMOURIK F, 1990, MOL BIOL MEMBRANE BO, P345	14	229	241	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					848	850		10.1038/355848a0	http://dx.doi.org/10.1038/355848a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538765				2022-12-28	WOS:A1992HF63600063
J	JUKES, TH				JUKES, TH			TODAYS NON-ORWELLIAN ANIMAL FARM	NATURE			English	Editorial Material											JUKES, TH (corresponding author), UNIV CALIF BERKELEY,DEPT INTEGRAT BIOL,BERKELEY,CA 94720, USA.							LASLEY FA, 1988, US BROILER IND; Lepkovsky S, 1935, Science, V82, P326, DOI 10.1126/science.82.2127.326; POND WG, 1983, SCI AM, V249, P96; SINGER P, 1991, NATURE, V353, P613, DOI 10.1038/353613a0	4	4	4	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					582	582		10.1038/355582a0	http://dx.doi.org/10.1038/355582a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538742				2022-12-28	WOS:A1992HD54700018
J	SHIRODKAR, S; EWEN, M; DECAPRIO, JA; MORGAN, J; LIVINGSTON, DM; CHITTENDEN, T				SHIRODKAR, S; EWEN, M; DECAPRIO, JA; MORGAN, J; LIVINGSTON, DM; CHITTENDEN, T			THE TRANSCRIPTION FACTOR E2F INTERACTS WITH THE RETINOBLASTOMA PRODUCT AND A P107-CYCLIN-A COMPLEX IN A CELL CYCLE-REGULATED MANNER	CELL			English	Article							ADENOVIRUS E1A PROTEINS; SV40 LARGE-T; GENE-PRODUCT; SUSCEPTIBILITY GENE; TRANS-ACTIVATION; DNA-REPLICATION; RB GENE; TRANSACTIVATION; PROMOTER; BINDING	E2F is a transcription factor believed to play a role in the activation of genes required for cellular proliferation. Its regulation is likely important for maintenance of G0 and for the initiation of cell growth. The retinoblastoma product (RB) forms a complex with E2F in G1 in primary and established human cells. As these cells enter S, a second E2F-containing complex appears. It contains p107, a nuclear "pocket" protein with similarities in structure and protein-binding properties to RB, and cyclin A, a cyclin believed to play a role in facilitating DNA replication. Hence, the regulation of E2F is carried out differently in G1 or S. The presence of cyclin A and a pocket protein, a possible cell growth regulator, in the same S phase-associated complex suggests a link between the function of E2F and the regulation of the DNA replication process.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	SHIRODKAR, S (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.							BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; EWEN ME, 1992, IN PRESS SCIENCE; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1988, ANTIBODIES LABORATOR; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; REICHEL R, 1988, P NATL ACAD SCI USA, V85, P387, DOI 10.1073/pnas.85.2.387; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	50	587	603	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					157	166		10.1016/0092-8674(92)90214-W	http://dx.doi.org/10.1016/0092-8674(92)90214-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1531040				2022-12-28	WOS:A1992GZ58300017
J	VANCE, RP				VANCE, RP			AN INTRODUCTION TO THE PHILOSOPHICAL PRESUPPOSITIONS OF THE ANIMAL LIBERATION RIGHTS MOVEMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									WAKE FOREST UNIV, BOWMAN GRAY SCH MED, MED HUMANITIES SECT, WINSTON SALEM, NC 27103 USA	Wake Forest University; Wake Forest Baptist Medical Center	VANCE, RP (corresponding author), BOWMAN GRAY SCH MED, DEPT PATHOL, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.							Anscombe Gertrude E.M, 1981, ETHICS RELIG POLITIC; BENTHAM J, 1843, WORKS J BENTHAM, V2, P501; BENTHAM J, 1843, WORKS J BENTHAM, V3, P221; BENTHAM J, 1962, WORKS J BENTHAM, V1, P143; Clark Stephen R. L., 1977, MORAL STATUS ANIMALS; COHEN C, 1986, NEW ENGL J MED, V315, P865, DOI 10.1056/NEJM198610023151405; DeGrazia David, 1991, Kennedy Inst Ethics J, V1, P48; DRESSER R, 1986, BIOLAW, P253; Frey R G, 1988, Between Species, V4, P191; Frey R. G., 1983, RIGHTS KILLING SUFFE; Frey R.G., 1980, INTERESTS RIGHTS CAS; GOODPASTER KE, 1976, PERSPECTIVES MORALIT; Hauerwas S., 1981, COMMUNITY CHARACTER; HORTON L, 1989, J NATL CANCER I, V81, P736, DOI 10.1093/jnci/81.10.736; HORTON L, 1988, SRA-J SOC RES ADMIN, V19, P5; Humber James, 1987, BIOMEDICAL ETHICS RE, P89; MACINTYRE A, 1984, MONIST, V67, P498, DOI 10.5840/monist198467438; MACINTYRE A, 1980, KNOWING VALUING, P18; MACINTYRE A, 1988, WHOSE JUSTICE RATIOA; MACINTYRE A, 1978, SELF IMAGES AGE, P136; MacIntyre A., 1984, AFTER VIRTUE; MacIntyre A., 1990, 3 RIVAL VERSIONS MOR; MacIntyre Alasdair, 1975, EVALUATION EXPLANATI, P97; MCCABE K, 1990, WASHINGTONIAN, V25, P72; MCCABE K, 1986, WASHINGTONIAN    AUG, V21, P112; MILLER BL, 1991, NEW ENGL J MED, V325, P1581; Moore G.E., 1993, SELECTED WRITINGS, P1; MORGAN R, 1980, LOVE ANGER ORG HDB; NEWKIRK I, 1990, SAVE ANIMALS; NICOLL CS, 1990, ENDOCRINOLOGY, V127, P985; PARDES H, 1991, NEW ENGL J MED, V324, P1640, DOI 10.1056/NEJM199106063242306; Rachels J., 1990, CREATED ANIMALS MORA; Regan T, 1982, ALL DWELL THEREIN AN; REGAN T, 1991, GE MOORE ELEMENTS ET; REGAN T, 1985, NY REV BOOKS    0425, P56; Regan T., 1989, ANIMAL RIGHTS HUMAN; Regan Tom, 1983, CASE ANIMAL RIGHTS; ROLLIN B, 1990, EXPT ANIMAL BIOMEDIC, V1; Rollin B.E., 1981, ANIMAL RIGHTS HUMAN; ROLLIN BE, 1989, UNHEEDED CRY; RORTY R, 1967, LINGUISTIC TURN; Rorty Richard, 1979, PHILOS MIRROR NATURE; SAPONTIZIS SF, 1987, MORALS REASON ANIMAL; SINGER P, 1980, PHILOS PUBLIC AFF, V9, P325; SINGER P, 1989, NY REV BOOKS    0202, P36; SINGER P, 1985, NY REV BOOKS    0117, P46; Singer P., 1990, ANIMAL LIBERATION; Singer Peter, 1985, DEFENSE ANIMALS; SMITH SJ, 1988, JAMA-J AM MED ASSOC, V259, P2007, DOI 10.1001/jama.259.13.2007; STROH GW, 1979, AM ETHICAL THOUGHT; SUMNER LW, 1988, J MED PHILOS, V13, P159, DOI 10.1093/jmp/13.2.159; Urmson J.O., 1956, PHILOS ANAL; Williams B., 1985, ETHICS LIMITS PHILOS; Wittgenstein L., 1967, PHILOS INVESTIGATION; 1990, ANIMAL RIGHTS HDB; 1990, 1990 P HOUS DEL CHIC, P392	56	15	15	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1715	1719		10.1001/jama.268.13.1715	http://dx.doi.org/10.1001/jama.268.13.1715			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	JQ376	1527881				2022-12-28	WOS:A1992JQ37600034
J	SAWYERS, CL; CALLAHAN, W; WITTE, ON				SAWYERS, CL; CALLAHAN, W; WITTE, ON			DOMINANT NEGATIVE MYC BLOCKS TRANSFORMATION BY ABL ONCOGENES	CELL			English	Article							HUMAN C-MYC; CHRONIC MYELOGENOUS LEUKEMIA; GTPASE-ACTIVATING PROTEIN; TYROSINE KINASE-ACTIVITY; DNA-BINDING; PHILADELPHIA-CHROMOSOME; LYMPHOID-CELLS; V-SRC; RAS; SEQUENCES	A link between ABL oncogenes and MYC is suggested by the transformation synergy that is observed when MYC is expressed at high levels. Dominant negative MYC proteins were overexpressed in fibroblasts to determine if MYC complements ABL oncogene transformation or is essential for this process. Transformation by both v-abl and BCR-ABL oncogenes was reduced 5- to 10-fold, whereas transformation by the serine/threonine kinase oncogene v-mos was unaffected. Using a retrovirus construct modified to express BCR-ABL and MYC genes simultaneously, we show that dominant negative MYC suppressed transformation of primary mouse bone marrow pre-B cells by BCR-ABL. These observations demonstrate that c-MYC is essential for transformation and help define the pathway by which these proteins cause transformation.	UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, DEPT MICROBIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, DEPT MOLEC GENET, LOS ANGELES, CA 90024 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	SAWYERS, CL (corresponding author), UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, DEPT MED, LOS ANGELES, CA 90024 USA.		Sawyers, Charles/G-5327-2016					BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLICK M, 1987, CANCER GENET CYTOGEN, V27, P349, DOI 10.1016/0165-4608(87)90018-5; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEAN M, 1987, ONCOGENE RES, V1, P279; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MCCARTHY DM, 1984, LANCET, V2, P1362; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; ROSENBERG N, 1978, J EXP MED, V147, P1126, DOI 10.1084/jem.147.4.1126; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, ONCOGENE, V6, P2297; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608	43	359	369	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					901	910		10.1016/0092-8674(92)90241-4	http://dx.doi.org/10.1016/0092-8674(92)90241-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525828				2022-12-28	WOS:A1992JN78100006
J	FISCHER, L; GERARD, M; CHALUT, C; LUTZ, Y; HUMBERT, S; KANNO, M; CHAMBON, P; EGLY, JM				FISCHER, L; GERARD, M; CHALUT, C; LUTZ, Y; HUMBERT, S; KANNO, M; CHAMBON, P; EGLY, JM			CLONING OF THE 62-KILODALTON COMPONENT OF BASIC TRANSCRIPTION FACTOR-BTF2	SCIENCE			English	Article							RNA POLYMERASE-II; INITIATION-FACTOR; BINDING-FACTOR; FACTOR TFIIE; PURIFICATION; MOTIFS; SEQUENCE; PROTEIN; SUBUNIT; LIVER	Cloning of the mammalian basic transcription factors serves as a major step in understanding the mechanism of transcription initiation. The 62-kilodalton component (p62) of one of these transcription factors, BTF2 was cloned and overexpressed. A monoclonal antibody to this polypeptide inhibited transcription in vitro. Immunoaffinity experiments demonstrated that the 62-kilodalton component is closely associated with the other polypeptides present in the BTF2 factor. Sequence similarity suggests that BTF2 may be the human counterpart of RNA polymerase II initiation factor b from yeast.	FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Humbert, Sandrine/S-2981-2016; GERARD, Matthieu/D-2235-2014	GERARD, Matthieu/0000-0001-8956-0597; Chalut, Christian/0000-0002-4849-1369; Humbert, Sandrine/0000-0002-9501-2658; Kanno, masamoto/0000-0001-9169-3444				ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; Burton N, 1991, Protein Expr Purif, V2, P432, DOI 10.1016/1046-5928(91)90105-R; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CHALUT C, UNPUB; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; FEAVER WJ, 1991, COMMUNICATION, V266, P19000; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1992, J BIOL CHEM, V267, P2786; FLORES O, 1989, J BIOL CHEM, V264, P8915; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILEADI O, UNPUB; GROTH SFD, 1980, J IMMUNOL METHODS, V35, P1; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KITAJIMA S, 1989, P NATL ACAD SCI USA, V86, P6106, DOI 10.1073/pnas.86.16.6106; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MONCOLLIN V, 1992, P NATL ACAD SCI USA, V89, P397, DOI 10.1073/pnas.89.1.397; MONCOLLIN V, IN PRESS; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; REICK LM, 1987, J IMMUNOL METHODS, V100, P123; REINBERG D, COMMUNICATION; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAMUELS M, 1986, J BIOL CHEM, V261, P203; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; Summers M.D., 1987, B TEXAS AGR EXPT STA, V1555; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x	37	99	101	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1392	1395		10.1126/science.1529339	http://dx.doi.org/10.1126/science.1529339			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529339				2022-12-28	WOS:A1992JL61200031
J	LETOURNEUR, F; KLAUSNER, RD				LETOURNEUR, F; KLAUSNER, RD			A NOVEL DI-LEUCINE MOTIF AND A TYROSINE-BASED MOTIF INDEPENDENTLY MEDIATE LYSOSOMAL TARGETING AND ENDOCYTOSIS OF CD3 CHAINS	CELL			English	Article							CELL ANTIGEN RECEPTOR; ENDOPLASMIC-RETICULUM; MEMBRANE GLYCOPROTEIN; CYTOPLASMIC DOMAIN; TRANSMEMBRANE PROTEINS; INTERLEUKIN-2 RECEPTOR; MOLECULAR-CLONING; ACID-PHOSPHATASE; INTERNALIZATION; DEGRADATION	Partial complexes of the T cell antigen receptor lacking zeta-chains are delivered to lysosomes. Chimeric proteins composed of the Tac antigen fused to the cytoplasmic domains of each CD3 chain has allowed the identification of lysosomal targeting sequences. Tac-gamma and Tac-delta chimeras are retained in the endoplasmic reticulum because of the presence of basic residues reminiscent of sequences responsible for the localization of endoplasmic reticulum resident proteins. Truncation of these retention motifs revealed lysosomal targeting of both Tac-gamma and delta-chimeras. A di-leucine- and a tyrosine-based motif are individually sufficient to induce both endocytosis and delivery to lysosomes of Tac. In contrast with chimeras containing only one of these motifs, the chimera containing both was predominantly delivered directly to lysosomes without going through the cell surface. These two sequences may represent two families of targeting motifs that determine the fate of proteins within the peripheral membrane system.			LETOURNEUR, F (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.			Letourneur, Francois/0000-0003-2232-6127				BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BANIYASH M, 1988, J BIOL CHEM, V263, P449; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; FURUNO K, 1989, J BIOCHEM-TOKYO, V106, P717, DOI 10.1093/oxfordjournals.jbchem.a122922; FURUNO K, 1989, J BIOCHEM-TOKYO, V106, P708, DOI 10.1093/oxfordjournals.jbchem.a122921; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HURTLEY SM, 1989, ANN REV CELL BIOL, V5, P227; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON K F, 1991, Journal of Cell Biology, V115, p244A; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KLAUSNER R D, 1989, New Biologist, V1, P3; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LEBERER E, 1989, J BIOL CHEM, V264, P3484; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SELDIN RF, 1990, CURRENT PROTOCOLS MO, P921; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THIES RS, 1990, J BIOL CHEM, V265, P10132; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; VEGA MA, 1991, J BIOL CHEM, V266, P16269; WEISSMAN AM, 1986, P NATL ACAD SCI USA, V83, P1463, DOI 10.1073/pnas.83.5.1463; WHITE J, 1989, J IMMUNOL, V143, P1822; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	59	515	528	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1143	1157		10.1016/0092-8674(92)90636-Q	http://dx.doi.org/10.1016/0092-8674(92)90636-Q			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1535555				2022-12-28	WOS:A1992JA43100009
J	MOHR, G; ZHANG, AX; GIANELOS, JA; BELFORT, M; LAMBOWITZ, AM				MOHR, G; ZHANG, AX; GIANELOS, JA; BELFORT, M; LAMBOWITZ, AM			THE NEUROSPORA CYT-18 PROTEIN SUPPRESSES DEFECTS IN THE PHAGE-T4 TD INTRON BY STABILIZING THE CATALYTICALLY ACTIVE STRUCTURE OF THE INTRON CORE	CELL			English	Article							TRANSFER RNA-SYNTHETASE; GROUP-I INTRONS; MESSENGER-RNA; YEAST; GENE; MITOCHONDRIA; TETRAHYMENA; INVOLVEMENT; SEQUENCES; EXCISION	The Neurospora CYT-18 protein, a tyrosyl-tRNA synthetase, which functions in splicing group I introns in mitochondria, promotes splicing of mutants of the distantly related bacteriophage T4 td intron. In an in vivo assay, wild-type CYT-18 protein expressed in E. coli suppressed mutations in the td intron's catalytic core. CYT-18-suppressible mutations were also suppressed by high Mg2+ or spermidine in vitro, suggesting they affect intron structure. Both the N- and C-terminal domains of CYT-18 are required for efficient splicing, but CYT-18 with a large C-terminal truncation retains some activity. Our results indicate that CYT-18 interacts with conserved structural features of group I introns, and they provide direct evidence that a protein promotes splicing by stabilizing the catalytically active structure of the intron RNA.	OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; NEW YORK STATE DEPT HLTH,WADSWORTH CTR LAB & RES,MOLEC GENET PROGRAM,ALBANY,NY 12201; SUNY ALBANY,SCH PUBL HLTH,ALBANY,NY 12222	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	MOHR, G (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.			Belfort, Marlene/0000-0002-1592-5618; Mohr, Georg/0000-0002-6411-0685	NIGMS NIH HHS [GM39422, GM44844, GM37951] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037951, R37GM039422, R01GM039422, R37GM037951, R01GM044844] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BEDOUELLE H, 1990, BIOCHIMIE, V72, P589, DOI 10.1016/0300-9084(90)90122-W; BELFORT M, 1990, METHOD ENZYMOL, V181, P521; BELFORT M, 1987, COLD SPRING HARB SYM, V52, P181, DOI 10.1101/SQB.1987.052.01.023; BELFORT M, 1983, J BIOL CHEM, V258, P2045; BELFORT M, 1990, ANNU REV GENET, V24, P363; BELLPEDERSEN D, 1991, J BACTERIOL, V173, P1193, DOI 10.1128/jb.173.3.1193-1200.1991; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHANDRY PS, 1987, GENE DEV, V1, P1028, DOI 10.1101/gad.1.9.1028; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHERNIACK AD, 1990, CELL, V62, P745, DOI 10.1016/0092-8674(90)90119-Y; CHERNIACK AD, 1991, THESIS OHIO STATE U; COLLINS RA, 1985, J MOL BIOL, V184, P413, DOI 10.1016/0022-2836(85)90291-8; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; EHRENMAN K, 1989, NUCLEIC ACIDS RES, V17, P9147, DOI 10.1093/nar/17.22.9147; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GARRIGA G, 1986, CELL, V46, P669, DOI 10.1016/0092-8674(86)90342-9; GUO QB, 1991, J BIOL CHEM, V266, P1809; HEUER TS, 1991, P NATL ACAD SCI USA, V88, P11105, DOI 10.1073/pnas.88.24.11105; HILL J, 1985, J BIOL CHEM, V260, P3235; KAMPER U, 1992, MOL CELL BIOL, V12, P499; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; KITTLE JD, 1991, GENE DEV, V5, P1009, DOI 10.1101/gad.5.6.1009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LUSK JE, 1968, J BIOL CHEM, V243, P2618; MAJUMDER AL, 1989, MOL CELL BIOL, V9, P2089, DOI 10.1128/MCB.9.5.2089; MCGRAW P, 1983, J BIOL CHEM, V258, P9459; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1991, NATURE, V354, P164, DOI 10.1038/354164a0; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; SALVO JL, 1992, J BIOL CHEM, V267, P2845; SCHROEDER R, 1991, BIOCHEMISTRY-US, V30, P3295, DOI 10.1021/bi00227a018; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	36	102	105	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					483	494		10.1016/0092-8674(92)90449-M	http://dx.doi.org/10.1016/0092-8674(92)90449-M			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1533818				2022-12-28	WOS:A1992HT07800010
J	WONG, I; LOHMAN, TM				WONG, I; LOHMAN, TM			ALLOSTERIC EFFECTS OF NUCLEOTIDE COFACTORS ON ESCHERICHIA-COLI REP HELICASE DNA-BINDING	SCIENCE			English	Article							GENE-PRODUCT; PROTEIN; REPLICATION; PURIFICATION; UVRD; ENZYME; RHO; MUTATIONS; MECHANISM; COMPONENT	The Escherichia coli Rep helicase unwinds duplex DNA during replication. The functional helicase appears to be a dimer that forms only on binding DNA. Both protomers of the dimer can bind either single-stranded or duplex DNA. Because binding and hydrolysis of adenosine triphosphate (ATP) are essential for helicase function, the energetics of DNA binding and DNA-induced Rep dimerization were studied quantitatively in the presence of the nucleotide cofactors adenosine diphosphate (ADP) and the nonhydrolyzable ATP analog AMPP(NH)P. Large allosteric effects of nucleotide cofactors on DNA binding to Rep were observed. Binding of ADP favored Rep dimers in which both protomers bound single-stranded DNA, whereas binding of AMPP(NH)P favored simultaneous binding of both single-stranded and duplex DNA to the Rep dimer. A rolling model for the active unwinding of duplex DNA by the dimeric Rep helicase is proposed that explains vectorial unwinding and predicts that helicase translocation along DNA is coupled to ATP binding, whereas ATP hydrolysis drives unwinding of multiple DNA base pairs for each catalytic event.			WONG, I (corresponding author), WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.				NIGMS NIH HHS [R01 GM045948, GM30498, GM45948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030498, R01GM045948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5247; ARAI N, 1981, J BIOL CHEM, V256, P5294; BAILLY V, 1991, P NATL ACAD SCI USA, V88, P9712, DOI 10.1073/pnas.88.21.9712; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BRIDGES BA, 1981, MUTAT RES, V82, P229, DOI 10.1016/0027-5107(81)90152-4; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHAO KL, 1990, J BIOL CHEM, V265, P1067; COLASANTI J, 1987, MOL GEN GENET, V209, P382, DOI 10.1007/BF00329669; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DYKSTRA CC, 1984, COLD SPRING HARB SYM, V49, P463, DOI 10.1101/SQB.1984.049.01.052; EISENBERG S, 1977, P NATL ACAD SCI USA, V74, P3198, DOI 10.1073/pnas.74.8.3198; FASSLER JS, 1985, J BACTERIOL, V161, P609, DOI 10.1128/JB.161.2.609-614.1985; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GEIDER K, 1981, ANNU REV BIOCHEM, V50, P233, DOI 10.1146/annurev.bi.50.070181.001313; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; HILL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4796, DOI 10.1073/pnas.78.8.4796; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LANE D, 1988, NATURE, V334, P478, DOI 10.1038/334478a0; LANE HED, 1974, J BACTERIOL, V120, P805, DOI 10.1128/JB.120.2.805-814.1974; LANE HED, 1975, J MOL BIOL, V97, P99; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LIU CC, 1981, J BIOL CHEM, V256, P2813; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1989, P NATL ACAD SCI USA, V86, P4430, DOI 10.1073/pnas.86.12.4430; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATTHEWS BW, 1973, ANNU REV BIOPHYS BIO, V2, P257, DOI 10.1146/annurev.bb.02.060173.001353; RAY BK, 1985, J BIOL CHEM, V260, P7651; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, UNPUB; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SEO YS, 1991, J BIOL CHEM, V266, P13161; SMITH GR, 1990, NUCLEIC ACIDS MOL BI, V4, P78; STEINMETZ EJ, 1990, J BIOL CHEM, V265, P18408; THOMMES P, 1990, FEBS LETT, V268, P325, DOI 10.1016/0014-5793(90)81279-W; WASHBURN BK, 1991, J BACTERIOL, V173, P2569, DOI 10.1128/jb.173.8.2569-2575.1991; WONG I, 1992, J BIOL CHEM, V267, P7596; YARRANTON GT, 1979, J BIOL CHEM, V254, P2002; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658	45	177	180	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					350	355		10.1126/science.256.5055.350	http://dx.doi.org/10.1126/science.256.5055.350			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1533057				2022-12-28	WOS:A1992HP03200028
J	REDMON, B; PYZDROWSKI, KL; ELSON, MK; KAY, NE; DALMASSO, AP; NUTTALL, FQ				REDMON, B; PYZDROWSKI, KL; ELSON, MK; KAY, NE; DALMASSO, AP; NUTTALL, FQ			HYPOGLYCEMIA DUE TO A MONOCLONAL INSULIN-BINDING ANTIBODY IN MULTIPLE-MYELOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							C-PEPTIDE; AUTOANTIBODIES; IMMUNOGLOBULIN; PARAPROTEIN; GAMMOPATHY; TUMORS; ASSAY		VET AFFAIRS MED CTR,ENDOCRINOL METAB & NUTR SECT,MINNEAPOLIS,MN; VET AFFAIRS MED CTR,HEMATOL ONCOL SECT,MINNEAPOLIS,MN; VET AFFAIRS MED CTR,DEPT NUCL MED,MINNEAPOLIS,MN; VET AFFAIRS MED CTR,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities				Redmon, J. Bruce/0000-0002-1883-9467				ARCHAMBEAUDMOUVEROUX F, 1989, BIOMED PHARMACOTHER, V43, P581, DOI 10.1016/0753-3322(89)90036-X; BLOCK MB, 1972, DIABETES, V21, P1013, DOI 10.2337/diab.21.10.1013; DAUGHADAY WH, 1989, ENDOCRIN METAB CLIN, V18, P91, DOI 10.1016/S0889-8529(18)30390-6; FARHANGI M, 1976, NEW ENGL J MED, V294, P177, DOI 10.1056/NEJM197601222940401; FORSTER H, 1972, DIABETES, V21, P1102, DOI 10.2337/diab.21.11.1102; GOLDMAN J, 1978, DIABETES, V27, P653, DOI 10.2337/diab.27.6.653; GOLDMAN J, 1979, J CLIN INVEST, V63, P1050, DOI 10.1172/JCI109374; HARBOE M, 1969, SCAND J HAEMATOL, V6, P416; HEFFERNAN AG, 1972, POSTGRAD MED J, V48, P238, DOI 10.1136/pgmj.48.558.238; Hirata Y, 1987, HYPOGLYCEMIA, V38, P105; KILGORE LL, 1985, J CLIN INVEST, V76, P225, DOI 10.1172/JCI111951; KUZUYA H, 1977, DIABETES, V26, P22, DOI 10.2337/diabetes.26.1.22; KUZUYA T, 1976, DIABETOLOGIA, V12, P511, DOI 10.1007/BF01219516; LATOV N, 1980, NEW ENGL J MED, V303, P618, DOI 10.1056/NEJM198009113031105; MEGYESI K, 1974, J CLIN ENDOCR METAB, V38, P931, DOI 10.1210/jcem-38-5-931; NISSAN S, 1968, NEW ENGL J MED, V278, P177, DOI 10.1056/NEJM196801252780402; PALMER JP, 1987, DIABETES METAB REV, V3, P1005, DOI 10.1002/dmr.5610030409; PAVELIC K, 1983, BLOOD, V61, P925; RUSSELLJONES DL, 1990, BRIT J HAEMATOL, V76, P151, DOI 10.1111/j.1365-2141.1990.tb07854.x; SERVICE FJ, 1977, J LAB CLIN MED, V90, P180; SLUITER WJ, 1986, BRIT J HAEMATOL, V62, P679, DOI 10.1111/j.1365-2141.1986.tb04091.x; TRIMARCHI F, 1982, J CLIN ENDOCR METAB, V54, P1045, DOI 10.1210/jcem-54-5-1045; WASADA T, 1989, DIABETES CARE, V12, P147, DOI 10.2337/diacare.12.2.147; WILKIN TJ, 1984, BRIT MED J, V288, P349, DOI 10.1136/bmj.288.6414.349; ZETTERVALL O, 1978, ACTA MED SCAND, V204, P521	25	58	59	1	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1992	326	15					994	998		10.1056/NEJM199204093261505	http://dx.doi.org/10.1056/NEJM199204093261505			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM285	1545852	Bronze			2022-12-28	WOS:A1992HM28500005
J	DRICKAMER, MA; LACHS, MS				DRICKAMER, MA; LACHS, MS			SHOULD PATIENTS WITH ALZHEIMERS-DISEASE BE TOLD THEIR DIAGNOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									YALE UNIV,SCH MED,NEW HAVEN,CT 06510	Yale University	DRICKAMER, MA (corresponding author), W HAVEN VET AFFAIRS MED CTR,W HAVEN,CT 06516, USA.							BOK S, 1978, LYING MORAL CHOICE P, P220; CASSEL CK, 1985, TEACHING NURSING HOM, P109; CASSILETH BR, 1980, ANN INTERN MED, V92, P832, DOI 10.7326/0003-4819-92-6-832; ERDE EL, 1988, J FAM PRACTICE, V26, P401; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; HOWELL T, 1990, J GEN INTERN MED, V5, P431, DOI 10.1007/BF02599434; JONAS H, 1978, HASTINGS CENT REP, V8, P31, DOI 10.2307/3560975; KATZMAN R, 1991, J AM GERIATR SOC, V39, P5516; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KUKULL WA, 1990, NEUROLOGY, V40, P1364, DOI 10.1212/WNL.40.9.1364; LO B, 1991, ANN INTERN MED, V114, P895, DOI 10.7326/0003-4819-114-10-895; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; PARFIT D, 1986, REASONS PERSONS, P236; REIFLER BV, 1982, AM J PSYCHIAT, V139, P623; REISER SJ, 1980, ANN INTERN MED, V92, P837, DOI 10.7326/0003-4819-92-6-837; van Oosten F F, 1991, Med Law, V10, P31; VANDIJK PTM, 1991, J AM GERIATR SOC, V39, P603, DOI 10.1111/j.1532-5415.1991.tb03602.x; WARREN JW, 1986, NEW ENGL J MED, V315, P1124, DOI 10.1056/NEJM198610303151804; WINOGRAD CH, 1988, TREATMENTS ALZHEIMER, P3; 1991, CAN MED ASSOC J, V144, P425; 1987, GUIDELINES TERMINATI; 1983, SUMMING UP FINAL REP, P65	23	109	109	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					947	951		10.1056/NEJM199204023261410	http://dx.doi.org/10.1056/NEJM199204023261410			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1542346				2022-12-28	WOS:A1992HL26100010
J	ROWLEY, R; HUDSON, J; YOUNG, PG				ROWLEY, R; HUDSON, J; YOUNG, PG			THE WEE1 PROTEIN-KINASE IS REQUIRED FOR RADIATION-INDUCED MITOTIC DELAY	NATURE			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; DNA DAMAGE; MITOSIS; GENE; CELLS; MUTATION; DIVISION; MUTANTS	CELLULAR feedback or 'checkpoint' mechanisms maintain the order of completion of essential, cell-cycle related functions 1-3. In the budding yeast, for example, the RAD9 gene product is required to delay progression into mitosis in response to DNA damage 2,4-6. Similarly, in fission yeast, the cdc25 and cdc2 gene products influence the ability of cells to delay mitosis in response to the inhibition of DNA synthesis 7. Because these two checkpoint controls regulate the same event, mitosis, we observed the effect of gamma-irradiation on cell cycle progression in fission yeast, to test whether the two controls require the same cell-cycle regulatory elements. We show that gamma-radiation-induced mitotic delay requires functional wee1 protein kinase but does not seem to involve the cdc25 pathway. Mitotic delay in response to DNA damage is thus distinct from the delay induced by inhibition of DNA synthesis, which involves cdc25 but is not dependent on wee1.	QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada	ROWLEY, R (corresponding author), UNIV UTAH,MED CTR,DEPT RADIOL,SALT LAKE CITY,UT 84132, USA.							DOIDA Y, 1969, RADIAT RES, V38, P513, DOI 10.2307/3572611; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; Fantes P.A., 1989, MOL BIOL FISSION YEA, P127; FEATHERSTONE C, 1991, NATURE, V349, P508; FEILOTTER H, 1991, GENETICS, V127, P309; FLEIG UN, 1991, MOL GEN GENET, V226, P432, DOI 10.1007/BF00260656; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; Gutz H., 1974, HDB GENETICS, V1, P395; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HUDSON JD, 1990, GENETICS, V126, P309; KRAKOFF IH, 1968, CANCER RES, V28, P1559; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEEPER DB, 1973, RADIAT RES, V53, P326, DOI 10.2307/3573538; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; NURSE P, 1980, GENETICS, V96, P627; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; WEIBEZAHN KF, 1985, MUTAT RES, V145, P177, DOI 10.1016/0167-8817(85)90025-2; WEINERT T, 1989, J CELL SCI S, V12, P145; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554	32	128	134	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					353	355		10.1038/356353a0	http://dx.doi.org/10.1038/356353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549179				2022-12-28	WOS:A1992HK79400069
J	OLEARY, MP				OLEARY, MP			ELIMINATING HIV FROM SEMINAL FLUID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											OLEARY, MP (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,BOSTON,MA 02111, USA.							ANDERSON DJ, 1990, HETEROSEXUAL TRANSMI, P167; KIESSLING AA, 1989, P NATL ACAD SCI USA, V86, P5109, DOI 10.1073/pnas.86.13.5109; KILEGER IN, 1991, J INFECT DIS, V163, P386; PORTIS JL, 1990, HETEROSEXUAL TRANSMI, P107	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1677	1677						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1542180				2022-12-28	WOS:A1992HJ59700040
J	CHAO, MV				CHAO, MV			GROWTH-FACTOR SIGNALING - WHERE IS THE SPECIFICITY	CELL			English	Review							PC12 PHEOCHROMOCYTOMA CELLS; DIFFERENTIATION; ONCOGENE; PROTEIN; MICROINJECTION; EXPRESSION; INHIBITION; OUTGROWTH				CHAO, MV (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL & ANAT,DIV HEMATOL ONCOL,NEW YORK,NY 10021, USA.			Chao, Moses/0000-0002-6969-3744				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BORASIO GD, 1989, NEURON, V2, P1087; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; KIM UH, 1991, J BIOL CHEM, V266, P1359; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MUTOH T, 1988, J BIOL CHEM, V263, P15853; POLLOCK JD, 1990, J NEUROSCI, V10, P2626; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; QUI MS, 1991, J CELL BIOL, V115, P795; SEELEY PJ, 1984, J CELL BIOL, V98, P417, DOI 10.1083/jcb.98.2.417; THOMAS SM, 1992, CELL, V68; TISCHLER AS, 1975, NATURE, V258, P341, DOI 10.1038/258341a0; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WOOD KW, 1992, CELL, V68	22	338	362	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					995	997		10.1016/0092-8674(92)90068-N	http://dx.doi.org/10.1016/0092-8674(92)90068-N			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547509				2022-12-28	WOS:A1992HK67400001
J	GAUL, U; MARDON, G; RUBIN, GM				GAUL, U; MARDON, G; RUBIN, GM			A PUTATIVE RAS GTPASE ACTIVATING PROTEIN ACTS AS A NEGATIVE REGULATOR OF SIGNALING BY THE SEVENLESS RECEPTOR TYROSINE KINASE	CELL			English	Article							DEVELOPING DROSOPHILA EYE; CELL-CELL-INTERACTION; SACCHAROMYCES-CEREVISIAE; P21 GTPASE; GENE; DOMAIN; GAP; MELANOGASTER; ENCODES; RETINA	A Drosophila gene with similarity to the mammalian Ras GTPase activating protein has been isolated in screens for mutations that affect eye development. Inactivation of the locus, Gap1, mimics constitutive activation of the Sevenless receptor tyrosine kinase and eliminates the need for a functional Sevenless protein in the R7 cell. Our results suggest that Gap1 acts as a negative regulator of signaling by Sevenless by down-regulating the activity of the Ras1 protein, which has been shown to be a key element in signaling by Sevenless.			GAUL, U (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.			Rubin, Gerald/0000-0001-8762-8703				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; ENGELS W, 1989, MOBILE DNA, P375; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; FRANCESCHINI N, 1971, KYBERNETIK, V9, P152; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; IMAI Y, 1991, MOL CELL BIOL, V11, P3088, DOI 10.1128/MCB.11.6.3088; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MLODZIK M, 1991, METHODS NEUROSCIENCE, V9; MONTELL C, 1987, J NEUROSCI, V7, P1558; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; Poodry C.A., 1980, Genetics and Biology of Drosophila, V2d, P407; READY DF, 1989, TRENDS NEUROSCI, V12, P101; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBERTSON HM, 1988, GENETICS, V118, P461; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL D, 1986, MOL CELL BIOL, V6, P2241, DOI 10.1128/MCB.6.6.2241; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VAESSIN A, 1987, GENETICS, V116, P433; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	63	276	278	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1007	1019		10.1016/0092-8674(92)90073-L	http://dx.doi.org/10.1016/0092-8674(92)90073-L			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547500				2022-12-28	WOS:A1992HK67400005
J	POWDERLY, WG; SAAG, MS; CLOUD, GA; ROBINSON, P; MEYER, RD; JACOBSON, JM; GRAYBILL, JR; SUGAR, AM; MCAULIFFE, VJ; FOLLANSBEE, SE; TUAZON, CU; STERN, JJ; FEINBERG, J; HAFNER, R; DISMUKES, WE				POWDERLY, WG; SAAG, MS; CLOUD, GA; ROBINSON, P; MEYER, RD; JACOBSON, JM; GRAYBILL, JR; SUGAR, AM; MCAULIFFE, VJ; FOLLANSBEE, SE; TUAZON, CU; STERN, JJ; FEINBERG, J; HAFNER, R; DISMUKES, WE			A CONTROLLED TRIAL OF FLUCONAZOLE OR AMPHOTERICIN-B TO PREVENT RELAPSE OF CRYPTOCOCCAL MENINGITIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL FLUCONAZOLE; CLINICAL-TRIALS; NEOFORMANS; AIDS; INFECTION; THERAPY	Background. After primary treatment for cryptococcal meningitis, patients with the acquired immunodeficiency syndrome (AIDS) require some form of continued suppressive therapy to prevent relapse. Methods. We conducted a multicenter, randomized trial that compared fluconazole (200 mg per day given orally) with amphotericin B (1 mg per kilogram of body weight per week given intravenously) in patients with AIDS who had completed primary therapy for cryptococcal meningitis with amphotericin B (greater-than-or-equal-to 15 mg per kilogram). To be eligible, patients had to have at least two negative cultures of cerebrospinal fluid immediately before randomization. The primary end point was relapse of cryptococcal disease as confirmed by biopsy or culture. Results. Of 218 patients initially enrolled, 119 were assigned to fluconazole and 99 to amphotericin B. Twenty-three patients were found not to have met the entry criteria; six other patients assigned to amphotericin B did not receive it and were lost to follow-up. of the remaining 189 patients, after a median follow-up of 286 days 14 of 78 receiving amphotericin B (18 percent) and 2 of 111 assigned to fluconazole (2 percent) had relapses of symptomatic cryptococcal disease (P < 0.001 by Fisher's exact test). There was a difference of 19 percent in the estimated probability of remaining relapse-free at one year between the fluconazole group (97 percent) and the amphotericin B group (78 percent) (95 percent confidence interval, 7 percent to 31 percent; P < 0.001). Serious drug-related toxicity was more frequent in the amphotericin B group (P = 0.02), as were bacterial infections (P = 0.004) and bacteremia (P = 0.002). Conclusions. Fluconazole taken by mouth is superior to weekly intravenous therapy with amphotericin B to prevent relapse in patients with AIDS-associated cryptococcal meningitis after primary treatment with amphotericin B.	GEORGE WASHINGTON UNIV,DIV INFECT DIS,WASHINGTON,DC 20052; ST LOUIS VET AFFAIRS MED CTR,ST LOUIS,MO; VET AFFAIRS MED CTR,BRONX,NY; AUDIE MURPHY VET AFFAIRS HOSP,SAN ANTONIO,TX; DAVIES MED CTR,SAN FRANCISCO,CA; BOSTON CITY HOSP,DEPT MED,BOSTON,MA 02118; CEDARS SINAI MED CTR,DEPT MED,DIV INFECT DIS,LOS ANGELES,CA 90048; UNIV ALABAMA,SCH MED,DEPT MED,DIV INFECT DIS,BIRMINGHAM,AL 35233; UNIV ALABAMA,SCH MED,CTR COMPREHENS CANC,DIV BIOSTAT,BIRMINGHAM,AL 35233; NIAID,DIV AIDS,BETHESDA,MD 20892; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284; VET AFFAIRS MED CTR,BIRMINGHAM,AL; NYU MED CTR,NEW YORK,NY 10016; PENN HOSP,PHILADELPHIA,PA 19107; PFIZER INC,CENT RES,GROTON,CT 06340; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024; MT SINAI MED CTR,DEPT MED,DIV INFECT DIS,NEW YORK,NY 10029; BOSTON UNIV HOSP,BOSTON,MA 02218	George Washington University; US Department of Veterans Affairs; Veterans Health Administration (VHA); California Pacific Medical Center; Boston Medical Center; Cedars Sinai Medical Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); New York University; University of Pennsylvania; Pennsylvania Medicine; Pfizer; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Icahn School of Medicine at Mount Sinai; Boston University	POWDERLY, WG (corresponding author), WASHINGTON UNIV,SCH MED,DIV INFECT DIS,BOX 8011,660 S EUCLID,ST LOUIS,MO 63110, USA.			feinberg, judith/0000-0003-4206-7214; Powderly, William/0000-0001-7808-3086	NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI052562] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13148] Funding Source: Medline; NIAID NIH HHS [N01 AI52562] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; BOZZETTE SA, 1991, NEW ENGL J MED, V324, P580, DOI 10.1056/NEJM199102283240902; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; CLARK RA, 1990, J ACQ IMMUN DEF SYND, V3, P480; COX DR, 1972, J R STAT SOC B, V34, P187; DISMUKES WE, 1988, J INFECT DIS, V157, P624, DOI 10.1093/infdis/157.4.624; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOVACS JA, 1985, ANN INTERN MED, V103, P533, DOI 10.7326/0003-4819-103-4-533; LARSEN RA, 1989, ANN INTERN MED, V111, P125, DOI 10.7326/0003-4819-111-2-125; LARSEN RA, 1990, J INFECT DIS, V162, P727, DOI 10.1093/infdis/162.3.727; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; ROBINSON PA, 1990, REV INFECT DIS, V12, pS349; Snedecor G.W., 1980, STAT METHODS, V7; STERN JJ, 1988, AM J MED, V85, P477, DOI 10.1016/S0002-9343(88)80081-0; SUGAR AM, 1988, AM J MED, V85, P481, DOI 10.1016/S0002-9343(88)80082-2; ZUGER A, 1988, ANN INTERN MED, V109, P592, DOI 10.7326/0003-4819-109-7-592; ZUGER A, 1986, ANN INTERN MED, V104, P234, DOI 10.7326/0003-4819-104-2-234	17	276	283	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1992	326	12					793	798		10.1056/NEJM199203193261203	http://dx.doi.org/10.1056/NEJM199203193261203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ592	1538722				2022-12-28	WOS:A1992HJ59200003
J	NAIR, BC; DEVICO, AL; NAKAMURA, S; COPELAND, TD; CHEN, Y; PATEL, A; ONEIL, T; OROSZLAN, S; GALLO, RC; SARNGADHARAN, MG				NAIR, BC; DEVICO, AL; NAKAMURA, S; COPELAND, TD; CHEN, Y; PATEL, A; ONEIL, T; OROSZLAN, S; GALLO, RC; SARNGADHARAN, MG			IDENTIFICATION OF A MAJOR GROWTH-FACTOR FOR AIDS KAPOSIS-SARCOMA CELLS AS ONCOSTATIN-M	SCIENCE			English	Article							YOUNG HOMOSEXUAL MEN; LONG-TERM CULTURE; REGULATOR; LESIONS; PROTEIN	Conditioned medium from human T cell leukemia virus type 2 (HTLV-II)-infected T cells supports the growth and long-term culture of cells derived from acquired immunodeficiency syndrome (AIDS)-associated Kaposi's sarcoma lesions (AIDS-KS cells). A protein of 30 kilodaltons was purified from conditioned medium that supports the growth of AIDS-KS cells. The amino-terminal sequence of this protein was identical to the amino-terminal sequence of Oncostatin M, a glycoprotein that inhibits the growth of a variety of cancer cells. Oncostatin M from conditioned medium stimulated a twofold increase in the growth of AIDS-KS cells at a concentration of less than 1 nanogram of the protein per milliliter of medium.	ADV BIOSCIENCE LABS INC,DEPT CELL BIOL,KENSINGTON,MD 20895; NCI,FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS,BASIC RES PROGRAM,FREDERICK,MD 21702; NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [N01-CP-73723, N01-CO-74101] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP073723] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARILLARI G, UNPUB; BROWN TJ, 1987, J IMMUNOL, V139, P2977; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, CANCER CELL-MON REV, V1, P93; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FRIEDMANKIEN AE, 1981, J AM ACAD DERMATOL, V5, P468, DOI 10.1016/S0190-9622(81)80010-2; GOTTLIEB GJ, 1982, HUM PATHOL, V13, P882, DOI 10.1016/S0046-8177(82)80047-6; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MCNUTT NS, 1983, AM J PATHOL, V111, P62; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	16	225	233	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1430	1432		10.1126/science.1542792	http://dx.doi.org/10.1126/science.1542792			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542792				2022-12-28	WOS:A1992HH74400055
J	GILBERT, CD; WIESEL, TN				GILBERT, CD; WIESEL, TN			RECEPTIVE-FIELD DYNAMICS IN ADULT PRIMARY VISUAL-CORTEX	NATURE			English	Article							SOMATOSENSORY CORTEX; DIGIT AMPUTATION; STRIATE CORTEX; NERVE INJURY; REORGANIZATION; CAT; ORGANIZATION; CONNECTIONS; LESIONS; RESPONSES	THE adult brain has a remarkable ability to adjust to changes in sensory input. Removal of afferent input to the somatosensory, auditory, motor or visual cortex results in a marked change of cortical topography 1-10. Changes in sensory activity can, over a period of months, alter receptive field size and cortical topography 11. Here we remove visual input by focal binocular retinal lesions and record from the same cortical sites before and within minutes after making the lesion and find immediate striking increases in receptive field size for cortical cells with receptive fields near the edge of the retinal scotoma. After a few months even the cortical areas that were initially silenced by the lesion recover visual activity, representing retinotopic loci surrounding the lesion. At the level of the lateral geniculate nucleus, which provides the visual input to the striate cortex, a large silent region remains. Furthermore, anatomical studies show that the spread of geniculocortical afferents is insufficient to account for the cortical recovery. The results indicate that the topographic reorganization within the cortex was largely due to synaptic changes intrinsic to the cortex, perhaps through the plexus of long-range horizontal connections.			GILBERT, CD (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CLARK SA, 1988, NATURE, V332, P444, DOI 10.1038/332444a0; CRANE HD, 1983, SCIENCE, V221, P1078, DOI 10.1126/science.221.4615.1078; CUSICK CG, 1990, BRAIN RES, V537, P355, DOI 10.1016/0006-8993(90)90385-O; DEVOR M, 1978, NATURE, V276, P75, DOI 10.1038/276075a0; DONOGHUE JP, 1990, EXP BRAIN RES, V79, P479; EYSEL UT, 1981, EXP BRAIN RES, V41, P256; FENDICK M, 1983, VISION RES, V23, P145, DOI 10.1016/0042-6989(83)90137-2; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1990, COLD SPRING HARB SYM, V55, P663; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GILBERT CD, 1983, J NEUROSCI, V3, P1116; HEINEN SJ, 1991, EXP BRAIN RES, V83, P670; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; KALASKA J, 1979, J NEUROPHYSIOL, V42, P618, DOI 10.1152/jn.1979.42.2.618; Kanizsa G., 1979, ESSAYS GESTALT PERCE; KRAUSKOPF J, 1961, AM J PSYCHOL, V80, P632; MARTIN KAC, 1984, J PHYSL, V353, P4463; MCKEE SP, 1978, PERCEPT PSYCHOPHYS, V24, P25; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; PARADISO MA, 1991, VISION RES, V31, P1221, DOI 10.1016/0042-6989(91)90047-9; RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0; ROBERTSON D, 1989, J COMP NEUROL, V282, P456, DOI 10.1002/cne.902820311; ROCKLAND KS, 1983, J COMP NEUROL, V216, P303, DOI 10.1002/cne.902160307; Rockland KS, 1982, BRAIN RES, V169, P19; SANES JN, 1990, EXP BRAIN RES, V79, P479; SANES JN, 1988, P NATL ACAD SCI USA, V85, P2003, DOI 10.1073/pnas.85.6.2003; TSO DY, 1988, J NEUROSCI, V8, P1712; TSO DY, 1986, J NEUROSCI, V6, P1160; YARBUS A. L., 1957, BIOFIZIKA [TRANSL], V2, P683	32	649	653	2	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					150	152		10.1038/356150a0	http://dx.doi.org/10.1038/356150a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545866				2022-12-28	WOS:A1992HH73100058
J	WOLINSKY, SM; WIKE, CM; KORBER, BTM; HUTTO, C; PARKS, WP; ROSENBLUM, LL; KUNSTMAN, KJ; FURTADO, MR; MUNOZ, JL				WOLINSKY, SM; WIKE, CM; KORBER, BTM; HUTTO, C; PARKS, WP; ROSENBLUM, LL; KUNSTMAN, KJ; FURTADO, MR; MUNOZ, JL			SELECTIVE TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS FROM MOTHERS TO INFANTS	SCIENCE			English	Article							REVERSE-TRANSCRIPTASE; RECEPTOR-BINDING; CD4 RECEPTOR; AMINO-ACIDS; NEUTRALIZATION; HIV; ANTIBODIES; ENVELOPE; SEQUENCE; CHIMPANZEES	Multiple human immunodeficiency virus type-1 sequences from the V3 and V4-V5 regions of the envelope gene were analyzed from three mother-infant pairs. The infants' viral sequences were less diverse than those of their mothers. In two pairs, a proviral form infrequently found in the mother predominated in her infant. A conserved N-linked glycosylation site within the V3 region present in each mother's sequence set, was absent in all of the infants' sequence sets. These findings demonstrate that a minor subset of maternal virus is transmitted to the infant.	NYU,SCH MED,DEPT PEDIAT,NEW YORK,NY 10016; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; UNIV MIAMI,SCH MED,DEPT PEDIAT,MIAMI,FL 33136	New York University; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Miami	WOLINSKY, SM (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611, USA.		Wolinsky, Steven/B-2893-2012	Korber, Bette/0000-0002-2026-5757; Furtado, Manohar/0000-0001-6016-1357; Wolinsky, Steven/0000-0002-9625-6697	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI032535] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-32535] Funding Source: Medline; NICHD NIH HHS [HD26619-01] Funding Source: Medline; PHS HHS [P01-25569] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDIMAN WA, 1991, LANCET, P253; ANDIMAN WA, 1990, AM J DIS CHILD, V144, P75; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BOTARELLI P, 1991, J IMMUNOL, V147, P3128; BROLIDEN PA, 1990, J VIROL, V64, P936, DOI 10.1128/JVI.64.2.936-940.1990; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; EIGEN M, 1987, COLD SPRING HARB SYM, V52, P307, DOI 10.1101/SQB.1987.052.01.036; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FURTADO MR, 1991, VIROLOGY, V185, P258, DOI 10.1016/0042-6822(91)90773-5; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JONES IM, 1991, NATURE, V352, P198, DOI 10.1038/352198b0; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEIRDER J, 1988, J VIROL, V62, P3084; LEONARD CK, 1990, J BIOL CHEM, V265, P10372; LI WH, 1985, MOL BIOL EVOL, V2, P160; LOONEY DJ, 1988, SCIENCE, V241, P357, DOI 10.1126/science.3388046; MANO H, 1991, AIDS RES HUM RETROV, V7, P83, DOI 10.1089/aid.1991.7.83; MCNEARNEY T, 1990, P NATL ACAD SCI USA, V87, P1917, DOI 10.1073/pnas.87.5.1917; MELOEN RH, 1989, J GEN VIROL, V70, P1505, DOI 10.1099/0022-1317-70-6-1505; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MOK JYQ, 1989, ARCH DIS CHILD, V64, P1140, DOI 10.1136/adc.64.8.1140; MYERS G, 1991, HUMAN RETROVIRUSES A; MYERS G, 1991, RETROVIRIDAE, V1, P1; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; NEI M, 1986, MOL BIOL EVOL, V3, P418; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RADEMAKER PW, 1988, ANN REV BIOCH, V57, P839; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SODORA DL, 1989, J VIROL, V63, P5184, DOI 10.1128/JVI.63.12.5184-5193.1989; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; STIEHM ER, 1966, PEDIATRICS, V37, P717; SWOFFORD D, 1988, THESIS U ILLINOIS UR; TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; 1987, MMWR-MORBID MORTAL W, V36, P225	50	532	541	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1134	1137		10.1126/science.1546316	http://dx.doi.org/10.1126/science.1546316			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546316				2022-12-28	WOS:A1992HF63200044
J	STEVENS, ME; SUMMERFIELD, GP; HALL, AA; BECK, CA; HARDING, AJ; COVESMITH, JR; PATERSON, AD				STEVENS, ME; SUMMERFIELD, GP; HALL, AA; BECK, CA; HARDING, AJ; COVESMITH, JR; PATERSON, AD			COST-BENEFITS OF LOW-DOSE SUBCUTANEOUS ERYTHROPOIETIN IN PATIENTS WITH ANEMIA OF END STAGE RENAL-DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECOMBINANT HUMAN ERYTHROPOIETIN; PERITONEAL-DIALYSIS; ANEMIA; FAILURE	Objective - To assess the cost benefits of low dose subcutaneous recombinant human erythropoietin in correcting the anaemia of end stage renal disease. Design - Three year retrospective study. Setting - Subregional nephrology service serving a mixed urban and rural population of 800 000. Subjects - 60 patients with symptoms of anaemic end stage renal disease treated with erythropoietin (43 receiving haemodialysis; 11 receiving continuous ambulatory peritoneal dialysis; two with predialysis end stage renal disease; four with failing renal transplants). Main outcome measures - Costs and savings of achieving and maintaining a haemoglobin concentration of 85-105 g/l with erythropoietin. Results - All patients treated with erythropoietin achieved the target haemoglobin concentration at median induction doses of 97 (95% confidence interval 95 to 108) units/kg/week, and this was maintained with 79 (75 to 95) units/kg/week at an average annual cost per patient of L2260. Admissions related to anaemia were virtually eliminated (246 v 1 inpatient days for 12 months before and after starting erythropoietin). 54 patients required no blood transfusions after starting erythropoietin, and the total requirements fell from 230 to 21 units in the 12 months before and after starting erythropoietin. Iron stores were maintained with oral or intravenous iron. All patients reported increased wellbeing, appetite, and exercise capacity. Hypertension developed or worsened in 30 patients, resulting in hospital admissions in five patients, one of whom had seizures. Conclusion - Low dose subcutaneous erythropoietin restores haemoglobin concentrations sufficiently to abolish blood transfusion requirements and reduce morbidity. The net cost of erythropoietin prescribed in this way (L2260/patient/year) was largely offset by savings in costs of hospital admissions. The true annual cost to the NHS was around L1200 per patient.	MIDDLESBROUGH GEN HOSP, DEPT BLOOD TRANSFUS, MIDDLESBROUGH, ENGLAND		STEVENS, ME (corresponding author), S CLEVELAND HOSP, NEPHROL & GEN MED, MIDDLESBROUGH TS4 3BW, ENGLAND.							BOMMER J, 1988, LANCET, V2, P406; CASATI S, 1987, BMJ-BRIT MED J, V295, P1017, DOI 10.1136/bmj.295.6605.1017; ESCHBACH JW, 1989, NEW ENGL J MED, V321, P158, DOI 10.1056/NEJM198907203210305; ESCHBACH JW, 1988, AM J KIDNEY DIS, V11, P203, DOI 10.1016/S0272-6386(88)80150-1; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; ESCHBACH JW, 1989, KIDNEY INT, V35, P134, DOI 10.1038/ki.1989.18; GABRIEL R, 1991, BRIT MED J, V302, P248, DOI 10.1136/bmj.302.6771.248; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; LEESE B, 1971, COSTS BENEFITS USE E; MACDOUGALL IC, 1990, LANCET, V335, P489, DOI 10.1016/0140-6736(90)90733-L; MACDOUGALL IC, 1990, BMJ-BRIT MED J, V300, P655, DOI 10.1136/bmj.300.6725.655; POLLOK M, 1989, CONTRIB NEPHROL, V76, P201; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; SINAITRIEMAN L, 1989, J PEDIATR-US, V114, P550, DOI 10.1016/S0022-3476(89)80692-4; STEVENS JM, 1989, LANCET, V1, P1388; TAYLOR JE, 1991, BMJ-BRIT MED J, V302, P272, DOI 10.1136/bmj.302.6771.272-a; WINEARLS CG, 1989, NEPHROL DIAL TRANSPL, V4, P323, DOI 10.1093/oxfordjournals.ndt.a091884; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6; 1990, RECOMMENDATIONS USE	19	43	43	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 22	1992	304	6825					474	477		10.1136/bmj.304.6825.474	http://dx.doi.org/10.1136/bmj.304.6825.474			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547417	Bronze, Green Published			2022-12-28	WOS:A1992HF55500020
J	SMYTHE, C; NEWPORT, JW				SMYTHE, C; NEWPORT, JW			COUPLING OF MITOSIS TO THE COMPLETION OF S PHASE IN XENOPUS OCCURS VIA MODULATION OF THE TYROSINE KINASE THAT PHOSPHORYLATES P34CDC2	CELL			English	Article							CYCLE CONTROL GENE; MATURATION-PROMOTING FACTOR; CDC2 PROTEIN-KINASE; CELL-CYCLE; FISSION YEAST; DNA-REPLICATION; MITOTIC CONTROL; MESSENGER-RNA; EGGS; ACTIVATION	In cell-free extracts derived from Xenopus eggs which oscillate between S phase and mitosis, incompletely replicated DNA blocks the activation of p34cdc2-cyclin by maintaining p34cdc2 in a tyrosine-phosphorylated form. We used a recombinant cyclin fusion protein to generate a substrate to measure the ability of the tyrosine kinase(s) to phosphorylate and inactivate p34cdc2 in the absence of tyrosine phosphatase activity. p34cdc2 tyrosine phosphorylation is highly regulated during the cell cycle, being elevated in S phase and attenuated in mitosis. The elevation in p34cdc2 tyrosine phosphorylation rate occurs in response to the presence of incompletely replicated DNA. Moreover, okadaic acid and caffeine, which uncouple the dependence of mitosis on the completion of S phase, increase unphosphorylated p34cdc2 by attenuating tyrosine kinase function. These data indicate that the control system, which monitors the state of DNA replication, modulates the function of the tyrosine kinase by a phosphorylation/dephosphorylation mechanism, ensuring that mitosis occurs only when S phase is complete.			SMYTHE, C (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,B-022,LA JOLLA,CA 92093, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033523, R37GM033523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33523-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HUTCHISON C, 1989, J CELL SCI, V93, P605; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, NATURE, V339, P287; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; OHKURA H, 1988, EMBO J, V7, P1465, DOI 10.1002/j.1460-2075.1988.tb02964.x; OHKURA H, 1989, CEYCELL, V57, P998; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	42	214	221	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					787	797		10.1016/0092-8674(92)90153-4	http://dx.doi.org/10.1016/0092-8674(92)90153-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1531451				2022-12-28	WOS:A1992HF44000018
J	BERG, AT; SHINNAR, S; HAUSER, WA; ALEMANY, M; SHAPIRO, ED; SALOMON, ME; CRAIN, EF				BERG, AT; SHINNAR, S; HAUSER, WA; ALEMANY, M; SHAPIRO, ED; SALOMON, ME; CRAIN, EF			A PROSPECTIVE-STUDY OF RECURRENT FEBRILE SEIZURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM DIAZEPAM PROPHYLAXIS; NATIONAL COHORT; CONVULSIONS; EPILEPSY; PREDICTORS; CHILDHOOD; LIFE; RISK	Background. Febrile seizures occur in 2 to 4 percent of all children, approximately one third of whom will have recurrent febrile seizures. Little is known about predictors of recurrence. Methods. In this prospective study, we identified 347 children (1 month to 10 years of age) who presented with a first febrile seizure at one of four pediatric emergency departments. Information about these children was collected from medical records and interviews with the parents, and the children were followed for a median of 20 months to ascertain whether febrile seizures recurred. Results. Recurrent febrile seizures occurred in 94 of the 347 children (27 percent) with a cumulative risk of 25 percent at one year and 30 percent at two years. The duration of fever before the initial seizure was associated with the risk of recurrence at one year: for fever lasting less than 1 hour, the risk of recurrence was 44 percent; for fever lasting 1 to 24 hours, 23 percent; and for fever lasting more than 24 hours, 13 percent (P<0.001). With each degree of increase in temperature (in degrees Fahrenheit), from 101-degrees-F (38.3-degrees-C) to greater-than-or-equal-to 105-degrees-F (40.6-degrees-C), the risk of recurrence at one year declined, from 35 percent to 30, 26, 20, and 13 percent (P for trend = 0.024). An age of less than 18 months and a family history of febrile seizures were also associated with an increased risk of recurrence. A family history of epilepsy, complex febrile seizures, and neurodevelopmental abnormalities did not increase the risk of recurrent febrile seizures. Conclusions. A shorter duration of fever before the initial febrile seizure and a lower temperature are associated with an increased risk of recurrence in children who have febrile seizures.	MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT NEUROL, BRONX, NY 10467 USA; MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT PEDIAT, BRONX, NY 10467 USA; MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, MONTEFIORE EINSTEIN EPILEPSY MANAGEMENT, BRONX, NY 10467 USA; COLUMBIA UNIV COLL PHYS & SURG, GERTRUDE SERGIEVSKY CTR, NEW YORK, NY 10032 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Columbia University	BERG, AT (corresponding author), YALE UNIV, SCH MED, DEPT PEDIAT, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.		Hauser, W Allen/AAB-5277-2020		NINDS NIH HHS [1R01 NS26151, 1R29 NS27728] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS027728, R01NS026151] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; ANNEGERS JF, 1990, EPILEPSY RES, V5, P209, DOI 10.1016/0920-1211(90)90040-3; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1980, Pediatrics, V66, P1009; Berg A T, 1992, Paediatr Perinat Epidemiol, V6, P145, DOI 10.1111/j.1365-3016.1992.tb00756.x; BERG A T, 1991, Epilepsia, V32, P84; BERG AT, 1992, EPILEPSIA, V33, P661, DOI 10.1111/j.1528-1157.1992.tb02344.x; BERG AT, 1990, J PEDIATR-US, V116, P329, DOI 10.1016/S0022-3476(05)82816-1; BREG W R, 1962, Pediatr Clin North Am, V9, P101; CAMFIELD CS, 1979, J PEDIATR-US, V95, P361, DOI 10.1016/S0022-3476(79)80507-7; CAMFIELD PR, 1980, J PEDIATR-US, V97, P16, DOI 10.1016/S0022-3476(80)80122-3; COX DR, 1972, J R STAT SOC B, V34, P187; DIXON WJ, 1985, BMDP STATISTICAL SOF, P555; Elandt-Johnson RC, 1980, SURVIVAL MODELS DATA, P150; ELRADHI AS, 1986, CLIN PEDIATR, V25, P311; FREEMAN JM, 1990, PEDIATRICS, V86, P624; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELSEY JL, 1986, MONOGRPAHS EPIDEMIOL, V1, P293; KNUDSEN FU, 1985, ARCH DIS CHILD, V60, P1045, DOI 10.1136/adc.60.11.1045; KNUDSEN FU, 1985, J PEDIATR-US, V106, P487, DOI 10.1016/S0022-3476(85)80688-0; Lennox MA, 1946, RES PUBL ASSOC RES N, V26, P342; LENNOX WG, 1953, PEDIATRICS, V11, P341; LENNOXBUCHTHAL MA, 1975, ACTA NEUROL SCAND, P77; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; OFFRINGA M, 1992, DEV MED CHILD NEUROL, V34, P15; POLLACK MA, 1978, AM J DIS CHILD, V132, P87, DOI 10.1001/archpedi.1978.02120260089021; PRUITT AW, 1985, PEDIATRICS, V76, P644; ROSMAN NP, 1992, CONT PEDIATR, V9, P12; ROSS EM, 1980, BRIT MED J, V280, P207, DOI 10.1136/bmj.280.6209.207; SHINNAR S, 1990, CURRENT THERAPY NEUR, P29; SHIRTS SB, 1987, EPILEPSIA, V28, P625; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; VERITY CM, 1991, BMJ-BRIT MED J, V303, P1373, DOI 10.1136/bmj.303.6814.1373; WOLF SM, 1978, PEDIATRICS, V61, P728; WOLF SM, 1989, ACTA PAEDIATR SCAND, V78, P291, DOI 10.1111/j.1651-2227.1989.tb11072.x; WOLF SM, 1977, PEDIATRICS, V59, P378	37	169	174	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1992	327	16					1122	1127		10.1056/NEJM199210153271603	http://dx.doi.org/10.1056/NEJM199210153271603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT153	1528207	Bronze			2022-12-28	WOS:A1992JT15300003
J	POWELL, SM; ZILZ, N; BEAZERBARCLAY, Y; BRYAN, TM; HAMILTON, SR; THIBODEAU, SN; VOGELSTEIN, B; KINZLER, KW				POWELL, SM; ZILZ, N; BEAZERBARCLAY, Y; BRYAN, TM; HAMILTON, SR; THIBODEAU, SN; VOGELSTEIN, B; KINZLER, KW			APC MUTATIONS OCCUR EARLY DURING COLORECTAL TUMORIGENESIS	NATURE			English	Article							GENES; IDENTIFICATION; CHROMOSOME-5Q21; CANCERS; LOCUS; FAP	HUMAN tumorigenesis is associated with the accumulation of mutations both in oncogenes and in tumour suppressor genes1-3. But in no common adult cancer have the mutations that are critical in the early stages of the tumorigenic process been defined. We have attempted to determine if mutations of the APC gene play such a role in human colorectal tumours, which evolve from small benign tumours (adenomas) to larger malignant tumours (carcinomas) over the course of several decades. Here we report that sequence analysis of 41 colorectal tumours revealed that the majority of colorectal carcinomas (60%) and adenomas (63%) contained a mutated APC gene. Furthermore, the APC gene met two criteria of importance for tumour initiation. First, mutations of this gene were found in the earliest tumours that could be analysed, including adenomas as small as 0.5 cm in diameter. Second, the frequency of such mutations remained constant as tumours progressed from benign to malignant stages. These data provide strong evidence that mutations of the APC gene play a major role in the early development of colorectal neoplasms.	JOHNS HOPKINS ONCOL CTR,424 N BOND ST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; MAYO CLIN & MAYO FDN,DEPT LAB MED,ROCHESTER,MN 55905	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Mayo Clinic			Bryan, Tracy M/B-8468-2014; Pillay, Nischalan/F-9536-2012	Bryan, Tracy/0000-0002-7990-5501				BAKER SJ, 1990, CANCER RES, V50, P7717; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TURNBULL RB, 1967, ANN SURG, V166, P420; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIJNEN J, 1991, NUCLEIC ACIDS RES, V19, P6965, DOI 10.1093/nar/19.24.6965-a	22	1590	1637	0	60	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					235	237		10.1038/359235a0	http://dx.doi.org/10.1038/359235a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1528264				2022-12-28	WOS:A1992JN94400061
J	FAHEY, K				FAHEY, K			THE PEACH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2029	2029						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552630				2022-12-28	WOS:A1992HM65000009
J	SINGER, DE; SCHACHAT, A; NATHAN, DM; PATZ, A; KAHN, R; AIELLO, LM; SMITH, R; MAZZAFERRI, EL; KREISBERG, RA; WHITE, LJ				SINGER, DE; SCHACHAT, A; NATHAN, DM; PATZ, A; KAHN, R; AIELLO, LM; SMITH, R; MAZZAFERRI, EL; KREISBERG, RA; WHITE, LJ			SCREENING GUIDELINES FOR DIABETIC-RETINOPATHY	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETIC RETINOPATHY; LIGHT COAGULATION; OPHTHALMOSCOPY; PHOTOGRAMMETRY; COST SAVINGS		Screening for diabetic retinopathy has been shown to be beneficial for the early detection and prevention of vision loss in diabetic patients. The recommendations of this guideline apply to the frequency of screening and to the methods used to screen patients (undilated and dilated ophthalmoscopy, stereoscopic fundus photography and nonmydriatic fundus photography). Specific screening recommendations are given for patients with type I diabetes, for patients with type II diabetes (these patients are further classified into various risk groups, such as patients with poor glucose control and patients with proteinuria), and for women with preexisting diabetes who are planning a pregnancy. In summary, this guideline stresses the importance of ongoing evaluation of retinopathy in the diabetic patient. It points out that the most sensitive screening technique is stereoscopic fundus photography and that this technique might provide the basis for more efficient screening strategies in the future. However, because this technique has not yet been widely used for screening, the guideline recommends yearly dilated ophthalmoscopic examination as the best current approach.	AMER COLL PHYSICIANS, DEPT SCI POLICY, INDEPENDENCE MALL W, 6TH ST & RACE, PHILADELPHIA, PA 19106 USA	American College of Physicians									0	84	85	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					683	685						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546870				2022-12-28	WOS:A1992HN84400012
J	OAKLEY, K; GOOCH, C; COCKCROFT, A				OAKLEY, K; GOOCH, C; COCKCROFT, A			REVIEW OF MANAGEMENT OF INCIDENTS INVOLVING EXPOSURE TO BLOOD IN A LONDON TEACHING HOSPITAL, 1989-91	BRITISH MEDICAL JOURNAL			English	Article							HEPATITIS-B; ZIDOVUDINE; INFECTION; INJURY; VIRUS	Objective-To review management of incidents involving exposure to blood reported to an occupational health unit. Design-Analysis of all reported incidents from january 1989 to June 1991. Setting-London teaching hospital. Subjects-447 health care workers and students. Main outcome measures-Immunisation against hepatitis B virus before exposure, proportion of known source patients tested for hepatitis B surface antigen and HIV antibodies, and reasons for not testing known source patients. Results-447 incidents were reported: 337 sharps injuries and 110 other exposures. 310 staff reporting incidents (205 (82%) nurses) were already immune to hepatitis B virus, nearly always because of immunisation. 345 source patients were identified, 77 of whom had already been tested for hepatitis B surface antigen (28 positive results) and 58 for HIV antibodies (18 positive results). Of those not previously tested, 145 of 266 were subsequently tested for hepatitis B surface antigen (two positive) and 149 of 287 for HIV antibodies (none positive). The main reasons for not testing source patients were that the incident was not considered a risk, that the patient had gone home, and that the clinical team were unwilling to ask the patient. Specific hepatitis B immunoglobulin was given to 18 staff who were not immune and was avoided in 11 cases by a negative result for the patient. Prophylactic zidovudine was discussed but not given to any staff member. Conclusions-Management of exposure to blood is improved by widespread immunisation against hepatitis B virus and by knowledge of source patients' hepatitis B virus and HIV status.	ROYAL FREE HAMSTEAD NHS TRUST,OCCUPAT HLTH UNIT,LONDON NW3 2QG,ENGLAND; ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND	University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								ASTBURY C, 1990, J SOC OCCUP MED, V40, P92; BOR R, 1991, BRIT MED J, V303, P905, DOI 10.1136/bmj.303.6807.905; BROWN EM, 1991, BRIT MED J, V303, P990, DOI 10.1136/bmj.303.6808.990; BURDEN AD, 1991, POSTGRAD MED J, V67, P256, DOI 10.1136/pgmj.67.785.256; JEFFRIES DJ, 1991, BRIT MED J, V302, P1349, DOI 10.1136/bmj.302.6789.1349; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; LOOKE DFM, 1990, LANCET, V335, P1280, DOI 10.1016/0140-6736(90)91343-9; MILLER PJ, 1989, J OCCUP ENVIRON MED, V31, P524, DOI 10.1097/00043764-198906000-00008; MILLER R, 1988, AIDS GUIDE CLIN COUN; PORTEOUS MJL, 1990, BRIT MED J, V301, P167, DOI 10.1136/bmj.301.6744.167; TAIT DR, 1991, BRIT MED J, V303, P581; YASSI A, 1990, BRIT J IND MED, V47, P645; 1989, MMWR, V38, pS6; 1990, GUIDANCE CLIN HLTH C; 1990, CODE PRACTICE SAFE U; 1990, HIV CAUSATIVE AGENT	16	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					949	951		10.1136/bmj.304.6832.949	http://dx.doi.org/10.1136/bmj.304.6832.949			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1530692	Green Published, Bronze			2022-12-28	WOS:A1992HP06400020
J	FELDMAN, AM				FELDMAN, AM			CAN WE ALTER SURVIVAL IN PATIENTS WITH CONGESTIVE-HEART-FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							IDIOPATHIC DILATED CARDIOMYOPATHY; LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; ADRENERGIC BLOCKING-DRUGS; RENIN-ANGIOTENSIN SYSTEM; VASODILATOR THERAPY; CONTROLLED TRIAL; PARTIAL AGONIST; DOUBLE-BLIND; CLINICAL-EXPERIENCE	Objective. - To assess the efficacy of pharmacologic therapy in improving survival in patients with congestive heart failure (CHF) in the context of recent investigational studies having mortality as an end point. Data Sources. - Data were obtained from English-language articles that reported both randomized and retrospective studies assessing the efficacy of pharmacologic therapy in the treatment of patients with CHF. The review included articles indexed under the terms congestive heart failure and drug therapy in the National Library of Medicine's MEDLINE database. Study Selection. - Studies selected for detailed review were those having mortality as a primary or secondary end point. Data Extraction. - Guidelines for assessing data quality and validity included study size, double-blind and randomized design, the number of end points, the sensitivity and specificity of objective measurements, and the validity of the statistical analysis. Data Synthesis. - Review of the existing literature demonstrates that pharmacologic agents that improve resting hemodynamics or exercise duration in patients with CHF may not necessarily prolong survival. However, recent studies demonstrate that angiotensin-converting enzyme inhibitors prolong survival in patients with symptomatic CHF, while at the same time improving exercise capacity and left ventricular performance. Although less well tolerated, the combination of hydralazine hydrochloride and isosorbide dinitrate therapy also improves survival, but to a lesser degree. New agents show promise, but definitive assessment requires the results of large, randomized and double-blind studies having mortality as an end point. Conclusions. - Mortality is an important end point in assessing the efficacy of drugs for the treatment of CHF.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University								AGOSTONI PG, 1986, BRIT HEART J, V55, P391; ANDERSON JL, 1985, AM J CARDIOL, V55, P471, DOI 10.1016/0002-9149(85)90396-0; ANDERSSON B, 1991, J AM COLL CARDIOL, V18, P1059, DOI 10.1016/0735-1097(91)90767-4; [Anonymous], 1990, Am J Cardiol, V66, P315; [Anonymous], 1990, Lancet, V336, P1; [Anonymous], 1986, Am J Cardiol, V57, P91; APPLEFELD MM, 1987, AM HEART J, V114, P589, DOI 10.1016/0002-8703(87)90757-5; ARNOLD SB, 1979, ANN INTERN MED, V91, P345, DOI 10.7326/0003-4819-91-3-345; BAIM DS, 1983, NEW ENGL J MED, V309, P748, DOI 10.1056/NEJM198309293091302; BAYLISS J, 1987, BRIT HEART J, V57, P17; BENOTTI JR, 1978, NEW ENGL J MED, V299, P1373, DOI 10.1056/NEJM197812212992501; BERGER M, 1985, CHEST, V88, P295, DOI 10.1378/chest.88.2.295; BHATIA SJS, 1986, AM HEART J, V111, P692, DOI 10.1016/0002-8703(86)90101-8; BRAUNWALD E, 1984, NEW ENGL J MED, V310, P459, DOI 10.1056/NEJM198402163100711; BRISTOW MR, 1991, CIRCULATION, V84, P1024, DOI 10.1161/01.CIR.84.3.1024; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; CHATTERJEE K, 1980, ANN INTERN MED, V92, P600, DOI 10.7326/0003-4819-92-5-600; CHATTERJEE K, 1988, AM J CARDIOL, V62, pA46, DOI 10.1016/S0002-9149(88)80085-7; CLELAND JGF, 1987, BRIT HEART J, V58, P572; COHN JN, 1974, JAMA-J AM MED ASSOC, V229, P1911, DOI 10.1001/jama.229.14.1911; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1987, CIRCULATION, V76, P443; COHN JN, 1983, J AM COLL CARDIOL, V2, P755; COLLINS JA, 1990, J HEART TRANSPLANT, V9, P205; COLUCCI WS, 1981, NEW ENGL J MED, V305, P185, DOI 10.1056/NEJM198107233050402; COLUCCI WS, 1988, J CLIN INVEST, V81, P1103, DOI 10.1172/JCI113423; CORBALAN R, 1990, AM J CARDIOL, V65, P644, DOI 10.1016/0002-9149(90)91045-8; COWLEY AJ, 1988, BRIT MED J, V297, P169, DOI 10.1136/bmj.297.6642.169; CURRIE PJ, 1984, J AM COLL CARDIOL, V3, P203, DOI 10.1016/S0735-1097(84)80449-0; CURTISS C, 1978, CIRCULATION, V58, P763, DOI 10.1161/01.CIR.58.5.763; DEFEYTER PJ, 1990, CIRCULATION, V81, P99; DIBIANCO R, 1989, NEW ENGL J MED, V320, P677, DOI 10.1056/NEJM198903163201101; DIES F, 1986, CIRCULATION, V74, P38; DIES F, 1989, CIRCULATION, V80, P175; EICHHORN EJ, 1990, CIRCULATION, V82, P473, DOI 10.1161/01.CIR.82.2.473; ENGELMEIER RS, 1985, CIRCULATION, V72, P536, DOI 10.1161/01.CIR.72.3.536; FELDMAN AM, 1991, AM J CARDIOL, V68, P1203, DOI 10.1016/0002-9149(91)90194-P; FIBULLA HR, 1989, J AM COLL CARDIOL, V13, P653; FOWLER MB, 1985, AM J CARDIOL, V55, pD120, DOI 10.1016/0002-9149(85)91066-5; FRANCIOSA JA, 1982, AM HEART J, V104, P587, DOI 10.1016/0002-8703(82)90231-9; FRANCIOSA JA, 1983, AM J CARDIOL, V51, P831, DOI 10.1016/S0002-9149(83)80141-6; FRANCIOSA JA, 1984, CIRCULATION, V70, P63, DOI 10.1161/01.CIR.70.1.63; FRANCIOSA JA, 1978, JAMA-J AM MED ASSOC, V240, P443, DOI 10.1001/jama.240.5.443; FRANCIS GS, 1986, AM J CARDIOL, V57, pB3, DOI 10.1016/0002-9149(86)90991-4; FURBERG CD, 1988, AM J CARDIOL, V62, pA41, DOI 10.1016/S0002-9149(88)80084-5; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; GILBERT EM, 1990, AM J MED, V88, P223, DOI 10.1016/0002-9343(90)90146-5; GOLDSMITH SR, 1983, J AM COLL CARDIOL, V1, P1385, DOI 10.1016/S0735-1097(83)80040-0; GOLDSTEIN S, 1988, JAMA-J AM MED ASSOC, V259, P539; GOTTLIEB SS, 1990, CIRCULATION, V81, P860, DOI 10.1161/01.CIR.81.3.860; GRADMAN A, 1989, J AM COLL CARDIOL, V14, P564, DOI 10.1016/0735-1097(89)90093-4; HANSTEEN V, 1982, BRIT MED J, V284, P155, DOI 10.1136/bmj.284.6310.155; HEILBRUNN SM, 1989, CIRCULATION, V79, P483, DOI 10.1161/01.CIR.79.3.483; HIGGINBOTHAM MB, 1983, AM J CARDIOL, V52, P782, DOI 10.1016/0002-9149(83)90415-0; HOHNLOSER SH, 1987, AM HEART J, V114, P1, DOI 10.1016/0002-8703(87)90299-7; HOLTZ J, 1987, J CARDIOVASC PHARM, V9, P348, DOI 10.1097/00005344-198703000-00011; IMPERATOMCGINLEY J, 1987, NEW ENGL J MED, V316, P793, DOI 10.1056/NEJM198703263161307; JAESCHKE R, 1990, AM J MED, V88, P279, DOI 10.1016/0002-9343(90)90154-6; JESSUP M, 1991, J AM COLL CARDIOL, V18, P1067, DOI 10.1016/0735-1097(91)90768-5; KATZ SD, 1989, CIRCULATION S2, V80, P176; KESSLER PD, 1987, AM HEART J, V113, P137, DOI 10.1016/0002-8703(87)90021-4; KRAMER BL, 1983, CIRCULATION, V67, P807, DOI 10.1161/01.CIR.67.4.807; LAMBERTZ H, 1984, CIRCULATION, V69, P298, DOI 10.1161/01.CIR.69.2.298; LEIER CV, 1983, ANN INTERN MED, V99, P490, DOI 10.7326/0003-4819-99-4-490; LEIER CV, 1977, CIRCULATION, V56, P468, DOI 10.1161/01.CIR.56.3.468; LEIER CV, 1983, CIRCULATION, V67, P817, DOI 10.1161/01.CIR.67.4.817; LEVINE TB, 1982, AM J CARDIOL, V49, P1659, DOI 10.1016/0002-9149(82)90243-0; LINDPAINTNER K, 1991, CIRC RES, V68, P905, DOI 10.1161/01.RES.68.4.905; LYNCH JJ, 1989, J CARDIOVASC PHARM, V14, P585, DOI 10.1097/00005344-198910000-00010; MARLOW HF, 1990, CIRCULATION, V81, P93; MASSIE B, 1985, CIRCULATION, V71, P963, DOI 10.1161/01.CIR.71.5.963; MCKAY CR, 1982, AM HEART J, V104, P575, DOI 10.1016/0002-8703(82)90229-0; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; MOLAJO AO, 1985, BRIT HEART J, V54, P17; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; MOSS AJ, 1981, CIRCULATION, V64, P1150, DOI 10.1161/01.CIR.64.6.1150; MULROW CD, 1988, JAMA-J AM MED ASSOC, V259, P3422, DOI 10.1001/jama.259.23.3422; PACKER M, 1984, CIRCULATION, V70, P1038, DOI 10.1161/01.CIR.70.6.1038; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PACKER M, 1990, CIRCULATION, V82, P77; PACKER M, 1988, European Heart Journal, V9, P105; PARMLEY WW, 1986, AM J CARDIOL, V57, pB34, DOI 10.1016/0002-9149(86)90996-3; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; POLLOCK SG, 1990, AM J CARDIOL, V66, P603, DOI 10.1016/0002-9149(90)90488-M; PRATT C, 1982, J CLIN PHARMACOL, V22, P335, DOI 10.1002/j.1552-4604.1982.tb02684.x; PRIDA XE, 1983, AM J MED, V75, P795, DOI 10.1016/0002-9343(83)90410-2; ROSENBAUM JS, 1987, J PHARMACOL EXP THER, V241, P354; ROUSSEAU MF, 1984, J AM COLL CARDIOL, V3, P472; RYDEN L, 1983, NEW ENGL J MED, V308, P614, DOI 10.1056/NEJM198303173081102; RYMAN KS, 1986, AM J CARDIOL, V58, P583, DOI 10.1016/0002-9149(86)90280-8; SALEM DN, 1988, PHARMACOTHERAPY, V8, P319; SASAYAMA S, 1990, CARDIOVASC DRUG THER, V4, P419; SONNENBLICK EH, 1985, AM J CARDIOL, V55, pB179, DOI 10.1016/0002-9149(85)90629-0; SWEDBERG K, 1980, BRIT HEART J, V44, P117; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; SWEDBERG K, 1990, CIRCULATION, V82, P1730, DOI 10.1161/01.CIR.82.5.1730; URETSKY BF, 1990, CIRCULATION, V82, P774, DOI 10.1161/01.CIR.82.3.774; VIGHOLTSORENSEN E, 1989, BRIT HEART J, V62, P335; WEBER KT, 1986, AM J CARDIOL, V58, P589, DOI 10.1016/0002-9149(86)90281-X	100	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1956	1961		10.1001/jama.267.14.1956	http://dx.doi.org/10.1001/jama.267.14.1956			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL677	1548829				2022-12-28	WOS:A1992HL67700031
J	BLUM, RW; HARMON, B; HARRIS, L; BERGEISEN, L; RESNICK, MD				BLUM, RW; HARMON, B; HARRIS, L; BERGEISEN, L; RESNICK, MD			AMERICAN-INDIAN ALASKA NATIVE YOUTH HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - To assess risk behaviors, health problems, worries and concerns, and resiliency-promoting factors among American Indian-Alaska Native adolescents. Design. - Survey. Setting. - Nonurban schools from eight Indian Health Service areas. Participants. - A total of 13454 seventh-through 12th-grade American Indian-Alaska Native youths. Main Outcome Measures. - A revised version of the Adolescent Health Survey, a comprehensive, anonymous, self-report questionnaire with 162 items addressing 1 0 dimensions of health. Results. - Poor physical health was reported by 2% of the study sample and was significantly correlated with social risk factors of physical and/or sexual abuse, suicide attempts, substance abuse, poor school performance, and nutritional inadequacies. Injury risk behaviors included never wearing seatbelts (44%), drinking and driving (37.9% of driving 10th through 12th graders), and riding with a driver who had been drinking (21.8%). Physical and sexual abuse prevalence was 10% and 13%, respectively, with 23.9% of females reporting physical abuse and 21.6% of females reporting sexual abuse by the 12th grade. Almost 6% of the entire sample endorsed signs of severe emotional distress. Eleven percent of the teens surveyed knew someone who had killed himself or herself, and 17% had attempted suicide themselves. Sixty-five percent of males and 56.8% of females reported having had intercourse by the 12th grade. Weekly or more frequent alcohol use rose from 8.2% of seventh graders to 14.1% by the 12th grade; for males, the survey noted an increase in regular alcohol use of 3% to 5% a year to 27.3% by the 12th grade. For each variable measured, rates are much higher for American Indian adolescents than those for rural white Minnesota youth, except for age at first intercourse and alcohol use. Conclusions. - American Indian-Alaska Native adolescents reported high rates of health-compromising behaviors and risk factors related to unintentional injury, substance use, poor self-assessed health status, emotional distress, and suicide. Interventions must be culturally sensitive, acknowledge the heterogeneity of Indian populations, be grounded in cultural traditions that promote health, and be developed with full participation of the involved communities.	SCH PUBL HLTH,PROGRAM HOSP & HLTH CARE ADM,ADOLESCENT HLTH PROGRAM,MINNEAPOLIS,MN; AMER ASSOC MED COLL,DIV MINOR HLTH EDUC & PREVENT,WASHINGTON,DC		BLUM, RW (corresponding author), UNIV MINNESOTA HOSP & CLIN,DIV GEN PEDIAT & ADOLESCENT HLTH,BOX 721,HARVARD ST & E RIVER RD,MINNEAPOLIS,MN 55455, USA.		Duran, Bonnie m/A-3029-2009		PHS HHS [MCJ-00985-10-2] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEAUVAIS F, 1989, AM J PUBLIC HEALTH, V79, P634, DOI 10.2105/AJPH.79.5.634; BERLIN IN, 1987, J COMMUNITY PSYCHOL, V15, P299, DOI 10.1002/1520-6629(198707)15:3<299::AID-JCOP2290150303>3.0.CO;2-6; BLUM R, 1987, JAMA-J AM MED ASSOC, V257, P3390, DOI 10.1001/jama.257.24.3390; BLUM RW, 1988, MINN MED, V71, P143; BLUM RW, 1991, JAMA-J AM MED ASSOC, V265, P2711, DOI 10.1001/jama.265.20.2711; BLUM RW, 1992, AM INDIAN YOUTH HLTH; Dizmang L., 1967, SUICIDE CHEYENNE IND; FREDERICK CJ, 1975, DHEW ADM7642 PUBL; Gans J., 1990, AM ADOLESCENTS HLTH; Green B. E., 1981, WHITE CLOUD J, V2, P22; Harris L., 1989, TECHNICAL REPORT ADO; IRWIN CE, 1991, HLTH AM YOUTH CURREN; JOHNSTON LD, 1989, ADM891638 US DEP HLT; KANDEL DB, 1984, AM J PUBLIC HEALTH, V74, P660, DOI 10.2105/AJPH.74.7.660; LUKER H, 1975, TAKING CHANCES ABORT; MCSHANE D, 1988, J ADOLESCENCE, V11, P87, DOI 10.1016/S0140-1971(88)80047-2; MILLER SI, 1971, INT J SOC PSYCHIATR, V17, P189, DOI 10.1177/002076407101700303; RESNICK MD, 1988, MINNESOTA PEDIATRICI, V50, P3; 1991, SUCCESSFUL REPLICABL; 1990, INDIAN ADOLESCENT ME; 1990, HDB CONDUCTING YOUTH; 1990, TRENDS INDIAN HLTH 1; 1991, OTAH468 OFF TECHN AS	23	207	208	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1637	1644		10.1001/jama.267.12.1637	http://dx.doi.org/10.1001/jama.267.12.1637			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HJ597	1542173				2022-12-28	WOS:A1992HJ59700031
J	HENKEL, T; ZABEL, U; VANZEE, K; MULLER, JM; FANNING, E; BAEUERLE, PA				HENKEL, T; ZABEL, U; VANZEE, K; MULLER, JM; FANNING, E; BAEUERLE, PA			INTRAMOLECULAR MASKING OF THE NUCLEAR LOCATION SIGNAL AND DIMERIZATION DOMAIN IN THE PRECURSOR FOR THE P50 NF-KAPPA-B SUBUNIT	CELL			English	Article							ENHANCER-BINDING-PROTEIN; TRANSCRIPTION FACTOR; REL ONCOGENE; 65-KD SUBUNIT; DNA; HOMOLOGY; RECEPTOR; CELLS; ACTIVATION; ANTIBODIES	We show that the non-DNA-binding precursor for the p50 subunit (p110), like NF-kappa-B, is subject to control of nuclear uptake. In contrast to p50, p110 was excluded from nuclei and unable to associate detectably with p50 or p65 NF-kappa-B subunits. The nuclear location signal in the N-terminal half of p110 was not accessible for monospecific antibodies. Removal of only 191 amino acids from the C-terminus of p110 restored antibody accessibility as well as nuclear uptake. The C-terminal half of p110, which is linked to the p50 portion via a glycine-rich hinge, could also noncovalently bind to p50. This helps to explain why p50, after cleavage of the precursor in intact cells, was still retained in an inactive form in the cytoplasm. Our study describes a novel mechanism of nuclear uptake control by masking of a nuclear location signal through a remote domain within a precursor molecule.	INST BIOCHEM,W-8000 MUNICH 2,GERMANY		HENKEL, T (corresponding author), UNIV MUNICH,GENZENTRUM,MOLEK BIOL LAB,KLOPFERSPITZ,W-8033 MARTINSRIED,GERMANY.							ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V344, P36; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FAN CM, 1991, NATURE, V354, P398; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; Graessmann A, 1980, Methods Enzymol, V65, P816; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MULLER M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P171, DOI 10.1016/0167-4781(91)90052-N; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, TRENDS CELL BIOL, V10, P3805; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VANZEE K, 1991, MOL CELL BIOL, V11, P5137, DOI 10.1128/MCB.11.10.5137; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	48	368	375	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1121	1133		10.1016/0092-8674(92)90083-O	http://dx.doi.org/10.1016/0092-8674(92)90083-O			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547506				2022-12-28	WOS:A1992HK67400015
J	ABELSON, J				ABELSON, J			RECOGNITION OF TRANSFER-RNA PRECURSORS - A ROLE FOR THE INTRON	SCIENCE			English	Editorial Material											ABELSON, J (corresponding author), CALTECH,DIV BIOL 14775,PASADENA,CA 91125, USA.							ABELSON J, 1991, HARVEY LECT, V85, P1; BALDI IM, 1992, SCIENCE, V255, P1404; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SCHULMAN LH, IN PRESS PROG NUCLEI	9	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1390	1390		10.1126/science.1542787	http://dx.doi.org/10.1126/science.1542787			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542787				2022-12-28	WOS:A1992HH74400042
J	HEUER, AH; FINK, DJ; LARAIA, VJ; ARIAS, JL; CALVERT, PD; KENDALL, K; MESSING, GL; BLACKWELL, J; RIEKE, PC; THOMPSON, DH; WHEELER, AP; VEIS, A; CAPLAN, AI				HEUER, AH; FINK, DJ; LARAIA, VJ; ARIAS, JL; CALVERT, PD; KENDALL, K; MESSING, GL; BLACKWELL, J; RIEKE, PC; THOMPSON, DH; WHEELER, AP; VEIS, A; CAPLAN, AI			INNOVATIVE MATERIALS PROCESSING STRATEGIES - A BIOMIMETIC APPROACH	SCIENCE			English	Article							BONE; CDS; VESICLES; MATRIX; CRYSTALLIZATION; PROTEINS; CEMENT; FILMS; MODEL	Many organisms construct structural ceramic (biomineral) composites from seemingly mundane materials; cell-mediated processes control both the nucleation and growth of mineral and the development of composite microarchitecture. Living systems fabricate biocomposites by: (i) confining biomineralization within specific subunit compartments; (ii) producing a specific mineral with defined crystal size and orientation; and (iii) packaging many incremental units together in a moving front process to form fully densified, macroscopic structures. By adapting biological principles, materials scientists are attempting to produce novel materials. To date, neither the elegance of the biomineral assembly mechanisms nor the intricate composite microarchitectures have been duplicated by nonbiological processing. However, substantial progress has been made in the understanding of how biomineralization occurs, and the first steps are now being taken to exploit the basic principles involved.	COLLATEK INC, COLUMBUS, OH 43201 USA; THREE M CO, DIV IND MINERALS, ST PAUL, MN 55144 USA; UNIV CHILE, FAC VET SCI, SANTIAGO, CHILE; UNIV ARIZONA, DEPT MAT SCI & ENGN, TUCSON, AZ 85721 USA; ICI ADV MAT, CHESHIRE WA7 4QE, ENGLAND; PENN STATE UNIV, DEPT MAT SCI & ENGN, UNIVERSITY PK, PA 16802 USA; CASE WESTERN RESERVE UNIV, DEPT MACROMOLEC SCI, CLEVELAND, OH 44106 USA; PACIFIC NW LAB, RICHLAND, WA 99352 USA; OREGON GRAD INST, BEAVERTON, OR 97006 USA; CLEMSON UNIV, DEPT BIOL SCI, CLEMSON, SC 29631 USA; NORTHWESTERN UNIV, SCH DENT, CHICAGO, IL 60611 USA; CASE WESTERN RESERVE UNIV, DEPT BIOL, CLEVELAND, OH 44106 USA	3M; Universidad de Chile; University of Arizona; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Case Western Reserve University; United States Department of Energy (DOE); Pacific Northwest National Laboratory; Clemson University; Northwestern University; Case Western Reserve University	HEUER, AH (corresponding author), CASE WESTERN RESERVE UNIV, DEPT MAT SCI & ENGN, CLEVELAND, OH 44106 USA.		Arias, Jose L/E-1206-2011	Caplan, Arnold/0000-0002-8677-6621				Addadi L., 1989, Connective Tissue Research, V21, P127, DOI 10.3109/03008208909050003; ADDADI L, 1991, ACS SYM SER, V444, P13; ALFORD NM, 1985, J MATER SCI, V20, P37, DOI 10.1007/BF00555896; ALPER M, 1991, MATERIALS SYNTHESIS; ARIAS JL, 1991, MATER RES SOC SYMP P, V218, P193; ARIAS JL, 1991, CONNECT TISSUE RES, V26, P37, DOI 10.3109/03008209109152162; ARIAS JM, UNPUB; BARLOW JW, 1991, 2ND C P INT C RAP PR, P1; BERMAN A, 1990, SCIENCE, V250, P667; BERMAN A, 1988, NATURE, V331, P556; BEVELANDER G, 1969, CALC TISS RES, V3, P84, DOI 10.1007/BF02058648; BIANCONI PA, 1991, NATURE, V349, P315, DOI 10.1038/349315a0; BIRCHALL JD, 1981, J CRYST GROWTH, V54, P323, DOI 10.1016/0022-0248(81)90476-0; BLAKEMORE RP, 1979, J BACTERIOL, V140, P720, DOI 10.1128/JB.140.2.720-729.1979; BOSKEY AL, 1989, BONE MINER, V6, P111, DOI 10.1016/0169-6009(89)90044-5; Boskey AL, 1986, CELL MEDIATED CALCIF, P175; Brockmann W., 1986, INT J ADHES ADHES, V6, P115; CAPLAN AI, 1984, SCI AM, V251, P84, DOI 10.1038/scientificamerican1084-84; Caplan AI, 1987, BONE MINERAL RES, P117; CHEN KC, 1990, BETTER CERAMICS CHEM, V4, P663; CLEGG WJ, 1990, NATURE, V347, P455, DOI 10.1038/347455a0; CURREY JD, 1977, PROC R SOC SER B-BIO, V196, P443, DOI 10.1098/rspb.1977.0050; DAMERON CT, 1989, NATURE, V338, P596, DOI 10.1038/338596a0; DEMANAY RE, 1982, ASME82GT264 PAP; DEUTSCH D, 1989, ANAT RECORD, V224, P189, DOI 10.1002/ar.1092240209; DIMUZIO MT, 1978, CALC TISS RES, V25, P169, DOI 10.1007/BF02010765; EANES ED, 1989, ANAT REC, V224, P220, DOI 10.1002/ar.1092240211; ERBEN HK, 1972, BIOMINERALISATION, V4, P15; ESAKI L, 1986, IEEE J QUANTUM ELECT, V22, P1611, DOI 10.1109/JQE.1986.1073162; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; GAY CV, 1978, METAB BONE DIS RELAT, V1, P105, DOI 10.1016/0221-8747(78)90045-0; GRAINGER DW, 1989, FEBS LETT, V252, P73, DOI 10.1016/0014-5793(89)80892-0; HERRON N, 1989, J AM CHEM SOC, V111, P530, DOI 10.1021/ja00184a021; HEYWOOD BR, 1990, J COLLOID INTERF SCI, V138, P295, DOI 10.1016/0021-9797(90)90211-6; HOLMESFARLEY SR, 1990, BETTER CERAMICS CHEM, V4, P439; HULING JC, 1991, CERAMIC POWDER SCI, V4, P401; INOUYE K, 1982, J PHYS CHEM-US, V86, P1465, DOI 10.1021/j100397a051; JACKSON AP, 1988, PROC R SOC SER B-BIO, V234, P415, DOI 10.1098/rspb.1988.0056; KENDALL K, 1983, PHILOS T R SOC A, V310, P139, DOI 10.1098/rsta.1983.0073; Kendall K., 1987, TRIBOLOGY PARTICULAT, P91; KENDALL K, 1984, Patent No. 112137; Kendall K, 1985, VERY HIGH STRENGTH C, P143; KINGERY WD, 1976, INTRO CERAMICS, P4; KINNE RW, 1987, J BIOL CHEM, V262, P10206; LEE H, 1988, J PHYS CHEM-US, V92, P2597, DOI 10.1021/j100320a040; LIU H, 1991, MATER RES SOC SYMP P, V218, P115; Lowenstam HA, 1989, BIOMINERALIZATION; MANN S, 1986, NATURE, V324, P565, DOI 10.1038/324565a0; Mann S., 1989, BIOMINERALIZATION CH; MARCUS HL, 1990, J MET            APR, P8; MARTIN TJ, 1989, ENDOCRIN METAB CLIN, V18, P833, DOI 10.1016/S0889-8529(18)30346-3; MEHROTRA V, 1991, SOLID STATE COMMUN, V77, P155, DOI 10.1016/0038-1098(91)90876-W; NAKAMURA O, 1991, MATER RES SOC SYMP P, V218, P275; PELLERIN N, 1991, MATER RES SOC SYMP P, V218, P123; POOLE AR, 1987, BIOL PROTEOGLYCANS, P187; PREISLER E, 1976, J APPL ELECTROCHEM, V6, P301, DOI 10.1007/BF00608915; PRICE PA, 1988, ANNU REV NUTR, V8, P865; PUTVINSKI TM, 1990, LANGMUIR, V6, P1567, DOI 10.1021/la00100a007; RIEKE PC, 1990, MATERIALS SYNTHESIS; ROSSETTI R, 1984, J CHEM PHYS, V80, P4464, DOI 10.1063/1.447228; SACHS E, 1991, 2TH NAT C RAP PROT U, P39; SAKATA K, 1989, CHEM LETT, P2159, DOI 10.1246/cl.1989.2159; SAKATA K, 1990, J CHEM SOC CHEM COMM, P504, DOI 10.1039/c39900000504; SIMKISS K, 1961, BIOL REV, V36, P321, DOI 10.1111/j.1469-185X.1961.tb01292.x; STEIGERWALD ML, 1988, J AM CHEM SOC, V110, P3046, DOI 10.1021/ja00218a008; TIRRELL DA, 1991, MRS BULL, V16, P23, DOI 10.1557/S0883769400056505; VANDEPOL FCM, 1990, AM CERAM SOC BULL, V69, P1959; Veis A., 1989, P189; WADA K, 1974, BIOMINERALIZATION RE, V6, P141; WALTON AG, 1979, FORMATION PROPERTIES; WANG Y, 1990, PHYS REV B, V42, P7253, DOI 10.1103/PhysRevB.42.7253; WEISSBUCH I, 1990, J AM CHEM SOC, V112, P7718, DOI 10.1021/ja00177a036; Wheeler A.P., 1989, P95; WHEELER AP, 1990, MATER RES SOC SYMP P, V174, P45; YASREBI M, 1990, BETTER CERAMICS CHEM, V4, P625; ZELINKSY BJJ, 1990, BETTER CERAMICS CHEM, V4	76	489	520	3	192	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1098	1105		10.1126/science.1546311	http://dx.doi.org/10.1126/science.1546311			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546311				2022-12-28	WOS:A1992HF63200034
J	SCHOFIELD, AE; REARDON, DM; TANNER, MJA				SCHOFIELD, AE; REARDON, DM; TANNER, MJA			DEFECTIVE ANION TRANSPORT ACTIVITY OF THE ABNORMAL BAND-3 IN HEREDITARY OVALOCYTIC RED-BLOOD-CELLS	NATURE			English	Article							HUMAN-ERYTHROCYTES; MALARIA PARASITES; PROTEIN; MELANESIANS; MEMBRANES; INVASION; EXCHANGE; INVITRO; CARRIER	HEREDITARY ovalocytosis is common in some areas of Melanesia and South East Asia where malaria is endemic. These red cells resist invasion by malarial parasites in vitro 1,2 and ovalocytic individuals are less parasitized than normal 3. This has been attributed to the greater rigidity of ovalocytic red cells 4,5. It has been suggested that South East Asian ovalocytosis results from the heterozygous presence of an altered membrane anion transporter (band 3) 6,7. We have used the polymerase chain reaction to clone the abnormal band 3 complementary DNA from an ovalocytic of Indian origin 8 and found two changes from the normal protein: a point mutation (Lys 56 --> Glu) and the deletion of the sequence AFSPQVLAA (residues 400-408), but no evidence for an N-terminal extension 7. The deletion is also found in the abnormal band 3 of South East Asian ovalocytes 9 and seems to be responsible for the unusual properties of the ovalocytic red cell. We show here that the membrane domain of the abnormal ovalocyte band 3 has a substantially altered structure and that the protein is defective in anion transport activity. The changed transport properties of the red cells may have a role in the reduced parasitaemia of ovalocytic individuals.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND; ADDENBROOKES HOSP,DEPT HAEMATOL,CAMBRIDGE CB2 2QQ,ENGLAND	University of Bristol; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMATO D, 1977, PAPUA NEW GUINEA MED, V20, P26; CABANTCHIK ZI, 1983, MOL PHARMACOL, V23, P92; CATTANI JA, 1987, T ROY SOC TROP MED H, V81, P705, DOI 10.1016/0035-9203(87)90001-0; HADLEY T, 1983, J CLIN INVEST, V71, P780, DOI 10.1172/JCI110827; HALESTRAP AP, 1976, BIOCHEM J, V156, P193, DOI 10.1042/bj1560193; JANAS T, 1989, AM J PHYSIOL, V257, pC601, DOI 10.1152/ajpcell.1989.257.4.C601; JONES GL, 1991, BIOCHIM BIOPHYS ACTA, V1096, P33; KIDSON C, 1981, P NATL ACAD SCI-BIOL, V78, P5829, DOI 10.1073/pnas.78.9.5829; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU SC, 1990, NEW ENGL J MED, V323, P1530, DOI 10.1056/NEJM199011293232205; MOHANDAS N, 1984, BLOOD, V63, P1385; PIMPLIKAR SW, 1986, J BIOL CHEM, V261, P9770; SAUL A, 1984, J CELL BIOL, V98, P1348, DOI 10.1083/jcb.98.4.1348; SCHOFIELD AE, IN PRESS J MOL BIOL; SERJEANTSON S, 1977, HUM GENET, V37, P161, DOI 10.1007/BF00393579; SHEARMAN MS, 1984, BIOCHEM J, V223, P673, DOI 10.1042/bj2230673; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TANNER MJA, 1991, BLOOD, V78, P2785; WAGNER S, 1987, AM J PHYSIOL, V253, pF213, DOI 10.1152/ajprenal.1987.253.2.F213; WEITH JO, 1982, PHILOS T R SOC LON B, V299, P383	21	154	155	1	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					836	838		10.1038/355836a0	http://dx.doi.org/10.1038/355836a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538763				2022-12-28	WOS:A1992HF63600059
J	RINI, JM; SCHULZEGAHMEN, U; WILSON, IA				RINI, JM; SCHULZEGAHMEN, U; WILSON, IA			STRUCTURAL EVIDENCE FOR INDUCED FIT AS A MECHANISM FOR ANTIBODY-ANTIGEN RECOGNITION	SCIENCE			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; 3-DIMENSIONAL STRUCTURE; HYPERVARIABLE REGIONS; BINDING; COMPLEX; PEPTIDE; PROTEIN; FAB; RESOLUTION; REFINEMENT	The three-dimensional structure of a specific antibody (Fab 17/9) to a peptide immunogen from influenza virus hemagglutinin [HA1(75-110)] and two independent crystal complexes of this antibody with bound peptide (Tyr(P100)-Leu(P108) have been determined by x-ray crystallographic techniques at 2.0 angstrom, 2.9 angstrom, and 3.1 angstrom resolution, respectively. The nonapeptide antigen assumes a type I beta-turn in the antibody combining site and interacts primarily with the Fab hypervariable loops L3, H2, and H3. Comparison of the bound and unbound Fab structures shows that a major rearrangement in the H3 loop accompanies antigen binding. This conformational change results in the creation of a binding pocket for the beta-turn of the peptide, allowing Tyr(P105) to be accommodated. The conformation of the peptide bound to the antibody shows similarity to its cognate sequence in the HA1, suggesting a possible mechanism for the cross-reactivity of this Fab with monomeric hemagglutinin. The structures of the free and antigen bound antibodies demonstrate the flexibility of the antibody combining site and provide an example of induced fit as a mechanism for antibody-antigen recognition.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023498] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23498] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BHAT TN, 1984, J APPL CRYSTALLOGR, V17, P244, DOI 10.1107/S0021889884011456; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; Colman PM, 1991, CURR OPIN STRUC BIOL, V1, P232, DOI 10.1016/0959-440X(91)90067-4; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; COLMAN PM, 1989, PHILOS T R SOC B, V323, P511, DOI 10.1098/rstb.1989.0028; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DYSON HJ, 1985, NATURE, V318, P480; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GETZOFF ED, 1987, NATURE, V326, P358; GEYSEN HM, UNPUB; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; HOPE H, 1989, ACTA CRYSTALLOGR B, V45, P190, DOI 10.1107/S0108768188013710; HOUGHTEN RA, 1986, VACCINES 86 NEW APPR, P21; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JANIN J, 1990, J BIOL CHEM, V265, P16027; JERNE NK, 1982, EMBO J, V1, P243, DOI 10.1002/j.1460-2075.1982.tb01154.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KOHLER H, 1989, METHOD ENZYMOL, V178, P3; LERNER RA, 1988, BIOESSAYS, V9, P107, DOI 10.1002/bies.950090402; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PINILLA C, 1991, PEPTIDES, P538; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SCHULZEGAHMEN U, 1988, J BIOL CHEM, V263, P17100; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WILSON IA, 1991, CIBA F SYMP, V159, P13; YEATES TO, 1988, J APPL CRYSTALLOGR, V21, P925, DOI 10.1107/S0021889888007927	49	511	524	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1992	255	5047					959	965		10.1126/science.1546293	http://dx.doi.org/10.1126/science.1546293			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546293				2022-12-28	WOS:A1992HE60500033
J	CHAMBERLAIN, J; MOSS, S; ELLMAN, R; JOHNS, L; FORREST, APM; KIRKPATRICK, AE; ANDERSON, TJ; THOMAS, B; PRICE, J; GIBBS, N; BOULTER, PS; WELLS, C; BECK, JS; BURTON, P				CHAMBERLAIN, J; MOSS, S; ELLMAN, R; JOHNS, L; FORREST, APM; KIRKPATRICK, AE; ANDERSON, TJ; THOMAS, B; PRICE, J; GIBBS, N; BOULTER, PS; WELLS, C; BECK, JS; BURTON, P			SPECIFICITY OF SCREENING IN UNITED-KINGDOM TRIAL OF EARLY DETECTION OF BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							MAMMOGRAPHY; REDUCTION; MORTALITY; NIJMEGEN	Objectives - To study the specificity of screening for breast cancer by clinical examination with or without mammography and to estimate the extra breast biopsies resulting from a population screening programme. Design - Non-randomised, population based study. Setting - Two screening districts (Edinburgh and Guildford) and four comparison districts (Dundee, Oxford, Southmead, and Stoke). Subjects - 49956 women aged 45-64 in the screening districts and 127109 women in the comparison districts. Interventions - The screening districts offered women annual screening by clinical examination, with mammography in alternate years for seven years. Main outcome measures - Numbers of true positive, false positive, true negative, and false negative results; specificity and predictive value of screening; numbers of benign and malignant biopsy specimens. Results - At their first mammographic and clinical screen 94% (30035/31997) of women without breast cancer were correctly classified as negative; 6% (1962) were referred for further investigation, but only 321 (1%) required a biopsy to establish that the suspicious lesion was not malignant. At subsequent screens specificity improved to 96%, and only 0.4% of women without cancer received biopsy. After the first screen the ratio of benign to malignant biopsy specimens was the same as that among women in the comparison centres, but because mammographic screening increased the number of women with both malignant and benign disease referred the number of biopsies was increased up to twofold in the years women were offered screening by mammography. Conclusion - Our provision of a prompt, highly specialised assessment of women with suspicious lesions at screening may have contributed to the relatively low specificities, while at the same time probably mitigating the adverse effects of low specificity.			CHAMBERLAIN, J (corresponding author), INST CANC RES,EPIDEMIOL SECT,CANC SCREENING EVALUAT UNIT,SUTTON SM2 5NG,ENGLAND.							ELLMAN R, 1989, BRIT J CANCER, V60, P781, DOI 10.1038/bjc.1989.359; LUNDGREN B, 1976, CANCER, V38, P1124, DOI 10.1002/1097-0142(197609)38:3<1124::AID-CNCR2820380312>3.0.CO;2-P; PEETERS PHM, 1989, INT J CANCER, V43, P226, DOI 10.1002/ijc.2910430209; ROBERTS MM, 1990, LANCET, V335, P241; SHAPIRO S, 1981, CANCER, V39, P618; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; VERBEEK ALM, 1984, LANCET, V1, P1222; 1981, BRIT J CANCER, V44, P618	9	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					346	349						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540731				2022-12-28	WOS:A1992HD38700022
J	LUND, E; DAHLBERG, JE				LUND, E; DAHLBERG, JE			CYCLIC 2',3'-PHOSPHATES AND NONTEMPLATED NUCLEOTIDES AT THE 3' END OF SPLICEOSOMAL U6 SMALL NUCLEAR RNAS	SCIENCE			English	Article							HELA-CELL EXTRACT; LUPUS ANTIGEN-LA; POLYMERASE-III; TRANSCRIPTION TERMINATION; 3'-TERMINAL PHOSPHATE; CAP STRUCTURE; INVITRO; U4; PROTEIN; YEAST	Spliceosomal U6 small nuclear RNA (U6 RNA) in species as diverse as man, frog, fruitfly, and soybean have at their 3' ends a cyclic 2',3'-phosphate (> p) apparently derived from uridylic acid residues that were added post-transcriptionally. The 3' ends of U6 RNA's from various sources may be processed in different ways, or to different extents, depending on the organism or stage of development. The presence of a > p terminus on U6 RNA may influence the activity of U6 RNA either directly during splicing or indirectly by ensuring that the RNA has a defined length or proper conformation (or both).			LUND, E (corresponding author), UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,1300 UNIV AVE,MADISON,WI 53706, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030220, R01GM030220] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30220] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS NC, 1986, P NATL ACAD SCI USA, V83, P221, DOI 10.1073/pnas.83.2.221; BARRELL BG, 1971, PROCEDURES NUCLEIC A, V2, P751; BASS BL, 1991, NATURE, V352, P283, DOI 10.1038/352283a0; BINDEREIF A, 1990, EMBO J, V9, P251, DOI 10.1002/j.1460-2075.1990.tb08102.x; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BRINGMANN P, 1984, EMBO J, V3, P1357, DOI 10.1002/j.1460-2075.1984.tb01977.x; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1989, NATURE, V337, P14, DOI 10.1038/337014a0; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CHOUDHURY K, 1988, J CELL PHYSIOL, V137, P529, DOI 10.1002/jcp.1041370319; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; Deutscher M P, 1973, Prog Nucleic Acid Res Mol Biol, V13, P51, DOI 10.1016/S0079-6603(08)60100-2; DEUTSCHER MP, 1990, METHOD ENZYMOL, V181, P434; EPSTEIN P, 1980, J BIOL CHEM, V255, P8901; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FIELD D, COMMUNICATION; FILIPOWICZ W, 1985, P NATL ACAD SCI USA, V82, P1316, DOI 10.1073/pnas.82.5.1316; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; FILIPOWICZ W, 1983, NUCLEIC ACIDS RES, V11, P1405, DOI 10.1093/nar/11.5.1405; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GUPTA S, 1991, NUCLEIC ACIDS RES, V19, P2073, DOI 10.1093/nar/19.suppl.2073; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HARADA F, 1980, BIOCHEM BIOPH RES CO, V95, P1332, DOI 10.1016/0006-291X(80)91620-4; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; HIRAI H, 1988, J BIOCH, V164, P991; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; HUTCHINS CJ, 1990, METHOD ENZYMOL, V181, P583; KONARSKA M, 1982, P NATL ACAD SCI-BIOL, V79, P1474, DOI 10.1073/pnas.79.5.1474; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; LUND E, 1987, GENE DEV, V1, P39, DOI 10.1101/gad.1.1.39; LUND E, 1985, SCIENCE, V229, P1271, DOI 10.1126/science.2412294; LUND E, UNPUB; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MATHEWS MB, 1984, MOL CELL BIOL, V4, P1134, DOI 10.1128/MCB.4.6.1134; NEU HC, 1964, J BIOL CHEM, V239, P2927; Nishimura S, 1972, Prog Nucleic Acid Res Mol Biol, V12, P49; OHSHIMA Y, 1981, NUCLEIC ACIDS RES, V9, P5145, DOI 10.1093/nar/9.19.5145; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; REDDY R, 1983, J BIOL CHEM, V258, P8352; REDDY R, 1987, J BIOL CHEM, V262, P75; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; Silberklang M, 1979, Methods Enzymol, V59, P58; SINGH R, 1990, MOL CELL BIOL, V10, P939, DOI 10.1128/MCB.10.3.939; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; TERNS MP, UNPUB; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; WOLFF T, IIN PRESS EMBO J; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0	56	120	121	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1992	255	5042					327	330		10.1126/science.1549778	http://dx.doi.org/10.1126/science.1549778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1549778				2022-12-28	WOS:A1992GZ69500041
J	LETOURNEUR, F; KLAUSNER, RD				LETOURNEUR, F; KLAUSNER, RD			ACTIVATION OF T-CELLS BY A TYROSINE KINASE ACTIVATION DOMAIN IN THE CYTOPLASMIC TAIL OF CD3-EPSILON	SCIENCE			English	Article							MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; COMPLEX; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; HYBRIDOMAS; PROTEIN	The multichain T cell antigen receptor functions by interacting with and activating one or more nonreceptor tyrosine kinases. The cytoplasmic tail of the zeta-chain can activate T cells independently of the rest of the receptor complex. The function of the remaining invariant CD3 chains remains unknown. A 22-amino acid region of the cytoplasmic tail of CD3-epsilon was also able to independently activate T cells. Stimulation of T cells by means of the cytoplasmic tails of either zeta or CD3-epsilon resulted in quantitatively distinct patterns of tyrosine phosphorylation, suggesting activation of different biochemical pathways.			LETOURNEUR, F (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.			Letourneur, Francois/0000-0003-2232-6127				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HSI ED, 1989, J BIOL CHEM, V264, P10836; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, J IMMUNOL, V144, P1591; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LETOURNEUR F, UNPUB; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; REITH M, 1983, NATURE, V338, P383; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SELDIN RF, 1990, CURRENT PROTOCOLS MO, V1, P921; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WHITE J, 1989, J IMMUNOL, V143, P1822	23	425	444	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					79	82		10.1126/science.1532456	http://dx.doi.org/10.1126/science.1532456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1532456				2022-12-28	WOS:A1992GX79100041
J	SCHNEIDERMAN, LJ; KRONICK, R; KAPLAN, RM; ANDERSON, JP; LANGER, RD				SCHNEIDERMAN, LJ; KRONICK, R; KAPLAN, RM; ANDERSON, JP; LANGER, RD			EFFECTS OF OFFERING ADVANCE DIRECTIVES ON MEDICAL TREATMENTS AND COSTS	ANNALS OF INTERNAL MEDICINE			English	Article						ADVANCE DIRECTIVES; ETHICS, MEDICAL; PATIENT CARE PLANNING; COST CONTROL; TERMINAL CARE	OF-LIFE EVALUATION; CARDIOPULMONARY RESUSCITATION; CLASSIFYING FUNCTION; INTERVIEWER MODES; HEALTH STATUS; CARE; PREFERENCES; PHYSICIANS; VALIDITY; INDEX	Objective: To examine the effects of advance directives on medical treatments and on patient satisfaction and well-being and to determine whether the enhancement of patient autonomy through advance directives provides a more ethically feasible approach to cost control than does the imposition of limits through rationing. Design: Randomized, controlled trial. Setting: University and Veterans Affairs medical center. Patients: Two hundred and four patients with life-threatening illnesses, 100 of whom died after enrollment in the study. Intervention: Patients randomly assigned to the experimental group were offered the California Durable Power of Attorney (a typical proxy-instruction directive), and patients assigned to the control group were not offered the advance directive. Hospital admissions were monitored to assure that a summary of the document was present in the active medical record at each hospitalization. Measurements: Cognitive function, patient satisfaction, pyschological well-being, health locus of control, sense of coherence, health-related quality of life, receipt of medical treatments, and medical treatment charges. Results: No significant differences were found between advance-directive and control groups regarding psychosocial variables, health outcome variables, and medical treatments or charges. Patients offered an advance directive had an average hospital stay of 40.8 days (95% Cl, 32.2 to 49.4 days), compared with an average of 33.1 days (95% Cl, 26.0 to 40.2 days) for controls. Patients offered an advance directive were charged an average of $19 502 (95% Cl, $13 030 to $25 974) for medical treatments in the last month of life compared with $19 700 (95% Cl, $13 704 to $25 696) for controls. Conclusions: Despite claims that public demand for longer life accounts for rising medical costs, most surveys suggest that patients are calling for less, not more, of the expensive, high-technology treatment often used in terminal phases of illness. Executing the California Durable Power of Attorney for Health Care and having a summary copy placed in the patient's medical record had no significant positive or negative effect on a patient's well-being, health status, medical treatments, or medical treatment charges.			SCHNEIDERMAN, LJ (corresponding author), UNIV CALIF SAN DIEGO, 9500 GILMAN DR, LA JOLLA, CA 92093 USA.		KAPLAN, Robert/AAK-7342-2021		AHRQ HHS [R18 HSO5617] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005617] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON JP, 1986, MED CARE, V24, P454, DOI 10.1097/00005650-198605000-00008; ANTONOVSKY A, 1981, HLTH STRESS COPING; BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; BUCHANA AE, 1989, DECIDING OTHERS ETHI; CALLAHAN D, 1990, WHAT KIND LIFE LIMIT, P80; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DiMatteo M R, 1980, J Community Health, V6, P18; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EVERHART MA, 1990, CHEST, V97, P159, DOI 10.1378/chest.97.1.159; FAZIO AF, 1977, VITAL HLTH STATIST 2; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Kaplan R., 1990, QUALITY LIFE ASSESSM, P131; KAPLAN RM, 1976, HEALTH SERV RES, V11, P478; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; KAPLAN RM, 1988, HEALTH SERV RES, V23, P203; KAPLAN RM, 1985, MEASUREMENT STRATEGI, P115; LANGER RD, 1991, INT J BIOMED COMPUT, V28, P161, DOI 10.1016/0020-7101(91)90052-G; Lubitz J, 1984, Health Care Financ Rev, V5, P117; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; SCHNEIDERMAN LJ, 1985, ANN INTERN MED, V102, P693, DOI 10.7326/0003-4819-102-5-693; SCHNEIDERMAN LJ, IN PRESS ARCH INTERN; SCITOVSKY AA, 1984, MILBANK Q, V62, P591, DOI 10.2307/3349838; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; TAYLOR H, 1990, NEW ENGL J MED, V322, P1891; UHLMANN RF, 1989, WESTERN J MED, V150, P705; UHLMANN RF, 1988, J GERONTOL, V43; WALLSTON KA, 1976, HLTH ED MONOGRAPHS, V16, P160; WAN T, 1977, GERONTOLOGIST, V17, P129; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; 1987, GUIDELINES TERMINATI; 1989, RESOLUTION LEGISLATI; 1989, CURRENT OPINIONS COU	36	238	240	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					599	606		10.7326/0003-4819-117-7-599	http://dx.doi.org/10.7326/0003-4819-117-7-599			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524334				2022-12-28	WOS:A1992JQ22600010
J	SOLARO, CR; LINGLE, CJ				SOLARO, CR; LINGLE, CJ			TRYPSIN-SENSITIVE, RAPID INACTIVATION OF A CALCIUM-ACTIVATED POTASSIUM CHANNEL	SCIENCE			English	Article							CA-2+-ACTIVATED K+ CHANNELS; PITUITARY CELL-LINE; RAT MUSCLE; DROSOPHILA MUSCLE; SMALL CONDUCTANCE; SODIUM-CHANNEL; CURRENTS; BLOCKADE; NEURONS; SECRETION	Most calcium-activated potassium channels couple changes in intracellular calcium to membrane excitability by conducting a current with a probability that depends directly on submembrane calcium concentration. In rat adrenal chromaffin cells, however, a large conductance, voltage- and calcium-activated potassium channel (BK) undergoes rapid inactivation, suggesting that this channel has a physiological role different than that of other BK channels. The inactivation of the BK channel, like that of the voltage-gated Shaker B potassium channel, is removed by trypsin digestion and channels are blocked by th Shaker B amino-terminal inactivating domain. Thus, this BK channel shares functional and possibly structural homologies with other inactivating voltage-gated potassium channels.	WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Lingle, Christopher/0000-0002-9916-3795				ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P567; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; CHUNG S K, 1991, Society for Neuroscience Abstracts, V17, P777; DECOURSEY TE, 1990, J GEN PHYSIOL, V95, P617, DOI 10.1085/jgp.95.4.617; FINDLAY I, 1985, FEBS LETT, V185, P4, DOI 10.1016/0014-5793(85)80729-8; GOH JW, 1987, J PHYSIOL-LONDON, V394, P315, DOI 10.1113/jphysiol.1987.sp016872; GONOI T, 1987, J GEN PHYSIOL, V89, P253, DOI 10.1085/jgp.89.2.253; HAMILL OP, 1981, PFLUGERS ARCH, V393, P254; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; IKEMOTO Y, 1989, BIOPHYS J, V56, P207, DOI 10.1016/S0006-3495(89)82665-7; IWATSUKI N, 1985, BIOCHIM BIOPHYS ACTA, V819, P249, DOI 10.1016/0005-2736(85)90180-4; KIDOKORO Y, 1980, J PHYSIOL-LONDON, V307, P199, DOI 10.1113/jphysiol.1980.sp013431; LANCASTER B, 1987, J PHYSIOL-LONDON, V387, P519, DOI 10.1113/jphysiol.1987.sp016587; LANG DG, 1990, J PHYSIOL-LONDON, V425, P117, DOI 10.1113/jphysiol.1990.sp018095; LANG DG, 1987, PFLUG ARCH EUR J PHY, V410, P614, DOI 10.1007/BF00581321; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; LATTORE R, 1990, ANN REV PHYSL, V51, P385; MACDERMOTT AB, 1982, NATURE, V300, P185, DOI 10.1038/300185a0; MARTY A, 1983, TRENDS NEUROSCI, V6, P262, DOI 10.1016/0166-2236(83)90115-7; MARTY A, 1989, TRENDS NEUROSCI, V12, P420, DOI 10.1016/0166-2236(89)90090-8; MILLER C, 1987, J GEN PHYSIOL, V90, P427, DOI 10.1085/jgp.90.3.427; MURRELLLAGNADO R, COMMUNICATION; NEELY A, 1992, J PHYSIOL-LONDON, V453, P97, DOI 10.1113/jphysiol.1992.sp019220; NOHMI M, 1984, BRAIN RES, V301, P146, DOI 10.1016/0006-8993(84)90412-8; PALLOTTA BS, 1985, J PHYSIOL-LONDON, V363, P501, DOI 10.1113/jphysiol.1985.sp015724; PALLOTTA BS, 1981, NATURE, V293, P471, DOI 10.1038/293471a0; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; ROMEY G, 1984, BIOCHEM BIOPH RES CO, V118, P669, DOI 10.1016/0006-291X(84)91355-X; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; SALA F, 1990, BIOPHYS J, V57, P313, DOI 10.1016/S0006-3495(90)82533-9; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; THOMPSON SH, 1977, J PHYSIOL-LONDON, V265, P465, DOI 10.1113/jphysiol.1977.sp011725; TORO L, 1992, Biophysical Journal, V61, pA379; VERGARA C, 1983, J GEN PHYSIOL, V82, P543, DOI 10.1085/jgp.82.4.543; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	43	100	100	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1694	1698		10.1126/science.1529355	http://dx.doi.org/10.1126/science.1529355			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529355				2022-12-28	WOS:A1992JN50100034
J	CUNNINGHAM, ET; RAVICH, WJ; JONES, B; DONNER, MW				CUNNINGHAM, ET; RAVICH, WJ; JONES, B; DONNER, MW			VAGAL REFLEXES REFERRED FROM THE UPPER AERODIGESTIVE TRACT - AN INFREQUENTLY RECOGNIZED CAUSE OF COMMON CARDIORESPIRATORY RESPONSES	ANNALS OF INTERNAL MEDICINE			English	Review						VAGUS NERVE; CARDIOVASCULAR DISEASES; RESPIRATORY TRACT DISEASES; SYNCOPE; GASTROESOPHAGEAL REFLUX	UPPER AIRWAY-OBSTRUCTION; SUDDEN INFANT DEATH; UPPER ALIMENTARY-TRACT; GASTROESOPHAGEAL REFLUX; PULMONARY-EDEMA; GLOSSOPHARYNGEAL NEURALGIA; TRACHEAL INTUBATION; SWALLOW SYNCOPE; VISCEROTOPIC REPRESENTATION; ENDOTRACHEAL INTUBATION	Objective: To review the physiologic basis for normal and abnormal vagal reflexes arising from the pharynx, larynx, and esophagus, as well as the relevance of vagal reflexes to the pathogenesis of such clinically common cardiorespiratory responses as bradycardia, tachycardia, dysrhythmia, coronary angiospasm, bronchospasm, laryngospasm, prolonged apnea, and singultus (hiccups). Data Sources: Pertinent articles and reviews were identified through a MEDLINE search (April 1966 to October 1991). Older studies and others not identified in the MEDLINE search were found through a manual search of the bibliographies of the retrieved articles. Study Selection: Experimental studies in both humans and animals, as well as case series and single case reports, were selected for evaluation and citation. In instances where a similar phenomenon was described in multiple independent reports, only studies that provided a novel finding or interpretation were cited. More authoritative book chapters and peer-reviewed summaries were also cited in support of commonly summaries principles. Data Extraction and Synthesis: Most of the clinical data are derived from case reports and small case series and are therefore anecdotal; equal weight was given to all such studies. Reports of conflicting observations or interpretations were clearly identified and were cited without exception. Conclusions: Stimulation of the upper aerodigestive tract can lead to clinically significant cardiorespiratory responses. Although the prevalence of and risk factors for such responses have not been established, we suggest that a pharyngeal, a laryngeal, or an esophageal source for abnormal cardiorespiratory responses be sought whenever a detailed clinical evaluation fails to reveal a cause, particularly when there are concurrent symptoms or signs of upper aerodigestive tract disease, such as dysphagia or gastroesophageal reflux.	JOHNS HOPKINS MED INST, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine								ALSTRUP P, 1973, ACTA MED SCAND, P365; ALTSCHULER SM, 1989, J COMP NEUROL, V283, P248, DOI 10.1002/cne.902830207; ANDREW BL, 1956, J PHYSIOL-LONDON, V133, P420, DOI 10.1113/jphysiol.1956.sp005597; ARCURI RA, 1953, ANESTHESIOLOGY, V14, P46, DOI 10.1097/00000542-195301000-00008; ARMSTRONG PW, 1985, CAN MED ASSOC J, V132, P1281; AXELROD FB, 1987, AM J GASTROENTEROL, V82, P159; BAIN WM, 1983, LARYNGOSCOPE, V93, P175; BAJAJ SC, 1972, GASTROENTEROLOGY, V62, P632; BARIN ES, 1986, ANAESTH INTENS CARE, V14, P54, DOI 10.1177/0310057X8601400112; BIDWAI AV, 1978, CAN ANAESTH SOC J, V25, P416, DOI 10.1007/BF03006572; BIEGER D, 1987, J COMP NEUROL, V262, P546, DOI 10.1002/cne.902620408; BLANC VF, 1974, ANESTH ANALG, V53, P202; BOGGS DF, 1982, J APPL PHYSIOL, V53, P455, DOI 10.1152/jappl.1982.53.2.455; BOLSER DC, 1991, J NEUROPHYSIOL, V65, P1042, DOI 10.1152/jn.1991.65.5.1042; BORTOLOTTI M, 1989, GUT, V30, P233, DOI 10.1136/gut.30.2.233; BOUGH EW, 1978, AM J GASTROENTEROL, V69, P655; BRICK JE, 1978, SOUTHERN MED J, V71, P1579, DOI 10.1097/00007611-197812000-00040; BROWNING TH, 1990, DIGEST DIS SCI, V35, P289, DOI 10.1007/BF01537404; BURNSTEIN CL, 1950, ANESTHESIOLOGY, V11, P299; Burnstein CL, 1950, ANESTHESIOLOGY, V11, P224; CERVERO F, 1986, PROG BRAIN RES, V67, P189; CLERC N, 1984, J AUTONOM NERV SYST, V10, P213, DOI 10.1016/0165-1838(84)90015-8; CONVERSE JG, 1952, ANESTHESIOLOGY, V13, P163, DOI 10.1097/00000542-195203000-00006; CUNNINGHAM E T JR, 1990, Dysphagia, V5, P35, DOI 10.1007/BF02407391; DAVIES AM, 1988, J APPL PHYSIOL, V64, P1412, DOI 10.1152/jappl.1988.64.4.1412; DAVIES AM, 1989, AM REV RESPIR DIS, V139, P668, DOI 10.1164/ajrccm/139.3.668; DAVIES HA, 1985, LANCET, V1, P1011; DAVIS HW, 1981, PEDIATR CLIN N AM, V28, P859; DENLINGE.JK, 1974, ANESTHESIOLOGY, V41, P409, DOI 10.1097/00000542-197410000-00024; DESCHNER WK, 1989, AM J GASTROENTEROL, V84, P1; DEVAULT M, 1960, ANESTHESIOLOGY, V21, P360, DOI 10.1097/00000542-196007000-00004; Doty RW, 1968, HDB PHYSL ALIMENTARY, P1861; DOWNING SE, 1975, PEDIATRICS, V55, P640; Dubner R., 1978, NEURAL BASIS ORAL FA, DOI 10.1007/978-1-4757-1682-5; EKSTROM T, 1988, EUR RESPIR J, V1, P636; ELAM MP, 1989, MIL MED, V154, P465; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; ENGEL TR, 1976, J ELECTROCARDIOL, V9, P69, DOI 10.1016/S0022-0736(76)80013-1; ENGELHARDT W, 1986, AM J CARDIOL, V58, P1113, DOI 10.1016/0002-9149(86)90128-1; FISHER MJ, 1989, DIGEST DIS SCI, V34, P1277, DOI 10.1007/BF01537278; FORBES AM, 1970, BRIT J ANAESTH, V42, P618, DOI 10.1093/bja/42.7.618; Gilbert NC, 1940, AM HEART J, V20, P519, DOI 10.1016/S0002-8703(40)90930-9; GLUCK M, 1986, ANN INTERN MED, V105, P219, DOI 10.7326/0003-4819-105-2-219; GOLDMAN JM, 1990, GUT, V31, P1, DOI 10.1136/gut.31.1.1; GOYAL RK, 1989, HDB PHYSL GASTROINTE, V1, P865; Greene CW, 1935, AM J PHYSIOL, V113, P361, DOI 10.1152/ajplegacy.1935.113.2.361; HEATON RW, 1984, CHEST, V86, P810, DOI 10.1378/chest.86.6.810; HERBST JJ, 1979, J PEDIATR-US, V95, P763, DOI 10.1016/S0022-3476(79)80733-7; IGLAUER S, 1936, ANN OTO RHINOL LARYN, V45, P875; KALLOO AN, 1989, DIGEST DIS SCI, V34, P1117, DOI 10.1007/BF01536384; KALLOOR GJ, 1977, AM HEART J, V93, P235, DOI 10.1016/S0002-8703(77)80317-7; KARLSSON JA, 1988, J APPL PHYSIOL, V65, P1007, DOI 10.1152/jappl.1988.65.3.1007; KENIGSBERG K, 1983, J PEDIATR SURG, V18, P542, DOI 10.1016/S0022-3468(83)80355-8; KING BD, 1954, ANESTHESIOLOGY, V15, P231, DOI 10.1097/00000542-195405000-00003; KOPALD HH, 1964, NEW ENGL J MED, V271, P1238, DOI 10.1056/NEJM196412102712404; KORPAS J, 1979, COUGH OTHER RESPIRAT; KRAMER P, 1955, GASTROENTEROLOGY, V29, P719; KUNIS RL, 1985, AM J CARDIOL, V55, P613, DOI 10.1016/0002-9149(85)90274-7; LAGERLUND TD, 1988, ARCH NEUROL-CHICAGO, V45, P472, DOI 10.1001/archneur.1988.00520280126031; LEAPE LL, 1977, PEDIATRICS, V60, P924; LEE KWT, 1983, ANESTHESIOLOGY, V59, P347; LEHR CS, 1965, ARCH ORAL BIOL, V10, P83; LEVIN B, 1972, NEUROLOGY, V22, P1086, DOI 10.1212/WNL.22.10.1086; LORCH DG, 1986, CHEST, V90, P802, DOI 10.1378/chest.90.6.802; Loughlin G M, 1989, Dysphagia, V3, P126; MACKENZIE J, 1906, BRIT MED J, V4, P1107; MANSFIELD LE, 1981, ANN ALLERGY, V47, P431; MCGOVERN FH, 1971, ANN OTO RHINOL LARYN, V80, P556, DOI 10.1177/000348947108000419; MEI N, 1985, PHYSIOL REV, V65, P211, DOI 10.1152/physrev.1985.65.2.211; MELLOW MH, 1983, GASTROENTEROLOGY, V85, P306; Miller A J, 1987, Dysphagia, V2, P72, DOI 10.1007/BF02408137; MILLER AJ, 1982, PHYSIOL REV, V62, P129, DOI 10.1152/physrev.1982.62.1.129; Miller AJ., 1986, DYSPHAGIA, V1, P91, DOI [DOI 10.1007/BF02407121, 10.1007/BF02407121]; NOBLE M J, 1959, Can Anaesth Soc J, V6, P267; PALMER ED, 1976, AM J GASTROENTEROL, V66, P513; PETERS NS, 1951, ANESTHESIOLOGY, V12, P673, DOI 10.1097/00000542-195111000-00001; PHIPPS RJ, 1976, J PHYSIOL-LONDON, V261, P563, DOI 10.1113/jphysiol.1976.sp011574; PICKENS DL, 1988, AM REV RESPIR DIS, V137, P113, DOI 10.1164/ajrccm/137.1.113; Piek J J, 1988, Ned Tijdschr Geneeskd, V132, P215; RANSBOTTOM JC, 1988, CLIN CARDIOL, V11, P51, DOI 10.1002/clc.4960110117; Reid LC, 1940, SURG GYNAEC OBST, V70, P157; RICHTER JE, 1989, ANN INTERN MED, V110, P66, DOI 10.7326/0003-4819-110-1-66; ROESLER H, 1960, AM J MED SCI, V240, P159; ROSCH W, 1969, DEUT MED WOCHENSCHR, V94, P2191; RUSHTON JG, 1981, ARCH NEUROL-CHICAGO, V38, P201, DOI 10.1001/archneur.1981.00510040027002; SAPRU RP, 1968, P ROY SOC MED, V61, P955, DOI 10.1177/003591576806101001; SATO T, 1990, AM J PHYSIOL, V259, pR282, DOI 10.1152/ajpregu.1990.259.2.R282; SCHERF D, 1945, NEW YORK STATE J MED, V45, P1647; SCHEY WL, 1981, RADIOLOGY, V140, P73, DOI 10.1148/radiology.140.1.7244245; SENGUPTA JN, 1989, J NEUROPHYSIOL, V61, P1001, DOI 10.1152/jn.1989.61.5.1001; Sessle B J, 1989, Dysphagia, V4, P61, DOI 10.1007/BF02407148; SHIM C, 1969, ANN INTERN MED, V71, P1149, DOI 10.7326/0003-4819-71-6-1149; SHINGAI T, 1976, JPN J PHYSIOL, V26, P455; SHIRAYAMA T, 1989, JPN J MED, V28, P647; SOFER S, 1984, CHEST, V86, P401, DOI 10.1378/chest.86.3.401; STJOHN JN, 1982, NEUROSURGERY, V10, P380, DOI 10.1227/00006123-198203000-00015; STJOHN JN, 1986, CAN MED ASSOC J, V134, P309; STOELTING RK, 1979, ANESTH ANALG, V58, P116; STOREY AT, 1975, EXP NEUROL, V47, P42, DOI 10.1016/0014-4886(75)90235-6; STRASBERG B, 1989, PROG CARDIOVASC DIS, V31, P379, DOI 10.1016/0033-0620(89)90032-7; SZUCS RA, 1989, RADIOLOGY, V170, P446, DOI 10.1148/radiology.170.2.2911666; TAMI TA, 1986, LARYNGOSCOPE, V96, P506, DOI 10.1288/00005537-198605000-00007; THACH BT, 1990, PROG CLIN BIOL RES, V345, P77; TOLMAN KG, 1975, AM J DIG DIS, V1, P315; TOMORI Z, 1969, J PHYSIOL-LONDON, V200, P25, DOI 10.1113/jphysiol.1969.sp008680; TUCHMAN DN, 1984, GASTROENTEROLOGY, V87, P872; TULCHINSKY M, 1988, RCH INTERN MED, V148, P1217; VANLOVEREN JR, 1990, NEUROLOGICAL SURGERY, P3943; WANDER GS, 1989, JPN HEART J, V30, P523; Weiss S, 1934, ARCH INTERN MED, V54, P931, DOI 10.1001/archinte.1934.00160180105008; Widdicombe J., 1986, HDB PHYSL SECT 3 RES, VII, P363; WIENER GJ, 1989, AM J GASTROENTEROL, V84, P1503; WIK B, 1975, BMJ-BRIT MED J, V3, P747, DOI 10.1136/bmj.3.5986.747; WINSTON SJ, 1987, CRIT CARE MED, V15, P1009, DOI 10.1097/00003246-198711000-00004; WOODY RC, 1986, PEDIATRICS, V78, P507; WRIGHT RA, 1990, GASTROENTEROLOGY, V99, P71, DOI 10.1016/0016-5085(90)91231-T; WYCOFF CC, 1960, ANESTHESIOLOGY, V21, P153, DOI 10.1097/00000542-196003000-00004; ZAVALA DC, 1981, CHEST, V79, P512, DOI 10.1378/chest.79.5.512; ZWILLICH C, 1982, J CLIN INVEST, V69, P1286, DOI 10.1172/JCI110568	119	43	43	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					575	582		10.7326/0003-4819-116-7-575	http://dx.doi.org/10.7326/0003-4819-116-7-575			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543313				2022-12-28	WOS:A1992HL25800010
J	MATTEVI, A; OBMOLOVA, G; SCHULZE, E; KALK, KH; WESTPHAL, AH; DEKOK, A; HOL, WGJ				MATTEVI, A; OBMOLOVA, G; SCHULZE, E; KALK, KH; WESTPHAL, AH; DEKOK, A; HOL, WGJ			ATOMIC-STRUCTURE OF THE CUBIC CORE OF THE PYRUVATE-DEHYDROGENASE MULTIENZYME COMPLEX	SCIENCE			English	Article							DIHYDROLIPOAMIDE ACETYLTRANSFERASE COMPONENT; ESCHERICHIA-COLI; CHLORAMPHENICOL ACETYLTRANSFERASE; NUCLEOTIDE-SEQUENCE; SUBUNIT STRUCTURE; SITE; MECHANISM; CRYSTALLIZATION; OVEREXPRESSION; MUTAGENESIS	The highly symmetric pyruvate dehydrogenase multienzyme complexes have molecular masses ranging from 5 to 10 million daltons. They consist of numerous copies of three different enzymes: pyruvate dehydrogenase, dihydrolipoyl transacetylase, and lipoamide dehydrogenase. The three-dimensional crystal structure of the catalytic domain of Azotobacter vinelandii dihydrolipoyl transacetylase has been determined at 2.6 angstrom (angstrom) resolution. Eight trimers assemble as a hollow truncated cube with an edge of 125 angstrom, forming the core of the multienzyme complex. Coenzyme A must enter the 29 angstrom long active site channel from the inside of the cube, and lipoamide must enter from the outside. The trimer of the catalytic domain of dihydrolipoyl transacetylase has a topology identical to chloramphenicol acetyl transferase. The atomic structure of the 24-subunit cubic core provides a framework for understanding all pyruvate dehydrogenase and related multienzyme complexes.	UNIV GRONINGEN, DEPT CHEM, BIOSON RES INST, NIJENBORGH 4, 9747 AG GRONINGEN, NETHERLANDS; AGR UNIV WAGENINGEN, DEPT BIOCHEM, 6703 HA WAGENINGEN, NETHERLANDS	University of Groningen; Wageningen University & Research			mattevi, andrea/K-5464-2012; Westphal, Adrie Herman/L-3517-2019; Mattevi, Andrea/R-4469-2019	mattevi, andrea/0000-0002-9523-7128; Westphal, Adrie Herman/0000-0003-4264-6267; Mattevi, Andrea/0000-0002-9523-7128				BANYARD SH, 1978, NATURE, V271, P282, DOI 10.1038/271282a0; BLEILE DM, 1979, P NATL ACAD SCI USA, V76, P4385, DOI 10.1073/pnas.76.9.4385; BOSMA HJ, 1984, EUR J BIOCHEM, V142, P541, DOI 10.1111/j.1432-1033.1984.tb08320.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURNS G, 1989, J BACTERIOL, V171, P665, DOI 10.1128/jb.171.2.665-668.1989; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; DEKOK A, 1985, EUR J BIOCHEM, V152, P35; DEROSIER DJ, 1971, P NATL ACAD SCI USA, V68, P1135, DOI 10.1073/pnas.68.6.1135; FULLER CC, 1979, BIOCHEM BIOPH RES CO, V90, P431, DOI 10.1016/0006-291X(79)91253-1; GIBBS MR, 1990, BIOCHEMISTRY-US, V29, P11261, DOI 10.1021/bi00503a015; GRANDE HJ, 1979, CATALYSIS CHEM BIOCH, P171; GUEST JR, 1987, FEMS MICROBIOL LETT, V44, P417, DOI 10.1111/j.1574-6968.1987.tb02324.x; GUEST JR, 1989, ANN N Y ACAD SCI, V573, P76; HACKERT ML, 1983, P NATL ACAD SCI-BIOL, V80, P2907, DOI 10.1073/pnas.80.10.2907; HACKERT ML, 1989, BIOCHEMISTRY-US, V28, P6816, DOI 10.1021/bi00443a006; HANEMAAIJER R, 1989, EUR J BIOCHEM, V179, P287, DOI 10.1111/j.1432-1033.1989.tb14553.x; HENDERSON CE, 1979, CELL, V17, P85, DOI 10.1016/0092-8674(79)90297-6; HODGSON JA, 1986, EUR J BIOCHEM, V158, P595, DOI 10.1111/j.1432-1033.1986.tb09796.x; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; JILKA JM, 1986, J BIOL CHEM, V261, P1858; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LESLIE AGW, 1990, J MOL BIOL, V213, P167, DOI 10.1016/S0022-2836(05)80129-9; LEWENDON A, 1990, BIOCHEMISTRY-US, V29, P2075, DOI 10.1021/bi00460a016; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MILES JS, 1988, J MOL BIOL, V202, P97, DOI 10.1016/0022-2836(88)90522-0; NIU XD, 1990, BIOCHEMISTRY-US, V29, P8614, DOI 10.1021/bi00489a017; OLIVER RM, 1982, ELECTRON MICROS, V18, P77; PACKMAN LC, 1984, EMBO J, V3, P1315, DOI 10.1002/j.1460-2075.1984.tb01969.x; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PATEL MS, 1990, ENDOCRINE BIOCH DEV; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PERHAM RN, 1981, NATURE, V292, P474, DOI 10.1038/292474a0; Pope M. T., 1983, HETEROPOLY ISOPOLY O; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1975, P NATL ACAD SCI USA, V72, P3068, DOI 10.1073/pnas.72.8.3068; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; RUSSELL GC, 1990, BIOCHEM J, V269, P443, DOI 10.1042/bj2690443; RUSSELL GC, 1991, P ROY SOC B-BIOL SCI, V243, P155, DOI 10.1098/rspb.1991.0025; RUSSELL GC, 1991, BIOCHIM BIOPHYS ACTA, V1076, P225, DOI 10.1016/0167-4838(91)90271-Z; SCHULZE E, 1991, EUR J BIOCHEM, V201, P561, DOI 10.1111/j.1432-1033.1991.tb16315.x; SCHULZE E, 1991, EUR J BIOCHEM, V202, P841, DOI 10.1111/j.1432-1033.1991.tb16441.x; SHEPHERD GB, 1977, BIOCHEMISTRY-US, V16, P5234, DOI 10.1021/bi00643a012; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P481, DOI 10.1111/j.1432-1033.1983.tb07490.x; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5; WAGNEKNECHT R, 1990, J BIOL CHEM, V36, P22402; YANG H, 1985, J BIOL CHEM, V260, P6049; YEAMAN SJ, 1986, TRENDS BIOCHEM SCI, V11, P293, DOI 10.1016/0968-0004(86)90033-2	52	237	277	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1992	255	5051					1544	1550		10.1126/science.1549782	http://dx.doi.org/10.1126/science.1549782			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1549782				2022-12-28	WOS:A1992HJ80900032
J	HENDERSON, RA; MICHEL, H; SAKAGUCHI, K; SHABANOWITZ, J; APPELLA, E; HUNT, DF; ENGELHARD, VH				HENDERSON, RA; MICHEL, H; SAKAGUCHI, K; SHABANOWITZ, J; APPELLA, E; HUNT, DF; ENGELHARD, VH			HLA-A2.1-ASSOCIATED PEPTIDES FROM A MUTANT-CELL LINE - A 2ND PATHWAY OF ANTIGEN PRESENTATION	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; VIRAL PEPTIDES; LYMPHOCYTE-T; PROTEIN; BINDING; INVITRO; GENE	Peptides extracted from HLA-A2.1 class I major histocompatibility complex (MHC) molecules expressed on the antigen processing mutant CEMx721.174.T2 were characterized by electrospray ionization-tandem mass spectrometry. Only seven dominant peptides were found, in contrast to over 200 associated with HLA-A2.1 on normal cells. These peptides were derived from the signal peptide domains of normal cellular proteins, were usually larger than nine residues, and were also associated with HLA-A2.1 in normal cells. These results suggest that proteolysis of signal peptide domains in the endoplasmic reticulum is a second mechanism for processing and presentation of peptides for association with class I molecules.	UNIV VIRGINIA,SCH MED,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22903; NCI,CELL BIOL LAB,BETHESDA,MD 20892	University of Virginia; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HENDERSON, RA (corresponding author), UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908, USA.		Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Sakaguchi, Kazuyasu/0000-0002-8434-4171; Engelhard, Victor/0000-0002-1741-0925	NIAID NIH HHS [AI20963] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020963, R37AI020963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; DEMARS R, 1991, NATURE, V351, P323; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; ENGELHARD VH, 1991, J IMMUNOL, V146, P1226; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FLIEGEL L, 1989, J BIOL CHEM, V264, P25122; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1992, SCIENCE, V255, P1260; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MICHEL HV, UNPUB; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0	32	511	533	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1264	1266		10.1126/science.1546329	http://dx.doi.org/10.1126/science.1546329			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546329				2022-12-28	WOS:A1992HG67700046
J	CHENEVERT, J; CORRADO, K; BENDER, A; PRINGLE, J; HERSKOWITZ, I				CHENEVERT, J; CORRADO, K; BENDER, A; PRINGLE, J; HERSKOWITZ, I			A YEAST GENE (BEM1) NECESSARY FOR CELL POLARIZATION WHOSE PRODUCT CONTAINS 2 SH3 DOMAINS	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PHEROMONE; SEQUENCE; PROTEIN; SIGNAL; FUSION; VIRUS	CELL polarization requires that a cellular axis or cell-surface site be chosen and that the cytoskeleton be organized with respect to it. Details of the link between the cytoskeleton and the chosen axis or site are not clear 1. Cells of the yeast Saccharomyces cerevisiae exhibit cell polarization in two phases of their life cycle, during vegetative growth and during mating, which reflects responses to intracellular and extracellular signals, respectively. Here we describe the isolation of two mutants defective specifically in cell polarization in response to peptide mating pheromones. The mutants carry special alleles (denoted bem1-s) of the BEM1 gene required for cell polarization during vegetative growth 2,3. Unlike other bem1 mutants, the bem1-s mutants are normal for vegetative growth. Complete deletion of BEM1 leads to the defect in polarization of vegetative cells seen in bem1 mutants 2,3. The predicted sequence of the BEM1 protein (Bem1p) reveals two copies of a domain (denoted SH3) that is found in many proteins associated with the cortical cytoskeleton and which may mediate binding to actin or some other component of the cell cortex 4,5. The sequence of Bem1p and the properties of mutants defective in this protein indicate that it may link the cytoskeleton to morphogenetic determinants on the cell surface.	UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	CHENEVERT, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.							BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; JACKSON CL, 1990, CELL, V63, P1039, DOI 10.1016/0092-8674(90)90507-B; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; Luna EJ, 1991, CURR OPIN CELL BIOL, V3, P120, DOI 10.1016/0955-0674(91)90174-W; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUGGIERI R, IN PRESS MOL CELL BI; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79	23	188	190	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1992	356	6364					77	79		10.1038/356077a0	http://dx.doi.org/10.1038/356077a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538785	Green Published			2022-12-28	WOS:A1992HG60200061
J	BLAUFOX, MD; LEE, HB; DAVIS, B; OBERMAN, A; WASSERTHEILSMOLLER, S; LANGFORD, H				BLAUFOX, MD; LEE, HB; DAVIS, B; OBERMAN, A; WASSERTHEILSMOLLER, S; LANGFORD, H			RENIN PREDICTS DIASTOLIC BLOOD-PRESSURE RESPONSE TO NONPHARMACOLOGIC AND PHARMACOLOGICAL THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMA-RENIN; ESSENTIAL HYPERTENSION; ALDOSTERONE; SYSTEM; INHIBITORS	Objective.-Plasma renin activity was measured at baseline and 6 months in a trial of nonpharmacologic therapy of mild hypertension to determine whether plasma renin activity predicts the diastolic blood pressure (DBP) response to nonpharmacologic therapy. Design, Setting, and Participants.-Randomized controlled trial of volunteers from the general community with mild hypertension (DBP between 90 and 100 mm Hg), off all antihypertensive therapy at baseline, treated in special research clinics (n = 593). Interventions.-Subjects were randomly assigned to usual, weight loss, or low sodium/high potassium diet and then randomly assigned to receive placebo, chlorthalidone, or atenolol. Main Outcome Measures.-Renin was analyzed as plasma renin activity and as a renin index (logarithm of 24-hour urinary sodium excretion times logarithm of plasma renin activity) (593 patients at baseline and 6 months) to correct for varied sodium intakes, The DBP was measured using the random zero device. Results.-Change in DBP at 6 months could be predicted from baseline plasma renin activity or renin index. The DBP was decreased after 6 months of therapy by 2 mm Hg for each unit increase in baseline plasma renin activity and by 0.16 mm Hg for each unit increase in baseline renin index. Patients in the highest renin index quartile had a greater DBP response to atenolol therapy, and patients in the lowest renin index quartile had a greater DBP response to chlorthalidone therapy. Weight loss diet achieved a greater reduction in DBP in patients with higher baseline renin index and had an additive effect on DBP response in both of the drug groups. Patients on a weight loss diet receiving placebo in the highest baseline renin index quartile had a reduction in DBP of 12.4 mm Hg, compared with 4.4 mm Hg in the lowest baseline renin index quartile (P = .009). A low sodium/high potassium diet had a lesser effect than a weight loss diet on pharmacologic therapy. As with the weight loss diet, patients on a low sodium/high potassium diet in the highest baseline renin index quartile had a greater reduction in DBP than patients in the lowest baseline renin index quartile. Conclusions.-These data suggest a significant relationship between baseline levels of plasma renin index and the likelihood of success of nonpharmacologic treatment of hypertension.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10461; UNIV TEXAS,HLTH SCI CTR,SCH PUBL HLTH,COORDINATING CTR CLIN TRIALS,HOUSTON,TX 77225; UNIV ALABAMA,MED CTR,DEPT MED,DIV GEN & PREVENT MED,BIRMINGHAM,AL 35294; UNIV MISSISSIPPI,MED CTR,DEPT MED,DIV ENDOCRINOL & HYPERTENS,JACKSON,MS 39216	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Alabama System; University of Alabama Birmingham; University of Mississippi; University of Mississippi Medical Center	BLAUFOX, MD (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NUCL MED,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Blaufox, MDonald/AAF-6965-2020	Blaufox, MDonald/0000-0002-4148-6866				ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; ATLAS SA, 1983, AM J NEPHROL, V3, P118, DOI 10.1159/000166701; BOULTER PR, 1974, J CLIN ENDOCR METAB, V38, P248, DOI 10.1210/jcem-38-2-248; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; BUHLER FR, 1984, AM J MED, V77, P36; BUHLER FR, 1982, CLIN SCI, V63, P439; CHINN RH, 1970, CLIN SCI, V39, P437, DOI 10.1042/cs0390437; DAVIS BR, 1989, CONTROL CLIN TRIALS, V10, P11; FERNANDEZREPOLLET E, 1987, J CLIN INVEST, V80, P1045, DOI 10.1172/JCI113158; KAPLAN NM, 1975, JAMA-J AM MED ASSOC, V231, P167, DOI 10.1001/jama.231.2.167; LANDSBERG L, 1989, AM J HYPERTENS, V2, pS125, DOI 10.1093/ajh/2.3.125S; LANGFORD HG, 1991, HYPERTENSION, V17, P210, DOI 10.1161/01.HYP.17.2.210; TUCK ML, 1981, NEW ENGL J MED, V304, P930, DOI 10.1056/NEJM198104163041602	13	33	33	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1221	1225		10.1001/jama.267.9.1221	http://dx.doi.org/10.1001/jama.267.9.1221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1538559				2022-12-28	WOS:A1992HF43900023
J	AMOURETTI, M; BERAUD, C; SAINTMARTIN, E				AMOURETTI, M; BERAUD, C; SAINTMARTIN, E			MEDICAL AUDIT IN FRANCE - FROM IDEAL TO REALITY	BRITISH MEDICAL JOURNAL			English	Article									UNIV BORDEAUX 2,QUAL ASSURANCE MED CARE LAB,F-33076 BORDEAUX,FRANCE	UDICE-French Research Universities; Universite de Bordeaux	AMOURETTI, M (corresponding author), UNIV BORDEAUX 2,GASTROENTEROL UNIT,F-33076 BORDEAUX,FRANCE.							ACAAR J, 1980, NOUV PRESSE MED, V9, P405; AMOURETTI MM, 1991, GASTROEN CLIN BIOL, V15, P297; ARMOGATHE JF, 1989, DEV EVALUATION MED; BERAUD C, 1989, J ECON MED, V7, P147; CABANIS JN, 1985, TECHNIQUES HOSPITALI, V472, P55; FESSLER JM, 1986, GESTIONS HOSPITALIER, V252, P21; GIRAUD A, 1991, CONSENSUS MED ANAL B; JOLLY D, 1982, HOPITAL PARIS, V68, P102; LEGALL JR, 1990, EVALUATION REANIMATI; LOMBRAIL P, 1987, GESTIONS HOSPITALIER, V269, P507; MCKEE CM, 1989, J ROY SOC MED, V82, P474, DOI 10.1177/014107688908200810; MELLIERE D, 1980, NOUV PRESSE MED, V9, P339; RAYMOND JM, 1990, GASTROEN CLIN BIOL, V14, P134; RAYMOND JM, 1991, GASTROENTEROL CLIN B, V15, pA18	14	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1992	304	6824					428	430		10.1136/bmj.304.6824.428	http://dx.doi.org/10.1136/bmj.304.6824.428			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1547393	Bronze, Green Published			2022-12-28	WOS:A1992HE38900024
J	COX, J; NAYLOR, CD				COX, J; NAYLOR, CD			THE CANADIAN-CARDIOVASCULAR-SOCIETY GRADING SCALE FOR ANGINA-PECTORIS - IS IT TIME FOR REFINEMENTS	ANNALS OF INTERNAL MEDICINE			English	Review						ANGINA PECTORIS; SEVERITY OF ILLNESS INDEX; CANADIAN-CARDIOVASCULAR-SOCIETY; CHEST PAIN; CLINIMETRICS	CORONARY-ARTERY DISEASE; CHRONIC STABLE ANGINA; SILENT MYOCARDIAL ISCHEMIA; HEART-DISEASE; CHEST PAIN; UNSTABLE ANGINA; NATURAL-HISTORY; ELECTROCARDIOGRAPHIC CHANGES; PROGNOSTIC IMPORTANCE; FUNCTIONAL STATUS	Objective: To appraise the measurement properties of the Canadian Cardiovascular Society (CCS) classification of stable angina pectoris. Data Sources: Relevant articles were identified through a MEDLINE search (1976 to November 1991). Bibliographies of retrieved articles were also reviewed. Study Selection: Studies chosen directly addressed the validity and reliability of the CCS scale. Recent studies and reviews of related topics (for example, silent ischemia) are selectively cited. Data Synthesis: No data address the scale's applicability, that is, how clinicians typically assign angina grades in practice. Comprehensiveness would be improved by coverage of the patient's perceptions of symptom burden; mixed exertional and rest symptoms; episodic or changing symptoms; and modifying factors. Reliability was assessed in one study with two clinicians; the interobserver, chance-corrected agreement on patient grading was 60%. Content validity (the ability of the scale to measure what it claims) is threatened by the unproven assumption of symptomatic or physiologic equivalence among diverse levels of different activities within any given grade of angina. Construct validity is uncertain, given weak relations between angina grade and noninvasive markers of ischemia, anatomical disease, or prognosis. The scale's responsiveness (the ability to detect the smallest clinically important changes) is limited by the reliance on four coarse gradations based on only ambulation or stair-climbing. Conclusions: The CCS scale for stable angina might be made more useful by developing measurements for patients' self-rated symptom burden and the changes they deem important; by adding items on clinical instability (that is, progressive symptoms or pain at rest); and by empirically testing the current scale to eliminate redundant or inconsistent elements.	SUNNYBROOK HLTH SCI CTR, CLIN EPIDEMIOL UNIT, A443, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ONTARIO, CANADA; DALHOUSIE UNIV, HALIFAX B3H 4H2, NS, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Dalhousie University; University of Toronto				Cox, Jafna/0000-0001-7908-5323				ALLISON RB, 1963, CIRCULATION, V27, P170, DOI 10.1161/01.CIR.27.2.170; ASSEY ME, 1988, AM J CARDIOL, V61, pF19; BIAGINI A, 1981, CLIN CARDIOL, V4, P315, DOI 10.1002/clc.4960040602; BURGGRAF GW, 1975, CIRCULATION, V51, P146, DOI 10.1161/01.CIR.51.1.146; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; CALLAHAM PR, 1989, J AM COLL CARDIOL, V14, P1175, DOI 10.1016/0735-1097(89)90413-0; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; CHASSIN MR, 1986, INDICATIONS SELECTED; COHN PF, 1985, AM J MED, V79, P2, DOI 10.1016/0002-9343(85)90486-3; COHN PF, 1981, AM J CARDIOL, V47, P233, DOI 10.1016/0002-9149(81)90391-X; COHN PF, 1986, AM J MED, V81, P2, DOI 10.1016/0002-9343(86)90971-X; COLE JP, 1978, AM J CARDIOL, V41, P227, DOI 10.1016/0002-9149(78)90161-3; DEHMER GJ, 1982, CURRENT PROBLEMS CAR, V12, P213; DETRE K, 1981, CIRCULATION, V63, P1329, DOI 10.1161/01.CIR.63.6.1329; DEYO RA, 1984, CONTROL CLIN TRIALS, V5, P223, DOI 10.1016/0197-2456(84)90026-6; DUNCAN B, 1976, BRIT MED J, V1, P981, DOI 10.1136/bmj.1.6016.981; EGSTRUP K, 1987, ACTA MED SCAND, V222, P301; EPSTEIN SE, 1988, NEW ENGL J MED, V318, P1038, DOI 10.1056/NEJM198804213181606; FARHI JI, 1986, AM J CARDIOL, V58, P547, DOI 10.1016/0002-9149(86)90031-7; FEINSTEIN AR, 1986, ANN INTERN MED, V105, P413, DOI 10.7326/0003-4819-105-3-413; FEINSTEIN AR, 1977, AM HEART J, V93, P172, DOI 10.1016/S0002-8703(77)80308-6; Feinstein AR, 1987, CLINIMETRICS; FINDLAY I N, 1988, European Heart Journal, V9, P2; GARBER CE, 1991, J AM COLL CARDIOL, V17, P1256, DOI 10.1016/S0735-1097(10)80132-9; GOLDMAN L, 1982, J CHRON DIS, V35, P763, DOI 10.1016/0021-9681(82)90087-X; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GOTTLIEB S O, 1987, American Journal of Cardiology, V60, p33J, DOI 10.1016/0002-9149(87)90681-3; GUYATT GH, 1989, J CLIN EPIDEMIOL, V42, P403, DOI 10.1016/0895-4356(89)90128-5; HAGMAN M, 1977, ACTA MED SCAND, V201, P571; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; HAUSMANN D, 1991, AM J CARDIOL, V67, P465, DOI 10.1016/0002-9149(91)90005-6; HEYDEN S, 1971, ARCH INTERN MED, V128, P961, DOI 10.1001/archinte.128.6.961; HLATKY MA, 1989, J CLIN EPIDEMIOL, V42, P381, DOI 10.1016/0895-4356(89)90125-X; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; HUMPHRIE.JO, 1974, CIRCULATION, V49, P489, DOI 10.1161/01.CIR.49.3.489; ISKANDRIAN AS, 1984, AM J CARDIOL, V53, P1239, DOI 10.1016/0002-9149(84)90071-7; JAFFE MD, 1980, LANCET, V2, P934; JOHNSON SM, 1982, AM HEART J, V103, P4, DOI 10.1016/0002-8703(82)90522-1; KANNEL WB, 1972, AM J CARDIOL, V29, P154, DOI 10.1016/0002-9149(72)90624-8; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; KOSSMANN CE, 1964, DISEASES HEART BLOOD, P112; LACROIX AZ, 1990, CIRCULATION, V81, P437, DOI 10.1161/01.CIR.81.2.437; MAHMARIAN JJ, 1990, CIRCULATION, V82, P1305, DOI 10.1161/01.CIR.82.4.1305; MARK DB, 1989, J AM COLL CARDIOL, V14, P885, DOI 10.1016/0735-1097(89)90459-2; MASERI A, 1980, BRIT HEART J, V43, P648; MASERI A, 1986, AM J MED, V80, P48, DOI 10.1016/0002-9343(86)90452-3; MCLENACHAN JM, 1991, CIRCULATION, V83, P1263, DOI 10.1161/01.CIR.83.4.1263; MEDALIE JH, 1973, AM J MED, V55, P583, DOI 10.1016/0002-9343(73)90179-4; MIRANDA CP, 1991, ANN INTERN MED, V114, P649, DOI 10.7326/0003-4819-114-8-649; MYERS WO, 1989, J THORAC CARDIOV SUR, V97, P487; MYERS WO, 1987, ANN THORAC SURG, V44, P471, DOI 10.1016/S0003-4975(10)62104-2; NAYLOR CD, 1990, LANCET, V335, P1070, DOI 10.1016/0140-6736(90)92640-4; NIXON PGF, 1987, AM HEART J, V114, P1542, DOI 10.1016/0002-8703(87)90583-7; PERMANYERMIRALDA G, 1991, J CLIN EPIDEMIOL, V44, P779, DOI 10.1016/0895-4356(91)90130-2; PROUDFIT W L, 1986, Canadian Journal of Cardiology, V2, P62; PROUDFIT WL, 1978, PROG CARDIOVASC DIS, V21, P53, DOI 10.1016/S0033-0620(78)80004-8; PROUDFIT WL, 1966, CIRCULATION, V33, P901, DOI 10.1161/01.CIR.33.6.901; PUPITA G, 1989, AM HEART J, V118, P539, DOI 10.1016/0002-8703(89)90270-6; QUYYUMI AA, 1985, BRIT HEART J, V54, P22; RAHIMTOOLA SH, 1985, CIRCULATION, V72, P123; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; ROSE G, 1968, BRIT J PREV SOC MED, V22, P12; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; SELZER A, 1972, AM J CARDIOL, V30, P306, DOI 10.1016/0002-9149(72)90079-3; SHUB C, 1990, MAYO CLIN PROC, V65, P233, DOI 10.1016/S0025-6196(12)65018-6; SMITH WCS, 1990, BRIT HEART J, V64, P295; SPIEKERMAN RE, 1962, CIRCULATION, V25, P57, DOI 10.1161/01.CIR.25.1.57; TAKARO T, 1982, CIRCULATION, V65, P60, DOI 10.1161/01.CIR.65.7.60; TSEVAT J, 1991, MED CARE, V29, P1153, DOI 10.1097/00005650-199111000-00007; VASSILIADIS IV, 1991, AM HEART J, V121, P1403, DOI 10.1016/0002-8703(91)90145-8; WARTAK J, 1984, AM HEART J, V107, P402, DOI 10.1016/0002-8703(84)90401-0; WATERS DD, 1985, J AM COLL CARDIOL, V6, P1011, DOI 10.1016/S0735-1097(85)80302-8; WEBSTER JS, 1974, AM J CARDIOL, V33, P195, DOI 10.1016/0002-9149(74)90274-4; WEINBLATT E, 1968, J CHRON DIS, V21, P231, DOI 10.1016/0021-9681(68)90060-X; WEINER DA, 1987, AM J CARDIOL, V59, P725, DOI 10.1016/0002-9149(87)91081-2; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; WEINER DA, 1978, AM HEART J, V96, P458, DOI 10.1016/0002-8703(78)90155-2; WIKLUND I, 1991, CLIN CARDIOL, V14, P204, DOI 10.1002/clc.4960140306	82	54	59	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					677	683		10.7326/0003-4819-117-8-677	http://dx.doi.org/10.7326/0003-4819-117-8-677			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530200				2022-12-28	WOS:A1992JR86100009
J	PEARSON, M; BJORNSON, R; PEARSON, G; ROHRMANN, G				PEARSON, M; BJORNSON, R; PEARSON, G; ROHRMANN, G			THE AUTOGRAPHA-CALIFORNICA BACULOVIRUS GENOME - EVIDENCE FOR MULTIPLE REPLICATION ORIGINS	SCIENCE			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; HOMOLOGOUS DNA; SEQUENCE; REGIONS; GENE	The Autographa californica multinucleocapsid nuclear polyhedrosis virus (AcMNPV), which is used for the overexpression of eukaryotic genes and is being engineered for possible use as a viral insecticide, has a circular, supercoiled genome of approximately 128 kilobases. Despite its widespread use, little is known about the mechanism by which AcMNPV replicates. Evidence is presented in this report that AcMNPV origins of DNA replication are repeated sequences each containing several closely related imperfect palindromes that are present in six regions distributed around the genome. Although AcMNPV infection-dependent plasmid replication was initiated by a single complete palindrome, the amount of replication was substantially increased in plasmids containing six or eight palindromes.	OREGON STATE UNIV,DEPT AGR CHEM,CORVALLIS,OR 97331; OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331	Oregon State University; Oregon State University					NIAID NIH HHS [AI21973] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021973] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COCHRAN MA, 1983, J VIROL, V45, P961, DOI 10.1128/JVI.45.3.961-970.1983; FRIESEN PD, 1987, J VIROL, V61, P2264, DOI 10.1128/JVI.61.7.2264-2272.1987; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GLOCKER B, 1992, J VIROL, V66, P3476, DOI 10.1128/JVI.66.6.3476-3484.1992; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUARINO LA, 1986, J VIROL, V60, P224, DOI 10.1128/JVI.60.1.224-229.1986; GUARINO LA, 1986, J VIROL, V60, P215, DOI 10.1128/JVI.60.1.215-223.1986; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Kornberg A., 1992, DNA REPLICATION; LIU AF, 1986, J GEN VIROL, V67, P2565, DOI 10.1099/0022-1317-67-11-2565; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; Sambrook J, 1989, MOL CLONING LABORATO; Summers M.D., 1987, B TEXAS AGR EXPT STA, V1555; [No title captured]	14	156	165	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1382	1384		10.1126/science.1529337	http://dx.doi.org/10.1126/science.1529337			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529337				2022-12-28	WOS:A1992JL61200027
J	LAMAS, GA; PFEFFER, MA; HAMM, P; WERTHEIMER, J; ROULEAU, JL; BRAUNWALD, E				LAMAS, GA; PFEFFER, MA; HAMM, P; WERTHEIMER, J; ROULEAU, JL; BRAUNWALD, E			DO THE RESULTS OF RANDOMIZED CLINICAL-TRIALS OF CARDIOVASCULAR DRUGS INFLUENCE MEDICAL-PRACTICE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; IMPACT	Background. Medical practice patterns change in response to a variety of stimuli, one of which may be the publication of the results of randomized clinical trials. We assessed the temporal association between the publication of clinical trials on myocardial infarction and changes in treatment practices for this disorder. Methods. We analyzed the use of aspirin before and after myocardial infarction and that of calcium antagonists after myocardial infarction in 2231 survivors of myocardial infarction enrolled in the Survival and Ventricular Enlargement (SAVE) study over a three-year period (from January 1987 through January 1990). The proportion of patients using these treatments was analyzed before and after the publication dates of three clinical trials: the Physicians' Health Study, published in January 1988, which supported the use of aspirin to prevent a first myocardial infarction; the Second International Study of Infarct Survival (ISIS-2), published in August 1988, which supported the use of aspirin after myocardial infarction; and the Multicenter Diltiazem Postinfarction Trial, published in August 1988, which reported a deleterious effect of diltiazem in some patients after myocardial infarction. Results. The use of aspirin before myocardial infarction increased from 16.2 percent to 23.9 percent between January 1987 and January 1990 (P<0.001). Enrollment in the study after the publication of the Physicians' Health Study independently predicted aspirin use before myocardial infarction (odds ratio, 1.43; 95 percent confidence interval, 1.11 to 1.85). The use of aspirin after myocardial infarction increased from 38.8 percent to 71.9 percent (P<0.001) during the three-year study period. Enrollment in the study after the publication of ISIS-2 independently predicted the use of aspirin after myocardial infarction (odds ratio, 2.28; 95 percent confidence interval, 1.89 to 2.76). The use of calcium antagonists after myocardial infarction decreased from 57.1 percent to 33.1 percent (P<0.001) during the study period. Enrollment in the study after the publication of the Multicenter Diltiazem Postinfarction Trial independently predicted the use of calcium antagonists after myocardial infarction (odds ratio, 0.47; 95 percent confidence interval, 0.39 to 0.57). Conclusions. These observations suggest that randomized clinical trials have a measurable influence on medical practice patterns.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV TEXAS, HLTH SCI CTR, SCH PUBL HLTH, SAN ANTONIO, TX 78284 USA; CHU SHERBROOKE, SHERBROOKE J1H 5N4, QUEBEC, CANADA; ALBERT EINSTEIN MED CTR, NO DIV, PHILADELPHIA, PA 19141 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, PHILADELPHIA, PA 19140 USA	Harvard University; Harvard Medical School; University of Texas System; University of Texas Health San Antonio; University of Sherbrooke; Yeshiva University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	LAMAS, GA (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, 75 FRANCIS ST, BOSTON, MA 02115 USA.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1976, Am J Ophthalmol, V81, P383; [Anonymous], 1986, Lancet, V2, P57; [Anonymous], 1988, NEW ENGL J MED; BEHAR S, 1988, EUR HEART J, V9, P354; BOISSEL JP, 1989, CONTROL CLIN TRIALS, V10, pS120; CHALMERS TC, 1974, MT SINAI J MED, V41, P753; CHALMERS TC, 1982, CONTROL CLIN TRIALS, V3, P285, DOI 10.1016/0197-2456(82)90012-5; Cochran W.G, 1957, STAT METHODS, V6th ed; FINEBERG HV, 1987, B CANCER, V74, P333; FRIEDMAN L, 1983, CONTROL CLIN TRIALS, V4, P513, DOI 10.1016/0197-2456(83)90032-6; FURBERG CD, 1989, ARZNEIMITTELFORSCH, V39-2, P986; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HJALMARSON A, 1981, LANCET, V2, P823; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MOSS A J, 1988, Journal of the American College of Cardiology, V11, p27A; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; MOYE LA, 1991, AM J CARDIOL, V68, pD70; PASSAMANI E, 1991, NEW ENGL J MED, V324, P1589, DOI 10.1056/NEJM199105303242209; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; STROSS JK, 1981, JAMA-J AM MED ASSOC, V246, P360, DOI 10.1001/jama.246.4.360; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; WERKO L, 1988, ACTA MED SCAND, V224, P409; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1988, J AM COLL CARDIOL  S, V12, pA3	28	230	232	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					241	247		10.1056/NEJM199207233270405	http://dx.doi.org/10.1056/NEJM199207233270405			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1535419				2022-12-28	WOS:A1992JE38100005
J	WHEELER, CJ; VONHOEGEN, P; PARNES, JR				WHEELER, CJ; VONHOEGEN, P; PARNES, JR			AN IMMUNOLOGICAL ROLE FOR THE CD8 BETA-CHAIN	NATURE			English	Article							TYROSINE-PROTEIN-KINASE; MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL RECEPTOR; MHC CLASS; MONOCLONAL-ANTIBODIES; ALPHA-3 DOMAIN; LYMPHOCYTES-T; EXPRESSION; MOLECULES; P56LCK	MATURE T cells can be functionally divided into two categories distinguished by surface expression of either CD4 or CD8, which in turn corresponds to restriction by and binding to class II or class I major histocompatibility complex proteins, respectively 1-8. CD8 can be expressed as a homodimer of the alpha-chain, or as a heterodimer of alpha- and beta-chains on human and mouse T cells, although most peripheral T cells seem to express CD8-alpha-beta heterodimers exclusively (reviewed in ref. 9). Functional characterization of CD8 has focused primarily on the effect of the alpha-chain, which enhances or reconstitutes T-cell responses in homodimeric form 10,11 and may play a specific role in thymic selection 12-14. In contrast, no role has been ascribed to CD8-beta or alpha-beta heterodimers specifically. Here we show that CD8-alpha-beta transfectants produce more interleukin-2 than CD8-alpha transfectants in response to specific stimuli. Increased interleukin-2 is also observed in cells expressing hybrid CD8-beta-alpha molecules (extracellular CD8-beta plus CD8-alpha transmembrane and cytoplasmic regions) on their surface. These results indicate that external portions of CD8-beta could be critical and that they may act independently of CD8-alpha in mediating their augmentation effect.	STANFORD UNIV, MED CTR, DEPT MED, DIV IMMUNOL & RHEUMATOL, STANFORD, CA 94305 USA	Stanford University								BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUESTONE JA, 1984, J IMMUNOGENET, V11, P197; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GELIEBTER J, 1988, MOL CELL BIOL, V8, P4342, DOI 10.1128/MCB.8.10.4342; GORMAN SD, 1988, J IMMUNOL, V140, P3646; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LEWIS J, 1988, J IMMUNOL, V141, P728; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MACDONALD HR, 1982, IMMUNOL REV, V68, P89, DOI 10.1111/j.1600-065X.1982.tb01061.x; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PORTOLES P, 1989, J IMMUNOL, V142, P4169; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SWAIN SL, 1981, P NATL ACAD SCI-BIOL, V78, P7101, DOI 10.1073/pnas.78.11.7101; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	33	80	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	1992	357	6375					247	249		10.1038/357247a0	http://dx.doi.org/10.1038/357247a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1534146				2022-12-28	WOS:A1992HV19500056
J	MCMAHON, AP; JOYNER, AL; BRADLEY, A; MCMAHON, JA				MCMAHON, AP; JOYNER, AL; BRADLEY, A; MCMAHON, JA			THE MIDBRAIN HINDBRAIN PHENOTYPE OF WNT-1--WNT-1- MICE RESULTS FROM STEPWISE DELETION OF ENGRAILED-EXPRESSING CELLS BY 9.5 DAYS POSTCOITUM	CELL			English	Article							SEGMENT-POLARITY GENE; MAMMARY ONCOGENE INT-1; NUCLEOTIDE-SEQUENCE; MOLECULAR ANALYSIS; MOUSE DEVELOPMENT; TUMOR VIRUS; STEM-CELLS; HOMEO BOX; DROSOPHILA; PROTEIN	Mice homozygous for null alleles of the putative signaling molecule Wnt-1 have a reproducible phenotype: loss of the midbrain and adjacent cerebellar component of the metencephalon. By examining embryonic expression of the mouse engrailed (En) genes, from 8.0 to 9.5 days postcoitum, we demonstrate that Wnt-1 primarily regulates midbrain development. The midbrain itself is required for normal development of the metencephalon. Thus, the observed neonatal phenotype is explained by a series of early events, within 48 hr of neural plate induction, that leads to a complete loss of En domains in the anterior central nervous system. Wnt-1 and a related gene, Wnt-3a, are coexpressed from early somite stages in dorsal aspects of the myelencephalon and spinal cord. We suggest that functional redundancy between these two genes accounts for the lack of a caudal central nervous system phenotype.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Baylor College of Medicine	MCMAHON, AP (corresponding author), ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT CELL & DEV BIOL, NUTLEY, NJ 07110 USA.			Bradley, Allan/0000-0002-2349-8839				ALVARADOMALLART RM, 1990, DEV BIOL, V139, P75, DOI 10.1016/0012-1606(90)90280-V; ALVARADOMALLART RM, 1984, DEV BIOL, V103, P378, DOI 10.1016/0012-1606(84)90326-9; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Cowan W.M., 1982, NEURONAL DEV, P377; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DiNardo S, 1990, Semin Cell Biol, V1, P173; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GARDNER CA, 1991, DEVELOPMENT, V113, P1037; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; ICHIJO H, 1990, DEVELOPMENT, V110, P331; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; Lane P. W., 1967, MOUSE NEWS LETT, V36, P40; MARTINEZ S, 1990, DEV BIOL, V139, P432, DOI 10.1016/0012-1606(90)90312-7; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1992, ADV DEV BIOL, V1, P31; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; NAKAMURA H, 1990, BRAIN RES, V511, P122, DOI 10.1016/0006-8993(90)90231-Y; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; TAM PPL, 1986, J EMBRYOL EXP MORPH, V92, P269; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	56	518	527	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					581	595		10.1016/0092-8674(92)90222-X	http://dx.doi.org/10.1016/0092-8674(92)90222-X			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1534034				2022-12-28	WOS:A1992HV08900003
J	VOGELSANG, GB; FARMER, ER; HESS, AD; ALTAMONTE, V; BESCHORNER, WE; JABS, DA; CORIO, RL; LEVIN, LS; COLVIN, OM; WINGARD, JR; SANTOS, GW				VOGELSANG, GB; FARMER, ER; HESS, AD; ALTAMONTE, V; BESCHORNER, WE; JABS, DA; CORIO, RL; LEVIN, LS; COLVIN, OM; WINGARD, JR; SANTOS, GW			THALIDOMIDE FOR THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; RAT MODEL; PREDNISONE	Background. Allogeneic bone marrow transplantation is an accepted therapy for hematologic cancer, aplastic anemia, and inherited immunodeficiencies. Chronic graft-versus-host disease (GVHD) is the principal complication in patients surviving more than 100 days. Thalidomide has been shown experimentally to be effective in treating GVHD. Methods. We treated 23 patients with chronic GVHD refractory to conventional treatment and 21 patients with "high-risk" chronic GVHD (identified as having at least two of the following three risk factors: chronic GVHD that has evolved from acute GVHD, lichenoid skin or mucous-membrane changes, and hepatic dysfunction; such patients have a high mortality rate) with thalidomide in a dose that produced a plasma level of 5-mu-g per milliliter two hours after administration. Therapy was continued for three months after a complete response or for six months after a partial response. Results. The overall actuarial survival of all enrolled patients was 64 percent. Survival was 76 percent among the patients receiving salvage therapy for refractory GVHD and 48 percent among those with high-risk GVHD. A complete response was observed in 14 patients, a partial response in 12 patients, and no response in 18. Side effects were minor, most notably sedation in almost all patients. Conclusions. In this preliminary trial, thalidomide appeared to be safe and effective for the treatment of chronic GVHD. A trial comparing thalidomide with prednisone in patients with newly diagnosed chronic GVHD will be required to demonstrate its relative efficacy.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BONE MARROW TRANSPLANT UNIT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT DERMATOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OPHTHALMOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Wingard, John/0000-0001-7478-5398	NCI NIH HHS [CA-15396, R01-CA-44783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044783, P01CA015396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNHILL RL, 1982, J AM ACAD DERMATOL, V7, P317, DOI 10.1016/S0190-9622(82)70118-5; BOUGHTON BJ, 1989, BONE MARROW TRANSPL, V4, P48; CHEN TL, 1989, DRUG METAB DISPOS, V17, P402; HENEY D, 1991, BRIT J HAEMATOL, V78, P23, DOI 10.1111/j.1365-2141.1991.tb04377.x; JONES RJ, 1989, BONE MARROW TRANSPL, V4, P15; MCCARTHY DM, 1988, LANCET, V2, P1135; PARKER PM, 1989, BLOOD S1, V74, pA123; SAURAT JH, 1988, LANCET, V1, P359; SHESKIN J, 1965, CLIN PHARMACOL THER, V6, P303; SHULMAN HM, 1978, AM J PATHOL, V91, P545; STORB R, 1983, ANN INTERN MED, V98, P461, DOI 10.7326/0003-4819-98-4-461; SULLIVAN KM, 1981, BLOOD, V57, P267, DOI 10.1182/blood.V57.2.267.267; SULLIVAN KM, 1988, BLOOD, V72, P546; SULLIVAN KM, 1988, BLOOD, V72, P555; SULLIVAN KM, 1990, BLOOD, V76, pA568; VOGELSANG GB, 1986, TRANSPLANTATION, V41, P644, DOI 10.1097/00007890-198605000-00018; VOGELSANG GB, 1989, BLOOD, V74, P507; VOGELSANG GB, 1986, TRANSPLANT P, V18, P904; VOGELSANG GB, 1988, BONE MARROW TRANSPL, V3, P393; WAGNER JE, 1988, BLOOD, V72, P1168; WINGARD JR, 1989, BLOOD, V74, P1428	21	357	374	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1992	326	16					1055	1058		10.1056/NEJM199204163261604	http://dx.doi.org/10.1056/NEJM199204163261604			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN738	1549151				2022-12-28	WOS:A1992HN73800004
J	MADOFF, RD; WILLIAMS, JG; CAUSHAJ, PF				MADOFF, RD; WILLIAMS, JG; CAUSHAJ, PF			CURRENT CONCEPTS - FECAL INCONTINENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ANAL-SPHINCTER; PELVIC FLOOR; DIABETES-MELLITUS; POSTANAL REPAIR; RECTAL PROLAPSE; ANORECTAL INCONTINENCE; PUDENDAL NERVES; BIOFEEDBACK; MANAGEMENT; CONTINENCE		UNIV BIRMINGHAM, DEPT CLIN SURG, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; UNIV MASSACHUSETTS, SCH MED, DEPT SURG, WORCESTER, MA 01605 USA	University of Birmingham; University of Massachusetts System; University of Massachusetts Worcester	MADOFF, RD (corresponding author), UNIV MINNESOTA, SCH MED,DEPT SURG,DIV COLON & RECTAL SURG,BOX 450, MAYO BLDG, DELAWARE ST, MINNEAPOLIS, MN 55455 USA.							BAETEN C, 1988, DIS COLON RECTUM, V31, P134, DOI 10.1007/BF02562646; BAETEN CGMI, 1991, LANCET, V338, P1163, DOI 10.1016/0140-6736(91)92030-6; BANNISTER JJ, 1987, GUT, V28, P1241; BARRETT JA, 1989, GUT, V30, P1244, DOI 10.1136/gut.30.9.1244; BARTOLO DCC, 1986, BRIT J SURG, V73, P1012, DOI 10.1002/bjs.1800731227; BARTOLO DCC, 1983, J NEUROL NEUROSUR PS, V46, P1115, DOI 10.1136/jnnp.46.12.1115; BARTOLO DCC, 1983, GASTROENTEROLOGY, V85, P68; BROWNING GGP, 1984, ANN SURG, V199, P351, DOI 10.1097/00000658-198403000-00017; BROWNING GGP, 1983, BRIT J SURG, V70, P101, DOI 10.1002/bjs.1800700216; CERULLI MA, 1979, GASTROENTEROLOGY, V76, P742; CHRISTIANSEN J, 1989, DIS COLON RECTUM, V32, P432, DOI 10.1007/BF02563699; Clarke M, 1979, HLTH TRENDS, V11, P17; CORMAN ML, 1985, BRIT J SURG, V72, pS21, DOI 10.1002/bjs.1800721314; CTERCTEKO G C, 1988, Australian and New Zealand Journal of Surgery, V58, P703, DOI 10.1111/j.1445-2197.1988.tb01100.x; FANG DT, 1984, DIS COLON RECTUM, V27, P720, DOI 10.1007/BF02554596; FRENCKNER B, 1975, GUT, V16, P482, DOI 10.1136/gut.16.6.482; HAKELIUS L, 1985, COLOPROCTOLOGY PELVI, P259; HENRY MM, 1980, BRIT J SURG, V67, P781, DOI 10.1002/bjs.1800671105; HENRY MM, 1985, COLOPROCTOLOGY PELVI, P299; HENTZ VR, 1982, PLAST RECONSTR SURG, V70, P82, DOI 10.1097/00006534-198207000-00017; HUNT TM, 1985, BRIT J SURG, V72, P491, DOI 10.1002/bjs.1800720629; JACOBS PPM, 1990, DIS COLON RECTUM, V33, P494, DOI 10.1007/BF02052145; JENSEN LL, 1991, DIS COLON RECTUM S, V34, pP6; KIFF ES, 1984, BRIT J SURG, V71, P614, DOI 10.1002/bjs.1800710817; KIFF ES, 1984, GUT, V25, P1279, DOI 10.1136/gut.25.11.1279; LABOW S, 1980, DIS COLON RECTUM, V23, P467, DOI 10.1007/BF02987077; LAURBERG S, 1988, BRIT J SURG, V75, P786, DOI 10.1002/bjs.1800750821; MACINTYRE IM, 1972, LANCET, V1, P1094; MACLEOD JH, 1987, GASTROENTEROLOGY, V93, P291, DOI 10.1016/0016-5085(87)91017-1; MADOFF RD, 1992, COLOPROCTOLOGY PELVI; MAHIEU P, 1984, GASTROINTEST RADIOL, V9, P253, DOI 10.1007/BF01887846; MANDELSTAM DA, 1985, COLOPROCTOLOGY PELVI, P217; MANNION JD, 1986, CIRC RES, V58, P298, DOI 10.1161/01.RES.58.2.298; McLaren S M, 1981, Health Bull (Edinb), V39, P157; MILLER R, 1989, BRIT J SURG, V76, P1058, DOI 10.1002/bjs.1800761024; NEILL ME, 1981, BRIT J SURG, V68, P531, DOI 10.1002/bjs.1800680804; PARKS AG, 1975, P ROY SOC MED, V68, P681; PARKS AG, 1977, GUT, V18, P656, DOI 10.1136/gut.18.8.656; PARKS AG, 1977, OPERATIVE SURGERY CO, P249; PEMBERTON JH, 1986, MAYO CLIN PROC, V61, P586, DOI 10.1016/S0025-6196(12)62009-6; PENA A, 1989, COLON RECTAL SURGERY, P249; PERCY JP, 1981, LANCET, V1, P16; RAO SSC, 1987, GASTROENTEROLOGY, V93, P1270, DOI 10.1016/0016-5085(87)90255-1; READ MG, 1982, BRIT J SURG, V69, P396, DOI 10.1002/bjs.1800690713; READ NW, 1979, GASTROENTEROLOGY, V76, P747; READ NW, 1986, GUT, V27, P283, DOI 10.1136/gut.27.3.283; RIBOLI EB, 1988, ARCH PHYS MED REHAB, V69, P29; ROGERS J, 1988, GUT, V29, P756, DOI 10.1136/gut.29.6.756; ROTHENBERGER DA, 1989, CURRENT SURGICAL THE, P185; SCHILLER LR, 1982, NEW ENGL J MED, V307, P1666, DOI 10.1056/NEJM198212303072702; SCHWEIGER M, 1979, DIS COLON RECTUM, V22, P415, DOI 10.1007/BF02586913; SMITH LE, 1990, PRACTICAL GUIDE ANOR; SNOOKS SJ, 1984, LANCET, V2, P546; SNOOKS SJ, 1985, BRIT J SURG, V72, pS15, DOI 10.1002/bjs.1800721311; Stephens FD., 1988, ANORECTAL MALFORMATI; SUN WM, 1990, GASTROENTEROLOGY, V99, P1372, DOI 10.1016/0016-5085(90)91164-2; SUN WM, 1990, GUT, V31, P1056, DOI 10.1136/gut.31.9.1056; SWASH M, 1985, COLOPROCTOLOGY PELVI, P129; Thomas T M, 1984, Community Med, V6, P216; THOMAS TM, 1987, COMMUNITY MED, V9, P232; TOBIN GW, 1986, AGE AGEING, V15, P41, DOI 10.1093/ageing/15.1.41; WALD A, 1984, NEW ENGL J MED, V310, P1282, DOI 10.1056/NEJM198405173102003; WALD A, 1983, J PEDIATR GASTR NUTR, V2, P302, DOI 10.1097/00005176-198302020-00015; WALKER WA, 1985, DIS COLON RECTUM, V28, P832, DOI 10.1007/BF02555487; WILLIAMS NS, 1991, LANCET, V338, P1166; WOMACK NR, 1988, BRIT J SURG, V75, P48, DOI 10.1002/bjs.1800750118; WONG WD, 1990, CIBA F SYMP, V151, P246; WRENN K, 1989, NEW ENGL J MED, V321, P658; WUNDERLICH M, 1983, J NEUROL SCI, V59, P97, DOI 10.1016/0022-510X(83)90084-9; YOSHIOKA K, 1989, BRIT J SURG, V76, P1054, DOI 10.1002/bjs.1800761023; YOSHIOKA K, 1989, DIS COLON RECTUM, V32, P39, DOI 10.1007/BF02554724; YOSHIOKA K, 1988, BRIT J SURG, V75, P1220, DOI 10.1002/bjs.1800751225	72	154	159	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 9	1992	326	15					1002	1007						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM285	1545835				2022-12-28	WOS:A1992HM28500007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW APPROVED ORPHAN DRUG TO TREAT PRECOCIOUS PUBERTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1721	1721						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545450				2022-12-28	WOS:A1992HK67200005
J	CHAN, BM; KASSNER, PD; SCHIRO, JA; BYERS, HR; KUPPER, TS; HEMLER, ME				CHAN, BM; KASSNER, PD; SCHIRO, JA; BYERS, HR; KUPPER, TS; HEMLER, ME			DISTINCT CELLULAR FUNCTIONS MEDIATED BY DIFFERENT VLA INTEGRIN ALPHA-SUBUNIT CYTOPLASMIC DOMAINS	CELL			English	Article							EXTRACELLULAR-MATRIX COMPONENTS; HUMAN-MELANOMA CELLS; FIBRONECTIN RECEPTOR; T-CELLS; MONOCLONAL-ANTIBODY; GENE-EXPRESSION; SIGNAL TRANSDUCTION; ADHESION MOLECULES; COLLAGEN RECEPTOR; LAMININ RECEPTOR	To characterize VLA alpha-subunit cytoplasmic domain functions, unaltered alpha-2 cDNA (called X2C2) and two chimeric cDNAs (called X2C5 and X2C4) were constructed with extracellular alpha-2 domains and cytoplasmic alpha-2, alpha-5, and alpha-4 domains respectively. Upon transfection into rhabdomyosarcoma (RD) cells, each construct yielded comparable expression levels, immunoprecipitation profiles, and avidity for collagen and laminin. However, while RDX2C2 and RDX2C5 transfectants mediated collagen gel contraction, RDX2C4 and a mock transfectant (RDpF) did not. Conversely, only RDX2C4 cells (but not RDX2C2 or RDX2C5) showed enhanced cell migration on collagen and laminin compared with RDpF cells. This indicates markedly differing roles for integrin alpha-subunit cytoplasmic domains in post-ligand binding events. Furthermore, stable exertion of physical force (collagen gel contraction) may involve fundamentally different cellular machinery than the transient adhesion occurring during cell migration. Finally, these findings provide insight into a functional flexibility perhaps resulting from multiple integrins binding to identical ligands.	WASHINGTON UNIV, SCH MED, DIV DERMATOL, ST LOUIS, MO 63110 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02129 USA	Washington University (WUSTL); Harvard University; Massachusetts General Hospital	CHAN, BM (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR VIROL, BOSTON, MA 02115 USA.		Kupper, Thomas/O-4962-2019	Kassner, Paul/0000-0002-1471-1191	NIAMS NIH HHS [AR40124] Funding Source: Medline; NIGMS NIH HHS [GM38903, GM46526] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046526, R01GM038903] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; BELLOWS CG, 1982, J CELL SCI, V58, P125; BLUM JL, 1987, EXP CELL RES, V173, P322, DOI 10.1016/0014-4827(87)90274-6; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; BYERS HR, 1991, AM J PATHOL, V139, P423; CAREY DJ, 1991, ANNU REV PHYSIOL, V53, P161, DOI 10.1146/annurev.physiol.53.1.161; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHAN BMC, 1991, J IMMUNOL, V147, P398; DANA N, 1991, P NATL ACAD SCI USA, V88, P3106, DOI 10.1073/pnas.88.8.3106; DAVIS LS, 1990, J IMMUNOL, V145, P785; DEDHAR S, 1987, J CELL BIOL, V105, P1175, DOI 10.1083/jcb.105.3.1175; DIPERSIO CM, 1991, MOL CELL BIOL, V11, P4405, DOI 10.1128/MCB.11.9.4405; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FRADET Y, 1984, P NATL ACAD SCI-BIOL, V81, P224, DOI 10.1073/pnas.81.1.224; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GRAHAM IL, 1989, J IMMUNOL, V142, P2352; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; HARRIS AK, 1981, NATURE, V290, P249, DOI 10.1038/290249a0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1983, J IMMUNOL, V131, P334; HEMLER ME, 1991, RECEPTORS EXTRACELLU, P255; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HOLERS VM, 1989, J EXP MED, V169, P1589, DOI 10.1084/jem.169.5.1589; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KAVANAUGH AF, 1991, J IMMUNOL, V146, P4149; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KIEFEL V, 1989, BLOOD, V73, P2219; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; KRAMER RH, 1989, J BIOL CHEM, V264, P15642; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAM SCT, 1989, BLOOD, V73, P1513; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MOYLE M, 1991, J BIOL CHEM, V266, P19650; MUELLER SC, 1989, J CELL BIOL, V109, P3455, DOI 10.1083/jcb.109.6.3455; NATHAN C, 1990, J CELL BIOL, V111, P2171, DOI 10.1083/jcb.111.5.2171; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PARDI R, 1989, J IMMUNOL, V143, P3157; PIRCHER H, 1986, EUR J IMMUNOL, V16, P172, DOI 10.1002/eji.1830160212; PISCHEL KD, 1987, J IMMUNOL, V138, P226; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; ROBERTS K, 1991, J EXP MED, V173, P231, DOI 10.1084/jem.173.1.231; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SINGER II, 1988, J CELL BIOL, V106, P2171, DOI 10.1083/jcb.106.6.2171; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STREULI CH, 1990, J CELL BIOL, V110, P1405; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAPLEY P, 1989, ONCOGENE, V4, P325; TOMASEK JJ, 1982, DEV BIOL, V92, P107, DOI 10.1016/0012-1606(82)90155-5; TSUJI T, 1990, J BIOL CHEM, V265, P7016; TSUJI T, 1991, J BIOCHEM-TOKYO, V109, P659, DOI 10.1093/oxfordjournals.jbchem.a123436; TUCKER RP, 1985, CELL MOTIL CYTOSKEL, V5, P225, DOI 10.1002/cm.970050305; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VANNOESEL C, 1988, NATURE, V333, P850, DOI 10.1038/333850a0; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YAMADA KM, 1990, CANCER RES, V50, P4485; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097; ZYLSTRA S, 1986, CANCER RES, V46, P6446	99	310	312	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1051	1060		10.1016/0092-8674(92)90077-P	http://dx.doi.org/10.1016/0092-8674(92)90077-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547502				2022-12-28	WOS:A1992HK67400009
J	MCGURL, B; PEARCE, G; OROZCOCARDENAS, M; RYAN, CA				MCGURL, B; PEARCE, G; OROZCOCARDENAS, M; RYAN, CA			STRUCTURE, EXPRESSION, AND ANTISENSE INHIBITION OF THE SYSTEMIN PRECURSOR GENE	SCIENCE			English	Article							INDUCED PROTEINASE-INHIBITORS; INDUCED TRYPSIN-INHIBITOR; DEDUCED PRIMARY STRUCTURE; PLANT-LEAVES; ALFALFA LEAVES; TOMATO PLANTS; DEFENSE; RESISTANCE; MECHANISM; INSECTS	A gene that encodes systemin, a mobile 18-amino acid polypeptide inducer of proteinase inhibitor synthesis in tomato and potato leaves, has been isolated from tomato, Lycopersicon esculentum. Induction of proteinase inhibitors in plants is a response to insect or pathogen attacks. The gene has 10 introns and 11 exons, ten of which are organized as five homologous pairs with an unrelated sequence in the eleventh, encoding systemin. Systemin is proteolytically processed from a 200-amino acid precursor protein, prosystemin. Prosystemin messenger RNA was found in all organs of the plant except the roots and was systemically wound-inducible in leaves. Tomato plants transformed with an antisense prosystemin complementary DNA exhibited greatly suppressed systemic wound induction of proteinase Inhibitor I and II synthesis in leaves.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164	Washington State University								BOWLES DJ, 1990, ANNU REV BIOCHEM, V59, P873, DOI 10.1146/annurev.bi.59.070190.004301; BRADSTOCK M, 1989, AUST LIT STUD, V14, P51; BROWN WE, 1985, BIOCHEMISTRY-US, V24, P2105, DOI 10.1021/bi00330a002; BROWN WE, 1984, BIOCHEMISTRY-US, V23, P3418, DOI 10.1021/bi00310a006; CHESSIN M, 1990, BOT REV, V56, P193, DOI 10.1007/BF02858325; DAVIES E, 1987, PLANT CELL ENVIRON, V10, P623, DOI 10.1111/j.1365-3040.1987.tb01844.x; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; DREYER DL, 1987, PLANT CELL ENVIRON, V10, P353; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; GRAHAM JS, 1985, J BIOL CHEM, V260, P6555; GRAHAM JS, 1986, PLANTA, V169, P399, DOI 10.1007/BF00392137; GRAHAM JS, 1985, J BIOL CHEM, V260, P6561; GREEN TR, 1972, SCIENCE, V175, P776, DOI 10.1126/science.175.4023.776; HARRIS RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P315, DOI 10.1016/0003-9861(89)90379-2; HILDER VA, 1987, NATURE, V330, P160, DOI 10.1038/330160a0; JOHNSON R, 1989, P NATL ACAD SCI USA, V86, P9871, DOI 10.1073/pnas.86.24.9871; JUNG LJ, 1991, SCIENCE, V251, P1130; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MCGURL B, IN PRESS PLANT MOL B; MCGURL B, UNPUB; NARVAEZVASQUEZ J, 1991, THESIS WASHINGTON ST; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PEARCE G, UNPUB; PENACORTES H, 1989, P NATL ACAD SCI USA, V86, P9851, DOI 10.1073/pnas.86.24.9851; ROBY D, 1987, PHYSL MOL PL PATH, V30, P6453; ROGERS SO, 1985, PLANT MOL BIOL, V5, P69, DOI 10.1007/BF00020088; RYAN CA, 1978, TRENDS BIOCHEM SCI, V3, P148, DOI 10.1016/S0968-0004(78)90098-1; RYAN CA, 1967, ANAL BIOCHEM, V19, P434, DOI 10.1016/0003-2697(67)90233-3; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; RYAN CA, 1991, ANNU REV PLANT PHYS, V42, P651, DOI 10.1146/annurev.pp.42.060191.003251; RYAN CA, 1968, PLANT PHYSIOL, V43, P1880, DOI 10.1104/pp.43.11.1880; SAMBROOK J, 1989, MOL CLONING LAB MANU, pCH9; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH7; THAIN JF, 1990, PLANT CELL ENVIRON, V13, P569, DOI 10.1111/j.1365-3040.1990.tb01074.x; TRAUTMAN R, 1971, IMMUNOCHEMISTRY, V8, P901, DOI 10.1016/0019-2791(71)90429-0	35	313	351	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 20	1992	255	5051					1570	1573		10.1126/science.1549783	http://dx.doi.org/10.1126/science.1549783			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1549783				2022-12-28	WOS:A1992HJ80900040
J	SPECHLER, SJ				SPECHLER, SJ			COMPARISON OF MEDICAL AND SURGICAL THERAPY FOR COMPLICATED GASTROESOPHAGEAL REFLUX DISEASE IN VETERANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESOPHAGITIS; OMEPRAZOLE; RANITIDINE; MANAGEMENT; RELAPSE; GASTRIN	Background. Conventional medical treatment for gastroesophageal reflux disease involves life-style modifications and combination drug therapy, but few studies have included these features in their protocols. Antireflux surgery has seldom been studied prospectively, and there have been no trials comparing modern medical and surgical treatments for reflux disease. Methods. We conducted a long-term, randomized trial of medical therapy (lifestyle modifications and up to four medications) and surgical therapy (Nissen fundoplication) in 247 patients (243 men and 4 women) with peptic esophageal ulcer, stricture, erosive esophagitis, or Barrett's esophagus. They received by random assignment either continuous medical therapy, medical therapy for symptoms only, or surgical therapy. Symptoms were assessed quarterly with a disease-activity index; esophagoscopy was performed at base line and each year for two years. The outcomes evaluated at one and two years included the activity index and the endoscopic grade of esophagitis. Results. Follow-up data were available for 176 patients at one year and for 106 patients at two years. The mean (+/- SE) activity-index score (possible range, 74 to 172) decreased in one year from 108 +/- 3 to 87 +/- 2 in the group receiving continuous medical therapy, from 107 +/- 3 to 88 +/- 2 in the group receiving medical therapy for symptoms only, and from 109 +/- 3 to 78 +/- 2 in the surgical-therapy group (P < 0.0001 for the change from base line, for all comparisons). The mean (+/- SE) grade of esophagitis (possible range, 1 to 4) decreased in the respective groups from 2.9 +/- 0.1 to 2.0 +/- 0.1, from 2.9 +/- 0.1 to 2.3 +/- 0.1, and from 2.9 +/- 0.1 to 1.4 +/- 0.1 (P < 0.005 vs. base line, for all comparisons). The mean activity-index score and the grade of esophagitis were significantly better in the surgical-therapy group than in either medical-therapy group during the two years of follow-up (P < 0.003). Conclusions. In men with complicated gastroesophageal reflux disease, surgery is significantly more effective than medical therapy in improving the symptoms and endoscopic signs of esophagitis for up to two years, although medical treatment is also effective.			SPECHLER, SJ (corresponding author), BETH ISRAEL HOSP, TREATMENT & RES CTR SWALLOWING & MOTIL DISORDERS, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							BEHAR J, 1975, NEW ENGL J MED, V293, P263, DOI 10.1056/NEJM197508072930602; CASTELL DO, 1986, ANN INTERN MED, V104, P112, DOI 10.7326/0003-4819-104-1-112; COLLEN MJ, 1990, GASTROENTEROLOGY, V98, P654, DOI 10.1016/0016-5085(90)90285-9; DEMEESTER TR, 1976, ANN SURG, V184, P459, DOI 10.1097/00000658-197610000-00009; DEMEESTER TR, 1980, J THORAC CARDIOV SUR, V79, P656; DEMEESTER TR, 1986, ANN SURG, V204, P9, DOI 10.1097/00000658-198607000-00002; DODDS WJ, 1976, ARCH INTERN MED, V136, P515, DOI 10.1001/archinte.136.5.515; FESTEN HPM, 1984, GASTROENTEROLOGY, V87, P1030; GLISE H, 1989, SCAND J GASTROENTERO, V24, P57, DOI 10.3109/00365528909091039; HETZEL DJ, 1988, GASTROENTEROLOGY, V95, P903, DOI 10.1016/0016-5085(88)90162-X; HOWARD J M, 1990, Gastroenterology, V98, pA61; KLINKENBERG-KNOL E C, 1990, Gastroenterology, V98, pA69; KOELZ HR, 1986, GASTROENTEROLOGY, V91, P1198, DOI 10.1016/S0016-5085(86)80017-8; LANDRENEAU RJ, 1989, POSTGRAD MED, V85, P117; LARSSON H, 1986, GASTROENTEROLOGY, V90, P391, DOI 10.1016/0016-5085(86)90938-8; LIEBERMAN DA, 1987, ARCH INTERN MED, V147, P1717, DOI 10.1001/archinte.147.10.1717; MCCALLUM RW, 1981, GASTROENTEROLOGY, V80, P285; PALMER ED, 1968, AM J MED, V44, P566, DOI 10.1016/0002-9343(68)90057-0; PAYNE WS, 1987, SURG CLIN N AM, V67, P443; RICHTER JE, 1986, J CLIN GASTROENTEROL, V8, P72, DOI 10.1097/00004836-198606001-00011; SCHLUCHTER MD, 1988, 86 TECHN REP; SHIRAZI SS, 1987, ARCH SURG-CHICAGO, V122, P548; SONNENBERG A, 1981, REFLUXTHERAPIE GASTR, P85; SPECHLER S J, 1990, Gastroenterology, V98, pA130; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; STOCKBRUEGGER RW, 1985, SCAND J GASTROENTERO, V20, P7, DOI 10.3109/00365528509093749; Woodward E R, 1977, World J Surg, V1, P453; 1988, HEARTBURN AM GALLUP	28	435	457	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1992	326	12					786	792		10.1056/NEJM199203193261202	http://dx.doi.org/10.1056/NEJM199203193261202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ592	1538721	Bronze			2022-12-28	WOS:A1992HJ59200002
J	MOMBAERTS, P; IACOMINI, J; JOHNSON, RS; HERRUP, K; TONEGAWA, S; PAPAIOANNOU, VE				MOMBAERTS, P; IACOMINI, J; JOHNSON, RS; HERRUP, K; TONEGAWA, S; PAPAIOANNOU, VE			RAG-1-DEFICIENT MICE HAVE NO MATURE LYMPHOCYTES-B AND LYMPHOCYTES-T	CELL			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; CELL ANTIGEN RECEPTOR; MURINE LEUKEMIA-VIRUS; SCID MICE; V(D)J RECOMBINATION; GENE REARRANGEMENTS; MOUSE; DIFFERENTIATION; EXPRESSION; GENERATION	The V(D)J recombination activation gene RAG-1 was isolated on the basis of its ability to activate V(D)J recombination on an artificial substrate in fibroblasts. This property and the expression pattern in tissues and cell lines indicate that RAG-1 either activates or catalyzes the V(D)J recombination reaction of immunoglobulin and T cell receptor genes. We here describe the introduction of a mutation in RAG-1 into the germline of mice via gene targeting in embryonic stem cells. RAG-1 -deficient mice have small lymphoid organs that do not contain mature B and T lymphocytes. The arrest of B and T cell differentiation occurs at an early stage and correlates with the inability to perform V(D)J recombination. The immune system of the RAG-1 mutant mice can be described as that of nonleaky scid mice. Although RAG-1 expression has been reported in the central nervous system of the mouse, no obvious neuroanatomical or behavioral abnormalities have been found in the RAG-1-deficient mice.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; SHRIVER CTR MENTAL RETARDAT,WALTHAM,MA 02254; TUFTS UNIV,SCH MED & VET MED,DEPT PATHOL,BOSTON,MA 02111	Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Tufts University	MOMBAERTS, P (corresponding author), MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.		Johnson, Randall/AAM-1189-2021; Herrup, Karl/C-5313-2014	Johnson, Randall/0000-0002-4084-6639; Papaioannou, Virginia/0000-0001-7558-8601; Herrup, Karl/0000-0001-7786-5844	NICHD NIH HHS [HD27295] Funding Source: Medline; NINDS NIH HHS [NS18381] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018381] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ALT F W, 1991, Current Biology, V1, P3, DOI 10.1016/0960-9822(91)90108-9; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P3927, DOI 10.1073/pnas.88.9.3927; BOSMA GC, 1988, J EXP MED, V167, P1016, DOI 10.1084/jem.167.3.1016; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARLSON LM, 1991, CELL, V64, P201, DOI 10.1016/0092-8674(91)90221-J; CARROLL AM, 1989, J IMMUNOL, V143, P1087; CARROLL AM, 1988, EUR J IMMUNOL, V18, P1965, DOI 10.1002/eji.1830181215; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; FULOP GM, 1988, CELL IMMUNOL, V113, P192, DOI 10.1016/0008-8749(88)90017-2; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P293; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCCUNE JM, 1991, CURR OPIN IMMUNOL, V3, P224, DOI 10.1016/0952-7915(91)90055-6; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOMBAERTS P, 1991, P NATL ACAD SCI USA, V88, P3084, DOI 10.1073/pnas.88.8.3084; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MULLEN RJ, 1977, NATURE, V270, P245, DOI 10.1038/270245a0; NOWAKOWSKI R S, 1984, Journal of Neurogenetics, V1, P249, DOI 10.3109/01677068409107090; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PAPAIOANNOU VE, 1981, TECHNIQUES LIFE SC 1, V116, P1; PETRINI JHJ, 1990, P NATL ACAD SCI USA, V87, P3450, DOI 10.1073/pnas.87.9.3450; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521	50	2338	2424	3	104	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					869	877		10.1016/0092-8674(92)90030-G	http://dx.doi.org/10.1016/0092-8674(92)90030-G			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547488				2022-12-28	WOS:A1992HH74800006
J	WILLIAMS, TM; FRIEDL, WA; FONG, ML; YAMADA, RM; SEDIVY, P; HAUN, JE				WILLIAMS, TM; FRIEDL, WA; FONG, ML; YAMADA, RM; SEDIVY, P; HAUN, JE			TRAVEL AT LOW ENERGETIC COST BY SWIMMING AND WAVE-RIDING BOTTLE-NOSED DOLPHINS	NATURE			English	Article							LOCOMOTION	OVER the past 50 years there has been much speculation about the energetic cost of swimming and wave-riding by dolphins 1-11. When aligned properly in front of the bow of moving ships 1-3, in the stern wake of small boats 4,5, on wind waves 6, and even in the wake of larger cetaceans 7-9, the animals appear to move effortlessly through the water without the benefit of propulsive strokes by the flukes. Theoretically, body streamlining as well as other anatomical and behavioural adaptations contribute to low transport costs in these animals. The economy of movement permitted by wave-riding has been perceived as an energetic advantage for the swimming dolphin 2,310, but has been hard to prove in the absence of physiological data for exercising cetaceans. Here we determine the aerobic and anaerobic costs of swimming and wave-riding in bottlenose dolphins and find that the minimum cost of transport for swimming dolphins is 1.29 +/- 0.05 J kg-1 m-1 at a cruising speed of 2.1 m s-1. Aerobic costs are nearly twice as high for swimming 12. seals and sea lions, and 8-12 times higher for human swimmers Wave-riding by dolphins provides additional benefits in terms of speed. The results indicate that behavioural, physiological and morphological factors make swimming an economical form of high-speed travel for dolphins.			WILLIAMS, TM (corresponding author), USN,CTR OCEANS SYST,HAWAII LAB,POB 997,CODE 511,KAILUA,HI 96734, USA.							Aleyev Y.G, 1977, NEKTON; AU D, 1980, NATURE, V284, P548, DOI 10.1038/284548a0; BARTHOLOMEW G. A., 1977, ANIMAL PHYSL PRINCIP, P57; BLAKE RW, 1983, J MAR BIOL ASSOC UK, V63, P61, DOI 10.1017/S0025315400049808; BRETT JR, 1964, J FISH RES BOARD CAN, V21, P1183, DOI 10.1139/f64-103; Fedak M.A., 1986, DIVING ANIMALS MAN, P11; Goforth H.W. Jr, 1990, P559; Gray J, 1936, J EXP BIOL, V13, P192; Hertel H., 1969, P31; HOMER I, 1972, J APPL PHYSIOL, V33, P502; LANG TG, 1966, SCIENCE, V152, P531, DOI 10.1126/science.152.3721.531; LANG TG, 1966, WHALES DOLPHINS PORP, P410; MCBRIDE AF, 1951, J MAMMAL, V32, P251, DOI 10.2307/1375657; NORRIS KENNETH S., 1961, UNIV CALIFORNIA PUBL ZOOL, V63, P291; PONGANIS PJ, 1990, J COMP PHYSIOL B, V160, P473; Ridgway S.H., 1972, P590; RIDGWAY SH, 1969, SCIENCE, V166, P1651, DOI 10.1126/science.166.3913.1651; SCHMIDTNIELSEN K, 1972, SCIENCE, V177, P222, DOI 10.1126/science.177.4045.222; SCHOLANDER PF, 1959, SCIENCE, V129, P1085, DOI 10.1126/science.129.3356.1085; SHANE SH, 1986, MAR MAMMAL SCI, V2, P34, DOI 10.1111/j.1748-7692.1986.tb00026.x; WILLIAMS T L, 1991, Journal of the Marine Biological Association of the United Kingdom, V71, P727; WILLIAMS TM, 1991, J COMP PHYSIOL B, V160, P637, DOI 10.1007/BF00571261; WILLIAMS TM, 1989, J COMP PHYSIOL A, V164, P815, DOI 10.1007/BF00616753; WILLIAMS TM, 1985, PHYSIOL ZOOL, V58, P576, DOI 10.1086/physzool.58.5.30158584; WOODCOCK AH, 1951, J EXP BIOL, V28, P215; WURSIG B, 1979, FISH B-NOAA, V77, P399; Zar JH, 1974, BIOSTATISTICAL ANAL	27	118	124	2	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					821	823		10.1038/355821a0	http://dx.doi.org/10.1038/355821a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538760				2022-12-28	WOS:A1992HF63600054
J	KROLL, DM; GOMPPER, G				KROLL, DM; GOMPPER, G			THE CONFORMATION OF FLUID MEMBRANES - MONTE-CARLO SIMULATIONS	SCIENCE			English	Article							TRIANGULATED RANDOM SURFACES; SELF-AVOIDING SURFACES; THERMAL FLUCTUATIONS; ELASTICITY; DIMENSIONS; CURVATURE; TENSION; MODEL	The conformation and scaling properties of self-avoiding fluid membranes with an extrinsic bending rigidity-kappa were studied with the use of Monte Carlo methods. For kappa = 0, the results are consistent with branched polymer behavior at large length scales. There is a smooth crossover from a crumpled to an extended state with increasing kappa, with a peak in the specific heat when the persistence length reaches the system size. The scale-dependent effective bending rigidity is a decreasing function of system size for all bare rigidities. These results indicate that fluid membranes are always crumpled at sufficiently long length scales.	FORSCHUNGSZENTRUM JULICH, INST FESTKORPERFORSCH, W-5170 JULICH 1, GERMANY; UNIV MUNICH, SEKT PHYS, W-8000 MUNICH, GERMANY	Helmholtz Association; Research Center Julich; University of Munich	KROLL, DM (corresponding author), UNIV MINNESOTA, AHPCRC, MINNEAPOLIS, MN 55455 USA.		Gompper, Gerhard/I-4886-2012	Gompper, Gerhard/0000-0002-8904-0986				AMBJORN J, 1985, NUCL PHYS B, V257, P433, DOI 10.1016/0550-3213(85)90356-6; AMBJORN J, 1986, NUCL PHYS B, V275, P161, DOI 10.1016/0550-3213(86)90594-8; BAILLIE CF, 1990, NUCL PHYS B, V335, P469, DOI 10.1016/0550-3213(90)90504-7; BAUMGARTNER A, 1990, PHYS REV A, V41, P5747, DOI 10.1103/PhysRevA.41.5747; BILLOIRE A, 1986, NUCL PHYS B, V275, P617, DOI 10.1016/0550-3213(86)90577-8; BOULATOV DV, 1986, NUCL PHYS B, V275, P641, DOI 10.1016/0550-3213(86)90578-X; BROCHARD F, 1975, J PHYS-PARIS, V36, P1035, DOI 10.1051/jphys:0197500360110103500; CATES ME, 1985, PHYS LETT B, V161, P363, DOI 10.1016/0370-2693(85)90779-8; DAVID F, 1991, J PHYS II, V1, P959, DOI 10.1051/jp2:1991120; DEGENNES PG, 1982, J PHYS CHEM-US, V86, P2294, DOI 10.1021/j100210a011; DIMIGLIO JM, 1985, PHYS REV LETT, V54, P1686; DUWE HP, 1990, J PHYS-PARIS, V51, P945, DOI 10.1051/jphys:019900051010094500; EVANS E, 1990, PHYS REV LETT, V64, P2094, DOI 10.1103/PhysRevLett.64.2094; FORSTER D, 1986, PHYS LETT A, V114, P115, DOI 10.1016/0375-9601(86)90536-0; FORSTER D, 1986, PHYS LETT A, V116, P57; FUJIKAWA K, 1983, NUCL PHYS B, V226, P437, DOI 10.1016/0550-3213(83)90202-X; GLAUS U, 1988, J STAT PHYS, V50, P1141, DOI 10.1007/BF01019158; GLAUS U, 1986, PHYS REV LETT, V56, P1996, DOI 10.1103/PhysRevLett.56.1996; GOMPPER G, 1991, J PHYS I, V1, P1411, DOI 10.1051/jp1:1991211; HO JS, 1990, EUROPHYS LETT, V12, P295, DOI 10.1209/0295-5075/12/4/002; Itzykson C, 1986, P GIFT SEMINAR JACA, V85, P130; KLEINERT H, 1986, PHYS LETT A, V114, P263, DOI 10.1016/0375-9601(86)90219-7; LIPOWSKY R, 1991, NATURE, V349, P475, DOI 10.1038/349475a0; MUTZ M, 1990, J PHYS-PARIS, V51, P991, DOI 10.1051/jphys:019900051010099100; NELSON DR, 1989, STATISTICAL MECHANIC; PELITI L, 1985, PHYS REV LETT, V54, P1690, DOI 10.1103/PhysRevLett.54.1690; SEUNG HS, 1988, PHYS REV A, V38, P1005, DOI 10.1103/PhysRevA.38.1005	27	104	104	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					968	971		10.1126/science.1546294	http://dx.doi.org/10.1126/science.1546294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546294				2022-12-28	WOS:A1992HE60500035
J	EPSTEIN, NR				EPSTEIN, NR			FRAME AND FOCUS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						ALZHEIMERS DISEASE; PHYSICIAN-PATIENT RELATIONS		A physician meets with an Alzheimer patient and the patient's wife. In the process, an examination is done, and the wife and physician discuss her ability to cope with her difficult responsibilities. They digress into her memories of past travels with her husband, and of the onset of his disease. The physician grapples with questions of bis own vulnerability and ponders some disquieting possibilities.											0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					690	690		10.7326/0003-4819-117-8-690	http://dx.doi.org/10.7326/0003-4819-117-8-690			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530201				2022-12-28	WOS:A1992JR86100011
J	MCNAMARA, ME				MCNAMARA, ME			KAREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1740	1740						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1527886				2022-12-28	WOS:A1992JQ37600039
J	SEIDEL, HM; POMPLIANO, DL; KNOWLES, JR				SEIDEL, HM; POMPLIANO, DL; KNOWLES, JR			EXONS AS MICROGENES	SCIENCE			English	Editorial Material							SPLICE JUNCTIONS; EVOLUTION; TETRAHYMENA; CODONS; INTRON; GENES		HARVARD UNIV, DEPT CHEM, 12 OXFORD ST, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, DEPT BIOCHEM, CAMBRIDGE, MA 02138 USA	Harvard University; Harvard University								Anfinsen C.B., 1971, ENZYMES, V4; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CRAIK CS, 1982, NATURE, V299, P180, DOI 10.1038/299180a0; GALAKATOS NG, 1987, BIOCHEMISTRY-US, V26, P8475, DOI 10.1021/bi00399a066; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GO M, 1987, COLD SPRING HARB SYM, V52, P915, DOI 10.1101/SQB.1987.052.01.100; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; HANYU N, 1986, EMBO J, V5, P1307, DOI 10.1002/j.1460-2075.1986.tb04360.x; Hori T., 1984, BIOCH NATURAL C P CO; LI CH, 1976, P NATL ACAD SCI USA, V73, P1476, DOI 10.1073/pnas.73.5.1476; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; NAITO Y, 1991, P NATL ACAD SCI USA, V88, P6672, DOI 10.1073/pnas.88.15.6672; ORGEL LE, 1987, COLD SPRING HARB SYM, V52, P9, DOI 10.1101/SQB.1987.052.01.004; OSAWA S, 1990, P ROY SOC B-BIOL SCI, V241, P19, DOI 10.1098/rspb.1990.0060; RICHARDS FM, 1971, ENZYMES, V4, P647; SEIDEL HM, 1992, BIOCHEMISTRY-US, V31, P2598, DOI 10.1021/bi00124a021; SENAPATHY P, 1988, P NATL ACAD SCI USA, V85, P1129, DOI 10.1073/pnas.85.4.1129; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; [No title captured]	21	29	31	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1992	257	5076					1489	1490		10.1126/science.1523407	http://dx.doi.org/10.1126/science.1523407			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523407				2022-12-28	WOS:A1992JM57000019
J	LUGOMIRO, VI; GREEN, M; MAZUR, L				LUGOMIRO, VI; GREEN, M; MAZUR, L			COMPARISON OF DIFFERENT METRONIDAZOLE THERAPEUTIC REGIMENS FOR BACTERIAL VAGINOSIS - A METAANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							GARDNERELLA-VAGINALIS VAGINITIS; NONSPECIFIC VAGINITIS	Objective.-To evaluate the treatment of bacterial vaginosis with metronidazole to determine if there is a therapeutic regimen that is superior to all others with regard to cure and recurrence rates. Data Sources.-Computer-assisted literature search, Medical Subject Index review, and references cited in articles identified. Study Selection.-Clinical trials comparing different oral metronidazole regimens in which diagnostic criteria for bacterial vaginosis and criteria to detect cure to treatment were described. Date Extraction.-Articles that met inclusion criteria were critically appraised and those that passed were included in the analysis. Of 52 initial articles, 10 met criteria for inclusion and passed critical appraisal. Data Synthesis.-Patients were divided in groups according to the duration of therapy received: group A (n=413), 2-g single dose; group B (n=193), 2-g single daily dose for 2 days; group C (n=317), 5 days; and group D (n=280), 7 days. Cure rates on initial evaluation for the groups were 85%, 87%, 86%, and 87%, respectively. Chi-2 contingency table analysis showed no significant difference in cure rates among the groups (P=.78). Only 465 of these patients were evaluated for recurrence of disease. There was no significant difference in cure rates after 4 weeks of therapy (P=.4). Conclusions.-A 2-g single-dose metronidazole regimen is as effective as a single daily dose given for 2 days or a 5-day course or a 7-day course.	UNIV TEXAS, HLTH SCI CTR, DEPT PEDIAT, HOUSTON, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston								ABRAMOWICZ M, 1986, MED LETT, V28, P23; AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9; BALDSON MJ, 1980, LANCET, V1, P501; BALSDON MJ, 1983, SCAND J INFECT DIS, P101; BLACKWELL A, 1983, SCAND J INFECT DIS, P103; BLACKWELL AL, 1983, LANCET, V2, P1379; BUMP RC, 1984, AM J OBSTET GYNECOL, V150, P917, DOI 10.1016/0002-9378(84)90381-8; ESCHENBACH DA, 1983, SCAND J INFECT DIS, P73; FREDRICSSON B, 1986, ZBL GYNAKOL, V108, P799; FREDRICSSON B, 1983, SCAND J INFECT DIS, P91; GARDNER HL, 1955, AM J OBSTET GYNECOL, V69, P962, DOI 10.1016/0002-9378(55)90095-8; GREENWOOD JR, 1980, INT J SYST BACTERIOL, V30, P170, DOI 10.1099/00207713-30-1-170; HAGSTROM B, 1983, SCAND J INFECT DIS, P95; HILLIER S, 1984, SEXUALLY TRANSMITTED, P547; HOVIK P, 1983, SCAND J INFECT DIS, P107; JENICEK M, 1989, J CLIN EPIDEMIOL, V42, P35, DOI 10.1016/0895-4356(89)90023-1; JERVE F, 1984, BRIT J VENER DIS, V60, P171; JERVE F, 1983, SCAND J INFECT DIS, P111; JONES BM, 1985, J ANTIMICROB CHEMOTH, V16, P189, DOI 10.1093/jac/16.2.189; MALOUF M, 1981, OBSTET GYNECOL, V57, P711; MCCUE JD, 1989, ARCH INTERN MED, V149, P565, DOI 10.1001/archinte.149.3.565; MINKOWSKI WL, 1983, J ADOLESCENT HEALTH, V4, P113, DOI 10.1016/S0197-0070(83)80030-8; MOHANTY KC, 1987, J ANTIMICROB CHEMOTH, V19, P393, DOI 10.1093/jac/19.3.393; NELSON MS, 1987, AM J EMERG MED, V5, P488, DOI 10.1016/0735-6757(87)90167-7; PETERSEN EE, 1983, SCAND J INFECT DIS, P97; PHEIFER TA, 1978, NEW ENGL J MED, V298, P1429, DOI 10.1056/NEJM197806292982601; PIOT P, 1985, SCAND J UROL NEPHROL, P229; PURDON A, 1984, OBSTET GYNECOL, V64, P271; SACKETT DL, 1981, CAN MED ASSOC J, V124, P1156; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SWEDBERG J, 1985, JAMA-J AM MED ASSOC, V254, P1046, DOI 10.1001/jama.254.8.1046; 1989, MMWR, V38, P36	32	54	59	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					92	95		10.1001/jama.268.1.92	http://dx.doi.org/10.1001/jama.268.1.92			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1535108				2022-12-28	WOS:A1992JA16500029
J	JAIN, J; MCCAFFREY, PG; VALGEARCHER, VE; RAO, A				JAIN, J; MCCAFFREY, PG; VALGEARCHER, VE; RAO, A			NUCLEAR FACTOR OF ACTIVATED T-CELLS CONTAINS FOS AND JUN	NATURE			English	Article							LYMPHOCYTE-SPECIFIC FACTORS; INTERLEUKIN-2 GENE; DNA-BINDING; PROTEIN; ENHANCER; ELEMENT; AP-1	THE nuclear factor NF-AT (ref. 1) is induced in T cells stimulated through the T-cell receptor/CD3 complex, and is required for interleukin-2 (IL-2) gene induction. Although NF-AT has not been cloned or purified, there is evidence that it is a major target for immunosuppression by cyclosporin A (CsA) and FK506 (refs 2-7). NF-AT induction may require two activation-dependent events: the CsA-sensitive translocation of a pre-existing component and the CsA-resistant synthesis of a nuclear component 8. Here we report that the newly synthesized nuclear component of NF-AT is the transcription factor AP-1. We show that the inducible nuclear form of NF-AT contains Fos and Jun proteins. Furthermore, we identify a pre-existing NF-AT-binding factor that is present in hypotonic extracts of unstimulated T cells. On the basis of binding, reconstitution and cotransfection experiments, we propose that activation of NF-AT occurs in at least two stages: a CsA-sensitive stage involving modification and/or translocation of the pre-existing NF-AT complex, and a CsA-insensitive stage involving the addition of newly synthesized Fos or Fos/Jun proteins to the pre-existing complex.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)								BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FISHER CL, 1991, J IMMUNOL, V146, P1743; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; POGNONEC P, 1989, ONCOGENE, V4, P691; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	26	492	503	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					801	804		10.1038/356801a0	http://dx.doi.org/10.1038/356801a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1533441				2022-12-28	WOS:A1992HR18600053
J	SEONG, RH; CHAMBERLAIN, JW; PARNES, JR				SEONG, RH; CHAMBERLAIN, JW; PARNES, JR			SIGNAL FOR T-CELL DIFFERENTIATION TO A CD4 CELL LINEAGE IS DELIVERED BY CD4 TRANSMEMBRANE REGION AND OR CYTOPLASMIC TAIL	NATURE			English	Article							HISTOCOMPATIBILITY COMPLEX ANTIGENS; TYROSINE-PROTEIN-KINASE; TRANSGENIC MICE; RECEPTOR DETERMINE; CD4/CD8 PHENOTYPE; LYMPHOCYTES-T; MOLECULES; EXPRESSION; THYMUS; PHOSPHORYLATION	MATURE T cells express either CD4 or CD8 on their surface. Most helper T cells express CD4, which binds to class II major histocompatibility complex (MHC) proteins, and most cytotoxic T cells express CD8, which binds to class I MHC proteins. In the thymus, mature CD4+CD8- and CD4- CD8+ T cells expressing alpha-beta-T-cell antigen receptors (TCR) develop from immature thymocytes through CD4+CD8+ alpha-beta-TCR+ intermediates 1. Experiments using mice transgenic for alpha-beta-TCR 2-5 suggest that the specificity of the TCR determines the CD4/CD8 phenotype of mature T cells. These results, however, do not indicate how a T cell differentiates into the CD4 or CD8 lineage. Here we show that the CD4 transmembrane region and/or cytoplasmic tail mediates the delivery of a specific signal that directs differentiation of T cells to a CD4 lineage. We generated transgenic mice expressing a hybrid molecule composed of the CD8-alpha extracellular domains linked to the CD4 transmembrane region and cytoplasmic tail. We predicted that this hybrid molecule would bind to class I MHC proteins through the extracellular domains but deliver the intracellular signals characteristic of CD4. By crossing our transgenic mice with mice expressing a transgenic alpha-beta-TCR specific for a particular antigen plus class I MHC protein, we were able to express the hybrid molecule in developing thymocytes expressing the class I MHC-restricted TCR. Our results show that the signal transduced by the hybrid molecule results in the differentiation of immature thymocytes expressing a class I-restricted TCR into mature T cells expressing CD4.	STANFORD UNIV, MED CTR,SCH MED,DEPT MED,DIV IMMUNOL & RHEUMATOL, STANFORD, CA 94305 USA; UNIV TORONTO, DEPT IMMUNOL, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV TORONTO, HOSP SICK CHILDREN, RES INST, TORONTO M5G 1X8, ONTARIO, CANADA	Stanford University; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Seong, Rho/0000-0001-5699-0718				BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GORMAN SD, 1987, P NATL ACAD SCI USA, V84, P7644, DOI 10.1073/pnas.84.21.7644; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; KAPPLER JW, 1978, J EXP MED, V148, P1510, DOI 10.1084/jem.148.6.1510; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEDBETTER JA, 1981, J EXP MED, V153, P1503, DOI 10.1084/jem.153.6.1503; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VONBOEHMER H, 1978, P NATL ACAD SCI USA, V75, P2434; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	22	83	83	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1992	356	6371					718	720		10.1038/356718a0	http://dx.doi.org/10.1038/356718a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1533274				2022-12-28	WOS:A1992HQ14600063
J	GIANNINI, EH; BREWER, EJ; KUZMINA, N; SHAIKOV, A; MAXIMOV, A; VORONTSOV, I; FINK, CW; NEWMAN, AJ; CASSIDY, JT; ZEMEL, LS				GIANNINI, EH; BREWER, EJ; KUZMINA, N; SHAIKOV, A; MAXIMOV, A; VORONTSOV, I; FINK, CW; NEWMAN, AJ; CASSIDY, JT; ZEMEL, LS			METHOTREXATE IN RESISTANT JUVENILE RHEUMATOID-ARTHRITIS - RESULTS OF THE USA-USSR DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DOSE METHOTREXATE; COLLABORATIVE STUDY-GROUP; STANDARD METHODOLOGY; SEGMENT-II; THERAPY; EFFICACY	Background. The antimetabolite methotrexate has been shown in placebo-controlled trials to be effective in adults with rheumatoid arthritis. Methotrexate may also be effective in children with resistant juvenile rheumatoid arthritis, but the supporting data are from uncontrolled trials. Methods. Centers in the United States and the Soviet Union participated in this randomized, controlled, double-blind trial designed to evaluate the effectiveness and safety of orally administered methotrexate. Patients received one of the following treatments each week for six months: 10 mg of methotrexate per square meter of body-surface area (low dose), 5 mg of methotrexate per square meter (very low dose), or placebo. The use of prednisone (less-than-or-equal-to 10 mg per day) and two nonsteroidal antiinflammatory drugs was also allowed. Results. The 127 children (mean age, 10.1 years) had a mean duration of disease of 5.1 years; 114 qualified for the analysis of efficacy. According to a composite index of several response variables, 63 percent of the children who received low-dose methotrexate improved, as compared with 32 percent of those in the very-low-dose group and 36 percent of those in the placebo group (P = 0.013). As compared with the placebo group, the low-dose group also had significantly larger mean reductions from base line in the number of joints with pain on motion (-11.0 vs. -7.1), the pain-severity score (-19.0 vs. -11.5), the number of joints with limited motion (-5.4 vs. -0.7), and the erythrocyte sedimentation rate (-19 vs. -6 mm per hour). In the methotrexate groups only three children had the drug discontinued because of mild-to-moderate side effects; none had severe toxicity. Conclusions. Methotrexate given weekly in low doses is an effective treatment for children with resistant juvenile rheumatoid arthritis, and at least in the short term this regimen is safe.	BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; ACAD MED SCI USSR, INST RHEUMATOL, MOSCOW 109801, USSR; ST PETERSBURG PEDIAT INST, DEPT CHILD DIS, ST PETERSBURG, USSR; UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT PEDIAT, DALLAS, TX 75235 USA; RAINBOW BABIES & CHILDRENS HOSP, CLEVELAND, OH 44106 USA; UNIV MISSOURI, DEPT CHILD HLTH, COLUMBIA, MO 65201 USA; NEWINGTON CHILDRENS HOSP, DEPT RHEUMATOL, NEWINGTON, CT 06111 USA	Baylor College of Medicine; Russian Academy of Medical Sciences; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University of Missouri System; University of Missouri Columbia	GIANNINI, EH (corresponding author), UNIV CINCINNATI, CHILDRENS HOSP MED CTR, COLL MED, DEPT PEDIAT, PAVILLION BLDG, CINCINNATI, OH 45229 USA.				FDA HHS [FD-R-000032] Funding Source: Medline	FDA HHS		ALARCON GS, 1989, ARTHRITIS RHEUM, V32, P671, DOI 10.1002/anr.1780320603; BAUM J, 1980, ARTHRITIS RHEUM, V23, P977, DOI 10.1002/art.1780230903; Brewer E J Jr, 1977, Arthritis Rheum, V20, P195; BREWER EJ, 1980, ARTHRITIS RHEUM, V23, P404, DOI 10.1002/art.1780230403; BREWER EJ, 1982, J RHEUMATOL, V9, P109; BREWER EJ, 1986, NEW ENGL J MED, V314, P1269, DOI 10.1056/NEJM198605153142001; CASSIDY JT, 1986, ARTHRITIS RHEUM, V29, P274, DOI 10.1002/art.1780290216; CASSIDY JT, 1990, TXB PEDIATRIC RHEUMA, P114; DOLGOPOLOVA AV, 1979, VOPR REVMATIZMA, V4, P3; EVANS J, 1990, HEPATOLOGY, V12, P954, DOI 10.1002/hep.1840120427; FURST DE, 1989, J RHEUMATOL, V16, P313; GEHAN EA, 1973, CANCER MED, P514; GIANNINI EH, 1988, ARTHRITIS RHEUM, V31, P15, DOI 10.1002/art.1780310103; GIANNINI EH, 1990, ARTHRITIS RHEUM, V33, P466, DOI 10.1002/art.1780330402; GIANNINI EH, 1991, J RHEUMATOL, V18, P1240; GIANNINI EH, 1982, J RHEUMATOL, V9, P114; HALLE F, 1991, CLIN EXP RHEUMATOL, V9, P297; HOWE S, 1991, ARTHRITIS RHEUM, V34, P873, DOI 10.1002/art.1780340713; KREMER JM, 1986, ARTHRITIS RHEUM, V29, P822, DOI 10.1002/art.1780290702; KREMER JM, 1988, ARTHRITIS RHEUM-US, V31, P577, DOI 10.1002/art.1780310501; MARTINI A, 1991, J PEDIATR-US, V119, P333, DOI 10.1016/S0022-3476(05)80765-6; MIELANTS H, 1991, J RHEUMATOL, V18, P978; PAULUS HE, 1990, ARTHRITIS RHEUM, V33, P477, DOI 10.1002/art.1780330403; Petty R, 1987, WORLD PEDIAT CHILD C, V3, P205; ROSE CD, 1990, J PEDIATR-US, V117, P653, DOI 10.1016/S0022-3476(05)80709-7; SINGH G, 1990, Arthritis and Rheumatism, V33, pS15; SPECKMAIER M, 1989, CLIN EXP RHEUMATOL, V7, P647; STEWART CF, 1991, ARTHRITIS RHEUM, V34, P1514; TOWNER SR, 1983, ARTHRITIS RHEUM-US, V26, P1208, DOI 10.1002/art.1780261006; TRUCKENBRODT H, 1986, ARTHRITIS RHEUM, V29, P801, DOI 10.1002/art.1780290616; WALLACE CA, 1989, ARTHRITIS RHEUM, V32, P677, DOI 10.1002/anr.1780320604; WEINBLATT ME, 1988, ARTHRITIS RHEUM, V31, P167, DOI 10.1002/art.1780310203; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; WILLIAMS HJ, 1985, ARTHRITIS RHEUM-US, V28, P721, DOI 10.1002/art.1780280702; WOLFE F, 1990, J RHEUMATOL, V17, P994; Zar J.H., 1999, ZAR KUHR 5 2019, V4th	36	454	477	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 16	1992	326	16					1043	1049		10.1056/NEJM199204163261602	http://dx.doi.org/10.1056/NEJM199204163261602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN738	1549149	Bronze			2022-12-28	WOS:A1992HN73800002
J	KIM, S; LANDY, A				KIM, S; LANDY, A			LAMBDA-INT PROTEIN BRIDGES BETWEEN HIGHER-ORDER COMPLEXES AT 2 DISTANT CHROMOSOMAL LOCI ATTL AND ATTR	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; INTEGRATION HOST FACTOR; BACTERIOPHAGE-LAMBDA; EXCISIVE RECOMBINATION; GENE-PRODUCT; ATTACHMENT SITE; BINDING-SITES; DNA COMPLEX; PURIFICATION; SEQUENCE	The excisive recombination reaction of bacteriophage lambda involves a specific and efficient juxtaposition of two distant higher order protein-DNA complexes on the chromosome of Escherichia coli. These complexes, which mediate synapsis and strand exchange, consist of two DNA sequences, attL and attR, the bivalent DNA binding protein Int, and the sequence-specific DNA bending proteins, IHF, Xis, and Fis. The protein-protein and protein-DNA interactions within, and between, these complexes were studied by various biochemical techniques and the patterns of synergism among pairs of mutants with marginally impaired recombination function were analyzed. The DNA bending proteins facilitated long-range tethering of high- and low-affinity DNA sites by the bivalent Int protein, and a specific map is proposed for the resulting Int bridges. These structural motifs provide a basis for postulating the mechanisms of site-specific recombination and may also be relevant to other pathways in which two distant chromosomal sites become associated.	BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912	Brown University			Kim, Sunghoon/AAE-8314-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013544, R01AI013544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033928, R01GM062723] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 13544] Funding Source: Medline; NIGMS NIH HHS [R01 GM062723, R01 GM033928, GM 33928] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI K, 1982, J BIOL CHEM, V257, P9658; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BALL CA, 1991, J BACTERIOL, V173, P4027, DOI 10.1128/jb.173.13.4027-4031.1991; BETTER M, 1982, P NATL ACAD SCI-BIOL, V79, P5837, DOI 10.1073/pnas.79.19.5837; BUSHMAN W, 1985, SCIENCE, V230, P906, DOI 10.1126/science.2932798; CRAIG NL, 1983, CELL, V35, P795, DOI 10.1016/0092-8674(83)90112-5; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DEVARGAS LM, 1991, P NATL ACAD SCI USA, V88, P588, DOI 10.1073/pnas.88.2.588; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; GARDNER JF, 1986, J MOL BIOL, V191, P181, DOI 10.1016/0022-2836(86)90255-X; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HSU PL, 1984, NATURE, V311, P721, DOI 10.1038/311721a0; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KIKUCHI Y, 1978, J BIOL CHEM, V253, P7149; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; KOTEWICZ M, 1980, J BIOL CHEM, V255, P2433; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LANDY A, 1977, SCIENCE, V197, P1147, DOI 10.1126/science.331474; LANDY A, UNPUB; NASH HA, 1981, J BIOL CHEM, V256, P9246; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NUMRYCH TE, 1990, NUCLEIC ACIDS RES, V18, P3953, DOI 10.1093/nar/18.13.3953; NUNESDUBY S, UNPUB; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; NUNESDUBY SE, 1989, CELL, V59, P197, DOI 10.1016/0092-8674(89)90881-7; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; POLLOCK TJ, 1983, J MOL BIOL, V170, P1, DOI 10.1016/S0022-2836(83)80224-1; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; ROSS W, 1983, CELL, V33, P261, DOI 10.1016/0092-8674(83)90355-0; ROSS W, 1982, P NATL ACAD SCI-BIOL, V79, P7724, DOI 10.1073/pnas.79.24.7724; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; THOMPSON JF, 1987, J MOL BIOL, V195, P481, DOI 10.1016/0022-2836(87)90177-X; THOMPSON JF, 1987, CELL, V50, P901, DOI 10.1016/0092-8674(87)90516-2; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; THOMPSON JF, 1986, J BACTERIOL, V168, P1343, DOI 10.1128/jb.168.3.1343-1351.1986; THOMPSON JF, 1988, DNA BENDING CURVATUR, P119; THOMPSON JF, 1989, MOBILE DNA, P1; WINOTO A, 1986, J MOL BIOL, V192, P677, DOI 10.1016/0022-2836(86)90286-X; YIN S, 1985, P NATL ACAD SCI USA, V82, P1040, DOI 10.1073/pnas.82.4.1040; ZAHN K, UNPUB	45	113	124	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					198	203		10.1126/science.1533056	http://dx.doi.org/10.1126/science.1533056			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1533056	Green Accepted			2022-12-28	WOS:A1992HM89600022
J	DEMARCHI, S; CECCHIN, E; VILLALTA, D; SEPIACCI, G; SANTINI, G; BARTOLI, E				DEMARCHI, S; CECCHIN, E; VILLALTA, D; SEPIACCI, G; SANTINI, G; BARTOLI, E			RELIEF OF PRURITUS AND DECREASES IN PLASMA HISTAMINE CONCENTRATIONS DURING ERYTHROPOIETIN THERAPY IN PATIENTS WITH UREMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC-RENAL-FAILURE; SPONTANEOUS RELEASE; HEMODIALYSIS; METABOLISM; LIDOCAINE; SKIN; FOOD	Background. The pathophysiologic aspects of pruritus in patients with chronic renal insufficiency are poorly understood, and there is no universally effective treatment. The improvement of pruritus in several patients receiving erythropoietin therapy raised the possibility that erythropoietin affects uremic pruritus directly. Methods. We undertook a 10-week placebo-controlled, double-blind, crossover study in a group of patients receiving hemodialysis who had severe pruritus, to investigate the effects of recombinant human erythropoietin on their pruritus and plasma histamine levels. Twenty patients with uremia, of whom 10 had severe pruritus and 10 did not, received erythropoietin (36 units per kilogram of body weight three times weekly) and placebo in random order, each for five weeks. The severity of pruritus was scored weekly, and plasma histamine levels were measured at the beginning and end of each five-week period. Results. Eight of the 10 patients with pruritus had marked reductions in their pruritus scores during erythropoietin therapy. The mean (+/- SE) pruritus score decreased from 25 +/- 3 to 6 +/- 1 in these patients. The pruritus returned within one week after the discontinuation of therapy. The improvement was not related to the change in hemoglobin level. These eight patients were successfully treated again with low doses of erythropoietin (18 units per kilogram three times weekly), and the effect has persisted for six months. The patients with pruritus had elevated plasma histamine concentrations (20.7 +/- 2.7 nmol per liter), as compared with the patients without pruritus (4.2 +/- 0.6 nmol per liter; P < 0.001) and normal subjects (2.1 +/- 0.2 nmol per liter; P < 0.001). Therapy with erythropoietin induced a decrease in plasma histamine concentrations in both groups of patients with uremia, and recurrences of pruritus after the discontinuation of erythropoietin were accompanied by increases in plasma histamine concentrations. Conclusions. Erythropoietin therapy lowers plasma histamine concentrations in patients with uremia and can result in marked improvement of pruritus.	SANTA MARIA ANGELI HOSP, DEPT IMMUNOL, PORDENONE, ITALY; GEN HOSP, DIALYSIS UNIT, CIVIDALE DEL FRIULI, ITALY		DEMARCHI, S (corresponding author), UNIV UDINE, SCH MED, DEPT INTERNAL MED, VIA TARTAGNA 39, I-33100 UDINE, ITALY.							BENCINI PL, 1985, NEPHRON, V40, P316, DOI 10.1159/000183485; CECCHIN E, 1990, KIDNEY INT, V37, P943, DOI 10.1038/ki.1990.69; COLLINSWORTH KA, 1975, CLIN PHARMACOL THER, V18, P59; DEMARCHI S, 1990, CLIN SCI, V78, P295, DOI 10.1042/cs0780295; DEMARCHI S, 1991, CLIN SCI, V81, P113, DOI 10.1042/cs0810113; DUO LJ, 1987, NEPHRON, V47, P179, DOI 10.1159/000184487; GILCHREST BA, 1979, ANN INTERN MED, V91, P17, DOI 10.7326/0003-4819-91-1-17; GILCHREST BA, 1982, ARCH DERMATOL, V118, P154, DOI 10.1001/archderm.118.3.154; GILCHREST BA, 1977, NEW ENGL J MED, V297, P136, DOI 10.1056/NEJM197707212970304; HAMPERS CL, 1968, NEW ENGL J MED, V279, P695, DOI 10.1056/NEJM196809262791307; KALECHMAN Y, 1990, J AM SOC NEPHROL, V1, P400; LORENZ W, 1982, KLIN WOCHENSCHR, V60, P896, DOI 10.1007/BF01716946; MASSRY SG, 1968, NEW ENGL J MED, V279, P697, DOI 10.1056/NEJM196809262791308; MATSUMOTO M, 1985, CLIN NEPHROL, V23, P285; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X; MCBRIDE P, 1988, J ALLERGY CLIN IMMUN, V82, P638, DOI 10.1016/0091-6749(88)90977-3; METTANG T, 1988, LANCET, V2, P748; METTANG T, 1990, CLIN NEPHROL, V34, P136; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; NIELSEN T, 1980, DAN MED BULL, V27, P269; Pfaffl W, 1988, Contrib Nephrol, V66, P195; RASKIN NH, 1976, NEW ENGL J MED, V294, P204, DOI 10.1056/NEJM197601222940406; ROSEN T, 1979, CUTIS, V23, P790; SALMONSON T, 1990, NEPHROL DIAL TRANSPL, V5, P742; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SCHAEFER R M, 1990, Nephrology Dialysis Transplantation, V5, P742; SENNESAEL JJ, 1991, KIDNEY INT, V40, P121, DOI 10.1038/ki.1991.189; SILVERBERG DS, 1977, BRIT MED J, V1, P752, DOI 10.1136/bmj.1.6063.752; STOCKENHUBER F, 1987, NEW ENGL J MED, V317, P386; STOCKENHUBER F, 1990, CLIN SCI, V79, P477, DOI 10.1042/cs0790477; TAPIA L, 1977, NEW ENGL J MED, V296, P261, DOI 10.1056/NEJM197702032960508; YATZIDIS H, 1975, BRIT MED J, V3, P352, DOI 10.1136/bmj.3.5979.352; YATZIDIS H, 1972, J AMER MED ASSOC, V222, P1183, DOI 10.1001/jama.1972.03210090063037; YOUNG AW, 1974, ARCH DERMATOL, V109, P107; YOUNG AW, 1973, NEW YORK STATE J MED, V73, P2670	35	111	116	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 9	1992	326	15					969	974						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM285	1545849				2022-12-28	WOS:A1992HM28500001
J	FEDSON, DS; WAJDA, A; NICOL, JP; ROOS, LL				FEDSON, DS; WAJDA, A; NICOL, JP; ROOS, LL			DISPARITY BETWEEN INFLUENZA VACCINATION RATES AND RISKS FOR INFLUENZA-ASSOCIATED HOSPITAL DISCHARGE AND DEATH IN MANITOBA IN 1982-1983	ANNALS OF INTERNAL MEDICINE			English	Article						HEALTH SERVICES FOR THE AGED; INFLUENZA; GERIATRICS; VACCINATION; PULMONARY DISEASE; PNEUMONIA	ACUTE RESPIRATORY-DISEASE; UNITED-STATES; PNEUMOCOCCAL IMMUNIZATION; EPIDEMIOLOGIC RATIONALE; ADMINISTRATIVE DATA; EXCESS MORTALITY; EPIDEMICS; PHYSICIANS; SHENANDOAH; ENGLAND	Objective: To determine, in a defined population, the percentage of persons who were discharged from a hospital or died of influenza-associated respiratory conditions who had a health care contact during the preceding vaccination season and to determine the relation between risk status for influenza-associated hospitalization and death and influenza vaccination rates. Design: An observational study using linked-record analysis of medical claims data. Setting and Patients: A probability sample of 100 000 noninstitutionalized adults living in Manitoba in 1982 to 1983. Measurements: Analysis of medical claims for influenza vaccination and hospital discharges and deaths for influenza-associated respiratory conditions during the 1982-83 influenza vaccination season and influenza outbreak period. Results: For the population as a whole, 50% to 60% of elderly persons (greater-than-or-equal-to 65 years of age ) and 30% to 40% of younger persons had one or more health care contacts during the influenza vaccination season but fewer than 10% of all persons had been discharged from a hospital. In contrast, for elderly persons hospitalized with respiratory conditions during the influenza outbreak period, approximately 80% had at least one health care contact during the vaccination season. Among the elderly, 39% to 46% of all those discharged for influenza-associated respiratory conditions and 62% to 67% of those who died had been discharged from hospital during the previous vaccination season. Persons discharged with high-risk conditions during the vaccination season were at greater risk for hospitalization with influenza-associated respiratory conditions but were less likely to be vaccinated than were those at lower risk. Conclusions: Most persons who were hospitalized with influenza-associated respiratory conditions had contact with health care providers during the preceding influenza vaccination season. Among elderly patients, previous hospital care was common, especially among those who died. The disparity between influenza vaccination rates and risks for influenza-associated hospital discharge and death supports a strategy of hospital-based influenza vaccination.	UNIV MANITOBA, MANITOBA CTR HLTH POLICY & EVALUAT, WINNIPEG R3T 2N2, MANITOBA, CANADA	University of Manitoba	FEDSON, DS (corresponding author), UNIV VIRGINIA, MED CTR, SCH MED, BOX 494, CHARLOTTESVILLE, VA 22908 USA.			Roos, Leslie L./0000-0002-4215-8346	NIA NIH HHS [5-R01 AG 09145] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009145] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLING DW, 1981, AM J EPIDEMIOL, V113, P30, DOI 10.1093/oxfordjournals.aje.a113063; AOKI FY, 1990, CLIN INVEST MED, V13, pB58; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; BARON RC, 1988, PUBLIC HEALTH REP, V103, P120; BLACKWELDER WC, 1982, AM REV RESPIR DIS, V125, P511, DOI 10.1164/arrd.1982.125.5.511; BLOOM HG, 1988, J AM GERIATR SOC, V36, P897, DOI 10.1111/j.1532-5415.1988.tb05782.x; FEDSON DS, 1983, AM J PUBLIC HEALTH, V73, P442, DOI 10.2105/AJPH.73.4.442; FEDSON DS, 1990, JAMA-J AM MED ASSOC, V264, P1117; FEDSON DS, 1987, CHEST, V91, P436, DOI 10.1378/chest.91.3.436; FEDSON DS, 1990, INFECT CONT HOSP EP, V11, P357; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; HARWARD MP, 1987, CLIN RES, V35, pA8; HUGHES JS, 1991, JAMA-J AM MED ASSOC, V265, P2347, DOI 10.1001/jama.265.18.2347; LIU KJ, 1987, AM J PUBLIC HEALTH, V77, P712; Mackenzie S G, 1991, Can Dis Wkly Rep, V17, P128; NICHOL KL, 1990, AM J MED, V89, P156, DOI 10.1016/0002-9343(90)90293-M; NICHOL KL, 1991, AM J MED, V91, P584, DOI 10.1016/0002-9343(91)90210-O; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; ROOS LL, 1982, MED CARE, V20, P266, DOI 10.1097/00005650-198203000-00003; ROOS LL, 1987, J CHRON DIS, V40, P41, DOI 10.1016/0021-9681(87)90095-6; ROOS LL, 1979, EVALUATION QUART, V3, P236, DOI 10.1177/0193841X7900300204; Roos N P, 1989, J Aging Health, V1, P411, DOI 10.1177/089826438900100401; Schoenbaum S C, 1990, Infect Dis Clin North Am, V4, P199; SHAPIRO E, 1984, GERONTOLOGIST, V24, P610, DOI 10.1093/geront/24.6.610; SPRENGER MJW, 1990, LANCET, V336, P382, DOI 10.1016/0140-6736(90)91929-5; TILLETT HE, 1983, INT J EPIDEMIOL, V12, P344, DOI 10.1093/ije/12.3.344; WAJDA A, 1987, COMPUT BIOL MED, V17, P239, DOI 10.1016/0010-4825(87)90010-2; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1988, CANADA YB 1988; 1989, 1988 89 MAN HLTH SER; 1989, MMWR, V38, P129; 1989, MMWR, V38, P124; 1988, NAITONAL HTLH EXPEND; 1989, CANADIAN IMMUNIZATIO, P59; 1990, MMWR, V39, P1	36	57	60	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					550	555		10.7326/0003-4819-116-7-550	http://dx.doi.org/10.7326/0003-4819-116-7-550			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543309				2022-12-28	WOS:A1992HL25800005
J	COOPER, GR; MYERS, GL; SMITH, SJ; SCHLANT, RC				COOPER, GR; MYERS, GL; SMITH, SJ; SCHLANT, RC			BLOOD LIPID MEASUREMENTS - VARIATIONS AND PRACTICAL UTILITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; HIGH-DENSITY-LIPOPROTEIN; FACTOR INTERVENTION TRIAL; CHOLESTEROL EDUCATION-PROGRAM; PRIMARY-PREVENTION TRIAL; RAISED ATHEROSCLEROTIC LESIONS; VLDL TRIGLYCERIDE KINETICS; COLESTIPOL-NIACIN THERAPY; ASSOCIATION STEP-1 DIET; COMBINED DRUG REGIMENS	Objective. - To describe the magnitude and impact of the major biological and analytical sources of variation in serum lipid and lipoprotein levels on risk of coronary heart disease; to present a way to qualitatively estimate the total intraindividual variation; and to demonstrate how to determine the number of specimens required to estimate, with 95% confidence, the 'true" underlying total cholesterol value in the serum of a patient. Data Sources. - Representative references on each source of variation were selected from more than 300 reviewed publications, most published within the past 5 years, to document current findings and concepts. Most articles reviewed were in English. Study Selections. - Studies on biological sources of variation were selected using the following criteria: representative of published findings, clear statement of either significant or insignificant results, and acquisition of clinical and laboratory data under standardized conditions. Representative results for special populations such as women and children are reported when results differ from those of adult men. Data Extraction. - References were selected based on acceptable experimental design and use of standardized laboratory lipid measurements. Data Synthesis. - The lipid levels considered representative for a selected source of variation arose from quantitative measurements by a suitably standardized laboratory. Statistical analysis of data was examined to assure reliability. The proposed method of estimating the biological coefficient of variation must be considered to give qualitative results, because only two or three serial specimens are collected in most cases for the estimation. Conclusions. - Concern has arisen about the magnitude, impact, and interpretation of preanalytical as well as analytical sources of variation on reported results of lipid measurements of an individual. Preanalytical sources of variation from behavioral, clinical, and sampling sources constitute about 60% of the total variation in a reported lipid measurement of an individual. A technique is presented to allow physicians to qualitatively estimate the intraindividual biological variation of a patient from the results of two or more specimens reported from a standardized laboratory and to determine whether additional specimens are needed to meet the National Cholesterol Education Program recommendation that the intraindividual serum total cholesterol coefficient of variation not exceed 5.0. A National Reference Method Network has been established to help solve analytical problems.	EMORY UNIV,SCH MED,DEPT MED,DIV CARDIOL,ATLANTA,GA 30322	Emory University	COOPER, GR (corresponding author), CTR DIS CONTROL,NATL CTR ENVIRONM HLTH & INJURY CONTROL,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA 30333, USA.							ALVAREZ C, 1986, CLIN CHEM, V32, P142; [Anonymous], 1988, CLIN CHEM, V34, P193; [Anonymous], 1977, CLIN CHEM, V23, P60; AUSTIN MA, 1990, ARTERIOSCLEROSIS, V10, P520, DOI 10.1161/01.ATV.10.4.520; BALLANTYNE CM, 1989, JAMA-J AM MED ASSOC, V262, P53, DOI 10.1001/jama.262.1.53; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BOOKSTEIN L, 1990, ARCH INTERN MED, V150, P1653, DOI 10.1001/archinte.150.8.1653; BRAVO EL, 1989, AM J HYPERTENS, V2, pS339; BRISCHETTO CS, 1983, AM J CARDIOL, V52, P675, DOI 10.1016/0002-9149(83)90396-X; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CASTELLI WP, 1977, LANCET, V2, P153; CASTELLI WP, 1986, AM J MED S2A, V80, pS23; CLOEY T, 1990, JAMA-J AM MED ASSOC, V263, P2788, DOI 10.1001/jama.263.20.2788; COHN JS, 1988, J LIPID RES, V29, P469; COHN JS, 1988, CLIN CHEM, V34, P2456; COOPER GR, 1988, CLIN CHEM, V34, pB95; COOPER GR, 1964, AUTOMAT ANAL CHEM, P67; CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784; CRIQUI MH, 1980, CIRCULATION, V62, P70; DEMACKER PNM, 1982, ATHEROSCLEROSIS, V45, P259, DOI 10.1016/0021-9150(82)90227-1; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; DONAHUE RP, 1988, AM J PUBLIC HEALTH, V78, P683, DOI 10.2105/AJPH.78.6.683; EKLUND LG, 1988, NEW ENGL J MED, V319, P1379; FORD RP, 1989, ANN CLIN BIOCHEM, V26, P281, DOI 10.1177/000456328902600314; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIED RE, 1992, JAMA-J AM MED ASSOC, V267, P811, DOI 10.1001/jama.267.6.811; GINSBERG HN, 1990, NEW ENGL J MED, V322, P574, DOI 10.1056/NEJM199003013220902; GORDON DJ, 1987, CIRCULATION, V76, P1224, DOI 10.1161/01.CIR.76.6.1224; GORDON T, 1981, CIRCULATION, V64, P63; GORE JM, 1984, AM J CARDIOL, V54, P722, DOI 10.1016/S0002-9149(84)80197-6; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849; GRUNDY SM, 1988, ARTERIOSCLEROSIS, V8, P95, DOI 10.1161/01.ATV.8.1.95; GRUNDY SM, 1990, J LIPID RES, V31, P1149; GRUNFELD C, 1991, AM J MED, V90, P154, DOI 10.1016/0002-9343(91)80154-E; HAGEN RD, 1986, PREV MED, V15, P18; HARDMAN AE, 1989, BRIT MED J, V299, P1204, DOI 10.1136/bmj.299.6709.1204-a; HARRIS WS, 1990, J LIPID RES, V31, P1549; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HOLME I, 1981, ARTERIOSCLEROSIS, V1, P250, DOI 10.1161/01.ATV.1.4.250; HOWES LG, 1987, J HYPERTENS        S, V5, P5361; HUGHES TA, 1987, ATHEROSCLEROSIS, V67, P105, DOI 10.1016/0021-9150(87)90271-1; IRWIG L, 1991, JAMA-J AM MED ASSOC, V266, P1678, DOI 10.1001/jama.266.12.1678; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JOVEN J, 1990, NEW ENGL J MED, V323, P579, DOI 10.1056/NEJM199008303230905; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; KARADI I, 1989, CLIN CHEM, V35, P2121; KREISS K, 1981, JAMA-J AM MED ASSOC, V245, P2505, DOI 10.1001/jama.245.24.2505; KRONE W, 1988, AM HEART J, V116, P1729, DOI 10.1016/0002-8703(88)90222-0; LAAKSO M, 1990, ARTERIOSCLEROSIS, V10, P223, DOI 10.1161/01.ATV.10.2.223; LAMPMAN RM, 1977, CIRCULATION, V55, P652, DOI 10.1161/01.CIR.55.4.652; LAPIDUS L, 1985, ACTA MED SCAND, V217, P481; LAROSA JC, 1977, HYPERLIPIDEMIA DIAGN, P205; LENFANT C, 1986, CIRCULATION, V73, P855, DOI 10.1161/01.CIR.73.5.855; LIND T, 1981, ADV CLIN CHEM, V21, P3; MACMAHON SW, 1985, ARTERIOSCLEROSIS, V5, P391, DOI 10.1161/01.ATV.5.4.391; MARKEL A, 1985, POSTGRAD MED J, V61, P395, DOI 10.1136/pgmj.61.715.395; MARKELL MS, 1989, AM J MED, V87, P61; MENDEZ I, 1987, NEUROLOGY, V37, P507, DOI 10.1212/WNL.37.3.507; MOGADAM M, 1990, ARCH INTERN MED, V150, P1645, DOI 10.1001/archinte.150.8.1645; MYERS GL, 1990, ARCH PATHOL LAB MED, V114, P1199; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; MYERS GL, 1990, FRESEN J ANAL CHEM, V338, P538, DOI 10.1007/BF00322533; MYERS LH, 1976, J LAB CLIN MED, V88, P491; NEWMAN B, 1990, AM J PUBLIC HEALTH, V80, P675, DOI 10.2105/AJPH.80.6.675; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; REAVEN GM, 1991, AM J MED, V90, pS7, DOI 10.1016/0002-9343(91)90028-V; REED DM, 1989, ARTERIOSCLEROSIS, V9, P560, DOI 10.1161/01.ATV.9.4.560; RIFAI N, 1989, CLIN CHEM, V35, P1066; ROUHLING K, 1980, ARTERY, V8, P140; RYDER REJ, 1984, BRIT MED J, V289, P1651, DOI 10.1136/bmj.289.6459.1651; SACKS FM, 1985, JAMA-J AM MED ASSOC, V254, P1337, DOI 10.1001/jama.254.10.1337; SCHOENBERGER JA, 1991, AM J MED, V90, pS1, DOI 10.1016/0002-9343(91)90026-T; SHEKELLE RB, 1984, ATHER REV, V12, P113; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; SWAIN JF, 1990, NEW ENGL J MED, V322, P147, DOI 10.1056/NEJM199001183220302; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; TAN MH, 1973, NEW ENGL J MED, V289, P416, DOI 10.1056/NEJM197308232890808; TASKINEN MR, 1987, AM HEART J, V113, P458, DOI 10.1016/0002-8703(87)90614-4; TERPSTRA J, 1978, EUR J CLIN INVEST, V8, P61, DOI 10.1111/j.1365-2362.1978.tb00813.x; THELLE DS, 1987, ATHEROSCLEROSIS, V67, P97, DOI 10.1016/0021-9150(87)90270-X; TUCKER LA, 1990, AM J PUBLIC HEALTH, V80, P1111, DOI 10.2105/AJPH.80.9.1111; VANDUSSELDORP M, 1990, AM J EPIDEMIOL, V132, P33, DOI 10.1093/oxfordjournals.aje.a115640; WALLENTIN L, 1980, AM J CLIN NUTR, V33, P1925, DOI 10.1093/ajcn/33.9.1925; WILLETT W, 1983, AM HEART J, V105, P417, DOI 10.1016/0002-8703(83)90358-7; WILLIAMS PT, 1989, ARTERIOSCLEROSIS, V9, P623, DOI 10.1161/01.ATV.9.5.623; WOLF RN, 1983, ARTERIOSCLEROSIS, V3, P160, DOI 10.1161/01.ATV.3.2.160; WOOD PD, 1979, LIPIDS, V14, P417, DOI 10.1007/BF02533428; WOOD PD, 1991, NEW ENGL J MED, V325, P461, DOI 10.1056/NEJM199108153250703; ZAVORONI I, 1989, NEW ENGL J MED, V320, P702; ZOCK PL, 1990, LANCET, V335, P1235, DOI 10.1016/0140-6736(90)91302-Q; 1988, RECOMMENDATIONS REGA; 1990, MMWR, V39, P541; 1990, JAMA-J AM MED ASSOC, V263, P1795; 1988, CAN MED ASSOC J, V139, P1; 1988, ARCH INTERN MED, V148, P36; 1981, NIH902964 NAT CHOL E, P1; 1984, JAMA-J AM MED ASSOC, V251, P351; [No title captured]	100	124	126	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1652	1660		10.1001/jama.267.12.1652	http://dx.doi.org/10.1001/jama.267.12.1652			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1542176				2022-12-28	WOS:A1992HJ59700034
J	GIMENO, CJ; LJUNGDAHL, PO; STYLES, CA; FINK, GR				GIMENO, CJ; LJUNGDAHL, PO; STYLES, CA; FINK, GR			UNIPOLAR CELL DIVISIONS IN THE YEAST SACCHAROMYCES-CEREVISIAE LEAD TO FILAMENTOUS GROWTH - REGULATION BY STARVATION AND RAS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; CAENORHABDITIS-ELEGANS; PROLINE UTILIZATION; GENES; INDUCTION; SELECTION; GENETICS; PROTEINS; MUTANTS	Diploid S. cerevisiae strains undergo a dimorphic transition that involves changes in cell shape and the pattern of cell division and results in invasive filamentous growth in response to starvation for nitrogen. Cells become long and thin and form pseudohyphae that grow away from the colony and invade the agar medium. Pseudohyphal growth allows yeast cells to forage for nutrients. Pseudohyphal growth requires the polar budding pattern of a/alpha-diploid cells; haploid axially budding cells of identical genotype cannot undergo this dimorphic transition. Constitutive activation of RAS2 or mutation of SHR3, a gene required for amino acid uptake, enhance the pseudohyphal phenotype; a dominant mutation in RSR1/BUD1 that causes random budding suppresses pseudohyphal growth.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	GIMENO, CJ (corresponding author), MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.		Ljungdahl, Per O/M-5258-2013	Ljungdahl, Per O/0000-0002-6625-3540	NIGMS NIH HHS [GM40266, GM12038-01, GM35010] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035010, R01GM040266, R37GM035010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BISSON LF, 1991, 1991 P INT S NNITR G, P136; BRANDRISS MC, 1979, J BACTERIOL, V140, P498, DOI 10.1128/JB.140.2.498-503.1979; BRANDRISS MC, 1980, J BACTERIOL, V143, P1403, DOI 10.1128/JB.143.3.1403-1410.1980; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BROWN CM, 1965, NATURE, V206, P676, DOI 10.1038/206676a0; CHAFFIN WL, 1984, J GEN MICROBIOL, V130, P431; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; DABROWA N, 1976, INFECT IMMUN, V13, P830, DOI 10.1128/IAI.13.3.830-835.1976; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EUBANKS VL, 1982, J FOOD SCI, V47, P1717, DOI 10.1111/j.1365-2621.1982.tb05019.x; Evans EG, 1989, MED MYCOLOGY PRACTIC; FREIFELDER D, 1960, J BACTERIOL, V80, P567, DOI 10.1128/JB.80.4.567-568.1960; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; GUILLIERMOND A, 1920, YEASTS; Gunning B.E.S., 1982, DEV ORDER ITS ORIGIN, P379; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HICKS JB, 1977, GENETICS, V85, P395; HOLMES AR, 1987, J GEN MICROBIOL, V133, P3219; HUANG Z, 1989, AM J ENOL VITICULT, V40, P135; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; INGLEDEW WM, 1987, AM J ENOL VITICULT, V38, P246; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnson M.H., 1986, EXPT APPROACHES MAMM, P35; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KULKARNI RK, 1981, EXP MYCOL, V5, P148, DOI 10.1016/0147-5975(81)90015-3; LAND GA, 1975, INFECT IMMUN, V11, P1014, DOI 10.1128/IAI.11.5.1014-1023.1975; Lodder J, 1970, YEASTS TAXONOMIC STU; MACDONALD F, 1983, J GEN MICROBIOL, V129, P431; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; Odds FC., 1988, CANDIDA CANDIDOSIS; OUGH CS, 1974, AM J ENOL VITICULT, V25, P7; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; PRINGLE JR, 1981, LIFE CYCLE INHERITAN, P97; RAYNER ADM, 1991, MYCOLOGIA, V83, P48, DOI 10.2307/3759832; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; RYTKA J, 1975, J BACTERIOL, V121, P562, DOI 10.1128/JB.121.2.562-570.1975; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; Shepherd M G, 1988, Curr Top Med Mycol, V2, P278; Sherman F., 1986, METHODS YEAST GENETI; SIDDIQUI AH, 1988, MOL CELL BIOL, V8, P4634, DOI 10.1128/MCB.8.11.4634; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH D, 1969, CAN J BOTANY, V47, P1061, DOI 10.1139/b69-151; Soll D. R., 1991, The fungal spore and disease initiation in plants and animals., P503; SUTHERLAND AE, 1990, DEV BIOL, V137, P13, DOI 10.1016/0012-1606(90)90003-2; TATCHELL K, 1984, NATURE, V309, P523, DOI 10.1038/309523a0; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X	58	993	1014	2	63	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1077	1090		10.1016/0092-8674(92)90079-R	http://dx.doi.org/10.1016/0092-8674(92)90079-R			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547504				2022-12-28	WOS:A1992HK67400011
J	SULSTON, J; DU, Z; THOMAS, K; WILSON, R; HILLIER, L; STADEN, R; HALLORAN, N; GREEN, P; THIERRYMIEG, J; QIU, L; DEAR, S; COULSON, A; CRAXTON, M; DURBIN, R; BERKS, M; METZSTEIN, M; HAWKINS, T; AINSCOUGH, R; WATERSTON, R				SULSTON, J; DU, Z; THOMAS, K; WILSON, R; HILLIER, L; STADEN, R; HALLORAN, N; GREEN, P; THIERRYMIEG, J; QIU, L; DEAR, S; COULSON, A; CRAXTON, M; DURBIN, R; BERKS, M; METZSTEIN, M; HAWKINS, T; AINSCOUGH, R; WATERSTON, R			THE C-ELEGANS GENOME SEQUENCING PROJECT - A BEGINNING	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PHENYLETHANOLAMINE N-METHYLTRANSFERASE; EMBRYONIC CELL LINEAGES; SIMPLEX VIRUS TYPE-1; DNA-SEQUENCE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; MESSENGER-RNA; GENE	The long-term goal of this project is the elucidation of the complete sequence of the Caenorhabditis elegans genome. During the first year methods have been developed and a strategy implemented that is amenable to large-scale sequencing. The three cosmids sequenced in this initial phase are surprisingly rich in genes, many of which have mammalian homologues.	WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; CTR RECH BIOCHIM MACROMOLEC & PHYS MATH,CNRS,F-34044 MONTPELLIER,FRANCE	Washington University (WUSTL); Centre National de la Recherche Scientifique (CNRS)	SULSTON, J (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		THIERRY-MIEG, Jean/F-1975-2017; Durbin, Richard/AAE-7178-2019; Wilson, Richard K./AAF-4139-2019	THIERRY-MIEG, Jean/0000-0002-0396-6789; Durbin, Richard/0000-0002-9130-1006; Wilson, Richard K./0000-0002-1992-1358				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANSORGE W, 1986, J BIOCHEM BIOPH METH, V13, P315, DOI 10.1016/0165-022X(86)90038-2; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOSSY B, 1984, EMBO J, V3, P2537, DOI 10.1002/j.1460-2075.1984.tb02169.x; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CANTOR CR, 1990, SCIENCE, V248, P49, DOI 10.1126/science.2181666; CHEN CM, 1986, J BIOL CHEM, V261, P5030; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; CRAXTON M, 1992, DNA SEQUENCING LABOR; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6; DOGNIN MJ, 1980, EUR J BIOCHEM, V112, P131, DOI 10.1111/j.1432-1033.1980.tb04995.x; DOWNING WL, 1990, J BACTERIOL, V172, P1621, DOI 10.1128/jb.172.3.1621-1627.1990; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EDGLEY ML, 1990, GENETIC MAPS, V5, P3; EIDE D, 1985, P NATL ACAD SCI USA, V82, P1756, DOI 10.1073/pnas.82.6.1756; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1989, EMBO J, V8, P3419, DOI 10.1002/j.1460-2075.1989.tb08506.x; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FRENKEL M, 1991, M63263 GENB ACC NUMB; FUKAO T, 1989, J BIOCHEM-TOKYO, V106, P197, DOI 10.1093/oxfordjournals.jbchem.a122832; GLEESON T, 1991, NUCLEIC ACIDS RES, V19, P6481, DOI 10.1093/nar/19.23.6481; GREER S, 1986, BIOCHEMISTRY-US, V25, P2736, DOI 10.1021/bi00357a069; HALL LMC, 1983, J MOL BIOL, V169, P83, DOI 10.1016/S0022-2836(83)80176-4; HAWKINS TL, 1991, NUCLEIC ACIDS RES, V19, P2784, DOI 10.1093/nar/19.10.2784; HAWKINS TL, UNPUB ELECTROPHORESI; HEINE U, 1986, J MOL BIOL, V188, P301, DOI 10.1016/0022-2836(86)90156-7; HERMAN RK, 1988, NEMATODE CAENORHABDI, P17; Hillier L, 1991, PCR Methods Appl, V1, P124; HUNKAPILLER T, 1991, SCIENCE, V254, P59, DOI 10.1126/science.1925562; KANEDA N, 1988, J BIOL CHEM, V263, P7672; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; LENDAHL U, 1984, CELL, V36, P1027, DOI 10.1016/0092-8674(84)90052-7; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OLSON M, 1991, GENOME DYNAMICS PROT, P1; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; POST LE, 1979, P NATL ACAD SCI USA, V76, P1697, DOI 10.1073/pnas.76.4.1697; PRASAD SS, 1991, GENOME, V34, P6, DOI 10.1139/g91-002; ROBERTS L, 1990, SCIENCE, V249, P1497, DOI 10.1126/science.2218490; ROBERTS L, 1990, SCIENCE, V248, P1310, DOI 10.1126/science.2356467; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SASAOKA T, 1989, NEUROCHEM INT, V15, P555, DOI 10.1016/0197-0186(89)90176-9; SAUER N, 1991, X55350 GENB ACC NUMB; SCHRIEFER LA, 1990, NUCLEIC ACIDS RES, V18, P7455, DOI 10.1093/nar/18.24.7455; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STINCHCOMB DT, 1985, MOL CELL BIOL, V5, P3484, DOI 10.1128/MCB.5.12.3484; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WATSON JD, 1990, SCIENCE, V248, P44, DOI 10.1126/science.2181665; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLS N, 1983, CELL, V33, P575, DOI 10.1016/0092-8674(83)90438-5; Wood WB, 1988, NEMATODE CAENORHABDI; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	70	470	520	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					37	41		10.1038/356037a0	http://dx.doi.org/10.1038/356037a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538779				2022-12-28	WOS:A1992HG60200046
J	VOYKSNER, RD				VOYKSNER, RD			ELECTROSPRAY LC/MS - CAN IT BE USED TO DETERMINE LOWER MOLECULAR-WEIGHT MOLECULES	NATURE			English	Article							MASS-SPECTROMETRY; ATMOSPHERIC-PRESSURE; ION-SOURCE; IONIZATION; EVAPORATION				VOYKSNER, RD (corresponding author), RES TRIANGLE INST,POB 12194,RES TRIANGLE PK,NC 27709, USA.							BLADES AT, 1991, ANAL CHEM, V63, P2109, DOI 10.1021/ac00019a009; COVEY TR, 1988, ORG MASS SPECTROM, V23, P178, DOI 10.1002/oms.1210230305; DODD EE, 1953, J APPL PHYS, V24, P73, DOI 10.1063/1.1721137; DOLE M, 1968, J CHEM PHYS, V49, P2240, DOI 10.1063/1.1670391; DUFFIN KL, 1991, ANAL CHEM, V63, P1781, DOI 10.1021/ac00017a023; DUFFIN KL, 1992, ANAL CHEM, V64, P61, DOI 10.1021/ac00025a012; FENN JB, 1990, MASS SPECTROM REV, V9, P37, DOI 10.1002/mas.1280090103; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; HIRAOKA K, 1992, ANAL CHEM, V64, P75, DOI 10.1021/ac00025a014; IKONOMOU MG, 1991, ANAL CHEM, V63, P1989, DOI 10.1021/ac00018a017; IRIBARNE JV, 1976, J CHEM PHYS, V64, P2287, DOI 10.1063/1.432536; LEE ED, 1989, J AM CHEM SOC, V111, P4600, DOI 10.1021/ja00195a012; LOO JA, 1992, ANAL CHEM, V64, P81, DOI 10.1021/ac00025a015; Quilliam M A, 1989, Rapid Commun Mass Spectrom, V3, P145, DOI 10.1002/rcm.1290030508; SAKAIRI M, 1991, ANAL CHEM, V63, P1488, DOI 10.1021/ac00014a026; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; STULTS JT, 1991, RAPID COMMUN MASS SP, V5, P259; THOMSON BA, 1979, J CHEM PHYS, V71, P4451, DOI 10.1063/1.438198; VOYKSNER RD, 1991, RAPID COMMUN MASS SP, V5, P263, DOI 10.1002/rcm.1290050604; WHITEHOUSE CM, 1985, ANAL CHEM, V57, P675, DOI 10.1021/ac00280a023; YAMASHITA M, 1984, J PHYS CHEM-US, V88, P4451, DOI 10.1021/j150664a002	21	22	22	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					86	87		10.1038/356086a0	http://dx.doi.org/10.1038/356086a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538788				2022-12-28	WOS:A1992HG60200064
J	MCCONNELL, RJ				MCCONNELL, RJ			ABNORMAL THYROID-FUNCTION TEST-RESULTS IN PATIENTS TAKING SALSALATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							THYROXINE-BINDING; HUMAN SERUM; SALICYLATE; INHIBITION	Objective.-To evaluate how the nonsteroidal anti-inflammatory agent salsalate affects the results of routine thyroid function tests. Design.-In a cohort of patients taking salsalate for various rheumatic conditions, thyroid function tests were performed with patients on and off the drug. Setting.-Primary care of ambulatory patients in a university medical center. Patients.-A convenience sample of 14 euthyroid subjects, none of whom was taking thyroid hormone or other medication recognized to alter thyroid function. Intervention. -Treatment with therapeutic doses of salsalate for a mean period of 44 weeks. Main Outcome Measures.-Serum levels of thyroxine (T4), free T4, thyroid hormone binding ratio, free T4 index (the product of T4 and the thyroid hormone binding ratio), triiodothyronine, and thyrotropin. Results.-Serum T4 dropped from a mean baseline level of 96.7 nmol/L off salsalate to 53.4 nmol/L on it (P < .001), and the free T4 index showed a parallel decline from 85.9 to 50.4 (P < .001), with both values falling into the hypothyroid range. Similarly, free T4 levels and total triiodothyronine concentrations were low in several patients treated with salsalate. Serum thyrotropin levels declined transiently, falling from a mean of 3.2 to 1.7 mU/L (P < .02) in patients treated for less than 3 weeks. Patients treated for longer periods had levels comparable to baseline. Despite these changes in the thyroid function test results, all subjects remained clinically euthyroid. Conclusion.-Salsalate commonly produces abnormalities in routine thyroid function test results similar to those found in central hypothyroidism.	COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032	Columbia University								AUSTEN FK, 1958, J CLIN INVEST, V37, P1131, DOI 10.1172/JCI103703; CHOPRA IJ, 1980, ENDOCRINOLOGY, V106, P1728, DOI 10.1210/endo-106-6-1728; DUSSAULT JH, 1976, J CLIN ENDOCR METAB, V43, P232, DOI 10.1210/jcem-43-1-232; HAMADA S, 1970, J CLIN ENDOCR METAB, V31, P166, DOI 10.1210/jcem-31-2-166; KABADI UM, 1987, J AM GERIATR SOC, V35, P255, DOI 10.1111/j.1532-5415.1987.tb02319.x; LARSEN PR, 1972, J CLIN INVEST, V51, P1125, DOI 10.1172/JCI106905; MCCONNELL RJ, 1989, ARTHRITIS RHEUM, V32, P1344, DOI 10.1002/anr.1780321031; RAMEY JN, 1976, J CLIN ENDOCR METAB, V43, P107, DOI 10.1210/jcem-43-1-107; SCHUSSLER GC, 1986, WERNERS THYROID, P381; SURKS MI, 1990, JAMA-J AM MED ASSOC, V263, P1529, DOI 10.1001/jama.263.11.1529; WITHERSPOON LR, 1984, CLIN CHEM, V30, P778; WOEBER KA, 1964, J CLIN INVEST, V43, P931, DOI 10.1172/JCI104979	12	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1242	1243		10.1001/jama.267.9.1242	http://dx.doi.org/10.1001/jama.267.9.1242			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1538562				2022-12-28	WOS:A1992HF43900027
J	GUNNELL, DJ				GUNNELL, DJ			MYSTERIOUS SLAPPED FACE RASH AT HOLIDAY CENTER	BRITISH MEDICAL JOURNAL			English	Article							CONTACT-DERMATITIS; SOAPS	Objective - To discover the cause of an outbreak of facial rash in a holiday centre. Design - Questionnaire survey of those with rash; analysis of samples of linen. Setting - Holiday centre in south west England. Patients - 98 holidaymakers presenting to the first aid post with a facial rash. Intervention - Replacement of bed linen with new linen in selected parts of the site. Results - The attack rate was 7.0-14.2/1000 for most accommodation areas in the centre, but in one accommodation area the rate was zero. The pH of rinse water from sheets varied from 7.4 to 9.0. Those parts of the accommodation provided with new linen had zero attack rates. Conclusion - The facial rash resulted from irritation from washing powder retained owing to insufficient rinsing during laundering. Modifications to the rinsing process led to a gradual disappearance of the rash.			GUNNELL, DJ (corresponding author), SOMERSET HLTH AUTHOR,PUBL HLTH MED,TAUNTON TA2 7PQ,ENGLAND.		Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470				DOEGLAS HMG, 1965, ARCH DERMATOL, V83, P175; DOOMSGOOSSENS AE, 1986, J AM ACAD DERMATOL, V15, P1, DOI 10.1016/S0190-9622(86)70135-7; HARPIN VA, 1983, J PEDIATR-US, V102, P419, DOI 10.1016/S0022-3476(83)80669-6; Kligman A M, 1978, Curr Probl Dermatol, V7, P1; MALTEN KE, 1981, CONTACT DERMATITIS, V7, P238, DOI 10.1111/j.1600-0536.1981.tb04059.x; MATHIAS CGT, 1986, OCCUP MED, V1, P205; OSMUNDSE.PE, 1969, BRIT J DERMATOL, V81, P799, DOI 10.1111/j.1365-2133.1969.tb15947.x; RYCROFT RJG, 1986, TXB DERMATOLOGY, P533; RYECROFT R, 1986, TXB DERMATOLOGY, P437; STRUBE DD, 1987, CUTIS, V39, P544	10	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					477	479		10.1136/bmj.304.6825.477	http://dx.doi.org/10.1136/bmj.304.6825.477			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547418	Green Published, Bronze			2022-12-28	WOS:A1992HF55500021
J	SMITH, RC; PREZELIN, BB; BAKER, KS; BIDIGARE, RR; BOUCHER, NP; COLEY, T; KARENTZ, D; MACINTYRE, S; MATLICK, HA; MENZIES, D; ONDRUSEK, M; WAN, Z; WATERS, KJ				SMITH, RC; PREZELIN, BB; BAKER, KS; BIDIGARE, RR; BOUCHER, NP; COLEY, T; KARENTZ, D; MACINTYRE, S; MATLICK, HA; MENZIES, D; ONDRUSEK, M; WAN, Z; WATERS, KJ			OZONE DEPLETION - ULTRAVIOLET-RADIATION AND PHYTOPLANKTON BIOLOGY IN ANTARCTIC WATERS	SCIENCE			English	Review							UV-B RADIATION; PERFORMANCE LIQUID-CHROMATOGRAPHY; SOUTHEASTERN BERING SEA; GREAT-BARRIER-REEF; ICE-EDGE ZONE; NATURAL-WATERS; PRIMARY PRODUCTIVITY; MARINE-PHYTOPLANKTON; AQUATIC ENVIRONMENT; ABSORBING-SUBSTANCE	The springtime stratospheric ozone (O3) layer over the Antarctic is thinning by as much as 50 percent, resulting in increased midultraviolet (UVB) radiation reaching the surface of the Southern Ocean. There is concern that phytoplankton communities confined to near-surface waters of the marginal ice zone will be harmed by increased UVB irradiance penetrating the ocean surface, thereby altering the dynamics of Antarctic marine ecosystems. Results from a 6-week cruise (Icecolors) in the marginal ice zone of the Bellingshausen Sea in austral spring of 1990 indicated that as the O3 layer thinned: (i) sea surface- and depth-dependent ratios of UVB irradiance (280 to 320 nanometers) to total irradiance (280 to 700 nanometers) increased and (ii) UVB inhibition of photosynthesis increased. These and other Icecolors findings suggest that O3-dependent shifts of in-water spectral irradiances alter the balance of spectrally dependent phytoplankton processes, including photoinhibition, photo-reactivation, photoprotection, and photosynthesis. A minimum 6 to 12 percent reduction in primary production associated with O3 depletion was estimated for the duration of the cruise.	UNIV CALIF SANTA BARBARA, UNIV CALIF MARINE BIOOPT, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, CTR REMOTE SENSING & ENVIRONM OPT, COMP SYST LAB, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT BIOL SCI, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, INST MARINE SCI, SANTA BARBARA, CA 93106 USA; UNIV CALIF SAN DIEGO, UNIV CALIF MARINE BIOOPT, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCRIPPS INST OCEANOG, LA JOLLA, CA 92093 USA; UNIV HAWAII, DEPT OCEANOG, HONOLULU, HI 96822 USA; MOSS LANDING MARINE LABS, MOSS LANDING, CA 95039 USA; UNIV CALIF SAN FRANCISCO, RADIOBIOL & ENVIRONM HLTH LAB, SAN FRANCISCO, CA 94143 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Hawaii System; Moss Landing Marine Laboratories; University of California System; University of California San Francisco	SMITH, RC (corresponding author), UNIV CALIF SANTA BARBARA, DEPT GEOG, SANTA BARBARA, CA 93106 USA.		Ondrusek, Michael/F-5617-2010	Ondrusek, Michael/0000-0002-5311-9094				Ainley D.G., 1988, P140; AINLEY DG, 1986, SCIENCE, V232, P847, DOI 10.1126/science.232.4752.847; ANDERSON JG, 1991, SCIENCE, V251, P39, DOI 10.1126/science.251.4989.39; BIDIGARE RR, 1989, PHOTOCHEM PHOTOBIOL, V50, P469, DOI 10.1111/j.1751-1097.1989.tb05551.x; BIDIGARE RR, 1985, LIMNOL OCEANOGR, V30, P432, DOI 10.4319/lo.1985.30.2.0432; BIDIGARE RR, 1989, MAR ECOL PROG SER, V56, P177, DOI 10.3354/meps056177; BOOTH C, COMMUNICATION; BRASSEUR G, 1987, ENVIRONMENT, V29, P6, DOI 10.1080/00139157.1987.9928845; BUHLMANN B, 1987, J PLANKTON RES, V9, P935, DOI 10.1093/plankt/9.5.935; CALDWELL MM, 1968, ECOL MONOGR, V38, P243, DOI 10.2307/1942430; CALDWELL MM, 1986, STRATOSPHERIC OZONE, P87; CALKINS J, 1980, NATURE, V283, P563, DOI 10.1038/283563a0; CARRETO JI, 1990, J PLANKTON RES, V12, P909, DOI 10.1093/plankt/12.5.909; CRAWFORD M, 1987, SCIENCE, V237, P1557, DOI 10.1126/science.237.4822.1557; CULLEN JJ, 1991, MAR BIOL, V111, P183, DOI 10.1007/BF01319699; DAMKAER DM, 1981, OECOLOGIA, V48, P178, DOI 10.1007/BF00347960; DAMKAER DM, 1983, OECOLOGIA, V60, P169, DOI 10.1007/BF00379518; DILLON TM, 1982, J GEOPHYS RES-OCEANS, V87, P9601, DOI 10.1029/JC087iC12p09601; DOHLER G, 1984, MAR BIOL, V83, P247, DOI 10.1007/BF00397456; DUNLAP WC, 1986, CORAL REEFS, V5, P155, DOI 10.1007/BF00298182; DUNLAP WC, 1986, J EXP MAR BIOL ECOL, V104, P239, DOI 10.1016/0022-0981(86)90108-5; ELSAYED SZ, 1971, BIOL ANTARCTIC SEAS, V4, P301; ELSAYED SZ, 1977, POLAR OCEANS, P463; FRASER WR, 1986, BIOSCIENCE, V36, P258, DOI 10.2307/1310216; FREDERICK JE, 1988, SCIENCE, V241, P438, DOI 10.1126/science.241.4864.438; FREDERICK JE, 1989, PHOTOCHEM PHOTOBIOL, V50, P443, DOI 10.1111/j.1751-1097.1989.tb05548.x; Fryxell G.A., 1984, Antarctic Journal of the United States, V19, P107; GARRISON DL, 1987, J PHYCOL, V23, P564; GIESKES WW, 1983, LIMNOL OCEANOGR, V28, P757, DOI 10.4319/lo.1983.28.4.0757; GIESKES WWC, 1983, MAR BIOL, V75, P179, DOI 10.1007/BF00406000; GORDON HR, 1985, APPL OPTICS, V24, P4172, DOI 10.1364/AO.24.004172; GRAN H. H., 1931, Conseil Perm. Internat. pour I'Explor. de la Mer. Rapp. et Proces-Verb., V75, P37; HADER DP, 1988, ARCH MICROBIOL, V150, P20, DOI 10.1007/BF00409712; HAXO FT, 1985, J PHYCOL, V21, P282; HIROSAWA T, 1983, ARCH MICROBIOL, V135, P98, DOI 10.1007/BF00408016; HOBSON LA, 1983, J PLANKTON RES, V5, P325, DOI 10.1093/plankt/5.3.325; HOLMHANSEN O, 1977, 3RD P SCAR S ANT BIO, P11; Hunter J. R., 1982, ROLE SOLAR ULTRAVIOL, P459; HUNTER JR, 1979, PHOTOCHEM PHOTOBIOL, V29, P325, DOI 10.1111/j.1751-1097.1979.tb07055.x; JEFFERY WR, 1990, DEV BIOL, V140, P388, DOI 10.1016/0012-1606(90)90088-Z; JERLOV NG, 1950, NATURE, V166, P111, DOI 10.1038/166111a0; JOKIEL PL, 1984, LIMNOL OCEANOGR, V29, P192, DOI 10.4319/lo.1984.29.1.0192; KARANAS JJ, 1979, LIMNOL OCEANOGR, V24, P1104, DOI 10.4319/lo.1979.24.6.1104; KARENTZ D, 1991, MAR BIOL, V108, P157, DOI 10.1007/BF01313484; KARENTZ D, 1991, J PHYCOL, V27, P326, DOI 10.1111/j.0022-3646.1991.00326.x; KARENTZ D, 1991, ANTARCT SCI, V3, P3, DOI 10.1017/S0954102091000032; KARENTZ D, 1990, LIMNOL OCEANOGR, V35, P549, DOI 10.4319/lo.1990.35.3.0549; KARENTZ S, 1991, NATURE, V350, P28, DOI 10.1038/350028b0; KRUEGER AP, COMMUNICATION; LARKUM AWD, 1983, ADV BOT RES, V10, P1, DOI 10.1016/S0065-2296(08)60260-8; LENOBLE J, 1956, ANN GEOPHYS, V12, P16; LUBIN D, IN PRESS J GEOPHYS R; MANTOURA RFC, 1983, ANAL CHIM ACTA, V151, P297, DOI 10.1016/S0003-2670(00)80092-6; MARSHALL PT, 1957, J CONS CONS INT EXPL, V23, P173; MASKE H, 1984, J PLANKTON RES, V6, P351, DOI 10.1093/plankt/6.2.351; MOLINA LT, 1986, J GEOPHYS RES-ATMOS, V91, P14501, DOI 10.1029/JD091iD13p14501; MOROWITZ HJ, 1950, SCIENCE, V111, P229; NELSON DM, 1989, DEEP-SEA RES, V36, P191, DOI 10.1016/0198-0149(89)90133-7; NELSON DM, 1987, J GEOPHYS RES-OCEANS, V92, P7181, DOI 10.1029/JC092iC07p07181; NIEBAUER HJ, 1985, CONT SHELF RES, V4, P367, DOI 10.1016/0278-4343(85)90001-9; PERRIN RA, 1987, HYDROBIOLOGIA, V146, P33, DOI 10.1007/BF00007575; PREZELIN BB, 1991, AQUAT SCI, V53, P136, DOI 10.1007/BF00877058; PREZELIN BB, 1987, MAR BIOL, V96, P563, DOI 10.1007/BF00397975; PREZELIN BB, 1991, J PLANKTON RES, V13, pS45; RINGELBERG J, 1984, HYDROBIOLOGIA, V112, P217, DOI 10.1007/BF00008087; ROBERTS L, 1989, SCIENCE, V244, P288, DOI 10.1126/science.244.4902.288; SCHOEBERL MR, 1991, SCIENCE, V251, P46, DOI 10.1126/science.251.4989.46; SHIBATA K, 1969, PLANT CELL PHYSIOL, V10, P325; SHICK JM, 1991, SYMBIOSIS, V10, P145; SIEBECK O, 1978, VERH INT VEREIN LIMN, V20, P2469; SIVALINGAM PM, 1974, BOT MAR, V17, P23, DOI 10.1515/botm.1974.17.1.23; Smith K. C., 1989, SCI PHOTOBIOLOGY, DOI DOI 10.1007/978-1-4615-8061-4; Smith R. C., 1982, ROLE SOLAR ULTRAVIOL, P509; SMITH RC, 1984, P SOC PHOTO-OPT INST, V489, P119; SMITH RC, 1981, APPL OPTICS, V20, P177, DOI 10.1364/AO.20.000177; SMITH RC, 1980, PHOTOCHEM PHOTOBIOL, V31, P585, DOI 10.1111/j.1751-1097.1980.tb03750.x; SMITH RC, 1980, SCIENCE, V208, P592, DOI 10.1126/science.208.4444.592; SMITH RC, 1989, PHOTOCHEM PHOTOBIOL, V50, P459, DOI 10.1111/j.1751-1097.1989.tb05550.x; SMITH RC, 1979, PHOTOCHEM PHOTOBIOL, V29, P311, DOI 10.1111/j.1751-1097.1979.tb07054.x; SMITH RC, 1984, APPL OPTICS, V23, P2791, DOI 10.1364/AO.23.002791; SMITH RC, 1987, MAR BIOL, V96, P575, DOI 10.1007/BF00397976; SMITH RC, 1986, P SPIE OCEAN OPT 8, V637, P95; SMITH RC, 1978, PHOTOCHEM PHOTOBIOL, V17, P471; SMITH RC, 1981, 8117 SCRIPPS I OC VI; SMITH RC, IN PRESS J GEOPHYS R; SMITH RC, 1989, OCEANOGRAPHY, V2, P4, DOI DOI 10.5670/0CEAN0G.1989.01; SMITH SL, 1986, CONT SHELF RES, V5, P215, DOI 10.1016/0278-4343(86)90016-6; Smith W. O. J., 1985, ANTARCTIC NUTR CYCLE, P70; SMITH WO, 1991, NATURE, V352, P514, DOI 10.1038/352514a0; SMITH WO, 1986, BIOSCIENCE, V36, P251, DOI 10.2307/1310215; SMITH WO, 1985, SCIENCE, V227, P163, DOI 10.1126/science.227.4683.163; SMITH WO, 1987, OCEANOGR MAR BIOL, V25, P11; SMITH WO, 1988, ANTARCTIC OCEAN RESO, P131, DOI DOI 10.1007/978-3-642-73724-4_10; SMITH WO, 1990, POLAR OCEANOGRAPHY B, P427; SOLOMON S, 1988, REV GEOPHYS, V26, P131, DOI 10.1029/RG026i001p00131; SOLOMON S, 1990, NATURE, V347, P347, DOI 10.1038/347347a0; Strickland J.D.H., 1972, PRACTICAL HDB SEWATE, DOI [10.2307/1979241, DOI 10.2307/1979241]; THORPE SA, 1977, PHILOS T R SOC A, V286, P125, DOI 10.1098/rsta.1977.0112; Torres A, COMMUNICATION; Voss K., 1986, P OCEAN OPT 8 SPIE, VVIII, P186; VOYTEK MA, 1990, AMBIO, V19, P52; WALSH JJ, 1986, CONT SHELF RES, V5, P259, DOI 10.1016/0278-4343(86)90018-X; Waters K J, 1990, OCEANOGRAPHY, V3, P18, DOI DOI 10.5670/OCEANOG.1990.03; WATSON R, 1988, OZONE TRENDS PANEL; WILSON DL, 1986, DEEP-SEA RES, V33, P1375, DOI 10.1016/0198-0149(86)90041-5; Worrest R. C., 1986, EFFECTS CHANGES STRA, P175; WORREST RC, 1981, PHOTOCHEM PHOTOBIOL, V33, P223, DOI 10.1111/j.1751-1097.1981.tb05328.x; WORREST RC, 1978, LIMNOL OCEANOGR, V17, P471; ZEPP RG, 1977, ENVIRON SCI TECHNOL, V11, P359, DOI 10.1021/es60127a013; [No title captured]; [No title captured]; 1984, CAUSES EFFECTS STRAT; 1987, STRATOSPHERIC OZONE	113	767	814	8	159	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1992	255	5047					952	959		10.1126/science.1546292	http://dx.doi.org/10.1126/science.1546292			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546292				2022-12-28	WOS:A1992HE60500032
